Sentence,Tags
"A new vitamin D analogue , 22 - oxacalcitriol ( OCT ) , has been shown to have promising characteristics .","(('A', 'O'), ('new', 'O'), ('vitamin', 'O'), ('D', 'O'), ('analogue', 'O'), (',', 'O'), ('22', 'O'), ('-', 'O'), ('oxacalcitriol', 'O'), ('(', 'O'), ('OCT', 'O'), (')', 'O'), (',', 'O'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('have', 'O'), ('promising', 'O'), ('characteristics', 'O'), ('.', 'O'))"
This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function .,"(('This', 'O'), ('study', 'O'), ('was', 'O'), ('undertaken', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('OCT', 'O'), ('on', 'O'), ('serum', 'O'), ('PTH', 'O'), ('levels', 'O'), ('and', 'O'), ('bone', 'O'), ('turnover', 'O'), ('in', 'O'), ('states', 'O'), ('of', 'O'), ('normal', 'O'), ('or', 'O'), ('impaired', 'O'), ('renal', 'O'), ('function', 'O'), ('.', 'O'))"
"METHODS : Sixty dogs were either nephrectomized ( Nx , N = 38 ) or sham - operated ( Sham , N = 22 ) .","(('METHODS', 'O'), (':', 'O'), ('Sixty', 'O'), ('dogs', 'O'), ('were', 'O'), ('either', 'O'), ('nephrectomized', 'B'), ('(', 'O'), ('Nx', 'O'), (',', 'O'), ('N', 'O'), ('=', 'O'), ('38', 'O'), (')', 'O'), ('or', 'O'), ('sham', 'O'), ('-', 'O'), ('operated', 'O'), ('(', 'O'), ('Sham', 'O'), (',', 'O'), ('N', 'O'), ('=', 'O'), ('22', 'O'), (')', 'O'), ('.', 'O'))"
The animals received supplemental phosphate to enhance PTH secretion .,"(('The', 'O'), ('animals', 'O'), ('received', 'O'), ('supplemental', 'O'), ('phosphate', 'O'), ('to', 'O'), ('enhance', 'O'), ('PTH', 'O'), ('secretion', 'O'), ('.', 'O'))"
"Fourteen weeks after the start of phosphate supplementation , half of the Nx and Sham dogs received doses of OCT ( three times per week ) ; the other half were given vehicle for 60 weeks .","(('Fourteen', 'O'), ('weeks', 'O'), ('after', 'O'), ('the', 'O'), ('start', 'O'), ('of', 'O'), ('phosphate', 'O'), ('supplementation', 'O'), (',', 'O'), ('half', 'O'), ('of', 'O'), ('the', 'O'), ('Nx', 'B'), ('and', 'O'), ('Sham', 'O'), ('dogs', 'O'), ('received', 'O'), ('doses', 'O'), ('of', 'O'), ('OCT', 'O'), ('(', 'O'), ('three', 'O'), ('times', 'O'), ('per', 'O'), ('week', 'O'), (')', 'O'), (';', 'O'), ('the', 'O'), ('other', 'O'), ('half', 'O'), ('were', 'O'), ('given', 'O'), ('vehicle', 'O'), ('for', 'O'), ('60', 'O'), ('weeks', 'O'), ('.', 'O'))"
"Thereafter , the treatment modalities for a subset of animals were crossed over for an additional eight months .","(('Thereafter', 'O'), (',', 'O'), ('the', 'O'), ('treatment', 'O'), ('modalities', 'O'), ('for', 'O'), ('a', 'O'), ('subset', 'O'), ('of', 'O'), ('animals', 'O'), ('were', 'O'), ('crossed', 'O'), ('over', 'O'), ('for', 'O'), ('an', 'O'), ('additional', 'O'), ('eight', 'O'), ('months', 'O'), ('.', 'O'))"
"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study , and bone biopsies were done at baseline , 60 weeks after OCT or vehicle treatment , and at the end of the crossover period .","(('Biochemical', 'O'), ('and', 'O'), ('hormonal', 'O'), ('indices', 'O'), ('of', 'O'), ('calcium', 'O'), ('and', 'O'), ('bone', 'O'), ('metabolism', 'O'), ('were', 'O'), ('measured', 'O'), ('throughout', 'O'), ('the', 'O'), ('study', 'O'), (',', 'O'), ('and', 'O'), ('bone', 'O'), ('biopsies', 'O'), ('were', 'O'), ('done', 'O'), ('at', 'O'), ('baseline', 'O'), (',', 'O'), ('60', 'O'), ('weeks', 'O'), ('after', 'O'), ('OCT', 'O'), ('or', 'O'), ('vehicle', 'O'), ('treatment', 'O'), (',', 'O'), ('and', 'O'), ('at', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('crossover', 'O'), ('period', 'O'), ('.', 'O'))"
"RESULTS : In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency .","(('RESULTS', 'O'), (':', 'O'), ('In', 'O'), ('Nx', 'B'), ('dogs', 'O'), (',', 'O'), ('OCT', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('serum', 'O'), ('PTH', 'O'), ('levels', 'O'), ('soon', 'O'), ('after', 'O'), ('the', 'O'), ('induction', 'O'), ('of', 'O'), ('renal', 'B'), ('insufficiency', 'I'), ('.', 'O'))"
"Serum PTH levels rose thereafter , but the rise was less pronounced compared with baseline than the rise seen in Nx control .","(('Serum', 'O'), ('PTH', 'O'), ('levels', 'O'), ('rose', 'O'), ('thereafter', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('rise', 'O'), ('was', 'O'), ('less', 'O'), ('pronounced', 'O'), ('compared', 'O'), ('with', 'O'), ('baseline', 'O'), ('than', 'O'), ('the', 'O'), ('rise', 'O'), ('seen', 'O'), ('in', 'O'), ('Nx', 'B'), ('control', 'O'), ('.', 'O'))"
"In animals with normal renal function , OCT induced a transient decrease in serum PTH levels at a dose of 0 . 1 microg / kg , which was not sustained with lowering of the doses .","(('In', 'O'), ('animals', 'O'), ('with', 'O'), ('normal', 'O'), ('renal', 'O'), ('function', 'O'), (',', 'O'), ('OCT', 'O'), ('induced', 'O'), ('a', 'O'), ('transient', 'O'), ('decrease', 'O'), ('in', 'O'), ('serum', 'O'), ('PTH', 'O'), ('levels', 'O'), ('at', 'O'), ('a', 'O'), ('dose', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('not', 'O'), ('sustained', 'O'), ('with', 'O'), ('lowering', 'O'), ('of', 'O'), ('the', 'O'), ('doses', 'O'), ('.', 'O'))"
"In addition , OCT improved mineralization lag time , ( that is , the rate at which osteoid mineralizes ) in both Nx and Sham dogs .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('OCT', 'O'), ('improved', 'O'), ('mineralization', 'O'), ('lag', 'O'), ('time', 'O'), (',', 'O'), ('(', 'O'), ('that', 'O'), ('is', 'O'), (',', 'O'), ('the', 'O'), ('rate', 'O'), ('at', 'O'), ('which', 'O'), ('osteoid', 'O'), ('mineralizes', 'O'), (')', 'O'), ('in', 'O'), ('both', 'O'), ('Nx', 'B'), ('and', 'O'), ('Sham', 'O'), ('dogs', 'O'), ('.', 'O'))"
There was a history of ischemic cardiac disease 9 years earlier .,"(('There', 'O'), ('was', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('ischemic', 'B'), ('cardiac', 'I'), ('disease', 'I'), ('9', 'O'), ('years', 'O'), ('earlier', 'O'), ('.', 'O'))"
"After receiving advanced cardiopulmonary resuscitation , the patient recovered cardiac rhythm .","(('After', 'O'), ('receiving', 'O'), ('advanced', 'O'), ('cardiopulmonary', 'O'), ('resuscitation', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('recovered', 'O'), ('cardiac', 'O'), ('rhythm', 'O'), ('.', 'O'))"
The ECG showed a junctional rhythm without ventricular arrhythmia .,"(('The', 'O'), ('ECG', 'O'), ('showed', 'O'), ('a', 'O'), ('junctional', 'O'), ('rhythm', 'O'), ('without', 'O'), ('ventricular', 'B'), ('arrhythmia', 'I'), ('.', 'O'))"
This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone ( IVMP ) .,"(('This', 'O'), ('study', 'O'), ('reviews', 'O'), ('the', 'O'), ('current', 'O'), ('proposed', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('sudden', 'B'), ('death', 'I'), ('after', 'O'), ('a', 'O'), ('high', 'O'), ('dose', 'O'), ('of', 'O'), ('intravenous', 'O'), ('methylprednisolone', 'O'), ('(', 'O'), ('IVMP', 'O'), (')', 'O'), ('.', 'O'))"
"These mechanisms are not well understood because , in most cases , the patients were not monitored at the moment of the event .","(('These', 'O'), ('mechanisms', 'O'), ('are', 'O'), ('not', 'O'), ('well', 'O'), ('understood', 'O'), ('because', 'O'), (',', 'O'), ('in', 'O'), ('most', 'O'), ('cases', 'O'), (',', 'O'), ('the', 'O'), ('patients', 'O'), ('were', 'O'), ('not', 'O'), ('monitored', 'O'), ('at', 'O'), ('the', 'O'), ('moment', 'O'), ('of', 'O'), ('the', 'O'), ('event', 'O'), ('.', 'O'))"
"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here , and the authors discount ventricular arrhythmia as the main mechanism .","(('Rapid', 'O'), ('infusion', 'O'), ('and', 'O'), ('underlying', 'O'), ('cardiac', 'B'), ('disease', 'I'), ('were', 'O'), ('important', 'O'), ('risk', 'O'), ('factors', 'O'), ('in', 'O'), ('the', 'O'), ('case', 'O'), ('reported', 'O'), ('here', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('authors', 'O'), ('discount', 'O'), ('ventricular', 'B'), ('arrhythmia', 'I'), ('as', 'O'), ('the', 'O'), ('main', 'O'), ('mechanism', 'O'), ('.', 'O'))"
"/ - 1 . 0 , p < 0 . 05 ) .","(('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
Urine N - acetyl - beta - D - glucosaminidase - - a marker of tubular damage ?,"(('Urine', 'O'), ('N', 'O'), ('-', 'O'), ('acetyl', 'O'), ('-', 'O'), ('beta', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('glucosaminidase', 'O'), ('-', 'O'), ('-', 'O'), ('a', 'O'), ('marker', 'O'), ('of', 'O'), ('tubular', 'B'), ('damage', 'O'), ('?', 'O'))"
"BACKGROUND : Although an indicator of renal tubular dysfunction , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .","(('BACKGROUND', 'O'), (':', 'O'), ('Although', 'O'), ('an', 'O'), ('indicator', 'O'), ('of', 'O'), ('renal', 'B'), ('tubular', 'I'), ('dysfunction', 'I'), (',', 'O'), ('an', 'O'), ('increased', 'O'), ('urinary', 'O'), ('N', 'O'), ('-', 'O'), ('acetyl', 'O'), ('-', 'O'), ('beta', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('glucosaminidase', 'O'), ('(', 'O'), ('NAG', 'O'), (')', 'O'), ('activity', 'O'), ('might', 'O'), ('reflect', 'O'), ('increased', 'O'), ('lysosomal', 'O'), ('activity', 'O'), ('in', 'O'), ('renal', 'O'), ('tubular', 'O'), ('cells', 'O'), ('.', 'O'))"
METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce proteinuria .,"(('METHODS', 'O'), (':', 'O'), ('Puromycin', 'O'), ('aminonucleoside', 'O'), ('(', 'O'), ('PAN', 'O'), (')', 'O'), ('was', 'O'), ('administered', 'O'), ('to', 'O'), ('Sprague', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('to', 'O'), ('induce', 'O'), ('proteinuria', 'B'), ('.', 'O'))"
"Total protein , albumin , NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days .","(('Total', 'O'), ('protein', 'O'), (',', 'O'), ('albumin', 'O'), (',', 'O'), ('NAG', 'O'), ('activity', 'O'), ('and', 'O'), ('protein', 'O'), ('electrophoretic', 'O'), ('pattern', 'O'), ('were', 'O'), ('assessed', 'O'), ('in', 'O'), ('daily', 'O'), ('urine', 'O'), ('samples', 'O'), ('for', 'O'), ('33', 'O'), ('days', 'O'), ('.', 'O'))"
"The morphological appearance of the kidneys was examined on days three , four , six , eight and thirty three and the NAG isoenzyme patterns on days zero , four , eight and thirty three .","(('The', 'O'), ('morphological', 'O'), ('appearance', 'O'), ('of', 'O'), ('the', 'O'), ('kidneys', 'O'), ('was', 'O'), ('examined', 'O'), ('on', 'O'), ('days', 'O'), ('three', 'O'), (',', 'O'), ('four', 'O'), (',', 'O'), ('six', 'O'), (',', 'O'), ('eight', 'O'), ('and', 'O'), ('thirty', 'O'), ('three', 'O'), ('and', 'O'), ('the', 'O'), ('NAG', 'O'), ('isoenzyme', 'O'), ('patterns', 'O'), ('on', 'O'), ('days', 'O'), ('zero', 'O'), (',', 'O'), ('four', 'O'), (',', 'O'), ('eight', 'O'), ('and', 'O'), ('thirty', 'O'), ('three', 'O'), ('.', 'O'))"
"RESULTS : Following intravenous PAN urine volume and urine NAG activity increased significantly by day two , but returned to normal by day four .","(('RESULTS', 'O'), (':', 'O'), ('Following', 'O'), ('intravenous', 'O'), ('PAN', 'O'), ('urine', 'O'), ('volume', 'O'), ('and', 'O'), ('urine', 'O'), ('NAG', 'O'), ('activity', 'O'), ('increased', 'O'), ('significantly', 'O'), ('by', 'O'), ('day', 'O'), ('two', 'O'), (',', 'O'), ('but', 'O'), ('returned', 'O'), ('to', 'O'), ('normal', 'O'), ('by', 'O'), ('day', 'O'), ('four', 'O'), ('.', 'O'))"
"After day four all treated animals exhibited a marked rise in urine albumin , total protein excretion and NAG activity .","(('After', 'O'), ('day', 'O'), ('four', 'O'), ('all', 'O'), ('treated', 'O'), ('animals', 'O'), ('exhibited', 'O'), ('a', 'O'), ('marked', 'O'), ('rise', 'O'), ('in', 'O'), ('urine', 'O'), ('albumin', 'O'), (',', 'O'), ('total', 'O'), ('protein', 'O'), ('excretion', 'O'), ('and', 'O'), ('NAG', 'O'), ('activity', 'O'), ('.', 'O'))"
Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards .,"(('Electrophoresis', 'O'), ('showed', 'O'), ('a', 'O'), ('generalised', 'O'), ('increase', 'O'), ('in', 'O'), ('middle', 'O'), ('and', 'O'), ('high', 'O'), ('molecular', 'O'), ('weight', 'O'), ('urine', 'O'), ('proteins', 'O'), ('from', 'O'), ('day', 'O'), ('four', 'O'), ('onwards', 'O'), ('.', 'O'))"
Protein droplets first appeared prominent in tubular cells on day four .,"(('Protein', 'O'), ('droplets', 'O'), ('first', 'O'), ('appeared', 'O'), ('prominent', 'O'), ('in', 'O'), ('tubular', 'O'), ('cells', 'O'), ('on', 'O'), ('day', 'O'), ('four', 'O'), ('.', 'O'))"
Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets ( day six onwards ) .,"(('Peak', 'O'), ('urine', 'O'), ('NAG', 'O'), ('activity', 'O'), ('and', 'O'), ('a', 'O'), ('change', 'O'), ('in', 'O'), ('NAG', 'O'), ('isoenzyme', 'O'), ('pattern', 'O'), ('coincided', 'O'), ('with', 'O'), ('both', 'O'), ('the', 'O'), ('peak', 'O'), ('proteinuria', 'B'), ('and', 'O'), ('the', 'O'), ('reduction', 'O'), ('in', 'O'), ('intracellular', 'O'), ('protein', 'O'), ('and', 'O'), ('NAG', 'O'), ('droplets', 'O'), ('(', 'O'), ('day', 'O'), ('six', 'O'), ('onwards', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSIONS : This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity , occurs when increased protein is presented to the tubular cells .","(('CONCLUSIONS', 'O'), (':', 'O'), ('This', 'O'), ('animal', 'O'), ('model', 'O'), ('demonstrates', 'O'), ('that', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('lysosomal', 'O'), ('turnover', 'O'), ('and', 'O'), ('hence', 'O'), ('urine', 'O'), ('NAG', 'O'), ('activity', 'O'), (',', 'O'), ('occurs', 'O'), ('when', 'O'), ('increased', 'O'), ('protein', 'O'), ('is', 'O'), ('presented', 'O'), ('to', 'O'), ('the', 'O'), ('tubular', 'O'), ('cells', 'O'), ('.', 'O'))"
Urine NAG activity is thus a measure of altered function in the renal tubules and not simply an indicator of damage .,"(('Urine', 'O'), ('NAG', 'O'), ('activity', 'O'), ('is', 'O'), ('thus', 'O'), ('a', 'O'), ('measure', 'O'), ('of', 'O'), ('altered', 'O'), ('function', 'O'), ('in', 'O'), ('the', 'O'), ('renal', 'O'), ('tubules', 'O'), ('and', 'O'), ('not', 'O'), ('simply', 'O'), ('an', 'O'), ('indicator', 'O'), ('of', 'O'), ('damage', 'O'), ('.', 'O'))"
All were associated with spinal anaesthesia using hyperbaric 5 % lignocaine .,"(('All', 'O'), ('were', 'O'), ('associated', 'O'), ('with', 'O'), ('spinal', 'O'), ('anaesthesia', 'O'), ('using', 'O'), ('hyperbaric', 'O'), ('5', 'O'), ('%', 'O'), ('lignocaine', 'O'), ('.', 'O'))"
Five cases had single - shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block .,"(('Five', 'O'), ('cases', 'O'), ('had', 'O'), ('single', 'O'), ('-', 'O'), ('shot', 'O'), ('spinal', 'O'), ('anaesthesia', 'O'), ('and', 'O'), ('one', 'O'), ('had', 'O'), ('a', 'O'), ('repeat', 'O'), ('spinal', 'O'), ('anaesthetic', 'O'), ('due', 'O'), ('to', 'O'), ('inadequate', 'O'), ('block', 'O'), ('.', 'O'))"
The dose of hyperbaric 5 % lignocaine administered ranged from 60 to 120 mg .,"(('The', 'O'), ('dose', 'O'), ('of', 'O'), ('hyperbaric', 'O'), ('5', 'O'), ('%', 'O'), ('lignocaine', 'O'), ('administered', 'O'), ('ranged', 'O'), ('from', 'O'), ('60', 'O'), ('to', 'O'), ('120', 'O'), ('mg', 'O'), ('.', 'O'))"
We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2 % and at a total dose preferably not exceeding 60 mg .,"(('We', 'O'), ('recommend', 'O'), ('that', 'O'), ('hyperbaric', 'O'), ('lignocaine', 'O'), ('should', 'O'), ('be', 'O'), ('administered', 'O'), ('in', 'O'), ('concentrations', 'O'), ('not', 'O'), ('greater', 'O'), ('than', 'O'), ('2', 'O'), ('%', 'O'), ('and', 'O'), ('at', 'O'), ('a', 'O'), ('total', 'O'), ('dose', 'O'), ('preferably', 'O'), ('not', 'O'), ('exceeding', 'O'), ('60', 'O'), ('mg', 'O'), ('.', 'O'))"
BACKGROUND : Sirolimus ( formerly rapamycin ) is an immunosuppressive agent that interferes with T - cell activation .,"(('BACKGROUND', 'O'), (':', 'O'), ('Sirolimus', 'O'), ('(', 'O'), ('formerly', 'O'), ('rapamycin', 'O'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('immunosuppressive', 'O'), ('agent', 'O'), ('that', 'O'), ('interferes', 'O'), ('with', 'O'), ('T', 'O'), ('-', 'O'), ('cell', 'O'), ('activation', 'O'), ('.', 'O'))"
"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .","(('Activated', 'O'), ('peripheral', 'O'), ('blood', 'O'), ('T', 'O'), ('cells', 'O'), ('from', 'O'), ('patients', 'O'), ('with', 'O'), ('psoriasis', 'B'), ('tended', 'O'), ('to', 'O'), ('exhibit', 'O'), ('greater', 'O'), ('spontaneous', 'O'), ('or', 'O'), ('dexamethasone', 'O'), ('-', 'O'), ('induced', 'O'), ('apoptosis', 'O'), ('than', 'O'), ('did', 'O'), ('normal', 'O'), ('T', 'O'), ('cells', 'O'), (',', 'O'), ('particularly', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('sirolimus', 'O'), ('.', 'O'))"
"These symptoms may be the result of drug - induced apoptosis of lesional leukocytes , especially activated T lymphocytes , and possibly release of inflammatory mediators .","(('These', 'O'), ('symptoms', 'O'), ('may', 'O'), ('be', 'O'), ('the', 'O'), ('result', 'O'), ('of', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('apoptosis', 'O'), ('of', 'O'), ('lesional', 'O'), ('leukocytes', 'O'), (',', 'O'), ('especially', 'O'), ('activated', 'O'), ('T', 'O'), ('lymphocytes', 'O'), (',', 'O'), ('and', 'O'), ('possibly', 'O'), ('release', 'O'), ('of', 'O'), ('inflammatory', 'O'), ('mediators', 'O'), ('.', 'O'))"
Effect of lithium maintenance therapy on thyroid and parathyroid function .,"(('Effect', 'O'), ('of', 'O'), ('lithium', 'O'), ('maintenance', 'O'), ('therapy', 'O'), ('on', 'O'), ('thyroid', 'O'), ('and', 'O'), ('parathyroid', 'O'), ('function', 'O'), ('.', 'O'))"
"OBJECTIVES : To assess changes induced by lithium maintenance therapy on the incidence of thyroid , parathyroid and ion alterations .","(('OBJECTIVES', 'O'), (':', 'O'), ('To', 'O'), ('assess', 'O'), ('changes', 'O'), ('induced', 'O'), ('by', 'O'), ('lithium', 'O'), ('maintenance', 'O'), ('therapy', 'O'), ('on', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('thyroid', 'O'), (',', 'I'), ('parathyroid', 'I'), ('and', 'O'), ('ion', 'O'), ('alterations', 'O'), ('.', 'O'))"
"These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with thyroid disease ) .","(('These', 'O'), ('were', 'O'), ('evaluated', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('lithium', 'O'), ('therapy', 'O'), (',', 'O'), ('age', 'O'), (',', 'O'), ('sex', 'O'), (',', 'O'), ('and', 'O'), ('family', 'O'), ('history', 'O'), ('(', 'O'), ('whether', 'O'), ('or', 'O'), ('not', 'O'), ('the', 'O'), ('patient', 'O'), ('had', 'O'), ('a', 'O'), ('first', 'O'), ('-', 'O'), ('degree', 'O'), ('relative', 'O'), ('with', 'O'), ('thyroid', 'B'), ('disease', 'I'), (')', 'O'), ('.', 'O'))"
DESIGN : Prospective study .,"(('DESIGN', 'O'), (':', 'O'), ('Prospective', 'O'), ('study', 'O'), ('.', 'O'))"
SETTING : Affective Disorders Clinic at St .,"(('SETTING', 'O'), (':', 'O'), ('Affective', 'B'), ('Disorders', 'I'), ('Clinic', 'O'), ('at', 'O'), ('St', 'O'), ('.', 'O'))"
"Mary ' s Hospital , Montreal .","(('Mary', 'O'), (""'"", 'O'), ('s', 'O'), ('Hospital', 'O'), (',', 'O'), ('Montreal', 'O'), ('.', 'O'))"
PATIENTS : One hundred and one patients ( 28 men and 73 women ) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year ' s to 32 years ' duration .,"(('PATIENTS', 'O'), (':', 'O'), ('One', 'O'), ('hundred', 'O'), ('and', 'O'), ('one', 'O'), ('patients', 'O'), ('(', 'O'), ('28', 'O'), ('men', 'O'), ('and', 'O'), ('73', 'O'), ('women', 'O'), (')', 'O'), ('with', 'O'), ('bipolar', 'B'), ('disorder', 'I'), ('receiving', 'O'), ('lithium', 'O'), ('maintenance', 'O'), ('therapy', 'O'), ('ranging', 'O'), ('from', 'O'), ('1', 'O'), ('year', 'O'), (""'"", 'O'), ('s', 'O'), ('to', 'O'), ('32', 'O'), ('years', 'O'), (""'"", 'O'), ('duration', 'O'), ('.', 'O'))"
The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital ' s out - patient clinics .,"(('The', 'O'), ('control', 'O'), ('group', 'O'), ('consisted', 'O'), ('of', 'O'), ('82', 'O'), ('patients', 'O'), ('with', 'O'), ('no', 'O'), ('psychiatric', 'O'), ('or', 'O'), ('endocrinological', 'O'), ('diagnoses', 'O'), ('from', 'O'), ('the', 'O'), ('hospital', 'O'), (""'"", 'O'), ('s', 'O'), ('out', 'O'), ('-', 'O'), ('patient', 'O'), ('clinics', 'O'), ('.', 'O'))"
"OUTCOME MEASURES : Laboratory analyses of calcium , magnesium and thyroid - stimulating hormone levels performed before beginning lithium therapy and at biannual follow - up .","(('OUTCOME', 'O'), ('MEASURES', 'O'), (':', 'O'), ('Laboratory', 'O'), ('analyses', 'O'), ('of', 'O'), ('calcium', 'O'), (',', 'O'), ('magnesium', 'O'), ('and', 'O'), ('thyroid', 'O'), ('-', 'O'), ('stimulating', 'O'), ('hormone', 'O'), ('levels', 'O'), ('performed', 'O'), ('before', 'O'), ('beginning', 'O'), ('lithium', 'O'), ('therapy', 'O'), ('and', 'O'), ('at', 'O'), ('biannual', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('.', 'O'))"
Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .,"(('Women', 'O'), ('over', 'O'), ('60', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('were', 'O'), ('more', 'O'), ('often', 'O'), ('affected', 'O'), ('by', 'O'), ('hypothyroidism', 'B'), ('than', 'O'), ('women', 'O'), ('under', 'O'), ('60', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('(', 'O'), ('34', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('versus', 'O'), ('31', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
Magnesium levels in patients on lithium treatment were unchanged from baseline levels .,"(('Magnesium', 'O'), ('levels', 'O'), ('in', 'O'), ('patients', 'O'), ('on', 'O'), ('lithium', 'O'), ('treatment', 'O'), ('were', 'O'), ('unchanged', 'O'), ('from', 'O'), ('baseline', 'O'), ('levels', 'O'), ('.', 'O'))"
"After lithium treatment , calcium levels were higher than either baseline levels or control levels .","(('After', 'O'), ('lithium', 'O'), ('treatment', 'O'), (',', 'O'), ('calcium', 'O'), ('levels', 'O'), ('were', 'O'), ('higher', 'O'), ('than', 'O'), ('either', 'O'), ('baseline', 'O'), ('levels', 'O'), ('or', 'O'), ('control', 'O'), ('levels', 'O'), ('.', 'O'))"
"Thus , lithium treatment counteracted the decrease in plasma calcium levels associated with aging .","(('Thus', 'O'), (',', 'O'), ('lithium', 'O'), ('treatment', 'O'), ('counteracted', 'O'), ('the', 'O'), ('decrease', 'O'), ('in', 'O'), ('plasma', 'O'), ('calcium', 'O'), ('levels', 'O'), ('associated', 'O'), ('with', 'O'), ('aging', 'O'), ('.', 'O'))"
Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .,"(('Severe', 'O'), ('immune', 'B'), ('hemolytic', 'I'), ('anemia', 'I'), ('associated', 'O'), ('with', 'O'), ('prophylactic', 'O'), ('use', 'O'), ('of', 'O'), ('cefotetan', 'O'), ('in', 'O'), ('obstetric', 'O'), ('and', 'O'), ('gynecologic', 'O'), ('procedures', 'O'), ('.', 'O'))"
"Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune hemolytic anemia .","(('Second', 'O'), ('-', 'O'), ('and', 'O'), ('third', 'O'), ('-', 'O'), ('generation', 'O'), ('cephalosporins', 'O'), (',', 'O'), ('especially', 'O'), ('cefotetan', 'O'), (',', 'O'), ('are', 'O'), ('increasingly', 'O'), ('associated', 'O'), ('with', 'O'), ('severe', 'O'), (',', 'O'), ('sometimes', 'O'), ('fatal', 'O'), ('immune', 'B'), ('hemolytic', 'I'), ('anemia', 'I'), ('.', 'O'))"
Eight of these cases of severe immune hemolytic anemia are described .,"(('Eight', 'O'), ('of', 'O'), ('these', 'O'), ('cases', 'O'), ('of', 'O'), ('severe', 'O'), ('immune', 'B'), ('hemolytic', 'I'), ('anemia', 'I'), ('are', 'O'), ('described', 'O'), ('.', 'O'))"
Platelet function is impaired by nonsteroidal anti - inflammatory drugs ( NSAIDs ) with prominent anti - inflammatory properties .,"(('Platelet', 'O'), ('function', 'O'), ('is', 'O'), ('impaired', 'O'), ('by', 'O'), ('nonsteroidal', 'O'), ('anti', 'O'), ('-', 'O'), ('inflammatory', 'O'), ('drugs', 'O'), ('(', 'O'), ('NSAIDs', 'O'), (')', 'O'), ('with', 'O'), ('prominent', 'O'), ('anti', 'O'), ('-', 'O'), ('inflammatory', 'O'), ('properties', 'O'), ('.', 'O'))"
Their safety in patients undergoing intracranial surgery is under debate .,"(('Their', 'O'), ('safety', 'O'), ('in', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('intracranial', 'O'), ('surgery', 'I'), ('is', 'O'), ('under', 'O'), ('debate', 'O'), ('.', 'O'))"
Treatment was continued for 3 days postoperatively .,"(('Treatment', 'O'), ('was', 'O'), ('continued', 'O'), ('for', 'O'), ('3', 'O'), ('days', 'O'), ('postoperatively', 'O'), ('.', 'O'))"
"Test blood samples were taken before treatment and surgery as well as on the first , third , and fifth postoperative mornings .","(('Test', 'O'), ('blood', 'O'), ('samples', 'O'), ('were', 'O'), ('taken', 'O'), ('before', 'O'), ('treatment', 'O'), ('and', 'O'), ('surgery', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('on', 'O'), ('the', 'O'), ('first', 'O'), (',', 'O'), ('third', 'O'), (',', 'O'), ('and', 'O'), ('fifth', 'O'), ('postoperative', 'O'), ('mornings', 'O'), ('.', 'O'))"
Aggregation was lower ( P < . 05 ) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day .,"(('Aggregation', 'O'), ('was', 'O'), ('lower', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('ketoprofen', 'O'), ('group', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('acetaminophen', 'O'), ('group', 'O'), ('just', 'O'), ('before', 'O'), ('surgery', 'O'), ('and', 'O'), ('on', 'O'), ('the', 'O'), ('third', 'O'), ('postoperative', 'O'), ('day', 'O'), ('.', 'O'))"
"Coagulation ( prothrombin time [ PT ] , activated partial thromboplastin time [ APPT ] , fibrinogen concentration , and antithrombin III [ AT III ] ) was comparable between the two groups .","(('Coagulation', 'O'), ('(', 'O'), ('prothrombin', 'O'), ('time', 'O'), ('[', 'O'), ('PT', 'O'), (']', 'O'), (',', 'O'), ('activated', 'O'), ('partial', 'O'), ('thromboplastin', 'O'), ('time', 'O'), ('[', 'O'), ('APPT', 'O'), (']', 'O'), (',', 'O'), ('fibrinogen', 'O'), ('concentration', 'O'), (',', 'O'), ('and', 'O'), ('antithrombin', 'O'), ('III', 'O'), ('[', 'O'), ('AT', 'O'), ('III', 'O'), (']', 'O'), (')', 'O'), ('was', 'O'), ('comparable', 'O'), ('between', 'O'), ('the', 'O'), ('two', 'O'), ('groups', 'O'), ('.', 'O'))"
"Male Sprague - Dawley rats were randomly assigned to a lead - treated group ( given lead acetate , 100 ppm , in drinking water and regular rat chow ) , a group given lead and vitamin E - fortified chow , or a normal control group given either regular food and water or vitamin E - fortified food for 12 weeks .","(('Male', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('were', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('a', 'O'), ('lead', 'O'), ('-', 'O'), ('treated', 'O'), ('group', 'O'), ('(', 'O'), ('given', 'O'), ('lead', 'O'), ('acetate', 'O'), (',', 'O'), ('100', 'O'), ('ppm', 'O'), (',', 'O'), ('in', 'O'), ('drinking', 'O'), ('water', 'O'), ('and', 'O'), ('regular', 'O'), ('rat', 'O'), ('chow', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('group', 'O'), ('given', 'O'), ('lead', 'O'), ('and', 'O'), ('vitamin', 'O'), ('E', 'O'), ('-', 'O'), ('fortified', 'O'), ('chow', 'O'), (',', 'O'), ('or', 'O'), ('a', 'O'), ('normal', 'O'), ('control', 'O'), ('group', 'O'), ('given', 'O'), ('either', 'O'), ('regular', 'O'), ('food', 'O'), ('and', 'O'), ('water', 'O'), ('or', 'O'), ('vitamin', 'O'), ('E', 'O'), ('-', 'O'), ('fortified', 'O'), ('food', 'O'), ('for', 'O'), ('12', 'O'), ('weeks', 'O'), ('.', 'O'))"
"Tail blood pressure , urinary NOx excretion , plasma malondialdehyde ( MDA ) , and endothelial and inducible NOS ( eNOS and iNOS ) isotypes in the aorta and kidney were measured .","(('Tail', 'O'), ('blood', 'O'), ('pressure', 'O'), (',', 'O'), ('urinary', 'O'), ('NOx', 'O'), ('excretion', 'O'), (',', 'O'), ('plasma', 'O'), ('malondialdehyde', 'O'), ('(', 'O'), ('MDA', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('endothelial', 'O'), ('and', 'O'), ('inducible', 'O'), ('NOS', 'O'), ('(', 'O'), ('eNOS', 'O'), ('and', 'O'), ('iNOS', 'O'), (')', 'O'), ('isotypes', 'O'), ('in', 'O'), ('the', 'O'), ('aorta', 'O'), ('and', 'O'), ('kidney', 'O'), ('were', 'O'), ('measured', 'O'), ('.', 'O'))"
"The lead - treated group exhibited a rise in blood pressure and plasma MDA concentration , a fall in urinary NOx excretion , and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression .","(('The', 'O'), ('lead', 'O'), ('-', 'O'), ('treated', 'O'), ('group', 'O'), ('exhibited', 'O'), ('a', 'O'), ('rise', 'O'), ('in', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('plasma', 'O'), ('MDA', 'O'), ('concentration', 'O'), (',', 'O'), ('a', 'O'), ('fall', 'O'), ('in', 'O'), ('urinary', 'O'), ('NOx', 'O'), ('excretion', 'O'), (',', 'O'), ('and', 'O'), ('a', 'O'), ('paradoxical', 'O'), ('rise', 'O'), ('in', 'O'), ('vascular', 'O'), ('and', 'O'), ('renal', 'O'), ('tissue', 'O'), ('eNOS', 'O'), ('and', 'O'), ('iNOS', 'O'), ('expression', 'O'), ('.', 'O'))"
"Vitamin E supplementation had no effect on either blood pressure , plasma MDA , or NOS expression in the control group .","(('Vitamin', 'O'), ('E', 'O'), ('supplementation', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('either', 'O'), ('blood', 'O'), ('pressure', 'O'), (',', 'O'), ('plasma', 'O'), ('MDA', 'O'), (',', 'O'), ('or', 'O'), ('NOS', 'O'), ('expression', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), ('.', 'O'))"
The study also revealed significant inhibition of NOS enzymatic activity by lead in cell - free preparations .,"(('The', 'O'), ('study', 'O'), ('also', 'O'), ('revealed', 'O'), ('significant', 'O'), ('inhibition', 'O'), ('of', 'O'), ('NOS', 'O'), ('enzymatic', 'O'), ('activity', 'O'), ('by', 'O'), ('lead', 'O'), ('in', 'O'), ('cell', 'O'), ('-', 'O'), ('free', 'O'), ('preparations', 'O'), ('.', 'O'))"
Fourteen healthy subjects served as controls .,"(('Fourteen', 'O'), ('healthy', 'O'), ('subjects', 'O'), ('served', 'O'), ('as', 'O'), ('controls', 'O'), ('.', 'O'))"
Aura symptoms were not elicited in any subject .,"(('Aura', 'O'), ('symptoms', 'O'), ('were', 'O'), ('not', 'O'), ('elicited', 'O'), ('in', 'O'), ('any', 'O'), ('subject', 'O'), ('.', 'O'))"
Little information is available to predict which patients are at highest risk for this complication .,"(('Little', 'O'), ('information', 'O'), ('is', 'O'), ('available', 'O'), ('to', 'O'), ('predict', 'O'), ('which', 'O'), ('patients', 'O'), ('are', 'O'), ('at', 'O'), ('highest', 'O'), ('risk', 'O'), ('for', 'O'), ('this', 'O'), ('complication', 'O'), ('.', 'O'))"
There were 3379 patients randomly assigned to enalapril with a median follow - up of 974 days and 3379 patients randomly assigned to placebo with a mean follow - up of 967 days .,"(('There', 'O'), ('were', 'O'), ('3379', 'O'), ('patients', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('enalapril', 'O'), ('with', 'O'), ('a', 'O'), ('median', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('of', 'O'), ('974', 'O'), ('days', 'O'), ('and', 'O'), ('3379', 'O'), ('patients', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('placebo', 'O'), ('with', 'O'), ('a', 'O'), ('mean', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('of', 'O'), ('967', 'O'), ('days', 'O'), ('.', 'O'))"
RESULTS : Patients randomly assigned to enalapril had a 33 % greater likelihood of decreased renal function than controls ( P = . 003 ) .,"(('RESULTS', 'O'), (':', 'O'), ('Patients', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('enalapril', 'O'), ('had', 'O'), ('a', 'O'), ('33', 'O'), ('%', 'O'), ('greater', 'O'), ('likelihood', 'O'), ('of', 'O'), ('decreased', 'O'), ('renal', 'O'), ('function', 'O'), ('than', 'O'), ('controls', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('003', 'O'), (')', 'O'), ('.', 'O'))"
"By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and diabetes were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .","(('By', 'O'), ('multivariate', 'O'), ('analysis', 'O'), (',', 'O'), ('in', 'O'), ('both', 'O'), ('the', 'O'), ('placebo', 'O'), ('and', 'O'), ('enalapril', 'O'), ('groups', 'O'), ('older', 'O'), ('age', 'O'), (',', 'O'), ('diuretic', 'O'), ('therapy', 'O'), (',', 'O'), ('and', 'O'), ('diabetes', 'B'), ('were', 'O'), ('associated', 'O'), ('with', 'O'), ('decreased', 'O'), ('renal', 'O'), ('function', 'O'), (',', 'O'), ('whereas', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('therapy', 'O'), ('and', 'O'), ('higher', 'O'), ('ejection', 'O'), ('fraction', 'O'), ('were', 'O'), ('renoprotective', 'O'), ('.', 'O'))"
"Older age was associated with a greater risk of developing decreased renal function in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .","(('Older', 'O'), ('age', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('greater', 'O'), ('risk', 'O'), ('of', 'O'), ('developing', 'O'), ('decreased', 'O'), ('renal', 'O'), ('function', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), (',', 'O'), ('but', 'O'), ('significantly', 'O'), ('more', 'O'), ('so', 'O'), ('in', 'O'), ('the', 'O'), ('enalapril', 'O'), ('group', 'O'), ('(', 'O'), ('enalapril', 'O'), (':', 'O'), ('risk', 'O'), ('ratio', 'O'), ('[', 'O'), ('RR', 'O'), (']', 'O'), ('1', 'O'), ('.', 'O'), ('42', 'O'), ('per', 'O'), ('10', 'O'), ('years', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), ('[', 'O'), ('CI', 'O'), (']', 'O'), ('1', 'O'), ('.', 'O'), ('32', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('52', 'O'), ('with', 'O'), ('enalapril', 'O'), (';', 'O'), ('placebo', 'O'), (':', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('18', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('12', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('25', 'O'), (')', 'O'), ('.', 'O'))"
"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .","(('Diuretic', 'O'), ('therapy', 'O'), ('was', 'O'), ('likewise', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('greater', 'O'), ('risk', 'O'), ('of', 'O'), ('decreased', 'O'), ('renal', 'O'), ('function', 'O'), ('in', 'O'), ('the', 'O'), ('enalapril', 'O'), ('group', 'O'), ('(', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('89', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('70', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('08', 'O'), (')', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('(', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('35', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('09', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('66', 'O'), (')', 'O'), ('.', 'O'))"
"Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with diabetes .","(('Conversely', 'O'), (',', 'O'), ('enalapril', 'O'), ('had', 'O'), ('a', 'O'), ('relative', 'O'), ('renoprotective', 'O'), ('effect', 'O'), ('(', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('33', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('13', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('53', 'O'), (')', 'O'), ('compared', 'O'), ('with', 'O'), ('placebo', 'O'), ('(', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('96', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('57', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('44', 'O'), (')', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('diabetes', 'B'), ('.', 'O'))"
"A lower risk of renal impairment was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 . 96 ) .","(('A', 'O'), ('lower', 'O'), ('risk', 'O'), ('of', 'O'), ('renal', 'B'), ('impairment', 'I'), ('was', 'O'), ('seen', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('with', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('therapy', 'O'), ('(', 'O'), ('RR', 'O'), ('0', 'O'), ('.', 'O'), ('70', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('0', 'O'), ('.', 'O'), ('57', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('85', 'O'), (')', 'O'), ('and', 'O'), ('higher', 'O'), ('baseline', 'O'), ('ejection', 'O'), ('fraction', 'O'), ('(', 'O'), ('RR', 'O'), ('0', 'O'), ('.', 'O'), ('93', 'O'), ('per', 'O'), ('5', 'O'), ('%', 'O'), ('increment', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('0', 'O'), ('.', 'O'), ('91', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('96', 'O'), (')', 'O'), ('.', 'O'))"
Diuretic use and advanced age increased this risk .,"(('Diuretic', 'O'), ('use', 'O'), ('and', 'O'), ('advanced', 'O'), ('age', 'O'), ('increased', 'O'), ('this', 'O'), ('risk', 'O'), ('.', 'O'))"
beta - Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy .,"(('beta', 'O'), ('-', 'O'), ('Blocker', 'O'), ('therapy', 'O'), ('and', 'O'), ('higher', 'O'), ('ejection', 'O'), ('fraction', 'O'), ('were', 'O'), ('renoprotective', 'O'), ('in', 'O'), ('all', 'O'), ('patients', 'O'), ('regardless', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O'))"
Vasopressin in the treatment of milrinone - induced hypotension in severe heart failure .,"(('Vasopressin', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('milrinone', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('in', 'O'), ('severe', 'O'), ('heart', 'B'), ('failure', 'I'), ('.', 'O'))"
The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension .,"(('The', 'O'), ('use', 'O'), ('of', 'O'), ('phosphodiesterase', 'O'), ('inhibitors', 'O'), ('such', 'O'), ('as', 'O'), ('milrinone', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('severe', 'O'), ('heart', 'B'), ('failure', 'I'), ('is', 'O'), ('frequently', 'O'), ('restricted', 'O'), ('because', 'O'), ('they', 'O'), ('cause', 'O'), ('vasodilation', 'B'), ('and', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"In patients with decompensated heart failure with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .","(('In', 'O'), ('patients', 'O'), ('with', 'O'), ('decompensated', 'B'), ('heart', 'I'), ('failure', 'I'), ('with', 'O'), ('hypotension', 'B'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('milrinone', 'O'), (',', 'O'), ('low', 'O'), ('doses', 'O'), ('of', 'O'), ('vasopressin', 'O'), ('restored', 'O'), ('blood', 'O'), ('pressure', 'O'), ('without', 'O'), ('inhibiting', 'O'), ('the', 'O'), ('inotropic', 'O'), ('effect', 'O'), ('of', 'O'), ('milrinone', 'O'), ('.', 'O'))"
Treatment of tacrolimus - related adverse effects by conversion to cyclosporine in liver transplant recipients .,"(('Treatment', 'O'), ('of', 'O'), ('tacrolimus', 'O'), ('-', 'O'), ('related', 'O'), ('adverse', 'O'), ('effects', 'O'), ('by', 'O'), ('conversion', 'O'), ('to', 'O'), ('cyclosporine', 'O'), ('in', 'O'), ('liver', 'O'), ('transplant', 'O'), ('recipients', 'O'), ('.', 'O'))"
"When tacrolimus side effects persist despite dose reduction , conversion to cyclosporine - based immunosuppression ( CyA ) is necessary .","(('When', 'O'), ('tacrolimus', 'O'), ('side', 'O'), ('effects', 'O'), ('persist', 'O'), ('despite', 'O'), ('dose', 'O'), ('reduction', 'O'), (',', 'O'), ('conversion', 'O'), ('to', 'O'), ('cyclosporine', 'O'), ('-', 'O'), ('based', 'O'), ('immunosuppression', 'O'), ('(', 'O'), ('CyA', 'O'), (')', 'O'), ('is', 'O'), ('necessary', 'O'), ('.', 'O'))"
"We characterized tacrolimus side effects that warranted discontinuation of the drug , and outcomes after conversion .","(('We', 'O'), ('characterized', 'O'), ('tacrolimus', 'O'), ('side', 'O'), ('effects', 'O'), ('that', 'O'), ('warranted', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('the', 'O'), ('drug', 'O'), (',', 'O'), ('and', 'O'), ('outcomes', 'O'), ('after', 'O'), ('conversion', 'O'), ('.', 'O'))"
"Of 388 liver recipients who received tacrolimus as primary immunosuppression , 70 required conversion to CyA .","(('Of', 'O'), ('388', 'O'), ('liver', 'O'), ('recipients', 'O'), ('who', 'O'), ('received', 'O'), ('tacrolimus', 'O'), ('as', 'O'), ('primary', 'O'), ('immunosuppression', 'O'), (',', 'O'), ('70', 'O'), ('required', 'O'), ('conversion', 'O'), ('to', 'O'), ('CyA', 'O'), ('.', 'O'))"
"We recorded indication for conversion , whether conversion was early or late after transplantation , tacrolimus dose and trough blood level at conversion , and incidence of rejection after conversion .","(('We', 'O'), ('recorded', 'O'), ('indication', 'O'), ('for', 'O'), ('conversion', 'O'), (',', 'O'), ('whether', 'O'), ('conversion', 'O'), ('was', 'O'), ('early', 'O'), ('or', 'O'), ('late', 'O'), ('after', 'O'), ('transplantation', 'O'), (',', 'O'), ('tacrolimus', 'O'), ('dose', 'O'), ('and', 'O'), ('trough', 'O'), ('blood', 'O'), ('level', 'O'), ('at', 'O'), ('conversion', 'O'), (',', 'O'), ('and', 'O'), ('incidence', 'O'), ('of', 'O'), ('rejection', 'O'), ('after', 'O'), ('conversion', 'O'), ('.', 'O'))"
Conversion was early in 29 patients ( 41 . 4 % ) and late in 41 ( 58 . 6 % ) .,"(('Conversion', 'O'), ('was', 'O'), ('early', 'O'), ('in', 'O'), ('29', 'O'), ('patients', 'O'), ('(', 'O'), ('41', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('late', 'O'), ('in', 'O'), ('41', 'O'), ('(', 'O'), ('58', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
All early - conversion patients showed improvement / resolution of symptoms .,"(('All', 'O'), ('early', 'O'), ('-', 'O'), ('conversion', 'O'), ('patients', 'O'), ('showed', 'O'), ('improvement', 'O'), ('/', 'O'), ('resolution', 'O'), ('of', 'O'), ('symptoms', 'O'), ('.', 'O'))"
"Among late - conversion patients , 37 ( 90 . 2 % ) had improvement / resolution ; in 4 ( 9 . 8 % ) , adverse effects persisted .","(('Among', 'O'), ('late', 'O'), ('-', 'O'), ('conversion', 'O'), ('patients', 'O'), (',', 'O'), ('37', 'O'), ('(', 'O'), ('90', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('improvement', 'O'), ('/', 'O'), ('resolution', 'O'), (';', 'O'), ('in', 'O'), ('4', 'O'), ('(', 'O'), ('9', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('adverse', 'O'), ('effects', 'O'), ('persisted', 'O'), ('.', 'O'))"
The overall rejection rate was 30 % .,"(('The', 'O'), ('overall', 'O'), ('rejection', 'O'), ('rate', 'O'), ('was', 'O'), ('30', 'O'), ('%', 'O'), ('.', 'O'))"
"Sixty - two patients ( 88 . 6 % ) are alive with functioning grafts 686 + / - 362 days ( range , 154 - 1433 days ) after conversion .","(('Sixty', 'O'), ('-', 'O'), ('two', 'O'), ('patients', 'O'), ('(', 'O'), ('88', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('alive', 'O'), ('with', 'O'), ('functioning', 'O'), ('grafts', 'O'), ('686', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('362', 'O'), ('days', 'O'), ('(', 'O'), ('range', 'O'), (',', 'O'), ('154', 'O'), ('-', 'O'), ('1433', 'O'), ('days', 'O'), (')', 'O'), ('after', 'O'), ('conversion', 'O'), ('.', 'O'))"
"When tacrolimus side effects are unresponsive to dose reduction , conversion to CyA can be accomplished safely , with no increased risk of rejection and excellent long - term outcome .","(('When', 'O'), ('tacrolimus', 'O'), ('side', 'O'), ('effects', 'O'), ('are', 'O'), ('unresponsive', 'O'), ('to', 'O'), ('dose', 'O'), ('reduction', 'O'), (',', 'O'), ('conversion', 'O'), ('to', 'O'), ('CyA', 'O'), ('can', 'O'), ('be', 'O'), ('accomplished', 'O'), ('safely', 'O'), (',', 'O'), ('with', 'O'), ('no', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('rejection', 'O'), ('and', 'O'), ('excellent', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('outcome', 'O'), ('.', 'O'))"
Ocular manifestations of juvenile rheumatoid arthritis .,"(('Ocular', 'O'), ('manifestations', 'O'), ('of', 'O'), ('juvenile', 'B'), ('rheumatoid', 'I'), ('arthritis', 'I'), ('.', 'O'))"
We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years .,"(('We', 'O'), ('followed', 'O'), ('210', 'O'), ('cases', 'O'), ('of', 'O'), ('juvenile', 'B'), ('rheumatoid', 'I'), ('arthritis', 'I'), ('closely', 'O'), ('for', 'O'), ('eleven', 'O'), ('years', 'O'), ('.', 'O'))"
"However , 30 % of the patients developed uveitis after 16 years of age .","(('However', 'O'), (',', 'O'), ('30', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('developed', 'O'), ('uveitis', 'B'), ('after', 'O'), ('16', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('.', 'O'))"
"Although 61 % of patients had a noncontributory ocular history on entry , 42 % had active uveitis on entry .","(('Although', 'O'), ('61', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('noncontributory', 'O'), ('ocular', 'O'), ('history', 'O'), ('on', 'O'), ('entry', 'O'), (',', 'O'), ('42', 'O'), ('%', 'O'), ('had', 'O'), ('active', 'O'), ('uveitis', 'B'), ('on', 'O'), ('entry', 'O'), ('.', 'O'))"
Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases .,"(('Our', 'O'), ('approach', 'O'), ('was', 'O'), ('effective', 'O'), ('in', 'O'), ('detecting', 'O'), ('uveitis', 'B'), ('in', 'O'), ('new', 'O'), ('cases', 'O'), ('and', 'O'), ('exacerbations', 'O'), ('of', 'O'), ('uveitis', 'B'), ('in', 'O'), ('established', 'O'), ('cases', 'O'), ('.', 'O'))"
"Even after early detection and prompt treatment , 41 % of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics .","(('Even', 'O'), ('after', 'O'), ('early', 'O'), ('detection', 'O'), ('and', 'O'), ('prompt', 'O'), ('treatment', 'O'), (',', 'O'), ('41', 'O'), ('%', 'O'), ('of', 'O'), ('cases', 'O'), ('of', 'O'), ('uveitis', 'B'), ('did', 'O'), ('not', 'O'), ('respond', 'O'), ('to', 'O'), ('more', 'O'), ('than', 'O'), ('six', 'O'), ('months', 'O'), ('of', 'O'), ('intensive', 'O'), ('topical', 'O'), ('treatment', 'O'), ('with', 'O'), ('corticosteroids', 'O'), ('and', 'O'), ('mydriatics', 'O'), ('.', 'O'))"
"Despite this , there was a dramatic decrease in the 50 % incidence of blinding complications of uveitis cited in earlier studies .","(('Despite', 'O'), ('this', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('dramatic', 'O'), ('decrease', 'O'), ('in', 'O'), ('the', 'O'), ('50', 'O'), ('%', 'O'), ('incidence', 'O'), ('of', 'O'), ('blinding', 'O'), ('complications', 'O'), ('of', 'O'), ('uveitis', 'B'), ('cited', 'O'), ('in', 'O'), ('earlier', 'O'), ('studies', 'O'), ('.', 'O'))"
Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular cataracts was found .,"(('Systemically', 'O'), ('administered', 'O'), ('corticosteroids', 'O'), ('were', 'O'), ('used', 'O'), ('in', 'O'), ('75', 'O'), ('of', 'O'), ('210', 'O'), ('cases', 'O'), (';', 'O'), ('a', 'O'), ('significant', 'O'), ('number', 'O'), ('of', 'O'), ('posterior', 'B'), ('subcapsular', 'I'), ('cataracts', 'I'), ('was', 'O'), ('found', 'O'), ('.', 'O'))"
This association with uveitis and JRA was not noted previously .,"(('This', 'O'), ('association', 'O'), ('with', 'O'), ('uveitis', 'B'), ('and', 'O'), ('JRA', 'B'), ('was', 'O'), ('not', 'O'), ('noted', 'O'), ('previously', 'O'), ('.', 'O'))"
"MATERIALS AND METHODS : CP was administered at doses of 50 , 100 and 200 mg . / kg .","(('MATERIALS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('CP', 'O'), ('was', 'O'), ('administered', 'O'), ('at', 'O'), ('doses', 'O'), ('of', 'O'), ('50', 'O'), (',', 'O'), ('100', 'O'), ('and', 'O'), ('200', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'))"
"i . p . to male rats , and their behavior observed and scored .","(('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('to', 'O'), ('male', 'O'), ('rats', 'O'), (',', 'O'), ('and', 'O'), ('their', 'O'), ('behavior', 'O'), ('observed', 'O'), ('and', 'O'), ('scored', 'O'), ('.', 'O'))"
The effects of morphine ( 0 . 5 to 4 mg . / kg . i . v . ) on CP - induced behavioral modifications were tested administered alone and after naloxone ( 1 mg . / kg . s . c . ) .,"(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('morphine', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('to', 'O'), ('4', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('on', 'O'), ('CP', 'O'), ('-', 'O'), ('induced', 'O'), ('behavioral', 'O'), ('modifications', 'O'), ('were', 'O'), ('tested', 'O'), ('administered', 'O'), ('alone', 'O'), ('and', 'O'), ('after', 'O'), ('naloxone', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
"In addition , 90 minutes after CP injection , that is , at the time of administration of morphine , the bladder was removed in some rats for histological examination .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('90', 'O'), ('minutes', 'O'), ('after', 'O'), ('CP', 'O'), ('injection', 'O'), (',', 'O'), ('that', 'O'), ('is', 'O'), (',', 'O'), ('at', 'O'), ('the', 'O'), ('time', 'O'), ('of', 'O'), ('administration', 'O'), ('of', 'O'), ('morphine', 'O'), (',', 'O'), ('the', 'O'), ('bladder', 'O'), ('was', 'O'), ('removed', 'O'), ('in', 'O'), ('some', 'O'), ('rats', 'O'), ('for', 'O'), ('histological', 'O'), ('examination', 'O'), ('.', 'O'))"
"Finally , to show that the bladder is essential for the CP - induced behavioral modifications , female rats also received CP at doses of 200 mg . / kg .","(('Finally', 'O'), (',', 'O'), ('to', 'O'), ('show', 'O'), ('that', 'O'), ('the', 'O'), ('bladder', 'O'), ('is', 'O'), ('essential', 'O'), ('for', 'O'), ('the', 'O'), ('CP', 'O'), ('-', 'O'), ('induced', 'O'), ('behavioral', 'O'), ('modifications', 'O'), (',', 'O'), ('female', 'O'), ('rats', 'O'), ('also', 'O'), ('received', 'O'), ('CP', 'O'), ('at', 'O'), ('doses', 'O'), ('of', 'O'), ('200', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'))"
"i . p . and of 20 mg . by the intravesical route , and acrolein at doses of 0 . 5 mg . by the intravesical route and of 5 mg . / kg .","(('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('and', 'O'), ('of', 'O'), ('20', 'O'), ('mg', 'O'), ('.', 'O'), ('by', 'O'), ('the', 'O'), ('intravesical', 'O'), ('route', 'O'), (',', 'O'), ('and', 'O'), ('acrolein', 'O'), ('at', 'O'), ('doses', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('.', 'O'), ('by', 'O'), ('the', 'O'), ('intravesical', 'O'), ('route', 'O'), ('and', 'O'), ('of', 'O'), ('5', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'))"
"i . v . RESULTS : CP dose - relatedly induced marked behavioral modifications in male rats : breathing rate decrease , closing of the eyes and occurrence of specific postures .","(('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('RESULTS', 'O'), (':', 'O'), ('CP', 'O'), ('dose', 'O'), ('-', 'O'), ('relatedly', 'O'), ('induced', 'O'), ('marked', 'O'), ('behavioral', 'O'), ('modifications', 'O'), ('in', 'O'), ('male', 'O'), ('rats', 'O'), (':', 'O'), ('breathing', 'O'), ('rate', 'O'), ('decrease', 'O'), (',', 'O'), ('closing', 'O'), ('of', 'O'), ('the', 'O'), ('eyes', 'O'), ('and', 'O'), ('occurrence', 'O'), ('of', 'O'), ('specific', 'O'), ('postures', 'O'), ('.', 'O'))"
A dose of 0 . 5 mg . / kg . produced a reduction of almost 50 % of the behavioral score induced by CP 200 mg . / kg .,"(('A', 'O'), ('dose', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'), ('produced', 'O'), ('a', 'O'), ('reduction', 'O'), ('of', 'O'), ('almost', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('behavioral', 'O'), ('score', 'O'), ('induced', 'O'), ('by', 'O'), ('CP', 'O'), ('200', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'))"
This effect was completely prevented by pretreatment with naloxone .,"(('This', 'O'), ('effect', 'O'), ('was', 'O'), ('completely', 'O'), ('prevented', 'O'), ('by', 'O'), ('pretreatment', 'O'), ('with', 'O'), ('naloxone', 'O'), ('.', 'O'))"
"At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer edema , were observed .","(('At', 'O'), ('the', 'O'), ('time', 'O'), ('of', 'O'), ('administration', 'O'), ('of', 'O'), ('morphine', 'O'), (',', 'O'), ('histological', 'O'), ('modifications', 'O'), ('of', 'O'), ('the', 'O'), ('bladder', 'O'), ('wall', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('chorionic', 'O'), ('and', 'O'), ('muscle', 'O'), ('layer', 'O'), ('edema', 'B'), (',', 'O'), ('were', 'O'), ('observed', 'O'), ('.', 'O'))"
"In female rats , CP 200 mg . / kg .","(('In', 'O'), ('female', 'O'), ('rats', 'O'), (',', 'O'), ('CP', 'O'), ('200', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'))"
i . p . produced the same marked behavioral modifications as those observed in male rats .,"(('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('produced', 'O'), ('the', 'O'), ('same', 'O'), ('marked', 'O'), ('behavioral', 'O'), ('modifications', 'O'), ('as', 'O'), ('those', 'O'), ('observed', 'O'), ('in', 'O'), ('male', 'O'), ('rats', 'O'), ('.', 'O'))"
"Administered at the dose of 20 mg . intravesically , CP did not produce any behavioral effects , whereas acrolein at 0 . 5 mg . intravesically induced behavioral modifications identical to those under CP 200 mg . / kg .","(('Administered', 'O'), ('at', 'O'), ('the', 'O'), ('dose', 'O'), ('of', 'O'), ('20', 'O'), ('mg', 'O'), ('.', 'O'), ('intravesically', 'O'), (',', 'O'), ('CP', 'O'), ('did', 'O'), ('not', 'O'), ('produce', 'O'), ('any', 'O'), ('behavioral', 'O'), ('effects', 'O'), (',', 'O'), ('whereas', 'O'), ('acrolein', 'O'), ('at', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('.', 'O'), ('intravesically', 'O'), ('induced', 'O'), ('behavioral', 'O'), ('modifications', 'O'), ('identical', 'O'), ('to', 'O'), ('those', 'O'), ('under', 'O'), ('CP', 'O'), ('200', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'))"
"i . p . , with the same maximal levels .","(('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (',', 'O'), ('with', 'O'), ('the', 'O'), ('same', 'O'), ('maximal', 'O'), ('levels', 'O'), ('.', 'O'))"
"Conversely , acrolein 5 mg . / kg .","(('Conversely', 'O'), (',', 'O'), ('acrolein', 'O'), ('5', 'O'), ('mg', 'O'), ('.', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'))"
i . v . did not produce any behavioral effects at all .,"(('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('did', 'O'), ('not', 'O'), ('produce', 'O'), ('any', 'O'), ('behavioral', 'O'), ('effects', 'O'), ('at', 'O'), ('all', 'O'), ('.', 'O'))"
Prednisolone - induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression .,"(('Prednisolone', 'O'), ('-', 'O'), ('induced', 'O'), ('muscle', 'B'), ('dysfunction', 'I'), ('is', 'O'), ('caused', 'O'), ('more', 'O'), ('by', 'O'), ('atrophy', 'B'), ('than', 'O'), ('by', 'O'), ('altered', 'O'), ('acetylcholine', 'O'), ('receptor', 'O'), ('expression', 'O'), ('.', 'O'))"
Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood .,"(('Large', 'O'), ('doses', 'O'), ('of', 'O'), ('glucocorticoids', 'O'), ('can', 'O'), ('alter', 'O'), ('muscle', 'O'), ('physiology', 'O'), ('and', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('neuromuscular', 'O'), ('blocking', 'O'), ('drugs', 'O'), ('by', 'O'), ('mechanisms', 'O'), ('not', 'O'), ('clearly', 'O'), ('understood', 'O'), ('.', 'O'))"
"We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology , and their relationship to changes in muscle size and acetylcholine receptor ( AChR ) expression .","(('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('moderate', 'O'), ('and', 'O'), ('large', 'O'), ('doses', 'O'), ('of', 'O'), ('prednisolone', 'O'), ('on', 'O'), ('muscle', 'O'), ('function', 'O'), ('and', 'O'), ('pharmacology', 'O'), (',', 'O'), ('and', 'O'), ('their', 'O'), ('relationship', 'O'), ('to', 'O'), ('changes', 'O'), ('in', 'O'), ('muscle', 'O'), ('size', 'O'), ('and', 'O'), ('acetylcholine', 'O'), ('receptor', 'O'), ('(', 'O'), ('AChR', 'O'), (')', 'O'), ('expression', 'O'), ('.', 'O'))"
"With institutional approval , 35 Sprague - Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg / kg prednisolone ( P10 group ) , 100 mg / kg prednisolone ( P100 group ) , or an equal volume of saline ( S group ) for 7 days .","(('With', 'O'), ('institutional', 'O'), ('approval', 'O'), (',', 'O'), ('35', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('were', 'O'), ('randomly', 'O'), ('allocated', 'O'), ('to', 'O'), ('receive', 'O'), ('daily', 'O'), ('subcutaneous', 'O'), ('doses', 'O'), ('of', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('prednisolone', 'O'), ('(', 'O'), ('P10', 'O'), ('group', 'O'), (')', 'O'), (',', 'O'), ('100', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('prednisolone', 'O'), ('(', 'O'), ('P100', 'O'), ('group', 'O'), (')', 'O'), (',', 'O'), ('or', 'O'), ('an', 'O'), ('equal', 'O'), ('volume', 'O'), ('of', 'O'), ('saline', 'O'), ('(', 'O'), ('S', 'O'), ('group', 'O'), (')', 'O'), ('for', 'O'), ('7', 'O'), ('days', 'O'), ('.', 'O'))"
A fourth group of rats was pair fed ( food restricted ) with the P100 rats for 7 days ( FR group ) .,"(('A', 'O'), ('fourth', 'O'), ('group', 'O'), ('of', 'O'), ('rats', 'O'), ('was', 'O'), ('pair', 'O'), ('fed', 'O'), ('(', 'O'), ('food', 'O'), ('restricted', 'O'), (')', 'O'), ('with', 'O'), ('the', 'O'), ('P100', 'O'), ('rats', 'O'), ('for', 'O'), ('7', 'O'), ('days', 'O'), ('(', 'O'), ('FR', 'O'), ('group', 'O'), (')', 'O'), ('.', 'O'))"
"Rate of body weight gain was depressed in the P100 , FR , and P10 groups compared with the S group .","(('Rate', 'O'), ('of', 'O'), ('body', 'O'), ('weight', 'O'), ('gain', 'O'), ('was', 'O'), ('depressed', 'O'), ('in', 'O'), ('the', 'O'), ('P100', 'O'), (',', 'O'), ('FR', 'O'), (',', 'O'), ('and', 'O'), ('P10', 'O'), ('groups', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('S', 'O'), ('group', 'O'), ('.', 'O'))"
Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups .,"(('Tibialis', 'O'), ('muscle', 'O'), ('mass', 'O'), ('was', 'O'), ('smaller', 'O'), ('in', 'O'), ('the', 'O'), ('P100', 'O'), ('group', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('P10', 'O'), ('or', 'O'), ('S', 'O'), ('groups', 'O'), ('.', 'O'))"
The 50 % effective dose of d - tubocurarine ( microg / kg ) in the tibialis muscle was smaller in the P10 ( 33 . 6 + / - 5 . 4 ) than in the S ( 61 . 9 + / - 5 . 0 ) or the P100 ( 71 . 3 + / - 9 . 6 ) groups .,"(('The', 'O'), ('50', 'O'), ('%', 'O'), ('effective', 'O'), ('dose', 'O'), ('of', 'O'), ('d', 'O'), ('-', 'O'), ('tubocurarine', 'O'), ('(', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('tibialis', 'O'), ('muscle', 'O'), ('was', 'O'), ('smaller', 'O'), ('in', 'O'), ('the', 'O'), ('P10', 'O'), ('(', 'O'), ('33', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('5', 'O'), ('.', 'O'), ('4', 'O'), (')', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('S', 'O'), ('(', 'O'), ('61', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('5', 'O'), ('.', 'O'), ('0', 'O'), (')', 'O'), ('or', 'O'), ('the', 'O'), ('P100', 'O'), ('(', 'O'), ('71', 'O'), ('.', 'O'), ('3', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('9', 'O'), ('.', 'O'), ('6', 'O'), (')', 'O'), ('groups', 'O'), ('.', 'O'))"
AChR expression was less in the P10 group than in the S group .,"(('AChR', 'O'), ('expression', 'O'), ('was', 'O'), ('less', 'O'), ('in', 'O'), ('the', 'O'), ('P10', 'O'), ('group', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('S', 'O'), ('group', 'O'), ('.', 'O'))"
"The evoked tensions correlated with muscle mass ( r ( 2 ) = 0 . 32 , P < 0 . 001 ) , however , not with expression of AChR .","(('The', 'O'), ('evoked', 'O'), ('tensions', 'O'), ('correlated', 'O'), ('with', 'O'), ('muscle', 'O'), ('mass', 'O'), ('(', 'O'), ('r', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('32', 'O'), (',', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('not', 'O'), ('with', 'O'), ('expression', 'O'), ('of', 'O'), ('AChR', 'O'), ('.', 'O'))"
The 50 % effective dose of d - tubocurarine did not correlate with muscle mass or AChR expression .,"(('The', 'O'), ('50', 'O'), ('%', 'O'), ('effective', 'O'), ('dose', 'O'), ('of', 'O'), ('d', 'O'), ('-', 'O'), ('tubocurarine', 'O'), ('did', 'O'), ('not', 'O'), ('correlate', 'O'), ('with', 'O'), ('muscle', 'O'), ('mass', 'O'), ('or', 'O'), ('AChR', 'O'), ('expression', 'O'), ('.', 'O'))"
"Our results suggest that the neuromuscular dysfunction after prednisolone is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .","(('Our', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('neuromuscular', 'B'), ('dysfunction', 'I'), ('after', 'O'), ('prednisolone', 'O'), ('is', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), (',', 'O'), ('and', 'O'), ('derives', 'O'), ('primarily', 'O'), ('from', 'O'), ('muscle', 'B'), ('atrophy', 'I'), ('and', 'O'), ('derives', 'O'), ('less', 'O'), ('so', 'O'), ('from', 'O'), ('changes', 'O'), ('in', 'O'), ('AChR', 'O'), ('expression', 'O'), ('.', 'O'))"
IMPLICATIONS : The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear .,"(('IMPLICATIONS', 'O'), (':', 'O'), ('The', 'O'), ('mechanisms', 'O'), ('by', 'O'), ('which', 'O'), ('chronic', 'O'), ('glucocorticoid', 'O'), ('therapy', 'O'), ('alters', 'O'), ('neuromuscular', 'O'), ('physiology', 'O'), ('and', 'O'), ('pharmacology', 'O'), ('are', 'O'), ('unclear', 'O'), ('.', 'O'))"
We suggest that the observed effects are dose - dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression .,"(('We', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('observed', 'O'), ('effects', 'O'), ('are', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('and', 'O'), ('derive', 'O'), ('primarily', 'O'), ('from', 'O'), ('muscle', 'B'), ('atrophy', 'I'), ('and', 'O'), ('derive', 'O'), ('less', 'O'), ('from', 'O'), ('changes', 'O'), ('in', 'O'), ('acetylcholine', 'O'), ('receptor', 'O'), ('expression', 'O'), ('.', 'O'))"
A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off - periods even in patients with complex on - off motor swings .,"(('A', 'O'), ('number', 'O'), ('of', 'O'), ('small', 'O'), ('scale', 'O'), ('clinical', 'O'), ('trials', 'O'), ('have', 'O'), ('unequivocally', 'O'), ('shown', 'O'), ('that', 'O'), ('intermittent', 'O'), ('subcutaneous', 'O'), ('apomorphine', 'O'), ('injections', 'O'), ('produce', 'O'), ('antiparkinsonian', 'O'), ('benefit', 'O'), ('close', 'O'), ('if', 'O'), ('not', 'O'), ('identical', 'O'), ('to', 'O'), ('that', 'O'), ('seen', 'O'), ('with', 'O'), ('levodopa', 'O'), ('and', 'O'), ('that', 'O'), ('apomorphine', 'O'), ('rescue', 'O'), ('injections', 'O'), ('can', 'O'), ('reliably', 'O'), ('revert', 'O'), ('off', 'O'), ('-', 'O'), ('periods', 'O'), ('even', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('complex', 'O'), ('on', 'O'), ('-', 'O'), ('off', 'O'), ('motor', 'O'), ('swings', 'O'), ('.', 'O'))"
"Continuous subcutaneous apomorphine infusions can reduce daily off - time by more than 50 % in this group of patients , which appears to be a stronger effect than that generally seen with add - on therapy with oral dopamine agonists or COMT inhibitors .","(('Continuous', 'O'), ('subcutaneous', 'O'), ('apomorphine', 'O'), ('infusions', 'O'), ('can', 'O'), ('reduce', 'O'), ('daily', 'O'), ('off', 'O'), ('-', 'O'), ('time', 'O'), ('by', 'O'), ('more', 'O'), ('than', 'O'), ('50', 'O'), ('%', 'O'), ('in', 'O'), ('this', 'O'), ('group', 'O'), ('of', 'O'), ('patients', 'O'), (',', 'O'), ('which', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('stronger', 'O'), ('effect', 'O'), ('than', 'O'), ('that', 'O'), ('generally', 'O'), ('seen', 'O'), ('with', 'O'), ('add', 'O'), ('-', 'O'), ('on', 'O'), ('therapy', 'O'), ('with', 'O'), ('oral', 'O'), ('dopamine', 'O'), ('agonists', 'O'), ('or', 'O'), ('COMT', 'O'), ('inhibitors', 'O'), ('.', 'O'))"
Extended follow - up studies of up to 8 years have demonstrated long - term persistence of apomorphine efficacy .,"(('Extended', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('studies', 'O'), ('of', 'O'), ('up', 'O'), ('to', 'O'), ('8', 'O'), ('years', 'O'), ('have', 'O'), ('demonstrated', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('persistence', 'O'), ('of', 'O'), ('apomorphine', 'O'), ('efficacy', 'O'), ('.', 'O'))"
"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and psychiatric complications play a lesser role .","(('The', 'O'), ('main', 'O'), ('side', 'O'), ('effects', 'O'), ('of', 'O'), ('subcutaneous', 'O'), ('apomorphine', 'O'), ('treatment', 'O'), ('are', 'O'), ('related', 'O'), ('to', 'O'), ('cutaneous', 'O'), ('tolerability', 'O'), ('problems', 'O'), (',', 'O'), ('whereas', 'O'), ('sedation', 'O'), ('and', 'O'), ('psychiatric', 'O'), ('complications', 'O'), ('play', 'O'), ('a', 'O'), ('lesser', 'O'), ('role', 'O'), ('.', 'O'))"
Probing peripheral and central cholinergic system responses .,"(('Probing', 'O'), ('peripheral', 'O'), ('and', 'O'), ('central', 'O'), ('cholinergic', 'O'), ('system', 'O'), ('responses', 'O'), ('.', 'O'))"
"OBJECTIVE : The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer ' s disease , yet correlations between central and peripheral responses have not been properly studied .","(('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('pharmacological', 'O'), ('response', 'O'), ('to', 'O'), ('drugs', 'O'), ('that', 'O'), ('act', 'O'), ('on', 'O'), ('the', 'O'), ('cholinergic', 'O'), ('system', 'O'), ('of', 'O'), ('the', 'O'), ('iris', 'O'), ('has', 'O'), ('been', 'O'), ('used', 'O'), ('to', 'O'), ('predict', 'O'), ('deficits', 'O'), ('in', 'O'), ('central', 'O'), ('cholinergic', 'O'), ('functioning', 'O'), ('due', 'O'), ('to', 'O'), ('diseases', 'O'), ('such', 'O'), ('as', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), (',', 'O'), ('yet', 'O'), ('correlations', 'O'), ('between', 'O'), ('central', 'O'), ('and', 'O'), ('peripheral', 'O'), ('responses', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('properly', 'O'), ('studied', 'O'), ('.', 'O'))"
"This study assessed the effect of normal aging on ( 1 ) the tropicamide - induced increase in pupil diameter , and ( 2 ) the reversal of this effect with pilocarpine .","(('This', 'O'), ('study', 'O'), ('assessed', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('normal', 'O'), ('aging', 'O'), ('on', 'O'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('the', 'O'), ('tropicamide', 'O'), ('-', 'O'), ('induced', 'O'), ('increase', 'O'), ('in', 'O'), ('pupil', 'O'), ('diameter', 'O'), (',', 'O'), ('and', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('the', 'O'), ('reversal', 'O'), ('of', 'O'), ('this', 'O'), ('effect', 'O'), ('with', 'O'), ('pilocarpine', 'O'), ('.', 'O'))"
Scopolamine was used as a positive control to detect age - dependent changes in central cholinergic functioning in the elderly .,"(('Scopolamine', 'O'), ('was', 'O'), ('used', 'O'), ('as', 'O'), ('a', 'O'), ('positive', 'O'), ('control', 'O'), ('to', 'O'), ('detect', 'O'), ('age', 'O'), ('-', 'O'), ('dependent', 'O'), ('changes', 'O'), ('in', 'O'), ('central', 'O'), ('cholinergic', 'O'), ('functioning', 'O'), ('in', 'O'), ('the', 'O'), ('elderly', 'O'), ('.', 'O'))"
DESIGN : Randomized double - blind controlled trial .,"(('DESIGN', 'O'), (':', 'O'), ('Randomized', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('controlled', 'O'), ('trial', 'O'), ('.', 'O'))"
PARTICIPANTS : Ten healthy elderly ( mean age 70 ) and 9 young ( mean age 33 ) volunteers .,"(('PARTICIPANTS', 'O'), (':', 'O'), ('Ten', 'O'), ('healthy', 'O'), ('elderly', 'O'), ('(', 'O'), ('mean', 'O'), ('age', 'O'), ('70', 'O'), (')', 'O'), ('and', 'O'), ('9', 'O'), ('young', 'O'), ('(', 'O'), ('mean', 'O'), ('age', 'O'), ('33', 'O'), (')', 'O'), ('volunteers', 'O'), ('.', 'O'))"
INTERVENTIONS : Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours .,"(('INTERVENTIONS', 'O'), (':', 'O'), ('Pupil', 'O'), ('diameter', 'O'), ('was', 'O'), ('monitored', 'O'), ('using', 'O'), ('a', 'O'), ('computerized', 'O'), ('infrared', 'O'), ('pupillometer', 'O'), ('over', 'O'), ('4', 'O'), ('hours', 'O'), ('.', 'O'))"
The study involved 4 sessions .,"(('The', 'O'), ('study', 'O'), ('involved', 'O'), ('4', 'O'), ('sessions', 'O'), ('.', 'O'))"
"In 1 session , tropicamide ( 20 microL , 0 . 01 % ) was administered to one eye and placebo to the other .","(('In', 'O'), ('1', 'O'), ('session', 'O'), (',', 'O'), ('tropicamide', 'O'), ('(', 'O'), ('20', 'O'), ('microL', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), ('%', 'O'), (')', 'O'), ('was', 'O'), ('administered', 'O'), ('to', 'O'), ('one', 'O'), ('eye', 'O'), ('and', 'O'), ('placebo', 'O'), ('to', 'O'), ('the', 'O'), ('other', 'O'), ('.', 'O'))"
"In another session , tropicamide ( 20 microL , 0 . 01 % ) was administered to both eyes , followed 23 minutes later by the application of pilocarpine ( 20 microL , 0 . 1 % ) to one eye and placebo to the other .","(('In', 'O'), ('another', 'O'), ('session', 'O'), (',', 'O'), ('tropicamide', 'O'), ('(', 'O'), ('20', 'O'), ('microL', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), ('%', 'O'), (')', 'O'), ('was', 'O'), ('administered', 'O'), ('to', 'O'), ('both', 'O'), ('eyes', 'O'), (',', 'O'), ('followed', 'O'), ('23', 'O'), ('minutes', 'O'), ('later', 'O'), ('by', 'O'), ('the', 'O'), ('application', 'O'), ('of', 'O'), ('pilocarpine', 'O'), ('(', 'O'), ('20', 'O'), ('microL', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('to', 'O'), ('one', 'O'), ('eye', 'O'), ('and', 'O'), ('placebo', 'O'), ('to', 'O'), ('the', 'O'), ('other', 'O'), ('.', 'O'))"
All eye drops were given in a randomized order .,"(('All', 'O'), ('eye', 'O'), ('drops', 'O'), ('were', 'O'), ('given', 'O'), ('in', 'O'), ('a', 'O'), ('randomized', 'O'), ('order', 'O'), ('.', 'O'))"
"In 2 separate sessions , a single dose of scopolamine ( 0 . 5 mg , intravenously ) or placebo was administered , and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours .","(('In', 'O'), ('2', 'O'), ('separate', 'O'), ('sessions', 'O'), (',', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('scopolamine', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), (',', 'O'), ('intravenously', 'O'), (')', 'O'), ('or', 'O'), ('placebo', 'O'), ('was', 'O'), ('administered', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('effects', 'O'), ('on', 'O'), ('word', 'O'), ('recall', 'O'), ('were', 'O'), ('measured', 'O'), ('using', 'O'), ('the', 'O'), ('Buschke', 'O'), ('Selective', 'O'), ('Reminding', 'O'), ('Test', 'O'), ('over', 'O'), ('2', 'O'), ('hours', 'O'), ('.', 'O'))"
RESULTS : There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point ( p > 0 . 05 ) .,"(('RESULTS', 'O'), (':', 'O'), ('There', 'O'), ('was', 'O'), ('no', 'O'), ('significant', 'O'), ('difference', 'O'), ('between', 'O'), ('elderly', 'O'), ('and', 'O'), ('young', 'O'), ('volunteers', 'O'), ('in', 'O'), ('pupillary', 'O'), ('response', 'O'), ('to', 'O'), ('tropicamide', 'O'), ('at', 'O'), ('any', 'O'), ('time', 'O'), ('point', 'O'), ('(', 'O'), ('p', 'O'), ('>', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"The elderly group had a significantly greater pilocarpine - induced net decrease in pupil size 85 , 125 , 165 and 215 minutes after administration , compared with the young group ( p < 0 . 05 ) .","(('The', 'O'), ('elderly', 'O'), ('group', 'O'), ('had', 'O'), ('a', 'O'), ('significantly', 'O'), ('greater', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('induced', 'O'), ('net', 'O'), ('decrease', 'O'), ('in', 'O'), ('pupil', 'O'), ('size', 'O'), ('85', 'O'), (',', 'O'), ('125', 'O'), (',', 'O'), ('165', 'O'), ('and', 'O'), ('215', 'O'), ('minutes', 'O'), ('after', 'O'), ('administration', 'O'), (',', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('young', 'O'), ('group', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSION : There is an age - related pupillary response to pilocarpine that is not found with tropicamide .,"(('CONCLUSION', 'O'), (':', 'O'), ('There', 'O'), ('is', 'O'), ('an', 'O'), ('age', 'O'), ('-', 'O'), ('related', 'O'), ('pupillary', 'O'), ('response', 'O'), ('to', 'O'), ('pilocarpine', 'O'), ('that', 'O'), ('is', 'O'), ('not', 'O'), ('found', 'O'), ('with', 'O'), ('tropicamide', 'O'), ('.', 'O'))"
"Thus , pilocarpine may be useful to assess variations in central cholinergic function in elderly patients .","(('Thus', 'O'), (',', 'O'), ('pilocarpine', 'O'), ('may', 'O'), ('be', 'O'), ('useful', 'O'), ('to', 'O'), ('assess', 'O'), ('variations', 'O'), ('in', 'O'), ('central', 'O'), ('cholinergic', 'O'), ('function', 'O'), ('in', 'O'), ('elderly', 'O'), ('patients', 'O'), ('.', 'O'))"
Analgesic effects were significant neither for medication nor group .,"(('Analgesic', 'O'), ('effects', 'O'), ('were', 'O'), ('significant', 'O'), ('neither', 'O'), ('for', 'O'), ('medication', 'O'), ('nor', 'O'), ('group', 'O'), ('.', 'O'))"
High - dose methylprednisolone may do more harm for spinal cord injury .,"(('High', 'O'), ('-', 'O'), ('dose', 'O'), ('methylprednisolone', 'O'), ('may', 'O'), ('do', 'O'), ('more', 'O'), ('harm', 'O'), ('for', 'O'), ('spinal', 'B'), ('cord', 'I'), ('injury', 'I'), ('.', 'O'))"
"In the NASCIS , there was no mention regarding the possibility of acute corticosteroid myopathy that high - dose methylprednisolone may cause .","(('In', 'O'), ('the', 'O'), ('NASCIS', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('mention', 'O'), ('regarding', 'O'), ('the', 'O'), ('possibility', 'O'), ('of', 'O'), ('acute', 'O'), ('corticosteroid', 'I'), ('myopathy', 'I'), ('that', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('methylprednisolone', 'O'), ('may', 'O'), ('cause', 'O'), ('.', 'O'))"
The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2 - day period for any clinical condition .,"(('The', 'O'), ('dosage', 'O'), ('of', 'O'), ('methylprednisolone', 'O'), ('recommended', 'O'), ('by', 'O'), ('the', 'O'), ('NASCIS', 'O'), ('3', 'O'), ('is', 'O'), ('the', 'O'), ('highest', 'O'), ('dose', 'O'), ('of', 'O'), ('steroids', 'O'), ('ever', 'O'), ('being', 'O'), ('used', 'O'), ('during', 'O'), ('a', 'O'), ('2', 'O'), ('-', 'O'), ('day', 'O'), ('period', 'O'), ('for', 'O'), ('any', 'O'), ('clinical', 'O'), ('condition', 'O'), ('.', 'O'))"
We hypothesize that it may cause some damage to the muscle of spinal cord injury patients .,"(('We', 'O'), ('hypothesize', 'O'), ('that', 'O'), ('it', 'O'), ('may', 'O'), ('cause', 'O'), ('some', 'O'), ('damage', 'O'), ('to', 'O'), ('the', 'O'), ('muscle', 'O'), ('of', 'O'), ('spinal', 'B'), ('cord', 'I'), ('injury', 'I'), ('patients', 'O'), ('.', 'O'))"
"Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .","(('Further', 'O'), (',', 'O'), ('steroid', 'B'), ('myopathy', 'I'), ('recovers', 'O'), ('naturally', 'O'), ('and', 'O'), ('the', 'O'), ('neurological', 'O'), ('improvement', 'O'), ('shown', 'O'), ('in', 'O'), ('the', 'O'), ('NASCIS', 'O'), ('may', 'O'), ('be', 'O'), ('just', 'O'), ('a', 'O'), ('recording', 'O'), ('of', 'O'), ('this', 'O'), ('natural', 'O'), ('motor', 'O'), ('recovery', 'O'), ('from', 'O'), ('the', 'O'), ('steroid', 'B'), ('myopathy', 'I'), (',', 'O'), ('instead', 'O'), ('of', 'O'), ('any', 'O'), ('protection', 'O'), ('that', 'O'), ('methylprednisolone', 'O'), ('offers', 'O'), ('to', 'O'), ('the', 'O'), ('spinal', 'B'), ('cord', 'I'), ('injury', 'I'), ('.', 'O'))"
"To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy .","(('To', 'O'), ('our', 'O'), ('knowledge', 'O'), (',', 'O'), ('this', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('discussion', 'O'), ('considering', 'O'), ('the', 'O'), ('possibility', 'O'), ('that', 'O'), ('the', 'O'), ('methylprednisolone', 'O'), ('recommended', 'O'), ('by', 'O'), ('NASCIS', 'O'), ('may', 'O'), ('cause', 'O'), ('acute', 'O'), ('corticosteroid', 'B'), ('myopathy', 'I'), ('.', 'O'))"
Conversion to rapamycin immunosuppression in renal transplant recipients : report of an initial experience .,"(('Conversion', 'O'), ('to', 'O'), ('rapamycin', 'O'), ('immunosuppression', 'O'), ('in', 'O'), ('renal', 'O'), ('transplant', 'O'), ('recipients', 'O'), (':', 'O'), ('report', 'O'), ('of', 'O'), ('an', 'O'), ('initial', 'O'), ('experience', 'O'), ('.', 'O'))"
BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) toxicity .,"(('BACKGROUND', 'O'), (':', 'O'), ('The', 'O'), ('aim', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('is', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('RAPA', 'O'), ('conversion', 'O'), ('in', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('cyclosporine', 'B'), ('(', 'O'), ('CsA', 'O'), (')', 'O'), ('or', 'O'), ('tacrolimus', 'B'), ('(', 'O'), ('Tac', 'O'), (')', 'O'), ('toxicity', 'O'), ('.', 'O'))"
METHODS : Twenty renal transplant recipients were switched to fixed dose rapamycin ( RAPA ) ( 5 mg / day ) 0 to 204 months posttransplant .,"(('METHODS', 'O'), (':', 'O'), ('Twenty', 'O'), ('renal', 'O'), ('transplant', 'O'), ('recipients', 'O'), ('were', 'O'), ('switched', 'O'), ('to', 'O'), ('fixed', 'O'), ('dose', 'O'), ('rapamycin', 'O'), ('(', 'O'), ('RAPA', 'O'), (')', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('0', 'O'), ('to', 'O'), ('204', 'O'), ('months', 'O'), ('posttransplant', 'O'), ('.', 'O'))"
Drug monitoring was not initially used to adjust doses .,"(('Drug', 'O'), ('monitoring', 'O'), ('was', 'O'), ('not', 'O'), ('initially', 'O'), ('used', 'O'), ('to', 'O'), ('adjust', 'O'), ('doses', 'O'), ('.', 'O'))"
Follow - up is 7 to 24 months .,"(('Follow', 'O'), ('-', 'O'), ('up', 'O'), ('is', 'O'), ('7', 'O'), ('to', 'O'), ('24', 'O'), ('months', 'O'), ('.', 'O'))"
There were no deaths .,"(('There', 'O'), ('were', 'O'), ('no', 'O'), ('deaths', 'O'), ('.', 'O'))"
RAPA levels were high ( > 15 ng / ml ) in 7 of 13 ( 54 % ) patients .,"(('RAPA', 'O'), ('levels', 'O'), ('were', 'O'), ('high', 'O'), ('(', 'O'), ('>', 'O'), ('15', 'O'), ('ng', 'O'), ('/', 'O'), ('ml', 'O'), (')', 'O'), ('in', 'O'), ('7', 'O'), ('of', 'O'), ('13', 'O'), ('(', 'O'), ('54', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('.', 'O'))"
CONCLUSIONS : RAPA conversion provides adequate immunosuppression to enable CsA withdrawal .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('RAPA', 'O'), ('conversion', 'O'), ('provides', 'O'), ('adequate', 'O'), ('immunosuppression', 'O'), ('to', 'O'), ('enable', 'O'), ('CsA', 'O'), ('withdrawal', 'O'), ('.', 'O'))"
Six of the patients were no longer receiving vigabatrin .,"(('Six', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('were', 'O'), ('no', 'O'), ('longer', 'O'), ('receiving', 'O'), ('vigabatrin', 'O'), ('.', 'O'))"
METHODS : The central and peripheral fields were examined with the Humphrey Visual Field Analyzer .,"(('METHODS', 'O'), (':', 'O'), ('The', 'O'), ('central', 'O'), ('and', 'O'), ('peripheral', 'O'), ('fields', 'O'), ('were', 'O'), ('examined', 'O'), ('with', 'O'), ('the', 'O'), ('Humphrey', 'O'), ('Visual', 'O'), ('Field', 'O'), ('Analyzer', 'O'), ('.', 'O'))"
"Full visual electrophysiology , including flash electroretinography ( ERG ) , pattern electroretinography , multifocal ERG using the VERIS system , electro - oculography , and flash and pattern visual evoked potentials , was undertaken .","(('Full', 'O'), ('visual', 'O'), ('electrophysiology', 'O'), (',', 'O'), ('including', 'O'), ('flash', 'O'), ('electroretinography', 'O'), ('(', 'O'), ('ERG', 'O'), (')', 'O'), (',', 'O'), ('pattern', 'O'), ('electroretinography', 'O'), (',', 'O'), ('multifocal', 'O'), ('ERG', 'O'), ('using', 'O'), ('the', 'O'), ('VERIS', 'O'), ('system', 'O'), (',', 'O'), ('electro', 'O'), ('-', 'O'), ('oculography', 'O'), (',', 'O'), ('and', 'O'), ('flash', 'O'), ('and', 'O'), ('pattern', 'O'), ('visual', 'O'), ('evoked', 'O'), ('potentials', 'O'), (',', 'O'), ('was', 'O'), ('undertaken', 'O'), ('.', 'O'))"
The eighth exhibited concentric constriction .,"(('The', 'O'), ('eighth', 'O'), ('exhibited', 'O'), ('concentric', 'O'), ('constriction', 'O'), ('.', 'O'))"
Most electrophysiological responses were usually just within normal limits ; two patients had subnormal Arden electro - oculography indices ; and one patient showed an abnormally delayed photopic b wave .,"(('Most', 'O'), ('electrophysiological', 'O'), ('responses', 'O'), ('were', 'O'), ('usually', 'O'), ('just', 'O'), ('within', 'O'), ('normal', 'O'), ('limits', 'O'), (';', 'O'), ('two', 'O'), ('patients', 'O'), ('had', 'O'), ('subnormal', 'O'), ('Arden', 'O'), ('electro', 'O'), ('-', 'O'), ('oculography', 'O'), ('indices', 'O'), (';', 'O'), ('and', 'O'), ('one', 'O'), ('patient', 'O'), ('showed', 'O'), ('an', 'O'), ('abnormally', 'O'), ('delayed', 'O'), ('photopic', 'O'), ('b', 'O'), ('wave', 'O'), ('.', 'O'))"
"However , five patients showed delayed 30 - Hz flicker b waves , and seven patients showed delayed oscillatory potentials .","(('However', 'O'), (',', 'O'), ('five', 'O'), ('patients', 'O'), ('showed', 'O'), ('delayed', 'O'), ('30', 'O'), ('-', 'O'), ('Hz', 'O'), ('flicker', 'O'), ('b', 'O'), ('waves', 'O'), (',', 'O'), ('and', 'O'), ('seven', 'O'), ('patients', 'O'), ('showed', 'O'), ('delayed', 'O'), ('oscillatory', 'O'), ('potentials', 'O'), ('.', 'O'))"
Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level .,"(('Multifocal', 'O'), ('ERG', 'O'), ('showed', 'O'), ('abnormalities', 'O'), ('that', 'O'), ('sometimes', 'O'), ('correlated', 'O'), ('with', 'O'), ('the', 'O'), ('visual', 'O'), ('field', 'O'), ('appearance', 'O'), ('and', 'O'), ('confirmed', 'O'), ('that', 'O'), ('the', 'O'), ('deficit', 'O'), ('occurs', 'O'), ('at', 'O'), ('the', 'O'), ('retinal', 'O'), ('level', 'O'), ('.', 'O'))"
The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn .,"(('The', 'O'), ('field', 'B'), ('defects', 'I'), ('and', 'O'), ('some', 'O'), ('electrophysiological', 'B'), ('abnormalities', 'I'), ('persist', 'O'), ('when', 'O'), ('vigabatrin', 'O'), ('therapy', 'O'), ('is', 'O'), ('withdrawn', 'O'), ('.', 'O'))"
"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5 , 10 , 20 , 30 , and 40 microg / kg / min every 5 minutes .","(('DSE', 'O'), ('was', 'O'), ('performed', 'O'), ('with', 'O'), ('intravenous', 'O'), ('dobutamine', 'O'), ('infusion', 'O'), ('with', 'O'), ('an', 'O'), ('incremental', 'O'), ('doses', 'O'), ('of', 'O'), ('5', 'O'), (',', 'O'), ('10', 'O'), (',', 'O'), ('20', 'O'), (',', 'O'), ('30', 'O'), (',', 'O'), ('and', 'O'), ('40', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('min', 'O'), ('every', 'O'), ('5', 'O'), ('minutes', 'O'), ('.', 'O'))"
"Of the 51 patients , 7 patients showed asynergy with ST elevation .","(('Of', 'O'), ('the', 'O'), ('51', 'O'), ('patients', 'O'), (',', 'O'), ('7', 'O'), ('patients', 'O'), ('showed', 'O'), ('asynergy', 'O'), ('with', 'O'), ('ST', 'O'), ('elevation', 'O'), ('.', 'O'))"
"STUDY OBJECTIVE : To determine the effect of metoprolol on dobutamine stress testing with technetium - 99m sestamibi single - photon emission computed tomography imaging and ST - segment monitoring , and to assess the impact of intravenous glucagon on metoprolol ' s effects .","(('STUDY', 'O'), ('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('determine', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('metoprolol', 'O'), ('on', 'O'), ('dobutamine', 'O'), ('stress', 'O'), ('testing', 'O'), ('with', 'O'), ('technetium', 'O'), ('-', 'O'), ('99m', 'O'), ('sestamibi', 'O'), ('single', 'O'), ('-', 'O'), ('photon', 'O'), ('emission', 'O'), ('computed', 'O'), ('tomography', 'O'), ('imaging', 'O'), ('and', 'O'), ('ST', 'O'), ('-', 'O'), ('segment', 'O'), ('monitoring', 'O'), (',', 'O'), ('and', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('impact', 'O'), ('of', 'O'), ('intravenous', 'O'), ('glucagon', 'O'), ('on', 'O'), ('metoprolol', 'O'), (""'"", 'O'), ('s', 'O'), ('effects', 'O'), ('.', 'O'))"
"DESIGN : Randomized , double - blind , placebo - controlled trial .","(('DESIGN', 'O'), (':', 'O'), ('Randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('trial', 'O'), ('.', 'O'))"
SETTING : Community hospital .,"(('SETTING', 'O'), (':', 'O'), ('Community', 'O'), ('hospital', 'O'), ('.', 'O'))"
PATIENTS : Twenty - two patients with known reversible perfusion defects .,"(('PATIENTS', 'O'), (':', 'O'), ('Twenty', 'O'), ('-', 'O'), ('two', 'O'), ('patients', 'O'), ('with', 'O'), ('known', 'O'), ('reversible', 'O'), ('perfusion', 'B'), ('defects', 'I'), ('.', 'O'))"
INTERVENTION : Patients underwent dobutamine stress tests per standard protocol .,"(('INTERVENTION', 'O'), (':', 'O'), ('Patients', 'O'), ('underwent', 'O'), ('dobutamine', 'O'), ('stress', 'O'), ('tests', 'O'), ('per', 'O'), ('standard', 'O'), ('protocol', 'O'), ('.', 'O'))"
"Before dobutamine was begun , no therapy was given during the first visit , and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg .","(('Before', 'O'), ('dobutamine', 'O'), ('was', 'O'), ('begun', 'O'), (',', 'O'), ('no', 'O'), ('therapy', 'O'), ('was', 'O'), ('given', 'O'), ('during', 'O'), ('the', 'O'), ('first', 'O'), ('visit', 'O'), (',', 'O'), ('and', 'O'), ('patients', 'O'), ('were', 'O'), ('randomized', 'O'), ('on', 'O'), ('subsequent', 'O'), ('visits', 'O'), ('to', 'O'), ('receive', 'O'), ('metoprolol', 'O'), ('or', 'O'), ('metoprolol', 'O'), ('plus', 'O'), ('glucagon', 'O'), ('1', 'O'), ('mg', 'O'), ('.', 'O'))"
Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats / minute or a total intravenous dose of 20 mg .,"(('Metoprolol', 'O'), ('was', 'O'), ('dosed', 'O'), ('to', 'O'), ('achieve', 'O'), ('a', 'O'), ('resting', 'O'), ('predobutamine', 'O'), ('heart', 'O'), ('rate', 'O'), ('below', 'O'), ('65', 'O'), ('beats', 'O'), ('/', 'O'), ('minute', 'O'), ('or', 'O'), ('a', 'O'), ('total', 'O'), ('intravenous', 'O'), ('dose', 'O'), ('of', 'O'), ('20', 'O'), ('mg', 'O'), ('.', 'O'))"
"MEASUREMENTS AND MAIN RESULTS : Metoprolol reduced maximum heart rate 31 % , summed stress scores 29 % , and summed difference scores 43 % versus control .","(('MEASUREMENTS', 'O'), ('AND', 'O'), ('MAIN', 'O'), ('RESULTS', 'O'), (':', 'O'), ('Metoprolol', 'O'), ('reduced', 'O'), ('maximum', 'O'), ('heart', 'O'), ('rate', 'O'), ('31', 'O'), ('%', 'O'), (',', 'O'), ('summed', 'O'), ('stress', 'O'), ('scores', 'O'), ('29', 'O'), ('%', 'O'), (',', 'O'), ('and', 'O'), ('summed', 'O'), ('difference', 'O'), ('scores', 'O'), ('43', 'O'), ('%', 'O'), ('versus', 'O'), ('control', 'O'), ('.', 'O'))"
Metoprolol plus glucagon also reduced the maximum heart rate 29 % versus control .,"(('Metoprolol', 'O'), ('plus', 'O'), ('glucagon', 'O'), ('also', 'O'), ('reduced', 'O'), ('the', 'O'), ('maximum', 'O'), ('heart', 'O'), ('rate', 'O'), ('29', 'O'), ('%', 'O'), ('versus', 'O'), ('control', 'O'), ('.', 'O'))"
"Summed stress and summed difference scores were not significantly reduced , although they were 18 % and 30 % lower , respectively , than control .","(('Summed', 'O'), ('stress', 'O'), ('and', 'O'), ('summed', 'O'), ('difference', 'O'), ('scores', 'O'), ('were', 'O'), ('not', 'O'), ('significantly', 'O'), ('reduced', 'O'), (',', 'O'), ('although', 'O'), ('they', 'O'), ('were', 'O'), ('18', 'O'), ('%', 'O'), ('and', 'O'), ('30', 'O'), ('%', 'O'), ('lower', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('than', 'O'), ('control', 'O'), ('.', 'O'))"
No significant differences were found in any parameter between metoprolol and metoprolol - glucagon .,"(('No', 'O'), ('significant', 'O'), ('differences', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('any', 'O'), ('parameter', 'O'), ('between', 'O'), ('metoprolol', 'O'), ('and', 'O'), ('metoprolol', 'O'), ('-', 'O'), ('glucagon', 'O'), ('.', 'O'))"
"Glucagon 1 mg , although somewhat effective , does not correct this effect to the extent that it can be administered clinically .","(('Glucagon', 'O'), ('1', 'O'), ('mg', 'O'), (',', 'O'), ('although', 'O'), ('somewhat', 'O'), ('effective', 'O'), (',', 'O'), ('does', 'O'), ('not', 'O'), ('correct', 'O'), ('this', 'O'), ('effect', 'O'), ('to', 'O'), ('the', 'O'), ('extent', 'O'), ('that', 'O'), ('it', 'O'), ('can', 'O'), ('be', 'O'), ('administered', 'O'), ('clinically', 'O'), ('.', 'O'))"
Evidence of functional somatotopy in GPi from results of pallidotomy .,"(('Evidence', 'O'), ('of', 'O'), ('functional', 'O'), ('somatotopy', 'O'), ('in', 'O'), ('GPi', 'O'), ('from', 'O'), ('results', 'O'), ('of', 'O'), ('pallidotomy', 'O'), ('.', 'O'))"
"The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms , and hence could be variable .","(('The', 'O'), ('outcome', 'O'), ('of', 'O'), ('pallidotomy', 'O'), ('in', 'O'), ('which', 'O'), ('the', 'O'), ('lesion', 'O'), ('involves', 'O'), ('the', 'O'), ('ventral', 'O'), ('and', 'O'), ('dorsal', 'O'), ('GPi', 'O'), ('could', 'O'), ('be', 'O'), ('the', 'O'), ('net', 'O'), ('effect', 'O'), ('of', 'O'), ('alteration', 'O'), ('in', 'O'), ('the', 'O'), ('activity', 'O'), ('of', 'O'), ('pathways', 'O'), ('which', 'O'), ('mediate', 'O'), ('different', 'O'), ('symptoms', 'O'), (',', 'O'), ('and', 'O'), ('hence', 'O'), ('could', 'O'), ('be', 'O'), ('variable', 'O'), ('.', 'O'))"
Screening for stimulant use in adult emergency department seizure patients .,"(('Screening', 'O'), ('for', 'O'), ('stimulant', 'O'), ('use', 'O'), ('in', 'O'), ('adult', 'O'), ('emergency', 'O'), ('department', 'O'), ('seizure', 'O'), ('patients', 'O'), ('.', 'O'))"
OBJECTIVE : The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients .,"(('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('objective', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('prevalence', 'O'), ('of', 'O'), ('positive', 'O'), ('plasma', 'O'), ('drug', 'O'), ('screening', 'O'), ('for', 'O'), ('cocaine', 'O'), ('or', 'O'), ('amphetamine', 'O'), ('in', 'O'), ('adult', 'O'), ('emergency', 'O'), ('department', 'O'), ('seizure', 'O'), ('patients', 'O'), ('.', 'O'))"
METHODS : This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation .,"(('METHODS', 'O'), (':', 'O'), ('This', 'O'), ('prospective', 'O'), ('study', 'O'), ('evaluated', 'O'), ('consecutive', 'O'), ('eligible', 'O'), ('seizure', 'B'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('a', 'O'), ('plasma', 'O'), ('sample', 'O'), ('collected', 'O'), ('as', 'O'), ('part', 'O'), ('of', 'O'), ('their', 'O'), ('clinical', 'O'), ('evaluation', 'O'), ('.', 'O'))"
Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme - mediated immunoassay methodology .,"(('Plasma', 'O'), ('was', 'O'), ('tested', 'O'), ('for', 'O'), ('amphetamine', 'O'), ('and', 'O'), ('the', 'O'), ('cocaine', 'O'), ('metabolite', 'O'), ('benzoylecgonine', 'O'), ('using', 'O'), ('enzyme', 'O'), ('-', 'O'), ('mediated', 'O'), ('immunoassay', 'O'), ('methodology', 'O'), ('.', 'O'))"
Plasma samples with benzoylecgonine greater than 150 ng / mL or an amphetamine greater than 500 ng / mL were defined as positive .,"(('Plasma', 'O'), ('samples', 'O'), ('with', 'O'), ('benzoylecgonine', 'O'), ('greater', 'O'), ('than', 'O'), ('150', 'O'), ('ng', 'O'), ('/', 'O'), ('mL', 'O'), ('or', 'O'), ('an', 'O'), ('amphetamine', 'O'), ('greater', 'O'), ('than', 'O'), ('500', 'O'), ('ng', 'O'), ('/', 'O'), ('mL', 'O'), ('were', 'O'), ('defined', 'O'), ('as', 'O'), ('positive', 'O'), ('.', 'O'))"
"RESULTS : Fourteen of 248 ( 5 . 6 % , 95 % CI 2 . 7 % - 8 . 5 % ) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples ( 0 % , 95 % CI 0 - 1 . 2 % ) were positive for amphetamine .","(('RESULTS', 'O'), (':', 'O'), ('Fourteen', 'O'), ('of', 'O'), ('248', 'O'), ('(', 'O'), ('5', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('2', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), ('-', 'O'), ('8', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('plasma', 'O'), ('samples', 'O'), ('were', 'O'), ('positive', 'O'), ('by', 'O'), ('immunoassay', 'O'), ('testing', 'O'), ('for', 'O'), ('benzoylecgonine', 'O'), ('and', 'O'), ('no', 'O'), ('samples', 'O'), ('(', 'O'), ('0', 'O'), ('%', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('0', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('positive', 'O'), ('for', 'O'), ('amphetamine', 'O'), ('.', 'O'))"
"CONCLUSIONS : During this study period , routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield .","(('CONCLUSIONS', 'O'), (':', 'O'), ('During', 'O'), ('this', 'O'), ('study', 'O'), ('period', 'O'), (',', 'O'), ('routine', 'O'), ('plasma', 'O'), ('screening', 'O'), ('for', 'O'), ('cocaine', 'O'), ('and', 'O'), ('amphetamines', 'O'), ('in', 'O'), ('adult', 'O'), ('seizure', 'B'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('low', 'O'), ('yield', 'O'), ('.', 'O'))"
"After substituting VPA with zonisamide , the serum sodium level returned to normal .","(('After', 'O'), ('substituting', 'O'), ('VPA', 'O'), ('with', 'O'), ('zonisamide', 'O'), (',', 'O'), ('the', 'O'), ('serum', 'O'), ('sodium', 'O'), ('level', 'O'), ('returned', 'O'), ('to', 'O'), ('normal', 'O'), ('.', 'O'))"
Association of nitric oxide production and apoptosis in a model of experimental nephropathy .,"(('Association', 'O'), ('of', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('production', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('in', 'O'), ('a', 'O'), ('model', 'O'), ('of', 'O'), ('experimental', 'O'), ('nephropathy', 'B'), ('.', 'O'))"
BACKGROUND : In recent studies increased amounts of nitric oxide ( NO ) and apoptosis have been implicated in various pathological conditions in the kidney .,"(('BACKGROUND', 'O'), (':', 'O'), ('In', 'O'), ('recent', 'O'), ('studies', 'O'), ('increased', 'O'), ('amounts', 'O'), ('of', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('(', 'O'), ('NO', 'O'), (')', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('have', 'O'), ('been', 'O'), ('implicated', 'O'), ('in', 'O'), ('various', 'O'), ('pathological', 'O'), ('conditions', 'O'), ('in', 'O'), ('the', 'O'), ('kidney', 'O'), ('.', 'O'))"
METHODS : The alteration in the NO pathway was assessed by measuring nitrite levels in serum / urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney ( IPRK ) system .,"(('METHODS', 'O'), (':', 'O'), ('The', 'O'), ('alteration', 'O'), ('in', 'O'), ('the', 'O'), ('NO', 'O'), ('pathway', 'O'), ('was', 'O'), ('assessed', 'O'), ('by', 'O'), ('measuring', 'O'), ('nitrite', 'O'), ('levels', 'O'), ('in', 'O'), ('serum', 'O'), ('/', 'O'), ('urine', 'O'), ('and', 'O'), ('by', 'O'), ('evaluating', 'O'), ('the', 'O'), ('changes', 'O'), ('in', 'O'), ('vascular', 'O'), ('reactivity', 'O'), ('of', 'O'), ('the', 'O'), ('isolated', 'O'), ('perfused', 'O'), ('rat', 'O'), ('kidney', 'O'), ('(', 'O'), ('IPRK', 'O'), (')', 'O'), ('system', 'O'), ('.', 'O'))"
Rats were stratified into control groups and ADR - induced nephropathy groups .,"(('Rats', 'O'), ('were', 'O'), ('stratified', 'O'), ('into', 'O'), ('control', 'O'), ('groups', 'O'), ('and', 'O'), ('ADR', 'B'), ('-', 'O'), ('induced', 'O'), ('nephropathy', 'B'), ('groups', 'O'), ('.', 'O'))"
"These two groups were then divided into : group 1 , animals receiving saline ; and group 2 , animals receiving aminoguanidine ( AG ) which is a specific inhibitor of inducible - NO synthase .","(('These', 'O'), ('two', 'O'), ('groups', 'O'), ('were', 'O'), ('then', 'O'), ('divided', 'O'), ('into', 'O'), (':', 'O'), ('group', 'O'), ('1', 'O'), (',', 'O'), ('animals', 'O'), ('receiving', 'O'), ('saline', 'O'), (';', 'O'), ('and', 'O'), ('group', 'O'), ('2', 'O'), (',', 'O'), ('animals', 'O'), ('receiving', 'O'), ('aminoguanidine', 'O'), ('(', 'O'), ('AG', 'O'), (')', 'O'), ('which', 'O'), ('is', 'O'), ('a', 'O'), ('specific', 'O'), ('inhibitor', 'O'), ('of', 'O'), ('inducible', 'O'), ('-', 'O'), ('NO', 'O'), ('synthase', 'O'), ('.', 'O'))"
"On day 21 , rats were sacrificed after obtaining material for biochemical analysis .","(('On', 'O'), ('day', 'O'), ('21', 'O'), (',', 'O'), ('rats', 'O'), ('were', 'O'), ('sacrificed', 'O'), ('after', 'O'), ('obtaining', 'O'), ('material', 'O'), ('for', 'O'), ('biochemical', 'O'), ('analysis', 'O'), ('.', 'O'))"
They also had significantly higher levels of proteinuria compared with control and treatment groups ( P < 0 . 05 ) .,"(('They', 'O'), ('also', 'O'), ('had', 'O'), ('significantly', 'O'), ('higher', 'O'), ('levels', 'O'), ('of', 'O'), ('proteinuria', 'B'), ('compared', 'O'), ('with', 'O'), ('control', 'O'), ('and', 'O'), ('treatment', 'O'), ('groups', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
Urine nitrite levels were significantly increased in the ADR - nephropathy group ( P < 0 . 05 ) .,"(('Urine', 'O'), ('nitrite', 'O'), ('levels', 'O'), ('were', 'O'), ('significantly', 'O'), ('increased', 'O'), ('in', 'O'), ('the', 'O'), ('ADR', 'B'), ('-', 'I'), ('nephropathy', 'I'), ('group', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - nephropathy group .,"(('In', 'O'), ('the', 'O'), ('IPRK', 'O'), ('phenylephrine', 'O'), ('and', 'O'), ('acetylcholine', 'O'), ('related', 'O'), ('responses', 'O'), ('were', 'O'), ('significantly', 'O'), ('impaired', 'O'), ('in', 'O'), ('the', 'O'), ('ADR', 'B'), ('-', 'I'), ('nephropathy', 'I'), ('group', 'O'), ('.', 'O'))"
Apoptosis was not detected in controls .,"(('Apoptosis', 'O'), ('was', 'O'), ('not', 'O'), ('detected', 'O'), ('in', 'O'), ('controls', 'O'), ('.', 'O'))"
"However , in the ADR - nephropathy group , numerous apoptotic cells were identified in the tubulointerstitial areas .","(('However', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('ADR', 'B'), ('-', 'I'), ('nephropathy', 'I'), ('group', 'O'), (',', 'O'), ('numerous', 'O'), ('apoptotic', 'O'), ('cells', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('the', 'O'), ('tubulointerstitial', 'O'), ('areas', 'O'), ('.', 'O'))"
"Double staining revealed numerous interstitial apoptotic cells to stain for ED1 , a marker for monocytes / macrophages .","(('Double', 'O'), ('staining', 'O'), ('revealed', 'O'), ('numerous', 'O'), ('interstitial', 'O'), ('apoptotic', 'O'), ('cells', 'O'), ('to', 'O'), ('stain', 'O'), ('for', 'O'), ('ED1', 'O'), (',', 'O'), ('a', 'O'), ('marker', 'O'), ('for', 'O'), ('monocytes', 'O'), ('/', 'O'), ('macrophages', 'O'), ('.', 'O'))"
Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels .,"(('Treatment', 'O'), ('with', 'O'), ('AG', 'O'), ('prevented', 'O'), ('the', 'O'), ('impairment', 'O'), ('of', 'O'), ('renal', 'O'), ('vascular', 'O'), ('bed', 'O'), ('responses', 'O'), ('and', 'O'), ('reduced', 'O'), ('both', 'O'), ('urine', 'O'), ('nitrite', 'O'), ('levels', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('to', 'O'), ('control', 'O'), ('levels', 'O'), ('.', 'O'))"
"Sodium thiopenthal was administered intraperitoneally into male rats pre - treated with melatonin ( 0 . 05 , 0 . 5 , 5 and 50 mg / kg ) .","(('Sodium', 'O'), ('thiopenthal', 'O'), ('was', 'O'), ('administered', 'O'), ('intraperitoneally', 'O'), ('into', 'O'), ('male', 'O'), ('rats', 'O'), ('pre', 'O'), ('-', 'O'), ('treated', 'O'), ('with', 'O'), ('melatonin', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), (',', 'O'), ('5', 'O'), ('and', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('.', 'O'))"
"Antitumor efficacy was assessed by objective tumor response rates ( World Health Organization criteria ) , time to progression , and survival .","(('Antitumor', 'O'), ('efficacy', 'O'), ('was', 'O'), ('assessed', 'O'), ('by', 'O'), ('objective', 'O'), ('tumor', 'B'), ('response', 'O'), ('rates', 'O'), ('(', 'O'), ('World', 'O'), ('Health', 'O'), ('Organization', 'O'), ('criteria', 'O'), (')', 'O'), (',', 'O'), ('time', 'O'), ('to', 'O'), ('progression', 'O'), (',', 'O'), ('and', 'O'), ('survival', 'O'), ('.', 'O'))"
"Median cumulative doxorubicin dose at onset was more than 2 , 220 mg / m ( 2 ) for MC versus 480 mg / m ( 2 ) for AC ( P = . 0001 , hazard ratio , 5 . 04 ) .","(('Median', 'O'), ('cumulative', 'O'), ('doxorubicin', 'O'), ('dose', 'O'), ('at', 'O'), ('onset', 'O'), ('was', 'O'), ('more', 'O'), ('than', 'O'), ('2', 'O'), (',', 'O'), ('220', 'O'), ('mg', 'O'), ('/', 'O'), ('m', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('for', 'O'), ('MC', 'B'), ('versus', 'O'), ('480', 'O'), ('mg', 'O'), ('/', 'O'), ('m', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('for', 'O'), ('AC', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('0001', 'O'), (',', 'O'), ('hazard', 'O'), ('ratio', 'O'), (',', 'O'), ('5', 'O'), ('.', 'O'), ('04', 'O'), (')', 'O'), ('.', 'O'))"
"Antitumor efficacy of MC versus AC was comparable : objective response rates , 43 % versus 43 % ; median time to progression , 5 . 1 % versus 5 . 5 months ; median time to treatment failure , 4 . 6 versus 4 . 4 months ; and median survival , 19 versus 16 months .","(('Antitumor', 'O'), ('efficacy', 'O'), ('of', 'O'), ('MC', 'O'), ('versus', 'O'), ('AC', 'O'), ('was', 'O'), ('comparable', 'O'), (':', 'O'), ('objective', 'O'), ('response', 'O'), ('rates', 'O'), (',', 'O'), ('43', 'O'), ('%', 'O'), ('versus', 'O'), ('43', 'O'), ('%', 'O'), (';', 'O'), ('median', 'O'), ('time', 'O'), ('to', 'O'), ('progression', 'O'), (',', 'O'), ('5', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), ('versus', 'O'), ('5', 'O'), ('.', 'O'), ('5', 'O'), ('months', 'O'), (';', 'O'), ('median', 'O'), ('time', 'O'), ('to', 'O'), ('treatment', 'O'), ('failure', 'O'), (',', 'O'), ('4', 'O'), ('.', 'O'), ('6', 'O'), ('versus', 'O'), ('4', 'O'), ('.', 'O'), ('4', 'O'), ('months', 'O'), (';', 'O'), ('and', 'O'), ('median', 'O'), ('survival', 'O'), (',', 'O'), ('19', 'O'), ('versus', 'O'), ('16', 'O'), ('months', 'O'), ('.', 'O'))"
"The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced convulsions .","(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('N', 'O'), ('-', 'O'), ('nitro', 'O'), ('-', 'O'), ('L', 'O'), ('-', 'O'), ('arginine', 'O'), ('-', 'O'), ('methyl', 'O'), ('ester', 'O'), ('(', 'O'), ('L', 'O'), ('-', 'O'), ('NAME', 'O'), (')', 'O'), ('a', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('(', 'O'), ('NO', 'O'), (')', 'O'), ('synthase', 'O'), ('inhibitor', 'O'), ('and', 'O'), ('L', 'O'), ('-', 'O'), ('arginine', 'O'), (',', 'O'), ('a', 'O'), ('NO', 'O'), ('precursor', 'O'), (',', 'O'), ('were', 'O'), ('investigated', 'O'), ('on', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('.', 'O'))"
"In the first experiment , four groups of mice received physiological saline ( 0 . 9 % ) , L - arginine ( 300 mg / kg , i . p . ) , L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) , respectively .","(('In', 'O'), ('the', 'O'), ('first', 'O'), ('experiment', 'O'), (',', 'O'), ('four', 'O'), ('groups', 'O'), ('of', 'O'), ('mice', 'O'), ('received', 'O'), ('physiological', 'O'), ('saline', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('L', 'O'), ('-', 'O'), ('arginine', 'O'), ('(', 'O'), ('300', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('L', 'O'), ('-', 'O'), ('NAME', 'O'), ('(', 'O'), ('100', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('and', 'O'), ('diazepam', 'O'), ('(', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Thirty minutes after these injections , all mice received lidocaine ( 50 mg / kg , i . p . ) .","(('Thirty', 'O'), ('minutes', 'O'), ('after', 'O'), ('these', 'O'), ('injections', 'O'), (',', 'O'), ('all', 'O'), ('mice', 'O'), ('received', 'O'), ('lidocaine', 'O'), ('(', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
"In the second experiment , four groups of mice received similar treatment in the first experiment , and 30 min after these injections , all mice received a higher dose of lidocaine ( 80 mg / kg ) .","(('In', 'O'), ('the', 'O'), ('second', 'O'), ('experiment', 'O'), (',', 'O'), ('four', 'O'), ('groups', 'O'), ('of', 'O'), ('mice', 'O'), ('received', 'O'), ('similar', 'O'), ('treatment', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('experiment', 'O'), (',', 'O'), ('and', 'O'), ('30', 'O'), ('min', 'O'), ('after', 'O'), ('these', 'O'), ('injections', 'O'), (',', 'O'), ('all', 'O'), ('mice', 'O'), ('received', 'O'), ('a', 'O'), ('higher', 'O'), ('dose', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('(', 'O'), ('80', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('.', 'O'))"
"L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced convulsions .","(('L', 'O'), ('-', 'O'), ('NAME', 'O'), ('(', 'O'), ('100', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('and', 'O'), ('diazepam', 'O'), ('(', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('(', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('.', 'O'))"
"In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced convulsions significantly .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('the', 'O'), ('L', 'O'), ('-', 'O'), ('arginine', 'O'), ('treatment', 'O'), ('increased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('(', 'O'), ('80', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('significantly', 'O'), ('.', 'O'))"
These results may suggest that NO is a proconvulsant mediator in lidocaine - induced convulsions .,"(('These', 'O'), ('results', 'O'), ('may', 'O'), ('suggest', 'O'), ('that', 'O'), ('NO', 'O'), ('is', 'O'), ('a', 'O'), ('proconvulsant', 'O'), ('mediator', 'O'), ('in', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('.', 'O'))"
"In a second group , the development of anemia was prevented by rHuEPO ( 1000 IU / kg ) administered s . c . three times / week starting 7 days before carboplatin application .","(('In', 'O'), ('a', 'O'), ('second', 'O'), ('group', 'O'), (',', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('anemia', 'B'), ('was', 'O'), ('prevented', 'O'), ('by', 'O'), ('rHuEPO', 'O'), ('(', 'O'), ('1000', 'O'), ('IU', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('administered', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), ('three', 'O'), ('times', 'O'), ('/', 'O'), ('week', 'O'), ('starting', 'O'), ('7', 'O'), ('days', 'O'), ('before', 'O'), ('carboplatin', 'O'), ('application', 'O'), ('.', 'O'))"
"Four days after carboplatin treatment , tumors ( DS - sarcoma of the rat ) were implanted s . c . onto the hind food dorsum .","(('Four', 'O'), ('days', 'O'), ('after', 'O'), ('carboplatin', 'O'), ('treatment', 'O'), (',', 'O'), ('tumors', 'B'), ('(', 'O'), ('DS', 'B'), ('-', 'I'), ('sarcoma', 'I'), ('of', 'I'), ('the', 'O'), ('rat', 'O'), (')', 'O'), ('were', 'O'), ('implanted', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), ('onto', 'O'), ('the', 'O'), ('hind', 'O'), ('food', 'O'), ('dorsum', 'O'), ('.', 'O'))"
Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se .,"(('Neither', 'O'), ('carboplatin', 'O'), ('nor', 'O'), ('rHuEPO', 'O'), ('treatment', 'O'), ('influenced', 'O'), ('tumor', 'B'), ('growth', 'O'), ('rate', 'O'), ('per', 'O'), ('se', 'O'), ('.', 'O'))"
"When tumors were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .","(('When', 'O'), ('tumors', 'B'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('cyclophosphamide', 'O'), ('(', 'O'), ('60', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('5', 'O'), ('days', 'O'), ('after', 'O'), ('implantation', 'O'), (',', 'O'), ('a', 'O'), ('growth', 'O'), ('delay', 'O'), ('with', 'O'), ('a', 'O'), ('subsequent', 'O'), ('regrowth', 'O'), ('of', 'O'), ('the', 'O'), ('tumors', 'B'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
"In the anemia group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .","(('In', 'O'), ('the', 'O'), ('anemia', 'B'), ('group', 'O'), (',', 'O'), ('the', 'O'), ('growth', 'O'), ('delay', 'O'), ('was', 'O'), ('significantly', 'O'), ('shorter', 'O'), ('compared', 'O'), ('with', 'O'), ('nonanemic', 'O'), ('controls', 'O'), ('(', 'O'), ('13', 'O'), ('.', 'O'), ('3', 'O'), ('days', 'O'), ('versus', 'O'), ('8', 'O'), ('.', 'O'), ('6', 'O'), ('days', 'O'), (')', 'O'), ('.', 'O'))"
"In the group where anemia was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .","(('In', 'O'), ('the', 'O'), ('group', 'O'), ('where', 'O'), ('anemia', 'B'), ('was', 'O'), ('prevented', 'O'), ('by', 'O'), ('rHuEPO', 'O'), ('treatment', 'O'), (',', 'O'), ('growth', 'O'), ('delay', 'O'), ('was', 'O'), ('comparable', 'O'), ('with', 'O'), ('that', 'O'), ('of', 'O'), ('nonanemic', 'O'), ('controls', 'O'), ('(', 'O'), ('13', 'O'), ('.', 'O'), ('3', 'O'), ('days', 'O'), (')', 'O'), ('.', 'O'))"
Echocardiographic identification of the disorder can be made .,"(('Echocardiographic', 'O'), ('identification', 'O'), ('of', 'O'), ('the', 'O'), ('disorder', 'O'), ('can', 'O'), ('be', 'O'), ('made', 'O'), ('.', 'O'))"
We believe that the ultrasound features of this disorder have not been previously reported .,"(('We', 'O'), ('believe', 'O'), ('that', 'O'), ('the', 'O'), ('ultrasound', 'O'), ('features', 'O'), ('of', 'O'), ('this', 'O'), ('disorder', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('previously', 'O'), ('reported', 'O'), ('.', 'O'))"
Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments .,"(('Diltiazem', 'O'), ('was', 'O'), ('used', 'O'), ('as', 'O'), ('a', 'O'), ('comparison', 'O'), ('drug', 'O'), ('and', 'O'), ('autonomic', 'O'), ('blockade', 'O'), ('with', 'O'), ('atropine', 'O'), ('and', 'O'), ('nadolol', 'O'), ('was', 'O'), ('applied', 'O'), ('in', 'O'), ('some', 'O'), ('experiments', 'O'), ('.', 'O'))"
Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil .,"(('Underlying', 'O'), ('electrophysiological', 'O'), ('mechanisms', 'O'), ('were', 'O'), ('studied', 'O'), ('in', 'O'), ('detail', 'O'), ('in', 'O'), ('five', 'O'), ('additional', 'O'), ('dogs', 'O'), ('under', 'O'), ('control', 'O'), ('conditions', 'O'), ('and', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('the', 'O'), ('higher', 'O'), ('dose', 'O'), ('of', 'O'), ('verapamil', 'O'), ('.', 'O'))"
Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade .,"(('Neither', 'O'), ('verapamil', 'O'), ('nor', 'O'), ('diltiazem', 'O'), ('affected', 'O'), ('atrial', 'O'), ('conduction', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('autonomic', 'O'), ('blockade', 'O'), ('.', 'O'))"
"Blood samples were collected at baseline , 10 , 20 and 60 min after start of infusion .","(('Blood', 'O'), ('samples', 'O'), ('were', 'O'), ('collected', 'O'), ('at', 'O'), ('baseline', 'O'), (',', 'O'), ('10', 'O'), (',', 'O'), ('20', 'O'), ('and', 'O'), ('60', 'O'), ('min', 'O'), ('after', 'O'), ('start', 'O'), ('of', 'O'), ('infusion', 'O'), ('.', 'O'))"
There was no difference between the area under the CGRP curve ( AUCCGRP ) on GTN vs . placebo day in either patients ( P = 0 . 65 ) or controls ( P = 0 . 48 ) .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('difference', 'O'), ('between', 'O'), ('the', 'O'), ('area', 'O'), ('under', 'O'), ('the', 'O'), ('CGRP', 'O'), ('curve', 'O'), ('(', 'O'), ('AUCCGRP', 'O'), (')', 'O'), ('on', 'O'), ('GTN', 'O'), ('vs', 'O'), ('.', 'O'), ('placebo', 'O'), ('day', 'O'), ('in', 'O'), ('either', 'O'), ('patients', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('65', 'O'), (')', 'O'), ('or', 'O'), ('controls', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('48', 'O'), (')', 'O'), ('.', 'O'))"
The AUCCGRP recorded on the GTN day did not differ between patients and controls ( P = 0 . 36 ) .,"(('The', 'O'), ('AUCCGRP', 'O'), ('recorded', 'O'), ('on', 'O'), ('the', 'O'), ('GTN', 'O'), ('day', 'O'), ('did', 'O'), ('not', 'O'), ('differ', 'O'), ('between', 'O'), ('patients', 'O'), ('and', 'O'), ('controls', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('36', 'O'), (')', 'O'), ('.', 'O'))"
"Both in patients and controls , CGRP levels changed significantly over time , on both the GTN and placebo days ( P < 0 . 05 ) .","(('Both', 'O'), ('in', 'O'), ('patients', 'O'), ('and', 'O'), ('controls', 'O'), (',', 'O'), ('CGRP', 'O'), ('levels', 'O'), ('changed', 'O'), ('significantly', 'O'), ('over', 'O'), ('time', 'O'), (',', 'O'), ('on', 'O'), ('both', 'O'), ('the', 'O'), ('GTN', 'O'), ('and', 'O'), ('placebo', 'O'), ('days', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
Oxacillin was discontinued and patient was treated with corticosteroids .,"(('Oxacillin', 'O'), ('was', 'O'), ('discontinued', 'O'), ('and', 'O'), ('patient', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('corticosteroids', 'O'), ('.', 'O'))"
The rash disappeared after three weeks and renal function returned to normal .,"(('The', 'O'), ('rash', 'O'), ('disappeared', 'O'), ('after', 'O'), ('three', 'O'), ('weeks', 'O'), ('and', 'O'), ('renal', 'O'), ('function', 'O'), ('returned', 'O'), ('to', 'O'), ('normal', 'O'), ('.', 'O'))"
"However , in half of the cases no etiologic factor is identified .","(('However', 'O'), (',', 'O'), ('in', 'O'), ('half', 'O'), ('of', 'O'), ('the', 'O'), ('cases', 'O'), ('no', 'O'), ('etiologic', 'O'), ('factor', 'O'), ('is', 'O'), ('identified', 'O'), ('.', 'O'))"
"Usually it is a self - limited disorder , but corticosteroid therapy may be needed in life - threatening cases since early treatment with corticosteroids in severe cases can prevent complications .","(('Usually', 'O'), ('it', 'O'), ('is', 'O'), ('a', 'O'), ('self', 'O'), ('-', 'O'), ('limited', 'O'), ('disorder', 'O'), (',', 'O'), ('but', 'O'), ('corticosteroid', 'O'), ('therapy', 'O'), ('may', 'O'), ('be', 'O'), ('needed', 'O'), ('in', 'O'), ('life', 'O'), ('-', 'O'), ('threatening', 'O'), ('cases', 'O'), ('since', 'O'), ('early', 'O'), ('treatment', 'O'), ('with', 'O'), ('corticosteroids', 'O'), ('in', 'O'), ('severe', 'O'), ('cases', 'O'), ('can', 'O'), ('prevent', 'O'), ('complications', 'O'), ('.', 'O'))"
The renal pathology in a case of lithium - induced diabetes insipidus .,"(('The', 'O'), ('renal', 'O'), ('pathology', 'O'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('lithium', 'B'), ('-', 'I'), ('induced', 'I'), ('diabetes', 'I'), ('insipidus', 'I'), ('.', 'O'))"
A case of lithium - induced diabetes insipidus is reported .,"(('A', 'O'), ('case', 'O'), ('of', 'O'), ('lithium', 'B'), ('-', 'O'), ('induced', 'O'), ('diabetes', 'B'), ('insipidus', 'I'), ('is', 'O'), ('reported', 'O'), ('.', 'O'))"
At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron .,"(('At', 'O'), ('necropsy', 'O'), ('microscopy', 'O'), ('shoed', 'O'), ('unique', 'O'), ('and', 'O'), ('extensive', 'O'), ('damage', 'O'), ('to', 'O'), ('cells', 'O'), ('lining', 'O'), ('the', 'O'), ('distal', 'O'), ('nephron', 'O'), ('.', 'O'))"
"It is suggested that these changes represent a specific toxic effect of lithium , reported here for the first time in man .","(('It', 'O'), ('is', 'O'), ('suggested', 'O'), ('that', 'O'), ('these', 'O'), ('changes', 'O'), ('represent', 'O'), ('a', 'O'), ('specific', 'O'), ('toxic', 'O'), ('effect', 'O'), ('of', 'O'), ('lithium', 'O'), (',', 'O'), ('reported', 'O'), ('here', 'O'), ('for', 'O'), ('the', 'O'), ('first', 'O'), ('time', 'O'), ('in', 'O'), ('man', 'O'), ('.', 'O'))"
Ultrasound of the liver and abdominal CT were normal .,"(('Ultrasound', 'O'), ('of', 'O'), ('the', 'O'), ('liver', 'O'), ('and', 'O'), ('abdominal', 'O'), ('CT', 'O'), ('were', 'O'), ('normal', 'O'), ('.', 'O'))"
An ERCP showed normal biliary anatomy .,"(('An', 'O'), ('ERCP', 'O'), ('showed', 'O'), ('normal', 'O'), ('biliary', 'O'), ('anatomy', 'O'), ('.', 'O'))"
"Metformin hydrochloride was discontinued , and the patient ' s jaundice resolved slowly over a period of several months .","(('Metformin', 'O'), ('hydrochloride', 'O'), ('was', 'O'), ('discontinued', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('jaundice', 'B'), ('resolved', 'O'), ('slowly', 'O'), ('over', 'O'), ('a', 'O'), ('period', 'O'), ('of', 'O'), ('several', 'O'), ('months', 'O'), ('.', 'O'))"
"Systemic toxicity and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .","(('Systemic', 'O'), ('toxicity', 'O'), ('and', 'O'), ('resuscitation', 'O'), ('in', 'O'), ('bupivacaine', 'O'), ('-', 'O'), (',', 'O'), ('levobupivacaine', 'O'), ('-', 'O'), (',', 'O'), ('or', 'O'), ('ropivacaine', 'O'), ('-', 'O'), ('infused', 'O'), ('rats', 'O'), ('.', 'O'))"
"We compared the systemic toxicity of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .","(('We', 'O'), ('compared', 'O'), ('the', 'O'), ('systemic', 'O'), ('toxicity', 'O'), ('of', 'O'), ('bupivacaine', 'O'), (',', 'O'), ('levobupivacaine', 'O'), (',', 'O'), ('and', 'O'), ('ropivacaine', 'O'), ('in', 'O'), ('anesthetized', 'O'), ('rats', 'O'), ('.', 'O'))"
We also compared the ability to resuscitate rats after lethal doses of these local anesthetics .,"(('We', 'O'), ('also', 'O'), ('compared', 'O'), ('the', 'O'), ('ability', 'O'), ('to', 'O'), ('resuscitate', 'O'), ('rats', 'O'), ('after', 'O'), ('lethal', 'O'), ('doses', 'O'), ('of', 'O'), ('these', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('.', 'O'))"
"Bupivacaine , levobupivacaine , or ropivacaine was infused at a rate of 2 mg .","(('Bupivacaine', 'O'), (',', 'O'), ('levobupivacaine', 'O'), (',', 'O'), ('or', 'O'), ('ropivacaine', 'O'), ('was', 'O'), ('infused', 'O'), ('at', 'O'), ('a', 'O'), ('rate', 'O'), ('of', 'O'), ('2', 'O'), ('mg', 'O'), ('.', 'O'))"
kg ( - 1 ) .,"(('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
"min ( - 1 ) while electrocardiogram , electroencephalogram , and arterial pressure were continuously monitored .","(('min', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('while', 'O'), ('electrocardiogram', 'O'), (',', 'O'), ('electroencephalogram', 'O'), (',', 'O'), ('and', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('were', 'O'), ('continuously', 'O'), ('monitored', 'O'), ('.', 'O'))"
Epinephrine 0 . 01 mg / kg was administered at 1 - min intervals while external cardiac compressions were applied .,"(('Epinephrine', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('was', 'O'), ('administered', 'O'), ('at', 'O'), ('1', 'O'), ('-', 'O'), ('min', 'O'), ('intervals', 'O'), ('while', 'O'), ('external', 'O'), ('cardiac', 'O'), ('compressions', 'O'), ('were', 'O'), ('applied', 'O'), ('.', 'O'))"
Resuscitation was considered successful when a systolic arterial pressure > or = 100 mm Hg was achieved within 5 min .,"(('Resuscitation', 'O'), ('was', 'O'), ('considered', 'O'), ('successful', 'O'), ('when', 'O'), ('a', 'O'), ('systolic', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('>', 'O'), ('or', 'O'), ('=', 'O'), ('100', 'O'), ('mm', 'O'), ('Hg', 'O'), ('was', 'O'), ('achieved', 'O'), ('within', 'O'), ('5', 'O'), ('min', 'O'), ('.', 'O'))"
The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine .,"(('The', 'O'), ('cumulative', 'O'), ('doses', 'O'), ('of', 'O'), ('levobupivacaine', 'O'), ('and', 'O'), ('ropivacaine', 'O'), ('that', 'O'), ('produced', 'O'), ('seizures', 'O'), ('were', 'O'), ('similar', 'O'), ('and', 'O'), ('were', 'O'), ('larger', 'O'), ('than', 'O'), ('those', 'O'), ('of', 'O'), ('bupivacaine', 'O'), ('.', 'O'))"
The number of successful resuscitations did not differ among groups .,"(('The', 'O'), ('number', 'O'), ('of', 'O'), ('successful', 'O'), ('resuscitations', 'O'), ('did', 'O'), ('not', 'O'), ('differ', 'O'), ('among', 'O'), ('groups', 'O'), ('.', 'O'))"
"However , a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups .","(('However', 'O'), (',', 'O'), ('a', 'O'), ('smaller', 'O'), ('dose', 'O'), ('of', 'O'), ('epinephrine', 'O'), ('was', 'O'), ('required', 'O'), ('in', 'O'), ('the', 'O'), ('Ropivacaine', 'O'), ('group', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('other', 'O'), ('groups', 'O'), ('.', 'O'))"
We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('the', 'O'), ('systemic', 'O'), ('toxicity', 'O'), ('of', 'O'), ('levobupivacaine', 'O'), ('is', 'O'), ('intermediate', 'O'), ('between', 'O'), ('that', 'O'), ('of', 'O'), ('ropivacaine', 'O'), ('and', 'O'), ('bupivacaine', 'O'), ('when', 'O'), ('administered', 'O'), ('at', 'O'), ('the', 'O'), ('same', 'O'), ('rate', 'O'), ('and', 'O'), ('that', 'O'), ('ropivacaine', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiac', 'B'), ('arrest', 'I'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('more', 'O'), ('susceptible', 'O'), ('to', 'O'), ('treatment', 'O'), ('than', 'O'), ('that', 'O'), ('induced', 'O'), ('by', 'O'), ('bupivacaine', 'O'), ('or', 'O'), ('levobupivacaine', 'O'), ('.', 'O'))"
"The patients concurrent medications included didanosine , hydroxyzine , promethazine , hydrocortisone , and prochlorperazine .","(('The', 'O'), ('patients', 'O'), ('concurrent', 'O'), ('medications', 'O'), ('included', 'O'), ('didanosine', 'O'), (',', 'O'), ('hydroxyzine', 'O'), (',', 'O'), ('promethazine', 'O'), (',', 'O'), ('hydrocortisone', 'O'), (',', 'O'), ('and', 'O'), ('prochlorperazine', 'O'), ('.', 'O'))"
"Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .","(('Despite', 'O'), ('administration', 'O'), ('of', 'O'), ('phenytoin', 'O'), ('and', 'O'), ('lorazepam', 'O'), (',', 'O'), ('the', 'O'), ('seizures', 'O'), ('persisted', 'O'), ('and', 'O'), ('occurred', 'O'), ('only', 'O'), ('during', 'O'), ('amphotercin', 'O'), ('B', 'O'), ('administration', 'O'), ('.', 'O'))"
Didanosine also has a potential for inducing seizures .,"(('Didanosine', 'O'), ('also', 'O'), ('has', 'O'), ('a', 'O'), ('potential', 'O'), ('for', 'O'), ('inducing', 'O'), ('seizures', 'O'), ('.', 'O'))"
"However , these other potential causes of seizure were ruled out .","(('However', 'O'), (',', 'O'), ('these', 'O'), ('other', 'O'), ('potential', 'O'), ('causes', 'O'), ('of', 'O'), ('seizure', 'O'), ('were', 'O'), ('ruled', 'O'), ('out', 'O'), ('.', 'O'))"
CONCLUSIONS : Amphotericin B seems to be the probable cause of the seizures .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Amphotericin', 'O'), ('B', 'O'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('the', 'O'), ('probable', 'O'), ('cause', 'O'), ('of', 'O'), ('the', 'O'), ('seizures', 'O'), ('.', 'O'))"
"To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .","(('To', 'O'), ('date', 'O'), (',', 'O'), ('only', 'O'), ('three', 'O'), ('cases', 'O'), ('of', 'O'), ('seizures', 'O'), ('associated', 'O'), ('with', 'O'), ('amphotericin', 'O'), ('B', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), (',', 'O'), ('but', 'O'), ('healthcare', 'O'), ('providers', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('the', 'O'), ('potential', 'O'), ('for', 'O'), ('this', 'O'), ('rare', 'O'), ('adverse', 'O'), ('effect', 'O'), ('.', 'O'))"
Sirolimus and mycophenolate mofetil for calcineurin - free immunosuppression in renal transplant recipients .,"(('Sirolimus', 'O'), ('and', 'O'), ('mycophenolate', 'O'), ('mofetil', 'O'), ('for', 'O'), ('calcineurin', 'O'), ('-', 'O'), ('free', 'O'), ('immunosuppression', 'O'), ('in', 'O'), ('renal', 'O'), ('transplant', 'O'), ('recipients', 'O'), ('.', 'O'))"
"Calcineurin inhibitors , such as cyclosporine and tacrolimus , have been available for almost 20 years .","(('Calcineurin', 'O'), ('inhibitors', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('cyclosporine', 'O'), ('and', 'O'), ('tacrolimus', 'O'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('available', 'O'), ('for', 'O'), ('almost', 'O'), ('20', 'O'), ('years', 'O'), ('.', 'O'))"
The use of these drugs in combination with other agents has led to the development of new paradigms of immunosuppressive therapy .,"(('The', 'O'), ('use', 'O'), ('of', 'O'), ('these', 'O'), ('drugs', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('other', 'O'), ('agents', 'O'), ('has', 'O'), ('led', 'O'), ('to', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('new', 'O'), ('paradigms', 'O'), ('of', 'O'), ('immunosuppressive', 'O'), ('therapy', 'O'), ('.', 'O'))"
This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients .,"(('This', 'O'), ('paper', 'O'), ('reviews', 'O'), ('the', 'O'), ('results', 'O'), ('of', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('have', 'O'), ('investigated', 'O'), ('these', 'O'), ('new', 'O'), ('approaches', 'O'), ('to', 'O'), ('immunosuppression', 'O'), ('in', 'O'), ('renal', 'O'), ('transplant', 'O'), ('recipients', 'O'), ('.', 'O'))"
"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous , respiratory and anaphylactoid reactions induced by nonsteroidal anti - inflammatory drugs ( NSAIDs ) .","(('Previous', 'O'), ('studies', 'O'), ('evaluated', 'O'), ('the', 'O'), ('tolerance', 'O'), ('of', 'O'), ('nimesulide', 'O'), ('and', 'O'), ('paracetamol', 'O'), ('in', 'O'), ('subjects', 'O'), ('with', 'O'), ('cutaneous', 'B'), (',', 'I'), ('respiratory', 'I'), ('and', 'I'), ('anaphylactoid', 'I'), ('reactions', 'I'), ('induced', 'O'), ('by', 'O'), ('nonsteroidal', 'B'), ('anti', 'I'), ('-', 'I'), ('inflammatory', 'I'), ('drugs', 'O'), ('(', 'O'), ('NSAIDs', 'O'), (')', 'O'), ('.', 'O'))"
"Furthermore , we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide .","(('Furthermore', 'O'), (',', 'O'), ('we', 'O'), ('evaluated', 'O'), ('whether', 'O'), ('some', 'O'), ('factors', 'O'), ('have', 'O'), ('the', 'O'), ('potential', 'O'), ('to', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('reaction', 'O'), ('to', 'O'), ('paracetamol', 'O'), ('and', 'O'), ('nimesulide', 'O'), ('.', 'O'))"
A total of 75 / 829 ( 9 . 4 % ) patients experienced reactions to nimesulide or paracetamol .,"(('A', 'O'), ('total', 'O'), ('of', 'O'), ('75', 'O'), ('/', 'O'), ('829', 'O'), ('(', 'O'), ('9', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('experienced', 'O'), ('reactions', 'O'), ('to', 'O'), ('nimesulide', 'O'), ('or', 'O'), ('paracetamol', 'O'), ('.', 'O'))"
"Of the 715 patients tested with nimesulide 62 ( 8 . 6 % ) showed a positive test , while of 114 subjects submitted to the challenge with paracetamol , 13 ( 9 . 6 % ) did not tolerate this drug .","(('Of', 'O'), ('the', 'O'), ('715', 'O'), ('patients', 'O'), ('tested', 'O'), ('with', 'O'), ('nimesulide', 'O'), ('62', 'O'), ('(', 'O'), ('8', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), ('showed', 'O'), ('a', 'O'), ('positive', 'O'), ('test', 'O'), (',', 'O'), ('while', 'O'), ('of', 'O'), ('114', 'O'), ('subjects', 'O'), ('submitted', 'O'), ('to', 'O'), ('the', 'O'), ('challenge', 'O'), ('with', 'O'), ('paracetamol', 'O'), (',', 'O'), ('13', 'O'), ('(', 'O'), ('9', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), ('did', 'O'), ('not', 'O'), ('tolerate', 'O'), ('this', 'O'), ('drug', 'O'), ('.', 'O'))"
Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for glaucoma .,"(('Comparison', 'O'), ('of', 'O'), ('aqueous', 'O'), ('and', 'O'), ('gellan', 'O'), ('ophthalmic', 'O'), ('timolol', 'O'), ('with', 'O'), ('placebo', 'O'), ('on', 'O'), ('the', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('heart', 'O'), ('rate', 'O'), ('response', 'O'), ('in', 'O'), ('patients', 'O'), ('on', 'O'), ('treatment', 'O'), ('for', 'O'), ('glaucoma', 'B'), ('.', 'O'))"
PURPOSE : Topical beta - blocker treatment is routine therapy in the management of patients with glaucoma .,"(('PURPOSE', 'O'), (':', 'O'), ('Topical', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('treatment', 'O'), ('is', 'O'), ('routine', 'O'), ('therapy', 'O'), ('in', 'O'), ('the', 'O'), ('management', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('glaucoma', 'B'), ('.', 'O'))"
"Therapy results in systemic absorption , however , the degree of reduction of resting and peak heart rate has not been quantified .","(('Therapy', 'O'), ('results', 'O'), ('in', 'O'), ('systemic', 'O'), ('absorption', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('the', 'O'), ('degree', 'O'), ('of', 'O'), ('reduction', 'O'), ('of', 'O'), ('resting', 'O'), ('and', 'O'), ('peak', 'O'), ('heart', 'O'), ('rate', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('quantified', 'O'), ('.', 'O'))"
"DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate .","(('DESIGN', 'O'), (':', 'O'), ('This', 'O'), ('trial', 'O'), ('evaluated', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('placebo', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('aqueous', 'O'), ('timolol', 'O'), ('(', 'O'), ('timolol', 'O'), ('solution', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('timolol', 'O'), ('suspension', 'O'), ('that', 'O'), ('forms', 'O'), ('a', 'O'), ('gel', 'O'), ('on', 'O'), ('application', 'O'), ('to', 'O'), ('the', 'O'), ('conjunctiva', 'O'), ('(', 'O'), ('timolol', 'O'), ('gellan', 'O'), (')', 'O'), ('on', 'O'), ('the', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('heart', 'O'), ('rate', 'O'), ('in', 'O'), ('patients', 'O'), ('currently', 'O'), ('being', 'O'), ('treated', 'O'), ('for', 'O'), ('glaucoma', 'B'), ('to', 'O'), ('quantify', 'O'), ('the', 'O'), ('reduction', 'O'), ('in', 'O'), ('mean', 'O'), ('heart', 'O'), ('rate', 'O'), ('.', 'O'))"
"On the 13th day of each period , heart rate was recorded continuously during a typical , ambulant 24 - hour period .","(('On', 'O'), ('the', 'O'), ('13th', 'O'), ('day', 'O'), ('of', 'O'), ('each', 'O'), ('period', 'O'), (',', 'O'), ('heart', 'O'), ('rate', 'O'), ('was', 'O'), ('recorded', 'O'), ('continuously', 'O'), ('during', 'O'), ('a', 'O'), ('typical', 'O'), (',', 'O'), ('ambulant', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('period', 'O'), ('.', 'O'))"
"RESULTS : Both timolol solution and timolol gellan reduced the mean 24 - hour heart rate compared with placebo ( P < or = . 001 ) , and this reduction was most pronounced during the daytime ( - 7 . 5 % change in mean heart rate , - 5 . 7 beats / min ) .","(('RESULTS', 'O'), (':', 'O'), ('Both', 'O'), ('timolol', 'O'), ('solution', 'O'), ('and', 'O'), ('timolol', 'O'), ('gellan', 'O'), ('reduced', 'O'), ('the', 'O'), ('mean', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('heart', 'O'), ('rate', 'O'), ('compared', 'O'), ('with', 'O'), ('placebo', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('or', 'O'), ('=', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('this', 'O'), ('reduction', 'O'), ('was', 'O'), ('most', 'O'), ('pronounced', 'O'), ('during', 'O'), ('the', 'O'), ('daytime', 'O'), ('(', 'O'), ('-', 'O'), ('7', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('change', 'O'), ('in', 'O'), ('mean', 'O'), ('heart', 'O'), ('rate', 'O'), (',', 'O'), ('-', 'O'), ('5', 'O'), ('.', 'O'), ('7', 'O'), ('beats', 'O'), ('/', 'O'), ('min', 'O'), (')', 'O'), ('.', 'O'))"
"Timolol gellan showed a numerically but not significantly smaller reduction in 24 - hour heart rate , compared with timolol solution .","(('Timolol', 'O'), ('gellan', 'O'), ('showed', 'O'), ('a', 'O'), ('numerically', 'O'), ('but', 'O'), ('not', 'O'), ('significantly', 'O'), ('smaller', 'O'), ('reduction', 'O'), ('in', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('heart', 'O'), ('rate', 'O'), (',', 'O'), ('compared', 'O'), ('with', 'O'), ('timolol', 'O'), ('solution', 'O'), ('.', 'O'))"
"During the night , the mean 12 - hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution ; the difference between solution and gellan treatments was statistically significant ( P = . 01 ) .","(('During', 'O'), ('the', 'O'), ('night', 'O'), (',', 'O'), ('the', 'O'), ('mean', 'O'), ('12', 'O'), ('-', 'O'), ('hour', 'O'), ('heart', 'O'), ('rate', 'O'), ('on', 'O'), ('placebo', 'O'), ('and', 'O'), ('timolol', 'O'), ('gellan', 'O'), ('were', 'O'), ('both', 'O'), ('significantly', 'O'), ('less', 'O'), ('than', 'O'), ('on', 'O'), ('timolol', 'O'), ('solution', 'O'), (';', 'O'), ('the', 'O'), ('difference', 'O'), ('between', 'O'), ('solution', 'O'), ('and', 'O'), ('gellan', 'O'), ('treatments', 'O'), ('was', 'O'), ('statistically', 'O'), ('significant', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSIONS : Both timolol solution and timolol gellan decrease the mean 24 - hour heart rate compared with placebo .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Both', 'O'), ('timolol', 'O'), ('solution', 'O'), ('and', 'O'), ('timolol', 'O'), ('gellan', 'O'), ('decrease', 'O'), ('the', 'O'), ('mean', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('heart', 'O'), ('rate', 'O'), ('compared', 'O'), ('with', 'O'), ('placebo', 'O'), ('.', 'O'))"
This response was most pronounced during the active daytime period .,"(('This', 'O'), ('response', 'O'), ('was', 'O'), ('most', 'O'), ('pronounced', 'O'), ('during', 'O'), ('the', 'O'), ('active', 'O'), ('daytime', 'O'), ('period', 'O'), ('.', 'O'))"
"Although exercise performance was not assessed in this trial , reductions of this magnitude should not have substantial clinical consequences .","(('Although', 'O'), ('exercise', 'O'), ('performance', 'O'), ('was', 'O'), ('not', 'O'), ('assessed', 'O'), ('in', 'O'), ('this', 'O'), ('trial', 'O'), (',', 'O'), ('reductions', 'O'), ('of', 'O'), ('this', 'O'), ('magnitude', 'O'), ('should', 'O'), ('not', 'O'), ('have', 'O'), ('substantial', 'O'), ('clinical', 'O'), ('consequences', 'O'), ('.', 'O'))"
Management strategies for ribavirin - induced hemolytic anemia in the treatment of hepatitis C : clinical and economic implications .,"(('Management', 'O'), ('strategies', 'O'), ('for', 'O'), ('ribavirin', 'O'), ('-', 'O'), ('induced', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('C', 'I'), (':', 'O'), ('clinical', 'O'), ('and', 'O'), ('economic', 'O'), ('implications', 'O'), ('.', 'O'))"
Uncertainty was evaluated using sensitivity analyses .,"(('Uncertainty', 'O'), ('was', 'O'), ('evaluated', 'O'), ('using', 'O'), ('sensitivity', 'O'), ('analyses', 'O'), ('.', 'O'))"
The results of the one - way sensitivity analyses ranged from 57 to 317 .,"(('The', 'O'), ('results', 'O'), ('of', 'O'), ('the', 'O'), ('one', 'O'), ('-', 'O'), ('way', 'O'), ('sensitivity', 'O'), ('analyses', 'O'), ('ranged', 'O'), ('from', 'O'), ('57', 'O'), ('to', 'O'), ('317', 'O'), ('.', 'O'))"
"In comparison , the cost of 48 weeks of combination therapy is 16 , 459 .","(('In', 'O'), ('comparison', 'O'), (',', 'O'), ('the', 'O'), ('cost', 'O'), ('of', 'O'), ('48', 'O'), ('weeks', 'O'), ('of', 'O'), ('combination', 'O'), ('therapy', 'O'), ('is', 'O'), ('16', 'O'), (',', 'O'), ('459', 'O'), ('.', 'O'))"
Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans .,"(('Preliminary', 'O'), ('efficacy', 'O'), ('assessment', 'O'), ('of', 'O'), ('intrathecal', 'O'), ('injection', 'O'), ('of', 'O'), ('an', 'O'), ('American', 'O'), ('formulation', 'O'), ('of', 'O'), ('adenosine', 'O'), ('in', 'O'), ('humans', 'O'), ('.', 'O'))"
"The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical hypersensitivity .","(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('screen', 'O'), ('for', 'O'), ('efficacy', 'O'), ('of', 'O'), ('a', 'O'), ('different', 'O'), ('formulation', 'O'), ('of', 'O'), ('adenosine', 'O'), ('marketed', 'O'), ('in', 'O'), ('the', 'O'), ('US', 'O'), (',', 'O'), ('using', 'O'), ('both', 'O'), ('acute', 'O'), ('noxious', 'O'), ('stimulation', 'O'), ('and', 'O'), ('capsaicin', 'O'), ('-', 'O'), ('evoked', 'O'), ('mechanical', 'B'), ('hypersensitivity', 'I'), ('.', 'O'))"
"METHODS : Following Food and Drug Administration and institutional review board approval and written informed consent , 65 volunteers were studied in two trials : an open - label , dose - escalating trial with intrathecal adenosine doses of 0 . 25 - 2 . 0 mg and a double - blind , placebo - controlled trial of adenosine , 2 mg .","(('METHODS', 'O'), (':', 'O'), ('Following', 'O'), ('Food', 'O'), ('and', 'O'), ('Drug', 'O'), ('Administration', 'O'), ('and', 'O'), ('institutional', 'O'), ('review', 'O'), ('board', 'O'), ('approval', 'O'), ('and', 'O'), ('written', 'O'), ('informed', 'O'), ('consent', 'O'), (',', 'O'), ('65', 'O'), ('volunteers', 'O'), ('were', 'O'), ('studied', 'O'), ('in', 'O'), ('two', 'O'), ('trials', 'O'), (':', 'O'), ('an', 'O'), ('open', 'O'), ('-', 'O'), ('label', 'O'), (',', 'O'), ('dose', 'O'), ('-', 'O'), ('escalating', 'O'), ('trial', 'O'), ('with', 'O'), ('intrathecal', 'O'), ('adenosine', 'O'), ('doses', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('25', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('and', 'O'), ('a', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('trial', 'O'), ('of', 'O'), ('adenosine', 'O'), (',', 'O'), ('2', 'O'), ('mg', 'O'), ('.', 'O'))"
"In contrast , residence time of adenosine in cerebrospinal fluid was short ( < 4 h ) .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('residence', 'O'), ('time', 'O'), ('of', 'O'), ('adenosine', 'O'), ('in', 'O'), ('cerebrospinal', 'O'), ('fluid', 'O'), ('was', 'O'), ('short', 'O'), ('(', 'O'), ('<', 'O'), ('4', 'O'), ('h', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of hypersensitivity , presumed to reflect central sensitization in humans after peripheral capsaicin injection .","(('CONCLUSIONS', 'O'), (':', 'O'), ('These', 'O'), ('results', 'O'), ('show', 'O'), ('selective', 'O'), ('inhibition', 'O'), ('by', 'O'), ('intrathecal', 'O'), ('adenosine', 'O'), ('of', 'O'), ('hypersensitivity', 'B'), (',', 'O'), ('presumed', 'O'), ('to', 'O'), ('reflect', 'O'), ('central', 'O'), ('sensitization', 'O'), ('in', 'O'), ('humans', 'O'), ('after', 'O'), ('peripheral', 'O'), ('capsaicin', 'O'), ('injection', 'O'), ('.', 'O'))"
Delayed - onset heparin - induced thrombocytopenia .,"(('Delayed', 'O'), ('-', 'O'), ('onset', 'O'), ('heparin', 'B'), ('-', 'I'), ('induced', 'I'), ('thrombocytopenia', 'I'), ('.', 'O'))"
Delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes .,"(('Delayed', 'O'), ('recognition', 'O'), ('and', 'O'), ('treatment', 'O'), ('of', 'O'), ('heparin', 'B'), ('-', 'I'), ('induced', 'I'), ('thrombocytopenia', 'I'), ('contribute', 'O'), ('to', 'O'), ('poor', 'O'), ('patient', 'O'), ('outcomes', 'O'), ('.', 'O'))"
OBJECTIVE : To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced thrombocytopenia are delayed .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('describe', 'O'), ('and', 'O'), ('increase', 'O'), ('awareness', 'O'), ('of', 'O'), ('a', 'O'), ('clinical', 'O'), ('scenario', 'O'), ('in', 'O'), ('which', 'O'), ('the', 'O'), ('onset', 'O'), ('or', 'O'), ('manifestations', 'O'), ('of', 'O'), ('heparin', 'B'), ('-', 'I'), ('induced', 'I'), ('thrombocytopenia', 'I'), ('are', 'O'), ('delayed', 'O'), ('.', 'O'))"
DESIGN : Retrospective case series .,"(('DESIGN', 'O'), (':', 'O'), ('Retrospective', 'O'), ('case', 'O'), ('series', 'O'), ('.', 'O'))"
SETTING : Three large urban hospitals ( with active cardiovascular surgery programs ) .,"(('SETTING', 'O'), (':', 'O'), ('Three', 'O'), ('large', 'O'), ('urban', 'O'), ('hospitals', 'O'), ('(', 'O'), ('with', 'O'), ('active', 'O'), ('cardiovascular', 'O'), ('surgery', 'O'), ('programs', 'O'), (')', 'O'), ('.', 'O'))"
Platelet counts were mildly decreased in all but 2 patients on second presentation .,"(('Platelet', 'O'), ('counts', 'O'), ('were', 'O'), ('mildly', 'O'), ('decreased', 'O'), ('in', 'O'), ('all', 'O'), ('but', 'O'), ('2', 'O'), ('patients', 'O'), ('on', 'O'), ('second', 'O'), ('presentation', 'O'), ('.', 'O'))"
"On readmission , 11 patients received therapeutic heparin , which worsened the patients ' clinical condition and , in all 11 cases , decreased the platelet count ( mean at readmission , 143 x 10 ( 9 ) cells / L ; mean nadir after heparin re - exposure , 39 x 10 ( 9 ) cells / L ) .","(('On', 'O'), ('readmission', 'O'), (',', 'O'), ('11', 'O'), ('patients', 'O'), ('received', 'O'), ('therapeutic', 'O'), ('heparin', 'O'), (',', 'O'), ('which', 'O'), ('worsened', 'O'), ('the', 'O'), ('patients', 'O'), (""'"", 'O'), ('clinical', 'O'), ('condition', 'O'), ('and', 'O'), (',', 'O'), ('in', 'O'), ('all', 'O'), ('11', 'O'), ('cases', 'O'), (',', 'O'), ('decreased', 'O'), ('the', 'O'), ('platelet', 'O'), ('count', 'O'), ('(', 'O'), ('mean', 'O'), ('at', 'O'), ('readmission', 'O'), (',', 'O'), ('143', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('9', 'O'), (')', 'O'), ('cells', 'O'), ('/', 'O'), ('L', 'O'), (';', 'O'), ('mean', 'O'), ('nadir', 'O'), ('after', 'O'), ('heparin', 'O'), ('re', 'O'), ('-', 'O'), ('exposure', 'O'), (',', 'O'), ('39', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('9', 'O'), (')', 'O'), ('cells', 'O'), ('/', 'O'), ('L', 'O'), (')', 'O'), ('.', 'O'))"
Results of serologic tests for heparin - induced antibodies were positive in all patients .,"(('Results', 'O'), ('of', 'O'), ('serologic', 'O'), ('tests', 'O'), ('for', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('antibodies', 'O'), ('were', 'O'), ('positive', 'O'), ('in', 'O'), ('all', 'O'), ('patients', 'O'), ('.', 'O'))"
"Subsequent treatments included alternative anticoagulants ( 11 patients ) , thrombolytic drugs ( 3 patients ) , inferior vena cava filters ( 3 patients ) and , eventually , warfarin ( 11 patients ) .","(('Subsequent', 'O'), ('treatments', 'O'), ('included', 'O'), ('alternative', 'O'), ('anticoagulants', 'O'), ('(', 'O'), ('11', 'O'), ('patients', 'O'), (')', 'O'), (',', 'O'), ('thrombolytic', 'O'), ('drugs', 'O'), ('(', 'O'), ('3', 'O'), ('patients', 'O'), (')', 'O'), (',', 'O'), ('inferior', 'O'), ('vena', 'O'), ('cava', 'O'), ('filters', 'O'), ('(', 'O'), ('3', 'O'), ('patients', 'O'), (')', 'O'), ('and', 'O'), (',', 'O'), ('eventually', 'O'), (',', 'O'), ('warfarin', 'O'), ('(', 'O'), ('11', 'O'), ('patients', 'O'), (')', 'O'), ('.', 'O'))"
Three patients died .,"(('Three', 'O'), ('patients', 'O'), ('died', 'O'), ('.', 'O'))"
CONCLUSIONS : Delayed - onset heparin - induced thrombocytopenia is increasingly being recognized .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Delayed', 'O'), ('-', 'O'), ('onset', 'O'), ('heparin', 'B'), ('-', 'O'), ('induced', 'I'), ('thrombocytopenia', 'I'), ('is', 'O'), ('increasingly', 'O'), ('being', 'O'), ('recognized', 'O'), ('.', 'O'))"
"When serum prolactin levels normalized in all four subjects ( mean 11 . 2 + / - 10 . 9 ng / mL ) , the cabergoline dose was reduced to 1 mg / week in three of four subjects .","(('When', 'O'), ('serum', 'O'), ('prolactin', 'O'), ('levels', 'O'), ('normalized', 'O'), ('in', 'O'), ('all', 'O'), ('four', 'O'), ('subjects', 'O'), ('(', 'O'), ('mean', 'O'), ('11', 'O'), ('.', 'O'), ('2', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('10', 'O'), ('.', 'O'), ('9', 'O'), ('ng', 'O'), ('/', 'O'), ('mL', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('cabergoline', 'O'), ('dose', 'O'), ('was', 'O'), ('reduced', 'O'), ('to', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('week', 'O'), ('in', 'O'), ('three', 'O'), ('of', 'O'), ('four', 'O'), ('subjects', 'O'), ('.', 'O'))"
"The mean duration of therapy with cabergoline was 523 . 5 + / - 129 . 7 days , and the mean duration of therapy with risperidone was 788 . 5 + / - 162 . 5 days .","(('The', 'O'), ('mean', 'O'), ('duration', 'O'), ('of', 'O'), ('therapy', 'O'), ('with', 'O'), ('cabergoline', 'O'), ('was', 'O'), ('523', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('129', 'O'), ('.', 'O'), ('7', 'O'), ('days', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('mean', 'O'), ('duration', 'O'), ('of', 'O'), ('therapy', 'O'), ('with', 'O'), ('risperidone', 'O'), ('was', 'O'), ('788', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('162', 'O'), ('.', 'O'), ('5', 'O'), ('days', 'O'), ('.', 'O'))"
Cabergoline was well tolerated without adverse effects .,"(('Cabergoline', 'O'), ('was', 'O'), ('well', 'O'), ('tolerated', 'O'), ('without', 'O'), ('adverse', 'O'), ('effects', 'O'), ('.', 'O'))"
"There was no evidence for viral , autoimmune , or metabolic causes of hepatitis .","(('There', 'O'), ('was', 'O'), ('no', 'O'), ('evidence', 'O'), ('for', 'O'), ('viral', 'O'), (',', 'O'), ('autoimmune', 'O'), (',', 'O'), ('or', 'O'), ('metabolic', 'O'), ('causes', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('.', 'O'))"
The alanine aminotransferase was elevated to a peak concentration of 1533 U / L and the serum bilirubin reached a peak of 17 . 0 mg / dL .,"(('The', 'O'), ('alanine', 'O'), ('aminotransferase', 'O'), ('was', 'O'), ('elevated', 'O'), ('to', 'O'), ('a', 'O'), ('peak', 'O'), ('concentration', 'O'), ('of', 'O'), ('1533', 'O'), ('U', 'O'), ('/', 'O'), ('L', 'O'), ('and', 'O'), ('the', 'O'), ('serum', 'O'), ('bilirubin', 'O'), ('reached', 'O'), ('a', 'O'), ('peak', 'O'), ('of', 'O'), ('17', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('/', 'O'), ('dL', 'O'), ('.', 'O'))"
There was slow improvement over 4 months .,"(('There', 'O'), ('was', 'O'), ('slow', 'O'), ('improvement', 'O'), ('over', 'O'), ('4', 'O'), ('months', 'O'), ('.', 'O'))"
Accidental reexposure by the patient to dipyrone was uneventful .,"(('Accidental', 'O'), ('reexposure', 'O'), ('by', 'O'), ('the', 'O'), ('patient', 'O'), ('to', 'O'), ('dipyrone', 'O'), ('was', 'O'), ('uneventful', 'O'), ('.', 'O'))"
"However , the torsadogenic potential of metoclopramide , a commonly used antiemetic and prokinetic drug , has not been reported in the literature , despite its chemical similarity to procainamide .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('torsadogenic', 'O'), ('potential', 'O'), ('of', 'O'), ('metoclopramide', 'O'), (',', 'O'), ('a', 'O'), ('commonly', 'O'), ('used', 'O'), ('antiemetic', 'O'), ('and', 'O'), ('prokinetic', 'O'), ('drug', 'O'), (',', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), (',', 'O'), ('despite', 'O'), ('its', 'O'), ('chemical', 'O'), ('similarity', 'O'), ('to', 'O'), ('procainamide', 'O'), ('.', 'O'))"
These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs .,"(('These', 'O'), ('two', 'O'), ('episodes', 'O'), ('were', 'O'), ('suppressed', 'O'), ('successfully', 'O'), ('after', 'O'), ('discontinuing', 'O'), ('the', 'O'), ('offending', 'O'), ('drugs', 'O'), ('and', 'O'), ('administering', 'O'), ('class', 'O'), ('IB', 'O'), ('drugs', 'O'), ('.', 'O'))"
Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs .,"(('Dopamine', 'O'), ('D2', 'O'), ('receptor', 'O'), ('signaling', 'O'), ('controls', 'O'), ('neuronal', 'O'), ('cell', 'O'), ('death', 'O'), ('induced', 'O'), ('by', 'O'), ('muscarinic', 'O'), ('and', 'O'), ('glutamatergic', 'O'), ('drugs', 'O'), ('.', 'O'))"
"In this respect , little is known about the role of DA receptors in the occurrence of epilepsy - induced neuronal cell death .","(('In', 'O'), ('this', 'O'), ('respect', 'O'), (',', 'O'), ('little', 'O'), ('is', 'O'), ('known', 'O'), ('about', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('DA', 'O'), ('receptors', 'O'), ('in', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('epilepsy', 'B'), ('-', 'O'), ('induced', 'O'), ('neuronal', 'B'), ('cell', 'I'), ('death', 'I'), ('.', 'O'))"
"We compared these results with those previously obtained with kainic acid ( KA ) , a potent glutamate agonist .","(('We', 'O'), ('compared', 'O'), ('these', 'O'), ('results', 'O'), ('with', 'O'), ('those', 'O'), ('previously', 'O'), ('obtained', 'O'), ('with', 'O'), ('kainic', 'O'), ('acid', 'O'), ('(', 'O'), ('KA', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('potent', 'O'), ('glutamate', 'O'), ('agonist', 'O'), ('.', 'O'))"
"However , pilocarpine - induced seizures result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .","(('However', 'O'), (',', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('result', 'O'), ('in', 'O'), ('a', 'O'), ('more', 'O'), ('widespread', 'O'), ('neuronal', 'B'), ('death', 'O'), ('in', 'O'), ('both', 'O'), ('WT', 'O'), ('and', 'O'), ('D2R', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('brains', 'O'), ('in', 'O'), ('comparison', 'O'), ('to', 'O'), ('KA', 'O'), ('.', 'O'))"
"Thus , the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine .","(('Thus', 'O'), (',', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('D2R', 'O'), ('lowers', 'O'), ('the', 'O'), ('threshold', 'O'), ('for', 'O'), ('seizures', 'O'), ('induced', 'O'), ('by', 'O'), ('both', 'O'), ('glutamate', 'O'), ('and', 'O'), ('acetylcholine', 'O'), ('.', 'O'))"
"Moreover , the dopaminergic control of epilepsy - induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .","(('Moreover', 'O'), (',', 'O'), ('the', 'O'), ('dopaminergic', 'O'), ('control', 'O'), ('of', 'O'), ('epilepsy', 'B'), ('-', 'O'), ('induced', 'O'), ('neurodegeneration', 'B'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('mediated', 'O'), ('by', 'O'), ('distinct', 'O'), ('interactions', 'O'), ('of', 'O'), ('D2R', 'O'), ('signaling', 'O'), ('with', 'O'), ('these', 'O'), ('two', 'O'), ('neurotransmitters', 'O'), ('.', 'O'))"
"Pregnenolone sulphate ( PREGS ) has generated interest as one of the most potent memory - enhancing neurosteroids to be examined in rodent learning studies , with particular importance in the ageing process .","(('Pregnenolone', 'O'), ('sulphate', 'O'), ('(', 'O'), ('PREGS', 'O'), (')', 'O'), ('has', 'O'), ('generated', 'O'), ('interest', 'O'), ('as', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('most', 'O'), ('potent', 'O'), ('memory', 'O'), ('-', 'O'), ('enhancing', 'O'), ('neurosteroids', 'O'), ('to', 'O'), ('be', 'O'), ('examined', 'O'), ('in', 'O'), ('rodent', 'O'), ('learning', 'O'), ('studies', 'O'), (',', 'O'), ('with', 'O'), ('particular', 'O'), ('importance', 'O'), ('in', 'O'), ('the', 'O'), ('ageing', 'O'), ('process', 'O'), ('.', 'O'))"
The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems .,"(('The', 'O'), ('mechanism', 'O'), ('by', 'O'), ('which', 'O'), ('this', 'O'), ('endogenous', 'O'), ('steroid', 'O'), ('enhances', 'O'), ('memory', 'O'), ('formation', 'O'), ('is', 'O'), ('hypothesized', 'O'), ('to', 'O'), ('involve', 'O'), ('actions', 'O'), ('on', 'O'), ('glutamatergic', 'O'), ('and', 'O'), ('GABAergic', 'O'), ('systems', 'O'), ('.', 'O'))"
This hypothesis stems from findings that PREGS is a potent positive modulator of N - methyl - d - aspartate receptors ( NMDARs ) and a negative modulator of gamma - aminobutyric acid ( A ) receptors ( GABA ( A ) Rs ) .,"(('This', 'O'), ('hypothesis', 'O'), ('stems', 'O'), ('from', 'O'), ('findings', 'O'), ('that', 'O'), ('PREGS', 'O'), ('is', 'O'), ('a', 'O'), ('potent', 'O'), ('positive', 'O'), ('modulator', 'O'), ('of', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('d', 'O'), ('-', 'O'), ('aspartate', 'O'), ('receptors', 'O'), ('(', 'O'), ('NMDARs', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('negative', 'O'), ('modulator', 'O'), ('of', 'O'), ('gamma', 'O'), ('-', 'O'), ('aminobutyric', 'O'), ('acid', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), ('receptors', 'O'), ('(', 'O'), ('GABA', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), ('Rs', 'O'), (')', 'O'), ('.', 'O'))"
"To investigate this hypothesis , the present study in rats examined the memory - altering abilities of structural analogs of PREGS , which differ in their modulation of NMDAR and / or GABA ( A ) R function .","(('To', 'O'), ('investigate', 'O'), ('this', 'O'), ('hypothesis', 'O'), (',', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('in', 'O'), ('rats', 'O'), ('examined', 'O'), ('the', 'O'), ('memory', 'O'), ('-', 'O'), ('altering', 'O'), ('abilities', 'O'), ('of', 'O'), ('structural', 'O'), ('analogs', 'O'), ('of', 'O'), ('PREGS', 'O'), (',', 'O'), ('which', 'O'), ('differ', 'O'), ('in', 'O'), ('their', 'O'), ('modulation', 'O'), ('of', 'O'), ('NMDAR', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('GABA', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), ('R', 'O'), ('function', 'O'), ('.', 'O'))"
"The analogs tested were : 11 - ketopregnenolone sulphate ( an agent that is inactive at GABA ( A ) Rs and NMDARs ) , epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate , an inhibitor of both GABA ( A ) Rs and NMDARs ) , and a newly synthesized ( - ) PREGS enantiomer ( which is identical to PREGS in effects on GABA ( A ) Rs and NMDARs ) .","(('The', 'O'), ('analogs', 'O'), ('tested', 'O'), ('were', 'O'), (':', 'O'), ('11', 'O'), ('-', 'O'), ('ketopregnenolone', 'O'), ('sulphate', 'O'), ('(', 'O'), ('an', 'O'), ('agent', 'O'), ('that', 'O'), ('is', 'O'), ('inactive', 'O'), ('at', 'O'), ('GABA', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), ('Rs', 'O'), ('and', 'O'), ('NMDARs', 'O'), (')', 'O'), (',', 'O'), ('epipregnanolone', 'O'), ('(', 'O'), ('[', 'O'), ('3beta', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('-', 'O'), ('5beta', 'O'), ('-', 'O'), ('pregnan', 'O'), ('-', 'O'), ('20', 'O'), ('-', 'O'), ('one', 'O'), (']', 'O'), ('sulphate', 'O'), (',', 'O'), ('an', 'O'), ('inhibitor', 'O'), ('of', 'O'), ('both', 'O'), ('GABA', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), ('Rs', 'O'), ('and', 'O'), ('NMDARs', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('a', 'O'), ('newly', 'O'), ('synthesized', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('PREGS', 'O'), ('enantiomer', 'O'), ('(', 'O'), ('which', 'O'), ('is', 'O'), ('identical', 'O'), ('to', 'O'), ('PREGS', 'O'), ('in', 'O'), ('effects', 'O'), ('on', 'O'), ('GABA', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), ('Rs', 'O'), ('and', 'O'), ('NMDARs', 'O'), (')', 'O'), ('.', 'O'))"
Both PREGS and its ( - ) enantiomer blocked the effects of scopolamine .,"(('Both', 'O'), ('PREGS', 'O'), ('and', 'O'), ('its', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('enantiomer', 'O'), ('blocked', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('scopolamine', 'O'), ('.', 'O'))"
"The results show that , unlike PREGS , 11 - ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine , suggesting that altering the modulation of NMDA receptors diminishes the memory - enhancing effects of PREGS .","(('The', 'O'), ('results', 'O'), ('show', 'O'), ('that', 'O'), (',', 'O'), ('unlike', 'O'), ('PREGS', 'O'), (',', 'O'), ('11', 'O'), ('-', 'O'), ('ketopregnenolone', 'O'), ('sulphate', 'O'), ('and', 'O'), ('epipregnanolone', 'O'), ('sulphate', 'O'), ('failed', 'O'), ('to', 'O'), ('block', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('scopolamine', 'O'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('altering', 'O'), ('the', 'O'), ('modulation', 'O'), ('of', 'O'), ('NMDA', 'O'), ('receptors', 'O'), ('diminishes', 'O'), ('the', 'O'), ('memory', 'O'), ('-', 'O'), ('enhancing', 'O'), ('effects', 'O'), ('of', 'O'), ('PREGS', 'O'), ('.', 'O'))"
These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids .,"(('These', 'O'), ('results', 'O'), ('identify', 'O'), ('a', 'O'), ('novel', 'O'), ('neuropharmacological', 'O'), ('site', 'O'), ('for', 'O'), ('the', 'O'), ('modulation', 'O'), ('of', 'O'), ('memory', 'O'), ('processes', 'O'), ('by', 'O'), ('neuroactive', 'O'), ('steroids', 'O'), ('.', 'O'))"
Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced heart failure .,"(('Activation', 'O'), ('of', 'O'), ('poly', 'O'), ('(', 'O'), ('ADP', 'O'), ('-', 'O'), ('ribose', 'O'), (')', 'O'), ('polymerase', 'O'), ('contributes', 'O'), ('to', 'O'), ('development', 'O'), ('of', 'O'), ('doxorubicin', 'B'), ('-', 'O'), ('induced', 'O'), ('heart', 'B'), ('failure', 'I'), ('.', 'O'))"
Activation of the nuclear enzyme poly ( ADP - ribose ) polymerase ( PARP ) by oxidant - mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress .,"(('Activation', 'O'), ('of', 'O'), ('the', 'O'), ('nuclear', 'O'), ('enzyme', 'O'), ('poly', 'O'), ('(', 'O'), ('ADP', 'O'), ('-', 'O'), ('ribose', 'O'), (')', 'O'), ('polymerase', 'O'), ('(', 'O'), ('PARP', 'O'), (')', 'O'), ('by', 'O'), ('oxidant', 'O'), ('-', 'O'), ('mediated', 'O'), ('DNA', 'O'), ('damage', 'O'), ('is', 'O'), ('an', 'O'), ('important', 'O'), ('pathway', 'O'), ('of', 'O'), ('cell', 'B'), ('dysfunction', 'I'), ('and', 'O'), ('tissue', 'B'), ('injury', 'I'), ('in', 'O'), ('conditions', 'O'), ('associated', 'O'), ('with', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('.', 'O'))"
"Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX .","(('Using', 'O'), ('a', 'O'), ('dual', 'O'), ('approach', 'O'), ('of', 'O'), ('PARP', 'O'), ('-', 'O'), ('1', 'O'), ('suppression', 'O'), (',', 'O'), ('by', 'O'), ('genetic', 'O'), ('deletion', 'O'), ('or', 'O'), ('pharmacological', 'O'), ('inhibition', 'O'), ('with', 'O'), ('the', 'O'), ('phenanthridinone', 'O'), ('PARP', 'O'), ('inhibitor', 'O'), ('PJ34', 'O'), (',', 'O'), ('we', 'O'), ('now', 'O'), ('demonstrate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('PARP', 'O'), ('in', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('induced', 'O'), ('by', 'O'), ('DOX', 'O'), ('.', 'O'))"
PARP - 1 + / + and PARP - 1 - / - mice received a single injection of DOX ( 25 mg / kg i . p ) .,"(('PARP', 'O'), ('-', 'O'), ('1', 'O'), ('+', 'O'), ('/', 'O'), ('+', 'O'), ('and', 'O'), ('PARP', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('received', 'O'), ('a', 'O'), ('single', 'O'), ('injection', 'O'), ('of', 'O'), ('DOX', 'O'), ('(', 'O'), ('25', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), (')', 'O'), ('.', 'O'))"
"Five days after DOX administration , left ventricular performance was significantly depressed in PARP - 1 + / + mice , but only to a smaller extent in PARP - 1 - / - ones .","(('Five', 'O'), ('days', 'O'), ('after', 'O'), ('DOX', 'O'), ('administration', 'O'), (',', 'O'), ('left', 'O'), ('ventricular', 'O'), ('performance', 'O'), ('was', 'O'), ('significantly', 'O'), ('depressed', 'O'), ('in', 'O'), ('PARP', 'O'), ('-', 'O'), ('1', 'O'), ('+', 'O'), ('/', 'O'), ('+', 'O'), ('mice', 'O'), (',', 'O'), ('but', 'O'), ('only', 'O'), ('to', 'O'), ('a', 'O'), ('smaller', 'O'), ('extent', 'O'), ('in', 'O'), ('PARP', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('ones', 'O'), ('.', 'O'))"
Similar experiments were conducted in BALB / c mice treated with PJ34 or vehicle .,"(('Similar', 'O'), ('experiments', 'O'), ('were', 'O'), ('conducted', 'O'), ('in', 'O'), ('BALB', 'O'), ('/', 'O'), ('c', 'O'), ('mice', 'O'), ('treated', 'O'), ('with', 'O'), ('PJ34', 'O'), ('or', 'O'), ('vehicle', 'O'), ('.', 'O'))"
Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals .,"(('Treatment', 'O'), ('with', 'O'), ('a', 'O'), ('PJ34', 'O'), ('significantly', 'O'), ('improved', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('and', 'O'), ('increased', 'O'), ('the', 'O'), ('survival', 'O'), ('of', 'O'), ('the', 'O'), ('animals', 'O'), ('.', 'O'))"
In addition PJ34 significantly reduced the DOX - induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart .,"(('In', 'O'), ('addition', 'O'), ('PJ34', 'O'), ('significantly', 'O'), ('reduced', 'O'), ('the', 'O'), ('DOX', 'O'), ('-', 'O'), ('induced', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('serum', 'O'), ('lactate', 'O'), ('dehydrogenase', 'O'), ('and', 'O'), ('creatine', 'O'), ('kinase', 'O'), ('activities', 'O'), ('but', 'O'), ('not', 'O'), ('metalloproteinase', 'O'), ('activation', 'O'), ('in', 'O'), ('the', 'O'), ('heart', 'O'), ('.', 'O'))"
Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB .,"(('Selective', 'O'), ('distal', 'B'), ('tubular', 'I'), ('epithelial', 'I'), ('toxicity', 'I'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('the', 'O'), ('profound', 'O'), ('potassium', 'B'), ('wasting', 'I'), ('that', 'O'), ('is', 'O'), ('a', 'O'), ('major', 'O'), ('clinical', 'O'), ('side', 'O'), ('effect', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('AmB', 'O'), ('.', 'O'))"
Potassium depletion also potentiates the tubular toxicity of AmB .,"(('Potassium', 'O'), ('depletion', 'O'), ('also', 'O'), ('potentiates', 'O'), ('the', 'O'), ('tubular', 'O'), ('toxicity', 'O'), ('of', 'O'), ('AmB', 'O'), ('.', 'O'))"
RESULTS : Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone ( P = 0 . 0027 ) .,"(('RESULTS', 'O'), (':', 'O'), ('Patients', 'O'), ('receiving', 'O'), ('concomitant', 'O'), ('AmB', 'O'), ('and', 'O'), ('spironolactone', 'O'), ('had', 'O'), ('significantly', 'O'), ('higher', 'O'), ('plasma', 'O'), ('potassium', 'O'), ('levels', 'O'), ('than', 'O'), ('those', 'O'), ('receiving', 'O'), ('AmB', 'O'), ('alone', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0027', 'O'), (')', 'O'), ('.', 'O'))"
Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range ( P = 0 . 022 ) .,"(('Those', 'O'), ('patients', 'O'), ('receiving', 'O'), ('AmB', 'O'), ('and', 'O'), ('spironolactone', 'O'), ('required', 'O'), ('significantly', 'O'), ('less', 'O'), ('potassium', 'O'), ('supplementation', 'O'), ('to', 'O'), ('maintain', 'O'), ('their', 'O'), ('plasma', 'O'), ('potassium', 'O'), ('within', 'O'), ('the', 'O'), ('normal', 'O'), ('range', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('022', 'O'), (')', 'O'), ('.', 'O'))"
"Moreover , urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone ( P = 0 . 040 ) .","(('Moreover', 'O'), (',', 'O'), ('urinary', 'O'), ('potassium', 'O'), ('losses', 'O'), ('were', 'O'), ('significantly', 'O'), ('less', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('AmB', 'O'), ('and', 'O'), ('spironolactone', 'O'), ('than', 'O'), ('those', 'O'), ('receiving', 'O'), ('AmB', 'O'), ('alone', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('040', 'O'), (')', 'O'), ('.', 'O'))"
Erectile function was assessed 6 weeks following uni - and bilateral injections of 6 - hydroxydopamine in the substantia nigra nucleus of the brain .,"(('Erectile', 'O'), ('function', 'O'), ('was', 'O'), ('assessed', 'O'), ('6', 'O'), ('weeks', 'O'), ('following', 'O'), ('uni', 'O'), ('-', 'O'), ('and', 'O'), ('bilateral', 'O'), ('injections', 'O'), ('of', 'O'), ('6', 'O'), ('-', 'O'), ('hydroxydopamine', 'O'), ('in', 'O'), ('the', 'O'), ('substantia', 'O'), ('nigra', 'O'), ('nucleus', 'O'), ('of', 'O'), ('the', 'O'), ('brain', 'O'), ('.', 'O'))"
Behavioral apomorphine - induced penile erections were reduced ( 5 / 8 ) and increased ( 3 / 8 ) in uni - and bilateral lesioned animals .,"(('Behavioral', 'O'), ('apomorphine', 'O'), ('-', 'O'), ('induced', 'O'), ('penile', 'O'), ('erections', 'O'), ('were', 'O'), ('reduced', 'O'), ('(', 'O'), ('5', 'O'), ('/', 'O'), ('8', 'O'), (')', 'O'), ('and', 'O'), ('increased', 'O'), ('(', 'O'), ('3', 'O'), ('/', 'O'), ('8', 'O'), (')', 'O'), ('in', 'O'), ('uni', 'O'), ('-', 'O'), ('and', 'O'), ('bilateral', 'O'), ('lesioned', 'O'), ('animals', 'O'), ('.', 'O'))"
"Intracavernous pressures , following electrical stimulation of the cavernous nerve , decreased in lesioned animals .","(('Intracavernous', 'O'), ('pressures', 'O'), (',', 'O'), ('following', 'O'), ('electrical', 'O'), ('stimulation', 'O'), ('of', 'O'), ('the', 'O'), ('cavernous', 'O'), ('nerve', 'O'), (',', 'O'), ('decreased', 'O'), ('in', 'O'), ('lesioned', 'O'), ('animals', 'O'), ('.', 'O'))"
Lesions of the substantia nigra were confirmed by histology .,"(('Lesions', 'O'), ('of', 'O'), ('the', 'O'), ('substantia', 'O'), ('nigra', 'I'), ('were', 'O'), ('confirmed', 'O'), ('by', 'O'), ('histology', 'O'), ('.', 'O'))"
Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats .,"(('Concentration', 'O'), ('of', 'O'), ('dopamine', 'O'), ('and', 'O'), ('its', 'O'), ('metabolites', 'O'), ('were', 'O'), ('decreased', 'O'), ('in', 'O'), ('the', 'O'), ('striatum', 'O'), ('of', 'O'), ('substantia', 'O'), ('nigra', 'O'), ('lesioned', 'O'), ('rats', 'O'), ('.', 'O'))"
The response of morphine was potentiated by nicotine .,"(('The', 'O'), ('response', 'O'), ('of', 'O'), ('morphine', 'O'), ('was', 'O'), ('potentiated', 'O'), ('by', 'O'), ('nicotine', 'O'), ('.', 'O'))"
"Intraperitoneal administration of atropine , but not intraperitoneal or intracerebroventricular injection of hexamethonium , decreased the effect of a single dose of morphine .","(('Intraperitoneal', 'O'), ('administration', 'O'), ('of', 'O'), ('atropine', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('intraperitoneal', 'O'), ('or', 'O'), ('intracerebroventricular', 'O'), ('injection', 'O'), ('of', 'O'), ('hexamethonium', 'O'), (',', 'O'), ('decreased', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('morphine', 'O'), ('.', 'O'))"
An overshooting of peak grip force by 51 % ( P < 0 . 05 ) and of static grip force by 45 % ( P < 0 . 01 ) was observed in the ON - compared with the OFF - drug condition .,"(('An', 'O'), ('overshooting', 'O'), ('of', 'O'), ('peak', 'O'), ('grip', 'O'), ('force', 'O'), ('by', 'O'), ('51', 'O'), ('%', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('and', 'O'), ('of', 'O'), ('static', 'O'), ('grip', 'O'), ('force', 'O'), ('by', 'O'), ('45', 'O'), ('%', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('ON', 'O'), ('-', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('OFF', 'O'), ('-', 'O'), ('drug', 'O'), ('condition', 'O'), ('.', 'O'))"
No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication .,"(('No', 'O'), ('correlation', 'O'), ('was', 'O'), ('observed', 'O'), ('between', 'O'), ('forces', 'O'), ('and', 'O'), ('the', 'O'), ('motor', 'O'), ('score', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('with', 'O'), ('the', 'O'), ('daily', 'O'), ('dose', 'O'), ('of', 'O'), ('dopaminergic', 'O'), ('medication', 'O'), ('.', 'O'))"
Behavioral effects of MK - 801 on reserpine - treated mice .,"(('Behavioral', 'O'), ('effects', 'O'), ('of', 'O'), ('MK', 'O'), ('-', 'O'), ('801', 'O'), ('on', 'O'), ('reserpine', 'O'), ('-', 'O'), ('treated', 'O'), ('mice', 'O'), ('.', 'O'))"
"The effects of dizocilpine ( MK - 801 ) , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , were studied on dopamine - related behaviors induced by reserpine treatments .","(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('dizocilpine', 'O'), ('(', 'O'), ('MK', 'O'), ('-', 'O'), ('801', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('noncompetitive', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('aspartate', 'O'), ('(', 'O'), ('NMDA', 'O'), (')', 'O'), ('receptor', 'O'), ('antagonist', 'O'), (',', 'O'), ('were', 'O'), ('studied', 'O'), ('on', 'O'), ('dopamine', 'O'), ('-', 'O'), ('related', 'O'), ('behaviors', 'O'), ('induced', 'O'), ('by', 'O'), ('reserpine', 'O'), ('treatments', 'O'), ('.', 'O'))"
"This phenomenon may be interpreted as a benign , short - term and self - limiting side effect which does not contraindicate the use of risperidone or interfere with treatment .","(('This', 'O'), ('phenomenon', 'O'), ('may', 'O'), ('be', 'O'), ('interpreted', 'O'), ('as', 'O'), ('a', 'O'), ('benign', 'O'), (',', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('and', 'O'), ('self', 'O'), ('-', 'O'), ('limiting', 'O'), ('side', 'O'), ('effect', 'O'), ('which', 'O'), ('does', 'O'), ('not', 'O'), ('contraindicate', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('risperidone', 'O'), ('or', 'O'), ('interfere', 'O'), ('with', 'O'), ('treatment', 'O'), ('.', 'O'))"
Conclusions based on two case reports should be taken with appropriate caution .,"(('Conclusions', 'O'), ('based', 'O'), ('on', 'O'), ('two', 'O'), ('case', 'O'), ('reports', 'O'), ('should', 'O'), ('be', 'O'), ('taken', 'O'), ('with', 'O'), ('appropriate', 'O'), ('caution', 'O'), ('.', 'O'))"
"In addition , a distal tubular acidification defect may result , thus impairing the normal compensatory drop in urine pH .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('a', 'O'), ('distal', 'B'), ('tubular', 'O'), ('acidification', 'O'), ('defect', 'O'), ('may', 'O'), ('result', 'O'), (',', 'O'), ('thus', 'O'), ('impairing', 'O'), ('the', 'O'), ('normal', 'O'), ('compensatory', 'O'), ('drop', 'O'), ('in', 'O'), ('urine', 'O'), ('pH', 'O'), ('.', 'O'))"
Ketamine in war / tropical surgery ( a final tribute to the racemic mixture ) .,"(('Ketamine', 'O'), ('in', 'O'), ('war', 'O'), ('/', 'O'), ('tropical', 'O'), ('surgery', 'O'), ('(', 'O'), ('a', 'O'), ('final', 'O'), ('tribute', 'O'), ('to', 'O'), ('the', 'O'), ('racemic', 'O'), ('mixture', 'O'), (')', 'O'), ('.', 'O'))"
"A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients , aged from 6 weeks to 70 years , undergoing limb and abdominal surgery including caesarian sections and interventions in neonates .","(('A', 'O'), ('technique', 'O'), ('of', 'O'), ('continuous', 'O'), ('intravenous', 'O'), ('anaesthesia', 'O'), ('with', 'O'), ('ketamine', 'O'), ('was', 'O'), ('used', 'O'), ('successfully', 'O'), ('during', 'O'), ('the', 'O'), ('Somalia', 'O'), ('civil', 'O'), ('war', 'O'), ('in', 'O'), ('1994', 'O'), ('and', 'O'), ('in', 'O'), ('north', 'O'), ('Uganda', 'O'), ('in', 'O'), ('1999', 'O'), ('for', 'O'), ('64', 'O'), ('operations', 'O'), ('in', 'O'), ('62', 'O'), ('patients', 'O'), (',', 'O'), ('aged', 'O'), ('from', 'O'), ('6', 'O'), ('weeks', 'O'), ('to', 'O'), ('70', 'O'), ('years', 'O'), (',', 'O'), ('undergoing', 'O'), ('limb', 'B'), ('and', 'I'), ('abdominal', 'I'), ('surgery', 'O'), ('including', 'O'), ('caesarian', 'O'), ('sections', 'O'), ('and', 'O'), ('interventions', 'O'), ('in', 'O'), ('neonates', 'O'), ('.', 'O'))"
Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air / oxygen only .,"(('Operations', 'O'), ('lasting', 'O'), ('up', 'O'), ('to', 'O'), ('2h', 'O'), ('could', 'O'), ('be', 'O'), ('performed', 'O'), ('in', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('sophisticated', 'O'), ('equipment', 'O'), ('such', 'O'), ('as', 'O'), ('pulse', 'O'), ('oximeters', 'O'), ('or', 'O'), ('ventilators', 'O'), ('in', 'O'), ('patients', 'O'), ('on', 'O'), ('spontaneous', 'O'), ('ventilation', 'O'), ('breathing', 'O'), ('air', 'O'), ('/', 'O'), ('oxygen', 'O'), ('only', 'O'), ('.', 'O'))"
"After premedication with diazepam , glycopyrrolate and local anaesthesia , and induction with standard doses of ketamine , a maintenance dose of 10 - 20 microg / kg / min of ketamine proved safe and effective .","(('After', 'O'), ('premedication', 'O'), ('with', 'O'), ('diazepam', 'O'), (',', 'O'), ('glycopyrrolate', 'O'), ('and', 'O'), ('local', 'O'), ('anaesthesia', 'O'), (',', 'O'), ('and', 'O'), ('induction', 'O'), ('with', 'O'), ('standard', 'O'), ('doses', 'O'), ('of', 'O'), ('ketamine', 'O'), (',', 'O'), ('a', 'O'), ('maintenance', 'O'), ('dose', 'O'), ('of', 'O'), ('10', 'O'), ('-', 'O'), ('20', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('min', 'O'), ('of', 'O'), ('ketamine', 'O'), ('proved', 'O'), ('safe', 'O'), ('and', 'O'), ('effective', 'O'), ('.', 'O'))"
"Emphasis was placed on bedside clinical monitoring , relying heavily on the heart rate .","(('Emphasis', 'O'), ('was', 'O'), ('placed', 'O'), ('on', 'O'), ('bedside', 'O'), ('clinical', 'O'), ('monitoring', 'O'), (',', 'O'), ('relying', 'O'), ('heavily', 'O'), ('on', 'O'), ('the', 'O'), ('heart', 'O'), ('rate', 'O'), ('.', 'O'))"
"An antisialogue was usually unnecessary in operations lasting up to 2 h , glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects , especially in a hot climate .","(('An', 'O'), ('antisialogue', 'O'), ('was', 'O'), ('usually', 'O'), ('unnecessary', 'O'), ('in', 'O'), ('operations', 'O'), ('lasting', 'O'), ('up', 'O'), ('to', 'O'), ('2', 'O'), ('h', 'O'), (',', 'O'), ('glycopyrrolate', 'O'), ('being', 'O'), ('the', 'O'), ('best', 'O'), ('choice', 'O'), ('for', 'O'), ('its', 'O'), ('lowest', 'O'), ('psychotropic', 'O'), ('and', 'O'), ('chronotropic', 'O'), ('effects', 'O'), (',', 'O'), ('especially', 'O'), ('in', 'O'), ('a', 'O'), ('hot', 'O'), ('climate', 'O'), ('.', 'O'))"
"Experience in war / tropical settings suggests this technique could be useful in civilian contexts such as outdoor life - saving emergency surgery or in mass casualties where , e . g . amputation and rapid extrication were required .","(('Experience', 'O'), ('in', 'O'), ('war', 'O'), ('/', 'O'), ('tropical', 'O'), ('settings', 'O'), ('suggests', 'O'), ('this', 'O'), ('technique', 'O'), ('could', 'O'), ('be', 'O'), ('useful', 'O'), ('in', 'O'), ('civilian', 'O'), ('contexts', 'O'), ('such', 'O'), ('as', 'O'), ('outdoor', 'O'), ('life', 'O'), ('-', 'O'), ('saving', 'O'), ('emergency', 'O'), ('surgery', 'O'), ('or', 'O'), ('in', 'O'), ('mass', 'O'), ('casualties', 'O'), ('where', 'O'), (',', 'O'), ('e', 'O'), ('.', 'O'), ('g', 'O'), ('.', 'O'), ('amputation', 'O'), ('and', 'O'), ('rapid', 'O'), ('extrication', 'O'), ('were', 'O'), ('required', 'O'), ('.', 'O'))"
Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children .,"(('Intravenous', 'O'), ('ribavirin', 'O'), ('treatment', 'O'), ('for', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('immunocompromised', 'B'), ('children', 'O'), ('.', 'O'))"
BACKGROUND : Adenovirus is an important cause of morbidity and mortality in the immunocompromised host .,"(('BACKGROUND', 'O'), (':', 'O'), ('Adenovirus', 'B'), ('is', 'O'), ('an', 'O'), ('important', 'O'), ('cause', 'O'), ('of', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), ('in', 'O'), ('the', 'O'), ('immunocompromised', 'B'), ('host', 'O'), ('.', 'O'))"
"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children , where case fatality rates as high as 50 % to 80 % have been reported .","(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('pediatrics', 'O'), ('is', 'O'), ('increasing', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('growing', 'O'), ('numbers', 'O'), ('of', 'O'), ('immunocompromised', 'B'), ('children', 'O'), (',', 'O'), ('where', 'O'), ('case', 'O'), ('fatality', 'O'), ('rates', 'O'), ('as', 'O'), ('high', 'O'), ('as', 'O'), ('50', 'O'), ('%', 'O'), ('to', 'O'), ('80', 'O'), ('%', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O'))"
"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease , nor are there any prospective randomized , controlled trials of potentially useful anti - adenovirus therapies .","(('There', 'O'), ('are', 'O'), ('no', 'O'), ('approved', 'O'), ('antiviral', 'O'), ('agents', 'O'), ('with', 'O'), ('proven', 'O'), ('efficacy', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), (',', 'O'), ('nor', 'O'), ('are', 'O'), ('there', 'O'), ('any', 'O'), ('prospective', 'O'), ('randomized', 'O'), (',', 'O'), ('controlled', 'O'), ('trials', 'O'), ('of', 'O'), ('potentially', 'O'), ('useful', 'O'), ('anti', 'O'), ('-', 'O'), ('adenovirus', 'B'), ('therapies', 'O'), ('.', 'O'))"
Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series .,"(('Apparent', 'O'), ('clinical', 'O'), ('success', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('is', 'O'), ('limited', 'O'), ('to', 'O'), ('a', 'O'), ('few', 'O'), ('case', 'O'), ('reports', 'O'), ('and', 'O'), ('small', 'O'), ('series', 'O'), ('.', 'O'))"
Experience is greatest with intravenous ribavirin and cidofovir .,"(('Experience', 'O'), ('is', 'O'), ('greatest', 'O'), ('with', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('and', 'O'), ('cidofovir', 'O'), ('.', 'O'))"
"Ribavirin , a guanosine analogue , has broad antiviral activity against both RNA and DNA viruses , including documented activity against adenovirus in vitro .","(('Ribavirin', 'O'), (',', 'O'), ('a', 'O'), ('guanosine', 'O'), ('analogue', 'O'), (',', 'O'), ('has', 'O'), ('broad', 'O'), ('antiviral', 'O'), ('activity', 'O'), ('against', 'O'), ('both', 'O'), ('RNA', 'O'), ('and', 'O'), ('DNA', 'O'), ('viruses', 'O'), (',', 'O'), ('including', 'O'), ('documented', 'O'), ('activity', 'O'), ('against', 'O'), ('adenovirus', 'O'), ('in', 'O'), ('vitro', 'O'), ('.', 'O'))"
The most common adverse effect of intravenous ribavirin is reversible mild anemia .,"(('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('effect', 'O'), ('of', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('is', 'O'), ('reversible', 'O'), ('mild', 'O'), ('anemia', 'B'), ('.', 'O'))"
OBJECTIVE : We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature .,"(('OBJECTIVE', 'O'), (':', 'O'), ('We', 'O'), ('report', 'O'), ('our', 'O'), ('experience', 'O'), ('with', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('therapy', 'O'), ('for', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('a', 'O'), ('series', 'O'), ('of', 'O'), ('immunocompromised', 'B'), ('children', 'O'), ('and', 'O'), ('review', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease .,"(('DESIGN', 'O'), ('/', 'O'), ('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('retrospectively', 'O'), ('reviewed', 'O'), ('the', 'O'), ('medical', 'O'), ('records', 'O'), ('of', 'O'), ('5', 'O'), ('children', 'O'), ('treated', 'O'), ('with', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('for', 'O'), ('documented', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('.', 'O'))"
The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease .,"(('The', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplant', 'O'), ('patient', 'O'), ('also', 'O'), ('received', 'O'), ('intravenous', 'O'), ('cidofovir', 'O'), ('for', 'O'), ('progressive', 'O'), ('disseminated', 'O'), ('disease', 'O'), ('.', 'O'))"
"An additional 3 children developed adenovirus pneumonia ; 2 were neonates , 1 of whom had partial DiGeorge syndrome .","(('An', 'O'), ('additional', 'O'), ('3', 'O'), ('children', 'O'), ('developed', 'O'), ('adenovirus', 'B'), ('pneumonia', 'I'), (';', 'O'), ('2', 'O'), ('were', 'O'), ('neonates', 'O'), (',', 'O'), ('1', 'O'), ('of', 'O'), ('whom', 'O'), ('had', 'O'), ('partial', 'B'), ('DiGeorge', 'B'), ('syndrome', 'I'), ('.', 'O'))"
The remaining infant had recently undergone a cardiac transplant .,"(('The', 'O'), ('remaining', 'O'), ('infant', 'O'), ('had', 'O'), ('recently', 'O'), ('undergone', 'O'), ('a', 'O'), ('cardiac', 'O'), ('transplant', 'O'), ('.', 'O'))"
Intravenous ribavirin was administered on a compassionate - use protocol .,"(('Intravenous', 'O'), ('ribavirin', 'O'), ('was', 'O'), ('administered', 'O'), ('on', 'O'), ('a', 'O'), ('compassionate', 'O'), ('-', 'O'), ('use', 'O'), ('protocol', 'O'), ('.', 'O'))"
The remaining 3 children died of adenovirus disease .,"(('The', 'O'), ('remaining', 'O'), ('3', 'O'), ('children', 'O'), ('died', 'O'), ('of', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('.', 'O'))"
Intravenous ribavirin therapy was well tolerated .,"(('Intravenous', 'O'), ('ribavirin', 'O'), ('therapy', 'O'), ('was', 'O'), ('well', 'O'), ('tolerated', 'O'), ('.', 'O'))"
"DISCUSSION : Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease , namely solid - organ and bone marrow transplant recipients , neonates , and children with immunodeficiency .","(('DISCUSSION', 'O'), (':', 'O'), ('Our', 'O'), ('series', 'O'), ('of', 'O'), ('patients', 'O'), ('is', 'O'), ('representative', 'O'), ('of', 'O'), ('the', 'O'), ('spectrum', 'O'), ('of', 'O'), ('immunocompromised', 'B'), ('children', 'O'), ('at', 'O'), ('greatest', 'O'), ('risk', 'O'), ('for', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), (',', 'O'), ('namely', 'O'), ('solid', 'O'), ('-', 'O'), ('organ', 'O'), ('and', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplant', 'O'), ('recipients', 'O'), (',', 'O'), ('neonates', 'O'), (',', 'O'), ('and', 'O'), ('children', 'O'), ('with', 'O'), ('immunodeficiency', 'B'), ('.', 'O'))"
"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the infection .","(('Although', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('was', 'O'), ('not', 'O'), ('effective', 'O'), ('for', 'O'), ('all', 'O'), ('children', 'O'), ('with', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('this', 'O'), ('series', 'O'), ('or', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), (',', 'O'), ('therapy', 'O'), ('is', 'O'), ('unlikely', 'O'), ('to', 'O'), ('be', 'O'), ('of', 'O'), ('benefit', 'O'), ('if', 'O'), ('begun', 'O'), ('late', 'O'), ('in', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('the', 'O'), ('infection', 'O'), ('.', 'O'))"
"Early identification , eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response .","(('Early', 'O'), ('identification', 'O'), (',', 'O'), ('eg', 'O'), ('by', 'O'), ('polymerase', 'O'), ('chain', 'O'), ('reaction', 'O'), ('of', 'O'), ('those', 'O'), ('patients', 'O'), ('at', 'O'), ('risk', 'O'), ('of', 'O'), ('disseminated', 'B'), ('adenovirus', 'I'), ('disease', 'I'), ('may', 'O'), ('permit', 'O'), ('earlier', 'O'), ('antiviral', 'O'), ('treatment', 'O'), ('and', 'O'), ('better', 'O'), ('evaluation', 'O'), ('of', 'O'), ('therapeutic', 'O'), ('response', 'O'), ('.', 'O'))"
CONCLUSIONS : Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Two', 'O'), ('of', 'O'), ('5', 'O'), ('children', 'O'), ('with', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('treated', 'O'), ('with', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('recovered', 'O'), ('.', 'O'))"
"The availability of newer rapid diagnostic techniques , such as polymerase chain reaction , may make earlier , more effective treatment of adenovirus infection possible .","(('The', 'O'), ('availability', 'O'), ('of', 'O'), ('newer', 'O'), ('rapid', 'O'), ('diagnostic', 'O'), ('techniques', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('polymerase', 'O'), ('chain', 'O'), ('reaction', 'O'), (',', 'O'), ('may', 'O'), ('make', 'O'), ('earlier', 'O'), (',', 'O'), ('more', 'O'), ('effective', 'O'), ('treatment', 'O'), ('of', 'O'), ('adenovirus', 'B'), ('infection', 'I'), ('possible', 'O'), ('.', 'O'))"
"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous ribavirin , is clearly required to demonstrate the most effective and least toxic therapy .","(('Given', 'O'), ('the', 'O'), ('seriousness', 'O'), ('and', 'O'), ('increasing', 'O'), ('prevalence', 'O'), ('of', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('certain', 'O'), ('hosts', 'O'), (',', 'O'), ('especially', 'O'), ('children', 'O'), (',', 'O'), ('a', 'O'), ('large', 'O'), (',', 'O'), ('multicenter', 'O'), ('clinical', 'O'), ('trial', 'O'), ('of', 'O'), ('potentially', 'O'), ('useful', 'O'), ('anti', 'O'), ('-', 'O'), ('adenoviral', 'O'), ('therapies', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), (',', 'O'), ('is', 'O'), ('clearly', 'O'), ('required', 'O'), ('to', 'O'), ('demonstrate', 'O'), ('the', 'O'), ('most', 'O'), ('effective', 'O'), ('and', 'O'), ('least', 'O'), ('toxic', 'O'), ('therapy', 'O'), ('.', 'O'))"
He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids .,"(('He', 'O'), ('initially', 'O'), ('presented', 'O'), ('to', 'O'), ('hospital', 'O'), ('after', 'O'), ('six', 'O'), ('hours', 'O'), ('with', 'O'), ('mild', 'O'), ('hypotension', 'B'), ('and', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('activated', 'O'), ('charcoal', 'O'), ('and', 'O'), ('intravenous', 'O'), ('fluids', 'O'), ('.', 'O'))"
He was resuscitated with high dose ( 13 . 5 g ) intravenous calcium and adrenaline ( epinephrine ) .,"(('He', 'O'), ('was', 'O'), ('resuscitated', 'O'), ('with', 'O'), ('high', 'O'), ('dose', 'O'), ('(', 'O'), ('13', 'O'), ('.', 'O'), ('5', 'O'), ('g', 'O'), (')', 'O'), ('intravenous', 'O'), ('calcium', 'O'), ('and', 'O'), ('adrenaline', 'O'), ('(', 'O'), ('epinephrine', 'O'), (')', 'O'), ('.', 'O'))"
He required inotropic support and temporary pacing over the next 48 hours .,"(('He', 'O'), ('required', 'O'), ('inotropic', 'O'), ('support', 'O'), ('and', 'O'), ('temporary', 'O'), ('pacing', 'O'), ('over', 'O'), ('the', 'O'), ('next', 'O'), ('48', 'O'), ('hours', 'O'), ('.', 'O'))"
The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered .,"(('The', 'O'), ('case', 'O'), ('also', 'O'), ('highlights', 'O'), ('the', 'O'), ('problems', 'O'), ('with', 'O'), ('delayed', 'O'), ('toxicity', 'O'), ('when', 'O'), ('whole', 'O'), ('bowel', 'O'), ('irrigation', 'O'), ('is', 'O'), ('not', 'O'), ('administered', 'O'), ('.', 'O'))"
Low - molecular - weight heparin for the treatment of patients with mechanical heart valves .,"(('Low', 'O'), ('-', 'O'), ('molecular', 'O'), ('-', 'O'), ('weight', 'O'), ('heparin', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('mechanical', 'B'), ('heart', 'I'), ('valves', 'I'), ('.', 'O'))"
"BACKGROUND : The interruption of oral anticoagulant ( OAC ) administration is sometimes indicated in patients with mechanical heart valves , mainly before noncardiac surgery , non - surgical interventions , and pregnancy .","(('BACKGROUND', 'O'), (':', 'O'), ('The', 'O'), ('interruption', 'O'), ('of', 'O'), ('oral', 'O'), ('anticoagulant', 'O'), ('(', 'O'), ('OAC', 'O'), (')', 'O'), ('administration', 'O'), ('is', 'O'), ('sometimes', 'O'), ('indicated', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('mechanical', 'B'), ('heart', 'I'), ('valves', 'I'), (',', 'O'), ('mainly', 'O'), ('before', 'O'), ('noncardiac', 'O'), ('surgery', 'O'), (',', 'O'), ('non', 'O'), ('-', 'O'), ('surgical', 'O'), ('interventions', 'O'), (',', 'O'), ('and', 'O'), ('pregnancy', 'O'), ('.', 'O'))"
Unfractionated heparin ( UH ) is currently the substitute for selected patients .,"(('Unfractionated', 'O'), ('heparin', 'O'), ('(', 'O'), ('UH', 'O'), (')', 'O'), ('is', 'O'), ('currently', 'O'), ('the', 'O'), ('substitute', 'O'), ('for', 'O'), ('selected', 'O'), ('patients', 'O'), ('.', 'O'))"
"Low - molecular - weight heparin ( LMWH ) offers theoretical advantages over UH , but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves .","(('Low', 'O'), ('-', 'O'), ('molecular', 'O'), ('-', 'O'), ('weight', 'O'), ('heparin', 'O'), ('(', 'O'), ('LMWH', 'O'), (')', 'O'), ('offers', 'O'), ('theoretical', 'O'), ('advantages', 'O'), ('over', 'O'), ('UH', 'O'), (',', 'O'), ('but', 'O'), ('is', 'O'), ('not', 'O'), ('currently', 'O'), ('considered', 'O'), ('in', 'O'), ('clinical', 'O'), ('guidelines', 'O'), ('as', 'O'), ('an', 'O'), ('alternative', 'O'), ('to', 'O'), ('UH', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('prosthetic', 'O'), ('valves', 'O'), ('.', 'O'))"
HYPOTHESIS : The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice .,"(('HYPOTHESIS', 'O'), (':', 'O'), ('The', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('review', 'O'), ('the', 'O'), ('data', 'O'), ('accumulated', 'O'), ('so', 'O'), ('far', 'O'), ('on', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('LMWH', 'O'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('population', 'O'), ('and', 'O'), ('to', 'O'), ('discuss', 'O'), ('its', 'O'), ('applicability', 'O'), ('in', 'O'), ('common', 'O'), ('practice', 'O'), ('.', 'O'))"
"METHODS : For this paper , the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed .","(('METHODS', 'O'), (':', 'O'), ('For', 'O'), ('this', 'O'), ('paper', 'O'), (',', 'O'), ('the', 'O'), ('current', 'O'), ('medical', 'O'), ('literature', 'O'), ('on', 'O'), ('LMWH', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('mechanical', 'B'), ('heart', 'I'), ('valves', 'I'), ('was', 'O'), ('extensively', 'O'), ('reviewed', 'O'), ('.', 'O'))"
RESULTS : There were eight series and six case reports .,"(('RESULTS', 'O'), (':', 'O'), ('There', 'O'), ('were', 'O'), ('eight', 'O'), ('series', 'O'), ('and', 'O'), ('six', 'O'), ('case', 'O'), ('reports', 'O'), ('.', 'O'))"
"None of the studies was randomized , and only one was prospective .","(('None', 'O'), ('of', 'O'), ('the', 'O'), ('studies', 'O'), ('was', 'O'), ('randomized', 'O'), (',', 'O'), ('and', 'O'), ('only', 'O'), ('one', 'O'), ('was', 'O'), ('prospective', 'O'), ('.', 'O'))"
"After excluding case reports , the following groups were constructed : ( a ) short - term administration , after valve insertion ( n = 212 ) ; ( b ) short - term , perioperative ( noncardiac ) / periprocedural ( n = 114 ) ; ( c ) long - term , due to intolerance to OAC ( n = 16 ) ; ( d ) long - term , in pregnancy ( n = 10 ) .","(('After', 'O'), ('excluding', 'O'), ('case', 'O'), ('reports', 'O'), (',', 'O'), ('the', 'O'), ('following', 'O'), ('groups', 'O'), ('were', 'O'), ('constructed', 'O'), (':', 'O'), ('(', 'O'), ('a', 'O'), (')', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('administration', 'O'), (',', 'O'), ('after', 'O'), ('valve', 'O'), ('insertion', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('212', 'O'), (')', 'O'), (';', 'O'), ('(', 'O'), ('b', 'O'), (')', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), (',', 'O'), ('perioperative', 'O'), ('(', 'O'), ('noncardiac', 'O'), (')', 'O'), ('/', 'O'), ('periprocedural', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('114', 'O'), (')', 'O'), (';', 'O'), ('(', 'O'), ('c', 'O'), (')', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), (',', 'O'), ('due', 'O'), ('to', 'O'), ('intolerance', 'B'), ('to', 'I'), ('OAC', 'I'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('16', 'O'), (')', 'O'), (';', 'O'), ('(', 'O'), ('d', 'O'), (')', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), (',', 'O'), ('in', 'O'), ('pregnancy', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('10', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSIONS : In patients with mechanical heart valves , short - term LMWH therapy compares favorably with UH .","(('CONCLUSIONS', 'O'), (':', 'O'), ('In', 'O'), ('patients', 'O'), ('with', 'O'), ('mechanical', 'B'), ('heart', 'I'), ('valves', 'I'), (',', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('LMWH', 'O'), ('therapy', 'O'), ('compares', 'O'), ('favorably', 'O'), ('with', 'O'), ('UH', 'O'), ('.', 'O'))"
Data on mid - and long - term LMWH administration in these patients are sparse .,"(('Data', 'O'), ('on', 'O'), ('mid', 'O'), ('-', 'O'), ('and', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('LMWH', 'O'), ('administration', 'O'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('are', 'O'), ('sparse', 'O'), ('.', 'O'))"
Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves .,"(('Further', 'O'), ('randomized', 'O'), ('studies', 'O'), ('are', 'O'), ('needed', 'O'), ('to', 'O'), ('confirm', 'O'), ('the', 'O'), ('safety', 'O'), ('and', 'O'), ('precise', 'O'), ('indications', 'O'), ('for', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('LMWH', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('mechanical', 'B'), ('heart', 'I'), ('valves', 'I'), ('.', 'O'))"
The patient received metoclopramide 10 mg i . v . five times during 48 h .,"(('The', 'O'), ('patient', 'O'), ('received', 'O'), ('metoclopramide', 'O'), ('10', 'O'), ('mg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('five', 'O'), ('times', 'O'), ('during', 'O'), ('48', 'O'), ('h', 'O'), ('.', 'O'))"
"The patient received atropine 0 . 5 - 1 mg and chest compressions , before sinus rhythm again took over .","(('The', 'O'), ('patient', 'O'), ('received', 'O'), ('atropine', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('-', 'O'), ('1', 'O'), ('mg', 'O'), ('and', 'O'), ('chest', 'O'), ('compressions', 'O'), (',', 'O'), ('before', 'O'), ('sinus', 'O'), ('rhythm', 'O'), ('again', 'O'), ('took', 'O'), ('over', 'O'), ('.', 'O'))"
We interpret this as episodes of cardiac arrest caused by metoclopramide .,"(('We', 'O'), ('interpret', 'O'), ('this', 'O'), ('as', 'O'), ('episodes', 'O'), ('of', 'O'), ('cardiac', 'B'), ('arrest', 'I'), ('caused', 'O'), ('by', 'O'), ('metoclopramide', 'O'), ('.', 'O'))"
The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction .,"(('The', 'O'), ('rapid', 'O'), ('injection', 'O'), ('via', 'O'), ('the', 'O'), ('central', 'O'), ('venous', 'O'), ('route', 'O'), ('and', 'O'), ('the', 'O'), ('concomitant', 'O'), ('tapering', 'O'), ('of', 'O'), ('dopamine', 'O'), ('infusion', 'O'), ('might', 'O'), ('have', 'O'), ('contributed', 'O'), ('in', 'O'), ('precipitating', 'O'), ('the', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('.', 'O'))"
Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline .,"(('Rats', 'O'), ('were', 'O'), ('administered', 'O'), ('fenoldopam', 'O'), ('for', 'O'), ('24', 'O'), ('hours', 'O'), ('by', 'O'), ('intravenous', 'O'), ('infusion', 'O'), ('with', 'O'), ('or', 'O'), ('without', 'O'), ('following', 'O'), ('repeated', 'O'), ('daily', 'O'), ('oral', 'O'), ('administrations', 'O'), ('of', 'O'), ('theophylline', 'O'), ('.', 'O'))"
"Irrespective of theophylline administration , iNOS antigens were remarkably abundant in ED - 1 - positive cells on day 5 and 8 post - fenoldopam - infusion ( DPI ) ; bFGF antigens were remarkably abundant in ED - 1 - positive cells on 1 and 3 DPI ; TGF - beta1 antigens were observed in ED - 1 - positive cells on and after 5 DPI .","(('Irrespective', 'O'), ('of', 'O'), ('theophylline', 'O'), ('administration', 'O'), (',', 'O'), ('iNOS', 'O'), ('antigens', 'O'), ('were', 'O'), ('remarkably', 'O'), ('abundant', 'O'), ('in', 'O'), ('ED', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('positive', 'O'), ('cells', 'O'), ('on', 'O'), ('day', 'O'), ('5', 'O'), ('and', 'O'), ('8', 'O'), ('post', 'O'), ('-', 'O'), ('fenoldopam', 'O'), ('-', 'O'), ('infusion', 'O'), ('(', 'O'), ('DPI', 'O'), (')', 'O'), (';', 'O'), ('bFGF', 'O'), ('antigens', 'O'), ('were', 'O'), ('remarkably', 'O'), ('abundant', 'O'), ('in', 'O'), ('ED', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('positive', 'O'), ('cells', 'O'), ('on', 'O'), ('1', 'O'), ('and', 'O'), ('3', 'O'), ('DPI', 'O'), (';', 'O'), ('TGF', 'O'), ('-', 'O'), ('beta1', 'O'), ('antigens', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('ED', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('positive', 'O'), ('cells', 'O'), ('on', 'O'), ('and', 'O'), ('after', 'O'), ('5', 'O'), ('DPI', 'O'), ('.', 'O'))"
"On the other hand , TGF - beta1 was not considered to have a suppressive effect on iNOS expression in these models .","(('On', 'O'), ('the', 'O'), ('other', 'O'), ('hand', 'O'), (',', 'O'), ('TGF', 'O'), ('-', 'O'), ('beta1', 'O'), ('was', 'O'), ('not', 'O'), ('considered', 'O'), ('to', 'O'), ('have', 'O'), ('a', 'O'), ('suppressive', 'O'), ('effect', 'O'), ('on', 'O'), ('iNOS', 'O'), ('expression', 'O'), ('in', 'O'), ('these', 'O'), ('models', 'O'), ('.', 'O'))"
"The striatum as a target for anti - rigor effects of an antagonist of mGluR1 , but not an agonist of group II metabotropic glutamate receptors .","(('The', 'O'), ('striatum', 'O'), ('as', 'O'), ('a', 'O'), ('target', 'O'), ('for', 'O'), ('anti', 'O'), ('-', 'O'), ('rigor', 'O'), ('effects', 'O'), ('of', 'O'), ('an', 'O'), ('antagonist', 'O'), ('of', 'O'), ('mGluR1', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('an', 'O'), ('agonist', 'O'), ('of', 'O'), ('group', 'O'), ('II', 'O'), ('metabotropic', 'O'), ('glutamate', 'O'), ('receptors', 'O'), ('.', 'O'))"
"The aim of the present study was to find out whether the metabotropic receptor 1 ( mGluR1 ) and group II mGluRs , localized in the striatum , are involved in antiparkinsonian - like effects in rats .","(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('find', 'O'), ('out', 'O'), ('whether', 'O'), ('the', 'O'), ('metabotropic', 'O'), ('receptor', 'O'), ('1', 'O'), ('(', 'O'), ('mGluR1', 'O'), (')', 'O'), ('and', 'O'), ('group', 'O'), ('II', 'O'), ('mGluRs', 'O'), (',', 'O'), ('localized', 'O'), ('in', 'O'), ('the', 'O'), ('striatum', 'O'), (',', 'O'), ('are', 'O'), ('involved', 'O'), ('in', 'O'), ('antiparkinsonian', 'O'), ('-', 'O'), ('like', 'O'), ('effects', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid ( AIDA ; 0 . 5 - 15 microg / 0 . 5 microl ) , a potent and selective mGluR1 antagonist , or ( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate ( 2R , 4R - APDC ; 7 . 5 - 15 microg / 0 . 5 microl ) , a selective group II agonist , was injected bilaterally into the striatum of haloperidol","(('(', 'O'), ('RS', 'O'), (')', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('aminoindan', 'O'), ('-', 'O'), ('1', 'O'), (',', 'O'), ('5', 'O'), ('-', 'O'), ('dicarboxylic', 'O'), ('acid', 'O'), ('(', 'O'), ('AIDA', 'O'), (';', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('-', 'O'), ('15', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('potent', 'O'), ('and', 'O'), ('selective', 'O'), ('mGluR1', 'O'), ('antagonist', 'O'), (',', 'O'), ('or', 'O'), ('(', 'O'), ('2R', 'O'), (',', 'O'), ('4R', 'O'), (')', 'O'), ('-', 'O'), ('4', 'O'), ('-', 'O'), ('aminopyrrolidine', 'O'), ('-', 'O'), ('2', 'O'), (',', 'O'), ('4', 'O'), ('-', 'O'), ('dicarboxylate', 'O'), ('(', 'O'), ('2R', 'O'), (',', 'O'), ('4R', 'O'), ('-', 'O'), ('APDC', 'O'), (';', 'O'), ('7', 'O'), ('.', 'O'), ('5', 'O'), ('-', 'O'), ('15', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('selective', 'O'), ('group', 'O'), ('II', 'O'), ('agonist', 'O'), (',', 'O'), ('was', 'O'), ('injected', 'O'), ('bilaterally', 'O'), ('into', 'O'), ('the', 'O'), ('striatum', 'O'), ('of', 'O'), ('haloperidol', 'O'))"
animals .,"(('animals', 'O'), ('.', 'O'))"
"In contrast , 2R , 4R - APDC injections were ineffective .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('2R', 'O'), (',', 'O'), ('4R', 'O'), ('-', 'O'), ('APDC', 'O'), ('injections', 'O'), ('were', 'O'), ('ineffective', 'O'), ('.', 'O'))"
A phase II study of thalidomide in advanced metastatic renal cell carcinoma .,"(('A', 'O'), ('phase', 'O'), ('II', 'O'), ('study', 'O'), ('of', 'O'), ('thalidomide', 'O'), ('in', 'O'), ('advanced', 'B'), ('metastatic', 'I'), ('renal', 'I'), ('cell', 'I'), ('carcinoma', 'I'), ('.', 'O'))"
"OBJECTIVES : To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .","(('OBJECTIVES', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('the', 'O'), ('toxicity', 'O'), ('and', 'O'), ('activity', 'O'), ('of', 'O'), ('thalidomide', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('advanced', 'B'), ('metastatic', 'I'), ('renal', 'I'), ('cell', 'I'), ('cancer', 'I'), ('and', 'O'), ('to', 'O'), ('measure', 'O'), ('changes', 'O'), ('of', 'O'), ('one', 'O'), ('angiogenic', 'O'), ('factor', 'O'), (',', 'O'), ('vascular', 'O'), ('endothelial', 'O'), ('growth', 'O'), ('factor', 'O'), ('(', 'O'), ('VEGF', 'O'), (')', 'O'), ('165', 'O'), (',', 'O'), ('with', 'O'), ('therapy', 'O'), ('.', 'O'))"
PATIENTS AND METHODS : 29 patients were enrolled on a study of thalidomide using an intra - patient dose escalation schedule .,"(('PATIENTS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('29', 'O'), ('patients', 'O'), ('were', 'O'), ('enrolled', 'O'), ('on', 'O'), ('a', 'O'), ('study', 'O'), ('of', 'O'), ('thalidomide', 'O'), ('using', 'O'), ('an', 'O'), ('intra', 'O'), ('-', 'O'), ('patient', 'O'), ('dose', 'O'), ('escalation', 'O'), ('schedule', 'O'), ('.', 'O'))"
Patients began thalidomide at 400 mg / d and escalated as tolerated to 1200 mg / d by day 54 .,"(('Patients', 'O'), ('began', 'O'), ('thalidomide', 'O'), ('at', 'O'), ('400', 'O'), ('mg', 'O'), ('/', 'O'), ('d', 'O'), ('and', 'O'), ('escalated', 'O'), ('as', 'O'), ('tolerated', 'O'), ('to', 'O'), ('1200', 'O'), ('mg', 'O'), ('/', 'O'), ('d', 'O'), ('by', 'O'), ('day', 'O'), ('54', 'O'), ('.', 'O'))"
Fifty - nine per cent of patients had had previous therapy with IL - 2 and 52 % were performance status 2 or 3 .,"(('Fifty', 'O'), ('-', 'O'), ('nine', 'O'), ('per', 'O'), ('cent', 'O'), ('of', 'O'), ('patients', 'O'), ('had', 'O'), ('had', 'O'), ('previous', 'O'), ('therapy', 'O'), ('with', 'O'), ('IL', 'O'), ('-', 'O'), ('2', 'O'), ('and', 'O'), ('52', 'O'), ('%', 'O'), ('were', 'O'), ('performance', 'O'), ('status', 'O'), ('2', 'O'), ('or', 'O'), ('3', 'O'), ('.', 'O'))"
Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients .,"(('Systemic', 'O'), ('plasma', 'O'), ('VEGF165', 'O'), ('levels', 'O'), ('were', 'O'), ('measured', 'O'), ('by', 'O'), ('dual', 'O'), ('monoclonal', 'O'), ('ELISA', 'O'), ('in', 'O'), ('8', 'O'), ('patients', 'O'), ('.', 'O'))"
Systemic plasma VEGF165 levels did not change with therapy .,"(('Systemic', 'O'), ('plasma', 'O'), ('VEGF165', 'O'), ('levels', 'O'), ('did', 'O'), ('not', 'O'), ('change', 'O'), ('with', 'O'), ('therapy', 'O'), ('.', 'O'))"
CONCLUSION : These results are consistent with a low level of activity of thalidomide in renal cell carcinoma .,"(('CONCLUSION', 'O'), (':', 'O'), ('These', 'O'), ('results', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('a', 'O'), ('low', 'O'), ('level', 'O'), ('of', 'O'), ('activity', 'O'), ('of', 'O'), ('thalidomide', 'O'), ('in', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('.', 'O'))"
"Administration of doses over 800 mg / day was difficult to achieve in this patient population , however lower doses were practical .","(('Administration', 'O'), ('of', 'O'), ('doses', 'O'), ('over', 'O'), ('800', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('was', 'O'), ('difficult', 'O'), ('to', 'O'), ('achieve', 'O'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('population', 'O'), (',', 'O'), ('however', 'O'), ('lower', 'O'), ('doses', 'O'), ('were', 'O'), ('practical', 'O'), ('.', 'O'))"
"The dose - response relationship , if any , of thalidomide for renal cell carcinoma is unclear .","(('The', 'O'), ('dose', 'O'), ('-', 'O'), ('response', 'O'), ('relationship', 'O'), (',', 'O'), ('if', 'O'), ('any', 'O'), (',', 'O'), ('of', 'O'), ('thalidomide', 'O'), ('for', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('is', 'O'), ('unclear', 'O'), ('.', 'O'))"
This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine - induced myalgia in patients undergoing general anesthesia for gynecological surgery .,"(('This', 'O'), ('study', 'O'), ('was', 'O'), ('undertaken', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('pretreatment', 'O'), ('on', 'O'), ('reduction', 'O'), ('of', 'O'), ('succinylcholine', 'O'), ('-', 'O'), ('induced', 'O'), ('myalgia', 'B'), ('in', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('general', 'O'), ('anesthesia', 'O'), ('for', 'O'), ('gynecological', 'O'), ('surgery', 'O'), ('.', 'O'))"
"One hundred and thirty - five patients were assigned to one of three groups in a prospective , double blind , randomized manner .","(('One', 'O'), ('hundred', 'O'), ('and', 'O'), ('thirty', 'O'), ('-', 'O'), ('five', 'O'), ('patients', 'O'), ('were', 'O'), ('assigned', 'O'), ('to', 'O'), ('one', 'O'), ('of', 'O'), ('three', 'O'), ('groups', 'O'), ('in', 'O'), ('a', 'O'), ('prospective', 'O'), (',', 'O'), ('double', 'O'), ('blind', 'O'), (',', 'O'), ('randomized', 'O'), ('manner', 'O'), ('.', 'O'))"
"Group PS , the control group , received normal saline and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group LS , lidocaine 1 . 5 mg x kg ( - 1 ) and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group PR , normal saline and rocuronium 0 . 6 mg x kg ( - 1 ) .","(('Group', 'O'), ('PS', 'O'), (',', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), (',', 'O'), ('received', 'O'), ('normal', 'O'), ('saline', 'O'), ('and', 'O'), ('succinylcholine', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('x', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), (';', 'O'), ('Group', 'O'), ('LS', 'O'), (',', 'O'), ('lidocaine', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('x', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('and', 'O'), ('succinylcholine', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('x', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), (';', 'O'), ('Group', 'O'), ('PR', 'O'), (',', 'O'), ('normal', 'O'), ('saline', 'O'), ('and', 'O'), ('rocuronium', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('mg', 'O'), ('x', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
"Morphine 0 . 1 mg x kg ( - 1 ) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor , ECG and pulse oximetry .","(('Morphine', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('mg', 'O'), ('x', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('iv', 'O'), ('was', 'O'), ('given', 'O'), ('for', 'O'), ('premedication', 'O'), ('and', 'O'), ('all', 'O'), ('patients', 'O'), ('were', 'O'), ('monitored', 'O'), ('with', 'O'), ('a', 'O'), ('noninvasive', 'O'), ('blood', 'O'), ('pressure', 'O'), ('monitor', 'O'), (',', 'O'), ('ECG', 'O'), ('and', 'O'), ('pulse', 'O'), ('oximetry', 'O'), ('.', 'O'))"
"Anesthesia was induced with 5 mg . kg ( - 1 ) thiopental iv . followed by succinylcholine ( Group PS , LS ) or rocuronium ( Group PR ) for tracheal intubation .","(('Anesthesia', 'O'), ('was', 'O'), ('induced', 'O'), ('with', 'O'), ('5', 'O'), ('mg', 'O'), ('.', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('thiopental', 'O'), ('iv', 'O'), ('.', 'O'), ('followed', 'O'), ('by', 'O'), ('succinylcholine', 'O'), ('(', 'O'), ('Group', 'O'), ('PS', 'O'), (',', 'O'), ('LS', 'O'), (')', 'O'), ('or', 'O'), ('rocuronium', 'O'), ('(', 'O'), ('Group', 'O'), ('PR', 'O'), (')', 'O'), ('for', 'O'), ('tracheal', 'O'), ('intubation', 'O'), ('.', 'O'))"
The blood pressure and heart rate of each patient were monitored on nine occasions .,"(('The', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('heart', 'O'), ('rate', 'O'), ('of', 'O'), ('each', 'O'), ('patient', 'O'), ('were', 'O'), ('monitored', 'O'), ('on', 'O'), ('nine', 'O'), ('occasions', 'O'), ('.', 'O'))"
"Twenty - four hours later , any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management .","(('Twenty', 'O'), ('-', 'O'), ('four', 'O'), ('hours', 'O'), ('later', 'O'), (',', 'O'), ('any', 'O'), ('myalgia', 'B'), ('experienced', 'O'), ('was', 'O'), ('assessed', 'O'), ('according', 'O'), ('to', 'O'), ('a', 'O'), ('structured', 'O'), ('questionaire', 'O'), ('and', 'O'), ('graded', 'O'), ('by', 'O'), ('a', 'O'), ('four', 'O'), ('point', 'O'), ('scale', 'O'), ('by', 'O'), ('one', 'O'), ('investigator', 'O'), ('blinded', 'O'), ('to', 'O'), ('the', 'O'), ('intraoperative', 'O'), ('management', 'O'), ('.', 'O'))"
"At 24 h , the incidence of myalgia was higher in Group PS than in Group LS and PR ( p < 0 . 05 ) .","(('At', 'O'), ('24', 'O'), ('h', 'O'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('myalgia', 'B'), ('was', 'O'), ('higher', 'O'), ('in', 'O'), ('Group', 'O'), ('PS', 'O'), ('than', 'O'), ('in', 'O'), ('Group', 'O'), ('LS', 'O'), ('and', 'O'), ('PR', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups .,"(('The', 'O'), ('changes', 'O'), ('in', 'O'), ('systolic', 'O'), ('and', 'O'), ('diastolic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('heart', 'O'), ('rate', 'O'), ('were', 'O'), ('not', 'O'), ('significant', 'O'), ('among', 'O'), ('the', 'O'), ('three', 'O'), ('groups', 'O'), ('.', 'O'))"
"Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to seizures in mice lacking sodium channel beta 2 - subunits .","(('Reduced', 'O'), ('sodium', 'O'), ('channel', 'O'), ('density', 'O'), (',', 'O'), ('altered', 'O'), ('voltage', 'O'), ('dependence', 'O'), ('of', 'O'), ('inactivation', 'O'), (',', 'O'), ('and', 'O'), ('increased', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('seizures', 'O'), ('in', 'O'), ('mice', 'O'), ('lacking', 'O'), ('sodium', 'O'), ('channel', 'O'), ('beta', 'O'), ('2', 'O'), ('-', 'O'), ('subunits', 'O'), ('.', 'O'))"
"Sodium channel beta - subunits modulate channel gating , assembly , and cell surface expression in heterologous cell systems .","(('Sodium', 'O'), ('channel', 'O'), ('beta', 'O'), ('-', 'O'), ('subunits', 'O'), ('modulate', 'O'), ('channel', 'O'), ('gating', 'O'), (',', 'O'), ('assembly', 'O'), (',', 'O'), ('and', 'O'), ('cell', 'O'), ('surface', 'O'), ('expression', 'O'), ('in', 'O'), ('heterologous', 'O'), ('cell', 'O'), ('systems', 'O'), ('.', 'O'))"
"We generated beta2 ( - / - ) mice to investigate the role of beta2 in control of sodium channel density , localization , and function in neurons in vivo .","(('We', 'O'), ('generated', 'O'), ('beta2', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('beta2', 'O'), ('in', 'O'), ('control', 'O'), ('of', 'O'), ('sodium', 'O'), ('channel', 'O'), ('density', 'O'), (',', 'O'), ('localization', 'O'), (',', 'O'), ('and', 'O'), ('function', 'O'), ('in', 'O'), ('neurons', 'O'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
Measurements of [ ( 3 ) H ] saxitoxin ( STX ) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2 ( - / - ) neurons .,"(('Measurements', 'O'), ('of', 'O'), ('[', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('H', 'O'), (']', 'O'), ('saxitoxin', 'O'), ('(', 'O'), ('STX', 'O'), (')', 'O'), ('binding', 'O'), ('showed', 'O'), ('a', 'O'), ('significant', 'O'), ('reduction', 'O'), ('in', 'O'), ('the', 'O'), ('level', 'O'), ('of', 'O'), ('plasma', 'O'), ('membrane', 'O'), ('sodium', 'O'), ('channels', 'O'), ('in', 'O'), ('beta2', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('neurons', 'O'), ('.', 'O'))"
The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons .,"(('The', 'O'), ('loss', 'O'), ('of', 'O'), ('beta2', 'O'), ('resulted', 'O'), ('in', 'O'), ('negative', 'O'), ('shifts', 'O'), ('in', 'O'), ('the', 'O'), ('voltage', 'O'), ('dependence', 'O'), ('of', 'O'), ('inactivation', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('significant', 'O'), ('decreases', 'O'), ('in', 'O'), ('sodium', 'O'), ('current', 'O'), ('density', 'O'), ('in', 'O'), ('acutely', 'O'), ('dissociated', 'O'), ('hippocampal', 'O'), ('neurons', 'O'), ('.', 'O'))"
"The integral of the compound action potential in optic nerve was significantly reduced , and the threshold for action potential generation was increased , indicating a reduction in the level of functional plasma membrane sodium channels .","(('The', 'O'), ('integral', 'O'), ('of', 'O'), ('the', 'O'), ('compound', 'O'), ('action', 'O'), ('potential', 'O'), ('in', 'O'), ('optic', 'O'), ('nerve', 'O'), ('was', 'O'), ('significantly', 'O'), ('reduced', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('threshold', 'O'), ('for', 'O'), ('action', 'O'), ('potential', 'O'), ('generation', 'O'), ('was', 'O'), ('increased', 'O'), (',', 'O'), ('indicating', 'O'), ('a', 'O'), ('reduction', 'O'), ('in', 'O'), ('the', 'O'), ('level', 'O'), ('of', 'O'), ('functional', 'O'), ('plasma', 'O'), ('membrane', 'O'), ('sodium', 'O'), ('channels', 'O'), ('.', 'O'))"
"In contrast , the conduction velocity , the number and size of axons in the optic nerve , and the specific localization of Na ( v ) 1 . 6 channels in the nodes of Ranvier were unchanged .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('the', 'O'), ('conduction', 'O'), ('velocity', 'O'), (',', 'O'), ('the', 'O'), ('number', 'O'), ('and', 'O'), ('size', 'O'), ('of', 'O'), ('axons', 'O'), ('in', 'O'), ('the', 'O'), ('optic', 'O'), ('nerve', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('specific', 'O'), ('localization', 'O'), ('of', 'O'), ('Na', 'O'), ('(', 'O'), ('v', 'O'), (')', 'O'), ('1', 'O'), ('.', 'O'), ('6', 'O'), ('channels', 'O'), ('in', 'O'), ('the', 'O'), ('nodes', 'O'), ('of', 'O'), ('Ranvier', 'O'), ('were', 'O'), ('unchanged', 'O'), ('.', 'O'))"
"beta2 ( - / - ) mice displayed increased susceptibility to seizures , as indicated by reduced latency and threshold for pilocarpine - induced seizures , but seemed normal in other neurological tests .","(('beta2', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('displayed', 'O'), ('increased', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('seizures', 'O'), (',', 'O'), ('as', 'O'), ('indicated', 'O'), ('by', 'O'), ('reduced', 'O'), ('latency', 'O'), ('and', 'O'), ('threshold', 'O'), ('for', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), (',', 'O'), ('but', 'O'), ('seemed', 'O'), ('normal', 'O'), ('in', 'O'), ('other', 'O'), ('neurological', 'O'), ('tests', 'O'), ('.', 'O'))"
Our observations show that beta2 - subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability .,"(('Our', 'O'), ('observations', 'O'), ('show', 'O'), ('that', 'O'), ('beta2', 'O'), ('-', 'O'), ('subunits', 'O'), ('play', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('sodium', 'O'), ('channel', 'O'), ('density', 'O'), ('and', 'O'), ('function', 'O'), ('in', 'O'), ('neurons', 'O'), ('in', 'O'), ('vivo', 'O'), ('and', 'O'), ('are', 'O'), ('required', 'O'), ('for', 'O'), ('normal', 'O'), ('action', 'O'), ('potential', 'O'), ('generation', 'O'), ('and', 'O'), ('control', 'O'), ('of', 'O'), ('excitability', 'O'), ('.', 'O'))"
OBJECTIVE : To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('fatal', 'O'), ('liver', 'B'), ('failure', 'I'), ('possibly', 'O'), ('associated', 'O'), ('with', 'O'), ('concurrent', 'O'), ('use', 'O'), ('of', 'O'), ('bupropion', 'O'), ('and', 'O'), ('carbimazole', 'O'), ('.', 'O'))"
He received a 10 - day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation .,"(('He', 'O'), ('received', 'O'), ('a', 'O'), ('10', 'O'), ('-', 'O'), ('day', 'O'), ('course', 'O'), ('of', 'O'), ('bupropion', 'O'), ('as', 'O'), ('an', 'O'), ('aid', 'O'), ('for', 'O'), ('smoking', 'O'), ('cessation', 'O'), ('10', 'O'), ('weeks', 'O'), ('prior', 'O'), ('to', 'O'), ('presentation', 'O'), ('.', 'O'))"
He developed acute liver failure with rapid deterioration of renal function .,"(('He', 'O'), ('developed', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('with', 'O'), ('rapid', 'O'), ('deterioration', 'O'), ('of', 'O'), ('renal', 'O'), ('function', 'I'), ('.', 'O'))"
Death resulted 19 days after the onset of symptoms .,"(('Death', 'O'), ('resulted', 'O'), ('19', 'O'), ('days', 'O'), ('after', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('symptoms', 'O'), ('.', 'O'))"
Pyeloureteral filling defects associated with systemic anticoagulation : a case report .,"(('Pyeloureteral', 'B'), ('filling', 'I'), ('defects', 'I'), ('associated', 'O'), ('with', 'O'), ('systemic', 'O'), ('anticoagulation', 'O'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography .,"(('A', 'O'), ('case', 'O'), ('is', 'O'), ('presented', 'O'), ('that', 'O'), ('is', 'O'), ('unique', 'O'), ('in', 'O'), ('that', 'O'), ('the', 'O'), ('acute', 'O'), ('onset', 'O'), ('and', 'O'), ('the', 'O'), ('rapid', 'O'), ('resolution', 'O'), ('of', 'O'), ('pyeloureteral', 'B'), ('filling', 'I'), ('defects', 'I'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('were', 'O'), ('documented', 'O'), ('by', 'O'), ('radiography', 'O'), ('.', 'O'))"
There is no evidence of antecedent or concurrent infection in this patient .,"(('There', 'O'), ('is', 'O'), ('no', 'O'), ('evidence', 'O'), ('of', 'O'), ('antecedent', 'O'), ('or', 'O'), ('concurrent', 'O'), ('infection', 'O'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('.', 'O'))"
BACKGROUND : The use of iodinated contrast medium can result in nephropathy .,"(('BACKGROUND', 'O'), (':', 'O'), ('The', 'O'), ('use', 'O'), ('of', 'O'), ('iodinated', 'O'), ('contrast', 'O'), ('medium', 'O'), ('can', 'O'), ('result', 'O'), ('in', 'O'), ('nephropathy', 'B'), ('.', 'O'))"
The study involved 129 patients with diabetes with serum creatinine concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .,"(('The', 'O'), ('study', 'O'), ('involved', 'O'), ('129', 'O'), ('patients', 'O'), ('with', 'O'), ('diabetes', 'B'), ('with', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('concentrations', 'O'), ('of', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('to', 'O'), ('3', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('who', 'O'), ('underwent', 'O'), ('coronary', 'O'), ('or', 'O'), ('aortofemoral', 'O'), ('angiography', 'O'), ('.', 'O'))"
The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography .,"(('The', 'O'), ('primary', 'O'), ('end', 'O'), ('point', 'O'), ('was', 'O'), ('the', 'O'), ('peak', 'O'), ('increase', 'O'), ('from', 'O'), ('base', 'O'), ('line', 'O'), ('in', 'O'), ('the', 'O'), ('creatinine', 'O'), ('concentration', 'O'), ('during', 'O'), ('the', 'O'), ('three', 'O'), ('days', 'O'), ('after', 'O'), ('angiography', 'O'), ('.', 'O'))"
"Other end points were an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , an increase of 1 . 0 mg per deciliter or more , and a change in the creatinine concentration from day 0 to day 7 .","(('Other', 'O'), ('end', 'O'), ('points', 'O'), ('were', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('creatinine', 'O'), ('concentration', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('or', 'O'), ('more', 'O'), (',', 'O'), ('an', 'O'), ('increase', 'O'), ('of', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('or', 'O'), ('more', 'O'), (',', 'O'), ('and', 'O'), ('a', 'O'), ('change', 'O'), ('in', 'O'), ('the', 'O'), ('creatinine', 'O'), ('concentration', 'O'), ('from', 'O'), ('day', 'O'), ('0', 'O'), ('to', 'O'), ('day', 'O'), ('7', 'O'), ('.', 'O'))"
RESULTS : The creatinine concentration increased significantly less in patients who received iodixanol .,"(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('creatinine', 'O'), ('concentration', 'O'), ('increased', 'O'), ('significantly', 'O'), ('less', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('received', 'O'), ('iodixanol', 'O'), ('.', 'O'))"
"From day 0 to day 3 , the mean peak increase in creatinine was 0 . 13 mg per deciliter in the iodixanol group and 0 . 55 mg per deciliter in the iohexol group ( P = 0 . 001 ; the increase with iodixanol minus the increase with iohexol , - 0 . 42 mg per deciliter [ 95 percent confidence interval , - 0 . 73 to - 0 . 22 ] ) .","(('From', 'O'), ('day', 'O'), ('0', 'O'), ('to', 'O'), ('day', 'O'), ('3', 'O'), (',', 'O'), ('the', 'O'), ('mean', 'O'), ('peak', 'O'), ('increase', 'O'), ('in', 'O'), ('creatinine', 'O'), ('was', 'O'), ('0', 'O'), ('.', 'O'), ('13', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('in', 'O'), ('the', 'O'), ('iodixanol', 'O'), ('group', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'), ('55', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('in', 'O'), ('the', 'O'), ('iohexol', 'O'), ('group', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (';', 'O'), ('the', 'O'), ('increase', 'O'), ('with', 'O'), ('iodixanol', 'O'), ('minus', 'O'), ('the', 'O'), ('increase', 'O'), ('with', 'O'), ('iohexol', 'O'), (',', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('42', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('[', 'O'), ('95', 'O'), ('percent', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('73', 'O'), ('to', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('22', 'O'), (']', 'O'), (')', 'O'), ('.', 'O'))"
"Two of the 64 patients in the iodixanol group ( 3 percent ) had an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , as compared with 17 of the 65 patients in the iohexol group ( 26 percent ) ( P = 0 . 002 ; odds ratio for such an increase in the iodixanol group , 0 . 09 [ 95 percent confidence interval , 0 . 02 to 0 . 41 ] ) .","(('Two', 'O'), ('of', 'O'), ('the', 'O'), ('64', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('iodixanol', 'O'), ('group', 'O'), ('(', 'O'), ('3', 'O'), ('percent', 'O'), (')', 'O'), ('had', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('creatinine', 'O'), ('concentration', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('or', 'O'), ('more', 'O'), (',', 'O'), ('as', 'O'), ('compared', 'O'), ('with', 'O'), ('17', 'O'), ('of', 'O'), ('the', 'O'), ('65', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('iohexol', 'O'), ('group', 'O'), ('(', 'O'), ('26', 'O'), ('percent', 'O'), (')', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('002', 'O'), (';', 'O'), ('odds', 'O'), ('ratio', 'O'), ('for', 'O'), ('such', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('iodixanol', 'O'), ('group', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('09', 'O'), ('[', 'O'), ('95', 'O'), ('percent', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('02', 'O'), ('to', 'O'), ('0', 'O'), ('.', 'O'), ('41', 'O'), (']', 'O'), (')', 'O'), ('.', 'O'))"
"No patient receiving iodixanol had an increase of 1 . 0 mg per deciliter or more , but 10 patients in the iohexol group ( 15 percent ) did .","(('No', 'O'), ('patient', 'O'), ('receiving', 'O'), ('iodixanol', 'O'), ('had', 'O'), ('an', 'O'), ('increase', 'O'), ('of', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('or', 'O'), ('more', 'O'), (',', 'O'), ('but', 'O'), ('10', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('iohexol', 'O'), ('group', 'O'), ('(', 'O'), ('15', 'O'), ('percent', 'O'), (')', 'O'), ('did', 'O'), ('.', 'O'))"
"The mean change in the creatinine concentration from day 0 to day 7 was 0 . 07 mg per deciliter in the iodixanol group and 0 . 24 mg per deciliter in the iohexol group ( P = 0 . 003 ; value in the iodixanol group minus the value in the iohexol group , - 0 . 17 mg per deciliter [ 95 percent confidence interval , - 0 . 34 to - 0 . 07 ] ) .","(('The', 'O'), ('mean', 'O'), ('change', 'O'), ('in', 'O'), ('the', 'O'), ('creatinine', 'O'), ('concentration', 'O'), ('from', 'O'), ('day', 'O'), ('0', 'O'), ('to', 'O'), ('day', 'O'), ('7', 'O'), ('was', 'O'), ('0', 'O'), ('.', 'O'), ('07', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('in', 'O'), ('the', 'O'), ('iodixanol', 'O'), ('group', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'), ('24', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('in', 'O'), ('the', 'O'), ('iohexol', 'O'), ('group', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('003', 'O'), (';', 'O'), ('value', 'O'), ('in', 'O'), ('the', 'O'), ('iodixanol', 'O'), ('group', 'O'), ('minus', 'O'), ('the', 'O'), ('value', 'O'), ('in', 'O'), ('the', 'O'), ('iohexol', 'O'), ('group', 'O'), (',', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('17', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('[', 'O'), ('95', 'O'), ('percent', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('34', 'O'), ('to', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('07', 'O'), (']', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSIONS : Nephropathy induced by contrast medium may be less likely to develop in high - risk patients when iodixanol is used rather than a low - osmolar , nonionic contrast medium .","(('CONCLUSIONS', 'O'), (':', 'O'), ('Nephropathy', 'B'), ('induced', 'O'), ('by', 'O'), ('contrast', 'O'), ('medium', 'O'), ('may', 'O'), ('be', 'O'), ('less', 'O'), ('likely', 'O'), ('to', 'O'), ('develop', 'O'), ('in', 'O'), ('high', 'O'), ('-', 'O'), ('risk', 'O'), ('patients', 'O'), ('when', 'O'), ('iodixanol', 'O'), ('is', 'O'), ('used', 'O'), ('rather', 'O'), ('than', 'O'), ('a', 'O'), ('low', 'O'), ('-', 'O'), ('osmolar', 'O'), (',', 'O'), ('nonionic', 'O'), ('contrast', 'O'), ('medium', 'O'), ('.', 'O'))"
"Streptomycin was administered to the inner ear by osmotic pump for 24 h , and edaravone ( n = 8 ) or saline ( n = 6 ) was intraperitoneally injected once a day for 7 days .","(('Streptomycin', 'O'), ('was', 'O'), ('administered', 'O'), ('to', 'O'), ('the', 'O'), ('inner', 'O'), ('ear', 'O'), ('by', 'O'), ('osmotic', 'O'), ('pump', 'O'), ('for', 'O'), ('24', 'O'), ('h', 'O'), (',', 'O'), ('and', 'O'), ('edaravone', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('8', 'O'), (')', 'O'), ('or', 'O'), ('saline', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('6', 'O'), (')', 'O'), ('was', 'O'), ('intraperitoneally', 'O'), ('injected', 'O'), ('once', 'O'), ('a', 'O'), ('day', 'O'), ('for', 'O'), ('7', 'O'), ('days', 'O'), ('.', 'O'))"
We observed horizontal vestibulo - ocular reflex as a marker of postoperative vestibular function .,"(('We', 'O'), ('observed', 'O'), ('horizontal', 'O'), ('vestibulo', 'O'), ('-', 'O'), ('ocular', 'O'), ('reflex', 'O'), ('as', 'O'), ('a', 'O'), ('marker', 'O'), ('of', 'O'), ('postoperative', 'O'), ('vestibular', 'O'), ('function', 'O'), ('.', 'O'))"
Animals injected with saline showed statistically smaller gains than those injected with edaravone .,"(('Animals', 'O'), ('injected', 'O'), ('with', 'O'), ('saline', 'O'), ('showed', 'O'), ('statistically', 'O'), ('smaller', 'O'), ('gains', 'O'), ('than', 'O'), ('those', 'O'), ('injected', 'O'), ('with', 'O'), ('edaravone', 'O'), ('.', 'O'))"
Phenylpropanolamine ( PPA ) is a sympathetic amine used in over - the - counter cold remedies and weight - control preparations worldwide .,"(('Phenylpropanolamine', 'O'), ('(', 'O'), ('PPA', 'O'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('sympathetic', 'O'), ('amine', 'O'), ('used', 'O'), ('in', 'O'), ('over', 'O'), ('-', 'O'), ('the', 'O'), ('-', 'O'), ('counter', 'O'), ('cold', 'O'), ('remedies', 'O'), ('and', 'O'), ('weight', 'O'), ('-', 'O'), ('control', 'O'), ('preparations', 'O'), ('worldwide', 'O'), ('.', 'O'))"
"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA , even at doses generally considered to be safe .","(('Physicians', 'O'), ('and', 'O'), ('patients', 'O'), ('should', 'O'), ('be', 'O'), ('alert', 'O'), ('to', 'O'), ('the', 'O'), ('potential', 'O'), ('cardiac', 'O'), ('risk', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('PPA', 'O'), (',', 'O'), ('even', 'O'), ('at', 'O'), ('doses', 'O'), ('generally', 'O'), ('considered', 'O'), ('to', 'O'), ('be', 'O'), ('safe', 'O'), ('.', 'O'))"
Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus .,"(('Differential', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('high', 'O'), ('serum', 'O'), ('creatine', 'O'), ('kinase', 'O'), ('levels', 'O'), ('in', 'O'), ('systemic', 'B'), ('lupus', 'I'), ('erythematosus', 'I'), ('.', 'O'))"
We report the clinical and bioptic findings for a 57 - year - old woman with severe chloroquine - induced myopathy .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('clinical', 'O'), ('and', 'O'), ('bioptic', 'O'), ('findings', 'O'), ('for', 'O'), ('a', 'O'), ('57', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('severe', 'O'), ('chloroquine', 'B'), ('-', 'O'), ('induced', 'O'), ('myopathy', 'B'), ('.', 'O'))"
Additional therapy with chloroquine ( CQ ) was started because of arthralgia .,"(('Additional', 'O'), ('therapy', 'O'), ('with', 'O'), ('chloroquine', 'O'), ('(', 'O'), ('CQ', 'O'), (')', 'O'), ('was', 'O'), ('started', 'O'), ('because', 'O'), ('of', 'O'), ('arthralgia', 'B'), ('.', 'O'))"
"At the same time , slightly increased creatine kinase ( CK ) levels were noted .","(('At', 'O'), ('the', 'O'), ('same', 'O'), ('time', 'O'), (',', 'O'), ('slightly', 'O'), ('increased', 'O'), ('creatine', 'O'), ('kinase', 'O'), ('(', 'O'), ('CK', 'O'), (')', 'O'), ('levels', 'O'), ('were', 'O'), ('noted', 'O'), ('.', 'O'))"
"The CK increase persisted , however , and she developed progressive muscular weakness and muscular atrophy .","(('The', 'O'), ('CK', 'O'), ('increase', 'O'), ('persisted', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('and', 'O'), ('she', 'O'), ('developed', 'O'), ('progressive', 'O'), ('muscular', 'B'), ('weakness', 'I'), ('and', 'O'), ('muscular', 'B'), ('atrophy', 'I'), ('.', 'O'))"
"Routine controls revealed markedly elevated CK levels of 1 , 700 U / l .","(('Routine', 'O'), ('controls', 'O'), ('revealed', 'O'), ('markedly', 'O'), ('elevated', 'O'), ('CK', 'O'), ('levels', 'O'), ('of', 'O'), ('1', 'O'), (',', 'O'), ('700', 'O'), ('U', 'O'), ('/', 'O'), ('l', 'O'), ('.', 'O'))"
"As it revealed chloroquine - induced myopathy , medication was stopped .","(('As', 'O'), ('it', 'O'), ('revealed', 'O'), ('chloroquine', 'B'), ('-', 'O'), ('induced', 'O'), ('myopathy', 'B'), (',', 'O'), ('medication', 'O'), ('was', 'O'), ('stopped', 'O'), ('.', 'O'))"
"The subject , a 31 - year - old female smoker , was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained - release bupropion as an active control .","(('The', 'O'), ('subject', 'O'), (',', 'O'), ('a', 'O'), ('31', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('female', 'O'), ('smoker', 'O'), (',', 'O'), ('was', 'O'), ('participating', 'O'), ('in', 'O'), ('a', 'O'), ('clinical', 'O'), ('trial', 'O'), ('evaluating', 'O'), ('an', 'O'), ('investigational', 'O'), ('medication', 'O'), ('for', 'O'), ('smoking', 'O'), ('cessation', 'O'), ('that', 'O'), ('used', 'O'), ('sustained', 'O'), ('-', 'O'), ('release', 'O'), ('bupropion', 'O'), ('as', 'O'), ('an', 'O'), ('active', 'O'), ('control', 'O'), ('.', 'O'))"
"After 5 weeks of bupropion use , the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence .","(('After', 'O'), ('5', 'O'), ('weeks', 'O'), ('of', 'O'), ('bupropion', 'O'), ('use', 'O'), (',', 'O'), ('the', 'O'), ('subject', 'O'), ('experienced', 'O'), ('a', 'O'), ('generalized', 'B'), ('tonic', 'I'), ('clonic', 'I'), ('seizure', 'I'), ('after', 'O'), ('staying', 'O'), ('up', 'O'), ('nearly', 'O'), ('all', 'O'), ('night', 'O'), ('packing', 'O'), ('and', 'O'), ('moving', 'O'), ('to', 'O'), ('a', 'O'), ('new', 'O'), ('residence', 'O'), ('.', 'O'))"
The patient had no other risk factors for seizures .,"(('The', 'O'), ('patient', 'O'), ('had', 'O'), ('no', 'O'), ('other', 'O'), ('risk', 'O'), ('factors', 'O'), ('for', 'O'), ('seizures', 'O'), ('.', 'O'))"
The pathogenesis of this myalgia is still unclear ; inflammation has been suggested but without convincing evidence .,"(('The', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('this', 'O'), ('myalgia', 'B'), ('is', 'O'), ('still', 'O'), ('unclear', 'O'), (';', 'O'), ('inflammation', 'O'), ('has', 'O'), ('been', 'O'), ('suggested', 'O'), ('but', 'O'), ('without', 'O'), ('convincing', 'O'), ('evidence', 'O'), ('.', 'O'))"
We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia .,"(('We', 'O'), ('designed', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('to', 'O'), ('investigate', 'O'), ('whether', 'O'), ('an', 'O'), ('inflammatory', 'O'), ('reaction', 'O'), ('contributes', 'O'), ('to', 'O'), ('this', 'O'), ('myalgia', 'B'), ('.', 'O'))"
The incidence and severity of succinylcholine - associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .,"(('The', 'O'), ('incidence', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('succinylcholine', 'B'), ('-', 'O'), ('associated', 'O'), ('myalgia', 'B'), ('was', 'O'), ('determined', 'O'), ('in', 'O'), ('64', 'O'), ('patients', 'O'), ('pretreated', 'O'), ('with', 'O'), ('saline', 'O'), ('or', 'O'), ('dexamethasone', 'O'), ('before', 'O'), ('succinylcholine', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('32', 'O'), ('for', 'O'), ('each', 'O'), (')', 'O'), ('.', 'O'))"
"Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .","(('Incidence', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('myalgia', 'B'), ('did', 'O'), ('not', 'O'), ('differ', 'O'), ('significantly', 'O'), ('between', 'O'), ('the', 'O'), ('two', 'O'), ('groups', 'O'), (':', 'O'), ('15', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('dexamethasone', 'O'), ('group', 'O'), ('complained', 'O'), ('of', 'O'), ('myalgia', 'B'), ('compared', 'O'), ('with', 'O'), ('18', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('saline', 'O'), ('group', 'O'), (',', 'O'), ('and', 'O'), ('severe', 'O'), ('myalgia', 'B'), ('was', 'O'), ('reported', 'O'), ('by', 'O'), ('five', 'O'), ('patients', 'O'), ('and', 'O'), ('three', 'O'), ('patients', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('not', 'O'), ('significant', 'O'), (')', 'O'), ('.', 'O'))"
"At 48 h after surgery , 12 patients in both groups still suffered from myalgia ( not significant ) .","(('At', 'O'), ('48', 'O'), ('h', 'O'), ('after', 'O'), ('surgery', 'O'), (',', 'O'), ('12', 'O'), ('patients', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('still', 'O'), ('suffered', 'O'), ('from', 'O'), ('myalgia', 'B'), ('(', 'O'), ('not', 'O'), ('significant', 'O'), (')', 'O'), ('.', 'O'))"
"In addition , interleukin - 6 ( IL - 6 ) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('interleukin', 'O'), ('-', 'O'), ('6', 'O'), ('(', 'O'), ('IL', 'O'), ('-', 'O'), ('6', 'O'), (')', 'O'), ('as', 'O'), ('an', 'O'), ('early', 'O'), ('marker', 'O'), ('of', 'O'), ('inflammation', 'O'), ('was', 'O'), ('assessed', 'O'), ('in', 'O'), ('a', 'O'), ('subgroup', 'O'), ('of', 'O'), ('10', 'O'), ('patients', 'O'), ('pretreated', 'O'), ('with', 'O'), ('saline', 'O'), ('.', 'O'))"
"We found an increase of IL - 6 for only three patients , but only one patient reported myalgia ; no relationship between myalgia and the increase of IL - 6 was found .","(('We', 'O'), ('found', 'O'), ('an', 'O'), ('increase', 'O'), ('of', 'O'), ('IL', 'O'), ('-', 'O'), ('6', 'O'), ('for', 'O'), ('only', 'O'), ('three', 'O'), ('patients', 'O'), (',', 'O'), ('but', 'O'), ('only', 'O'), ('one', 'O'), ('patient', 'O'), ('reported', 'O'), ('myalgia', 'B'), (';', 'O'), ('no', 'O'), ('relationship', 'O'), ('between', 'O'), ('myalgia', 'B'), ('and', 'O'), ('the', 'O'), ('increase', 'O'), ('of', 'O'), ('IL', 'O'), ('-', 'O'), ('6', 'O'), ('was', 'O'), ('found', 'O'), ('.', 'O'))"
"In conclusion , there is no evidence for an inflammatory origin of succinylcholine - associated myalgia .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('there', 'O'), ('is', 'O'), ('no', 'O'), ('evidence', 'O'), ('for', 'O'), ('an', 'O'), ('inflammatory', 'O'), ('origin', 'O'), ('of', 'O'), ('succinylcholine', 'B'), ('-', 'O'), ('associated', 'O'), ('myalgia', 'B'), ('.', 'O'))"
"Oral administration of lindane ( 2 . 5 , 5 , 10 and 15 mg / kg , body weight ) for 5 days was found to produce a dose - dependent increase in the activity of P450 dependent 7 - ethoxyresorufin - O - deethylase ( EROD ) , 7 - pentoxyresorufin - O - dealkylase ( PROD ) and N - nitrosodimethylamine demethylase ( NDMA - d ) in rat brain and liver .","(('Oral', 'O'), ('administration', 'O'), ('of', 'O'), ('lindane', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), (',', 'O'), ('5', 'O'), (',', 'O'), ('10', 'O'), ('and', 'O'), ('15', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('body', 'O'), ('weight', 'O'), (')', 'O'), ('for', 'O'), ('5', 'O'), ('days', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('produce', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('activity', 'O'), ('of', 'O'), ('P450', 'O'), ('dependent', 'O'), ('7', 'O'), ('-', 'O'), ('ethoxyresorufin', 'O'), ('-', 'O'), ('O', 'O'), ('-', 'O'), ('deethylase', 'O'), ('(', 'O'), ('EROD', 'O'), (')', 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('pentoxyresorufin', 'O'), ('-', 'O'), ('O', 'O'), ('-', 'O'), ('dealkylase', 'O'), ('(', 'O'), ('PROD', 'O'), (')', 'O'), ('and', 'O'), ('N', 'O'), ('-', 'O'), ('nitrosodimethylamine', 'O'), ('demethylase', 'O'), ('(', 'O'), ('NDMA', 'O'), ('-', 'O'), ('d', 'O'), (')', 'O'), ('in', 'O'), ('rat', 'O'), ('brain', 'O'), ('and', 'O'), ('liver', 'O'), ('.', 'O'))"
A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose ( 2 . 5 mg / kg ) of lindane was increased from 5 days to 15 or 21 days .,"(('A', 'O'), ('significant', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('hepatic', 'O'), ('and', 'O'), ('brain', 'O'), ('P450', 'O'), ('monooxygenases', 'O'), ('was', 'O'), ('also', 'O'), ('observed', 'O'), ('when', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('exposure', 'O'), ('of', 'O'), ('low', 'O'), ('dose', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('of', 'O'), ('lindane', 'O'), ('was', 'O'), ('increased', 'O'), ('from', 'O'), ('5', 'O'), ('days', 'O'), ('to', 'O'), ('15', 'O'), ('or', 'O'), ('21', 'O'), ('days', 'O'), ('.', 'O'))"
"As observed with different doses , the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain .","(('As', 'O'), ('observed', 'O'), ('with', 'O'), ('different', 'O'), ('doses', 'O'), (',', 'O'), ('the', 'O'), ('magnitude', 'O'), ('of', 'O'), ('induction', 'O'), ('in', 'O'), ('the', 'O'), ('activity', 'O'), ('of', 'O'), ('P450', 'O'), ('monooxygenases', 'O'), ('was', 'O'), ('several', 'O'), ('fold', 'O'), ('higher', 'O'), ('in', 'O'), ('liver', 'O'), ('microsomes', 'O'), ('when', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('brain', 'O'), ('.', 'O'))"
"Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1 / 1A2 , 2B1 / 2B2 and 2E1 isoenzymes .","(('Western', 'O'), ('blotting', 'O'), ('studies', 'O'), ('have', 'O'), ('indicated', 'O'), ('that', 'O'), ('the', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('P450', 'O'), ('enzymes', 'O'), ('could', 'O'), ('be', 'O'), ('due', 'O'), ('to', 'O'), ('the', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('expression', 'O'), ('of', 'O'), ('P450', 'O'), ('1A1', 'O'), ('/', 'O'), ('1A2', 'O'), (',', 'O'), ('2B1', 'O'), ('/', 'O'), ('2B2', 'O'), ('and', 'O'), ('2E1', 'O'), ('isoenzymes', 'O'), ('.', 'O'))"
"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD , EROD and NDMA - d are due to the increase in the levels of P450 2B1 / 2B2 , 1A1 / 1A2 and 2E1 isoenzymes , respectively .","(('In', 'O'), ('vitro', 'O'), ('studies', 'O'), ('using', 'O'), ('organic', 'O'), ('inhibitors', 'O'), ('specific', 'O'), ('for', 'O'), ('individual', 'O'), ('P450', 'O'), ('isoenzymes', 'O'), ('and', 'O'), ('antibody', 'O'), ('inhibition', 'O'), ('experiments', 'O'), ('have', 'O'), ('further', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('the', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('activity', 'O'), ('of', 'O'), ('PROD', 'O'), (',', 'O'), ('EROD', 'O'), ('and', 'O'), ('NDMA', 'O'), ('-', 'O'), ('d', 'O'), ('are', 'O'), ('due', 'O'), ('to', 'O'), ('the', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('levels', 'O'), ('of', 'O'), ('P450', 'O'), ('2B1', 'O'), ('/', 'O'), ('2B2', 'O'), (',', 'O'), ('1A1', 'O'), ('/', 'O'), ('1A2', 'O'), ('and', 'O'), ('2E1', 'O'), ('isoenzymes', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .","(('Induction', 'O'), ('studies', 'O'), ('have', 'O'), ('further', 'O'), ('shown', 'O'), ('that', 'O'), ('while', 'O'), ('pretreatment', 'O'), ('of', 'O'), ('3', 'O'), ('-', 'O'), ('methylcholanthrene', 'O'), ('(', 'O'), ('MC', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('inducer', 'O'), ('of', 'O'), ('P4501A1', 'O'), ('/', 'O'), ('1A2', 'O'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('produce', 'O'), ('any', 'O'), ('significant', 'O'), ('effect', 'O'), ('in', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('lindane', 'O'), ('induced', 'O'), ('convulsions', 'O'), (',', 'O'), ('pretreatment', 'O'), ('with', 'O'), ('phenobarbital', 'O'), ('(', 'O'), ('PB', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('inducer', 'O'), ('of', 'O'), ('P450', 'O'), ('2B1', 'O'), ('/', 'O'), ('2B2', 'O'), ('or', 'O'), ('ethanol', 'O'), (',', 'O'), ('an', 'O'), ('inducer', 'O'), ('of', 'O'), ('P450', 'O'), ('2E1', 'O'), ('catalysed', 'O'), ('reactions', 'O'), (',', 'O'), ('significantly', 'O'), ('increased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('lindane', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('.', 'O'))"
"Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .","(('Similarly', 'O'), (',', 'O'), ('when', 'O'), ('the', 'O'), ('P450', 'O'), ('-', 'O'), ('mediated', 'O'), ('metabolism', 'O'), ('of', 'O'), ('lindane', 'O'), ('was', 'O'), ('blocked', 'O'), ('by', 'O'), ('cobalt', 'O'), ('chloride', 'O'), ('incidence', 'O'), ('of', 'O'), ('convulsions', 'O'), ('was', 'O'), ('increased', 'O'), ('in', 'O'), ('animals', 'O'), ('treated', 'O'), ('with', 'O'), ('lindane', 'O'), ('indicating', 'O'), ('that', 'O'), ('lindane', 'O'), ('per', 'O'), ('se', 'O'), ('or', 'O'), ('its', 'O'), ('metabolites', 'O'), ('formed', 'O'), ('by', 'O'), ('PB', 'O'), ('or', 'O'), ('ethanol', 'O'), ('inducible', 'O'), ('P450', 'O'), ('isoenzymes', 'O'), ('are', 'O'), ('involved', 'O'), ('in', 'O'), ('its', 'O'), ('neurobehavioral', 'O'), ('toxicity', 'O'), ('.', 'O'))"
COC use was ascertained through mailed questionnaires .,"(('COC', 'O'), ('use', 'O'), ('was', 'O'), ('ascertained', 'O'), ('through', 'O'), ('mailed', 'O'), ('questionnaires', 'O'), ('.', 'O'))"
Sales statistics of COCs and CPA / EE were provided through Danish Drug Statistics .,"(('Sales', 'O'), ('statistics', 'O'), ('of', 'O'), ('COCs', 'O'), ('and', 'O'), ('CPA', 'O'), ('/', 'O'), ('EE', 'O'), ('were', 'O'), ('provided', 'O'), ('through', 'O'), ('Danish', 'O'), ('Drug', 'O'), ('Statistics', 'O'), ('.', 'O'))"
"Of these women , 67 were on levonorgestrel - containing COCs .","(('Of', 'O'), ('these', 'O'), ('women', 'O'), (',', 'O'), ('67', 'O'), ('were', 'O'), ('on', 'O'), ('levonorgestrel', 'O'), ('-', 'O'), ('containing', 'O'), ('COCs', 'O'), ('.', 'O'))"
Eleven were on CPA / EE .,"(('Eleven', 'O'), ('were', 'O'), ('on', 'O'), ('CPA', 'O'), ('/', 'O'), ('EE', 'O'), ('.', 'O'))"
Comparison of developmental toxicology of aspirin ( acetylsalicylic acid ) in rats using selected dosing paradigms .,"(('Comparison', 'O'), ('of', 'O'), ('developmental', 'O'), ('toxicology', 'O'), ('of', 'O'), ('aspirin', 'O'), ('(', 'O'), ('acetylsalicylic', 'O'), ('acid', 'O'), (')', 'O'), ('in', 'O'), ('rats', 'O'), ('using', 'O'), ('selected', 'O'), ('dosing', 'O'), ('paradigms', 'O'), ('.', 'O'))"
BACKGROUND : Analysis of the literature for nonsteroidal anti - inflammatory drugs ( NSAIDs ) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis .,"(('BACKGROUND', 'O'), (':', 'O'), ('Analysis', 'O'), ('of', 'O'), ('the', 'O'), ('literature', 'O'), ('for', 'O'), ('nonsteroidal', 'O'), ('anti', 'O'), ('-', 'O'), ('inflammatory', 'O'), ('drugs', 'O'), ('(', 'O'), ('NSAIDs', 'O'), (')', 'O'), ('suggests', 'O'), ('that', 'O'), ('a', 'O'), ('low', 'O'), ('incidence', 'O'), ('of', 'O'), ('developmental', 'O'), ('anomalies', 'I'), ('occurs', 'O'), ('in', 'O'), ('rats', 'O'), ('given', 'O'), ('NSAIDs', 'O'), ('on', 'O'), ('specific', 'O'), ('days', 'O'), ('during', 'O'), ('organogenesis', 'O'), ('.', 'O'))"
"Aspirin ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces developmental anomalies when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ . Teratology 4 : 15 - 24 , 1971 ) .","(('Aspirin', 'O'), ('(', 'O'), ('acetylsalicylic', 'O'), ('acid', 'O'), ('[', 'O'), ('ASA', 'O'), (']', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('irreversible', 'O'), ('cyclooxygenase', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), ('inhibitor', 'O'), (',', 'O'), ('induces', 'O'), ('developmental', 'B'), ('anomalies', 'I'), ('when', 'O'), ('administered', 'O'), ('to', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('on', 'O'), ('gestational', 'O'), ('day', 'O'), ('(', 'O'), ('GD', 'O'), (')', 'O'), ('9', 'O'), (',', 'O'), ('10', 'O'), (',', 'O'), ('or', 'O'), ('11', 'O'), ('(', 'O'), ('Kimmel', 'O'), ('CA', 'O'), (',', 'O'), ('Wilson', 'O'), ('JG', 'O'), (',', 'O'), ('Schumacher', 'O'), ('HJ', 'O'), ('.', 'O'), ('Teratology', 'O'), ('4', 'O'), (':', 'O'), ('15', 'O'), ('-', 'O'), ('24', 'O'), (',', 'O'), ('1971', 'O'), (')', 'O'), ('.', 'O'))"
There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17 .,"(('There', 'O'), ('are', 'O'), ('no', 'O'), ('published', 'O'), ('ASA', 'B'), ('studies', 'O'), ('using', 'O'), ('the', 'O'), ('multiple', 'O'), ('dosing', 'O'), ('paradigm', 'O'), ('of', 'O'), ('GDs', 'O'), ('6', 'O'), ('to', 'O'), ('17', 'O'), ('.', 'O'))"
"METHODS : ASA was administered as a single dose on GD 9 ( 0 , 250 , 500 , or 625 mg / kg ) , 10 ( 0 , 500 , 625 , or 750 mg / kg ) , or 11 ( 0 , 500 , 750 , or 1000 mg / kg ) and from GD 6 to GD 17 ( 0 , 50 , 125 , or 250 mg / kg a day ) in the multiple dose study to SD rats .","(('METHODS', 'O'), (':', 'O'), ('ASA', 'O'), ('was', 'O'), ('administered', 'O'), ('as', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('on', 'O'), ('GD', 'O'), ('9', 'O'), ('(', 'O'), ('0', 'O'), (',', 'O'), ('250', 'O'), (',', 'O'), ('500', 'O'), (',', 'O'), ('or', 'O'), ('625', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('10', 'O'), ('(', 'O'), ('0', 'O'), (',', 'O'), ('500', 'O'), (',', 'O'), ('625', 'O'), (',', 'O'), ('or', 'O'), ('750', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('or', 'O'), ('11', 'O'), ('(', 'O'), ('0', 'O'), (',', 'O'), ('500', 'O'), (',', 'O'), ('750', 'O'), (',', 'O'), ('or', 'O'), ('1000', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('and', 'O'), ('from', 'O'), ('GD', 'O'), ('6', 'O'), ('to', 'O'), ('GD', 'O'), ('17', 'O'), ('(', 'O'), ('0', 'O'), (',', 'O'), ('50', 'O'), (',', 'O'), ('125', 'O'), (',', 'O'), ('or', 'O'), ('250', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('a', 'O'), ('day', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('multiple', 'O'), ('dose', 'O'), ('study', 'O'), ('to', 'O'), ('SD', 'B'), ('rats', 'O'), ('.', 'O'))"
"Animals were killed on GD 21 , and fetuses were examined viscerally .","(('Animals', 'O'), ('were', 'O'), ('killed', 'O'), ('on', 'O'), ('GD', 'O'), ('21', 'O'), (',', 'O'), ('and', 'O'), ('fetuses', 'O'), ('were', 'O'), ('examined', 'O'), ('viscerally', 'O'), ('.', 'O'))"
Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis ( GDs 6 to 17 ) .,"(('Variations', 'O'), ('and', 'O'), ('malformations', 'O'), ('were', 'O'), ('similar', 'O'), ('when', 'O'), ('ASA', 'O'), ('was', 'O'), ('administered', 'O'), ('as', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('or', 'O'), ('during', 'O'), ('the', 'O'), ('period', 'O'), ('of', 'O'), ('organogenesis', 'O'), ('(', 'O'), ('GDs', 'O'), ('6', 'O'), ('to', 'O'), ('17', 'O'), (')', 'O'), ('.', 'O'))"
"It was also evident that , by titrating the dose to achieve a maximum tolerated dose , malformations that normally occur at low incidence , as reported from previous single dose studies , could also be induced with ASA given at multiple doses .","(('It', 'O'), ('was', 'O'), ('also', 'O'), ('evident', 'O'), ('that', 'O'), (',', 'O'), ('by', 'O'), ('titrating', 'O'), ('the', 'O'), ('dose', 'O'), ('to', 'O'), ('achieve', 'O'), ('a', 'O'), ('maximum', 'O'), ('tolerated', 'O'), ('dose', 'O'), (',', 'O'), ('malformations', 'B'), ('that', 'O'), ('normally', 'O'), ('occur', 'O'), ('at', 'O'), ('low', 'O'), ('incidence', 'O'), (',', 'O'), ('as', 'O'), ('reported', 'O'), ('from', 'O'), ('previous', 'O'), ('single', 'O'), ('dose', 'O'), ('studies', 'O'), (',', 'O'), ('could', 'O'), ('also', 'O'), ('be', 'O'), ('induced', 'O'), ('with', 'O'), ('ASA', 'O'), ('given', 'O'), ('at', 'O'), ('multiple', 'O'), ('doses', 'O'), ('.', 'O'))"
Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids : report of a double - blind multicenter study .,"(('Reversal', 'O'), ('of', 'O'), ('central', 'O'), ('benzodiazepine', 'O'), ('effects', 'O'), ('by', 'O'), ('flumazenil', 'O'), ('after', 'O'), ('intravenous', 'O'), ('conscious', 'O'), ('sedation', 'O'), ('with', 'O'), ('diazepam', 'O'), ('and', 'O'), ('opioids', 'O'), (':', 'O'), ('report', 'O'), ('of', 'O'), ('a', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('multicenter', 'O'), ('study', 'O'), ('.', 'O'))"
The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II .,"(('The', 'O'), ('Flumazenil', 'O'), ('in', 'O'), ('Intravenous', 'O'), ('Conscious', 'O'), ('Sedation', 'O'), ('with', 'O'), ('Diazepam', 'O'), ('Multicenter', 'O'), ('Study', 'O'), ('Group', 'O'), ('II', 'O'), ('.', 'O'))"
"The efficacy and safety of a new benzodiazepine antagonist , flumazenil , were assessed in a double - blind multicenter study .","(('The', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('of', 'O'), ('a', 'O'), ('new', 'O'), ('benzodiazepine', 'O'), ('antagonist', 'O'), (',', 'O'), ('flumazenil', 'O'), (',', 'O'), ('were', 'O'), ('assessed', 'O'), ('in', 'O'), ('a', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('multicenter', 'O'), ('study', 'O'), ('.', 'O'))"
"Flumazenil ( mean dose , 0 . 76 mg ) or placebo ( mean dose , 8 . 9 ml ) was administered intravenously to 130 and 67 patients , respectively , who had been given diazepam in conjunction with an opioid ( fentanyl , meperidine , or morphine ) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures .","(('Flumazenil', 'O'), ('(', 'O'), ('mean', 'O'), ('dose', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('76', 'O'), ('mg', 'O'), (')', 'O'), ('or', 'O'), ('placebo', 'O'), ('(', 'O'), ('mean', 'O'), ('dose', 'O'), (',', 'O'), ('8', 'O'), ('.', 'O'), ('9', 'O'), ('ml', 'O'), (')', 'O'), ('was', 'O'), ('administered', 'O'), ('intravenously', 'O'), ('to', 'O'), ('130', 'O'), ('and', 'O'), ('67', 'O'), ('patients', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('who', 'O'), ('had', 'O'), ('been', 'O'), ('given', 'O'), ('diazepam', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('an', 'O'), ('opioid', 'O'), ('(', 'O'), ('fentanyl', 'O'), (',', 'O'), ('meperidine', 'O'), (',', 'O'), ('or', 'O'), ('morphine', 'O'), (')', 'O'), ('for', 'O'), ('the', 'O'), ('induction', 'O'), ('and', 'O'), ('maintenance', 'O'), ('of', 'O'), ('intravenous', 'O'), ('conscious', 'O'), ('sedation', 'O'), ('for', 'O'), ('diagnostic', 'O'), ('or', 'O'), ('therapeutic', 'O'), ('surgical', 'O'), ('procedures', 'O'), ('.', 'O'))"
The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo .,"(('The', 'O'), ('group', 'O'), ('assessable', 'O'), ('for', 'O'), ('efficacy', 'O'), ('comprised', 'O'), ('122', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('flumazenil', 'O'), ('and', 'O'), ('64', 'O'), ('patients', 'O'), ('given', 'O'), ('placebo', 'O'), ('.', 'O'))"
"After 5 minutes , 80 / 115 ( 70 % ) flumazenil - treated patients , compared with 21 / 63 ( 33 % ) placebo - treated patients , were completely awake and alert , as indicated by a score of 5 on the Observer ' s Assessment of Alertness / Sedation Scale .","(('After', 'O'), ('5', 'O'), ('minutes', 'O'), (',', 'O'), ('80', 'O'), ('/', 'O'), ('115', 'O'), ('(', 'O'), ('70', 'O'), ('%', 'O'), (')', 'O'), ('flumazenil', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), (',', 'O'), ('compared', 'O'), ('with', 'O'), ('21', 'O'), ('/', 'O'), ('63', 'O'), ('(', 'O'), ('33', 'O'), ('%', 'O'), (')', 'O'), ('placebo', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), (',', 'O'), ('were', 'O'), ('completely', 'O'), ('awake', 'O'), ('and', 'O'), ('alert', 'O'), (',', 'O'), ('as', 'O'), ('indicated', 'O'), ('by', 'O'), ('a', 'O'), ('score', 'O'), ('of', 'O'), ('5', 'O'), ('on', 'O'), ('the', 'O'), ('Observer', 'O'), (""'"", 'O'), ('s', 'O'), ('Assessment', 'O'), ('of', 'O'), ('Alertness', 'O'), ('/', 'O'), ('Sedation', 'O'), ('Scale', 'O'), ('.', 'O'))"
Ninety - five percent of patients in each group who attained a score of 5 at the 5 - minute assessment showed no loss of alertness throughout the 180 - minute assessment period .,"(('Ninety', 'O'), ('-', 'O'), ('five', 'O'), ('percent', 'O'), ('of', 'O'), ('patients', 'O'), ('in', 'O'), ('each', 'O'), ('group', 'O'), ('who', 'O'), ('attained', 'O'), ('a', 'O'), ('score', 'O'), ('of', 'O'), ('5', 'O'), ('at', 'O'), ('the', 'O'), ('5', 'O'), ('-', 'O'), ('minute', 'O'), ('assessment', 'O'), ('showed', 'O'), ('no', 'O'), ('loss', 'O'), ('of', 'O'), ('alertness', 'O'), ('throughout', 'O'), ('the', 'O'), ('180', 'O'), ('-', 'O'), ('minute', 'O'), ('assessment', 'O'), ('period', 'O'), ('.', 'O'))"
Flumazenil - treated patients also performed significantly better on the Finger - to - Nose Test and the recall of pictures shown at the 5 - minute assessment .,"(('Flumazenil', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), ('also', 'O'), ('performed', 'O'), ('significantly', 'O'), ('better', 'O'), ('on', 'O'), ('the', 'O'), ('Finger', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('Nose', 'O'), ('Test', 'O'), ('and', 'O'), ('the', 'O'), ('recall', 'O'), ('of', 'O'), ('pictures', 'O'), ('shown', 'O'), ('at', 'O'), ('the', 'O'), ('5', 'O'), ('-', 'O'), ('minute', 'O'), ('assessment', 'O'), ('.', 'O'))"
"Flumazenil was well tolerated , with no serious adverse effects reported .","(('Flumazenil', 'O'), ('was', 'O'), ('well', 'O'), ('tolerated', 'O'), (',', 'O'), ('with', 'O'), ('no', 'O'), ('serious', 'O'), ('adverse', 'O'), ('effects', 'O'), ('reported', 'O'), ('.', 'O'))"
"Thirty - nine ( 30 % ) of flumazenil - treated patients , compared with 17 ( 25 % ) of placebo - treated patients had one or more drug - related adverse experiences .","(('Thirty', 'O'), ('-', 'O'), ('nine', 'O'), ('(', 'O'), ('30', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('flumazenil', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), (',', 'O'), ('compared', 'O'), ('with', 'O'), ('17', 'O'), ('(', 'O'), ('25', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('placebo', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), ('had', 'O'), ('one', 'O'), ('or', 'O'), ('more', 'O'), ('drug', 'O'), ('-', 'O'), ('related', 'O'), ('adverse', 'O'), ('experiences', 'O'), ('.', 'O'))"
Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids .,"(('Flumazenil', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('promptly', 'O'), ('reverse', 'O'), ('sedation', 'O'), ('induced', 'O'), ('by', 'O'), ('diazepam', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('opioids', 'O'), ('.', 'O'))"
It appears that methylphenidate precipitated the patient ' s pathological behavior .,"(('It', 'O'), ('appears', 'O'), ('that', 'O'), ('methylphenidate', 'O'), ('precipitated', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('pathological', 'O'), ('behavior', 'O'), ('.', 'O'))"
The combination of both side effects is extremely rare .,"(('The', 'O'), ('combination', 'O'), ('of', 'O'), ('both', 'O'), ('side', 'O'), ('effects', 'O'), ('is', 'O'), ('extremely', 'O'), ('rare', 'O'), ('.', 'O'))"
Potential deleterious effect of furosemide in radiocontrast nephropathy .,"(('Potential', 'O'), ('deleterious', 'O'), ('effect', 'O'), ('of', 'O'), ('furosemide', 'O'), ('in', 'O'), ('radiocontrast', 'B'), ('nephropathy', 'I'), ('.', 'O'))"
The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy .,"(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('efficacy', 'O'), ('of', 'O'), ('furosemide', 'O'), ('in', 'O'), ('addition', 'O'), ('to', 'O'), ('intravenous', 'O'), ('fluids', 'O'), ('in', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('radiocontrast', 'B'), ('nephropathy', 'I'), ('.', 'O'))"
"18 patients , referred to a radiocontrast study , considered at risk because of preexisting renal insufficiency , were enrolled in a prospective , randomized , controlled trial , performed at the secondary care center of a 1 , 100 - bed private university hospital .","(('18', 'O'), ('patients', 'O'), (',', 'O'), ('referred', 'O'), ('to', 'O'), ('a', 'O'), ('radiocontrast', 'O'), ('study', 'O'), (',', 'O'), ('considered', 'O'), ('at', 'O'), ('risk', 'O'), ('because', 'O'), ('of', 'O'), ('preexisting', 'O'), ('renal', 'B'), ('insufficiency', 'I'), (',', 'O'), ('were', 'O'), ('enrolled', 'O'), ('in', 'O'), ('a', 'O'), ('prospective', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('controlled', 'O'), ('trial', 'O'), (',', 'O'), ('performed', 'O'), ('at', 'O'), ('the', 'O'), ('secondary', 'O'), ('care', 'O'), ('center', 'O'), ('of', 'O'), ('a', 'O'), ('1', 'O'), (',', 'O'), ('100', 'O'), ('-', 'O'), ('bed', 'O'), ('private', 'O'), ('university', 'O'), ('hospital', 'O'), ('.', 'O'))"
"In addition to fluids , the treatment group received furosemide ( mean dose 110 mg ) intravenously 30 min prior to the injection of contrast material .","(('In', 'O'), ('addition', 'O'), ('to', 'O'), ('fluids', 'O'), (',', 'O'), ('the', 'O'), ('treatment', 'O'), ('group', 'O'), ('received', 'O'), ('furosemide', 'O'), ('(', 'O'), ('mean', 'O'), ('dose', 'O'), ('110', 'O'), ('mg', 'O'), (')', 'O'), ('intravenously', 'O'), ('30', 'O'), ('min', 'O'), ('prior', 'O'), ('to', 'O'), ('the', 'O'), ('injection', 'O'), ('of', 'O'), ('contrast', 'O'), ('material', 'O'), ('.', 'O'))"
The control group received fluids ( mean 3 liters ) .,"(('The', 'O'), ('control', 'O'), ('group', 'O'), ('received', 'O'), ('fluids', 'O'), ('(', 'O'), ('mean', 'O'), ('3', 'O'), ('liters', 'O'), (')', 'O'), ('.', 'O'))"
"Radiological studies were mostly angiographies performed with both ionic and non - ionic contrast material , at an average dose of 245 ml .","(('Radiological', 'O'), ('studies', 'O'), ('were', 'O'), ('mostly', 'O'), ('angiographies', 'O'), ('performed', 'O'), ('with', 'O'), ('both', 'O'), ('ionic', 'O'), ('and', 'O'), ('non', 'O'), ('-', 'O'), ('ionic', 'O'), ('contrast', 'O'), ('material', 'O'), (',', 'O'), ('at', 'O'), ('an', 'O'), ('average', 'O'), ('dose', 'O'), ('of', 'O'), ('245', 'O'), ('ml', 'O'), ('.', 'O'))"
Furosemide may be deleterious in the prevention of radiocontrast nephropathy .,"(('Furosemide', 'O'), ('may', 'O'), ('be', 'O'), ('deleterious', 'O'), ('in', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('radiocontrast', 'B'), ('nephropathy', 'I'), ('.', 'O'))"
VII .,"(('VII', 'O'), ('.', 'O'))"
"During a ten - year period , 348 women were studied for a total of 5 , 877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters .","(('During', 'O'), ('a', 'O'), ('ten', 'O'), ('-', 'O'), ('year', 'O'), ('period', 'O'), (',', 'O'), ('348', 'O'), ('women', 'O'), ('were', 'O'), ('studied', 'O'), ('for', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('5', 'O'), (',', 'O'), ('877', 'O'), ('patient', 'O'), ('months', 'O'), ('in', 'O'), ('four', 'O'), ('separate', 'O'), ('studies', 'O'), ('relating', 'O'), ('oral', 'O'), ('contraceptives', 'O'), ('to', 'O'), ('changes', 'O'), ('in', 'O'), ('hematologic', 'O'), ('parameters', 'O'), ('.', 'O'))"
Severe complications developed in four patients .,"(('Severe', 'O'), ('complications', 'O'), ('developed', 'O'), ('in', 'O'), ('four', 'O'), ('patients', 'O'), ('.', 'O'))"
Some of these findings represented the most extreme abnormalities seen in the entire group of patients ; some increased further during therapy .,"(('Some', 'O'), ('of', 'O'), ('these', 'O'), ('findings', 'O'), ('represented', 'O'), ('the', 'O'), ('most', 'O'), ('extreme', 'O'), ('abnormalities', 'O'), ('seen', 'O'), ('in', 'O'), ('the', 'O'), ('entire', 'O'), ('group', 'O'), ('of', 'O'), ('patients', 'O'), (';', 'O'), ('some', 'O'), ('increased', 'O'), ('further', 'O'), ('during', 'O'), ('therapy', 'O'), ('.', 'O'))"
All four patients were of the A or AB blood group .,"(('All', 'O'), ('four', 'O'), ('patients', 'O'), ('were', 'O'), ('of', 'O'), ('the', 'O'), ('A', 'O'), ('or', 'O'), ('AB', 'O'), ('blood', 'O'), ('group', 'O'), ('.', 'O'))"
It appears from these data that hematologic work - ups may be useful in women who are about to start long - term oral contraceptive therapy .,"(('It', 'O'), ('appears', 'O'), ('from', 'O'), ('these', 'O'), ('data', 'O'), ('that', 'O'), ('hematologic', 'O'), ('work', 'O'), ('-', 'O'), ('ups', 'O'), ('may', 'O'), ('be', 'O'), ('useful', 'O'), ('in', 'O'), ('women', 'O'), ('who', 'O'), ('are', 'O'), ('about', 'O'), ('to', 'O'), ('start', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('oral', 'O'), ('contraceptive', 'O'), ('therapy', 'O'), ('.', 'O'))"
1 .,"(('1', 'O'), ('.', 'O'))"
2 .,"(('2', 'O'), ('.', 'O'))"
Conscious SHR ( male 300 - 350 g ) were subjected to 90 degrees head - up tilts for 60 s following acute administration of prazosin ( 0 . 1 mg kg - 1 i . p . ) or rauwolscine ( 3 mg kg - 1 i . v . ) .,"(('Conscious', 'O'), ('SHR', 'O'), ('(', 'O'), ('male', 'O'), ('300', 'O'), ('-', 'O'), ('350', 'O'), ('g', 'O'), (')', 'O'), ('were', 'O'), ('subjected', 'O'), ('to', 'O'), ('90', 'O'), ('degrees', 'O'), ('head', 'O'), ('-', 'O'), ('up', 'O'), ('tilts', 'O'), ('for', 'O'), ('60', 'O'), ('s', 'O'), ('following', 'O'), ('acute', 'O'), ('administration', 'O'), ('of', 'O'), ('prazosin', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('mg', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('or', 'O'), ('rauwolscine', 'O'), ('(', 'O'), ('3', 'O'), ('mg', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
The basal MAP of conscious SHR was reduced to a similar extent by prazosin ( - 23 % ( - ) - 26 % MAP ) and rauwolscine ( - 16 % ( - ) - 33 % MAP ) .,"(('The', 'O'), ('basal', 'O'), ('MAP', 'O'), ('of', 'O'), ('conscious', 'O'), ('SHR', 'O'), ('was', 'O'), ('reduced', 'O'), ('to', 'O'), ('a', 'O'), ('similar', 'O'), ('extent', 'O'), ('by', 'O'), ('prazosin', 'O'), ('(', 'O'), ('-', 'O'), ('23', 'O'), ('%', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('26', 'O'), ('%', 'O'), ('MAP', 'O'), (')', 'O'), ('and', 'O'), ('rauwolscine', 'O'), ('(', 'O'), ('-', 'O'), ('16', 'O'), ('%', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('33', 'O'), ('%', 'O'), ('MAP', 'O'), (')', 'O'), ('.', 'O'))"
3 .,"(('3', 'O'), ('.', 'O'))"
Conscious SHR were treated for 4 days with prazosin at 2 mg kg - 1 day - 1 i . p . for chronic alpha 1 - adrenoceptor blockade .,"(('Conscious', 'O'), ('SHR', 'O'), ('were', 'O'), ('treated', 'O'), ('for', 'O'), ('4', 'O'), ('days', 'O'), ('with', 'O'), ('prazosin', 'O'), ('at', 'O'), ('2', 'O'), ('mg', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('day', 'O'), ('-', 'O'), ('1', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('for', 'O'), ('chronic', 'O'), ('alpha', 'O'), ('1', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('blockade', 'O'), ('.', 'O'))"
MAP in conscious SHR after chronic prazosin treatment was 14 % lower than in the untreated SHR ( n = 8 ) .,"(('MAP', 'O'), ('in', 'O'), ('conscious', 'O'), ('SHR', 'O'), ('after', 'O'), ('chronic', 'O'), ('prazosin', 'O'), ('treatment', 'O'), ('was', 'O'), ('14', 'O'), ('%', 'O'), ('lower', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('untreated', 'O'), ('SHR', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('8', 'O'), (')', 'O'), ('.', 'O'))"
"Conversely , administration of rauwolscine ( 3 mg kg - 1 i . v . ) in chronic prazosin treated SHR decreased the basal MAP by 12 - 31 % ( n = 4 ) , and subsequent tilts induced further drops of MAP by 19 - 23 % in these rats .","(('Conversely', 'O'), (',', 'O'), ('administration', 'O'), ('of', 'O'), ('rauwolscine', 'O'), ('(', 'O'), ('3', 'O'), ('mg', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('in', 'O'), ('chronic', 'O'), ('prazosin', 'O'), ('treated', 'O'), ('SHR', 'O'), ('decreased', 'O'), ('the', 'O'), ('basal', 'O'), ('MAP', 'O'), ('by', 'O'), ('12', 'O'), ('-', 'O'), ('31', 'O'), ('%', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('4', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('subsequent', 'O'), ('tilts', 'O'), ('induced', 'O'), ('further', 'O'), ('drops', 'O'), ('of', 'O'), ('MAP', 'O'), ('by', 'O'), ('19', 'O'), ('-', 'O'), ('23', 'O'), ('%', 'O'), ('in', 'O'), ('these', 'O'), ('rats', 'O'), ('.', 'O'))"
4 .,"(('4', 'O'), ('.', 'O'))"
We describe a 5th case .,"(('We', 'O'), ('describe', 'O'), ('a', 'O'), ('5th', 'O'), ('case', 'O'), ('.', 'O'))"
The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine .,"(('The', 'O'), ('reaction', 'O'), ('may', 'O'), ('be', 'O'), ('mediated', 'O'), ('by', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('antibodies', 'O'), ('reactive', 'O'), ('against', 'O'), ('platelets', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('quinine', 'O'), ('.', 'O'))"
"Treatment has included use of plasma exchange , prednisone , aspirin , and dipyridamole .","(('Treatment', 'O'), ('has', 'O'), ('included', 'O'), ('use', 'O'), ('of', 'O'), ('plasma', 'O'), ('exchange', 'O'), (',', 'O'), ('prednisone', 'O'), (',', 'O'), ('aspirin', 'O'), (',', 'O'), ('and', 'O'), ('dipyridamole', 'O'), ('.', 'O'))"
The patients have all regained some degree of renal function .,"(('The', 'O'), ('patients', 'O'), ('have', 'O'), ('all', 'O'), ('regained', 'O'), ('some', 'O'), ('degree', 'O'), ('of', 'O'), ('renal', 'O'), ('function', 'O'), ('.', 'O'))"
"However , it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement .","(('However', 'O'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('unclear', 'O'), ('whether', 'O'), ('pharmacological', 'O'), ('treatment', 'O'), ('or', 'O'), ('spontaneous', 'O'), ('resolution', 'O'), ('is', 'O'), ('responsible', 'O'), ('for', 'O'), ('the', 'O'), ('improvement', 'O'), ('.', 'O'))"
"It is important to recognize this reaction when it occurs and to avoid further quinine exposure , since the reaction seems to be recurrent .","(('It', 'O'), ('is', 'O'), ('important', 'O'), ('to', 'O'), ('recognize', 'O'), ('this', 'O'), ('reaction', 'O'), ('when', 'O'), ('it', 'O'), ('occurs', 'O'), ('and', 'O'), ('to', 'O'), ('avoid', 'O'), ('further', 'O'), ('quinine', 'O'), ('exposure', 'O'), (',', 'O'), ('since', 'O'), ('the', 'O'), ('reaction', 'O'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('recurrent', 'O'), ('.', 'O'))"
Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities .,"(('Analysis', 'O'), ('of', 'O'), ('the', 'O'), ('manifestations', 'O'), ('showed', 'O'), ('that', 'O'), ('severe', 'O'), ('impairment', 'B'), ('of', 'I'), ('memory', 'I'), ('accounted', 'O'), ('for', 'O'), ('virtually', 'O'), ('all', 'O'), ('of', 'O'), ('the', 'O'), ('abnormalities', 'O'), ('.', 'O'))"
There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain .,"(('There', 'O'), ('is', 'O'), ('evidence', 'O'), ('that', 'O'), ('cerebral', 'O'), ('reactions', 'O'), ('to', 'O'), ('drug', 'B'), ('toxicity', 'O'), ('can', 'O'), ('exhibit', 'O'), ('patterns', 'O'), ('that', 'O'), ('suggest', 'O'), ('highly', 'O'), ('selective', 'O'), ('involvement', 'O'), ('of', 'O'), ('functional', 'O'), ('subdivisions', 'O'), ('of', 'O'), ('the', 'O'), ('brain', 'O'), ('.', 'O'))"
Cefotetan - induced immune hemolytic anemia .,"(('Cefotetan', 'O'), ('-', 'O'), ('induced', 'O'), ('immune', 'B'), ('hemolytic', 'I'), ('anemia', 'I'), ('.', 'O'))"
Immune hemolytic anemia due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation cephalosporins .,"(('Immune', 'B'), ('hemolytic', 'I'), ('anemia', 'I'), ('due', 'O'), ('to', 'O'), ('a', 'O'), ('drug', 'O'), ('-', 'O'), ('adsorption', 'O'), ('mechanism', 'O'), ('has', 'O'), ('been', 'O'), ('described', 'O'), ('primarily', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('penicillins', 'O'), ('and', 'O'), ('first', 'O'), ('-', 'O'), ('generation', 'O'), ('cephalosporins', 'O'), ('.', 'O'))"
We describe a patient who developed anemia while receiving intravenous cefotetan .,"(('We', 'O'), ('describe', 'O'), ('a', 'O'), ('patient', 'O'), ('who', 'O'), ('developed', 'O'), ('anemia', 'B'), ('while', 'O'), ('receiving', 'O'), ('intravenous', 'O'), ('cefotetan', 'O'), ('.', 'O'))"
Cefotetan - dependent antibodies were detected in the patient ' s serum and in an eluate prepared from his red blood cells .,"(('Cefotetan', 'O'), ('-', 'O'), ('dependent', 'O'), ('antibodies', 'O'), ('were', 'O'), ('detected', 'O'), ('in', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('serum', 'O'), ('and', 'O'), ('in', 'O'), ('an', 'O'), ('eluate', 'O'), ('prepared', 'O'), ('from', 'O'), ('his', 'O'), ('red', 'O'), ('blood', 'O'), ('cells', 'O'), ('.', 'O'))"
"The eluate also reacted weakly with red blood cells in the absence of cefotetan , suggesting the concomitant formation of warm - reactive autoantibodies .","(('The', 'O'), ('eluate', 'O'), ('also', 'O'), ('reacted', 'O'), ('weakly', 'O'), ('with', 'O'), ('red', 'O'), ('blood', 'O'), ('cells', 'O'), ('in', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('cefotetan', 'O'), (',', 'O'), ('suggesting', 'O'), ('the', 'O'), ('concomitant', 'O'), ('formation', 'O'), ('of', 'O'), ('warm', 'O'), ('-', 'O'), ('reactive', 'O'), ('autoantibodies', 'O'), ('.', 'O'))"
"These observations , in conjunction with clinical and laboratory evidence of extravascular hemolysis , are consistent with drug - induced hemolytic anemia , possibly involving both drug - adsorption and autoantibody formation mechanisms .","(('These', 'O'), ('observations', 'O'), (',', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('clinical', 'O'), ('and', 'O'), ('laboratory', 'O'), ('evidence', 'O'), ('of', 'O'), ('extravascular', 'B'), ('hemolysis', 'I'), (',', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), (',', 'O'), ('possibly', 'O'), ('involving', 'O'), ('both', 'O'), ('drug', 'O'), ('-', 'O'), ('adsorption', 'O'), ('and', 'O'), ('autoantibody', 'O'), ('formation', 'O'), ('mechanisms', 'O'), ('.', 'O'))"
This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins .,"(('This', 'O'), ('case', 'O'), ('emphasizes', 'O'), ('the', 'O'), ('need', 'O'), ('for', 'O'), ('increased', 'O'), ('awareness', 'O'), ('of', 'O'), ('hemolytic', 'B'), ('reactions', 'O'), ('to', 'O'), ('all', 'O'), ('cephalosporins', 'O'), ('.', 'O'))"
METHODS : Male Wistar rats ( 150 - 200 g ; 6 rats per group ) were treated with saline or mesna 5 min ( i . p . ) before and 2 and 6 h after ( v . o . ) administration of IFS .,"(('METHODS', 'O'), (':', 'O'), ('Male', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('(', 'O'), ('150', 'O'), ('-', 'O'), ('200', 'O'), ('g', 'O'), (';', 'O'), ('6', 'O'), ('rats', 'O'), ('per', 'O'), ('group', 'O'), (')', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('saline', 'O'), ('or', 'O'), ('mesna', 'O'), ('5', 'O'), ('min', 'O'), ('(', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('before', 'O'), ('and', 'O'), ('2', 'O'), ('and', 'O'), ('6', 'O'), ('h', 'O'), ('after', 'O'), ('(', 'O'), ('v', 'O'), ('.', 'O'), ('o', 'O'), ('.', 'O'), (')', 'O'), ('administration', 'O'), ('of', 'O'), ('IFS', 'O'), ('.', 'O'))"
"One , two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna .","(('One', 'O'), (',', 'O'), ('two', 'O'), ('or', 'O'), ('three', 'O'), ('doses', 'O'), ('of', 'O'), ('mesna', 'O'), ('were', 'O'), ('replaced', 'O'), ('with', 'O'), ('dexamethasone', 'O'), ('alone', 'O'), ('or', 'O'), ('with', 'O'), ('dexamethasone', 'O'), ('plus', 'O'), ('mesna', 'O'), ('.', 'O'))"
"RESULTS : The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84 . 79 % and 89 . 13 % , respectively .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('replacement', 'O'), ('of', 'O'), ('the', 'O'), ('last', 'O'), ('dose', 'O'), ('or', 'O'), ('the', 'O'), ('last', 'O'), ('two', 'O'), ('doses', 'O'), ('of', 'O'), ('mesna', 'O'), ('with', 'O'), ('dexamethasone', 'O'), ('reduced', 'O'), ('the', 'O'), ('increase', 'O'), ('in', 'O'), ('bladder', 'O'), ('wet', 'O'), ('weight', 'O'), ('induced', 'O'), ('by', 'O'), ('IFS', 'B'), ('by', 'O'), ('84', 'O'), ('.', 'O'), ('79', 'O'), ('%', 'O'), ('and', 'O'), ('89', 'O'), ('.', 'O'), ('13', 'O'), ('%', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"In addition , it almost abolished the macroscopic and microscopic alterations induced by IFS .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('it', 'O'), ('almost', 'O'), ('abolished', 'O'), ('the', 'O'), ('macroscopic', 'O'), ('and', 'O'), ('microscopic', 'O'), ('alterations', 'O'), ('induced', 'O'), ('by', 'O'), ('IFS', 'B'), ('.', 'O'))"
"Moreover , the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically .","(('Moreover', 'O'), (',', 'O'), ('the', 'O'), ('addition', 'O'), ('of', 'O'), ('dexamethasone', 'O'), ('to', 'O'), ('the', 'O'), ('last', 'O'), ('two', 'O'), ('doses', 'O'), ('of', 'O'), ('mesna', 'O'), ('was', 'O'), ('more', 'O'), ('efficient', 'O'), ('than', 'O'), ('three', 'O'), ('doses', 'O'), ('of', 'O'), ('mesna', 'O'), ('alone', 'O'), ('when', 'O'), ('evaluated', 'O'), ('microscopically', 'O'), ('.', 'O'))"
All patients received short course of steroids .,"(('All', 'O'), ('patients', 'O'), ('received', 'O'), ('short', 'O'), ('course', 'O'), ('of', 'O'), ('steroids', 'O'), ('.', 'O'))"
All patients achieved complete remission without withdrawal of ATRA .,"(('All', 'O'), ('patients', 'O'), ('achieved', 'O'), ('complete', 'O'), ('remission', 'O'), ('without', 'O'), ('withdrawal', 'O'), ('of', 'O'), ('ATRA', 'O'), ('.', 'O'))"
Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala - kindled rats .,"(('Effect', 'O'), ('of', 'O'), ('some', 'O'), ('convulsants', 'O'), ('on', 'O'), ('the', 'O'), ('protective', 'O'), ('activity', 'O'), ('of', 'O'), ('loreclezole', 'O'), ('and', 'O'), ('its', 'O'), ('combinations', 'O'), ('with', 'O'), ('valproate', 'O'), ('or', 'O'), ('clonazepam', 'O'), ('in', 'O'), ('amygdala', 'O'), ('-', 'O'), ('kindled', 'O'), ('rats', 'O'), ('.', 'O'))"
"Loreclezole ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both seizure and afterdischarge durations .","(('Loreclezole', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('exerted', 'O'), ('a', 'O'), ('significant', 'O'), ('protective', 'O'), ('action', 'O'), ('in', 'O'), ('amygdala', 'O'), ('-', 'O'), ('kindled', 'O'), ('rats', 'O'), (',', 'O'), ('reducing', 'O'), ('both', 'O'), ('seizure', 'O'), ('and', 'O'), ('afterdischarge', 'O'), ('durations', 'O'), ('.', 'O'))"
"The combinations of loreclezole ( 2 . 5 mg / kg ) with valproate , clonazepam , or carbamazepine ( applied at their subprotective doses ) also exhibited antiseizure effect in this test .","(('The', 'O'), ('combinations', 'O'), ('of', 'O'), ('loreclezole', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('with', 'O'), ('valproate', 'O'), (',', 'O'), ('clonazepam', 'O'), (',', 'O'), ('or', 'O'), ('carbamazepine', 'O'), ('(', 'O'), ('applied', 'O'), ('at', 'O'), ('their', 'O'), ('subprotective', 'O'), ('doses', 'O'), (')', 'O'), ('also', 'O'), ('exhibited', 'O'), ('antiseizure', 'O'), ('effect', 'O'), ('in', 'O'), ('this', 'O'), ('test', 'O'), ('.', 'O'))"
"However , only two first combinations occurred to be of pharmacodynamic nature .","(('However', 'O'), (',', 'O'), ('only', 'O'), ('two', 'O'), ('first', 'O'), ('combinations', 'O'), ('occurred', 'O'), ('to', 'O'), ('be', 'O'), ('of', 'O'), ('pharmacodynamic', 'O'), ('nature', 'O'), ('.', 'O'))"
"Among several chemoconvulsants , bicuculline , N - methyl - D - aspartic acid and BAY k - 8644 ( the opener of L - type calcium channels ) reversed the protective activity of loreclezole alone and its combination with valproate .","(('Among', 'O'), ('several', 'O'), ('chemoconvulsants', 'O'), (',', 'O'), ('bicuculline', 'O'), (',', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('aspartic', 'O'), ('acid', 'O'), ('and', 'O'), ('BAY', 'O'), ('k', 'O'), ('-', 'O'), ('8644', 'O'), ('(', 'O'), ('the', 'O'), ('opener', 'O'), ('of', 'O'), ('L', 'O'), ('-', 'O'), ('type', 'O'), ('calcium', 'O'), ('channels', 'O'), (')', 'O'), ('reversed', 'O'), ('the', 'O'), ('protective', 'O'), ('activity', 'O'), ('of', 'O'), ('loreclezole', 'O'), ('alone', 'O'), ('and', 'O'), ('its', 'O'), ('combination', 'O'), ('with', 'O'), ('valproate', 'O'), ('.', 'O'))"
"On the other hand , bicuculline , aminophylline and BAY k - 8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam .","(('On', 'O'), ('the', 'O'), ('other', 'O'), ('hand', 'O'), (',', 'O'), ('bicuculline', 'O'), (',', 'O'), ('aminophylline', 'O'), ('and', 'O'), ('BAY', 'O'), ('k', 'O'), ('-', 'O'), ('8644', 'O'), ('inhibited', 'O'), ('the', 'O'), ('anticonvulsive', 'O'), ('action', 'O'), ('of', 'O'), ('loreclezole', 'O'), ('combined', 'O'), ('with', 'O'), ('clonazepam', 'O'), ('.', 'O'))"
The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L - type of calcium channels .,"(('The', 'O'), ('results', 'O'), ('support', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('the', 'O'), ('protective', 'O'), ('activity', 'O'), ('of', 'O'), ('loreclezole', 'O'), ('and', 'O'), ('its', 'O'), ('combinations', 'O'), ('with', 'O'), ('other', 'O'), ('antiepileptics', 'O'), ('may', 'O'), ('involve', 'O'), ('potentiation', 'O'), ('of', 'O'), ('GABAergic', 'O'), ('neurotransmission', 'O'), ('and', 'O'), ('blockade', 'O'), ('of', 'O'), ('L', 'O'), ('-', 'O'), ('type', 'O'), ('of', 'O'), ('calcium', 'O'), ('channels', 'O'), ('.', 'O'))"
We investigated the potential role of mitochondrial injury in the onset of these lesions .,"(('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('potential', 'O'), ('role', 'O'), ('of', 'O'), ('mitochondrial', 'O'), ('injury', 'O'), ('in', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('these', 'O'), ('lesions', 'O'), ('.', 'O'))"
METHODS : Rats were treated with intravenous doxorubicin ( 1 mg kg ( - 1 ) week ( - 1 ) ) for 7 weeks and were sacrificed either 1 week ( ' short - term ' ) or 30 weeks ( ' long - term ' ) following the last dose .,"(('METHODS', 'O'), (':', 'O'), ('Rats', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('intravenous', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('week', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), (')', 'O'), ('for', 'O'), ('7', 'O'), ('weeks', 'O'), ('and', 'O'), ('were', 'O'), ('sacrificed', 'O'), ('either', 'O'), ('1', 'O'), ('week', 'O'), ('(', 'O'), (""'"", 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), (""'"", 'O'), (')', 'O'), ('or', 'O'), ('30', 'O'), ('weeks', 'O'), ('(', 'O'), (""'"", 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), (""'"", 'O'), (')', 'O'), ('following', 'O'), ('the', 'O'), ('last', 'O'), ('dose', 'O'), ('.', 'O'))"
Additional rats received a single dose either 6 days or 2 h prior to euthanasia .,"(('Additional', 'O'), ('rats', 'O'), ('received', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('either', 'O'), ('6', 'O'), ('days', 'O'), ('or', 'O'), ('2', 'O'), ('h', 'O'), ('prior', 'O'), ('to', 'O'), ('euthanasia', 'O'), ('.', 'O'))"
All rats were killed at 48 weeks of age .,"(('All', 'O'), ('rats', 'O'), ('were', 'O'), ('killed', 'O'), ('at', 'O'), ('48', 'O'), ('weeks', 'O'), ('of', 'O'), ('age', 'O'), ('.', 'O'))"
"Finally , we quantified both nuclear and mitochondrial DNA ( mtDNA ) as well as superoxide production and the 4834 base pair ' common ' mtDNA deletion .","(('Finally', 'O'), (',', 'O'), ('we', 'O'), ('quantified', 'O'), ('both', 'O'), ('nuclear', 'O'), ('and', 'O'), ('mitochondrial', 'O'), ('DNA', 'O'), ('(', 'O'), ('mtDNA', 'O'), (')', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('superoxide', 'O'), ('production', 'O'), ('and', 'O'), ('the', 'O'), ('4834', 'O'), ('base', 'O'), ('pair', 'O'), (""'"", 'O'), ('common', 'O'), (""'"", 'O'), ('mtDNA', 'O'), ('deletion', 'O'), ('.', 'O'))"
"In addition , expression of the mtDNA - encoded COX subunit I was reduced and mtDNA levels were decreased .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('expression', 'O'), ('of', 'O'), ('the', 'O'), ('mtDNA', 'O'), ('-', 'O'), ('encoded', 'O'), ('COX', 'O'), ('subunit', 'O'), ('I', 'O'), ('was', 'O'), ('reduced', 'O'), ('and', 'O'), ('mtDNA', 'O'), ('levels', 'O'), ('were', 'O'), ('decreased', 'O'), ('.', 'O'))"
Injury was positively correlated with superoxide production and the activities of nucleus - encoded mitochondrial or cytoplasmic enzymes .,"(('Injury', 'O'), ('was', 'O'), ('positively', 'O'), ('correlated', 'O'), ('with', 'O'), ('superoxide', 'O'), ('production', 'O'), ('and', 'O'), ('the', 'O'), ('activities', 'O'), ('of', 'O'), ('nucleus', 'O'), ('-', 'O'), ('encoded', 'O'), ('mitochondrial', 'O'), ('or', 'O'), ('cytoplasmic', 'O'), ('enzymes', 'O'), ('.', 'O'))"
Kidneys from the ' long - term ' group showed more mtDNA deletions than in ' short - term ' animals and these were not observed in the other groups .,"(('Kidneys', 'O'), ('from', 'O'), ('the', 'O'), (""'"", 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), (""'"", 'O'), ('group', 'O'), ('showed', 'O'), ('more', 'O'), ('mtDNA', 'O'), ('deletions', 'O'), ('than', 'O'), ('in', 'O'), (""'"", 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), (""'"", 'O'), ('animals', 'O'), ('and', 'O'), ('these', 'O'), ('were', 'O'), ('not', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('other', 'O'), ('groups', 'O'), ('.', 'O'))"
CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in doxorubicin - induced renal lesions .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('for', 'O'), ('quantitative', 'O'), ('and', 'O'), ('qualitative', 'O'), ('mtDNA', 'O'), ('alterations', 'O'), ('through', 'O'), ('the', 'O'), ('reduction', 'O'), ('of', 'O'), ('mtDNA', 'O'), ('-', 'O'), ('encoded', 'O'), ('respiratory', 'O'), ('chain', 'O'), ('function', 'O'), ('and', 'O'), ('induction', 'O'), ('of', 'O'), ('superoxide', 'O'), ('in', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('renal', 'B'), ('lesions', 'I'), ('.', 'O'))"
"Although there were significant improvements relative to baseline in sexual desire and orgasm intensity / pleasure on 50 mg ephedrine 1 - hr prior to sexual activity , significant improvements in these measures , as well as in sexual arousal and orgasmic ability also were noted with placebo .","(('Although', 'O'), ('there', 'O'), ('were', 'O'), ('significant', 'O'), ('improvements', 'O'), ('relative', 'O'), ('to', 'O'), ('baseline', 'O'), ('in', 'O'), ('sexual', 'O'), ('desire', 'O'), ('and', 'O'), ('orgasm', 'O'), ('intensity', 'O'), ('/', 'O'), ('pleasure', 'O'), ('on', 'O'), ('50', 'O'), ('mg', 'O'), ('ephedrine', 'O'), ('1', 'O'), ('-', 'O'), ('hr', 'O'), ('prior', 'O'), ('to', 'O'), ('sexual', 'O'), ('activity', 'O'), (',', 'O'), ('significant', 'O'), ('improvements', 'O'), ('in', 'O'), ('these', 'O'), ('measures', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('in', 'O'), ('sexual', 'O'), ('arousal', 'O'), ('and', 'O'), ('orgasmic', 'O'), ('ability', 'O'), ('also', 'O'), ('were', 'O'), ('noted', 'O'), ('with', 'O'), ('placebo', 'O'), ('.', 'O'))"
These findings highlight the importance of conducting placebo - controlled trials for this condition .,"(('These', 'O'), ('findings', 'O'), ('highlight', 'O'), ('the', 'O'), ('importance', 'O'), ('of', 'O'), ('conducting', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('trials', 'O'), ('for', 'O'), ('this', 'O'), ('condition', 'O'), ('.', 'O'))"
A pilot study .,"(('A', 'O'), ('pilot', 'O'), ('study', 'O'), ('.', 'O'))"
This pilot study examines whether hormone therapy for breast cancer affects cognition .,"(('This', 'O'), ('pilot', 'O'), ('study', 'O'), ('examines', 'O'), ('whether', 'O'), ('hormone', 'O'), ('therapy', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('affects', 'O'), ('cognition', 'O'), ('.', 'O'))"
"Patients participating in a randomised trial of anastrozole , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without breast cancer ( n = 35 ) completed a battery of neuropsychological measures .","(('Patients', 'O'), ('participating', 'O'), ('in', 'O'), ('a', 'O'), ('randomised', 'O'), ('trial', 'O'), ('of', 'O'), ('anastrozole', 'O'), (',', 'O'), ('tamoxifen', 'O'), ('alone', 'O'), ('or', 'O'), ('combined', 'O'), ('(', 'O'), ('ATAC', 'O'), (')', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('94', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('group', 'O'), ('of', 'O'), ('women', 'O'), ('without', 'O'), ('breast', 'B'), ('cancer', 'I'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('35', 'O'), (')', 'O'), ('completed', 'O'), ('a', 'O'), ('battery', 'O'), ('of', 'O'), ('neuropsychological', 'O'), ('measures', 'O'), ('.', 'O'))"
"Compared with the control group , the patients were impaired on a processing speed task ( p = 0 . 032 ) and on a measure of immediate verbal memory ( p = 0 . 026 ) after controlling for the use of hormone replacement therapy in both groups .","(('Compared', 'O'), ('with', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), (',', 'O'), ('the', 'O'), ('patients', 'O'), ('were', 'O'), ('impaired', 'O'), ('on', 'O'), ('a', 'O'), ('processing', 'O'), ('speed', 'O'), ('task', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('032', 'O'), (')', 'O'), ('and', 'O'), ('on', 'O'), ('a', 'O'), ('measure', 'O'), ('of', 'O'), ('immediate', 'O'), ('verbal', 'O'), ('memory', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('026', 'O'), (')', 'O'), ('after', 'O'), ('controlling', 'O'), ('for', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('hormone', 'O'), ('replacement', 'O'), ('therapy', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('.', 'O'))"
Patient group performance was not significantly related to length of treatment or measures of psychological morbidity .,"(('Patient', 'O'), ('group', 'O'), ('performance', 'O'), ('was', 'O'), ('not', 'O'), ('significantly', 'O'), ('related', 'O'), ('to', 'O'), ('length', 'O'), ('of', 'O'), ('treatment', 'O'), ('or', 'O'), ('measures', 'O'), ('of', 'O'), ('psychological', 'O'), ('morbidity', 'O'), ('.', 'O'))"
The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer .,"(('The', 'O'), ('results', 'O'), ('showed', 'O'), ('specific', 'O'), ('impairments', 'O'), ('in', 'O'), ('processing', 'O'), ('speed', 'O'), ('and', 'O'), ('verbal', 'O'), ('memory', 'O'), ('in', 'O'), ('women', 'O'), ('receiving', 'O'), ('hormonal', 'O'), ('therapy', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
"Verbal memory may be especially sensitive to changes in oestrogen levels , a finding commonly reported in studies of hormone replacement therapy in healthy women .","(('Verbal', 'O'), ('memory', 'O'), ('may', 'O'), ('be', 'O'), ('especially', 'O'), ('sensitive', 'O'), ('to', 'O'), ('changes', 'O'), ('in', 'O'), ('oestrogen', 'O'), ('levels', 'O'), (',', 'O'), ('a', 'O'), ('finding', 'O'), ('commonly', 'O'), ('reported', 'O'), ('in', 'O'), ('studies', 'O'), ('of', 'O'), ('hormone', 'O'), ('replacement', 'O'), ('therapy', 'O'), ('in', 'O'), ('healthy', 'O'), ('women', 'O'), ('.', 'O'))"
In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly .,"(('In', 'O'), ('view', 'O'), ('of', 'O'), ('the', 'O'), ('increased', 'O'), ('use', 'O'), ('of', 'O'), ('hormone', 'O'), ('therapies', 'O'), ('in', 'O'), ('an', 'O'), ('adjuvant', 'O'), ('and', 'O'), ('preventative', 'O'), ('setting', 'O'), ('their', 'O'), ('impact', 'O'), ('on', 'O'), ('cognitive', 'O'), ('functioning', 'O'), ('should', 'O'), ('be', 'O'), ('investigated', 'O'), ('more', 'O'), ('thoroughly', 'O'), ('.', 'O'))"
Expression of p300 protects cardiac myocytes from apoptosis in vivo .,"(('Expression', 'O'), ('of', 'O'), ('p300', 'O'), ('protects', 'O'), ('cardiac', 'O'), ('myocytes', 'O'), ('from', 'O'), ('apoptosis', 'O'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
Doxorubicin is an anti - tumor agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .,"(('Doxorubicin', 'O'), ('is', 'O'), ('an', 'O'), ('anti', 'O'), ('-', 'O'), ('tumor', 'B'), ('agent', 'O'), ('that', 'O'), ('represses', 'O'), ('cardiac', 'O'), ('-', 'O'), ('specific', 'O'), ('gene', 'O'), ('expression', 'O'), ('and', 'O'), ('induces', 'O'), ('myocardial', 'O'), ('cell', 'O'), ('apoptosis', 'O'), ('.', 'O'))"
"Doxorubicin depletes cardiac p300 , a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes .","(('Doxorubicin', 'O'), ('depletes', 'O'), ('cardiac', 'O'), ('p300', 'O'), (',', 'O'), ('a', 'O'), ('transcriptional', 'O'), ('coactivator', 'O'), ('that', 'O'), ('is', 'O'), ('required', 'O'), ('for', 'O'), ('the', 'O'), ('maintenance', 'O'), ('of', 'O'), ('the', 'O'), ('differentiated', 'O'), ('phenotype', 'O'), ('of', 'O'), ('cardiac', 'O'), ('myocytes', 'O'), ('.', 'O'))"
"However , the role of p300 in protection against doxorubicin - induced apoptosis is unknown .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('p300', 'O'), ('in', 'O'), ('protection', 'O'), ('against', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('apoptosis', 'O'), ('is', 'O'), ('unknown', 'O'), ('.', 'O'))"
Transgenic mice overexpressing p300 in the heart and wild - type mice were subjected to doxorubicin treatment .,"(('Transgenic', 'O'), ('mice', 'O'), ('overexpressing', 'O'), ('p300', 'O'), ('in', 'O'), ('the', 'O'), ('heart', 'O'), ('and', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('mice', 'O'), ('were', 'O'), ('subjected', 'O'), ('to', 'O'), ('doxorubicin', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Compared with wild - type mice , transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha - sarcomeric actin .","(('Compared', 'O'), ('with', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('mice', 'O'), (',', 'O'), ('transgenic', 'O'), ('mice', 'O'), ('exhibited', 'O'), ('higher', 'O'), ('survival', 'O'), ('rate', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('more', 'O'), ('preserved', 'O'), ('left', 'O'), ('ventricular', 'O'), ('function', 'O'), ('and', 'O'), ('cardiac', 'O'), ('expression', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('sarcomeric', 'O'), ('actin', 'O'), ('.', 'O'))"
Doxorubicin induced myocardial cell apoptosis in wild - type mice but not in transgenic mice .,"(('Doxorubicin', 'O'), ('induced', 'O'), ('myocardial', 'O'), ('cell', 'O'), ('apoptosis', 'O'), ('in', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('mice', 'O'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('transgenic', 'O'), ('mice', 'O'), ('.', 'O'))"
"Expression of p300 increased the cardiac level of bcl - 2 and mdm - 2 , but not that of p53 or other members of the bcl - 2 family .","(('Expression', 'O'), ('of', 'O'), ('p300', 'O'), ('increased', 'O'), ('the', 'O'), ('cardiac', 'O'), ('level', 'O'), ('of', 'O'), ('bcl', 'O'), ('-', 'O'), ('2', 'O'), ('and', 'O'), ('mdm', 'O'), ('-', 'O'), ('2', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('that', 'O'), ('of', 'O'), ('p53', 'O'), ('or', 'O'), ('other', 'O'), ('members', 'O'), ('of', 'O'), ('the', 'O'), ('bcl', 'O'), ('-', 'O'), ('2', 'O'), ('family', 'O'), ('.', 'O'))"
These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin - induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo .,"(('These', 'O'), ('findings', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('overexpression', 'O'), ('of', 'O'), ('p300', 'O'), ('protects', 'O'), ('cardiac', 'O'), ('myocytes', 'O'), ('from', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('apoptosis', 'O'), ('and', 'O'), ('reduces', 'O'), ('the', 'O'), ('extent', 'O'), ('of', 'O'), ('acute', 'B'), ('heart', 'B'), ('failure', 'I'), ('in', 'O'), ('adult', 'O'), ('mice', 'O'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
Methimazole is a widely used and generally well - tolerated antithyroid agent .,"(('Methimazole', 'O'), ('is', 'O'), ('a', 'O'), ('widely', 'O'), ('used', 'O'), ('and', 'O'), ('generally', 'O'), ('well', 'O'), ('-', 'O'), ('tolerated', 'O'), ('antithyroid', 'O'), ('agent', 'O'), ('.', 'O'))"
The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications .,"(('The', 'O'), ('patient', 'O'), ('continued', 'O'), ('treatment', 'O'), ('for', 'O'), ('another', 'O'), ('4', 'O'), ('days', 'O'), ('after', 'O'), ('the', 'O'), ('appearance', 'O'), ('of', 'O'), ('jaundice', 'B'), ('until', 'O'), ('she', 'O'), ('finished', 'O'), ('both', 'O'), ('medications', 'O'), ('.', 'O'))"
"Over the following 9 days , the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole .","(('Over', 'O'), ('the', 'O'), ('following', 'O'), ('9', 'O'), ('days', 'O'), (',', 'O'), ('the', 'O'), ('symptoms', 'O'), ('improved', 'O'), ('and', 'O'), ('plasma', 'O'), ('bilirubin', 'O'), ('levels', 'O'), ('were', 'O'), ('normal', 'O'), ('after', 'O'), ('12', 'O'), ('weeks', 'O'), ('without', 'O'), ('methimazole', 'O'), ('.', 'O'))"
"Physicians and patients should be aware of this adverse effect so that , upon occurrence , they can discontinue methimazole therapy and avoid unnecessary invasive procedures .","(('Physicians', 'O'), ('and', 'O'), ('patients', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('this', 'O'), ('adverse', 'O'), ('effect', 'O'), ('so', 'O'), ('that', 'O'), (',', 'O'), ('upon', 'O'), ('occurrence', 'O'), (',', 'O'), ('they', 'O'), ('can', 'O'), ('discontinue', 'O'), ('methimazole', 'O'), ('therapy', 'O'), ('and', 'O'), ('avoid', 'O'), ('unnecessary', 'O'), ('invasive', 'O'), ('procedures', 'O'), ('.', 'O'))"
The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient .,"(('The', 'O'), ('cardiac', 'B'), ('toxicity', 'O'), ('intrinsically', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('aggressive', 'O'), ('chemotherapy', 'O'), ('employed', 'O'), ('could', 'O'), ('function', 'O'), ('as', 'O'), ('a', 'O'), ('triggering', 'O'), ('factor', 'O'), ('for', 'O'), ('the', 'O'), ('arrhythmia', 'B'), ('in', 'O'), ('the', 'O'), ('predisposed', 'O'), ('myocardium', 'O'), ('of', 'O'), ('this', 'O'), ('patient', 'O'), ('.', 'O'))"
OBJECTIVE : To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced liver injury .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('assess', 'O'), ('lymphocyte', 'O'), ('reactivity', 'O'), ('to', 'O'), ('dilevalol', 'O'), ('and', 'O'), ('to', 'O'), ('serum', 'O'), ('containing', 'O'), ('putative', 'O'), ('ex', 'O'), ('vivo', 'O'), ('dilevalol', 'O'), ('antigens', 'O'), ('or', 'O'), ('metabolites', 'O'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('dilevalol', 'B'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('injury', 'I'), ('.', 'O'))"
PATIENT : A 58 - year - old woman with a clinical diagnosis of dilevalol - induced liver injury .,"(('PATIENT', 'O'), (':', 'O'), ('A', 'O'), ('58', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('a', 'O'), ('clinical', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('dilevalol', 'B'), ('-', 'O'), ('induced', 'I'), ('liver', 'I'), ('injury', 'I'), ('.', 'O'))"
METHODS : Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake .,"(('METHODS', 'O'), (':', 'O'), ('Peripheral', 'O'), ('blood', 'O'), ('mononuclear', 'O'), ('cells', 'O'), ('collected', 'O'), ('from', 'O'), ('the', 'O'), ('patient', 'O'), ('were', 'O'), ('cultured', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('a', 'O'), ('solution', 'O'), ('of', 'O'), ('dilevalol', 'O'), ('and', 'O'), ('also', 'O'), ('with', 'O'), ('sera', 'O'), ('collected', 'O'), ('from', 'O'), ('a', 'O'), ('volunteer', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('dilevalol', 'O'), ('intake', 'O'), ('.', 'O'))"
A similar protocol was performed with lymphocytes from a healthy subject .,"(('A', 'O'), ('similar', 'O'), ('protocol', 'O'), ('was', 'O'), ('performed', 'O'), ('with', 'O'), ('lymphocytes', 'O'), ('from', 'O'), ('a', 'O'), ('healthy', 'O'), ('subject', 'O'), ('.', 'O'))"
RESULTS : No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions .,"(('RESULTS', 'O'), (':', 'O'), ('No', 'O'), ('lymphocyte', 'O'), ('proliferation', 'O'), ('was', 'O'), ('observed', 'O'), ('either', 'O'), ('in', 'O'), ('the', 'O'), ('patient', 'O'), ('or', 'O'), ('in', 'O'), ('the', 'O'), ('healthy', 'O'), ('volunteer', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('dilevalol', 'O'), ('solutions', 'O'), ('.', 'O'))"
A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake .,"(('A', 'O'), ('significant', 'O'), ('proliferative', 'O'), ('response', 'O'), ('to', 'O'), ('serum', 'O'), ('collected', 'O'), ('after', 'O'), ('dilevalol', 'O'), ('intake', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('case', 'O'), ('of', 'O'), ('the', 'O'), ('patient', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('proliferative', 'O'), ('response', 'O'), ('to', 'O'), ('the', 'O'), ('serum', 'O'), ('collected', 'O'), ('before', 'O'), ('the', 'O'), ('drug', 'O'), ('intake', 'O'), ('.', 'O'))"
No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions .,"(('No', 'O'), ('reactivity', 'O'), ('was', 'O'), ('found', 'O'), ('when', 'O'), ('lymphocytes', 'O'), ('from', 'O'), ('the', 'O'), ('healthy', 'O'), ('subject', 'O'), ('were', 'O'), ('tested', 'O'), ('under', 'O'), ('similar', 'O'), ('conditions', 'O'), ('.', 'O'))"
"CONCLUSIONS : The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced liver injury .","(('CONCLUSIONS', 'O'), (':', 'O'), ('The', 'O'), ('methodology', 'O'), ('used', 'O'), ('allowed', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('lymphocyte', 'O'), ('sensitization', 'O'), ('to', 'O'), ('sera', 'O'), ('containing', 'O'), ('ex', 'O'), ('vivo', 'O'), ('-', 'O'), ('prepared', 'O'), ('dilevalol', 'O'), ('antigens', 'O'), (',', 'O'), ('suggesting', 'O'), ('the', 'O'), ('involvement', 'O'), ('of', 'O'), ('an', 'O'), ('immunologic', 'O'), ('mechanism', 'O'), ('in', 'O'), ('dilevalol', 'O'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('injury', 'I'), ('.', 'O'))"
"However , the molecular basis for the decreased renal sodium excretion remains undefined .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('molecular', 'O'), ('basis', 'O'), ('for', 'O'), ('the', 'O'), ('decreased', 'O'), ('renal', 'O'), ('sodium', 'O'), ('excretion', 'O'), ('remains', 'O'), ('undefined', 'O'), ('.', 'O'))"
We hypothesized that epithelial Na channel ( ENaC ) subunit dysregulation may be responsible for the increased sodium retention .,"(('We', 'O'), ('hypothesized', 'O'), ('that', 'O'), ('epithelial', 'O'), ('Na', 'O'), ('channel', 'O'), ('(', 'O'), ('ENaC', 'O'), (')', 'O'), ('subunit', 'O'), ('dysregulation', 'O'), ('may', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('the', 'O'), ('increased', 'O'), ('sodium', 'O'), ('retention', 'O'), ('.', 'O'))"
"An experimental group of rats was treated with puromycin aminonucleoside ( PAN ; 180 mg / kg iv ) , whereas the control group received only vehicle .","(('An', 'O'), ('experimental', 'O'), ('group', 'O'), ('of', 'O'), ('rats', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('(', 'O'), ('PAN', 'O'), (';', 'O'), ('180', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('iv', 'O'), (')', 'O'), (',', 'O'), ('whereas', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), ('received', 'O'), ('only', 'O'), ('vehicle', 'O'), ('.', 'O'))"
The protein abundance of alpha - ENaC and beta - ENaC was increased in the inner stripe of the outer medulla ( ISOM ) and in the inner medulla ( IM ) but was not altered in the cortex .,"(('The', 'O'), ('protein', 'O'), ('abundance', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('ENaC', 'O'), ('and', 'O'), ('beta', 'O'), ('-', 'O'), ('ENaC', 'O'), ('was', 'O'), ('increased', 'O'), ('in', 'O'), ('the', 'O'), ('inner', 'O'), ('stripe', 'O'), ('of', 'O'), ('the', 'O'), ('outer', 'O'), ('medulla', 'O'), ('(', 'O'), ('ISOM', 'O'), (')', 'O'), ('and', 'O'), ('in', 'O'), ('the', 'O'), ('inner', 'O'), ('medulla', 'O'), ('(', 'O'), ('IM', 'O'), (')', 'O'), ('but', 'O'), ('was', 'O'), ('not', 'O'), ('altered', 'O'), ('in', 'O'), ('the', 'O'), ('cortex', 'O'), ('.', 'O'))"
"gamma - ENaC abundance was increased in the cortex , ISOM , and IM .","(('gamma', 'O'), ('-', 'O'), ('ENaC', 'O'), ('abundance', 'O'), ('was', 'O'), ('increased', 'O'), ('in', 'O'), ('the', 'O'), ('cortex', 'O'), (',', 'O'), ('ISOM', 'O'), (',', 'O'), ('and', 'O'), ('IM', 'O'), ('.', 'O'))"
"Immunoperoxidase brightfield - and laser - scanning confocal fluorescence microscopy demonstrated increased targeting of alpha - ENaC , beta - ENaC , and gamma - ENaC subunits to the apical plasma membrane in the distal convoluted tubule ( DCT2 ) , connecting tubule , and cortical and medullary collecting duct segments .","(('Immunoperoxidase', 'O'), ('brightfield', 'O'), ('-', 'O'), ('and', 'O'), ('laser', 'O'), ('-', 'O'), ('scanning', 'O'), ('confocal', 'O'), ('fluorescence', 'O'), ('microscopy', 'O'), ('demonstrated', 'O'), ('increased', 'O'), ('targeting', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('ENaC', 'O'), (',', 'O'), ('beta', 'O'), ('-', 'O'), ('ENaC', 'O'), (',', 'O'), ('and', 'O'), ('gamma', 'O'), ('-', 'O'), ('ENaC', 'O'), ('subunits', 'O'), ('to', 'O'), ('the', 'O'), ('apical', 'O'), ('plasma', 'O'), ('membrane', 'O'), ('in', 'O'), ('the', 'O'), ('distal', 'O'), ('convoluted', 'O'), ('tubule', 'O'), ('(', 'O'), ('DCT2', 'O'), (')', 'O'), (',', 'O'), ('connecting', 'O'), ('tubule', 'O'), (',', 'O'), ('and', 'O'), ('cortical', 'O'), ('and', 'O'), ('medullary', 'O'), ('collecting', 'O'), ('duct', 'O'), ('segments', 'O'), ('.', 'O'))"
"Immunoelectron microscopy further revealed an increased labeling of alpha - ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN - treated rats , indicating enhanced apical targeting of alpha - ENaC subunits .","(('Immunoelectron', 'O'), ('microscopy', 'O'), ('further', 'O'), ('revealed', 'O'), ('an', 'O'), ('increased', 'O'), ('labeling', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('ENaC', 'O'), ('in', 'O'), ('the', 'O'), ('apical', 'O'), ('plasma', 'O'), ('membrane', 'O'), ('of', 'O'), ('cortical', 'O'), ('collecting', 'O'), ('duct', 'O'), ('principal', 'O'), ('cells', 'O'), ('of', 'O'), ('PAN', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), (',', 'O'), ('indicating', 'O'), ('enhanced', 'O'), ('apical', 'O'), ('targeting', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('ENaC', 'O'), ('subunits', 'O'), ('.', 'O'))"
"In contrast , the protein abundances of Na ( + ) / H ( + ) exchanger type 3 ( NHE3 ) , Na ( + ) - K ( + ) - 2Cl ( - ) cotransporter ( BSC - 1 ) , and thiazide - sensitive Na ( + ) - Cl ( - ) cotransporter ( TSC ) were decreased .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('the', 'O'), ('protein', 'O'), ('abundances', 'O'), ('of', 'O'), ('Na', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('/', 'O'), ('H', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('exchanger', 'O'), ('type', 'O'), ('3', 'O'), ('(', 'O'), ('NHE3', 'O'), (')', 'O'), (',', 'O'), ('Na', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('-', 'O'), ('K', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('-', 'O'), ('2Cl', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('cotransporter', 'O'), ('(', 'O'), ('BSC', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('thiazide', 'O'), ('-', 'O'), ('sensitive', 'O'), ('Na', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('-', 'O'), ('Cl', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('cotransporter', 'O'), ('(', 'O'), ('TSC', 'O'), (')', 'O'), ('were', 'O'), ('decreased', 'O'), ('.', 'O'))"
"Moreover , the abundance of the alpha ( 1 ) - subunit of the Na - K - ATPase was decreased in the cortex and ISOM , but it remained unchanged in the IM .","(('Moreover', 'O'), (',', 'O'), ('the', 'O'), ('abundance', 'O'), ('of', 'O'), ('the', 'O'), ('alpha', 'O'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('-', 'O'), ('subunit', 'O'), ('of', 'O'), ('the', 'O'), ('Na', 'O'), ('-', 'O'), ('K', 'O'), ('-', 'O'), ('ATPase', 'O'), ('was', 'O'), ('decreased', 'O'), ('in', 'O'), ('the', 'O'), ('cortex', 'O'), ('and', 'O'), ('ISOM', 'O'), (',', 'O'), ('but', 'O'), ('it', 'O'), ('remained', 'O'), ('unchanged', 'O'), ('in', 'O'), ('the', 'O'), ('IM', 'O'), ('.', 'O'))"
"The decreased abundance of NHE3 , BSC - 1 , TSC , and Na - K - ATPase may play a compensatory role to promote sodium excretion .","(('The', 'O'), ('decreased', 'O'), ('abundance', 'O'), ('of', 'O'), ('NHE3', 'O'), (',', 'O'), ('BSC', 'O'), ('-', 'O'), ('1', 'O'), (',', 'O'), ('TSC', 'O'), (',', 'O'), ('and', 'O'), ('Na', 'O'), ('-', 'O'), ('K', 'O'), ('-', 'O'), ('ATPase', 'O'), ('may', 'O'), ('play', 'O'), ('a', 'O'), ('compensatory', 'O'), ('role', 'O'), ('to', 'O'), ('promote', 'O'), ('sodium', 'O'), ('excretion', 'O'), ('.', 'O'))"
Pallidal stimulation : an alternative to pallidotomy ?,"(('Pallidal', 'O'), ('stimulation', 'O'), (':', 'O'), ('an', 'O'), ('alternative', 'O'), ('to', 'O'), ('pallidotomy', 'O'), ('?', 'O'))"
"Another lesioning procedure , ventrolateral thalamotomy , has become a powerful alternative to stimulate the nucleus ventralis intermedius , producing high long - term success rates and low morbidity rates .","(('Another', 'O'), ('lesioning', 'O'), ('procedure', 'O'), (',', 'O'), ('ventrolateral', 'O'), ('thalamotomy', 'O'), (',', 'O'), ('has', 'O'), ('become', 'O'), ('a', 'O'), ('powerful', 'O'), ('alternative', 'O'), ('to', 'O'), ('stimulate', 'O'), ('the', 'O'), ('nucleus', 'O'), ('ventralis', 'O'), ('intermedius', 'O'), (',', 'O'), ('producing', 'O'), ('high', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('success', 'O'), ('rates', 'O'), ('and', 'O'), ('low', 'O'), ('morbidity', 'O'), ('rates', 'O'), ('.', 'O'))"
Pallidal stimulation has not met with the same success .,"(('Pallidal', 'O'), ('stimulation', 'O'), ('has', 'O'), ('not', 'O'), ('met', 'O'), ('with', 'O'), ('the', 'O'), ('same', 'O'), ('success', 'O'), ('.', 'O'))"
"Considering the small increase in the patient ' s independence , the high costs of bilateral implants , and the difficulty most patients experience in handling the devices , the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy .","(('Considering', 'O'), ('the', 'O'), ('small', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('independence', 'O'), (',', 'O'), ('the', 'O'), ('high', 'O'), ('costs', 'O'), ('of', 'O'), ('bilateral', 'O'), ('implants', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('difficulty', 'O'), ('most', 'O'), ('patients', 'O'), ('experience', 'O'), ('in', 'O'), ('handling', 'O'), ('the', 'O'), ('devices', 'O'), (',', 'O'), ('the', 'O'), ('question', 'O'), ('arises', 'O'), ('as', 'O'), ('to', 'O'), ('whether', 'O'), ('bilateral', 'O'), ('pallidal', 'O'), ('stimulation', 'O'), ('is', 'O'), ('a', 'O'), ('real', 'O'), ('alternative', 'O'), ('to', 'O'), ('pallidotomy', 'O'), ('.', 'O'))"
The incidence rates of events were determined in all patients ( n = 7934 ) and in users of low - dose ( < or = 325 mg daily ) aspirin ( n = 1051 ) and nonusers of aspirin ( n = 6883 ) .,"(('The', 'O'), ('incidence', 'O'), ('rates', 'O'), ('of', 'O'), ('events', 'O'), ('were', 'O'), ('determined', 'O'), ('in', 'O'), ('all', 'O'), ('patients', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('7934', 'O'), (')', 'O'), ('and', 'O'), ('in', 'O'), ('users', 'O'), ('of', 'O'), ('low', 'O'), ('-', 'O'), ('dose', 'O'), ('(', 'O'), ('<', 'O'), ('or', 'O'), ('=', 'O'), ('325', 'O'), ('mg', 'O'), ('daily', 'O'), (')', 'O'), ('aspirin', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('1051', 'O'), (')', 'O'), ('and', 'O'), ('nonusers', 'O'), ('of', 'O'), ('aspirin', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('6883', 'O'), (')', 'O'), ('.', 'O'))"
The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses .,"(('The', 'O'), ('rates', 'O'), ('of', 'O'), ('events', 'O'), ('in', 'O'), ('users', 'O'), ('of', 'O'), ('aspirin', 'O'), ('were', 'O'), ('similar', 'O'), ('for', 'O'), ('all', 'O'), ('3', 'O'), ('treatment', 'O'), ('groups', 'O'), ('and', 'O'), ('across', 'O'), ('valdecoxib', 'O'), ('doses', 'O'), ('.', 'O'))"
"The annual incidence of warfarin - related bleeding at Brigham and Women ' s Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .","(('The', 'O'), ('annual', 'O'), ('incidence', 'O'), ('of', 'O'), ('warfarin', 'B'), ('-', 'O'), ('related', 'I'), ('bleeding', 'I'), ('at', 'O'), ('Brigham', 'O'), ('and', 'O'), ('Women', 'O'), (""'"", 'O'), ('s', 'O'), ('Hospital', 'O'), ('increased', 'O'), ('from', 'O'), ('0', 'O'), ('.', 'O'), ('97', 'O'), ('/', 'O'), ('1', 'O'), (',', 'O'), ('000', 'O'), ('patient', 'O'), ('admissions', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('time', 'O'), ('period', 'O'), ('(', 'O'), ('January', 'O'), ('1995', 'O'), ('to', 'O'), ('October', 'O'), ('1998', 'O'), (')', 'O'), ('to', 'O'), ('1', 'O'), ('.', 'O'), ('19', 'O'), ('/', 'O'), ('1', 'O'), (',', 'O'), ('000', 'O'), ('patient', 'O'), ('admissions', 'O'), ('in', 'O'), ('the', 'O'), ('second', 'O'), ('time', 'O'), ('period', 'O'), ('(', 'O'), ('November', 'O'), ('1998', 'O'), ('to', 'O'), ('August', 'O'), ('2002', 'O'), (')', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('.', 'O'))"
Various doses of yohimbine were used to determine the ideal dose for each patient .,"(('Various', 'O'), ('doses', 'O'), ('of', 'O'), ('yohimbine', 'O'), ('were', 'O'), ('used', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('ideal', 'O'), ('dose', 'O'), ('for', 'O'), ('each', 'O'), ('patient', 'O'), ('.', 'O'))"
RESULTS : Five of the six patients experienced improved sexual functioning after taking yohimbine .,"(('RESULTS', 'O'), (':', 'O'), ('Five', 'O'), ('of', 'O'), ('the', 'O'), ('six', 'O'), ('patients', 'O'), ('experienced', 'O'), ('improved', 'O'), ('sexual', 'O'), ('functioning', 'O'), ('after', 'O'), ('taking', 'O'), ('yohimbine', 'O'), ('.', 'O'))"
One patient who failed to comply with yohimbine treatment had no therapeutic effects .,"(('One', 'O'), ('patient', 'O'), ('who', 'O'), ('failed', 'O'), ('to', 'O'), ('comply', 'O'), ('with', 'O'), ('yohimbine', 'O'), ('treatment', 'O'), ('had', 'O'), ('no', 'O'), ('therapeutic', 'O'), ('effects', 'O'), ('.', 'O'))"
"Side effects of yohimbine included excessive sweating , increased anxiety , and a wound - up feeling in some patients .","(('Side', 'O'), ('effects', 'O'), ('of', 'O'), ('yohimbine', 'O'), ('included', 'O'), ('excessive', 'B'), ('sweating', 'O'), (',', 'O'), ('increased', 'O'), ('anxiety', 'O'), (',', 'O'), ('and', 'O'), ('a', 'O'), ('wound', 'B'), ('-', 'O'), ('up', 'O'), ('feeling', 'O'), ('in', 'O'), ('some', 'O'), ('patients', 'O'), ('.', 'O'))"
Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication .,"(('Future', 'O'), ('controlled', 'O'), ('studies', 'O'), ('are', 'O'), ('needed', 'O'), ('to', 'O'), ('further', 'O'), ('investigate', 'O'), ('the', 'O'), ('effectiveness', 'O'), ('and', 'O'), ('safety', 'O'), ('of', 'O'), ('yohimbine', 'O'), ('for', 'O'), ('this', 'O'), ('indication', 'O'), ('.', 'O'))"
"As standard practice at our institution , patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation .","(('As', 'O'), ('standard', 'O'), ('practice', 'O'), ('at', 'O'), ('our', 'O'), ('institution', 'O'), (',', 'O'), ('patients', 'O'), ('who', 'O'), ('are', 'O'), ('scheduled', 'O'), ('to', 'O'), ('receive', 'O'), ('a', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplant', 'O'), ('are', 'O'), ('treated', 'O'), ('prophylactically', 'O'), ('with', 'O'), ('forced', 'O'), ('hydration', 'O'), ('and', 'O'), ('bladder', 'O'), ('irrigation', 'O'), ('.', 'O'))"
Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases .,"(('Autologous', 'O'), ('haematopoietic', 'O'), ('stem', 'O'), ('cell', 'O'), ('transplantation', 'O'), ('is', 'O'), ('now', 'O'), ('a', 'O'), ('feasible', 'O'), ('and', 'O'), ('effective', 'O'), ('treatment', 'O'), ('for', 'O'), ('selected', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('autoimmune', 'B'), ('diseases', 'I'), ('.', 'O'))"
"Worldwide , over 650 patients have been transplanted in the context of phase I and II clinical trials .","(('Worldwide', 'O'), (',', 'O'), ('over', 'O'), ('650', 'O'), ('patients', 'O'), ('have', 'O'), ('been', 'O'), ('transplanted', 'O'), ('in', 'O'), ('the', 'O'), ('context', 'O'), ('of', 'O'), ('phase', 'O'), ('I', 'O'), ('and', 'O'), ('II', 'O'), ('clinical', 'O'), ('trials', 'O'), ('.', 'O'))"
The results are encouraging enough to begin randomised phase III trials .,"(('The', 'O'), ('results', 'O'), ('are', 'O'), ('encouraging', 'O'), ('enough', 'O'), ('to', 'O'), ('begin', 'O'), ('randomised', 'O'), ('phase', 'O'), ('III', 'O'), ('trials', 'O'), ('.', 'O'))"
"However , as predicted , significant transplant - related morbidity and mortality have been observed .","(('However', 'O'), (',', 'O'), ('as', 'O'), ('predicted', 'O'), (',', 'O'), ('significant', 'O'), ('transplant', 'O'), ('-', 'O'), ('related', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('.', 'O'))"
This is primarily due to complications related to either the stage of the disease at transplant or due to infections .,"(('This', 'O'), ('is', 'O'), ('primarily', 'O'), ('due', 'O'), ('to', 'O'), ('complications', 'O'), ('related', 'O'), ('to', 'O'), ('either', 'O'), ('the', 'O'), ('stage', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), ('at', 'O'), ('transplant', 'O'), ('or', 'O'), ('due', 'O'), ('to', 'O'), ('infections', 'O'), ('.', 'O'))"
The number of deaths related to cardiac toxicity is low .,"(('The', 'O'), ('number', 'O'), ('of', 'O'), ('deaths', 'O'), ('related', 'O'), ('to', 'O'), ('cardiac', 'B'), ('toxicity', 'I'), ('is', 'O'), ('low', 'O'), ('.', 'O'))"
"However , caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage , for example , systemic sclerosis patients .","(('However', 'O'), (',', 'O'), ('caution', 'O'), ('is', 'O'), ('required', 'O'), ('when', 'O'), ('cyclophosphamide', 'O'), ('or', 'O'), ('anthracyclines', 'O'), ('such', 'O'), ('as', 'O'), ('mitoxantrone', 'O'), ('are', 'O'), ('used', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('possible', 'O'), ('underlying', 'O'), ('heart', 'B'), ('damage', 'I'), (',', 'O'), ('for', 'O'), ('example', 'O'), (',', 'O'), ('systemic', 'B'), ('sclerosis', 'I'), ('patients', 'O'), ('.', 'O'))"
"In November 2002 , a meeting was held in Florence , bringing together a number of experts in various fields , including rheumatology , cardiology , neurology , pharmacology and transplantation medicine .","(('In', 'O'), ('November', 'O'), ('2002', 'O'), (',', 'O'), ('a', 'O'), ('meeting', 'O'), ('was', 'O'), ('held', 'O'), ('in', 'O'), ('Florence', 'O'), (',', 'O'), ('bringing', 'O'), ('together', 'O'), ('a', 'O'), ('number', 'O'), ('of', 'O'), ('experts', 'O'), ('in', 'O'), ('various', 'O'), ('fields', 'O'), (',', 'O'), ('including', 'O'), ('rheumatology', 'O'), (',', 'O'), ('cardiology', 'O'), (',', 'O'), ('neurology', 'O'), (',', 'O'), ('pharmacology', 'O'), ('and', 'O'), ('transplantation', 'O'), ('medicine', 'O'), ('.', 'O'))"
"The object of the meeting was to analyse existing data , both published or available , in the European Group for Blood and Marrow Transplantation autoimmune disease database , and to propose a safe approach to such patients .","(('The', 'O'), ('object', 'O'), ('of', 'O'), ('the', 'O'), ('meeting', 'O'), ('was', 'O'), ('to', 'O'), ('analyse', 'O'), ('existing', 'O'), ('data', 'O'), (',', 'O'), ('both', 'O'), ('published', 'O'), ('or', 'O'), ('available', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('European', 'O'), ('Group', 'O'), ('for', 'O'), ('Blood', 'O'), ('and', 'O'), ('Marrow', 'O'), ('Transplantation', 'O'), ('autoimmune', 'B'), ('disease', 'I'), ('database', 'O'), (',', 'O'), ('and', 'O'), ('to', 'O'), ('propose', 'O'), ('a', 'O'), ('safe', 'O'), ('approach', 'O'), ('to', 'O'), ('such', 'O'), ('patients', 'O'), ('.', 'O'))"
A full cardiological assessment before and during the transplant emerged as the major recommendation .,"(('A', 'O'), ('full', 'O'), ('cardiological', 'O'), ('assessment', 'O'), ('before', 'O'), ('and', 'O'), ('during', 'O'), ('the', 'O'), ('transplant', 'O'), ('emerged', 'O'), ('as', 'O'), ('the', 'O'), ('major', 'O'), ('recommendation', 'O'), ('.', 'O'))"
Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes ?,"(('Does', 'O'), ('supplemental', 'O'), ('vitamin', 'O'), ('C', 'O'), ('increase', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('risk', 'O'), ('in', 'O'), ('women', 'O'), ('with', 'O'), ('diabetes', 'B'), ('?', 'O'))"
"BACKGROUND : Vitamin C acts as a potent antioxidant ; however , it can also be a prooxidant and glycate protein under certain circumstances in vitro .","(('BACKGROUND', 'O'), (':', 'O'), ('Vitamin', 'O'), ('C', 'O'), ('acts', 'O'), ('as', 'O'), ('a', 'O'), ('potent', 'O'), ('antioxidant', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('it', 'O'), ('can', 'O'), ('also', 'O'), ('be', 'O'), ('a', 'O'), ('prooxidant', 'O'), ('and', 'O'), ('glycate', 'O'), ('protein', 'O'), ('under', 'O'), ('certain', 'O'), ('circumstances', 'O'), ('in', 'O'), ('vitro', 'O'), ('.', 'O'))"
OBJECTIVE : The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease .,"(('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('objective', 'O'), ('was', 'O'), ('to', 'O'), ('examine', 'O'), ('the', 'O'), ('relation', 'O'), ('between', 'O'), ('vitamin', 'O'), ('C', 'O'), ('intake', 'O'), ('and', 'O'), ('mortality', 'O'), ('from', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('.', 'O'))"
"RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .","(('RESULTS', 'O'), (':', 'O'), ('After', 'O'), ('adjustment', 'O'), ('for', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('risk', 'O'), ('factors', 'O'), (',', 'O'), ('type', 'O'), ('of', 'O'), ('diabetes', 'B'), ('medication', 'O'), ('used', 'O'), (',', 'O'), ('duration', 'O'), ('of', 'O'), ('diabetes', 'B'), (',', 'O'), ('and', 'O'), ('intakes', 'O'), ('of', 'O'), ('folate', 'O'), (',', 'O'), ('vitamin', 'O'), ('E', 'O'), (',', 'O'), ('and', 'O'), ('beta', 'O'), ('-', 'O'), ('carotene', 'O'), (',', 'O'), ('the', 'O'), ('adjusted', 'O'), ('relative', 'O'), ('risks', 'O'), ('of', 'O'), ('total', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('mortality', 'O'), ('were', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('97', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('11', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('47', 'O'), (',', 'O'), ('and', 'O'), ('1', 'O'), ('.', 'O'), ('84', 'O'), ('(', 'O'), ('P', 'O'), ('for', 'O'), ('trend', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('across', 'O'), ('quintiles', 'O'), ('of', 'O'), ('total', 'O'), ('vitamin', 'O'), ('C', 'O'), ('intake', 'O'), ('from', 'O'), ('food', 'O'), ('and', 'O'), ('supplements', 'O'), ('.', 'O'))"
"When dietary and supplemental vitamin C were analyzed separately , only supplemental vitamin C showed a positive association with mortality endpoints .","(('When', 'O'), ('dietary', 'O'), ('and', 'O'), ('supplemental', 'O'), ('vitamin', 'O'), ('C', 'O'), ('were', 'O'), ('analyzed', 'O'), ('separately', 'O'), (',', 'O'), ('only', 'O'), ('supplemental', 'O'), ('vitamin', 'O'), ('C', 'O'), ('showed', 'O'), ('a', 'O'), ('positive', 'O'), ('association', 'O'), ('with', 'O'), ('mortality', 'O'), ('endpoints', 'O'), ('.', 'O'))"
Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline .,"(('Vitamin', 'O'), ('C', 'O'), ('intake', 'O'), ('was', 'O'), ('unrelated', 'O'), ('to', 'O'), ('mortality', 'O'), ('from', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('in', 'O'), ('the', 'O'), ('nondiabetic', 'O'), ('subjects', 'O'), ('at', 'O'), ('baseline', 'O'), ('.', 'O'))"
CONCLUSION : A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes .,"(('CONCLUSION', 'O'), (':', 'O'), ('A', 'O'), ('high', 'O'), ('vitamin', 'O'), ('C', 'O'), ('intake', 'O'), ('from', 'O'), ('supplements', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('mortality', 'O'), ('in', 'O'), ('postmenopausal', 'O'), ('women', 'O'), ('with', 'O'), ('diabetes', 'B'), ('.', 'O'))"
Optical coherence tomography can measure axonal loss in patients with ethambutol - induced optic neuropathy .,"(('Optical', 'O'), ('coherence', 'O'), ('tomography', 'O'), ('can', 'O'), ('measure', 'O'), ('axonal', 'O'), ('loss', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('ethambutol', 'B'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('.', 'O'))"
"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity , contrast sensitivity , and color vision .","(('A', 'O'), ('serious', 'O'), ('complication', 'O'), ('of', 'O'), ('ethambutol', 'O'), ('is', 'O'), ('an', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('that', 'O'), ('impairs', 'O'), ('visual', 'O'), ('acuity', 'O'), (',', 'O'), ('contrast', 'O'), ('sensitivity', 'O'), (',', 'O'), ('and', 'O'), ('color', 'O'), ('vision', 'O'), ('.', 'O'))"
"However , early on , when the toxic optic neuropathy is mild and partly reversible , the funduscopic findings are often subtle and easy to miss .","(('However', 'O'), (',', 'O'), ('early', 'O'), ('on', 'O'), (',', 'O'), ('when', 'O'), ('the', 'O'), ('toxic', 'B'), ('optic', 'I'), ('neuropathy', 'I'), ('is', 'O'), ('mild', 'O'), ('and', 'O'), ('partly', 'O'), ('reversible', 'O'), (',', 'O'), ('the', 'O'), ('funduscopic', 'O'), ('findings', 'O'), ('are', 'O'), ('often', 'O'), ('subtle', 'O'), ('and', 'O'), ('easy', 'O'), ('to', 'O'), ('miss', 'O'), ('.', 'O'))"
"In addition , OCT ( OCT 3000 , Humphrey - Zeiss , Dublin , CA ) was performed on both eyes of each subject using the retinal nerve fiber layer ( RNFL ) analysis protocol .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('OCT', 'O'), ('(', 'O'), ('OCT', 'O'), ('3000', 'O'), (',', 'O'), ('Humphrey', 'O'), ('-', 'O'), ('Zeiss', 'O'), (',', 'O'), ('Dublin', 'O'), (',', 'O'), ('CA', 'O'), (')', 'O'), ('was', 'O'), ('performed', 'O'), ('on', 'O'), ('both', 'O'), ('eyes', 'O'), ('of', 'O'), ('each', 'O'), ('subject', 'O'), ('using', 'O'), ('the', 'O'), ('retinal', 'O'), ('nerve', 'O'), ('fiber', 'O'), ('layer', 'O'), ('(', 'O'), ('RNFL', 'O'), (')', 'O'), ('analysis', 'O'), ('protocol', 'O'), ('.', 'O'))"
OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL .,"(('OCT', 'O'), ('interpolates', 'O'), ('data', 'O'), ('from', 'O'), ('100', 'O'), ('points', 'O'), ('around', 'O'), ('the', 'O'), ('optic', 'O'), ('nerve', 'O'), ('to', 'O'), ('effectively', 'O'), ('map', 'O'), ('out', 'O'), ('the', 'O'), ('RNFL', 'O'), ('.', 'O'))"
"RESULTS : The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT , n = 661 .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('results', 'O'), ('were', 'O'), ('compared', 'O'), ('to', 'O'), ('the', 'O'), ('calculated', 'O'), ('average', 'O'), ('RNFL', 'O'), ('of', 'O'), ('normal', 'O'), ('eyes', 'O'), ('accumulated', 'O'), ('from', 'O'), ('four', 'O'), ('prior', 'O'), ('studies', 'O'), ('using', 'O'), ('OCT', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('661', 'O'), ('.', 'O'))"
"There was a combined mean loss of 46 % of fibers from the superior , inferior , and nasal quadrants in the ( six ) eyes of all three subjects ( mean average thickness of 55 + / - 29 microm ) .","(('There', 'O'), ('was', 'O'), ('a', 'O'), ('combined', 'O'), ('mean', 'O'), ('loss', 'O'), ('of', 'O'), ('46', 'O'), ('%', 'O'), ('of', 'O'), ('fibers', 'O'), ('from', 'O'), ('the', 'O'), ('superior', 'O'), (',', 'O'), ('inferior', 'O'), (',', 'O'), ('and', 'O'), ('nasal', 'O'), ('quadrants', 'O'), ('in', 'O'), ('the', 'O'), ('(', 'O'), ('six', 'O'), (')', 'O'), ('eyes', 'O'), ('of', 'O'), ('all', 'O'), ('three', 'O'), ('subjects', 'O'), ('(', 'O'), ('mean', 'O'), ('average', 'O'), ('thickness', 'O'), ('of', 'O'), ('55', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('29', 'O'), ('microm', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSIONS : The OCT results in these patients with EMB - induced optic neuropathy show considerable loss especially of the temporal fibers .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('The', 'O'), ('OCT', 'O'), ('results', 'O'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('with', 'O'), ('EMB', 'B'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('show', 'O'), ('considerable', 'O'), ('loss', 'O'), ('especially', 'O'), ('of', 'O'), ('the', 'O'), ('temporal', 'O'), ('fibers', 'O'), ('.', 'O'))"
This is consistent with prior histopathological studies that show predominant loss of parvo - cellular axons ( or small - caliber axons ) within the papillo - macular bundle in toxic or hereditary optic neuropathies .,"(('This', 'O'), ('is', 'O'), ('consistent', 'O'), ('with', 'O'), ('prior', 'O'), ('histopathological', 'O'), ('studies', 'O'), ('that', 'O'), ('show', 'O'), ('predominant', 'O'), ('loss', 'O'), ('of', 'O'), ('parvo', 'O'), ('-', 'O'), ('cellular', 'O'), ('axons', 'O'), ('(', 'O'), ('or', 'O'), ('small', 'O'), ('-', 'O'), ('caliber', 'O'), ('axons', 'O'), (')', 'O'), ('within', 'O'), ('the', 'O'), ('papillo', 'O'), ('-', 'O'), ('macular', 'O'), ('bundle', 'O'), ('in', 'O'), ('toxic', 'B'), ('or', 'I'), ('hereditary', 'I'), ('optic', 'I'), ('neuropathies', 'I'), ('.', 'O'))"
OCT can be a valuable tool in the quantitative analysis of optic neuropathies .,"(('OCT', 'O'), ('can', 'O'), ('be', 'O'), ('a', 'O'), ('valuable', 'O'), ('tool', 'O'), ('in', 'O'), ('the', 'O'), ('quantitative', 'O'), ('analysis', 'O'), ('of', 'O'), ('optic', 'B'), ('neuropathies', 'I'), ('.', 'O'))"
"Additionally , in terms of management of EMB - induced optic neuropathy , it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .","(('Additionally', 'O'), (',', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('management', 'O'), ('of', 'O'), ('EMB', 'O'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('important', 'O'), ('to', 'O'), ('properly', 'O'), ('manage', 'O'), ('ethambutol', 'O'), ('dosing', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('renal', 'B'), ('impairment', 'I'), ('and', 'O'), ('to', 'O'), ('achieve', 'O'), ('proper', 'O'), ('transition', 'O'), ('to', 'O'), ('a', 'O'), ('maintenance', 'O'), ('dose', 'O'), ('once', 'O'), ('an', 'O'), ('appropriate', 'O'), ('loading', 'O'), ('dose', 'O'), ('has', 'O'), ('been', 'O'), ('reached', 'O'), ('.', 'O'))"
"Despite the increasing need to identify and quantify tissue oxygenation at the cellular level , relatively few methods have been available .","(('Despite', 'O'), ('the', 'O'), ('increasing', 'O'), ('need', 'O'), ('to', 'O'), ('identify', 'O'), ('and', 'O'), ('quantify', 'O'), ('tissue', 'O'), ('oxygenation', 'O'), ('at', 'O'), ('the', 'O'), ('cellular', 'O'), ('level', 'O'), (',', 'O'), ('relatively', 'O'), ('few', 'O'), ('methods', 'O'), ('have', 'O'), ('been', 'O'), ('available', 'O'), ('.', 'O'))"
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C .,"(('Adequate', 'O'), ('timing', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('reduction', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('hemolysis', 'B'), ('during', 'O'), ('combination', 'O'), ('therapy', 'O'), ('of', 'O'), ('interferon', 'O'), ('and', 'O'), ('ribavirin', 'O'), ('for', 'O'), ('chronic', 'B'), ('hepatitis', 'I'), ('C', 'I'), ('.', 'O'))"
"Because of ribavirin - related hemolytic anemia , dose reduction is a common event in this therapy .","(('Because', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('-', 'O'), ('related', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), (',', 'O'), ('dose', 'O'), ('reduction', 'O'), ('is', 'O'), ('a', 'O'), ('common', 'O'), ('event', 'O'), ('in', 'O'), ('this', 'O'), ('therapy', 'O'), ('.', 'O'))"
In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy .,"(('In', 'O'), ('this', 'O'), ('clinical', 'O'), ('retrospective', 'O'), ('cohort', 'O'), ('study', 'O'), ('we', 'O'), ('have', 'O'), ('examined', 'O'), ('the', 'O'), ('suitable', 'O'), ('timing', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('reduction', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('hemolysis', 'B'), ('during', 'O'), ('combination', 'O'), ('therapy', 'O'), ('.', 'O'))"
"METHODS : Thirty - seven of 160 patients who had HCV - genotype 1b , had high virus load , and received 24 - week combination therapy developed anemia with hemoglobin level < 10 g / dl or anemia - related signs during therapy .","(('METHODS', 'O'), (':', 'O'), ('Thirty', 'O'), ('-', 'O'), ('seven', 'O'), ('of', 'O'), ('160', 'O'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('HCV', 'O'), ('-', 'O'), ('genotype', 'O'), ('1b', 'O'), (',', 'O'), ('had', 'O'), ('high', 'O'), ('virus', 'O'), ('load', 'O'), (',', 'O'), ('and', 'O'), ('received', 'O'), ('24', 'O'), ('-', 'O'), ('week', 'O'), ('combination', 'O'), ('therapy', 'O'), ('developed', 'O'), ('anemia', 'B'), ('with', 'O'), ('hemoglobin', 'O'), ('level', 'O'), ('<', 'O'), ('10', 'O'), ('g', 'O'), ('/', 'O'), ('dl', 'O'), ('or', 'O'), ('anemia', 'B'), ('-', 'O'), ('related', 'O'), ('signs', 'O'), ('during', 'O'), ('therapy', 'O'), ('.', 'O'))"
"After that , these 37 patients were reduced one tablet of ribavirin ( 200 mg ) per day .","(('After', 'O'), ('that', 'O'), (',', 'O'), ('these', 'O'), ('37', 'O'), ('patients', 'O'), ('were', 'O'), ('reduced', 'O'), ('one', 'O'), ('tablet', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('(', 'O'), ('200', 'O'), ('mg', 'O'), (')', 'O'), ('per', 'O'), ('day', 'O'), ('.', 'O'))"
"After reduction of ribavirin , 27 of 37 patients could continue combination therapy for a total of 24 weeks ( group A ) .","(('After', 'O'), ('reduction', 'O'), ('of', 'O'), ('ribavirin', 'O'), (',', 'O'), ('27', 'O'), ('of', 'O'), ('37', 'O'), ('patients', 'O'), ('could', 'O'), ('continue', 'O'), ('combination', 'O'), ('therapy', 'O'), ('for', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('24', 'O'), ('weeks', 'O'), ('(', 'O'), ('group', 'O'), ('A', 'O'), (')', 'O'), ('.', 'O'))"
"However , 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or anemia - related severe side effects occurred ( group B ) .","(('However', 'O'), (',', 'O'), ('10', 'O'), ('of', 'O'), ('37', 'O'), ('patients', 'O'), ('with', 'O'), ('reduction', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('could', 'O'), ('not', 'O'), ('continue', 'O'), ('combination', 'O'), ('therapy', 'O'), ('because', 'O'), ('their', 'O'), ('<', 'O'), ('8', 'O'), ('.', 'O'), ('5', 'O'), ('g', 'O'), ('/', 'O'), ('dl', 'O'), ('hemoglobin', 'O'), ('values', 'O'), ('decreased', 'O'), ('to', 'O'), ('or', 'O'), ('anemia', 'B'), ('-', 'O'), ('related', 'O'), ('severe', 'O'), ('side', 'O'), ('effects', 'O'), ('occurred', 'O'), ('(', 'O'), ('group', 'O'), ('B', 'O'), (')', 'O'), ('.', 'O'))"
We assessed the final efficacy and safety after reduction of ribavirin in groups A and B .,"(('We', 'O'), ('assessed', 'O'), ('the', 'O'), ('final', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('after', 'O'), ('reduction', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('in', 'O'), ('groups', 'O'), ('A', 'O'), ('and', 'O'), ('B', 'O'), ('.', 'O'))"
"RESULTS : A sustained virological response ( SVR ) was 29 . 6 % ( 8 / 27 ) in group A and 10 % ( 1 / 10 ) in group B , respectively .","(('RESULTS', 'O'), (':', 'O'), ('A', 'O'), ('sustained', 'O'), ('virological', 'O'), ('response', 'O'), ('(', 'O'), ('SVR', 'O'), (')', 'O'), ('was', 'O'), ('29', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('(', 'O'), ('8', 'O'), ('/', 'O'), ('27', 'O'), (')', 'O'), ('in', 'O'), ('group', 'O'), ('A', 'O'), ('and', 'O'), ('10', 'O'), ('%', 'O'), ('(', 'O'), ('1', 'O'), ('/', 'O'), ('10', 'O'), (')', 'O'), ('in', 'O'), ('group', 'O'), ('B', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"A 34 . 4 % ( 12 / 27 ) of SVR + biological response in group A was higher than 10 % ( 1 / 10 ) in group B ( P = 0 . 051 ) , with slight significance .","(('A', 'O'), ('34', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('(', 'O'), ('12', 'O'), ('/', 'O'), ('27', 'O'), (')', 'O'), ('of', 'O'), ('SVR', 'O'), ('+', 'O'), ('biological', 'O'), ('response', 'O'), ('in', 'O'), ('group', 'O'), ('A', 'O'), ('was', 'O'), ('higher', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('(', 'O'), ('1', 'O'), ('/', 'O'), ('10', 'O'), (')', 'O'), ('in', 'O'), ('group', 'O'), ('B', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('051', 'O'), (')', 'O'), (',', 'O'), ('with', 'O'), ('slight', 'O'), ('significance', 'O'), ('.', 'O'))"
"With respect to hemoglobin level at the time of ribavirin reduction , a rate of continuation of therapy in patients with > or = 10 g / dl hemoglobin was higher than that in patients with < 10 g / dl ( P = 0 . 036 ) .","(('With', 'O'), ('respect', 'O'), ('to', 'O'), ('hemoglobin', 'O'), ('level', 'O'), ('at', 'O'), ('the', 'O'), ('time', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('reduction', 'O'), (',', 'O'), ('a', 'O'), ('rate', 'O'), ('of', 'O'), ('continuation', 'O'), ('of', 'O'), ('therapy', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('>', 'O'), ('or', 'O'), ('=', 'O'), ('10', 'O'), ('g', 'O'), ('/', 'O'), ('dl', 'O'), ('hemoglobin', 'O'), ('was', 'O'), ('higher', 'O'), ('than', 'O'), ('that', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('<', 'O'), ('10', 'O'), ('g', 'O'), ('/', 'O'), ('dl', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('036', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSIONS : Reduction of ribavirin at hemoglobin level > or = 10 g / dl is suitable in terms of efficacy and side effects .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Reduction', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('at', 'O'), ('hemoglobin', 'O'), ('level', 'O'), ('>', 'O'), ('or', 'O'), ('=', 'O'), ('10', 'O'), ('g', 'O'), ('/', 'O'), ('dl', 'O'), ('is', 'O'), ('suitable', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('efficacy', 'O'), ('and', 'O'), ('side', 'O'), ('effects', 'O'), ('.', 'O'))"
The study was performed on sexually mature male rats .,"(('The', 'O'), ('study', 'O'), ('was', 'O'), ('performed', 'O'), ('on', 'O'), ('sexually', 'O'), ('mature', 'O'), ('male', 'O'), ('rats', 'O'), ('.', 'O'))"
Serum concentrations of prolactin ( PRL ) and testosterone ( T ) were measured .,"(('Serum', 'O'), ('concentrations', 'O'), ('of', 'O'), ('prolactin', 'O'), ('(', 'O'), ('PRL', 'O'), (')', 'O'), ('and', 'O'), ('testosterone', 'O'), ('(', 'O'), ('T', 'O'), (')', 'O'), ('were', 'O'), ('measured', 'O'), ('.', 'O'))"
Tissue sections were evaluated with light and electron microscopy .,"(('Tissue', 'O'), ('sections', 'O'), ('were', 'O'), ('evaluated', 'O'), ('with', 'O'), ('light', 'O'), ('and', 'O'), ('electron', 'O'), ('microscopy', 'O'), ('.', 'O'))"
Immunohistochemical reactions for Anti - Proliferating Cell Nuclear Antigen ( PCNA ) were performed .,"(('Immunohistochemical', 'O'), ('reactions', 'O'), ('for', 'O'), ('Anti', 'O'), ('-', 'O'), ('Proliferating', 'O'), ('Cell', 'O'), ('Nuclear', 'O'), ('Antigen', 'O'), ('(', 'O'), ('PCNA', 'O'), (')', 'O'), ('were', 'O'), ('performed', 'O'), ('.', 'O'))"
"In rats of the experimental group , the mean concentration of : PRL was more than twice higher , whereas T concentration was almost twice lower than that in the control group .","(('In', 'O'), ('rats', 'O'), ('of', 'O'), ('the', 'O'), ('experimental', 'O'), ('group', 'O'), (',', 'O'), ('the', 'O'), ('mean', 'O'), ('concentration', 'O'), ('of', 'O'), (':', 'O'), ('PRL', 'O'), ('was', 'O'), ('more', 'O'), ('than', 'O'), ('twice', 'O'), ('higher', 'O'), (',', 'O'), ('whereas', 'O'), ('T', 'O'), ('concentration', 'O'), ('was', 'O'), ('almost', 'O'), ('twice', 'O'), ('lower', 'O'), ('than', 'O'), ('that', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), ('.', 'O'))"
"Electron microscopy revealed changes in columnar epithelial cells , concerning organelles , engaged in protein synthesis and secretion .","(('Electron', 'O'), ('microscopy', 'O'), ('revealed', 'O'), ('changes', 'O'), ('in', 'O'), ('columnar', 'O'), ('epithelial', 'O'), ('cells', 'O'), (',', 'O'), ('concerning', 'O'), ('organelles', 'O'), (',', 'O'), ('engaged', 'O'), ('in', 'O'), ('protein', 'O'), ('synthesis', 'O'), ('and', 'O'), ('secretion', 'O'), ('.', 'O'))"
The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual - perfusion technique and with thallium - 201 single - photon emission tomography ( SPECT ) .,"(('The', 'O'), ('perfusion', 'O'), ('defect', 'O'), ('produced', 'O'), ('in', 'O'), ('16', 'O'), ('open', 'O'), ('chest', 'O'), ('dogs', 'O'), ('was', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('anatomic', 'O'), ('area', 'O'), ('at', 'O'), ('risk', 'O'), ('measured', 'O'), ('by', 'O'), ('the', 'O'), ('postmortem', 'O'), ('dual', 'O'), ('-', 'O'), ('perfusion', 'O'), ('technique', 'O'), ('and', 'O'), ('with', 'O'), ('thallium', 'O'), ('-', 'O'), ('201', 'O'), ('single', 'O'), ('-', 'O'), ('photon', 'O'), ('emission', 'O'), ('tomography', 'O'), ('(', 'O'), ('SPECT', 'O'), (')', 'O'), ('.', 'O'))"
The perfusion defect correlated significantly with the anatomic area at risk ( r = 0 . 74 ; p less than 0 . 002 ) .,"(('The', 'O'), ('perfusion', 'O'), ('defect', 'O'), ('correlated', 'O'), ('significantly', 'O'), ('with', 'O'), ('the', 'O'), ('anatomic', 'O'), ('area', 'O'), ('at', 'O'), ('risk', 'O'), ('(', 'O'), ('r', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('74', 'O'), (';', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('002', 'O'), (')', 'O'), ('.', 'O'))"
The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk ( r = 0 . 61 ; p = 0 . 02 ) .,"(('The', 'O'), ('size', 'O'), ('of', 'O'), ('the', 'O'), ('perfusion', 'O'), ('defect', 'O'), ('during', 'O'), ('stenosis', 'O'), ('correlated', 'O'), ('significantly', 'O'), ('with', 'O'), ('the', 'O'), ('anatomic', 'O'), ('area', 'O'), ('at', 'O'), ('risk', 'O'), ('(', 'O'), ('r', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('61', 'O'), (';', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('02', 'O'), (')', 'O'), ('.', 'O'))"
The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium - 201 SPECT .,"(('The', 'O'), ('results', 'O'), ('obtained', 'O'), ('show', 'O'), ('a', 'O'), ('correlation', 'O'), ('with', 'O'), ('the', 'O'), ('anatomic', 'O'), ('area', 'O'), ('at', 'O'), ('risk', 'O'), ('similar', 'O'), ('to', 'O'), ('that', 'O'), ('obtained', 'O'), ('with', 'O'), ('thallium', 'O'), ('-', 'O'), ('201', 'O'), ('SPECT', 'O'), ('.', 'O'))"
"In a microdialysis study , 10 muL of saline ( group C ; n = 8 ) or 30 mug of morphine ( group M ; n = 8 ) was injected intrathecally ( IT ) 0 . 5 h after reflow , and 30 mug of morphine ( group SM ; n = 8 ) or 10 muL of saline ( group SC ; n = 8 ) was injected IT 0 . 5 h after sham operation .","(('In', 'O'), ('a', 'O'), ('microdialysis', 'O'), ('study', 'O'), (',', 'O'), ('10', 'O'), ('muL', 'O'), ('of', 'O'), ('saline', 'O'), ('(', 'O'), ('group', 'O'), ('C', 'O'), (';', 'O'), ('n', 'O'), ('=', 'O'), ('8', 'O'), (')', 'O'), ('or', 'O'), ('30', 'O'), ('mug', 'O'), ('of', 'O'), ('morphine', 'O'), ('(', 'O'), ('group', 'O'), ('M', 'O'), (';', 'O'), ('n', 'O'), ('=', 'O'), ('8', 'O'), (')', 'O'), ('was', 'O'), ('injected', 'O'), ('intrathecally', 'O'), ('(', 'O'), ('IT', 'O'), (')', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('h', 'O'), ('after', 'O'), ('reflow', 'O'), (',', 'O'), ('and', 'O'), ('30', 'O'), ('mug', 'O'), ('of', 'O'), ('morphine', 'O'), ('(', 'O'), ('group', 'O'), ('SM', 'O'), (';', 'O'), ('n', 'O'), ('=', 'O'), ('8', 'O'), (')', 'O'), ('or', 'O'), ('10', 'O'), ('muL', 'O'), ('of', 'O'), ('saline', 'O'), ('(', 'O'), ('group', 'O'), ('SC', 'O'), (';', 'O'), ('n', 'O'), ('=', 'O'), ('8', 'O'), (')', 'O'), ('was', 'O'), ('injected', 'O'), ('IT', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('h', 'O'), ('after', 'O'), ('sham', 'O'), ('operation', 'O'), ('.', 'O'))"
"Microdialysis samples were collected preischemia , before IT injection , and at 2 , 4 , 8 , 24 , and 48 h of reperfusion ( after IT injection ) .","(('Microdialysis', 'O'), ('samples', 'O'), ('were', 'O'), ('collected', 'O'), ('preischemia', 'O'), (',', 'O'), ('before', 'O'), ('IT', 'O'), ('injection', 'O'), (',', 'O'), ('and', 'O'), ('at', 'O'), ('2', 'O'), (',', 'O'), ('4', 'O'), (',', 'O'), ('8', 'O'), (',', 'O'), ('24', 'O'), (',', 'O'), ('and', 'O'), ('48', 'O'), ('h', 'O'), ('of', 'O'), ('reperfusion', 'O'), ('(', 'O'), ('after', 'O'), ('IT', 'O'), ('injection', 'O'), (')', 'O'), ('.', 'O'))"
"After IT morphine , the cerebrospinal fluid ( CSF ) glutamate concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .","(('After', 'O'), ('IT', 'O'), ('morphine', 'O'), (',', 'O'), ('the', 'O'), ('cerebrospinal', 'O'), ('fluid', 'O'), ('(', 'O'), ('CSF', 'O'), (')', 'O'), ('glutamate', 'O'), ('concentration', 'O'), ('was', 'O'), ('increased', 'O'), ('in', 'O'), ('group', 'O'), ('M', 'O'), ('relative', 'O'), ('to', 'O'), ('both', 'O'), ('baseline', 'O'), ('and', 'O'), ('group', 'O'), ('C', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
This increase persisted for 8 hrs .,"(('This', 'O'), ('increase', 'O'), ('persisted', 'O'), ('for', 'O'), ('8', 'O'), ('hrs', 'O'), ('.', 'O'))"
"Notably , this side effect has not been ever reported in the medical literature .","(('Notably', 'O'), (',', 'O'), ('this', 'O'), ('side', 'O'), ('effect', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('ever', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('medical', 'O'), ('literature', 'O'), ('.', 'O'))"
Clinicians should be aware of this reaction since prompt termination of parenteral administration leads to complete resolution .,"(('Clinicians', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('this', 'O'), ('reaction', 'O'), ('since', 'O'), ('prompt', 'O'), ('termination', 'O'), ('of', 'O'), ('parenteral', 'O'), ('administration', 'O'), ('leads', 'O'), ('to', 'O'), ('complete', 'O'), ('resolution', 'O'), ('.', 'O'))"
OBJECTIVE : To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('describe', 'O'), ('the', 'O'), ('unmasking', 'O'), ('of', 'O'), ('pheochromocytoma', 'B'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('treated', 'O'), ('with', 'O'), ('amisulpride', 'O'), ('and', 'O'), ('tiapride', 'O'), ('.', 'O'))"
"Both drugs were immediately discontinued , and the patient recovered after subsequent nicardipine and verapamil treatment .","(('Both', 'O'), ('drugs', 'O'), ('were', 'O'), ('immediately', 'O'), ('discontinued', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('patient', 'O'), ('recovered', 'O'), ('after', 'O'), ('subsequent', 'O'), ('nicardipine', 'O'), ('and', 'O'), ('verapamil', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Abdominal ultrasound showed an adrenal mass , and postoperative histologic examination confirmed the diagnosis of pheochromocytoma .","(('Abdominal', 'O'), ('ultrasound', 'O'), ('showed', 'O'), ('an', 'O'), ('adrenal', 'B'), ('mass', 'O'), (',', 'O'), ('and', 'O'), ('postoperative', 'O'), ('histologic', 'O'), ('examination', 'O'), ('confirmed', 'O'), ('the', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('pheochromocytoma', 'B'), ('.', 'O'))"
"DISCUSSION : Drug - induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs , but the underlying mechanism is unknown .","(('DISCUSSION', 'O'), (':', 'O'), ('Drug', 'O'), ('-', 'O'), ('induced', 'O'), ('symptoms', 'O'), ('of', 'O'), ('pheochromocytoma', 'B'), ('are', 'O'), ('often', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('substituted', 'O'), ('benzamide', 'O'), ('drugs', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('underlying', 'O'), ('mechanism', 'O'), ('is', 'O'), ('unknown', 'O'), ('.', 'O'))"
Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride .,"(('Physicians', 'O'), ('and', 'O'), ('other', 'O'), ('healthcare', 'O'), ('professionals', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('this', 'O'), ('potential', 'O'), ('adverse', 'O'), ('effect', 'O'), ('of', 'O'), ('tiapride', 'O'), ('and', 'O'), ('amisulpride', 'O'), ('.', 'O'))"
"Minor neurological dysfunction , cognitive development , and somatic development at the age of 3 to 7 years after dexamethasone treatment in very - low birth - weight infants .","(('Minor', 'O'), ('neurological', 'B'), ('dysfunction', 'I'), (',', 'O'), ('cognitive', 'O'), ('development', 'O'), (',', 'O'), ('and', 'O'), ('somatic', 'O'), ('development', 'O'), ('at', 'O'), ('the', 'O'), ('age', 'O'), ('of', 'O'), ('3', 'O'), ('to', 'O'), ('7', 'O'), ('years', 'O'), ('after', 'O'), ('dexamethasone', 'O'), ('treatment', 'O'), ('in', 'O'), ('very', 'O'), ('-', 'O'), ('low', 'O'), ('birth', 'O'), ('-', 'O'), ('weight', 'O'), ('infants', 'O'), ('.', 'O'))"
"The objective of this study was to assess minor neurological dysfunction , cognitive development , and somatic development after dexamethasone therapy in very - low - birthweight infants .","(('The', 'O'), ('objective', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('assess', 'O'), ('minor', 'O'), ('neurological', 'B'), ('dysfunction', 'I'), (',', 'O'), ('cognitive', 'O'), ('development', 'O'), (',', 'O'), ('and', 'O'), ('somatic', 'O'), ('development', 'O'), ('after', 'O'), ('dexamethasone', 'O'), ('therapy', 'O'), ('in', 'O'), ('very', 'O'), ('-', 'O'), ('low', 'O'), ('-', 'O'), ('birthweight', 'O'), ('infants', 'O'), ('.', 'O'))"
Thirty - three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment .,"(('Thirty', 'O'), ('-', 'O'), ('three', 'O'), ('children', 'O'), ('after', 'O'), ('dexamethasone', 'O'), ('treatment', 'O'), ('were', 'O'), ('matched', 'O'), ('to', 'O'), ('33', 'O'), ('children', 'O'), ('without', 'O'), ('dexamethasone', 'O'), ('treatment', 'O'), ('.', 'O'))"
Data were assessed at the age of 3 - 7 years .,"(('Data', 'O'), ('were', 'O'), ('assessed', 'O'), ('at', 'O'), ('the', 'O'), ('age', 'O'), ('of', 'O'), ('3', 'O'), ('-', 'O'), ('7', 'O'), ('years', 'O'), ('.', 'O'))"
Dexamethasone was started between the 7th and the 28th day of life over 7 days with a total dose of 2 . 35 mg / kg / day .,"(('Dexamethasone', 'O'), ('was', 'O'), ('started', 'O'), ('between', 'O'), ('the', 'O'), ('7th', 'O'), ('and', 'O'), ('the', 'O'), ('28th', 'O'), ('day', 'O'), ('of', 'O'), ('life', 'O'), ('over', 'O'), ('7', 'O'), ('days', 'O'), ('with', 'O'), ('a', 'O'), ('total', 'O'), ('dose', 'O'), ('of', 'O'), ('2', 'O'), ('.', 'O'), ('35', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('day', 'O'), ('.', 'O'))"
"There were no differences in demographic data , growth , and socio - economic status between the two groups .","(('There', 'O'), ('were', 'O'), ('no', 'O'), ('differences', 'O'), ('in', 'O'), ('demographic', 'O'), ('data', 'O'), (',', 'O'), ('growth', 'O'), (',', 'O'), ('and', 'O'), ('socio', 'O'), ('-', 'O'), ('economic', 'O'), ('status', 'O'), ('between', 'O'), ('the', 'O'), ('two', 'O'), ('groups', 'O'), ('.', 'O'))"
Fine motor skills and gross motor function were significantly better in the control group ( p < 0 . 01 ) .,"(('Fine', 'O'), ('motor', 'O'), ('skills', 'O'), ('and', 'O'), ('gross', 'O'), ('motor', 'O'), ('function', 'O'), ('were', 'O'), ('significantly', 'O'), ('better', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
"In the Draw - a - Man Test , the control group showed better results ( p < 0 . 001 ) .","(('In', 'O'), ('the', 'O'), ('Draw', 'O'), ('-', 'O'), ('a', 'O'), ('-', 'O'), ('Man', 'O'), ('Test', 'O'), (',', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), ('showed', 'O'), ('better', 'O'), ('results', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
"There were no differences in development of speech , social development , and the Kaufman Assessment Battery for Children .","(('There', 'O'), ('were', 'O'), ('no', 'O'), ('differences', 'O'), ('in', 'O'), ('development', 'O'), ('of', 'O'), ('speech', 'O'), (',', 'O'), ('social', 'O'), ('development', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('Kaufman', 'O'), ('Assessment', 'O'), ('Battery', 'O'), ('for', 'O'), ('Children', 'O'), ('.', 'O'))"
Neurological development was affected even without neurological diagnosis .,"(('Neurological', 'O'), ('development', 'O'), ('was', 'O'), ('affected', 'O'), ('even', 'O'), ('without', 'O'), ('neurological', 'O'), ('diagnosis', 'O'), ('.', 'O'))"
Further long - term follow - up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development .,"(('Further', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('studies', 'O'), ('will', 'O'), ('be', 'O'), ('necessary', 'O'), ('to', 'O'), ('fully', 'O'), ('evaluate', 'O'), ('the', 'O'), ('impact', 'O'), ('of', 'O'), ('dexamethasone', 'O'), ('on', 'O'), ('neurological', 'O'), ('and', 'O'), ('cognitive', 'O'), ('development', 'O'), ('.', 'O'))"
"Valproic acid I : time course of lipid peroxidation biomarkers , liver toxicity , and valproic acid metabolite levels in rats .","(('Valproic', 'O'), ('acid', 'O'), ('I', 'O'), (':', 'O'), ('time', 'O'), ('course', 'O'), ('of', 'O'), ('lipid', 'O'), ('peroxidation', 'O'), ('biomarkers', 'O'), (',', 'O'), ('liver', 'O'), ('toxicity', 'O'), (',', 'O'), ('and', 'O'), ('valproic', 'O'), ('acid', 'O'), ('metabolite', 'O'), ('levels', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"A single dose of valproic acid ( VPA ) , which is a widely used antiepileptic drug , is associated with oxidative stress in rats , as recently demonstrated by elevated levels of 15 - F ( 2t ) - isoprostane ( 15 - F ( 2t ) - IsoP ) .","(('A', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('valproic', 'O'), ('acid', 'O'), ('(', 'O'), ('VPA', 'O'), (')', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('a', 'O'), ('widely', 'O'), ('used', 'O'), ('antiepileptic', 'O'), ('drug', 'O'), (',', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('in', 'O'), ('rats', 'O'), (',', 'O'), ('as', 'O'), ('recently', 'O'), ('demonstrated', 'O'), ('by', 'O'), ('elevated', 'O'), ('levels', 'O'), ('of', 'O'), ('15', 'O'), ('-', 'O'), ('F', 'O'), ('(', 'O'), ('2t', 'O'), (')', 'O'), ('-', 'O'), ('isoprostane', 'O'), ('(', 'O'), ('15', 'O'), ('-', 'O'), ('F', 'O'), ('(', 'O'), ('2t', 'O'), (')', 'O'), ('-', 'O'), ('IsoP', 'O'), (')', 'O'), ('.', 'O'))"
"Oxidative stress was assessed by determining plasma and liver levels of 15 - F ( 2t ) - IsoP , lipid hydroperoxides ( LPO ) , and thiobarbituric acid reactive substances ( TBARs ) .","(('Oxidative', 'O'), ('stress', 'O'), ('was', 'O'), ('assessed', 'O'), ('by', 'O'), ('determining', 'O'), ('plasma', 'O'), ('and', 'O'), ('liver', 'O'), ('levels', 'O'), ('of', 'O'), ('15', 'O'), ('-', 'O'), ('F', 'O'), ('(', 'O'), ('2t', 'O'), (')', 'O'), ('-', 'O'), ('IsoP', 'O'), (',', 'O'), ('lipid', 'O'), ('hydroperoxides', 'O'), ('(', 'O'), ('LPO', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('thiobarbituric', 'O'), ('acid', 'O'), ('reactive', 'O'), ('substances', 'O'), ('(', 'O'), ('TBARs', 'O'), (')', 'O'), ('.', 'O'))"
Plasma and liver 15 - F ( 2t ) - IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control .,"(('Plasma', 'O'), ('and', 'O'), ('liver', 'O'), ('15', 'O'), ('-', 'O'), ('F', 'O'), ('(', 'O'), ('2t', 'O'), (')', 'O'), ('-', 'O'), ('IsoP', 'O'), ('were', 'O'), ('elevated', 'O'), ('and', 'O'), ('reached', 'O'), ('a', 'O'), ('plateau', 'O'), ('after', 'O'), ('day', 'O'), ('2', 'O'), ('of', 'O'), ('VPA', 'O'), ('treatment', 'O'), ('compared', 'O'), ('to', 'O'), ('control', 'O'), ('.', 'O'))"
"Liver LPO levels were not elevated until day 7 of treatment ( 1 . 8 - fold versus control , p < 0 . 05 ) .","(('Liver', 'O'), ('LPO', 'O'), ('levels', 'O'), ('were', 'O'), ('not', 'O'), ('elevated', 'O'), ('until', 'O'), ('day', 'O'), ('7', 'O'), ('of', 'O'), ('treatment', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('8', 'O'), ('-', 'O'), ('fold', 'O'), ('versus', 'O'), ('control', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"Liver and plasma TBARs were not increased until 14 days ( 2 - fold vs . control , p < 0 . 05 ) .","(('Liver', 'O'), ('and', 'O'), ('plasma', 'O'), ('TBARs', 'O'), ('were', 'O'), ('not', 'O'), ('increased', 'O'), ('until', 'O'), ('14', 'O'), ('days', 'O'), ('(', 'O'), ('2', 'O'), ('-', 'O'), ('fold', 'O'), ('vs', 'O'), ('.', 'O'), ('control', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"The liver levels of beta - oxidation metabolites of VPA were decreased by day 14 , while the levels of 4 - ene - VPA and ( E ) - 2 , 4 - diene - VPA were not elevated throughout the study .","(('The', 'O'), ('liver', 'O'), ('levels', 'O'), ('of', 'O'), ('beta', 'O'), ('-', 'O'), ('oxidation', 'O'), ('metabolites', 'O'), ('of', 'O'), ('VPA', 'O'), ('were', 'O'), ('decreased', 'O'), ('by', 'O'), ('day', 'O'), ('14', 'O'), (',', 'O'), ('while', 'O'), ('the', 'O'), ('levels', 'O'), ('of', 'O'), ('4', 'O'), ('-', 'O'), ('ene', 'O'), ('-', 'O'), ('VPA', 'O'), ('and', 'O'), ('(', 'O'), ('E', 'O'), (')', 'O'), ('-', 'O'), ('2', 'O'), (',', 'O'), ('4', 'O'), ('-', 'O'), ('diene', 'O'), ('-', 'O'), ('VPA', 'O'), ('were', 'O'), ('not', 'O'), ('elevated', 'O'), ('throughout', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
METHODS : Data were extracted from 2021 paired mother - infant records for the year 2000 birth cohort in New Hampshire ' s 25 delivery hospitals .,"(('METHODS', 'O'), (':', 'O'), ('Data', 'O'), ('were', 'O'), ('extracted', 'O'), ('from', 'O'), ('2021', 'O'), ('paired', 'O'), ('mother', 'O'), ('-', 'O'), ('infant', 'O'), ('records', 'O'), ('for', 'O'), ('the', 'O'), ('year', 'O'), ('2000', 'O'), ('birth', 'O'), ('cohort', 'O'), ('in', 'O'), ('New', 'O'), ('Hampshire', 'O'), (""'"", 'O'), ('s', 'O'), ('25', 'O'), ('delivery', 'O'), ('hospitals', 'O'), ('.', 'O'))"
All infants who were born to hepatitis B surface antigen - positive mothers also received hepatitis B immune globulin .,"(('All', 'O'), ('infants', 'O'), ('who', 'O'), ('were', 'O'), ('born', 'O'), ('to', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('surface', 'O'), ('antigen', 'O'), ('-', 'O'), ('positive', 'O'), ('mothers', 'O'), ('also', 'O'), ('received', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('immune', 'O'), ('globulin', 'O'), ('.', 'O'))"
Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination .,"(('Multivariate', 'O'), ('logistic', 'O'), ('regression', 'O'), ('showed', 'O'), ('that', 'O'), ('the', 'O'), ('month', 'O'), ('of', 'O'), ('delivery', 'O'), ('and', 'O'), ('infant', 'O'), ('birth', 'O'), ('weight', 'O'), ('were', 'O'), ('independent', 'O'), ('predictors', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('B', 'O'), ('vaccination', 'O'), ('.', 'O'))"
"The proportion of infants who were vaccinated in January and February 2000 ( 48 . 5 % and 67 . 5 % , respectively ) was less than any other months , whereas the proportion who were vaccinated in December 2000 ( 88 . 2 % ) was the highest .","(('The', 'O'), ('proportion', 'O'), ('of', 'O'), ('infants', 'O'), ('who', 'O'), ('were', 'O'), ('vaccinated', 'O'), ('in', 'O'), ('January', 'O'), ('and', 'O'), ('February', 'O'), ('2000', 'O'), ('(', 'O'), ('48', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('and', 'O'), ('67', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('was', 'O'), ('less', 'O'), ('than', 'O'), ('any', 'O'), ('other', 'O'), ('months', 'O'), (',', 'O'), ('whereas', 'O'), ('the', 'O'), ('proportion', 'O'), ('who', 'O'), ('were', 'O'), ('vaccinated', 'O'), ('in', 'O'), ('December', 'O'), ('2000', 'O'), ('(', 'O'), ('88', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('was', 'O'), ('the', 'O'), ('highest', 'O'), ('.', 'O'))"
"EXPERIMENTAL DESIGN : Because of their widespread use , the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .","(('EXPERIMENTAL', 'O'), ('DESIGN', 'O'), (':', 'O'), ('Because', 'O'), ('of', 'O'), ('their', 'O'), ('widespread', 'O'), ('use', 'O'), (',', 'O'), ('the', 'O'), ('hematologic', 'O'), ('toxicity', 'O'), ('following', 'O'), ('coadministration', 'O'), ('of', 'O'), ('dexrazoxane', 'O'), ('and', 'O'), ('these', 'O'), ('three', 'O'), ('structurally', 'O'), ('different', 'O'), ('DNA', 'O'), ('cleavage', 'O'), ('enhancers', 'O'), ('was', 'O'), ('investigated', 'O'), (':', 'O'), ('Sensitivity', 'O'), ('of', 'O'), ('human', 'O'), ('and', 'O'), ('murine', 'O'), ('blood', 'O'), ('progenitor', 'O'), ('cells', 'O'), ('to', 'O'), ('etoposide', 'O'), (',', 'O'), ('daunorubicin', 'O'), (',', 'O'), ('and', 'O'), ('doxorubicin', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('dexrazoxane', 'O'), ('was', 'O'), ('determined', 'O'), ('in', 'O'), ('granulocyte', 'O'), ('-', 'O'), ('macrophage', 'O'), ('colony', 'O'), ('forming', 'O'), ('assays', 'O'), ('.', 'O'))"
"Likewise , in vivo , B6D2F1 mice were treated with etoposide , daunorubicin , and doxorubicin , with or without dexrazoxane over a wide range of doses : posttreatment , a full hematologic evaluation was done .","(('Likewise', 'O'), (',', 'O'), ('in', 'O'), ('vivo', 'O'), (',', 'O'), ('B6D2F1', 'O'), ('mice', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('etoposide', 'O'), (',', 'O'), ('daunorubicin', 'O'), (',', 'O'), ('and', 'O'), ('doxorubicin', 'O'), (',', 'O'), ('with', 'O'), ('or', 'O'), ('without', 'O'), ('dexrazoxane', 'O'), ('over', 'O'), ('a', 'O'), ('wide', 'O'), ('range', 'O'), ('of', 'O'), ('doses', 'O'), (':', 'O'), ('posttreatment', 'O'), (',', 'O'), ('a', 'O'), ('full', 'O'), ('hematologic', 'O'), ('evaluation', 'O'), ('was', 'O'), ('done', 'O'), ('.', 'O'))"
"CONCLUSION : Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically , the potent antagonism of daunorubicin activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .","(('CONCLUSION', 'O'), (':', 'O'), ('Although', 'O'), ('our', 'O'), ('findings', 'O'), ('support', 'O'), ('the', 'O'), ('observation', 'O'), ('that', 'O'), ('dexrazoxane', 'O'), ('reduces', 'O'), ('neither', 'O'), ('hematologic', 'O'), ('activity', 'O'), ('nor', 'O'), ('antitumor', 'O'), ('activity', 'O'), ('from', 'O'), ('doxorubicin', 'O'), ('clinically', 'O'), (',', 'O'), ('the', 'O'), ('potent', 'O'), ('antagonism', 'O'), ('of', 'O'), ('daunorubicin', 'O'), ('activity', 'O'), ('raises', 'O'), ('concern', 'O'), (';', 'O'), ('a', 'O'), ('possible', 'O'), ('interference', 'O'), ('with', 'O'), ('anticancer', 'O'), ('efficacy', 'O'), ('certainly', 'O'), ('would', 'O'), ('call', 'O'), ('for', 'O'), ('renewed', 'O'), ('attention', 'O'), ('.', 'O'))"
Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane .,"(('Our', 'O'), ('data', 'O'), ('also', 'O'), ('suggest', 'O'), ('that', 'O'), ('significant', 'O'), ('etoposide', 'O'), ('dose', 'O'), ('escalation', 'O'), ('is', 'O'), ('perhaps', 'O'), ('possible', 'O'), ('by', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('dexrazoxane', 'O'), ('.', 'O'))"
"If successful , this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy .","(('If', 'O'), ('successful', 'O'), (',', 'O'), ('this', 'O'), ('represents', 'O'), ('an', 'O'), ('exciting', 'O'), ('mechanism', 'O'), ('for', 'O'), ('pharmacologic', 'O'), ('regulation', 'O'), ('of', 'O'), ('side', 'O'), ('effects', 'O'), ('from', 'O'), ('cytotoxic', 'O'), ('chemotherapy', 'O'), ('.', 'O'))"
"OBJECTIVES : To assess patients ' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol , and correlate their recall with their level of awareness as measured by bispectral index ( BIS ) monitoring .","(('OBJECTIVES', 'O'), (':', 'O'), ('To', 'O'), ('assess', 'O'), ('patients', 'O'), (""'"", 'O'), ('ability', 'O'), ('to', 'O'), ('repeat', 'O'), ('and', 'O'), ('recall', 'O'), ('words', 'O'), ('presented', 'O'), ('to', 'O'), ('them', 'O'), ('while', 'O'), ('undergoing', 'O'), ('procedural', 'O'), ('sedation', 'O'), ('with', 'O'), ('propofol', 'O'), (',', 'O'), ('and', 'O'), ('correlate', 'O'), ('their', 'O'), ('recall', 'O'), ('with', 'O'), ('their', 'O'), ('level', 'O'), ('of', 'O'), ('awareness', 'O'), ('as', 'O'), ('measured', 'O'), ('by', 'O'), ('bispectral', 'O'), ('index', 'O'), ('(', 'O'), ('BIS', 'O'), (')', 'O'), ('monitoring', 'O'), ('.', 'O'))"
"METHODS : This was a prospective , single - intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28 , 2002 , and October 31 , 2003 .","(('METHODS', 'O'), (':', 'O'), ('This', 'O'), ('was', 'O'), ('a', 'O'), ('prospective', 'O'), (',', 'O'), ('single', 'O'), ('-', 'O'), ('intervention', 'O'), ('study', 'O'), ('of', 'O'), ('consenting', 'O'), ('adult', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('procedural', 'O'), ('sedation', 'O'), ('with', 'O'), ('propofol', 'O'), ('between', 'O'), ('December', 'O'), ('28', 'O'), (',', 'O'), ('2002', 'O'), (',', 'O'), ('and', 'O'), ('October', 'O'), ('31', 'O'), (',', 'O'), ('2003', 'O'), ('.', 'O'))"
BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status .,"(('BIS', 'O'), ('monitoring', 'O'), ('was', 'O'), ('initiated', 'O'), ('starting', 'O'), ('3', 'O'), ('minutes', 'O'), ('before', 'O'), ('the', 'O'), ('procedure', 'O'), ('and', 'O'), ('continuing', 'O'), ('until', 'O'), ('the', 'O'), ('patient', 'O'), ('had', 'O'), ('regained', 'O'), ('baseline', 'O'), ('mental', 'O'), ('status', 'O'), ('.', 'O'))"
"At 1 - minute intervals during the procedural sedation , until the patient regained baseline mental status at the end of the procedure , a word from a standardized list was read aloud , and the patient was asked to immediately repeat the word to the investigator .","(('At', 'O'), ('1', 'O'), ('-', 'O'), ('minute', 'O'), ('intervals', 'O'), ('during', 'O'), ('the', 'O'), ('procedural', 'O'), ('sedation', 'O'), (',', 'O'), ('until', 'O'), ('the', 'O'), ('patient', 'O'), ('regained', 'O'), ('baseline', 'O'), ('mental', 'O'), ('status', 'O'), ('at', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('procedure', 'O'), (',', 'O'), ('a', 'O'), ('word', 'O'), ('from', 'O'), ('a', 'O'), ('standardized', 'O'), ('list', 'O'), ('was', 'O'), ('read', 'O'), ('aloud', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('patient', 'O'), ('was', 'O'), ('asked', 'O'), ('to', 'O'), ('immediately', 'O'), ('repeat', 'O'), ('the', 'O'), ('word', 'O'), ('to', 'O'), ('the', 'O'), ('investigator', 'O'), ('.', 'O'))"
The BIS score at the time the word was read and the patient ' s ability to repeat the word were recorded .,"(('The', 'O'), ('BIS', 'O'), ('score', 'O'), ('at', 'O'), ('the', 'O'), ('time', 'O'), ('the', 'O'), ('word', 'O'), ('was', 'O'), ('read', 'O'), ('and', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('ability', 'O'), ('to', 'O'), ('repeat', 'O'), ('the', 'O'), ('word', 'O'), ('were', 'O'), ('recorded', 'O'), ('.', 'O'))"
"After the procedure , the patient was asked to state all of the words from the list that he or she could recall , and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed .","(('After', 'O'), ('the', 'O'), ('procedure', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('was', 'O'), ('asked', 'O'), ('to', 'O'), ('state', 'O'), ('all', 'O'), ('of', 'O'), ('the', 'O'), ('words', 'O'), ('from', 'O'), ('the', 'O'), ('list', 'O'), ('that', 'O'), ('he', 'O'), ('or', 'O'), ('she', 'O'), ('could', 'O'), ('recall', 'O'), (',', 'O'), ('and', 'O'), ('to', 'O'), ('identify', 'O'), ('the', 'O'), ('last', 'O'), ('word', 'O'), ('recalled', 'O'), ('from', 'O'), ('prior', 'O'), ('to', 'O'), ('the', 'O'), ('start', 'O'), ('of', 'O'), ('the', 'O'), ('procedure', 'O'), ('and', 'O'), ('the', 'O'), ('first', 'O'), ('word', 'O'), ('recalled', 'O'), ('from', 'O'), ('after', 'O'), ('the', 'O'), ('procedure', 'O'), ('was', 'O'), ('completed', 'O'), ('.', 'O'))"
RESULTS : Seventy - five consenting patients were enrolled ; one patient was excluded from data analysis for a protocol violation .,"(('RESULTS', 'O'), (':', 'O'), ('Seventy', 'O'), ('-', 'O'), ('five', 'O'), ('consenting', 'O'), ('patients', 'O'), ('were', 'O'), ('enrolled', 'O'), (';', 'O'), ('one', 'O'), ('patient', 'O'), ('was', 'O'), ('excluded', 'O'), ('from', 'O'), ('data', 'O'), ('analysis', 'O'), ('for', 'O'), ('a', 'O'), ('protocol', 'O'), ('violation', 'O'), ('.', 'O'))"
No serious adverse events were noted during the procedural sedations .,"(('No', 'O'), ('serious', 'O'), ('adverse', 'O'), ('events', 'O'), ('were', 'O'), ('noted', 'O'), ('during', 'O'), ('the', 'O'), ('procedural', 'O'), ('sedations', 'O'), ('.', 'O'))"
The mean ( + / - standard deviation ) time of data collection was 16 . 4 minutes ( + / - 7 . 1 ; range 5 to 34 minutes ) .,"(('The', 'O'), ('mean', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('standard', 'O'), ('deviation', 'O'), (')', 'O'), ('time', 'O'), ('of', 'O'), ('data', 'O'), ('collection', 'O'), ('was', 'O'), ('16', 'O'), ('.', 'O'), ('4', 'O'), ('minutes', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('7', 'O'), ('.', 'O'), ('1', 'O'), (';', 'O'), ('range', 'O'), ('5', 'O'), ('to', 'O'), ('34', 'O'), ('minutes', 'O'), (')', 'O'), ('.', 'O'))"
The mean initial ( preprocedure ) BIS score was 97 . 1 ( + / - 2 . 3 ; range 92 to 99 ) .,"(('The', 'O'), ('mean', 'O'), ('initial', 'O'), ('(', 'O'), ('preprocedure', 'O'), (')', 'O'), ('BIS', 'O'), ('score', 'O'), ('was', 'O'), ('97', 'O'), ('.', 'O'), ('1', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('3', 'O'), (';', 'O'), ('range', 'O'), ('92', 'O'), ('to', 'O'), ('99', 'O'), (')', 'O'), ('.', 'O'))"
The mean lowest BIS score occurring during these procedural sedations was 66 . 9 ( + / - 14 . 4 ; range 33 to 91 ) .,"(('The', 'O'), ('mean', 'O'), ('lowest', 'O'), ('BIS', 'O'), ('score', 'O'), ('occurring', 'O'), ('during', 'O'), ('these', 'O'), ('procedural', 'O'), ('sedations', 'O'), ('was', 'O'), ('66', 'O'), ('.', 'O'), ('9', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('14', 'O'), ('.', 'O'), ('4', 'O'), (';', 'O'), ('range', 'O'), ('33', 'O'), ('to', 'O'), ('91', 'O'), (')', 'O'), ('.', 'O'))"
The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77 . 1 ( 95 % CI = 74 . 3 to 80 . 0 ) .,"(('The', 'O'), ('mean', 'O'), ('lowest', 'O'), ('BIS', 'O'), ('score', 'O'), ('corresponding', 'O'), ('to', 'O'), ('the', 'O'), ('ability', 'O'), ('of', 'O'), ('the', 'O'), ('patient', 'O'), ('to', 'O'), ('immediately', 'O'), ('repeat', 'O'), ('words', 'O'), ('read', 'O'), ('from', 'O'), ('the', 'O'), ('list', 'O'), ('was', 'O'), ('77', 'O'), ('.', 'O'), ('1', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('=', 'O'), ('74', 'O'), ('.', 'O'), ('3', 'O'), ('to', 'O'), ('80', 'O'), ('.', 'O'), ('0', 'O'), (')', 'O'), ('.', 'O'))"
The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96 . 7 ( + / - 2 . 4 ; range 84 to 98 ) .,"(('The', 'O'), ('mean', 'O'), ('BIS', 'O'), ('score', 'O'), ('corresponding', 'O'), ('to', 'O'), ('the', 'O'), ('last', 'O'), ('word', 'O'), ('recalled', 'O'), ('from', 'O'), ('prior', 'O'), ('to', 'O'), ('the', 'O'), ('initiation', 'O'), ('of', 'O'), ('the', 'O'), ('sedation', 'O'), ('was', 'O'), ('96', 'O'), ('.', 'O'), ('7', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('4', 'O'), (';', 'O'), ('range', 'O'), ('84', 'O'), ('to', 'O'), ('98', 'O'), (')', 'O'), ('.', 'O'))"
The mean BIS score corresponding to the first word recalled after the procedure was completed was 91 . 2 ( 95 % CI = 88 . 1 to 94 . 3 ) .,"(('The', 'O'), ('mean', 'O'), ('BIS', 'O'), ('score', 'O'), ('corresponding', 'O'), ('to', 'O'), ('the', 'O'), ('first', 'O'), ('word', 'O'), ('recalled', 'O'), ('after', 'O'), ('the', 'O'), ('procedure', 'O'), ('was', 'O'), ('completed', 'O'), ('was', 'O'), ('91', 'O'), ('.', 'O'), ('2', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('=', 'O'), ('88', 'O'), ('.', 'O'), ('1', 'O'), ('to', 'O'), ('94', 'O'), ('.', 'O'), ('3', 'O'), (')', 'O'), ('.', 'O'))"
All patients recalled at least one word that had been read to them during the protocol .,"(('All', 'O'), ('patients', 'O'), ('recalled', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('word', 'O'), ('that', 'O'), ('had', 'O'), ('been', 'O'), ('read', 'O'), ('to', 'O'), ('them', 'O'), ('during', 'O'), ('the', 'O'), ('protocol', 'O'), ('.', 'O'))"
"The mean lowest BIS score for any recalled word was 91 . 5 ( + / - 11 . 1 ; range 79 to 98 ) , and no words were recalled when the corresponding BIS score was less than 90 .","(('The', 'O'), ('mean', 'O'), ('lowest', 'O'), ('BIS', 'O'), ('score', 'O'), ('for', 'O'), ('any', 'O'), ('recalled', 'O'), ('word', 'O'), ('was', 'O'), ('91', 'O'), ('.', 'O'), ('5', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('11', 'O'), ('.', 'O'), ('1', 'O'), (';', 'O'), ('range', 'O'), ('79', 'O'), ('to', 'O'), ('98', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('no', 'O'), ('words', 'O'), ('were', 'O'), ('recalled', 'O'), ('when', 'O'), ('the', 'O'), ('corresponding', 'O'), ('BIS', 'O'), ('score', 'O'), ('was', 'O'), ('less', 'O'), ('than', 'O'), ('90', 'O'), ('.', 'O'))"
CONCLUSIONS : There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('There', 'O'), ('is', 'O'), ('a', 'O'), ('range', 'O'), ('of', 'O'), ('BIS', 'O'), ('scores', 'O'), ('during', 'O'), ('which', 'O'), ('sedated', 'O'), ('patients', 'O'), ('are', 'O'), ('able', 'O'), ('to', 'O'), ('repeat', 'O'), ('words', 'O'), ('read', 'O'), ('to', 'O'), ('them', 'O'), ('but', 'O'), ('are', 'O'), ('not', 'O'), ('able', 'O'), ('to', 'O'), ('subsequently', 'O'), ('recall', 'O'), ('these', 'O'), ('words', 'O'), ('.', 'O'))"
"The diagnosis depends on exclusion of other entities , such as heart failure , infection , and malignancy .","(('The', 'O'), ('diagnosis', 'O'), ('depends', 'O'), ('on', 'O'), ('exclusion', 'O'), ('of', 'O'), ('other', 'O'), ('entities', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('heart', 'B'), ('failure', 'I'), (',', 'O'), ('infection', 'B'), (',', 'O'), ('and', 'O'), ('malignancy', 'B'), ('.', 'O'))"
"While withdrawal of amiodarone leads to clinical improvement in majority of cases , this is not always possible or advisable .","(('While', 'O'), ('withdrawal', 'O'), ('of', 'O'), ('amiodarone', 'O'), ('leads', 'O'), ('to', 'O'), ('clinical', 'O'), ('improvement', 'O'), ('in', 'O'), ('majority', 'O'), ('of', 'O'), ('cases', 'O'), (',', 'O'), ('this', 'O'), ('is', 'O'), ('not', 'O'), ('always', 'O'), ('possible', 'O'), ('or', 'O'), ('advisable', 'O'), ('.', 'O'))"
Dose reduction or concomitant steroid therapy may have a role in selected patients .,"(('Dose', 'O'), ('reduction', 'O'), ('or', 'O'), ('concomitant', 'O'), ('steroid', 'O'), ('therapy', 'O'), ('may', 'O'), ('have', 'O'), ('a', 'O'), ('role', 'O'), ('in', 'O'), ('selected', 'O'), ('patients', 'O'), ('.', 'O'))"
"Amino acids 5 and 7 , two potent and selective competitive GluR5 KA receptor antagonists , exhibited high GluR5 receptor affinity over other glutamate receptors .","(('Amino', 'O'), ('acids', 'O'), ('5', 'O'), ('and', 'O'), ('7', 'O'), (',', 'O'), ('two', 'O'), ('potent', 'O'), ('and', 'O'), ('selective', 'O'), ('competitive', 'O'), ('GluR5', 'O'), ('KA', 'O'), ('receptor', 'O'), ('antagonists', 'O'), (',', 'O'), ('exhibited', 'O'), ('high', 'O'), ('GluR5', 'O'), ('receptor', 'O'), ('affinity', 'O'), ('over', 'O'), ('other', 'O'), ('glutamate', 'O'), ('receptors', 'O'), ('.', 'O'))"
No malignant lesion was found .,"(('No', 'O'), ('malignant', 'O'), ('lesion', 'O'), ('was', 'O'), ('found', 'O'), ('.', 'O'))"
Treatment included aggressive hydration and varied amounts of furosemide .,"(('Treatment', 'O'), ('included', 'O'), ('aggressive', 'O'), ('hydration', 'O'), ('and', 'O'), ('varied', 'O'), ('amounts', 'O'), ('of', 'O'), ('furosemide', 'O'), ('.', 'O'))"
"Of the 3 patients , 2 were ingesting acceptable doses of elemental calcium ( 1 g and 2 g daily , respectively ) in the form of calcium carbonate .","(('Of', 'O'), ('the', 'O'), ('3', 'O'), ('patients', 'O'), (',', 'O'), ('2', 'O'), ('were', 'O'), ('ingesting', 'O'), ('acceptable', 'O'), ('doses', 'O'), ('of', 'O'), ('elemental', 'O'), ('calcium', 'O'), ('(', 'O'), ('1', 'O'), ('g', 'O'), ('and', 'O'), ('2', 'O'), ('g', 'O'), ('daily', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('form', 'O'), ('of', 'O'), ('calcium', 'O'), ('carbonate', 'O'), ('.', 'O'))"
"Treatment with hydration , furosemide , and discontinuation of the calcium and vitamin D source is adequate .","(('Treatment', 'O'), ('with', 'O'), ('hydration', 'O'), (',', 'O'), ('furosemide', 'O'), (',', 'O'), ('and', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('the', 'O'), ('calcium', 'O'), ('and', 'O'), ('vitamin', 'O'), ('D', 'O'), ('source', 'O'), ('is', 'O'), ('adequate', 'O'), ('.', 'O'))"
Skin reactions associated with oral coumarin - derived anticoagulants are an uncommon occurrence .,"(('Skin', 'O'), ('reactions', 'O'), ('associated', 'O'), ('with', 'O'), ('oral', 'O'), ('coumarin', 'O'), ('-', 'O'), ('derived', 'O'), ('anticoagulants', 'O'), ('are', 'O'), ('an', 'O'), ('uncommon', 'O'), ('occurrence', 'O'), ('.', 'O'))"
"In 2 of the 4 patients , rechallenge with warfarin led to recurrence of the lesions .","(('In', 'O'), ('2', 'O'), ('of', 'O'), ('the', 'O'), ('4', 'O'), ('patients', 'O'), (',', 'O'), ('rechallenge', 'O'), ('with', 'O'), ('warfarin', 'O'), ('led', 'O'), ('to', 'O'), ('recurrence', 'O'), ('of', 'O'), ('the', 'O'), ('lesions', 'O'), ('.', 'O'))"
Cocaine - induced brainstem seizures and behavior .,"(('Cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('brainstem', 'B'), ('seizures', 'I'), ('and', 'O'), ('behavior', 'O'), ('.', 'O'))"
A variety of abnormal sensory / motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical ( electrode implants ) and DC electrical current stimulations and by acute and chronic administration of cocaine .,"(('A', 'O'), ('variety', 'O'), ('of', 'O'), ('abnormal', 'O'), ('sensory', 'O'), ('/', 'O'), ('motor', 'O'), ('behaviors', 'O'), ('associated', 'O'), ('with', 'O'), ('electrical', 'O'), ('discharges', 'O'), ('recorded', 'O'), ('from', 'O'), ('the', 'O'), ('bilateral', 'O'), ('brainstem', 'O'), ('were', 'O'), ('induced', 'O'), ('in', 'O'), ('adult', 'O'), ('WKY', 'B'), ('rats', 'O'), ('by', 'O'), ('mechanical', 'O'), ('(', 'O'), ('electrode', 'O'), ('implants', 'O'), (')', 'O'), ('and', 'O'), ('DC', 'O'), ('electrical', 'O'), ('current', 'O'), ('stimulations', 'O'), ('and', 'O'), ('by', 'O'), ('acute', 'O'), ('and', 'O'), ('chronic', 'O'), ('administration', 'O'), ('of', 'O'), ('cocaine', 'O'), ('.', 'O'))"
The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations .,"(('The', 'O'), ('electrode', 'O'), ('implant', 'O'), ('implicated', 'O'), ('one', 'O'), ('side', 'O'), ('or', 'O'), ('the', 'O'), ('other', 'O'), ('of', 'O'), ('the', 'O'), ('reticular', 'O'), ('system', 'O'), ('of', 'O'), ('the', 'O'), ('brainstem', 'O'), ('but', 'O'), ('subjects', 'O'), ('were', 'O'), ('not', 'O'), ('incapacitated', 'O'), ('by', 'O'), ('the', 'O'), ('stimulations', 'O'), ('.', 'O'))"
Cocaine ( 40 mg / kg ) was injected subcutaneously for an acute experiment and subsequent 20 mg / kg doses twice daily for 3 days in a chronic study .,"(('Cocaine', 'O'), ('(', 'O'), ('40', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('was', 'O'), ('injected', 'O'), ('subcutaneously', 'O'), ('for', 'O'), ('an', 'O'), ('acute', 'O'), ('experiment', 'O'), ('and', 'O'), ('subsequent', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('doses', 'O'), ('twice', 'O'), ('daily', 'O'), ('for', 'O'), ('3', 'O'), ('days', 'O'), ('in', 'O'), ('a', 'O'), ('chronic', 'O'), ('study', 'O'), ('.', 'O'))"
"Cocaine generated more abnormal behaviors in the brainstem perturbation group , especially the electrically perturbated subjects .","(('Cocaine', 'O'), ('generated', 'O'), ('more', 'O'), ('abnormal', 'O'), ('behaviors', 'O'), ('in', 'O'), ('the', 'O'), ('brainstem', 'O'), ('perturbation', 'O'), ('group', 'O'), (',', 'O'), ('especially', 'O'), ('the', 'O'), ('electrically', 'O'), ('perturbated', 'O'), ('subjects', 'O'), ('.', 'O'))"
Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states .,"(('Shifts', 'O'), ('in', 'O'), ('the', 'O'), ('power', 'O'), ('frequency', 'O'), ('spectra', 'O'), ('of', 'O'), ('the', 'O'), ('discharge', 'O'), ('patterns', 'O'), ('were', 'O'), ('noted', 'O'), ('between', 'O'), ('quiet', 'O'), ('and', 'O'), ('pacing', 'O'), ('behavioral', 'O'), ('states', 'O'), ('.', 'O'))"
These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('brainstem', 'O'), ('generates', 'O'), ('and', 'O'), ('propagates', 'O'), ('pathological', 'O'), ('discharges', 'O'), ('that', 'O'), ('can', 'O'), ('be', 'O'), ('elicited', 'O'), ('by', 'O'), ('mechanical', 'O'), ('and', 'O'), ('DC', 'O'), ('electrical', 'O'), ('perturbation', 'O'), ('.', 'O'))"
Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates .,"(('Cocaine', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('activate', 'O'), ('the', 'O'), ('discharge', 'O'), ('system', 'O'), ('and', 'O'), ('thus', 'O'), ('induce', 'O'), ('abnormal', 'O'), ('behaviors', 'O'), ('that', 'O'), ('are', 'O'), ('generated', 'O'), ('at', 'O'), ('the', 'O'), ('discharge', 'O'), ('site', 'O'), ('and', 'O'), ('at', 'O'), ('distant', 'O'), ('sites', 'O'), ('to', 'O'), ('which', 'O'), ('the', 'O'), ('discharge', 'O'), ('propagates', 'O'), ('.', 'O'))"
Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated .,"(('Cognitive', 'O'), ('functions', 'O'), ('may', 'O'), ('also', 'O'), ('be', 'O'), ('involved', 'O'), ('since', 'O'), ('dopaminergic', 'O'), ('and', 'O'), ('serotonergic', 'O'), ('cellular', 'O'), ('elements', 'O'), ('at', 'O'), ('the', 'O'), ('brainstem', 'O'), ('level', 'O'), ('are', 'O'), ('also', 'O'), ('implicated', 'O'), ('.', 'O'))"
Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy .,"(('Human', 'O'), ('malignant', 'B'), ('brain', 'I'), ('tumors', 'I'), ('have', 'O'), ('a', 'O'), ('poor', 'O'), ('prognosis', 'O'), ('in', 'O'), ('spite', 'O'), ('of', 'O'), ('surgery', 'O'), ('and', 'O'), ('radiation', 'O'), ('therapy', 'O'), ('.', 'O'))"
"Cubic phases consist of curved biocontinuous lipid bilayers , separating two congruent networks of water channels .","(('Cubic', 'O'), ('phases', 'O'), ('consist', 'O'), ('of', 'O'), ('curved', 'O'), ('biocontinuous', 'O'), ('lipid', 'O'), ('bilayers', 'O'), (',', 'O'), ('separating', 'O'), ('two', 'O'), ('congruent', 'O'), ('networks', 'O'), ('of', 'O'), ('water', 'O'), ('channels', 'O'), ('.', 'O'))"
"Used as a host for cytotoxic drugs , the gel - like matrix can easily be applied to the walls of a surgical resection cavity .","(('Used', 'O'), ('as', 'O'), ('a', 'O'), ('host', 'O'), ('for', 'O'), ('cytotoxic', 'O'), ('drugs', 'O'), (',', 'O'), ('the', 'O'), ('gel', 'O'), ('-', 'O'), ('like', 'O'), ('matrix', 'O'), ('can', 'O'), ('easily', 'O'), ('be', 'O'), ('applied', 'O'), ('to', 'O'), ('the', 'O'), ('walls', 'O'), ('of', 'O'), ('a', 'O'), ('surgical', 'O'), ('resection', 'O'), ('cavity', 'O'), ('.', 'O'))"
"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema , while the remaining patients received only a total of 15 mg paclitaxel .","(('Six', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('received', 'O'), ('more', 'O'), ('than', 'O'), ('15', 'O'), ('mg', 'O'), ('paclitaxel', 'O'), ('and', 'O'), ('suffered', 'O'), ('from', 'O'), ('moderate', 'O'), ('to', 'O'), ('severe', 'O'), ('brain', 'B'), ('edema', 'I'), (',', 'O'), ('while', 'O'), ('the', 'O'), ('remaining', 'O'), ('patients', 'O'), ('received', 'O'), ('only', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('15', 'O'), ('mg', 'O'), ('paclitaxel', 'O'), ('.', 'O'))"
"In the latter group , brain edema was markedly reduced and dealt medically .","(('In', 'O'), ('the', 'O'), ('latter', 'O'), ('group', 'O'), (',', 'O'), ('brain', 'B'), ('edema', 'I'), ('was', 'O'), ('markedly', 'O'), ('reduced', 'O'), ('and', 'O'), ('dealt', 'O'), ('medically', 'O'), ('.', 'O'))"
"However , there are few studies of angiographic effects of cocaine on human cerebral arteries .","(('However', 'O'), (',', 'O'), ('there', 'O'), ('are', 'O'), ('few', 'O'), ('studies', 'O'), ('of', 'O'), ('angiographic', 'O'), ('effects', 'O'), ('of', 'O'), ('cocaine', 'O'), ('on', 'O'), ('human', 'O'), ('cerebral', 'O'), ('arteries', 'O'), ('.', 'O'))"
Qualitative comparisons of small artery changes also were made .,"(('Qualitative', 'O'), ('comparisons', 'O'), ('of', 'O'), ('small', 'O'), ('artery', 'O'), ('changes', 'O'), ('also', 'O'), ('were', 'O'), ('made', 'O'), ('.', 'O'))"
RESULTS : Thirteen patients with positive cocaine toxicology were compared to 26 controls .,"(('RESULTS', 'O'), (':', 'O'), ('Thirteen', 'O'), ('patients', 'O'), ('with', 'O'), ('positive', 'O'), ('cocaine', 'O'), ('toxicology', 'O'), ('were', 'O'), ('compared', 'O'), ('to', 'O'), ('26', 'O'), ('controls', 'O'), ('.', 'O'))"
"There were no significant differences between groups in the mean diameters of the intradural internal carotid , sphenoidal segment of the middle cerebral , precommunicating segment of the anterior cerebral , or basilar arteries ( p greater than 0 . 05 for all comparisons , unpaired t - tests ) .","(('There', 'O'), ('were', 'O'), ('no', 'O'), ('significant', 'O'), ('differences', 'O'), ('between', 'O'), ('groups', 'O'), ('in', 'O'), ('the', 'O'), ('mean', 'O'), ('diameters', 'O'), ('of', 'O'), ('the', 'O'), ('intradural', 'O'), ('internal', 'O'), ('carotid', 'O'), (',', 'O'), ('sphenoidal', 'O'), ('segment', 'O'), ('of', 'O'), ('the', 'O'), ('middle', 'O'), ('cerebral', 'O'), (',', 'O'), ('precommunicating', 'O'), ('segment', 'O'), ('of', 'O'), ('the', 'O'), ('anterior', 'O'), ('cerebral', 'O'), (',', 'O'), ('or', 'O'), ('basilar', 'O'), ('arteries', 'O'), ('(', 'O'), ('p', 'O'), ('greater', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), ('for', 'O'), ('all', 'O'), ('comparisons', 'O'), (',', 'O'), ('unpaired', 'O'), ('t', 'O'), ('-', 'O'), ('tests', 'O'), (')', 'O'), ('.', 'O'))"
"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery ( p greater than 0 . 05 , unpaired t - tests ) .","(('There', 'O'), ('also', 'O'), ('were', 'O'), ('no', 'O'), ('significant', 'O'), ('differences', 'O'), ('between', 'O'), ('groups', 'O'), ('when', 'O'), ('expressing', 'O'), ('diameters', 'O'), ('as', 'O'), ('the', 'O'), ('sum', 'O'), ('of', 'O'), ('the', 'O'), ('precommunicating', 'O'), ('segment', 'O'), ('of', 'O'), ('the', 'O'), ('anterior', 'O'), ('cerebral', 'O'), ('+', 'O'), ('sphenoidal', 'O'), ('segment', 'O'), ('of', 'O'), ('the', 'O'), ('middle', 'O'), ('cerebral', 'O'), ('+', 'O'), ('supraclinoid', 'O'), ('internal', 'O'), ('carotid', 'O'), ('artery', 'O'), ('+', 'O'), ('basilar', 'O'), ('artery', 'O'), ('divided', 'O'), ('by', 'O'), ('the', 'O'), ('diameter', 'O'), ('of', 'O'), ('the', 'O'), ('petrous', 'O'), ('internal', 'O'), ('carotid', 'O'), ('artery', 'O'), ('(', 'O'), ('p', 'O'), ('greater', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (',', 'O'), ('unpaired', 'O'), ('t', 'O'), ('-', 'O'), ('tests', 'O'), (')', 'O'), ('.', 'O'))"
Qualitative assessments showed two arterial irregularities in the distal vasculature in each group .,"(('Qualitative', 'O'), ('assessments', 'O'), ('showed', 'O'), ('two', 'O'), ('arterial', 'O'), ('irregularities', 'O'), ('in', 'O'), ('the', 'O'), ('distal', 'O'), ('vasculature', 'O'), ('in', 'O'), ('each', 'O'), ('group', 'O'), ('.', 'O'))"
Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase - related pathways after multiple and single METH injections .,"(('Analysis', 'O'), ('of', 'O'), ('protein', 'O'), ('expression', 'O'), ('using', 'O'), ('antibody', 'O'), ('microarrays', 'O'), ('and', 'O'), ('Western', 'O'), ('blotting', 'O'), ('revealed', 'O'), ('differential', 'O'), ('changes', 'O'), ('in', 'O'), ('MAP', 'O'), ('kinase', 'O'), ('-', 'O'), ('related', 'O'), ('pathways', 'O'), ('after', 'O'), ('multiple', 'O'), ('and', 'O'), ('single', 'O'), ('METH', 'O'), ('injections', 'O'), ('.', 'O'))"
"There were statistically significant ( p < 0 . 05 ) decreases in MEK1 , Erk2p , GSK3alpha , 14 - 3 - 3e , and MEK7 in the striata of mice after multiple injections of METH .","(('There', 'O'), ('were', 'O'), ('statistically', 'O'), ('significant', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('decreases', 'O'), ('in', 'O'), ('MEK1', 'O'), (',', 'O'), ('Erk2p', 'O'), (',', 'O'), ('GSK3alpha', 'O'), (',', 'O'), ('14', 'O'), ('-', 'O'), ('3', 'O'), ('-', 'O'), ('3e', 'O'), (',', 'O'), ('and', 'O'), ('MEK7', 'O'), ('in', 'O'), ('the', 'O'), ('striata', 'O'), ('of', 'O'), ('mice', 'O'), ('after', 'O'), ('multiple', 'O'), ('injections', 'O'), ('of', 'O'), ('METH', 'O'), ('.', 'O'))"
"MEK1 was significantly decreased also after a single injection of METH , but to a much lesser degree than after multiple injections of METH .","(('MEK1', 'O'), ('was', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('also', 'O'), ('after', 'O'), ('a', 'O'), ('single', 'O'), ('injection', 'O'), ('of', 'O'), ('METH', 'O'), (',', 'O'), ('but', 'O'), ('to', 'O'), ('a', 'O'), ('much', 'O'), ('lesser', 'O'), ('degree', 'O'), ('than', 'O'), ('after', 'O'), ('multiple', 'O'), ('injections', 'O'), ('of', 'O'), ('METH', 'O'), ('.', 'O'))"
"In the frontal cortex , there was a statistically significant decrease in GSK3alpha after multiple ( but not single ) injections of METH .","(('In', 'O'), ('the', 'O'), ('frontal', 'O'), ('cortex', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('statistically', 'O'), ('significant', 'O'), ('decrease', 'O'), ('in', 'O'), ('GSK3alpha', 'O'), ('after', 'O'), ('multiple', 'O'), ('(', 'O'), ('but', 'O'), ('not', 'O'), ('single', 'O'), (')', 'O'), ('injections', 'O'), ('of', 'O'), ('METH', 'O'), ('.', 'O'))"
We then placed her on an additional 100 mg per day of quetiapine .,"(('We', 'O'), ('then', 'O'), ('placed', 'O'), ('her', 'O'), ('on', 'O'), ('an', 'O'), ('additional', 'O'), ('100', 'O'), ('mg', 'O'), ('per', 'O'), ('day', 'O'), ('of', 'O'), ('quetiapine', 'O'), ('.', 'O'))"
She has been in complete remission under the combined medications for more than one year and maintains a fair role function .,"(('She', 'O'), ('has', 'O'), ('been', 'O'), ('in', 'O'), ('complete', 'O'), ('remission', 'O'), ('under', 'O'), ('the', 'O'), ('combined', 'O'), ('medications', 'O'), ('for', 'O'), ('more', 'O'), ('than', 'O'), ('one', 'O'), ('year', 'O'), ('and', 'O'), ('maintains', 'O'), ('a', 'O'), ('fair', 'O'), ('role', 'O'), ('function', 'O'), ('.', 'O'))"
Chloroquine related complete heart block with blindness : case report .,"(('Chloroquine', 'O'), ('related', 'O'), ('complete', 'B'), ('heart', 'I'), ('block', 'I'), ('with', 'O'), ('blindness', 'B'), (':', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation .,"(('The', 'O'), ('heart', 'B'), ('block', 'I'), ('was', 'O'), ('treated', 'O'), ('by', 'O'), ('pacemaker', 'O'), ('insertion', 'O'), ('and', 'O'), ('the', 'O'), ('heart', 'B'), ('failure', 'I'), ('resolved', 'O'), ('spontaneously', 'O'), ('following', 'O'), ('chloroquine', 'O'), ('discontinuation', 'O'), ('.', 'O'))"
Effects of suprofen on the isolated perfused rat kidney .,"(('Effects', 'O'), ('of', 'O'), ('suprofen', 'O'), ('on', 'O'), ('the', 'O'), ('isolated', 'O'), ('perfused', 'O'), ('rat', 'O'), ('kidney', 'O'), ('.', 'O'))"
"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects , the mechanism of damage remains unclear .","(('Although', 'O'), ('suprofen', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('in', 'O'), ('greater', 'O'), ('than', 'O'), ('100', 'O'), ('subjects', 'O'), (',', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('damage', 'O'), ('remains', 'O'), ('unclear', 'O'), ('.', 'O'))"
"There were no significant differences in renal sodium excretion , oxygen consumption , or urinary flow rates in kidneys perfused with suprofen compared with the drug - free control groups .","(('There', 'O'), ('were', 'O'), ('no', 'O'), ('significant', 'O'), ('differences', 'O'), ('in', 'O'), ('renal', 'O'), ('sodium', 'O'), ('excretion', 'O'), (',', 'O'), ('oxygen', 'O'), ('consumption', 'O'), (',', 'O'), ('or', 'O'), ('urinary', 'O'), ('flow', 'O'), ('rates', 'O'), ('in', 'O'), ('kidneys', 'O'), ('perfused', 'O'), ('with', 'O'), ('suprofen', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('drug', 'O'), ('-', 'O'), ('free', 'O'), ('control', 'O'), ('groups', 'O'), ('.', 'O'))"
"In contrast , a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid ; no changes were found with suprofen in the absence of uric acid .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('a', 'O'), ('significant', 'O'), ('decline', 'O'), ('in', 'O'), ('glomerular', 'O'), ('filtration', 'O'), ('rate', 'O'), ('was', 'O'), ('found', 'O'), ('after', 'O'), ('the', 'O'), ('introduction', 'O'), ('of', 'O'), ('suprofen', 'O'), ('to', 'O'), ('the', 'O'), ('kidney', 'O'), ('perfused', 'O'), ('with', 'O'), ('uric', 'O'), ('acid', 'O'), (';', 'O'), ('no', 'O'), ('changes', 'O'), ('were', 'O'), ('found', 'O'), ('with', 'O'), ('suprofen', 'O'), ('in', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('uric', 'O'), ('acid', 'O'), ('.', 'O'))"
"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen , compared with drug - free controls .","(('A', 'O'), ('significant', 'O'), ('decrease', 'O'), ('in', 'O'), ('the', 'O'), ('baseline', 'O'), ('excretion', 'O'), ('rate', 'O'), ('of', 'O'), ('uric', 'O'), ('acid', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('rats', 'O'), ('given', 'O'), ('suprofen', 'O'), (',', 'O'), ('compared', 'O'), ('with', 'O'), ('drug', 'O'), ('-', 'O'), ('free', 'O'), ('controls', 'O'), ('.', 'O'))"
"However , the fractional excretion of uric acid was unchanged between the groups over the experimental period .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('fractional', 'O'), ('excretion', 'O'), ('of', 'O'), ('uric', 'O'), ('acid', 'O'), ('was', 'O'), ('unchanged', 'O'), ('between', 'O'), ('the', 'O'), ('groups', 'O'), ('over', 'O'), ('the', 'O'), ('experimental', 'O'), ('period', 'O'), ('.', 'O'))"
Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus .,"(('Rats', 'O'), ('were', 'O'), ('divided', 'O'), ('into', 'O'), ('eight', 'O'), ('groups', 'O'), ('and', 'O'), ('bilaterally', 'O'), ('cannulated', 'O'), ('into', 'O'), ('CA1', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('hippocampus', 'O'), ('.', 'O'))"
"One week later , they received repeatedly vehicles ( saline , DMSO , saline + DMSO ) , scopolamine ( 2 microg / 0 . 5 microl saline / side ; 30 min before training ) , ritanserin ( 2 , 4 and 8 microg / 0 . 5 microl DMSO / side ; 20 min before training ) and scopolamine ( 2 microg / 0 . 5 microl ; 30 min before ritanserin injection ) + ritanserin ( 4 microg / 0 . 5 microl DMSO ) through","(('One', 'O'), ('week', 'O'), ('later', 'O'), (',', 'O'), ('they', 'O'), ('received', 'O'), ('repeatedly', 'O'), ('vehicles', 'O'), ('(', 'O'), ('saline', 'O'), (',', 'O'), ('DMSO', 'O'), (',', 'O'), ('saline', 'O'), ('+', 'O'), ('DMSO', 'O'), (')', 'O'), (',', 'O'), ('scopolamine', 'O'), ('(', 'O'), ('2', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), ('saline', 'O'), ('/', 'O'), ('side', 'O'), (';', 'O'), ('30', 'O'), ('min', 'O'), ('before', 'O'), ('training', 'O'), (')', 'O'), (',', 'O'), ('ritanserin', 'O'), ('(', 'O'), ('2', 'O'), (',', 'O'), ('4', 'O'), ('and', 'O'), ('8', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), ('DMSO', 'O'), ('/', 'O'), ('side', 'O'), (';', 'O'), ('20', 'O'), ('min', 'O'), ('before', 'O'), ('training', 'O'), (')', 'O'), ('and', 'O'), ('scopolamine', 'O'), ('(', 'O'), ('2', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), (';', 'O'), ('30', 'O'), ('min', 'O'), ('before', 'O'), ('ritanserin', 'O'), ('injection', 'O'), (')', 'O'), ('+', 'O'), ('ritanserin', 'O'), ('(', 'O'), ('4', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), ('DMSO', 'O'), (')', 'O'), ('through', 'O'))"
cannulae each day .,"(('cannulae', 'O'), ('each', 'O'), ('day', 'O'), ('.', 'O'))"
Animals were tested for four consecutive days ( 4 trial / day ) in MWM during which the position of hidden platform was unchanged .,"(('Animals', 'O'), ('were', 'O'), ('tested', 'O'), ('for', 'O'), ('four', 'O'), ('consecutive', 'O'), ('days', 'O'), ('(', 'O'), ('4', 'O'), ('trial', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('in', 'O'), ('MWM', 'O'), ('during', 'O'), ('which', 'O'), ('the', 'O'), ('position', 'O'), ('of', 'O'), ('hidden', 'O'), ('platform', 'O'), ('was', 'O'), ('unchanged', 'O'), ('.', 'O'))"
"In the fifth day , the platform was elevated above the water surface in another position to evaluate the function of motor , motivational and visual systems .","(('In', 'O'), ('the', 'O'), ('fifth', 'O'), ('day', 'O'), (',', 'O'), ('the', 'O'), ('platform', 'O'), ('was', 'O'), ('elevated', 'O'), ('above', 'O'), ('the', 'O'), ('water', 'O'), ('surface', 'O'), ('in', 'O'), ('another', 'O'), ('position', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('function', 'O'), ('of', 'O'), ('motor', 'O'), (',', 'O'), ('motivational', 'O'), ('and', 'O'), ('visual', 'O'), ('systems', 'O'), ('.', 'O'))"
The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine - treated group as compared to saline group .,"(('The', 'O'), ('results', 'O'), ('showed', 'O'), ('a', 'O'), ('significant', 'O'), ('increase', 'O'), ('in', 'O'), ('escape', 'O'), ('latencies', 'O'), ('and', 'O'), ('traveled', 'O'), ('distances', 'O'), ('to', 'O'), ('find', 'O'), ('platform', 'O'), ('in', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('treated', 'O'), ('group', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('saline', 'O'), ('group', 'O'), ('.', 'O'))"
Ritanserin - treated rats ( 4 microg / 0 . 5 microl / side ) showed a significant decrease in the mentioned parameters as compared to DMSO - treated group .,"(('Ritanserin', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('(', 'O'), ('4', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), ('/', 'O'), ('side', 'O'), (')', 'O'), ('showed', 'O'), ('a', 'O'), ('significant', 'O'), ('decrease', 'O'), ('in', 'O'), ('the', 'O'), ('mentioned', 'O'), ('parameters', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('DMSO', 'O'), ('-', 'O'), ('treated', 'O'), ('group', 'O'), ('.', 'O'))"
"However , scopolamine and ritanserin co - administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine - treated rats .","(('However', 'O'), (',', 'O'), ('scopolamine', 'O'), ('and', 'O'), ('ritanserin', 'O'), ('co', 'O'), ('-', 'O'), ('administration', 'O'), ('resulted', 'O'), ('in', 'O'), ('a', 'O'), ('significant', 'O'), ('decrease', 'O'), ('in', 'O'), ('escape', 'O'), ('latencies', 'O'), ('and', 'O'), ('traveled', 'O'), ('distances', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('the', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('.', 'O'))"
"A rare cause , drug - induced vasculitis , may result from the production of antineutrophil cytoplasmic antibodies ( ANCAs ) in response to a medication .","(('A', 'O'), ('rare', 'O'), ('cause', 'O'), (',', 'O'), ('drug', 'B'), ('-', 'I'), ('induced', 'I'), ('vasculitis', 'I'), (',', 'O'), ('may', 'O'), ('result', 'O'), ('from', 'O'), ('the', 'O'), ('production', 'O'), ('of', 'O'), ('antineutrophil', 'O'), ('cytoplasmic', 'O'), ('antibodies', 'O'), ('(', 'O'), ('ANCAs', 'O'), (')', 'O'), ('in', 'O'), ('response', 'O'), ('to', 'O'), ('a', 'O'), ('medication', 'O'), ('.', 'O'))"
"The diagnosis of propylthiouracil ( PTU ) - associated vasculitis was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .","(('The', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('propylthiouracil', 'B'), ('(', 'O'), ('PTU', 'O'), (')', 'O'), ('-', 'O'), ('associated', 'O'), ('vasculitis', 'B'), ('was', 'O'), ('made', 'O'), ('by', 'O'), ('observation', 'O'), ('of', 'O'), ('consistent', 'O'), ('clinical', 'O'), ('features', 'O'), (',', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('elevated', 'O'), ('ANA', 'O'), ('and', 'O'), ('ANCA', 'O'), ('in', 'O'), ('the', 'O'), ('blood', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('observed', 'O'), ('clinical', 'O'), ('resolution', 'O'), ('of', 'O'), ('symptoms', 'O'), ('following', 'O'), ('withdrawal', 'O'), ('of', 'O'), ('PTU', 'O'), ('.', 'O'))"
Methanolic extracts from Pueraria thunbergiana exhibited an activation effect ( 46 % ) on ChAT in vitro .,"(('Methanolic', 'O'), ('extracts', 'O'), ('from', 'O'), ('Pueraria', 'O'), ('thunbergiana', 'O'), ('exhibited', 'O'), ('an', 'O'), ('activation', 'O'), ('effect', 'O'), ('(', 'O'), ('46', 'O'), ('%', 'O'), (')', 'O'), ('on', 'O'), ('ChAT', 'O'), ('in', 'O'), ('vitro', 'O'), ('.', 'O'))"
"Via the sequential isolation of Pueraria thunbergiana , the active component was ultimately identified as daidzein ( 4 ' , 7 - dihydroxy - isoflavone ) .","(('Via', 'O'), ('the', 'O'), ('sequential', 'O'), ('isolation', 'O'), ('of', 'O'), ('Pueraria', 'O'), ('thunbergiana', 'O'), (',', 'O'), ('the', 'O'), ('active', 'O'), ('component', 'O'), ('was', 'O'), ('ultimately', 'O'), ('identified', 'O'), ('as', 'O'), ('daidzein', 'O'), ('(', 'O'), ('4', 'O'), (""'"", 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('dihydroxy', 'O'), ('-', 'O'), ('isoflavone', 'O'), (')', 'O'), ('.', 'O'))"
Injections of scopolamine into mice resulted in impaired performance on Y - maze tests ( a 37 % decreases in alternation behavior ) .,"(('Injections', 'O'), ('of', 'O'), ('scopolamine', 'O'), ('into', 'O'), ('mice', 'O'), ('resulted', 'O'), ('in', 'O'), ('impaired', 'O'), ('performance', 'O'), ('on', 'O'), ('Y', 'O'), ('-', 'O'), ('maze', 'O'), ('tests', 'O'), ('(', 'O'), ('a', 'O'), ('37', 'O'), ('%', 'O'), ('decreases', 'O'), ('in', 'O'), ('alternation', 'O'), ('behavior', 'O'), (')', 'O'), ('.', 'O'))"
"By way of contrast , mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment ( an approximately 12 % - 21 % decrease in alternation behavior ) .","(('By', 'O'), ('way', 'O'), ('of', 'O'), ('contrast', 'O'), (',', 'O'), ('mice', 'O'), ('treated', 'O'), ('with', 'O'), ('daidzein', 'O'), ('prior', 'O'), ('to', 'O'), ('the', 'O'), ('scopolamine', 'O'), ('injections', 'O'), ('were', 'O'), ('noticeably', 'O'), ('protected', 'O'), ('from', 'O'), ('this', 'O'), ('performance', 'O'), ('impairment', 'O'), ('(', 'O'), ('an', 'O'), ('approximately', 'O'), ('12', 'O'), ('%', 'O'), ('-', 'O'), ('21', 'O'), ('%', 'O'), ('decrease', 'O'), ('in', 'O'), ('alternation', 'O'), ('behavior', 'O'), (')', 'O'), ('.', 'O'))"
"Tolterodine 2 mg , twice daily was given .","(('Tolterodine', 'O'), ('2', 'O'), ('mg', 'O'), (',', 'O'), ('twice', 'O'), ('daily', 'O'), ('was', 'O'), ('given', 'O'), ('.', 'O'))"
"After 8 weeks treatment , changes in micturition diary variables and tolerability were determined .","(('After', 'O'), ('8', 'O'), ('weeks', 'O'), ('treatment', 'O'), (',', 'O'), ('changes', 'O'), ('in', 'O'), ('micturition', 'O'), ('diary', 'O'), ('variables', 'O'), ('and', 'O'), ('tolerability', 'O'), ('were', 'O'), ('determined', 'O'), ('.', 'O'))"
Short form 36 ( SF36 ) questionaires ( Thai version ) were given before and after 8 weeks of treatment .,"(('Short', 'O'), ('form', 'O'), ('36', 'O'), ('(', 'O'), ('SF36', 'O'), (')', 'O'), ('questionaires', 'O'), ('(', 'O'), ('Thai', 'O'), ('version', 'O'), (')', 'O'), ('were', 'O'), ('given', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('8', 'O'), ('weeks', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O'))"
"RESULTS : At 8 weeks , all micturition per day decreased from 16 .","(('RESULTS', 'O'), (':', 'O'), ('At', 'O'), ('8', 'O'), ('weeks', 'O'), (',', 'O'), ('all', 'O'), ('micturition', 'O'), ('per', 'O'), ('day', 'O'), ('decreased', 'O'), ('from', 'O'), ('16', 'O'), ('.', 'O'))"
7 + / - 5 .,"(('7', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('5', 'O'), ('.', 'O'))"
3 to 6 .,"(('3', 'O'), ('to', 'O'), ('6', 'O'), ('.', 'O'))"
7 + / - 2 . 4 times per day .,"(('7', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('4', 'O'), ('times', 'O'), ('per', 'O'), ('day', 'O'), ('.', 'O'))"
"The SF - 36 scores changed significantly in the domains of physical functioning , role function emotional , social function and mental heath .","(('The', 'O'), ('SF', 'O'), ('-', 'O'), ('36', 'O'), ('scores', 'O'), ('changed', 'O'), ('significantly', 'O'), ('in', 'O'), ('the', 'O'), ('domains', 'O'), ('of', 'O'), ('physical', 'O'), ('functioning', 'O'), (',', 'O'), ('role', 'O'), ('function', 'O'), ('emotional', 'O'), (',', 'O'), ('social', 'O'), ('function', 'O'), ('and', 'O'), ('mental', 'O'), ('heath', 'O'), ('.', 'O'))"
"DESIGN : This was a randomized , double - blind study .","(('DESIGN', 'O'), (':', 'O'), ('This', 'O'), ('was', 'O'), ('a', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('study', 'O'), ('.', 'O'))"
SETTING : The study was conducted at a university hospital .,"(('SETTING', 'O'), (':', 'O'), ('The', 'O'), ('study', 'O'), ('was', 'O'), ('conducted', 'O'), ('at', 'O'), ('a', 'O'), ('university', 'O'), ('hospital', 'O'), ('.', 'O'))"
PATIENTS : Sixty patients were pretreated in a randomized double - blinded fashion with remifentanil 1 microg / kg or placebo .,"(('PATIENTS', 'O'), (':', 'O'), ('Sixty', 'O'), ('patients', 'O'), ('were', 'O'), ('pretreated', 'O'), ('in', 'O'), ('a', 'O'), ('randomized', 'O'), ('double', 'O'), ('-', 'O'), ('blinded', 'O'), ('fashion', 'O'), ('with', 'O'), ('remifentanil', 'O'), ('1', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), ('or', 'O'), ('placebo', 'O'), ('.', 'O'))"
"Two minutes after remifentanil or placebo injection , etomidate 0 . 3 mg / kg was given .","(('Two', 'O'), ('minutes', 'O'), ('after', 'O'), ('remifentanil', 'O'), ('or', 'O'), ('placebo', 'O'), ('injection', 'O'), (',', 'O'), ('etomidate', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('was', 'O'), ('given', 'O'), ('.', 'O'))"
Memory function and serotonin transporter promoter gene polymorphism in ecstasy ( MDMA ) users .,"(('Memory', 'O'), ('function', 'O'), ('and', 'O'), ('serotonin', 'O'), ('transporter', 'O'), ('promoter', 'O'), ('gene', 'O'), ('polymorphism', 'O'), ('in', 'O'), ('ecstasy', 'O'), ('(', 'O'), ('MDMA', 'O'), (')', 'O'), ('users', 'O'), ('.', 'O'))"
Because 5 - HT transporters play a key element in the regulation of synaptic 5 - HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5 - HT transporter promoter gene region ( 5 - HTTLPR ) when studying the effects of MDMA as well as cognitive functioning .,"(('Because', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('transporters', 'O'), ('play', 'O'), ('a', 'O'), ('key', 'O'), ('element', 'O'), ('in', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('synaptic', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('transmission', 'O'), ('it', 'O'), ('may', 'O'), ('be', 'O'), ('important', 'O'), ('to', 'O'), ('control', 'O'), ('for', 'O'), ('the', 'O'), ('potential', 'O'), ('covariance', 'O'), ('effect', 'O'), ('of', 'O'), ('a', 'O'), ('polymorphism', 'O'), ('in', 'O'), ('the', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('transporter', 'O'), ('promoter', 'O'), ('gene', 'O'), ('region', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('HTTLPR', 'O'), (')', 'O'), ('when', 'O'), ('studying', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('MDMA', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('cognitive', 'O'), ('functioning', 'O'), ('.', 'O'))"
"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function , as well as the effects of long - term abstention from MDMA , in subjects genotyped for 5 - HTTLPR .","(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('moderate', 'O'), ('and', 'O'), ('heavy', 'O'), ('MDMA', 'O'), ('use', 'O'), ('on', 'O'), ('cognitive', 'O'), ('function', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('abstention', 'O'), ('from', 'O'), ('MDMA', 'O'), (',', 'O'), ('in', 'O'), ('subjects', 'O'), ('genotyped', 'O'), ('for', 'O'), ('5', 'O'), ('-', 'O'), ('HTTLPR', 'O'), ('.', 'O'))"
A second aim of the study was to determine whether these effects differ for females and males .,"(('A', 'O'), ('second', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('determine', 'O'), ('whether', 'O'), ('these', 'O'), ('effects', 'O'), ('differ', 'O'), ('for', 'O'), ('females', 'O'), ('and', 'O'), ('males', 'O'), ('.', 'O'))"
"Fifteen moderate MDMA users ( < 55 lifetime tablets ) , 22 heavy MDMA + users ( > 55 lifetime tablets ) , 16 ex - MDMA + users ( last tablet > 1 year ago ) and 13 controls were compared on a battery of neuropsychological tests .","(('Fifteen', 'O'), ('moderate', 'O'), ('MDMA', 'O'), ('users', 'O'), ('(', 'O'), ('<', 'O'), ('55', 'O'), ('lifetime', 'O'), ('tablets', 'O'), (')', 'O'), (',', 'O'), ('22', 'O'), ('heavy', 'O'), ('MDMA', 'O'), ('+', 'O'), ('users', 'O'), ('(', 'O'), ('>', 'O'), ('55', 'O'), ('lifetime', 'O'), ('tablets', 'O'), (')', 'O'), (',', 'O'), ('16', 'O'), ('ex', 'O'), ('-', 'O'), ('MDMA', 'O'), ('+', 'O'), ('users', 'O'), ('(', 'O'), ('last', 'O'), ('tablet', 'O'), ('>', 'O'), ('1', 'O'), ('year', 'O'), ('ago', 'O'), (')', 'O'), ('and', 'O'), ('13', 'O'), ('controls', 'O'), ('were', 'O'), ('compared', 'O'), ('on', 'O'), ('a', 'O'), ('battery', 'O'), ('of', 'O'), ('neuropsychological', 'O'), ('tests', 'O'), ('.', 'O'))"
DNA from peripheral nuclear blood cells was genotyped for 5 - HTTLPR using standard polymerase chain reaction methods . A significant group effect was observed only on memory function tasks ( p = 0 . 04 ) but not on reaction times ( p = 0 . 61 ) or attention / executive functioning ( p = 0 . 59 ) .,"(('DNA', 'O'), ('from', 'O'), ('peripheral', 'O'), ('nuclear', 'O'), ('blood', 'O'), ('cells', 'O'), ('was', 'O'), ('genotyped', 'O'), ('for', 'O'), ('5', 'O'), ('-', 'O'), ('HTTLPR', 'O'), ('using', 'O'), ('standard', 'O'), ('polymerase', 'O'), ('chain', 'O'), ('reaction', 'O'), ('methods', 'O'), ('.', 'O'), ('A', 'O'), ('significant', 'O'), ('group', 'O'), ('effect', 'O'), ('was', 'O'), ('observed', 'O'), ('only', 'O'), ('on', 'O'), ('memory', 'O'), ('function', 'O'), ('tasks', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('04', 'O'), (')', 'O'), ('but', 'O'), ('not', 'O'), ('on', 'O'), ('reaction', 'O'), ('times', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('61', 'O'), (')', 'O'), ('or', 'O'), ('attention', 'O'), ('/', 'O'), ('executive', 'O'), ('functioning', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('59', 'O'), (')', 'O'), ('.', 'O'))"
Heavy and ex - MDMA + users performed significantly poorer on memory tasks than controls .,"(('Heavy', 'O'), ('and', 'O'), ('ex', 'O'), ('-', 'O'), ('MDMA', 'O'), ('+', 'O'), ('users', 'O'), ('performed', 'O'), ('significantly', 'O'), ('poorer', 'O'), ('on', 'O'), ('memory', 'O'), ('tasks', 'O'), ('than', 'O'), ('controls', 'O'), ('.', 'O'))"
No significant effect of 5 - HTTLPR or gender was observed .,"(('No', 'O'), ('significant', 'O'), ('effect', 'O'), ('of', 'O'), ('5', 'O'), ('-', 'O'), ('HTTLPR', 'O'), ('or', 'O'), ('gender', 'O'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
No effect of 5 - HTTLPR or gender on memory function or MDMA use was observed .,"(('No', 'O'), ('effect', 'O'), ('of', 'O'), ('5', 'O'), ('-', 'O'), ('HTTLPR', 'O'), ('or', 'O'), ('gender', 'O'), ('on', 'O'), ('memory', 'O'), ('function', 'O'), ('or', 'O'), ('MDMA', 'O'), ('use', 'O'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
"The current study dealt with the protective role of mangiferin , a polyphenol from Mangifera indica Linn .","(('The', 'O'), ('current', 'O'), ('study', 'O'), ('dealt', 'O'), ('with', 'O'), ('the', 'O'), ('protective', 'O'), ('role', 'O'), ('of', 'O'), ('mangiferin', 'O'), (',', 'O'), ('a', 'O'), ('polyphenol', 'O'), ('from', 'O'), ('Mangifera', 'O'), ('indica', 'O'), ('Linn', 'O'), ('.', 'O'))"
Cardiovascular risk with cyclooxygenase inhibitors : general problem with substance specific differences ?,"(('Cardiovascular', 'O'), ('risk', 'O'), ('with', 'O'), ('cyclooxygenase', 'O'), ('inhibitors', 'O'), (':', 'O'), ('general', 'O'), ('problem', 'O'), ('with', 'O'), ('substance', 'O'), ('specific', 'O'), ('differences', 'O'), ('?', 'O'))"
"Adverse cardiovascular effects occurred mainly , but not exclusively , in patients with concomitant risk factors .","(('Adverse', 'O'), ('cardiovascular', 'O'), ('effects', 'O'), ('occurred', 'O'), ('mainly', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('concomitant', 'O'), ('risk', 'O'), ('factors', 'O'), ('.', 'O'))"
"Cyclooxygenase inhibitors cause complex changes in renal , vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention .","(('Cyclooxygenase', 'O'), ('inhibitors', 'O'), ('cause', 'O'), ('complex', 'O'), ('changes', 'O'), ('in', 'O'), ('renal', 'O'), (',', 'O'), ('vascular', 'O'), ('and', 'O'), ('cardiac', 'O'), ('prostanoid', 'O'), ('profiles', 'O'), ('thereby', 'O'), ('increasing', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('and', 'O'), ('fluid', 'O'), ('retention', 'O'), ('.', 'O'))"
The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('cardiovascular', 'O'), ('adverse', 'O'), ('events', 'O'), ('tends', 'O'), ('to', 'O'), ('increase', 'O'), ('with', 'O'), ('the', 'O'), ('daily', 'O'), ('dose', 'O'), ('and', 'O'), ('total', 'O'), ('exposure', 'O'), ('time', 'O'), ('.', 'O'))"
"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance - specific differences , which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin - independent effects .","(('A', 'O'), ('comparison', 'O'), ('of', 'O'), ('individual', 'O'), ('selective', 'O'), ('and', 'O'), ('unselective', 'O'), ('cyclooxygenase', 'O'), ('inhibitors', 'O'), ('suggests', 'O'), ('substance', 'O'), ('-', 'O'), ('specific', 'O'), ('differences', 'O'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('depend', 'O'), ('on', 'O'), ('differences', 'O'), ('in', 'O'), ('pharmacokinetic', 'O'), ('parameters', 'O'), ('or', 'O'), ('inhibitory', 'O'), ('potency', 'O'), ('and', 'O'), ('may', 'O'), ('be', 'O'), ('contributed', 'O'), ('by', 'O'), ('prostaglandin', 'O'), ('-', 'O'), ('independent', 'O'), ('effects', 'O'), ('.', 'O'))"
"Diagnostic markers such as N - terminal pro brain natriuretic peptide ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious cardiovascular toxicity .","(('Diagnostic', 'O'), ('markers', 'O'), ('such', 'O'), ('as', 'O'), ('N', 'O'), ('-', 'O'), ('terminal', 'O'), ('pro', 'O'), ('brain', 'O'), ('natriuretic', 'O'), ('peptide', 'O'), ('(', 'O'), ('NT', 'O'), ('-', 'O'), ('proBNP', 'O'), (')', 'O'), ('or', 'O'), ('high', 'O'), ('-', 'O'), ('sensitive', 'O'), ('C', 'O'), ('-', 'O'), ('reactive', 'O'), ('protein', 'O'), ('might', 'O'), ('help', 'O'), ('in', 'O'), ('the', 'O'), ('early', 'O'), ('identification', 'O'), ('of', 'O'), ('patients', 'O'), ('at', 'O'), ('risk', 'O'), (',', 'O'), ('thus', 'O'), ('avoiding', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('serious', 'O'), ('cardiovascular', 'B'), ('toxicity', 'I'), ('.', 'O'))"
"Male Sprague - Dawley rats were injected with saline on postnatal day ( P ) 20 , or a convulsant dose of pilocarpine on P20 or P45 .","(('Male', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('were', 'O'), ('injected', 'O'), ('with', 'O'), ('saline', 'O'), ('on', 'O'), ('postnatal', 'O'), ('day', 'O'), ('(', 'O'), ('P', 'O'), (')', 'O'), ('20', 'O'), (',', 'O'), ('or', 'O'), ('a', 'O'), ('convulsant', 'O'), ('dose', 'O'), ('of', 'O'), ('pilocarpine', 'O'), ('on', 'O'), ('P20', 'O'), ('or', 'O'), ('P45', 'O'), ('.', 'O'))"
Mature rats were trained with sound - source location and sound - silence discriminations .,"(('Mature', 'O'), ('rats', 'O'), ('were', 'O'), ('trained', 'O'), ('with', 'O'), ('sound', 'O'), ('-', 'O'), ('source', 'O'), ('location', 'O'), ('and', 'O'), ('sound', 'O'), ('-', 'O'), ('silence', 'O'), ('discriminations', 'O'), ('.', 'O'))"
Control ( saline P20 ) rats acquired both discriminations immediately .,"(('Control', 'O'), ('(', 'O'), ('saline', 'O'), ('P20', 'O'), (')', 'O'), ('rats', 'O'), ('acquired', 'O'), ('both', 'O'), ('discriminations', 'O'), ('immediately', 'O'), ('.', 'O'))"
PURPOSE : NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine .,"(('PURPOSE', 'O'), (':', 'O'), ('NGF', 'O'), ('and', 'O'), ('PGs', 'O'), ('in', 'O'), ('the', 'O'), ('bladder', 'O'), ('can', 'O'), ('be', 'O'), ('affected', 'O'), ('by', 'O'), ('pathological', 'O'), ('changes', 'O'), ('in', 'O'), ('the', 'O'), ('bladder', 'O'), ('and', 'O'), ('these', 'O'), ('changes', 'O'), ('can', 'O'), ('be', 'O'), ('detected', 'O'), ('in', 'O'), ('urine', 'O'), ('.', 'O'))"
"Evaluation included patient history , urinalysis , a voiding diary and urodynamic studies .","(('Evaluation', 'O'), ('included', 'O'), ('patient', 'O'), ('history', 'O'), (',', 'O'), ('urinalysis', 'O'), (',', 'O'), ('a', 'O'), ('voiding', 'O'), ('diary', 'O'), ('and', 'O'), ('urodynamic', 'O'), ('studies', 'O'), ('.', 'O'))"
Urine samples were collected .,"(('Urine', 'O'), ('samples', 'O'), ('were', 'O'), ('collected', 'O'), ('.', 'O'))"
"NGF , PGE2 , PGF2alpha and PGI2 were measured using enzyme - linked immunosorbent assay and compared between the groups .","(('NGF', 'O'), (',', 'O'), ('PGE2', 'O'), (',', 'O'), ('PGF2alpha', 'O'), ('and', 'O'), ('PGI2', 'O'), ('were', 'O'), ('measured', 'O'), ('using', 'O'), ('enzyme', 'O'), ('-', 'O'), ('linked', 'O'), ('immunosorbent', 'O'), ('assay', 'O'), ('and', 'O'), ('compared', 'O'), ('between', 'O'), ('the', 'O'), ('groups', 'O'), ('.', 'O'))"
"Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting hemolytic anemia .","(('Although', 'O'), ('this', 'O'), ('regimen', 'O'), ('produces', 'O'), ('sustained', 'O'), ('virologic', 'O'), ('responses', 'O'), ('(', 'O'), ('SVRs', 'O'), (')', 'O'), ('in', 'O'), ('approximately', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), (',', 'O'), ('it', 'O'), ('can', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('potentially', 'O'), ('dose', 'O'), ('-', 'O'), ('limiting', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('.', 'O'))"
"In general , anemia can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .","(('In', 'O'), ('general', 'O'), (',', 'O'), ('anemia', 'B'), ('can', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), (',', 'O'), ('and', 'O'), ('may', 'O'), ('have', 'O'), ('negative', 'O'), ('effects', 'O'), ('on', 'O'), ('cerebral', 'O'), ('function', 'O'), ('and', 'O'), ('quality', 'O'), ('of', 'O'), ('life', 'O'), ('.', 'O'))"
"Although ribavirin - associated anemia can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .","(('Although', 'O'), ('ribavirin', 'O'), ('-', 'O'), ('associated', 'O'), ('anemia', 'B'), ('can', 'O'), ('be', 'O'), ('reversed', 'O'), ('by', 'O'), ('dose', 'O'), ('reduction', 'O'), ('or', 'O'), ('discontinuation', 'O'), (',', 'O'), ('this', 'O'), ('approach', 'O'), ('compromises', 'O'), ('outcomes', 'O'), ('by', 'O'), ('significantly', 'O'), ('decreasing', 'O'), ('SVR', 'O'), ('rates', 'O'), ('.', 'O'))"
Recombinant human erythropoietin has been used to manage ribavirin - associated anemia but has other potential disadvantages .,"(('Recombinant', 'O'), ('human', 'O'), ('erythropoietin', 'O'), ('has', 'O'), ('been', 'O'), ('used', 'O'), ('to', 'O'), ('manage', 'O'), ('ribavirin', 'B'), ('-', 'O'), ('associated', 'O'), ('anemia', 'I'), ('but', 'O'), ('has', 'O'), ('other', 'O'), ('potential', 'O'), ('disadvantages', 'O'), ('.', 'O'))"
"Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C .","(('Viramidine', 'O'), (',', 'O'), ('a', 'O'), ('liver', 'O'), ('-', 'O'), ('targeting', 'O'), ('prodrug', 'O'), ('of', 'O'), ('ribavirin', 'O'), (',', 'O'), ('has', 'O'), ('the', 'O'), ('potential', 'O'), ('to', 'O'), ('maintain', 'O'), ('the', 'O'), ('virologic', 'O'), ('efficacy', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('while', 'O'), ('decreasing', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('chronic', 'B'), ('hepatitis', 'I'), ('C', 'I'), ('.', 'O'))"
Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures .,"(('Impact', 'O'), ('of', 'O'), ('alcohol', 'O'), ('exposure', 'O'), ('after', 'O'), ('pregnancy', 'O'), ('recognition', 'O'), ('on', 'O'), ('ultrasonographic', 'O'), ('fetal', 'O'), ('growth', 'O'), ('measures', 'O'), ('.', 'O'))"
"BACKGROUND : More than 3 decades after Jones and Smith ( 1973 ) reported on the devastation caused by alcohol exposure on fetal development , the rates of heavy drinking during pregnancy remain relatively unchanged .","(('BACKGROUND', 'O'), (':', 'O'), ('More', 'O'), ('than', 'O'), ('3', 'O'), ('decades', 'O'), ('after', 'O'), ('Jones', 'O'), ('and', 'O'), ('Smith', 'O'), ('(', 'O'), ('1973', 'O'), (')', 'O'), ('reported', 'O'), ('on', 'O'), ('the', 'O'), ('devastation', 'O'), ('caused', 'O'), ('by', 'O'), ('alcohol', 'O'), ('exposure', 'O'), ('on', 'O'), ('fetal', 'O'), ('development', 'O'), (',', 'O'), ('the', 'O'), ('rates', 'O'), ('of', 'O'), ('heavy', 'O'), ('drinking', 'O'), ('during', 'O'), ('pregnancy', 'O'), ('remain', 'O'), ('relatively', 'O'), ('unchanged', 'O'), ('.', 'O'))"
Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes .,"(('Early', 'O'), ('identification', 'O'), ('of', 'O'), ('fetal', 'O'), ('alcohol', 'O'), ('exposure', 'O'), ('and', 'O'), ('maternal', 'O'), ('abstinence', 'O'), ('led', 'O'), ('to', 'O'), ('better', 'O'), ('infant', 'O'), ('outcomes', 'O'), ('.', 'O'))"
This study examined the utility of biometry for detecting alcohol - related fetal growth impairment .,"(('This', 'O'), ('study', 'O'), ('examined', 'O'), ('the', 'O'), ('utility', 'O'), ('of', 'O'), ('biometry', 'O'), ('for', 'O'), ('detecting', 'O'), ('alcohol', 'B'), ('-', 'O'), ('related', 'O'), ('fetal', 'B'), ('growth', 'I'), ('impairment', 'I'), ('.', 'O'))"
METHODS : We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study .,"(('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('obtained', 'O'), ('fetal', 'O'), ('ultrasound', 'O'), ('measures', 'O'), ('from', 'O'), ('routine', 'O'), ('ultrasound', 'O'), ('examinations', 'O'), ('for', 'O'), ('167', 'O'), ('pregnant', 'O'), ('hazardous', 'O'), ('drinkers', 'O'), ('who', 'O'), ('were', 'O'), ('enrolled', 'O'), ('in', 'O'), ('a', 'O'), ('brief', 'O'), ('alcohol', 'O'), ('intervention', 'O'), ('study', 'O'), ('.', 'O'))"
The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies .,"(('The', 'O'), ('fetal', 'O'), ('measures', 'O'), ('for', 'O'), ('women', 'O'), ('who', 'O'), ('quit', 'O'), ('after', 'O'), ('learning', 'O'), ('of', 'O'), ('their', 'O'), ('pregnancies', 'O'), ('were', 'O'), ('compared', 'O'), ('with', 'O'), ('measures', 'O'), ('for', 'O'), ('women', 'O'), ('who', 'O'), ('continued', 'O'), ('some', 'O'), ('drinking', 'O'), ('throughout', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('their', 'O'), ('pregnancies', 'O'), ('.', 'O'))"
"Because intensity of alcohol consumption is associated with poorer fetal outcomes , separate analyses were conducted for the heavy ( average of > or = 5 drinks per drinking day ) alcohol consumers .","(('Because', 'O'), ('intensity', 'O'), ('of', 'O'), ('alcohol', 'O'), ('consumption', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('poorer', 'O'), ('fetal', 'O'), ('outcomes', 'O'), (',', 'O'), ('separate', 'O'), ('analyses', 'O'), ('were', 'O'), ('conducted', 'O'), ('for', 'O'), ('the', 'O'), ('heavy', 'O'), ('(', 'O'), ('average', 'O'), ('of', 'O'), ('>', 'O'), ('or', 'O'), ('=', 'O'), ('5', 'O'), ('drinks', 'O'), ('per', 'O'), ('drinking', 'O'), ('day', 'O'), (')', 'O'), ('alcohol', 'O'), ('consumers', 'O'), ('.', 'O'))"
"Fetal measures from the heavy - exposed fetuses were also compared with measures from a nondrinking group that was representative of normal , uncomplicated pregnancies from our clinics .","(('Fetal', 'O'), ('measures', 'O'), ('from', 'O'), ('the', 'O'), ('heavy', 'O'), ('-', 'O'), ('exposed', 'O'), ('fetuses', 'O'), ('were', 'O'), ('also', 'O'), ('compared', 'O'), ('with', 'O'), ('measures', 'O'), ('from', 'O'), ('a', 'O'), ('nondrinking', 'O'), ('group', 'O'), ('that', 'O'), ('was', 'O'), ('representative', 'O'), ('of', 'O'), ('normal', 'O'), (',', 'O'), ('uncomplicated', 'O'), ('pregnancies', 'O'), ('from', 'O'), ('our', 'O'), ('clinics', 'O'), ('.', 'O'))"
RESULTS : Nearly half of the pregnant drinkers abstained after learning of their pregnancies .,"(('RESULTS', 'O'), (':', 'O'), ('Nearly', 'O'), ('half', 'O'), ('of', 'O'), ('the', 'O'), ('pregnant', 'O'), ('drinkers', 'O'), ('abstained', 'O'), ('after', 'O'), ('learning', 'O'), ('of', 'O'), ('their', 'O'), ('pregnancies', 'O'), ('.', 'O'))"
"When women reportedly quit drinking early in their pregnancies , fetal growth measures were not significantly different from a non - alcohol - exposed group , regardless of prior drinking patterns .","(('When', 'O'), ('women', 'O'), ('reportedly', 'O'), ('quit', 'O'), ('drinking', 'O'), ('early', 'O'), ('in', 'O'), ('their', 'O'), ('pregnancies', 'O'), (',', 'O'), ('fetal', 'O'), ('growth', 'O'), ('measures', 'O'), ('were', 'O'), ('not', 'O'), ('significantly', 'O'), ('different', 'O'), ('from', 'O'), ('a', 'O'), ('non', 'O'), ('-', 'O'), ('alcohol', 'O'), ('-', 'O'), ('exposed', 'O'), ('group', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('prior', 'O'), ('drinking', 'O'), ('patterns', 'O'), ('.', 'O'))"
Amphetamine abuse was predictive of larger cranial to body growth ratios .,"(('Amphetamine', 'B'), ('abuse', 'O'), ('was', 'O'), ('predictive', 'O'), ('of', 'O'), ('larger', 'O'), ('cranial', 'O'), ('to', 'O'), ('body', 'O'), ('growth', 'O'), ('ratios', 'O'), ('.', 'O'))"
CONCLUSIONS : Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Alterations', 'O'), ('in', 'O'), ('fetal', 'O'), ('biometric', 'O'), ('measurements', 'O'), ('were', 'O'), ('observed', 'O'), ('among', 'O'), ('the', 'O'), ('heavy', 'O'), ('drinkers', 'O'), ('only', 'O'), ('when', 'O'), ('they', 'O'), ('continued', 'O'), ('drinking', 'O'), ('after', 'O'), ('becoming', 'O'), ('aware', 'O'), ('of', 'O'), ('their', 'O'), ('pregnancies', 'O'), ('.', 'O'))"
"Although the reliance on self - reported drinking is a limitation in this study , these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects .","(('Although', 'O'), ('the', 'O'), ('reliance', 'O'), ('on', 'O'), ('self', 'O'), ('-', 'O'), ('reported', 'O'), ('drinking', 'O'), ('is', 'O'), ('a', 'O'), ('limitation', 'O'), ('in', 'O'), ('this', 'O'), ('study', 'O'), (',', 'O'), ('these', 'O'), ('findings', 'O'), ('support', 'O'), ('the', 'O'), ('benefits', 'O'), ('of', 'O'), ('early', 'O'), ('abstinence', 'O'), ('and', 'O'), ('the', 'O'), ('potential', 'O'), ('for', 'O'), ('ultrasound', 'O'), ('examinations', 'O'), ('in', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('fetal', 'O'), ('alcohol', 'O'), ('effects', 'O'), ('.', 'O'))"
Ethambutol - associated optic neuropathy .,"(('Ethambutol', 'B'), ('-', 'O'), ('associated', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('.', 'O'))"
CLINICAL PICTURE : Three patients with ethambutol - associated toxic optic neuropathy are described .,"(('CLINICAL', 'O'), ('PICTURE', 'O'), (':', 'O'), ('Three', 'O'), ('patients', 'O'), ('with', 'O'), ('ethambutol', 'O'), ('-', 'O'), ('associated', 'O'), ('toxic', 'B'), ('optic', 'I'), ('neuropathy', 'I'), ('are', 'O'), ('described', 'O'), ('.', 'O'))"
"TREATMENT : Despite stopping ethambutol on diagnosis , visual function continued to deteriorate for a few months .","(('TREATMENT', 'O'), (':', 'O'), ('Despite', 'O'), ('stopping', 'O'), ('ethambutol', 'O'), ('on', 'O'), ('diagnosis', 'O'), (',', 'O'), ('visual', 'O'), ('function', 'O'), ('continued', 'O'), ('to', 'O'), ('deteriorate', 'O'), ('for', 'O'), ('a', 'O'), ('few', 'O'), ('months', 'O'), ('.', 'O'))"
Subsequent improvement was mild in 2 cases .,"(('Subsequent', 'O'), ('improvement', 'O'), ('was', 'O'), ('mild', 'O'), ('in', 'O'), ('2', 'O'), ('cases', 'O'), ('.', 'O'))"
"In the third case , visual acuity and colour vision normalised but the optic discs were pale .","(('In', 'O'), ('the', 'O'), ('third', 'O'), ('case', 'O'), (',', 'O'), ('visual', 'O'), ('acuity', 'O'), ('and', 'O'), ('colour', 'O'), ('vision', 'O'), ('normalised', 'O'), ('but', 'O'), ('the', 'O'), ('optic', 'O'), ('discs', 'O'), ('were', 'O'), ('pale', 'O'), ('.', 'O'))"
OUTCOME : All 3 patients had some permanent loss of visual function .,"(('OUTCOME', 'O'), (':', 'O'), ('All', 'O'), ('3', 'O'), ('patients', 'O'), ('had', 'O'), ('some', 'O'), ('permanent', 'O'), ('loss', 'O'), ('of', 'O'), ('visual', 'O'), ('function', 'O'), ('.', 'O'))"
CONCLUSIONS : Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow - up .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Ethambutol', 'O'), ('usage', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('permanent', 'O'), ('visual', 'O'), ('loss', 'I'), ('and', 'O'), ('should', 'O'), ('be', 'O'), ('avoided', 'O'), ('if', 'O'), ('possible', 'O'), ('or', 'O'), ('used', 'O'), ('with', 'O'), ('caution', 'O'), ('and', 'O'), ('proper', 'O'), ('ophthalmological', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('.', 'O'))"
"The author postulates that in cases of ethambutol associated chiasmopathy , ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm .","(('The', 'O'), ('author', 'O'), ('postulates', 'O'), ('that', 'O'), ('in', 'O'), ('cases', 'O'), ('of', 'O'), ('ethambutol', 'O'), ('associated', 'O'), ('chiasmopathy', 'B'), (',', 'O'), ('ethambutol', 'O'), ('may', 'O'), ('initially', 'O'), ('affect', 'O'), ('the', 'O'), ('optic', 'O'), ('nerves', 'O'), ('and', 'O'), ('subsequently', 'O'), ('progress', 'O'), ('to', 'O'), ('involve', 'O'), ('the', 'O'), ('optic', 'O'), ('chiasm', 'O'), ('.', 'O'))"
Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1 . 2 mg alprazolam .,"(('Medical', 'O'), ('treatment', 'O'), ('was', 'O'), ('initiated', 'O'), ('at', 'O'), ('a', 'O'), ('daily', 'O'), ('dose', 'O'), ('of', 'O'), ('20', 'O'), ('mg', 'O'), ('paroxetine', 'O'), ('and', 'O'), ('1', 'O'), ('.', 'O'), ('2', 'O'), ('mg', 'O'), ('alprazolam', 'O'), ('.', 'O'))"
"Laboratory tests showed an elevation of creatine phosphokinase ( 2218 IU / L ) , aspartate aminotransferase ( 134 IU / L ) , alanine aminotransferase ( 78 IU / L ) , and BUN ( 27 . 9 mg / ml ) levels .","(('Laboratory', 'O'), ('tests', 'O'), ('showed', 'O'), ('an', 'O'), ('elevation', 'O'), ('of', 'O'), ('creatine', 'O'), ('phosphokinase', 'O'), ('(', 'O'), ('2218', 'O'), ('IU', 'O'), ('/', 'O'), ('L', 'O'), (')', 'O'), (',', 'O'), ('aspartate', 'O'), ('aminotransferase', 'O'), ('(', 'O'), ('134', 'O'), ('IU', 'O'), ('/', 'O'), ('L', 'O'), (')', 'O'), (',', 'O'), ('alanine', 'O'), ('aminotransferase', 'O'), ('(', 'O'), ('78', 'O'), ('IU', 'O'), ('/', 'O'), ('L', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('BUN', 'O'), ('(', 'O'), ('27', 'O'), ('.', 'O'), ('9', 'O'), ('mg', 'O'), ('/', 'O'), ('ml', 'O'), (')', 'O'), ('levels', 'O'), ('.', 'O'))"
The patient received bromocriptine and diazepam to treat his symptoms .,"(('The', 'O'), ('patient', 'O'), ('received', 'O'), ('bromocriptine', 'O'), ('and', 'O'), ('diazepam', 'O'), ('to', 'O'), ('treat', 'O'), ('his', 'O'), ('symptoms', 'O'), ('.', 'O'))"
"7 days later , the fever disappeared and the patient ' s serum CPK levels were normalized ( 175 IU / L ) .","(('7', 'O'), ('days', 'O'), ('later', 'O'), (',', 'O'), ('the', 'O'), ('fever', 'O'), ('disappeared', 'O'), ('and', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('serum', 'O'), ('CPK', 'O'), ('levels', 'O'), ('were', 'O'), ('normalized', 'O'), ('(', 'O'), ('175', 'O'), ('IU', 'O'), ('/', 'O'), ('L', 'O'), (')', 'O'), ('.', 'O'))"
The involvement of physiologic and environmental aspects specific to this patient was suspected .,"(('The', 'O'), ('involvement', 'O'), ('of', 'O'), ('physiologic', 'O'), ('and', 'O'), ('environmental', 'O'), ('aspects', 'O'), ('specific', 'O'), ('to', 'O'), ('this', 'O'), ('patient', 'O'), ('was', 'O'), ('suspected', 'O'), ('.', 'O'))"
Down - regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced convulsions and the counteraction by co - administration with local anesthetics .,"(('Down', 'O'), ('-', 'O'), ('regulation', 'O'), ('of', 'O'), ('norepinephrine', 'O'), ('transporter', 'O'), ('function', 'O'), ('induced', 'O'), ('by', 'O'), ('chronic', 'O'), ('administration', 'O'), ('of', 'O'), ('desipramine', 'O'), ('linking', 'O'), ('to', 'O'), ('the', 'O'), ('alteration', 'O'), ('of', 'O'), ('sensitivity', 'O'), ('of', 'O'), ('local', 'O'), ('-', 'O'), ('anesthetics', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('and', 'O'), ('the', 'O'), ('counteraction', 'O'), ('by', 'O'), ('co', 'O'), ('-', 'O'), ('administration', 'O'), ('with', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('.', 'O'))"
Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice .,"(('Alterations', 'O'), ('of', 'O'), ('norepinephrine', 'O'), ('transporter', 'O'), ('(', 'O'), ('NET', 'O'), (')', 'O'), ('function', 'O'), ('by', 'O'), ('chronic', 'O'), ('inhibition', 'O'), ('of', 'O'), ('NET', 'O'), ('in', 'O'), ('relation', 'O'), ('to', 'O'), ('sensitization', 'O'), ('to', 'O'), ('seizures', 'O'), ('induce', 'O'), ('by', 'O'), ('cocaine', 'O'), ('and', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('were', 'O'), ('studied', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"Daily administration of desipramine , an inhibitor of the NET , for 5 days decreased [ ( 3 ) H ] norepinephrine uptake in the P2 fractions of hippocampus but not cortex , striatum or amygdalae .","(('Daily', 'O'), ('administration', 'O'), ('of', 'O'), ('desipramine', 'O'), (',', 'O'), ('an', 'O'), ('inhibitor', 'O'), ('of', 'O'), ('the', 'O'), ('NET', 'O'), (',', 'O'), ('for', 'O'), ('5', 'O'), ('days', 'O'), ('decreased', 'O'), ('[', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('H', 'O'), (']', 'O'), ('norepinephrine', 'O'), ('uptake', 'O'), ('in', 'O'), ('the', 'O'), ('P2', 'O'), ('fractions', 'O'), ('of', 'O'), ('hippocampus', 'O'), ('but', 'O'), ('not', 'O'), ('cortex', 'O'), (',', 'O'), ('striatum', 'O'), ('or', 'O'), ('amygdalae', 'O'), ('.', 'O'))"
"Co - administration of lidocaine , bupivacaine or tricaine with desipramine reversed this effect .","(('Co', 'O'), ('-', 'O'), ('administration', 'O'), ('of', 'O'), ('lidocaine', 'O'), (',', 'O'), ('bupivacaine', 'O'), ('or', 'O'), ('tricaine', 'O'), ('with', 'O'), ('desipramine', 'O'), ('reversed', 'O'), ('this', 'O'), ('effect', 'O'), ('.', 'O'))"
Daily treatment of cocaine increased [ ( 3 ) H ] norepinephrine uptake into the hippocampus .,"(('Daily', 'O'), ('treatment', 'O'), ('of', 'O'), ('cocaine', 'O'), ('increased', 'O'), ('[', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('H', 'O'), (']', 'O'), ('norepinephrine', 'O'), ('uptake', 'O'), ('into', 'O'), ('the', 'O'), ('hippocampus', 'O'), ('.', 'O'))"
Daily administration of desipramine increased the incidence of appearance of lidocaine - induced convulsions and decreased that of cocaine - induced convulsions .,"(('Daily', 'O'), ('administration', 'O'), ('of', 'O'), ('desipramine', 'O'), ('increased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('appearance', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('and', 'O'), ('decreased', 'O'), ('that', 'O'), ('of', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('.', 'O'))"
Co - administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine .,"(('Co', 'O'), ('-', 'O'), ('administration', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('with', 'O'), ('desipramine', 'O'), ('reversed', 'O'), ('the', 'O'), ('changes', 'O'), ('of', 'O'), ('convulsive', 'O'), ('activity', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('and', 'O'), ('cocaine', 'O'), ('induced', 'O'), ('by', 'O'), ('repeated', 'O'), ('administration', 'O'), ('of', 'O'), ('desipramine', 'O'), ('.', 'O'))"
These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of lidocaine convulsions .,"(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('down', 'O'), ('-', 'O'), ('regulation', 'O'), ('of', 'O'), ('hippocampal', 'O'), ('NET', 'O'), ('induced', 'O'), ('by', 'O'), ('chronic', 'O'), ('administration', 'O'), ('of', 'O'), ('desipramine', 'O'), ('may', 'O'), ('be', 'O'), ('relevant', 'O'), ('to', 'O'), ('desipramine', 'O'), ('-', 'O'), ('induced', 'O'), ('sensitization', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('convulsions', 'O'), ('.', 'O'))"
Inhibition of Na ( + ) channels by local anesthetics may regulate desipramine - induced down - regulation of NET function .,"(('Inhibition', 'O'), ('of', 'O'), ('Na', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('channels', 'O'), ('by', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('may', 'O'), ('regulate', 'O'), ('desipramine', 'O'), ('-', 'O'), ('induced', 'O'), ('down', 'O'), ('-', 'O'), ('regulation', 'O'), ('of', 'O'), ('NET', 'O'), ('function', 'O'), ('.', 'O'))"
Repeated administration of cocaine induces up - regulation of hippocampal NET function .,"(('Repeated', 'O'), ('administration', 'O'), ('of', 'O'), ('cocaine', 'O'), ('induces', 'O'), ('up', 'O'), ('-', 'O'), ('regulation', 'O'), ('of', 'O'), ('hippocampal', 'O'), ('NET', 'O'), ('function', 'O'), ('.', 'O'))"
Desipramine - induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine .,"(('Desipramine', 'O'), ('-', 'O'), ('induced', 'O'), ('sensitization', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('seizures', 'O'), ('may', 'O'), ('have', 'O'), ('a', 'O'), ('mechanism', 'O'), ('distinct', 'O'), ('from', 'O'), ('kindling', 'O'), ('resulting', 'O'), ('from', 'O'), ('repeated', 'O'), ('administration', 'O'), ('of', 'O'), ('cocaine', 'O'), ('.', 'O'))"
"Dex increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma superoxide ( 5711 + / - 284 . 9 saline , 7931 + / - 392 . 8 U / ml dex , P < 0 . 001 ) .","(('Dex', 'O'), ('increased', 'O'), ('systolic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('(', 'O'), ('SBP', 'O'), (')', 'O'), ('from', 'O'), ('109', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('8', 'O'), ('to', 'O'), ('135', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('mmHg', 'O'), ('and', 'O'), ('plasma', 'O'), ('superoxide', 'O'), ('(', 'O'), ('5711', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('284', 'O'), ('.', 'O'), ('9', 'O'), ('saline', 'O'), (',', 'O'), ('7931', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('392', 'O'), ('.', 'O'), ('8', 'O'), ('U', 'O'), ('/', 'O'), ('ml', 'O'), ('dex', 'O'), (',', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
"In this prevention study , SBP in the atorva + dex group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the dex - only group ( P ' < 0 . 05 ) .","(('In', 'O'), ('this', 'O'), ('prevention', 'O'), ('study', 'O'), (',', 'O'), ('SBP', 'O'), ('in', 'O'), ('the', 'O'), ('atorva', 'O'), ('+', 'O'), ('dex', 'O'), ('group', 'O'), ('was', 'O'), ('increased', 'O'), ('from', 'O'), ('115', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('4', 'O'), ('to', 'O'), ('124', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('mmHg', 'O'), (',', 'O'), ('but', 'O'), ('this', 'O'), ('was', 'O'), ('significantly', 'O'), ('lower', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('dex', 'O'), ('-', 'O'), ('only', 'O'), ('group', 'O'), ('(', 'O'), ('P', 'O'), (""'"", 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"Plasma nitrate / nitrite ( NOx ) was decreased in dex - treated rats compared to saline - treated rats ( 11 . 2 + / - 1 . 08 microm , 15 . 3 + / - 1 . 17 microm , respectively , P < 0 . 05 ) .","(('Plasma', 'O'), ('nitrate', 'O'), ('/', 'O'), ('nitrite', 'O'), ('(', 'O'), ('NOx', 'O'), (')', 'O'), ('was', 'O'), ('decreased', 'O'), ('in', 'O'), ('dex', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('compared', 'O'), ('to', 'O'), ('saline', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('(', 'O'), ('11', 'O'), ('.', 'O'), ('2', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('08', 'O'), ('microm', 'O'), (',', 'O'), ('15', 'O'), ('.', 'O'), ('3', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('17', 'O'), ('microm', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
Atorva affected neither plasma NOx nor thymus weight .,"(('Atorva', 'O'), ('affected', 'O'), ('neither', 'O'), ('plasma', 'O'), ('NOx', 'O'), ('nor', 'O'), ('thymus', 'O'), ('weight', 'O'), ('.', 'O'))"
"The central nervous system toxicity of high - dose cytosine arabinoside is well recognized , but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported .","(('The', 'O'), ('central', 'O'), ('nervous', 'O'), ('system', 'O'), ('toxicity', 'O'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('cytosine', 'O'), ('arabinoside', 'O'), ('is', 'O'), ('well', 'O'), ('recognized', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('toxicity', 'O'), ('of', 'O'), ('cytosine', 'O'), ('arabinoside', 'O'), ('in', 'O'), ('the', 'O'), ('peripheral', 'O'), ('nervous', 'O'), ('system', 'O'), ('has', 'O'), ('been', 'O'), ('infrequently', 'O'), ('reported', 'O'), ('.', 'O'))"
"After he achieved complete remission , he received high - dose cytosine arabinoside treatment ( 2 g / m2 twice a day for 5 days ; total , 20 g / m2 ) as consolidation therapy .","(('After', 'O'), ('he', 'O'), ('achieved', 'O'), ('complete', 'O'), ('remission', 'O'), (',', 'O'), ('he', 'O'), ('received', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('cytosine', 'O'), ('arabinoside', 'O'), ('treatment', 'O'), ('(', 'O'), ('2', 'O'), ('g', 'O'), ('/', 'O'), ('m2', 'O'), ('twice', 'O'), ('a', 'O'), ('day', 'O'), ('for', 'O'), ('5', 'O'), ('days', 'O'), (';', 'O'), ('total', 'O'), (',', 'O'), ('20', 'O'), ('g', 'O'), ('/', 'O'), ('m2', 'O'), (')', 'O'), ('as', 'O'), ('consolidation', 'O'), ('therapy', 'O'), ('.', 'O'))"
Electromyogram and nerve - conduction studies showed peripheral neuropathy in both peroneal nerves .,"(('Electromyogram', 'O'), ('and', 'O'), ('nerve', 'O'), ('-', 'O'), ('conduction', 'O'), ('studies', 'O'), ('showed', 'O'), ('peripheral', 'B'), ('neuropathy', 'I'), ('in', 'O'), ('both', 'O'), ('peroneal', 'O'), ('nerves', 'O'), ('.', 'O'))"
"Although the mechanisms of peripheral neuropathy are still unclear , high - dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .","(('Although', 'O'), ('the', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('peripheral', 'B'), ('neuropathy', 'I'), ('are', 'O'), ('still', 'O'), ('unclear', 'O'), (',', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('cytosine', 'O'), ('arabinoside', 'O'), ('is', 'O'), ('a', 'O'), ('therapy', 'O'), ('that', 'O'), ('is', 'O'), ('potentially', 'O'), ('toxic', 'O'), ('to', 'O'), ('the', 'O'), ('peripheral', 'O'), ('nervous', 'O'), ('system', 'O'), (',', 'O'), ('and', 'O'), ('auto', 'O'), ('/', 'O'), ('alloimmunity', 'O'), ('may', 'O'), ('play', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('in', 'O'), ('these', 'O'), ('mechanisms', 'O'), ('.', 'O'))"
"Male rats were treated with MA ( 10 mg / kg , every 2 h for four injections ) .","(('Male', 'O'), ('rats', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('MA', 'O'), ('(', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('every', 'O'), ('2', 'O'), ('h', 'O'), ('for', 'O'), ('four', 'O'), ('injections', 'O'), (')', 'O'), ('.', 'O'))"
The rat received either alpha - TC ( 20 mg / kg ) intraperitoneally for 3 days and 30 min prior to MA administration or DFO ( 50 mg / kg ) subcutaneously 30 min before MA administration .,"(('The', 'O'), ('rat', 'O'), ('received', 'O'), ('either', 'O'), ('alpha', 'O'), ('-', 'O'), ('TC', 'O'), ('(', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('intraperitoneally', 'O'), ('for', 'O'), ('3', 'O'), ('days', 'O'), ('and', 'O'), ('30', 'O'), ('min', 'O'), ('prior', 'O'), ('to', 'O'), ('MA', 'O'), ('administration', 'O'), ('or', 'O'), ('DFO', 'O'), ('(', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('subcutaneously', 'O'), ('30', 'O'), ('min', 'O'), ('before', 'O'), ('MA', 'O'), ('administration', 'O'), ('.', 'O'))"
"The concentrations of dopamine ( DA ) , serotonin and their metabolites decreased significantly after MA administration , which was inhibited by the alpha - TC and DFO pretreatment .","(('The', 'O'), ('concentrations', 'O'), ('of', 'O'), ('dopamine', 'O'), ('(', 'O'), ('DA', 'O'), (')', 'O'), (',', 'O'), ('serotonin', 'O'), ('and', 'O'), ('their', 'O'), ('metabolites', 'O'), ('decreased', 'O'), ('significantly', 'O'), ('after', 'O'), ('MA', 'O'), ('administration', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('inhibited', 'O'), ('by', 'O'), ('the', 'O'), ('alpha', 'O'), ('-', 'O'), ('TC', 'O'), ('and', 'O'), ('DFO', 'O'), ('pretreatment', 'O'), ('.', 'O'))"
The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA - treated rats .,"(('The', 'O'), ('level', 'O'), ('of', 'O'), ('lipid', 'O'), ('peroxidation', 'O'), ('was', 'O'), ('higher', 'O'), ('and', 'O'), ('the', 'O'), ('reduced', 'O'), ('glutathione', 'O'), ('concentration', 'O'), ('was', 'O'), ('lower', 'O'), ('in', 'O'), ('the', 'O'), ('MA', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('.', 'O'))"
These changes were significantly attenuated by alpha - TC and DFO .,"(('These', 'O'), ('changes', 'O'), ('were', 'O'), ('significantly', 'O'), ('attenuated', 'O'), ('by', 'O'), ('alpha', 'O'), ('-', 'O'), ('TC', 'O'), ('and', 'O'), ('DFO', 'O'), ('.', 'O'))"
This suggests that alpha - TC and DFO ameliorate the MA - induced neuronal damage by decreasing the level of oxidative stress .,"(('This', 'O'), ('suggests', 'O'), ('that', 'O'), ('alpha', 'O'), ('-', 'O'), ('TC', 'O'), ('and', 'O'), ('DFO', 'O'), ('ameliorate', 'O'), ('the', 'O'), ('MA', 'B'), ('-', 'O'), ('induced', 'O'), ('neuronal', 'O'), ('damage', 'O'), ('by', 'O'), ('decreasing', 'O'), ('the', 'O'), ('level', 'O'), ('of', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('.', 'O'))"
1 .,"(('1', 'O'), ('.', 'O'))"
2 .,"(('2', 'O'), ('.', 'O'))"
The effect of fluphenazine and sulpiride was dose - dependent .,"(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('fluphenazine', 'O'), ('and', 'O'), ('sulpiride', 'O'), ('was', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('.', 'O'))"
3 .,"(('3', 'O'), ('.', 'O'))"
4 .,"(('4', 'O'), ('.', 'O'))"
5 .,"(('5', 'O'), ('.', 'O'))"
Sustained clinical improvement of a patient with decompensated hepatitis B virus - related cirrhosis after treatment with lamivudine monotherapy .,"(('Sustained', 'O'), ('clinical', 'O'), ('improvement', 'O'), ('of', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('decompensated', 'B'), ('hepatitis', 'I'), ('B', 'I'), ('virus', 'I'), ('-', 'I'), ('related', 'I'), ('cirrhosis', 'I'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('lamivudine', 'O'), ('monotherapy', 'O'), ('.', 'O'))"
"Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers , although the standard medical therapies have not been established up to now .","(('Recent', 'O'), ('development', 'O'), ('of', 'O'), ('vaccine', 'O'), ('for', 'O'), ('prevention', 'O'), ('is', 'O'), ('reported', 'O'), ('to', 'O'), ('be', 'O'), ('successful', 'O'), ('in', 'O'), ('reducing', 'O'), ('the', 'O'), ('size', 'O'), ('of', 'O'), ('chronically', 'O'), ('infected', 'O'), ('carriers', 'O'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('standard', 'O'), ('medical', 'O'), ('therapies', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('established', 'O'), ('up', 'O'), ('to', 'O'), ('now', 'O'), ('.', 'O'))"
"In this report , we encountered a patient with decompensated HBV - related cirrhosis who exhibited the dramatic improvements after antiviral therapy .","(('In', 'O'), ('this', 'O'), ('report', 'O'), (',', 'O'), ('we', 'O'), ('encountered', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('decompensated', 'B'), ('HBV', 'I'), ('-', 'I'), ('related', 'I'), ('cirrhosis', 'I'), ('who', 'O'), ('exhibited', 'O'), ('the', 'O'), ('dramatic', 'O'), ('improvements', 'O'), ('after', 'O'), ('antiviral', 'O'), ('therapy', 'O'), ('.', 'O'))"
The patient was a 50 - year - old woman .,"(('The', 'O'), ('patient', 'O'), ('was', 'O'), ('a', 'O'), ('50', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('.', 'O'))"
"Previous conventional medical treatments were not effective for this patient , thus this patient had been referred to our hospital .","(('Previous', 'O'), ('conventional', 'O'), ('medical', 'O'), ('treatments', 'O'), ('were', 'O'), ('not', 'O'), ('effective', 'O'), ('for', 'O'), ('this', 'O'), ('patient', 'O'), (',', 'O'), ('thus', 'O'), ('this', 'O'), ('patient', 'O'), ('had', 'O'), ('been', 'O'), ('referred', 'O'), ('to', 'O'), ('our', 'O'), ('hospital', 'O'), ('.', 'O'))"
"However , the administration of lamivudine , a reverse transcriptase inhibitor , for 23 months dramatically improved her liver severity .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('lamivudine', 'O'), (',', 'O'), ('a', 'O'), ('reverse', 'O'), ('transcriptase', 'O'), ('inhibitor', 'O'), (',', 'O'), ('for', 'O'), ('23', 'O'), ('months', 'O'), ('dramatically', 'O'), ('improved', 'O'), ('her', 'O'), ('liver', 'O'), ('severity', 'O'), ('.', 'O'))"
"During this period , no drug resistant mutant HBV emerged , and the serum HBV - DNA level was continuously suppressed .","(('During', 'O'), ('this', 'O'), ('period', 'O'), (',', 'O'), ('no', 'O'), ('drug', 'O'), ('resistant', 'O'), ('mutant', 'O'), ('HBV', 'O'), ('emerged', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('serum', 'O'), ('HBV', 'O'), ('-', 'O'), ('DNA', 'O'), ('level', 'O'), ('was', 'O'), ('continuously', 'O'), ('suppressed', 'O'), ('.', 'O'))"
These virological responses were also maintained even after the antiviral therapy was discontinued .,"(('These', 'O'), ('virological', 'O'), ('responses', 'O'), ('were', 'O'), ('also', 'O'), ('maintained', 'O'), ('even', 'O'), ('after', 'O'), ('the', 'O'), ('antiviral', 'O'), ('therapy', 'O'), ('was', 'O'), ('discontinued', 'O'), ('.', 'O'))"
"Moreover , both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient .","(('Moreover', 'O'), (',', 'O'), ('both', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('surface', 'O'), ('antigen', 'O'), ('and', 'O'), ('e', 'O'), ('antigen', 'O'), ('were', 'O'), ('observed', 'O'), ('to', 'O'), ('have', 'O'), ('disappeared', 'O'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('.', 'O'))"
"The administration of lamivudine to patients with HBV - related cirrhosis , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .","(('The', 'O'), ('administration', 'O'), ('of', 'O'), ('lamivudine', 'O'), ('to', 'O'), ('patients', 'O'), ('with', 'O'), ('HBV', 'B'), ('-', 'I'), ('related', 'I'), ('cirrhosis', 'I'), (',', 'O'), ('like', 'O'), ('our', 'O'), ('present', 'O'), ('case', 'O'), (',', 'O'), ('should', 'O'), ('be', 'O'), ('considered', 'O'), ('as', 'O'), ('an', 'O'), ('initial', 'O'), ('medical', 'O'), ('therapeutic', 'O'), ('option', 'O'), (',', 'O'), ('especially', 'O'), ('in', 'O'), ('countries', 'O'), ('where', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('is', 'O'), ('not', 'O'), ('reliably', 'O'), ('available', 'O'), ('.', 'O'))"
Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - cibenzoline were examined using two canine ventricular arrhythmia models .,"(('Antiarrhythmic', 'O'), ('effects', 'O'), ('of', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('and', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('were', 'O'), ('examined', 'O'), ('using', 'O'), ('two', 'O'), ('canine', 'O'), ('ventricular', 'B'), ('arrhythmia', 'I'), ('models', 'O'), ('.', 'O'))"
"Digitalis arrhythmia , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . ) injection of ouabain in pentobarbital - anesthetized dogs .","(('Digitalis', 'B'), ('arrhythmia', 'I'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('suppressed', 'O'), ('by', 'O'), ('Na', 'O'), ('channel', 'O'), ('blockers', 'O'), (',', 'O'), ('was', 'O'), ('induced', 'O'), ('by', 'O'), ('intermittent', 'O'), ('intravenous', 'O'), ('(', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('injection', 'O'), ('of', 'O'), ('ouabain', 'O'), ('in', 'O'), ('pentobarbital', 'O'), ('-', 'O'), ('anesthetized', 'O'), ('dogs', 'O'), ('.', 'O'))"
"The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and adrenaline - induced arrhythmia were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .","(('The', 'O'), ('minimum', 'O'), ('effective', 'O'), ('plasma', 'O'), ('concentrations', 'O'), ('of', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('for', 'O'), ('digitalis', 'O'), ('-', 'O'), ('and', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('arrhythmia', 'O'), ('were', 'O'), ('0', 'O'), ('.', 'O'), ('06', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('04', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'), ('7', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('micrograms', 'O'), ('/', 'O'), ('ml', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('mean', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('SD', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('6', 'O'), (')', 'O'), ('.', 'O'))"
"The stronger antiarrhythmic effect of ( - ) - cibenzoline indicates that ( - ) - isomer may have an effect nearly 5 - 20 times stronger in suppressing Na channels , but effects of both drugs on Ca channels may be almost equipotent .","(('The', 'O'), ('stronger', 'O'), ('antiarrhythmic', 'O'), ('effect', 'O'), ('of', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('indicates', 'O'), ('that', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('isomer', 'O'), ('may', 'O'), ('have', 'O'), ('an', 'O'), ('effect', 'O'), ('nearly', 'O'), ('5', 'O'), ('-', 'O'), ('20', 'O'), ('times', 'O'), ('stronger', 'O'), ('in', 'O'), ('suppressing', 'O'), ('Na', 'O'), ('channels', 'O'), (',', 'O'), ('but', 'O'), ('effects', 'O'), ('of', 'O'), ('both', 'O'), ('drugs', 'O'), ('on', 'O'), ('Ca', 'O'), ('channels', 'O'), ('may', 'O'), ('be', 'O'), ('almost', 'O'), ('equipotent', 'O'), ('.', 'O'))"
Passage of mannitol into the brain around gliomas : a potential cause of rebound phenomenon .,"(('Passage', 'O'), ('of', 'O'), ('mannitol', 'O'), ('into', 'O'), ('the', 'O'), ('brain', 'O'), ('around', 'O'), ('gliomas', 'B'), (':', 'O'), ('a', 'O'), ('potential', 'O'), ('cause', 'O'), ('of', 'O'), ('rebound', 'O'), ('phenomenon', 'O'), ('.', 'O'))"
A study on 21 patients .,"(('A', 'O'), ('study', 'O'), ('on', 'O'), ('21', 'O'), ('patients', 'O'), ('.', 'O'))"
Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .,"(('Leakage', 'O'), ('of', 'O'), ('mannitol', 'O'), ('into', 'O'), ('the', 'O'), ('brain', 'O'), ('parenchyma', 'O'), ('through', 'O'), ('an', 'O'), ('altered', 'O'), ('BBB', 'O'), ('and', 'O'), ('secondary', 'O'), ('reversal', 'O'), ('of', 'O'), ('osmotic', 'O'), ('gradient', 'O'), ('is', 'O'), ('considered', 'O'), ('the', 'O'), ('major', 'O'), ('cause', 'O'), ('of', 'O'), ('rebound', 'O'), ('.', 'O'))"
This has only been demonstrated experimentally in animals .,"(('This', 'O'), ('has', 'O'), ('only', 'O'), ('been', 'O'), ('demonstrated', 'O'), ('experimentally', 'O'), ('in', 'O'), ('animals', 'O'), ('.', 'O'))"
As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients .,"(('As', 'O'), ('a', 'O'), ('contribution', 'O'), ('to', 'O'), ('this', 'O'), ('issue', 'O'), ('we', 'O'), ('decided', 'O'), ('to', 'O'), ('research', 'O'), ('the', 'O'), ('possible', 'O'), ('passage', 'O'), ('of', 'O'), ('mannitol', 'O'), ('into', 'O'), ('the', 'O'), ('brain', 'O'), ('after', 'O'), ('administration', 'O'), ('to', 'O'), ('21', 'O'), ('brain', 'B'), ('tumor', 'I'), ('patients', 'O'), ('.', 'O'))"
Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al .,"(('Mannitol', 'O'), ('concentrations', 'O'), ('were', 'O'), ('measured', 'O'), ('in', 'O'), ('plasma', 'O'), ('and', 'O'), ('white', 'O'), ('matter', 'O'), ('by', 'O'), ('a', 'O'), ('modified', 'O'), ('version', 'O'), ('of', 'O'), ('the', 'O'), ('enzyme', 'O'), ('assay', 'O'), ('of', 'O'), ('Blonquist', 'O'), ('et', 'O'), ('al', 'O'), ('.', 'O'))"
"RESULTS : In most glioma patients , mannitol concentrations in white matter were 2 to 6 times higher than in plasma ( mean 3 . 5 times ) .","(('RESULTS', 'O'), (':', 'O'), ('In', 'O'), ('most', 'O'), ('glioma', 'B'), ('patients', 'O'), (',', 'O'), ('mannitol', 'O'), ('concentrations', 'O'), ('in', 'O'), ('white', 'O'), ('matter', 'O'), ('were', 'O'), ('2', 'O'), ('to', 'O'), ('6', 'O'), ('times', 'O'), ('higher', 'O'), ('than', 'O'), ('in', 'O'), ('plasma', 'O'), ('(', 'O'), ('mean', 'O'), ('3', 'O'), ('.', 'O'), ('5', 'O'), ('times', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSIONS : The results of our study show that even after a single bolus , mannitol may leak through the altered BBB near gliomas , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral edema and promoting rebound of ICP .","(('CONCLUSIONS', 'O'), (':', 'O'), ('The', 'O'), ('results', 'O'), ('of', 'O'), ('our', 'O'), ('study', 'O'), ('show', 'O'), ('that', 'O'), ('even', 'O'), ('after', 'O'), ('a', 'O'), ('single', 'O'), ('bolus', 'O'), (',', 'O'), ('mannitol', 'O'), ('may', 'O'), ('leak', 'O'), ('through', 'O'), ('the', 'O'), ('altered', 'O'), ('BBB', 'O'), ('near', 'O'), ('gliomas', 'B'), (',', 'O'), ('reversing', 'O'), ('the', 'O'), ('initial', 'O'), ('plasma', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('blood', 'O'), ('osmotic', 'O'), ('gradient', 'O'), (',', 'O'), ('aggravating', 'O'), ('peritumoral', 'B'), ('edema', 'I'), ('and', 'O'), ('promoting', 'O'), ('rebound', 'O'), ('of', 'O'), ('ICP', 'O'), ('.', 'O'))"
"METHODS : Data were analyzed from four similarly designed , randomized , double - blind , 3 - to 12 - week studies .","(('METHODS', 'O'), (':', 'O'), ('Data', 'O'), ('were', 'O'), ('analyzed', 'O'), ('from', 'O'), ('four', 'O'), ('similarly', 'O'), ('designed', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('3', 'O'), ('-', 'O'), ('to', 'O'), ('12', 'O'), ('-', 'O'), ('week', 'O'), ('studies', 'O'), ('.', 'O'))"
"Two studies evaluated quetiapine monotherapy ( up to 800 mg / day ) ( n = 209 ) versus placebo ( n = 198 ) , with lithium or haloperidol monotherapy as respective active controls .","(('Two', 'O'), ('studies', 'O'), ('evaluated', 'O'), ('quetiapine', 'O'), ('monotherapy', 'O'), ('(', 'O'), ('up', 'O'), ('to', 'O'), ('800', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('209', 'O'), (')', 'O'), ('versus', 'O'), ('placebo', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('198', 'O'), (')', 'O'), (',', 'O'), ('with', 'O'), ('lithium', 'O'), ('or', 'O'), ('haloperidol', 'O'), ('monotherapy', 'O'), ('as', 'O'), ('respective', 'O'), ('active', 'O'), ('controls', 'O'), ('.', 'O'))"
"Two studies evaluated quetiapine ( up to 800 mg / day ) in combination with a mood stabilizer ( lithium or divalproex , QTP + Li / DVP ) ( n = 196 ) compared to placebo and mood stabilizer ( PBO + Li / DVP ) ( n = 203 ) .","(('Two', 'O'), ('studies', 'O'), ('evaluated', 'O'), ('quetiapine', 'O'), ('(', 'O'), ('up', 'O'), ('to', 'O'), ('800', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('a', 'O'), ('mood', 'O'), ('stabilizer', 'O'), ('(', 'O'), ('lithium', 'O'), ('or', 'O'), ('divalproex', 'O'), (',', 'O'), ('QTP', 'O'), ('+', 'O'), ('Li', 'O'), ('/', 'O'), ('DVP', 'O'), (')', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('196', 'O'), (')', 'O'), ('compared', 'O'), ('to', 'O'), ('placebo', 'O'), ('and', 'O'), ('mood', 'O'), ('stabilizer', 'O'), ('(', 'O'), ('PBO', 'O'), ('+', 'O'), ('Li', 'O'), ('/', 'O'), ('DVP', 'O'), (')', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('203', 'O'), (')', 'O'), ('.', 'O'))"
No significant differences were observed between quetiapine and placebo on SAS and BARS scores .,"(('No', 'O'), ('significant', 'O'), ('differences', 'O'), ('were', 'O'), ('observed', 'O'), ('between', 'O'), ('quetiapine', 'O'), ('and', 'O'), ('placebo', 'O'), ('on', 'O'), ('SAS', 'O'), ('and', 'O'), ('BARS', 'O'), ('scores', 'O'), ('.', 'O'))"
Anticholinergic use was low and similar with quetiapine or placebo .,"(('Anticholinergic', 'O'), ('use', 'O'), ('was', 'O'), ('low', 'O'), ('and', 'O'), ('similar', 'O'), ('with', 'O'), ('quetiapine', 'O'), ('or', 'O'), ('placebo', 'O'), ('.', 'O'))"
Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis .,"(('Intravenous', 'O'), ('phenytoin', 'O'), ('was', 'O'), ('administered', 'O'), ('during', 'O'), ('the', 'O'), ('later', 'O'), ('part', 'O'), ('of', 'O'), ('the', 'O'), ('surgery', 'O'), ('for', 'O'), ('seizure', 'O'), ('prophylaxis', 'O'), ('.', 'O'))"
"As phenytoin is a commonly used drug , clinicians need to be aware of this interaction .","(('As', 'O'), ('phenytoin', 'O'), ('is', 'O'), ('a', 'O'), ('commonly', 'O'), ('used', 'O'), ('drug', 'O'), (',', 'O'), ('clinicians', 'O'), ('need', 'O'), ('to', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('this', 'O'), ('interaction', 'O'), ('.', 'O'))"
An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner .,"(('An', 'O'), ('important', 'O'), ('subset', 'O'), ('of', 'O'), ('children', 'O'), ('with', 'O'), ('nonketotic', 'B'), ('hyperglycinemia', 'I'), ('are', 'O'), ('atypical', 'O'), ('variants', 'O'), ('who', 'O'), ('present', 'O'), ('in', 'O'), ('a', 'O'), ('heterogeneous', 'O'), ('manner', 'O'), ('.', 'O'))"
"In the control group ( n = 7 ) , the mean arterial pressure ( MAP ) was not manipulated .","(('In', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('7', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('mean', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('(', 'O'), ('MAP', 'O'), (')', 'O'), ('was', 'O'), ('not', 'O'), ('manipulated', 'O'), ('.', 'O'))"
Specific gravity ( SG ) was determined in the subcortex and in two sites in the cortex ( core and periphery of the ischemic territory ) .,"(('Specific', 'O'), ('gravity', 'O'), ('(', 'O'), ('SG', 'O'), (')', 'O'), ('was', 'O'), ('determined', 'O'), ('in', 'O'), ('the', 'O'), ('subcortex', 'O'), ('and', 'O'), ('in', 'O'), ('two', 'O'), ('sites', 'O'), ('in', 'O'), ('the', 'O'), ('cortex', 'O'), ('(', 'O'), ('core', 'O'), ('and', 'O'), ('periphery', 'O'), ('of', 'O'), ('the', 'O'), ('ischemic', 'O'), ('territory', 'O'), (')', 'O'), ('.', 'O'))"
"The extent of neuronal injury was determined by 2 , 3 , 5 - triphenyltetrazolium staining .","(('The', 'O'), ('extent', 'O'), ('of', 'O'), ('neuronal', 'B'), ('injury', 'O'), ('was', 'O'), ('determined', 'O'), ('by', 'O'), ('2', 'O'), (',', 'O'), ('3', 'O'), (',', 'O'), ('5', 'O'), ('-', 'O'), ('triphenyltetrazolium', 'O'), ('staining', 'O'), ('.', 'O'))"
"In the ischemic core , there was no difference in SG in the subcortex and cortex in the two groups .","(('In', 'O'), ('the', 'O'), ('ischemic', 'O'), ('core', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('difference', 'O'), ('in', 'O'), ('SG', 'O'), ('in', 'O'), ('the', 'O'), ('subcortex', 'O'), ('and', 'O'), ('cortex', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('groups', 'O'), ('.', 'O'))"
Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin .,"(('Behavioral', 'O'), ('effects', 'O'), ('of', 'O'), ('pubertal', 'O'), ('anabolic', 'O'), ('androgenic', 'O'), ('steroid', 'O'), ('exposure', 'O'), ('in', 'O'), ('male', 'O'), ('rats', 'O'), ('with', 'O'), ('low', 'O'), ('serotonin', 'O'), ('.', 'O'))"
"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid ( AAS ) exposure and brain serotonin ( 5 - hydroxytryptamine , 5 - HT ) depletion on behavior of pubertal male rats .","(('The', 'O'), ('goal', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('interactive', 'O'), ('effects', 'O'), ('of', 'O'), ('chronic', 'O'), ('anabolic', 'O'), ('androgenic', 'O'), ('steroid', 'O'), ('(', 'O'), ('AAS', 'O'), (')', 'O'), ('exposure', 'O'), ('and', 'O'), ('brain', 'O'), ('serotonin', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('hydroxytryptamine', 'O'), (',', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), (')', 'O'), ('depletion', 'O'), ('on', 'O'), ('behavior', 'O'), ('of', 'O'), ('pubertal', 'O'), ('male', 'O'), ('rats', 'O'), ('.', 'O'))"
"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine ( PCPA 100 mg / kg , every other day ) ; controls received saline .","(('Serotonin', 'O'), ('was', 'O'), ('depleted', 'O'), ('beginning', 'O'), ('on', 'O'), ('postnatal', 'O'), ('day', 'O'), ('26', 'O'), ('with', 'O'), ('parachlorophenylalanine', 'O'), ('(', 'O'), ('PCPA', 'O'), ('100', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('every', 'O'), ('other', 'O'), ('day', 'O'), (')', 'O'), (';', 'O'), ('controls', 'O'), ('received', 'O'), ('saline', 'O'), ('.', 'O'))"
"At puberty ( P40 ) , half the PCPA - treated rats and half the saline - treated rats began treatment with testosterone ( T , 5 mg / kg , 5 days / week ) .","(('At', 'O'), ('puberty', 'O'), ('(', 'O'), ('P40', 'O'), (')', 'O'), (',', 'O'), ('half', 'O'), ('the', 'O'), ('PCPA', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('and', 'O'), ('half', 'O'), ('the', 'O'), ('saline', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('began', 'O'), ('treatment', 'O'), ('with', 'O'), ('testosterone', 'O'), ('(', 'O'), ('T', 'O'), (',', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('5', 'O'), ('days', 'O'), ('/', 'O'), ('week', 'O'), (')', 'O'), ('.', 'O'))"
"Brain levels of 5 - HT and its metabolite , 5 - hydroxyindoleacetic acid ( 5 - HIAA ) , were determined using HPLC .","(('Brain', 'O'), ('levels', 'O'), ('of', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('and', 'O'), ('its', 'O'), ('metabolite', 'O'), (',', 'O'), ('5', 'O'), ('-', 'O'), ('hydroxyindoleacetic', 'O'), ('acid', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('HIAA', 'O'), (')', 'O'), (',', 'O'), ('were', 'O'), ('determined', 'O'), ('using', 'O'), ('HPLC', 'O'), ('.', 'O'))"
PCPA significantly and substantially depleted 5 - HT and 5 - HIAA in all brain regions examined .,"(('PCPA', 'O'), ('significantly', 'O'), ('and', 'O'), ('substantially', 'O'), ('depleted', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('and', 'O'), ('5', 'O'), ('-', 'O'), ('HIAA', 'O'), ('in', 'O'), ('all', 'O'), ('brain', 'O'), ('regions', 'O'), ('examined', 'O'), ('.', 'O'))"
"Chronic T treatment significantly decreased 5 - HT and 5 - HIAA in certain brain areas , but to a much lesser extent than PCPA .","(('Chronic', 'O'), ('T', 'O'), ('treatment', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('and', 'O'), ('5', 'O'), ('-', 'O'), ('HIAA', 'O'), ('in', 'O'), ('certain', 'O'), ('brain', 'O'), ('areas', 'O'), (',', 'O'), ('but', 'O'), ('to', 'O'), ('a', 'O'), ('much', 'O'), ('lesser', 'O'), ('extent', 'O'), ('than', 'O'), ('PCPA', 'O'), ('.', 'O'))"
"The most striking effect of combining T + PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack , particularly following physical provocation .","(('The', 'O'), ('most', 'O'), ('striking', 'O'), ('effect', 'O'), ('of', 'O'), ('combining', 'O'), ('T', 'O'), ('+', 'O'), ('PCPA', 'O'), ('was', 'O'), ('a', 'O'), ('significant', 'O'), ('increase', 'O'), ('in', 'O'), ('attack', 'O'), ('frequency', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('a', 'O'), ('significant', 'O'), ('decrease', 'O'), ('in', 'O'), ('the', 'O'), ('latency', 'O'), ('to', 'O'), ('attack', 'O'), (',', 'O'), ('particularly', 'O'), ('following', 'O'), ('physical', 'O'), ('provocation', 'O'), ('.', 'O'))"
"Effects of UMB24 and ( + / - ) - SM 21 , putative sigma2 - preferring antagonists , on behavioral toxic and stimulant effects of cocaine in mice .","(('Effects', 'O'), ('of', 'O'), ('UMB24', 'O'), ('and', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('SM', 'O'), ('21', 'O'), (',', 'O'), ('putative', 'O'), ('sigma2', 'O'), ('-', 'O'), ('preferring', 'O'), ('antagonists', 'O'), (',', 'O'), ('on', 'O'), ('behavioral', 'O'), ('toxic', 'O'), ('and', 'O'), ('stimulant', 'O'), ('effects', 'O'), ('of', 'O'), ('cocaine', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive , lethal , locomotor stimulatory and rewarding actions of cocaine in mice .","(('Earlier', 'O'), ('studies', 'O'), ('have', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('antagonism', 'O'), ('of', 'O'), ('sigma1', 'O'), ('receptors', 'O'), ('attenuates', 'O'), ('the', 'O'), ('convulsive', 'O'), (',', 'O'), ('lethal', 'O'), (',', 'O'), ('locomotor', 'O'), ('stimulatory', 'O'), ('and', 'O'), ('rewarding', 'O'), ('actions', 'O'), ('of', 'O'), ('cocaine', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"In contrast , the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('the', 'O'), ('contribution', 'O'), ('of', 'O'), ('sigma2', 'O'), ('receptors', 'O'), ('is', 'O'), ('unclear', 'O'), ('because', 'O'), ('experimental', 'O'), ('tools', 'O'), ('to', 'O'), ('selectively', 'O'), ('target', 'O'), ('this', 'O'), ('subtype', 'O'), ('are', 'O'), ('unavailable', 'O'), ('.', 'O'))"
"To begin addressing this need , we characterized UMB24 ( 1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine ) and ( + / - ) - SM 21 ( 3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate ) in receptor binding and behavioral studies .","(('To', 'O'), ('begin', 'O'), ('addressing', 'O'), ('this', 'O'), ('need', 'O'), (',', 'O'), ('we', 'O'), ('characterized', 'O'), ('UMB24', 'O'), ('(', 'O'), ('1', 'O'), ('-', 'O'), ('(', 'O'), ('2', 'O'), ('-', 'O'), ('phenethyl', 'O'), (')', 'O'), ('-', 'O'), ('4', 'O'), ('-', 'O'), ('(', 'O'), ('2', 'O'), ('-', 'O'), ('pyridyl', 'O'), (')', 'O'), ('-', 'O'), ('piperazine', 'O'), (')', 'O'), ('and', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('SM', 'O'), ('21', 'O'), ('(', 'O'), ('3alpha', 'O'), ('-', 'O'), ('tropanyl', 'O'), ('-', 'O'), ('2', 'O'), ('-', 'O'), ('(', 'O'), ('4', 'O'), ('-', 'O'), ('chorophenoxy', 'O'), (')', 'O'), ('butyrate', 'O'), (')', 'O'), ('in', 'O'), ('receptor', 'O'), ('binding', 'O'), ('and', 'O'), ('behavioral', 'O'), ('studies', 'O'), ('.', 'O'))"
Receptor binding studies confirmed that UMB24 and ( + / - ) - SM 21 display preferential affinity for sigma2 over sigma1 receptors .,"(('Receptor', 'O'), ('binding', 'O'), ('studies', 'O'), ('confirmed', 'O'), ('that', 'O'), ('UMB24', 'O'), ('and', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('SM', 'O'), ('21', 'O'), ('display', 'O'), ('preferential', 'O'), ('affinity', 'O'), ('for', 'O'), ('sigma2', 'O'), ('over', 'O'), ('sigma1', 'O'), ('receptors', 'O'), ('.', 'O'))"
"In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated cocaine - induced convulsions and locomotor activity , but not lethality .","(('In', 'O'), ('behavioral', 'O'), ('studies', 'O'), (',', 'O'), ('pretreatment', 'O'), ('of', 'O'), ('Swiss', 'O'), ('Webster', 'O'), ('mice', 'O'), ('with', 'O'), ('UMB24', 'O'), ('or', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('SM', 'O'), ('21', 'O'), ('significantly', 'O'), ('attenuated', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('and', 'O'), ('locomotor', 'O'), ('activity', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('lethality', 'O'), ('.', 'O'))"
"When administered alone , ( + / - ) - SM 21 produced no significant effects compared to control injections of saline , but UMB24 had locomotor depressant actions .","(('When', 'O'), ('administered', 'O'), ('alone', 'O'), (',', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('SM', 'O'), ('21', 'O'), ('produced', 'O'), ('no', 'O'), ('significant', 'O'), ('effects', 'O'), ('compared', 'O'), ('to', 'O'), ('control', 'O'), ('injections', 'O'), ('of', 'O'), ('saline', 'O'), (',', 'O'), ('but', 'O'), ('UMB24', 'O'), ('had', 'O'), ('locomotor', 'O'), ('depressant', 'O'), ('actions', 'O'), ('.', 'O'))"
"Together , the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine , and further development of more selective , high affinity ligands are warranted .","(('Together', 'O'), (',', 'O'), ('the', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('sigma2', 'O'), ('receptor', 'O'), ('antagonists', 'O'), ('have', 'O'), ('the', 'O'), ('potential', 'O'), ('to', 'O'), ('attenuate', 'O'), ('some', 'O'), ('of', 'O'), ('the', 'O'), ('behavioral', 'O'), ('effects', 'O'), ('of', 'O'), ('cocaine', 'O'), (',', 'O'), ('and', 'O'), ('further', 'O'), ('development', 'O'), ('of', 'O'), ('more', 'O'), ('selective', 'O'), (',', 'O'), ('high', 'O'), ('affinity', 'O'), ('ligands', 'O'), ('are', 'O'), ('warranted', 'O'), ('.', 'O'))"
Clonidine is a frequently administered alpha2 - adrenergic agonist which can decrease heart rate and blood pressure .,"(('Clonidine', 'O'), ('is', 'O'), ('a', 'O'), ('frequently', 'O'), ('administered', 'O'), ('alpha2', 'O'), ('-', 'O'), ('adrenergic', 'O'), ('agonist', 'O'), ('which', 'O'), ('can', 'O'), ('decrease', 'O'), ('heart', 'O'), ('rate', 'O'), ('and', 'O'), ('blood', 'O'), ('pressure', 'O'), ('.', 'O'))"
"Without the knowledge of the medical personnel , the patient ' s mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety .","(('Without', 'O'), ('the', 'O'), ('knowledge', 'O'), ('of', 'O'), ('the', 'O'), ('medical', 'O'), ('personnel', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('mother', 'O'), ('administered', 'O'), ('three', 'O'), ('doses', 'O'), ('of', 'O'), ('clonidine', 'O'), ('during', 'O'), ('the', 'O'), ('evening', 'O'), ('before', 'O'), ('and', 'O'), ('morning', 'O'), ('of', 'O'), ('surgery', 'O'), ('to', 'O'), ('reduce', 'O'), ('anxiety', 'O'), ('.', 'O'))"
There are no previous reports of clonidine - associated cardiac arrest in a child undergoing induction of anesthesia .,"(('There', 'O'), ('are', 'O'), ('no', 'O'), ('previous', 'O'), ('reports', 'O'), ('of', 'O'), ('clonidine', 'O'), ('-', 'O'), ('associated', 'O'), ('cardiac', 'B'), ('arrest', 'I'), ('in', 'O'), ('a', 'O'), ('child', 'O'), ('undergoing', 'O'), ('induction', 'O'), ('of', 'O'), ('anesthesia', 'O'), ('.', 'O'))"
Angiotensin - converting enzyme ( ACE ) inhibitor - associated angioedema of the stomach and small intestine : a case report .,"(('Angiotensin', 'B'), ('-', 'O'), ('converting', 'O'), ('enzyme', 'O'), ('(', 'O'), ('ACE', 'O'), (')', 'O'), ('inhibitor', 'O'), ('-', 'O'), ('associated', 'O'), ('angioedema', 'B'), ('of', 'I'), ('the', 'I'), ('stomach', 'I'), ('and', 'I'), ('small', 'I'), ('intestine', 'I'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
"Physical exam , complete metabolic panel , and hemogram were in the normal range .","(('Physical', 'O'), ('exam', 'O'), (',', 'O'), ('complete', 'O'), ('metabolic', 'O'), ('panel', 'O'), (',', 'O'), ('and', 'O'), ('hemogram', 'O'), ('were', 'O'), ('in', 'O'), ('the', 'O'), ('normal', 'O'), ('range', 'O'), ('.', 'O'))"
She was discharged from the ER after a few hours of treatment with fluid and analgesics .,"(('She', 'O'), ('was', 'O'), ('discharged', 'O'), ('from', 'O'), ('the', 'O'), ('ER', 'O'), ('after', 'O'), ('a', 'O'), ('few', 'O'), ('hours', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('fluid', 'O'), ('and', 'O'), ('analgesics', 'O'), ('.', 'O'))"
"However , she returned to the ER the next day with the same complaints .","(('However', 'O'), (',', 'O'), ('she', 'O'), ('returned', 'O'), ('to', 'O'), ('the', 'O'), ('ER', 'O'), ('the', 'O'), ('next', 'O'), ('day', 'O'), ('with', 'O'), ('the', 'O'), ('same', 'O'), ('complaints', 'O'), ('.', 'O'))"
This time the physical exam was significant for a distended abdomen with dullness to percussion .,"(('This', 'O'), ('time', 'O'), ('the', 'O'), ('physical', 'O'), ('exam', 'O'), ('was', 'O'), ('significant', 'O'), ('for', 'O'), ('a', 'O'), ('distended', 'O'), ('abdomen', 'O'), ('with', 'O'), ('dullness', 'O'), ('to', 'O'), ('percussion', 'O'), ('.', 'O'))"
"CT scan of the abdomen revealed markedly thickened antrum of the stomach , duodenum and jejunum , along with fluid in the abdominal and pelvic cavity .","(('CT', 'O'), ('scan', 'O'), ('of', 'O'), ('the', 'O'), ('abdomen', 'O'), ('revealed', 'O'), ('markedly', 'O'), ('thickened', 'O'), ('antrum', 'O'), ('of', 'O'), ('the', 'O'), ('stomach', 'O'), (',', 'O'), ('duodenum', 'O'), ('and', 'O'), ('jejunum', 'O'), (',', 'O'), ('along', 'O'), ('with', 'O'), ('fluid', 'O'), ('in', 'O'), ('the', 'O'), ('abdominal', 'O'), ('and', 'O'), ('pelvic', 'O'), ('cavity', 'O'), ('.', 'O'))"
Carbamazepine - induced cardiac dysfunction .,"(('Carbamazepine', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
Characterization of two distinct clinical syndromes .,"(('Characterization', 'O'), ('of', 'O'), ('two', 'O'), ('distinct', 'O'), ('clinical', 'O'), ('syndromes', 'O'), ('.', 'O'))"
"From the analysis of these cases , two distinct forms of carbamazepine - associated cardiac dysfunction emerged .","(('From', 'O'), ('the', 'O'), ('analysis', 'O'), ('of', 'O'), ('these', 'O'), ('cases', 'O'), (',', 'O'), ('two', 'O'), ('distinct', 'O'), ('forms', 'O'), ('of', 'O'), ('carbamazepine', 'B'), ('-', 'O'), ('associated', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('emerged', 'O'), ('.', 'O'))"
"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .","(('Because', 'O'), ('carbamazepine', 'O'), ('is', 'O'), ('widely', 'O'), ('used', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('many', 'O'), ('neurologic', 'B'), ('and', 'I'), ('psychiatric', 'I'), ('conditions', 'I'), (',', 'O'), ('the', 'O'), ('recognition', 'O'), ('of', 'O'), ('the', 'O'), ('latter', 'O'), ('syndrome', 'O'), ('has', 'O'), ('important', 'O'), ('implications', 'O'), ('for', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('this', 'O'), ('drug', 'O'), ('in', 'O'), ('elderly', 'O'), ('patients', 'O'), ('.', 'O'))"
Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced cardiomyopathy with iodine - 125 - metaiodobenzylguanidine .,"(('Detection', 'O'), ('of', 'O'), ('abnormal', 'O'), ('cardiac', 'O'), ('adrenergic', 'O'), ('neuron', 'O'), ('activity', 'O'), ('in', 'O'), ('adriamycin', 'B'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('with', 'O'), ('iodine', 'O'), ('-', 'O'), ('125', 'O'), ('-', 'O'), ('metaiodobenzylguanidine', 'O'), ('.', 'O'))"
"Radiolabeled metaiodobenzylguanidine ( MIBG ) , an analog of norepinephrine ( NE ) , serves as an index of adrenergic neuron integrity and function .","(('Radiolabeled', 'O'), ('metaiodobenzylguanidine', 'O'), ('(', 'O'), ('MIBG', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('analog', 'O'), ('of', 'O'), ('norepinephrine', 'O'), ('(', 'O'), ('NE', 'O'), (')', 'O'), (',', 'O'), ('serves', 'O'), ('as', 'O'), ('an', 'O'), ('index', 'O'), ('of', 'O'), ('adrenergic', 'O'), ('neuron', 'O'), ('integrity', 'O'), ('and', 'O'), ('function', 'O'), ('.', 'O'))"
"Using a rat model of adriamycin - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin cardiomyopathy .","(('Using', 'O'), ('a', 'O'), ('rat', 'O'), ('model', 'O'), ('of', 'O'), ('adriamycin', 'B'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), (',', 'O'), ('we', 'O'), ('tested', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('abnormal', 'O'), ('cardiac', 'O'), ('adrenergic', 'O'), ('neuron', 'O'), ('activity', 'O'), ('may', 'O'), ('appear', 'O'), ('and', 'O'), ('be', 'O'), ('exacerbated', 'O'), ('dose', 'O'), ('-', 'O'), ('dependently', 'O'), ('in', 'O'), ('adriamycin', 'B'), ('cardiomyopathy', 'I'), ('.', 'O'))"
"There were no abnormalities or only isolated degeneration in the 1 - or 2 - wk treatment groups , isolated or scattered degeneration in half of the 3 - wk group , frequent scattered degeneration in the 4 - wk group , scattered or focal degeneration in the 5 - wk group , and extensive degeneration in the 8 - wk group .","(('There', 'O'), ('were', 'O'), ('no', 'O'), ('abnormalities', 'O'), ('or', 'O'), ('only', 'O'), ('isolated', 'B'), ('degeneration', 'I'), ('in', 'O'), ('the', 'O'), ('1', 'O'), ('-', 'O'), ('or', 'O'), ('2', 'O'), ('-', 'O'), ('wk', 'O'), ('treatment', 'O'), ('groups', 'O'), (',', 'O'), ('isolated', 'O'), ('or', 'O'), ('scattered', 'O'), ('degeneration', 'B'), ('in', 'O'), ('half', 'O'), ('of', 'O'), ('the', 'O'), ('3', 'O'), ('-', 'O'), ('wk', 'O'), ('group', 'O'), (',', 'O'), ('frequent', 'O'), ('scattered', 'O'), ('degeneration', 'B'), ('in', 'O'), ('the', 'O'), ('4', 'O'), ('-', 'O'), ('wk', 'O'), ('group', 'O'), (',', 'O'), ('scattered', 'O'), ('or', 'O'), ('focal', 'O'), ('degeneration', 'I'), ('in', 'O'), ('the', 'O'), ('5', 'O'), ('-', 'O'), ('wk', 'O'), ('group', 'O'), (',', 'O'), ('and', 'O'), ('extensive', 'O'), ('degeneration', 'B'), ('in', 'O'), ('the', 'O'), ('8', 'O'), ('-', 'O'), ('wk', 'O'), ('group', 'O'), ('.', 'O'))"
Myocardial accumulation of [ 125I ] MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less .,"(('Myocardial', 'O'), ('accumulation', 'O'), ('of', 'O'), ('[', 'O'), ('125I', 'O'), (']', 'O'), ('MIBG', 'O'), ('4', 'O'), ('hr', 'O'), ('after', 'O'), ('intravenous', 'O'), ('injection', 'O'), ('did', 'O'), ('not', 'O'), ('differ', 'O'), ('between', 'O'), ('the', 'O'), ('controls', 'O'), ('and', 'O'), ('the', 'O'), ('groups', 'O'), ('treated', 'O'), ('3', 'O'), ('wk', 'O'), ('or', 'O'), ('less', 'O'), ('.', 'O'))"
"However , the 4 - wk group had a slightly lower accumulation in the right ventricular wall ( 82 % of the control ) and significantly lower accumulation in the left ventricular wall ( about 66 % of the control : p less than 0 . 05 ) .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('4', 'O'), ('-', 'O'), ('wk', 'O'), ('group', 'O'), ('had', 'O'), ('a', 'O'), ('slightly', 'O'), ('lower', 'O'), ('accumulation', 'O'), ('in', 'O'), ('the', 'O'), ('right', 'O'), ('ventricular', 'O'), ('wall', 'O'), ('(', 'O'), ('82', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('control', 'O'), (')', 'O'), ('and', 'O'), ('significantly', 'O'), ('lower', 'O'), ('accumulation', 'O'), ('in', 'O'), ('the', 'O'), ('left', 'O'), ('ventricular', 'O'), ('wall', 'O'), ('(', 'O'), ('about', 'O'), ('66', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('control', 'O'), (':', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"In the 5 - wk group , MIBG accumulation in the right and left ventricular wall was 35 % and 27 % of that in controls , respectively ( p less than 0 . 001 ) .","(('In', 'O'), ('the', 'O'), ('5', 'O'), ('-', 'O'), ('wk', 'O'), ('group', 'O'), (',', 'O'), ('MIBG', 'O'), ('accumulation', 'O'), ('in', 'O'), ('the', 'O'), ('right', 'O'), ('and', 'O'), ('left', 'O'), ('ventricular', 'O'), ('wall', 'O'), ('was', 'O'), ('35', 'O'), ('%', 'O'), ('and', 'O'), ('27', 'O'), ('%', 'O'), ('of', 'O'), ('that', 'O'), ('in', 'O'), ('controls', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
"In the 8 - wk group , MIBG accumulation in the right and left ventricular wall was 18 % and 14 % of that in controls , respectively ( p less than 0 . 001 ) .","(('In', 'O'), ('the', 'O'), ('8', 'O'), ('-', 'O'), ('wk', 'O'), ('group', 'O'), (',', 'O'), ('MIBG', 'O'), ('accumulation', 'O'), ('in', 'O'), ('the', 'O'), ('right', 'O'), ('and', 'O'), ('left', 'O'), ('ventricular', 'O'), ('wall', 'O'), ('was', 'O'), ('18', 'O'), ('%', 'O'), ('and', 'O'), ('14', 'O'), ('%', 'O'), ('of', 'O'), ('that', 'O'), ('in', 'O'), ('controls', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
"Thus , MIBG accumulation in the myocardium decreased in an adriamycin dose - dependent manner .","(('Thus', 'O'), (',', 'O'), ('MIBG', 'O'), ('accumulation', 'O'), ('in', 'O'), ('the', 'O'), ('myocardium', 'O'), ('decreased', 'O'), ('in', 'O'), ('an', 'O'), ('adriamycin', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('manner', 'O'), ('.', 'O'))"
BACKGROUND : Methadone is prescribed to heroin addicts to decrease illicit opioid use .,"(('BACKGROUND', 'O'), (':', 'O'), ('Methadone', 'O'), ('is', 'O'), ('prescribed', 'O'), ('to', 'O'), ('heroin', 'O'), ('addicts', 'O'), ('to', 'O'), ('decrease', 'O'), ('illicit', 'O'), ('opioid', 'O'), ('use', 'O'), ('.', 'O'))"
"METHODS : In this cross - sectional study interview , ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis .","(('METHODS', 'O'), (':', 'O'), ('In', 'O'), ('this', 'O'), ('cross', 'O'), ('-', 'O'), ('sectional', 'O'), ('study', 'O'), ('interview', 'O'), (',', 'O'), ('ECGs', 'O'), ('and', 'O'), ('blood', 'O'), ('samples', 'O'), ('were', 'O'), ('collected', 'O'), ('in', 'O'), ('a', 'O'), ('population', 'O'), ('of', 'O'), ('adult', 'O'), ('heroin', 'O'), ('addicts', 'O'), ('treated', 'O'), ('with', 'O'), ('methadone', 'O'), ('or', 'O'), ('buprenorphine', 'O'), ('on', 'O'), ('a', 'O'), ('daily', 'O'), ('basis', 'O'), ('.', 'O'))"
"Of the patients at the Drug Addiction Service in the municipal of Copenhagen , 450 ( approximately 52 % ) were included .","(('Of', 'O'), ('the', 'O'), ('patients', 'O'), ('at', 'O'), ('the', 'O'), ('Drug', 'O'), ('Addiction', 'O'), ('Service', 'O'), ('in', 'O'), ('the', 'O'), ('municipal', 'O'), ('of', 'O'), ('Copenhagen', 'O'), (',', 'O'), ('450', 'O'), ('(', 'O'), ('approximately', 'O'), ('52', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('included', 'O'), ('.', 'O'))"
The QT interval was estimated from 12 lead ECGs .,"(('The', 'O'), ('QT', 'O'), ('interval', 'O'), ('was', 'O'), ('estimated', 'O'), ('from', 'O'), ('12', 'O'), ('lead', 'O'), ('ECGs', 'O'), ('.', 'O'))"
RESULTS : Methadone dose was associated with longer QT interval of 0 . 140 ms / mg ( p = 0 . 002 ) .,"(('RESULTS', 'O'), (':', 'O'), ('Methadone', 'O'), ('dose', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('longer', 'O'), ('QT', 'O'), ('interval', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('140', 'O'), ('ms', 'O'), ('/', 'O'), ('mg', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('002', 'O'), (')', 'O'), ('.', 'O'))"
No association between buprenorphine and QTc was found .,"(('No', 'O'), ('association', 'O'), ('between', 'O'), ('buprenorphine', 'O'), ('and', 'O'), ('QTc', 'O'), ('was', 'O'), ('found', 'O'), ('.', 'O'))"
None of the subjects treated with buprenorphine had QTc interval > 0 . 440 s ( ( 1 / 2 ) ) .,"(('None', 'O'), ('of', 'O'), ('the', 'O'), ('subjects', 'O'), ('treated', 'O'), ('with', 'O'), ('buprenorphine', 'O'), ('had', 'O'), ('QTc', 'O'), ('interval', 'O'), ('>', 'O'), ('0', 'O'), ('.', 'O'), ('440', 'O'), ('s', 'O'), ('(', 'O'), ('(', 'O'), ('1', 'O'), ('/', 'O'), ('2', 'O'), (')', 'O'), (')', 'O'), ('.', 'O'))"
The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH - immunoreactive neurons in the SN .,"(('The', 'O'), ('findings', 'O'), ('showed', 'O'), ('that', 'O'), ('peripheral', 'O'), ('iron', 'O'), ('dextran', 'I'), ('overload', 'I'), ('increased', 'O'), ('the', 'O'), ('iron', 'O'), ('staining', 'O'), ('positive', 'O'), ('cells', 'O'), ('and', 'O'), ('reduced', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('TH', 'O'), ('-', 'O'), ('immunoreactive', 'O'), ('neurons', 'O'), ('in', 'O'), ('the', 'O'), ('SN', 'O'), ('.', 'O'))"
"As a result , dopamine release and content , as well as its metabolites contents were decreased in caudate putamen .","(('As', 'O'), ('a', 'O'), ('result', 'O'), (',', 'O'), ('dopamine', 'O'), ('release', 'O'), ('and', 'O'), ('content', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('its', 'O'), ('metabolites', 'O'), ('contents', 'O'), ('were', 'O'), ('decreased', 'O'), ('in', 'O'), ('caudate', 'O'), ('putamen', 'O'), ('.', 'O'))"
Even more dramatic changes were found in chronic overload group .,"(('Even', 'O'), ('more', 'O'), ('dramatic', 'O'), ('changes', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('chronic', 'B'), ('overload', 'I'), ('group', 'O'), ('.', 'O'))"
The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload .,"(('The', 'O'), ('chronic', 'O'), ('iron', 'O'), ('overload', 'O'), ('may', 'O'), ('be', 'O'), ('more', 'O'), ('destructive', 'O'), ('to', 'O'), ('dopaminergic', 'O'), ('neurons', 'O'), ('than', 'O'), ('the', 'O'), ('acute', 'O'), ('iron', 'O'), ('overload', 'O'), ('.', 'O'))"
Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats .,"(('Attenuated', 'O'), ('disruption', 'O'), ('of', 'O'), ('prepulse', 'O'), ('inhibition', 'O'), ('by', 'O'), ('dopaminergic', 'O'), ('stimulation', 'O'), ('after', 'O'), ('maternal', 'O'), ('deprivation', 'O'), ('and', 'O'), ('adolescent', 'O'), ('corticosterone', 'O'), ('treatment', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"We investigated the effect of an early stress , in the form of maternal deprivation , combined with a later stress , simulated by chronic periadolescent corticosterone treatment , on behaviour in rats .","(('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('an', 'O'), ('early', 'O'), ('stress', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('form', 'O'), ('of', 'O'), ('maternal', 'O'), ('deprivation', 'O'), (',', 'O'), ('combined', 'O'), ('with', 'O'), ('a', 'O'), ('later', 'O'), ('stress', 'O'), (',', 'O'), ('simulated', 'O'), ('by', 'O'), ('chronic', 'O'), ('periadolescent', 'O'), ('corticosterone', 'O'), ('treatment', 'O'), (',', 'O'), ('on', 'O'), ('behaviour', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"Acute treatment with apomorphine caused disruption of prepulse inhibition ( PPI ) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment , but was surprisingly absent in rats that had undergone the combined early and late stress .","(('Acute', 'O'), ('treatment', 'O'), ('with', 'O'), ('apomorphine', 'O'), ('caused', 'O'), ('disruption', 'O'), ('of', 'O'), ('prepulse', 'O'), ('inhibition', 'O'), ('(', 'O'), ('PPI', 'O'), (')', 'O'), ('in', 'O'), ('controls', 'O'), ('and', 'O'), ('in', 'O'), ('rats', 'O'), ('that', 'O'), ('had', 'O'), ('undergone', 'O'), ('either', 'O'), ('maternal', 'O'), ('deprivation', 'O'), ('or', 'O'), ('corticosterone', 'O'), ('treatment', 'O'), (',', 'O'), ('but', 'O'), ('was', 'O'), ('surprisingly', 'O'), ('absent', 'O'), ('in', 'O'), ('rats', 'O'), ('that', 'O'), ('had', 'O'), ('undergone', 'O'), ('the', 'O'), ('combined', 'O'), ('early', 'O'), ('and', 'O'), ('late', 'O'), ('stress', 'O'), ('.', 'O'))"
"Amphetamine treatment significantly disrupted PPI in both non - deprived groups , but was absent in both maternally deprived groups .","(('Amphetamine', 'O'), ('treatment', 'O'), ('significantly', 'O'), ('disrupted', 'O'), ('PPI', 'O'), ('in', 'O'), ('both', 'O'), ('non', 'O'), ('-', 'O'), ('deprived', 'O'), ('groups', 'O'), (',', 'O'), ('but', 'O'), ('was', 'O'), ('absent', 'O'), ('in', 'O'), ('both', 'O'), ('maternally', 'O'), ('deprived', 'O'), ('groups', 'O'), ('.', 'O'))"
"The serotonin - 1A receptor agonist , 8 - OH - DPAT , induced a significant disruption of PPI in all groups .","(('The', 'O'), ('serotonin', 'O'), ('-', 'O'), ('1A', 'O'), ('receptor', 'O'), ('agonist', 'O'), (',', 'O'), ('8', 'O'), ('-', 'O'), ('OH', 'O'), ('-', 'O'), ('DPAT', 'O'), (',', 'O'), ('induced', 'O'), ('a', 'O'), ('significant', 'O'), ('disruption', 'O'), ('of', 'O'), ('PPI', 'O'), ('in', 'O'), ('all', 'O'), ('groups', 'O'), ('.', 'O'))"
"These results show an inhibitory interaction of early stress , caused by maternal deprivation , combined with ' adolescent ' stress , simulated by corticosterone treatment , on dopaminergic regulation of PPI .","(('These', 'O'), ('results', 'O'), ('show', 'O'), ('an', 'O'), ('inhibitory', 'O'), ('interaction', 'O'), ('of', 'O'), ('early', 'O'), ('stress', 'O'), (',', 'O'), ('caused', 'O'), ('by', 'O'), ('maternal', 'O'), ('deprivation', 'O'), (',', 'O'), ('combined', 'O'), ('with', 'O'), (""'"", 'O'), ('adolescent', 'O'), (""'"", 'O'), ('stress', 'O'), (',', 'O'), ('simulated', 'O'), ('by', 'O'), ('corticosterone', 'O'), ('treatment', 'O'), (',', 'O'), ('on', 'O'), ('dopaminergic', 'O'), ('regulation', 'O'), ('of', 'O'), ('PPI', 'O'), ('.', 'O'))"
"The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation , or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus .","(('The', 'O'), ('altered', 'O'), ('effects', 'O'), ('of', 'O'), ('apomorphine', 'O'), ('and', 'O'), ('amphetamine', 'O'), ('could', 'O'), ('indicate', 'O'), ('differential', 'O'), ('changes', 'O'), ('in', 'O'), ('dopamine', 'O'), ('receptor', 'O'), ('signalling', 'O'), ('leading', 'O'), ('to', 'O'), ('functional', 'O'), ('desensitisation', 'O'), (',', 'O'), ('or', 'O'), ('altered', 'O'), ('modulation', 'O'), ('of', 'O'), ('sensory', 'O'), ('gating', 'O'), ('in', 'O'), ('the', 'O'), ('nucleus', 'O'), ('accumbens', 'O'), ('by', 'O'), ('limbic', 'O'), ('structures', 'O'), ('such', 'O'), ('as', 'O'), ('the', 'O'), ('hippocampus', 'O'), ('.', 'O'))"
"During treatment of chronic hepatitis C patients with interferon and ribavirin , a lot of side effects are described .","(('During', 'O'), ('treatment', 'O'), ('of', 'O'), ('chronic', 'B'), ('hepatitis', 'I'), ('C', 'I'), ('patients', 'O'), ('with', 'O'), ('interferon', 'O'), ('and', 'O'), ('ribavirin', 'O'), (',', 'O'), ('a', 'O'), ('lot', 'O'), ('of', 'O'), ('side', 'O'), ('effects', 'O'), ('are', 'O'), ('described', 'O'), ('.', 'O'))"
She complained of seeing parasites and the larvae of fleas in her stools .,"(('She', 'O'), ('complained', 'O'), ('of', 'O'), ('seeing', 'O'), ('parasites', 'O'), ('and', 'O'), ('the', 'O'), ('larvae', 'O'), ('of', 'O'), ('fleas', 'O'), ('in', 'O'), ('her', 'O'), ('stools', 'O'), ('.', 'O'))"
This could not be confirmed by any technical examination .,"(('This', 'O'), ('could', 'O'), ('not', 'O'), ('be', 'O'), ('confirmed', 'O'), ('by', 'O'), ('any', 'O'), ('technical', 'O'), ('examination', 'O'), ('.', 'O'))"
All the complaints disappeared after stopping pegylated interferon alpha - 2b and reappeared after restarting it .,"(('All', 'O'), ('the', 'O'), ('complaints', 'O'), ('disappeared', 'O'), ('after', 'O'), ('stopping', 'O'), ('pegylated', 'O'), ('interferon', 'O'), ('alpha', 'O'), ('-', 'O'), ('2b', 'O'), ('and', 'O'), ('reappeared', 'O'), ('after', 'O'), ('restarting', 'O'), ('it', 'O'), ('.', 'O'))"
She had a complete sustained viral response .,"(('She', 'O'), ('had', 'O'), ('a', 'O'), ('complete', 'O'), ('sustained', 'O'), ('viral', 'O'), ('response', 'O'), ('.', 'O'))"
"Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease .","(('Phenobarbital', 'O'), ('(', 'O'), ('PB', 'O'), (')', 'O'), ('has', 'O'), ('a', 'O'), ('reputation', 'O'), ('for', 'O'), ('safety', 'O'), (',', 'O'), ('and', 'O'), ('it', 'O'), ('is', 'O'), ('commonly', 'O'), ('believed', 'O'), ('that', 'O'), ('PB', 'O'), ('-', 'O'), ('related', 'O'), ('increases', 'O'), ('in', 'O'), ('serum', 'O'), ('aminotransferase', 'O'), ('levels', 'O'), ('do', 'O'), ('not', 'O'), ('indicate', 'O'), ('or', 'O'), ('predict', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('significant', 'O'), ('chronic', 'B'), ('liver', 'I'), ('disease', 'I'), ('.', 'O'))"
Inflammatory reactions of internal and external hepatic biliary ducts were also seen .,"(('Inflammatory', 'O'), ('reactions', 'O'), ('of', 'O'), ('internal', 'O'), ('and', 'O'), ('external', 'O'), ('hepatic', 'O'), ('biliary', 'O'), ('ducts', 'O'), ('were', 'O'), ('also', 'O'), ('seen', 'O'), ('.', 'O'))"
"Our findings illustrate that PB may be associated with chronic liver damage , which may lead to more serious and deleterious consequences .","(('Our', 'O'), ('findings', 'O'), ('illustrate', 'O'), ('that', 'O'), ('PB', 'B'), ('may', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('chronic', 'B'), ('liver', 'I'), ('damage', 'I'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('lead', 'O'), ('to', 'O'), ('more', 'O'), ('serious', 'O'), ('and', 'O'), ('deleterious', 'O'), ('consequences', 'O'), ('.', 'O'))"
"For this reason , each clinician should recognize this entity in the differential diagnosis of PB - related asymptomatic chronic hepatic enzyme dysfunction .","(('For', 'O'), ('this', 'O'), ('reason', 'O'), (',', 'O'), ('each', 'O'), ('clinician', 'O'), ('should', 'O'), ('recognize', 'O'), ('this', 'O'), ('entity', 'O'), ('in', 'O'), ('the', 'O'), ('differential', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('PB', 'B'), ('-', 'O'), ('related', 'O'), ('asymptomatic', 'O'), ('chronic', 'B'), ('hepatic', 'I'), ('enzyme', 'I'), ('dysfunction', 'I'), ('.', 'O'))"
Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration .,"(('Recently', 'O'), ('published', 'O'), ('neuroimaging', 'O'), ('data', 'O'), ('suggest', 'O'), ('a', 'O'), ('common', 'O'), ('pathophysiology', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('variety', 'O'), ('of', 'O'), ('chemotherapy', 'O'), ('agents', 'O'), ('and', 'O'), ('modes', 'O'), ('of', 'O'), ('administration', 'O'), ('.', 'O'))"
We only included studies providing detailed neuroimaging data .,"(('We', 'O'), ('only', 'O'), ('included', 'O'), ('studies', 'O'), ('providing', 'O'), ('detailed', 'O'), ('neuroimaging', 'O'), ('data', 'O'), ('.', 'O'))"
"RESULTS : We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .","(('RESULTS', 'O'), (':', 'O'), ('We', 'O'), ('identified', 'O'), ('27', 'O'), ('reports', 'O'), ('of', 'O'), ('toxic', 'B'), ('leukoencephalopathy', 'I'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('methotrexate', 'O'), ('(', 'O'), ('intrathecal', 'O'), (',', 'O'), ('systemic', 'O'), (')', 'O'), (',', 'O'), ('5', 'O'), ('-', 'O'), ('fluorouracil', 'O'), ('and', 'O'), ('its', 'O'), ('derivative', 'O'), ('carmofur', 'O'), (',', 'O'), ('and', 'O'), ('capecitabine', 'O'), ('.', 'O'))"
Lesions exceeded the confines of adjacent vascular territories .,"(('Lesions', 'O'), ('exceeded', 'O'), ('the', 'O'), ('confines', 'O'), ('of', 'O'), ('adjacent', 'O'), ('vascular', 'O'), ('territories', 'O'), ('.', 'O'))"
Complete resolution of symptoms within 1 - 4 days was accompanied by normalisation of ADC abnormalities .,"(('Complete', 'O'), ('resolution', 'O'), ('of', 'O'), ('symptoms', 'O'), ('within', 'O'), ('1', 'O'), ('-', 'O'), ('4', 'O'), ('days', 'O'), ('was', 'O'), ('accompanied', 'O'), ('by', 'O'), ('normalisation', 'O'), ('of', 'O'), ('ADC', 'B'), ('abnormalities', 'I'), ('.', 'O'))"
"However , fluid attenuated inversion recovery ( FLAIR ) sequences frequently revealed persistent white matter abnormalities .","(('However', 'O'), (',', 'O'), ('fluid', 'O'), ('attenuated', 'O'), ('inversion', 'O'), ('recovery', 'O'), ('(', 'O'), ('FLAIR', 'O'), (')', 'O'), ('sequences', 'O'), ('frequently', 'O'), ('revealed', 'O'), ('persistent', 'O'), ('white', 'B'), ('matter', 'I'), ('abnormalities', 'I'), ('.', 'O'))"
CONCLUSIONS : Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Several', 'O'), ('pathophysiological', 'O'), ('models', 'O'), ('of', 'O'), ('delayed', 'B'), ('leukoencephalopathy', 'I'), ('after', 'O'), ('exposure', 'O'), ('to', 'O'), ('intrathecal', 'O'), ('or', 'O'), ('systemic', 'O'), ('chemotherapy', 'O'), ('have', 'O'), ('been', 'O'), ('proposed', 'O'), ('.', 'O'))"
RATIONALE : Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women .,"(('RATIONALE', 'O'), (':', 'O'), ('Fluoxetine', 'O'), ('is', 'O'), ('a', 'O'), ('selective', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('inhibitor', 'O'), ('antidepressant', 'O'), ('widely', 'O'), ('used', 'O'), ('by', 'O'), ('pregnant', 'O'), ('women', 'O'), ('.', 'O'))"
OBJECTIVES : To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate .,"(('OBJECTIVES', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('the', 'O'), ('fluoxetine', 'O'), ('effect', 'O'), ('on', 'O'), ('fetal', 'O'), ('rat', 'O'), ('pulmonary', 'O'), ('vascular', 'O'), ('smooth', 'O'), ('muscle', 'O'), ('mechanical', 'O'), ('properties', 'O'), ('and', 'O'), ('cell', 'O'), ('proliferation', 'O'), ('rate', 'O'), ('.', 'O'))"
METHODS : Pregnant rats were treated with fluoxetine ( 10 mg / kg ) from Day 11 through Day 21 of gestation .,"(('METHODS', 'O'), (':', 'O'), ('Pregnant', 'O'), ('rats', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('fluoxetine', 'O'), ('(', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('from', 'O'), ('Day', 'O'), ('11', 'O'), ('through', 'O'), ('Day', 'O'), ('21', 'O'), ('of', 'O'), ('gestation', 'O'), ('.', 'O'))"
MEASUREMENTS AND MAIN RESULTS : Fetuses were delivered by cesarean section .,"(('MEASUREMENTS', 'O'), ('AND', 'O'), ('MAIN', 'O'), ('RESULTS', 'O'), (':', 'O'), ('Fetuses', 'O'), ('were', 'O'), ('delivered', 'O'), ('by', 'O'), ('cesarean', 'O'), ('section', 'O'), ('.', 'O'))"
"Postnatal mortality was increased among experimental animals , and arterial oxygen saturation was 96 + / - 1 % in 1 - day - old control animals and significantly lower ( P < 0 . 01 ) in fluoxetine - exposed pups ( 79 + / - 2 % ) .","(('Postnatal', 'O'), ('mortality', 'O'), ('was', 'O'), ('increased', 'O'), ('among', 'O'), ('experimental', 'O'), ('animals', 'O'), (',', 'O'), ('and', 'O'), ('arterial', 'O'), ('oxygen', 'O'), ('saturation', 'O'), ('was', 'O'), ('96', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('%', 'O'), ('in', 'O'), ('1', 'O'), ('-', 'O'), ('day', 'O'), ('-', 'O'), ('old', 'O'), ('control', 'O'), ('animals', 'O'), ('and', 'O'), ('significantly', 'O'), ('lower', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('in', 'O'), ('fluoxetine', 'O'), ('-', 'O'), ('exposed', 'O'), ('pups', 'O'), ('(', 'O'), ('79', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
"In vitro , fluoxetine induced pulmonary arterial muscle contraction in fetal , but not adult , animals ( P < 0 . 01 ) and reduced serotonin - induced contraction at both ages ( P < 0 . 01 ) .","(('In', 'O'), ('vitro', 'O'), (',', 'O'), ('fluoxetine', 'O'), ('induced', 'O'), ('pulmonary', 'O'), ('arterial', 'O'), ('muscle', 'O'), ('contraction', 'O'), ('in', 'O'), ('fetal', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('adult', 'O'), (',', 'O'), ('animals', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('and', 'O'), ('reduced', 'O'), ('serotonin', 'O'), ('-', 'O'), ('induced', 'O'), ('contraction', 'O'), ('at', 'O'), ('both', 'O'), ('ages', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal , but not adult , cells ( P < 0 . 01 ) .","(('After', 'O'), ('in', 'O'), ('utero', 'O'), ('exposure', 'O'), ('to', 'O'), ('a', 'O'), ('low', 'O'), ('fluoxetine', 'O'), ('concentration', 'O'), ('the', 'O'), ('pulmonary', 'O'), ('arterial', 'O'), ('smooth', 'O'), ('muscle', 'O'), ('cell', 'O'), ('proliferation', 'O'), ('rate', 'O'), ('was', 'O'), ('significantly', 'O'), ('increased', 'O'), ('in', 'O'), ('fetal', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('adult', 'O'), (',', 'O'), ('cells', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
Disulfiram - induced transient optic and peripheral neuropathy : a case report .,"(('Disulfiram', 'O'), ('-', 'O'), ('induced', 'O'), ('transient', 'O'), ('optic', 'B'), ('and', 'I'), ('peripheral', 'I'), ('neuropathy', 'I'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
MATERIALS AND METHODS : A case report .,"(('MATERIALS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('A', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
"His vision was 6 / 15 and 2 / 60 in the right and left eyes , respectively .","(('His', 'O'), ('vision', 'O'), ('was', 'O'), ('6', 'O'), ('/', 'O'), ('15', 'O'), ('and', 'O'), ('2', 'O'), ('/', 'O'), ('60', 'O'), ('in', 'O'), ('the', 'O'), ('right', 'O'), ('and', 'O'), ('left', 'O'), ('eyes', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
Fundoscopy revealed bilaterally swollen optic nerve heads .,"(('Fundoscopy', 'O'), ('revealed', 'O'), ('bilaterally', 'O'), ('swollen', 'O'), ('optic', 'O'), ('nerve', 'O'), ('heads', 'O'), ('.', 'O'))"
Disulfiram discontinuation lead to an immediate symptomatic improvement .,"(('Disulfiram', 'O'), ('discontinuation', 'O'), ('lead', 'O'), ('to', 'O'), ('an', 'O'), ('immediate', 'O'), ('symptomatic', 'O'), ('improvement', 'O'), ('.', 'O'))"
CONCLUSION : Physicians initiating long - term disulfiram therapy should be aware of these adverse effects .,"(('CONCLUSION', 'O'), (':', 'O'), ('Physicians', 'O'), ('initiating', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('disulfiram', 'O'), ('therapy', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('these', 'O'), ('adverse', 'O'), ('effects', 'O'), ('.', 'O'))"
They should recommend annual ophthalmic reviews with visual field testing .,"(('They', 'O'), ('should', 'O'), ('recommend', 'O'), ('annual', 'O'), ('ophthalmic', 'O'), ('reviews', 'O'), ('with', 'O'), ('visual', 'O'), ('field', 'O'), ('testing', 'O'), ('.', 'O'))"
Patients should be reassured with respect to the reversibility of these adverse effects .,"(('Patients', 'O'), ('should', 'O'), ('be', 'O'), ('reassured', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('the', 'O'), ('reversibility', 'O'), ('of', 'O'), ('these', 'O'), ('adverse', 'O'), ('effects', 'O'), ('.', 'O'))"
Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants .,"(('Intraocular', 'O'), ('pressure', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('uveitis', 'B'), ('treated', 'O'), ('with', 'O'), ('fluocinolone', 'O'), ('acetonide', 'O'), ('implants', 'O'), ('.', 'O'))"
"DESIGN : Pooled data from 3 multicenter , double - masked , randomized , controlled , phase 2b / 3 clinical trials evaluating the safety and efficacy of the 0 . 59 - mg or 2 . 1 - mg FA intravitreal implant or standard therapy were analyzed .","(('DESIGN', 'O'), (':', 'O'), ('Pooled', 'O'), ('data', 'O'), ('from', 'O'), ('3', 'O'), ('multicenter', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('masked', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('controlled', 'O'), (',', 'O'), ('phase', 'O'), ('2b', 'O'), ('/', 'O'), ('3', 'O'), ('clinical', 'O'), ('trials', 'O'), ('evaluating', 'O'), ('the', 'O'), ('safety', 'O'), ('and', 'O'), ('efficacy', 'O'), ('of', 'O'), ('the', 'O'), ('0', 'O'), ('.', 'O'), ('59', 'O'), ('-', 'O'), ('mg', 'O'), ('or', 'O'), ('2', 'O'), ('.', 'O'), ('1', 'O'), ('-', 'O'), ('mg', 'O'), ('FA', 'O'), ('intravitreal', 'O'), ('implant', 'O'), ('or', 'O'), ('standard', 'O'), ('therapy', 'O'), ('were', 'O'), ('analyzed', 'O'), ('.', 'O'))"
"RESULTS : During the 3 - year follow - up , 71 . 0 % of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55 . 1 % , 24 . 7 % , and 6 . 2 % of eyes reached an IOP of 30 mm Hg or more , 40 mm Hg or more , and 50 mm Hg or more , respectively .","(('RESULTS', 'O'), (':', 'O'), ('During', 'O'), ('the', 'O'), ('3', 'O'), ('-', 'O'), ('year', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), (',', 'O'), ('71', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('of', 'O'), ('implanted', 'O'), ('eyes', 'O'), ('had', 'O'), ('an', 'O'), ('IOP', 'O'), ('increase', 'O'), ('of', 'O'), ('10', 'O'), ('mm', 'O'), ('Hg', 'O'), ('or', 'O'), ('more', 'O'), ('than', 'O'), ('baseline', 'O'), ('and', 'O'), ('55', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), (',', 'O'), ('24', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), (',', 'O'), ('and', 'O'), ('6', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('of', 'O'), ('eyes', 'O'), ('reached', 'O'), ('an', 'O'), ('IOP', 'O'), ('of', 'O'), ('30', 'O'), ('mm', 'O'), ('Hg', 'O'), ('or', 'O'), ('more', 'O'), (',', 'O'), ('40', 'O'), ('mm', 'O'), ('Hg', 'O'), ('or', 'O'), ('more', 'O'), (',', 'O'), ('and', 'O'), ('50', 'O'), ('mm', 'O'), ('Hg', 'O'), ('or', 'O'), ('more', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Topical IOP - lowering medication was administered in 74 . 8 % of implanted eyes , and IOP - lowering surgeries , most of which were trabeculectomies ( 76 . 2 % ) , were performed on 36 . 6 % of implanted eyes .","(('Topical', 'O'), ('IOP', 'O'), ('-', 'O'), ('lowering', 'O'), ('medication', 'O'), ('was', 'O'), ('administered', 'O'), ('in', 'O'), ('74', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('of', 'O'), ('implanted', 'O'), ('eyes', 'O'), (',', 'O'), ('and', 'O'), ('IOP', 'O'), ('-', 'O'), ('lowering', 'O'), ('surgeries', 'O'), (',', 'O'), ('most', 'O'), ('of', 'O'), ('which', 'O'), ('were', 'O'), ('trabeculectomies', 'O'), ('(', 'O'), ('76', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('were', 'O'), ('performed', 'O'), ('on', 'O'), ('36', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('of', 'O'), ('implanted', 'O'), ('eyes', 'O'), ('.', 'O'))"
Intraocular pressure - lowering surgeries were considered a success ( postoperative IOP of 6 - 21 mm Hg with or without additional IOP - lowering medication ) in 85 . 1 % of eyes at 1 year .,"(('Intraocular', 'O'), ('pressure', 'O'), ('-', 'O'), ('lowering', 'O'), ('surgeries', 'O'), ('were', 'O'), ('considered', 'O'), ('a', 'O'), ('success', 'O'), ('(', 'O'), ('postoperative', 'O'), ('IOP', 'O'), ('of', 'O'), ('6', 'O'), ('-', 'O'), ('21', 'O'), ('mm', 'O'), ('Hg', 'O'), ('with', 'O'), ('or', 'O'), ('without', 'O'), ('additional', 'O'), ('IOP', 'O'), ('-', 'O'), ('lowering', 'O'), ('medication', 'O'), (')', 'O'), ('in', 'O'), ('85', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('eyes', 'O'), ('at', 'O'), ('1', 'O'), ('year', 'O'), ('.', 'O'))"
CONCLUSION : Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery .,"(('CONCLUSION', 'O'), (':', 'O'), ('Elevated', 'O'), ('IOP', 'O'), ('is', 'O'), ('a', 'O'), ('significant', 'O'), ('complication', 'O'), ('with', 'O'), ('the', 'O'), ('FA', 'O'), ('intravitreal', 'O'), ('implant', 'O'), ('but', 'O'), ('may', 'O'), ('be', 'O'), ('controlled', 'O'), ('with', 'O'), ('medication', 'O'), ('and', 'O'), ('surgery', 'O'), ('.', 'O'))"
Myocardial Fas ligand expression increases susceptibility to AZT - induced cardiomyopathy .,"(('Myocardial', 'O'), ('Fas', 'O'), ('ligand', 'O'), ('expression', 'O'), ('increases', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('AZT', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
"of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .","(('of', 'O'), ('AZT', 'O'), ('(', 'O'), ('0', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('07', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), (',', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'), ('7', 'O'), ('mg', 'O'), ('/', 'O'), ('ml', 'O'), (')', 'O'), ('.', 'O'))"
"After 6 weeks , cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods .","(('After', 'O'), ('6', 'O'), ('weeks', 'O'), (',', 'O'), ('cardiac', 'O'), ('function', 'O'), ('was', 'O'), ('assessed', 'O'), ('by', 'O'), ('echocardiography', 'O'), ('and', 'O'), ('morphology', 'O'), ('was', 'O'), ('assessed', 'O'), ('by', 'O'), ('histopathologic', 'O'), ('and', 'O'), ('immunohistochemical', 'O'), ('methods', 'O'), ('.', 'O'))"
NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function .,"(('NTg', 'O'), ('and', 'O'), ('untreated', 'O'), ('FasL', 'O'), ('Tg', 'O'), ('mice', 'O'), ('showed', 'O'), ('little', 'O'), ('or', 'O'), ('no', 'O'), ('change', 'O'), ('in', 'O'), ('cardiac', 'O'), ('structure', 'O'), ('or', 'O'), ('function', 'O'), ('.', 'O'))"
"These changes were associated with an increased sarcolemmal expression of Fas and FasL , as well as increased activation of caspase 3 , translocation of calpain 1 to the sarcolemma and sarcomere , and increased numbers of cells undergoing apoptosis .","(('These', 'O'), ('changes', 'O'), ('were', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('sarcolemmal', 'O'), ('expression', 'O'), ('of', 'O'), ('Fas', 'O'), ('and', 'O'), ('FasL', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('increased', 'O'), ('activation', 'O'), ('of', 'O'), ('caspase', 'O'), ('3', 'O'), (',', 'O'), ('translocation', 'O'), ('of', 'O'), ('calpain', 'O'), ('1', 'O'), ('to', 'O'), ('the', 'O'), ('sarcolemma', 'O'), ('and', 'O'), ('sarcomere', 'O'), (',', 'O'), ('and', 'O'), ('increased', 'O'), ('numbers', 'O'), ('of', 'O'), ('cells', 'O'), ('undergoing', 'O'), ('apoptosis', 'O'), ('.', 'O'))"
"These were associated with changes in dystrophin and cardiac troponin I localization , as well as loss of sarcolemmal integrity .","(('These', 'O'), ('were', 'O'), ('associated', 'O'), ('with', 'O'), ('changes', 'O'), ('in', 'O'), ('dystrophin', 'O'), ('and', 'O'), ('cardiac', 'O'), ('troponin', 'O'), ('I', 'O'), ('localization', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('loss', 'O'), ('of', 'O'), ('sarcolemmal', 'O'), ('integrity', 'O'), ('.', 'O'))"
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .,"(('Gastrointestinal', 'O'), ('tolerability', 'O'), ('of', 'O'), ('etoricoxib', 'O'), ('in', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('patients', 'O'), (':', 'O'), ('results', 'O'), ('of', 'O'), ('the', 'O'), ('etoricoxib', 'O'), ('vs', 'O'), ('diclofenac', 'O'), ('sodium', 'O'), ('gastrointestinal', 'O'), ('tolerability', 'O'), ('and', 'O'), ('effectiveness', 'O'), ('trial', 'O'), ('(', 'O'), ('EDGE', 'O'), ('-', 'O'), ('II', 'O'), (')', 'O'), ('.', 'O'))"
Use of gastroprotective agents and low - dose aspirin was allowed .,"(('Use', 'O'), ('of', 'O'), ('gastroprotective', 'O'), ('agents', 'O'), ('and', 'O'), ('low', 'O'), ('-', 'O'), ('dose', 'O'), ('aspirin', 'O'), ('was', 'O'), ('allowed', 'O'), ('.', 'O'))"
The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences ( AEs ) .,"(('The', 'O'), ('prespecified', 'O'), ('primary', 'O'), ('end', 'O'), ('point', 'O'), ('consisted', 'O'), ('of', 'O'), ('the', 'O'), ('cumulative', 'O'), ('rate', 'O'), ('of', 'O'), ('patient', 'O'), ('discontinuations', 'O'), ('due', 'O'), ('to', 'O'), ('clinical', 'O'), ('and', 'O'), ('laboratory', 'O'), ('GI', 'O'), ('adverse', 'O'), ('experiences', 'O'), ('(', 'O'), ('AEs', 'O'), (')', 'O'), ('.', 'O'))"
Efficacy was evaluated using the Patient Global Assessment of Disease Status ( PGADS ; 0 - 4 point scale ) .,"(('Efficacy', 'O'), ('was', 'O'), ('evaluated', 'O'), ('using', 'O'), ('the', 'O'), ('Patient', 'O'), ('Global', 'O'), ('Assessment', 'O'), ('of', 'O'), ('Disease', 'O'), ('Status', 'O'), ('(', 'O'), ('PGADS', 'O'), (';', 'O'), ('0', 'O'), ('-', 'O'), ('4', 'O'), ('point', 'O'), ('scale', 'O'), (')', 'O'), ('.', 'O'))"
"RESULTS : Mean ( SD ; maximum ) duration of treatment was 19 . 3 ( 10 . 3 ; 32 . 9 ) and 19 . 1 ( 10 . 4 ; 33 . 1 ) months in the etoricoxib and diclofenac groups , respectively .","(('RESULTS', 'O'), (':', 'O'), ('Mean', 'O'), ('(', 'O'), ('SD', 'O'), (';', 'O'), ('maximum', 'O'), (')', 'O'), ('duration', 'O'), ('of', 'O'), ('treatment', 'O'), ('was', 'O'), ('19', 'O'), ('.', 'O'), ('3', 'O'), ('(', 'O'), ('10', 'O'), ('.', 'O'), ('3', 'O'), (';', 'O'), ('32', 'O'), ('.', 'O'), ('9', 'O'), (')', 'O'), ('and', 'O'), ('19', 'O'), ('.', 'O'), ('1', 'O'), ('(', 'O'), ('10', 'O'), ('.', 'O'), ('4', 'O'), (';', 'O'), ('33', 'O'), ('.', 'O'), ('1', 'O'), (')', 'O'), ('months', 'O'), ('in', 'O'), ('the', 'O'), ('etoricoxib', 'O'), ('and', 'O'), ('diclofenac', 'O'), ('groups', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Etoricoxib and diclofenac treatment resulted in similar efficacy ( PGADS mean changes from baseline - 0 . 62 vs - 0 . 58 , respectively ) .","(('Etoricoxib', 'O'), ('and', 'O'), ('diclofenac', 'O'), ('treatment', 'O'), ('resulted', 'O'), ('in', 'O'), ('similar', 'O'), ('efficacy', 'O'), ('(', 'O'), ('PGADS', 'O'), ('mean', 'O'), ('changes', 'O'), ('from', 'O'), ('baseline', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('62', 'O'), ('vs', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('58', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O'))"
Anxiogenic potential of ciprofloxacin and norfloxacin in rats .,"(('Anxiogenic', 'O'), ('potential', 'O'), ('of', 'O'), ('ciprofloxacin', 'O'), ('and', 'O'), ('norfloxacin', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"INTRODUCTION : The possible anxiogenic effects of fluoroquinolones , namely ciprofloxacin and norfloxacin , were investigated in adult Charles Foster albino rats of either sex , weighing 150 - 200 g .","(('INTRODUCTION', 'O'), (':', 'O'), ('The', 'O'), ('possible', 'O'), ('anxiogenic', 'O'), ('effects', 'O'), ('of', 'O'), ('fluoroquinolones', 'O'), (',', 'O'), ('namely', 'O'), ('ciprofloxacin', 'O'), ('and', 'O'), ('norfloxacin', 'O'), (',', 'O'), ('were', 'O'), ('investigated', 'O'), ('in', 'O'), ('adult', 'O'), ('Charles', 'O'), ('Foster', 'O'), ('albino', 'O'), ('rats', 'O'), ('of', 'O'), ('either', 'O'), ('sex', 'O'), (',', 'O'), ('weighing', 'O'), ('150', 'O'), ('-', 'O'), ('200', 'O'), ('g', 'O'), ('.', 'O'))"
"METHODS : The drugs were given orally , in doses of 50 mg / kg for five consecutive days and the experiments were performed on the fifth day .","(('METHODS', 'O'), (':', 'O'), ('The', 'O'), ('drugs', 'O'), ('were', 'O'), ('given', 'O'), ('orally', 'O'), (',', 'O'), ('in', 'O'), ('doses', 'O'), ('of', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('for', 'O'), ('five', 'O'), ('consecutive', 'O'), ('days', 'O'), ('and', 'O'), ('the', 'O'), ('experiments', 'O'), ('were', 'O'), ('performed', 'O'), ('on', 'O'), ('the', 'O'), ('fifth', 'O'), ('day', 'O'), ('.', 'O'))"
"The tests included open - field exploratory behaviour , elevated plus maze and elevated zero maze , social interaction and novelty - suppressed feeding latency behaviour .","(('The', 'O'), ('tests', 'O'), ('included', 'O'), ('open', 'O'), ('-', 'O'), ('field', 'O'), ('exploratory', 'O'), ('behaviour', 'O'), (',', 'O'), ('elevated', 'O'), ('plus', 'O'), ('maze', 'O'), ('and', 'O'), ('elevated', 'O'), ('zero', 'O'), ('maze', 'O'), (',', 'O'), ('social', 'O'), ('interaction', 'O'), ('and', 'O'), ('novelty', 'O'), ('-', 'O'), ('suppressed', 'O'), ('feeding', 'O'), ('latency', 'O'), ('behaviour', 'O'), ('.', 'O'))"
"However , ciprofloxacin - and norfloxacin - treated rats did not differ significantly from each other in various behavioural parameters .","(('However', 'O'), (',', 'O'), ('ciprofloxacin', 'O'), ('-', 'O'), ('and', 'O'), ('norfloxacin', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('did', 'O'), ('not', 'O'), ('differ', 'O'), ('significantly', 'O'), ('from', 'O'), ('each', 'O'), ('other', 'O'), ('in', 'O'), ('various', 'O'), ('behavioural', 'O'), ('parameters', 'O'), ('.', 'O'))"
CONCLUSION : The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin .,"(('CONCLUSION', 'O'), (':', 'O'), ('The', 'O'), ('present', 'O'), ('experimental', 'O'), ('findings', 'O'), ('substantiate', 'O'), ('the', 'O'), ('clinically', 'O'), ('observed', 'O'), ('anxiogenic', 'O'), ('potential', 'O'), ('of', 'O'), ('ciprofloxacin', 'O'), ('and', 'O'), ('norfloxacin', 'O'), ('.', 'O'))"
"METHODS : A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline ( control ) or remifentanil to a target Ce of 2 ng ml ( - 1 ) ( R2 ) , 4 ng ml ( - 1 ) ( R4 ) , or 6 ng ml ( - 1 ) ( R6 ) administered via TCI .","(('METHODS', 'O'), (':', 'O'), ('A', 'O'), ('total', 'O'), ('of', 'O'), ('128', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('general', 'O'), ('surgery', 'O'), ('were', 'O'), ('randomly', 'O'), ('allocated', 'O'), ('to', 'O'), ('receive', 'O'), ('normal', 'O'), ('saline', 'O'), ('(', 'O'), ('control', 'O'), (')', 'O'), ('or', 'O'), ('remifentanil', 'O'), ('to', 'O'), ('a', 'O'), ('target', 'O'), ('Ce', 'O'), ('of', 'O'), ('2', 'O'), ('ng', 'O'), ('ml', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('(', 'O'), ('R2', 'O'), (')', 'O'), (',', 'O'), ('4', 'O'), ('ng', 'O'), ('ml', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('(', 'O'), ('R4', 'O'), (')', 'O'), (',', 'O'), ('or', 'O'), ('6', 'O'), ('ng', 'O'), ('ml', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('(', 'O'), ('R6', 'O'), (')', 'O'), ('administered', 'O'), ('via', 'O'), ('TCI', 'O'), ('.', 'O'))"
"After the target Ce was achieved , the infusion of propofol was started .","(('After', 'O'), ('the', 'O'), ('target', 'O'), ('Ce', 'O'), ('was', 'O'), ('achieved', 'O'), (',', 'O'), ('the', 'O'), ('infusion', 'O'), ('of', 'O'), ('propofol', 'O'), ('was', 'O'), ('started', 'O'), ('.', 'O'))"
No significant complications were observed during the study .,"(('No', 'O'), ('significant', 'O'), ('complications', 'O'), ('were', 'O'), ('observed', 'O'), ('during', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
Dexmedetomidine and cardiac protection for non - cardiac surgery : a meta - analysis of randomised controlled trials .,"(('Dexmedetomidine', 'O'), ('and', 'O'), ('cardiac', 'O'), ('protection', 'O'), ('for', 'O'), ('non', 'B'), ('-', 'I'), ('cardiac', 'I'), ('surgery', 'I'), (':', 'O'), ('a', 'O'), ('meta', 'O'), ('-', 'O'), ('analysis', 'O'), ('of', 'O'), ('randomised', 'O'), ('controlled', 'O'), ('trials', 'O'), ('.', 'O'))"
We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non - cardiac surgery .,"(('We', 'O'), ('conducted', 'O'), ('a', 'O'), ('systematic', 'O'), ('review', 'O'), ('of', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('dexmedetomidine', 'O'), ('on', 'O'), ('cardiac', 'O'), ('outcomes', 'O'), ('following', 'O'), ('non', 'B'), ('-', 'I'), ('cardiac', 'I'), ('surgery', 'I'), ('.', 'O'))"
"We included prospective , randomised peri - operative studies of dexmedetomidine that reported mortality , cardiac morbidity or adverse drug events .","(('We', 'O'), ('included', 'O'), ('prospective', 'O'), (',', 'O'), ('randomised', 'O'), ('peri', 'O'), ('-', 'O'), ('operative', 'O'), ('studies', 'O'), ('of', 'O'), ('dexmedetomidine', 'O'), ('that', 'O'), ('reported', 'O'), ('mortality', 'O'), (',', 'O'), ('cardiac', 'B'), ('morbidity', 'O'), ('or', 'O'), ('adverse', 'O'), ('drug', 'O'), ('events', 'O'), ('.', 'O'))"
A PubMed Central and EMBASE search was conducted up to July 2007 .,"(('A', 'O'), ('PubMed', 'O'), ('Central', 'O'), ('and', 'O'), ('EMBASE', 'O'), ('search', 'O'), ('was', 'O'), ('conducted', 'O'), ('up', 'O'), ('to', 'O'), ('July', 'O'), ('2007', 'O'), ('.', 'O'))"
The reference lists of identified papers were examined for further trials .,"(('The', 'O'), ('reference', 'O'), ('lists', 'O'), ('of', 'O'), ('identified', 'O'), ('papers', 'O'), ('were', 'O'), ('examined', 'O'), ('for', 'O'), ('further', 'O'), ('trials', 'O'), ('.', 'O'))"
"Of 425 studies identified , 20 were included in the meta - analysis ( 840 patients ) .","(('Of', 'O'), ('425', 'O'), ('studies', 'O'), ('identified', 'O'), (',', 'O'), ('20', 'O'), ('were', 'O'), ('included', 'O'), ('in', 'O'), ('the', 'O'), ('meta', 'O'), ('-', 'O'), ('analysis', 'O'), ('(', 'O'), ('840', 'O'), ('patients', 'O'), (')', 'O'), ('.', 'O'))"
A randomised placebo - controlled trial of dexmedetomidine is warranted .,"(('A', 'O'), ('randomised', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('trial', 'O'), ('of', 'O'), ('dexmedetomidine', 'O'), ('is', 'O'), ('warranted', 'O'), ('.', 'O'))"
BACKGROUND : Clomiphene citrate ( CC ) is commonly prescribed for ovulation induction .,"(('BACKGROUND', 'O'), (':', 'O'), ('Clomiphene', 'O'), ('citrate', 'O'), ('(', 'O'), ('CC', 'O'), (')', 'O'), ('is', 'O'), ('commonly', 'O'), ('prescribed', 'O'), ('for', 'O'), ('ovulation', 'O'), ('induction', 'O'), ('.', 'O'))"
"It is considered safe , with minimal side effects .","(('It', 'O'), ('is', 'O'), ('considered', 'O'), ('safe', 'O'), (',', 'O'), ('with', 'O'), ('minimal', 'O'), ('side', 'O'), ('effects', 'O'), ('.', 'O'))"
Cardiac enzymes showed a peak rise in troponin I to 9 . 10 ng / mL .,"(('Cardiac', 'O'), ('enzymes', 'O'), ('showed', 'O'), ('a', 'O'), ('peak', 'O'), ('rise', 'O'), ('in', 'O'), ('troponin', 'O'), ('I', 'O'), ('to', 'O'), ('9', 'O'), ('.', 'O'), ('10', 'O'), ('ng', 'O'), ('/', 'O'), ('mL', 'O'), ('.', 'O'))"
An initial exercise stress test was normal .,"(('An', 'O'), ('initial', 'O'), ('exercise', 'O'), ('stress', 'O'), ('test', 'O'), ('was', 'O'), ('normal', 'O'), ('.', 'O'))"
"At the time of admission , the patient was at high risk of radiation injury to the fetus , so a coronary angiogram was postponed until the second trimester .","(('At', 'O'), ('the', 'O'), ('time', 'O'), ('of', 'O'), ('admission', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('was', 'O'), ('at', 'O'), ('high', 'O'), ('risk', 'O'), ('of', 'O'), ('radiation', 'O'), ('injury', 'O'), ('to', 'O'), ('the', 'O'), ('fetus', 'O'), (',', 'O'), ('so', 'O'), ('a', 'O'), ('coronary', 'O'), ('angiogram', 'O'), ('was', 'O'), ('postponed', 'O'), ('until', 'O'), ('the', 'O'), ('second', 'O'), ('trimester', 'O'), ('.', 'O'))"
It showed normal coronary vessels .,"(('It', 'O'), ('showed', 'O'), ('normal', 'O'), ('coronary', 'O'), ('vessels', 'O'), ('.', 'O'))"
"Given this life - threatening complication , appropriate prophylactic measures should be used in high - risk woman undergoing ovarian stimulation .","(('Given', 'O'), ('this', 'O'), ('life', 'O'), ('-', 'O'), ('threatening', 'O'), ('complication', 'O'), (',', 'O'), ('appropriate', 'O'), ('prophylactic', 'O'), ('measures', 'O'), ('should', 'O'), ('be', 'O'), ('used', 'O'), ('in', 'O'), ('high', 'O'), ('-', 'O'), ('risk', 'O'), ('woman', 'O'), ('undergoing', 'O'), ('ovarian', 'O'), ('stimulation', 'O'), ('.', 'O'))"
Many variations of this syndrome have been recently described in the literature .,"(('Many', 'O'), ('variations', 'O'), ('of', 'O'), ('this', 'O'), ('syndrome', 'O'), ('have', 'O'), ('been', 'O'), ('recently', 'O'), ('described', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
This report is followed by review of the literature .,"(('This', 'O'), ('report', 'O'), ('is', 'O'), ('followed', 'O'), ('by', 'O'), ('review', 'O'), ('of', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
Patients were treated with oral FDC of T + A or A QD before breakfast for 12 weeks ; blood pressure ( BP ) and heart rate were measured in the sitting position .,"(('Patients', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('oral', 'O'), ('FDC', 'O'), ('of', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), ('or', 'O'), ('A', 'O'), ('QD', 'O'), ('before', 'O'), ('breakfast', 'O'), ('for', 'O'), ('12', 'O'), ('weeks', 'O'), (';', 'O'), ('blood', 'O'), ('pressure', 'O'), ('(', 'O'), ('BP', 'O'), (')', 'O'), ('and', 'O'), ('heart', 'O'), ('rate', 'O'), ('were', 'O'), ('measured', 'O'), ('in', 'O'), ('the', 'O'), ('sitting', 'O'), ('position', 'O'), ('.', 'O'))"
"Primary efficacy end points were reduction in clinical systolic BP ( SBP ) / diastolic BP ( DBP ) from baseline to study end and number of responders ( ie , patients who achieved target SBP / DBP < 130 / < 80 mm Hg ) at end of study .","(('Primary', 'O'), ('efficacy', 'O'), ('end', 'O'), ('points', 'O'), ('were', 'O'), ('reduction', 'O'), ('in', 'O'), ('clinical', 'O'), ('systolic', 'O'), ('BP', 'O'), ('(', 'O'), ('SBP', 'O'), (')', 'O'), ('/', 'O'), ('diastolic', 'O'), ('BP', 'O'), ('(', 'O'), ('DBP', 'O'), (')', 'O'), ('from', 'O'), ('baseline', 'O'), ('to', 'O'), ('study', 'O'), ('end', 'O'), ('and', 'O'), ('number', 'O'), ('of', 'O'), ('responders', 'O'), ('(', 'O'), ('ie', 'O'), (',', 'O'), ('patients', 'O'), ('who', 'O'), ('achieved', 'O'), ('target', 'O'), ('SBP', 'O'), ('/', 'O'), ('DBP', 'O'), ('<', 'O'), ('130', 'O'), ('/', 'O'), ('<', 'O'), ('80', 'O'), ('mm', 'O'), ('Hg', 'O'), (')', 'O'), ('at', 'O'), ('end', 'O'), ('of', 'O'), ('study', 'O'), ('.', 'O'))"
"Tolerability was assessed by treatment - emergent adverse events , identified using physical examination , laboratory analysis , and electrocardiography .","(('Tolerability', 'O'), ('was', 'O'), ('assessed', 'O'), ('by', 'O'), ('treatment', 'O'), ('-', 'O'), ('emergent', 'O'), ('adverse', 'O'), ('events', 'O'), (',', 'O'), ('identified', 'O'), ('using', 'O'), ('physical', 'O'), ('examination', 'O'), (',', 'O'), ('laboratory', 'O'), ('analysis', 'O'), (',', 'O'), ('and', 'O'), ('electrocardiography', 'O'), ('.', 'O'))"
"RESULTS : A total of 210 patients were enrolled in the study ; 203 patients ( 143 men , 60 women ) completed the study while 7 were lost to follow - up ( 4 patients in the T + A group and 3 in the A group ) and considered with - drawn .","(('RESULTS', 'O'), (':', 'O'), ('A', 'O'), ('total', 'O'), ('of', 'O'), ('210', 'O'), ('patients', 'O'), ('were', 'O'), ('enrolled', 'O'), ('in', 'O'), ('the', 'O'), ('study', 'O'), (';', 'O'), ('203', 'O'), ('patients', 'O'), ('(', 'O'), ('143', 'O'), ('men', 'O'), (',', 'O'), ('60', 'O'), ('women', 'O'), (')', 'O'), ('completed', 'O'), ('the', 'O'), ('study', 'O'), ('while', 'O'), ('7', 'O'), ('were', 'O'), ('lost', 'O'), ('to', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('(', 'O'), ('4', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), ('group', 'O'), ('and', 'O'), ('3', 'O'), ('in', 'O'), ('the', 'O'), ('A', 'O'), ('group', 'O'), (')', 'O'), ('and', 'O'), ('considered', 'O'), ('with', 'O'), ('-', 'O'), ('drawn', 'O'), ('.', 'O'))"
"At study end , statistically significant percentage reductions from baseline within groups and between groups were observed in SBP ( T + A [ - 27 . 4 % ] ; A [ - 16 . 6 % ] ) and DBP ( T + A [ - 20 . 1 % ] ; A [ - 13 . 3 % ] ) ( all , P < 0 . 05 ) .","(('At', 'O'), ('study', 'O'), ('end', 'O'), (',', 'O'), ('statistically', 'O'), ('significant', 'O'), ('percentage', 'O'), ('reductions', 'O'), ('from', 'O'), ('baseline', 'O'), ('within', 'O'), ('groups', 'O'), ('and', 'O'), ('between', 'O'), ('groups', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('SBP', 'O'), ('(', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), ('[', 'O'), ('-', 'O'), ('27', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), (']', 'O'), (';', 'O'), ('A', 'O'), ('[', 'O'), ('-', 'O'), ('16', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), (']', 'O'), (')', 'O'), ('and', 'O'), ('DBP', 'O'), ('(', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), ('[', 'O'), ('-', 'O'), ('20', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), (']', 'O'), (';', 'O'), ('A', 'O'), ('[', 'O'), ('-', 'O'), ('13', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), (']', 'O'), (')', 'O'), ('(', 'O'), ('all', 'O'), (',', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
Response rates were 87 . 3 % ( 89 / 102 ) in the T + A group and 69 . 3 % ( 70 / 101 ) in the A group ( P < 0 . 05 ) .,"(('Response', 'O'), ('rates', 'O'), ('were', 'O'), ('87', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('(', 'O'), ('89', 'O'), ('/', 'O'), ('102', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), ('group', 'O'), ('and', 'O'), ('69', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('(', 'O'), ('70', 'O'), ('/', 'O'), ('101', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('A', 'O'), ('group', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"The prevalences of adverse events were not significantly different between the 2 treatment groups ( T + A , 16 . 0 % [ 17 / 106 ] ; A , 15 . 4 % [ 16 / 104 ] ) .","(('The', 'O'), ('prevalences', 'O'), ('of', 'O'), ('adverse', 'O'), ('events', 'O'), ('were', 'O'), ('not', 'O'), ('significantly', 'O'), ('different', 'O'), ('between', 'O'), ('the', 'O'), ('2', 'O'), ('treatment', 'O'), ('groups', 'O'), ('(', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), (',', 'O'), ('16', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('[', 'O'), ('17', 'O'), ('/', 'O'), ('106', 'O'), (']', 'O'), (';', 'O'), ('A', 'O'), (',', 'O'), ('15', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('[', 'O'), ('16', 'O'), ('/', 'O'), ('104', 'O'), (']', 'O'), (')', 'O'), ('.', 'O'))"
"METHODS : This study comprised 24 cognitively intact , health elderly adults ( 12 APOE epsilon4 carriers ) at an outpatient geriatric psychiatry research clinic .","(('METHODS', 'O'), (':', 'O'), ('This', 'O'), ('study', 'O'), ('comprised', 'O'), ('24', 'O'), ('cognitively', 'O'), ('intact', 'O'), (',', 'O'), ('health', 'O'), ('elderly', 'O'), ('adults', 'O'), ('(', 'O'), ('12', 'O'), ('APOE', 'O'), ('epsilon4', 'O'), ('carriers', 'O'), (')', 'O'), ('at', 'O'), ('an', 'O'), ('outpatient', 'O'), ('geriatric', 'O'), ('psychiatry', 'O'), ('research', 'O'), ('clinic', 'O'), ('.', 'O'))"
"This was a randomized , double blind , placebo - controlled , three - way , crossover experimental design .","(('This', 'O'), ('was', 'O'), ('a', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('blind', 'O'), (',', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), (',', 'O'), ('three', 'O'), ('-', 'O'), ('way', 'O'), (',', 'O'), ('crossover', 'O'), ('experimental', 'O'), ('design', 'O'), ('.', 'O'))"
All participants received 1 . 0 mg or 2 . 0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks .,"(('All', 'O'), ('participants', 'O'), ('received', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('or', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('trihexyphenidyl', 'O'), ('or', 'O'), ('placebo', 'O'), ('administered', 'O'), ('in', 'O'), ('counterbalanced', 'O'), ('sequences', 'O'), ('over', 'O'), ('a', 'O'), ('period', 'O'), ('of', 'O'), ('three', 'O'), ('consecutive', 'O'), ('weeks', 'O'), ('.', 'O'))"
"Bond and Lader ' s visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline , 1 , 2 . 5 , and 5 hours postdrug administration .","(('Bond', 'O'), ('and', 'O'), ('Lader', 'O'), (""'"", 'O'), ('s', 'O'), ('visual', 'O'), ('analog', 'O'), ('scales', 'O'), ('and', 'O'), ('alternate', 'O'), ('versions', 'O'), ('of', 'O'), ('the', 'O'), ('Buschke', 'O'), ('Selective', 'O'), ('Reminding', 'O'), ('Test', 'O'), ('were', 'O'), ('administered', 'O'), ('in', 'O'), ('a', 'O'), ('repeated', 'O'), ('measures', 'O'), ('design', 'O'), ('at', 'O'), ('baseline', 'O'), (',', 'O'), ('1', 'O'), (',', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), (',', 'O'), ('and', 'O'), ('5', 'O'), ('hours', 'O'), ('postdrug', 'O'), ('administration', 'O'), ('.', 'O'))"
"However , no significant effects were found with other visual analog scales reflecting subjective sedation and clear - headedness .","(('However', 'O'), (',', 'O'), ('no', 'O'), ('significant', 'O'), ('effects', 'O'), ('were', 'O'), ('found', 'O'), ('with', 'O'), ('other', 'O'), ('visual', 'O'), ('analog', 'O'), ('scales', 'O'), ('reflecting', 'O'), ('subjective', 'O'), ('sedation', 'O'), ('and', 'O'), ('clear', 'B'), ('-', 'O'), ('headedness', 'O'), ('.', 'O'))"
"Strategies of extended - interval and conventional dosing have been utilized extensively in the general medical population ; however , data are lacking to support a dosing strategy in the hematology / oncology population .","(('Strategies', 'O'), ('of', 'O'), ('extended', 'O'), ('-', 'O'), ('interval', 'O'), ('and', 'O'), ('conventional', 'O'), ('dosing', 'O'), ('have', 'O'), ('been', 'O'), ('utilized', 'O'), ('extensively', 'O'), ('in', 'O'), ('the', 'O'), ('general', 'O'), ('medical', 'O'), ('population', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('data', 'O'), ('are', 'O'), ('lacking', 'O'), ('to', 'O'), ('support', 'O'), ('a', 'O'), ('dosing', 'O'), ('strategy', 'O'), ('in', 'O'), ('the', 'O'), ('hematology', 'O'), ('/', 'O'), ('oncology', 'O'), ('population', 'O'), ('.', 'O'))"
"Six patients in the conventional group had a positive culture , compared with none in the extended - interval group ( P = 0 . 002 ) .","(('Six', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('conventional', 'O'), ('group', 'O'), ('had', 'O'), ('a', 'O'), ('positive', 'O'), ('culture', 'O'), (',', 'O'), ('compared', 'O'), ('with', 'O'), ('none', 'O'), ('in', 'O'), ('the', 'O'), ('extended', 'O'), ('-', 'O'), ('interval', 'O'), ('group', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('002', 'O'), (')', 'O'), ('.', 'O'))"
Efficacy could not be assessed .,"(('Efficacy', 'O'), ('could', 'O'), ('not', 'O'), ('be', 'O'), ('assessed', 'O'), ('.', 'O'))"
High dose dexmedetomidine as the sole sedative for pediatric MRI .,"(('High', 'O'), ('dose', 'O'), ('dexmedetomidine', 'O'), ('as', 'O'), ('the', 'O'), ('sole', 'O'), ('sedative', 'O'), ('for', 'O'), ('pediatric', 'O'), ('MRI', 'B'), ('.', 'O'))"
OBJECTIVE : This large - scale retrospective review evaluates the sedation profile of dexmedetomidine .,"(('OBJECTIVE', 'O'), (':', 'O'), ('This', 'O'), ('large', 'O'), ('-', 'O'), ('scale', 'O'), ('retrospective', 'O'), ('review', 'O'), ('evaluates', 'O'), ('the', 'O'), ('sedation', 'O'), ('profile', 'O'), ('of', 'O'), ('dexmedetomidine', 'O'), ('.', 'O'))"
"AIM : To determine the hemodynamic responses , efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging ( MRI ) studies .","(('AIM', 'O'), (':', 'O'), ('To', 'O'), ('determine', 'O'), ('the', 'O'), ('hemodynamic', 'O'), ('responses', 'O'), (',', 'O'), ('efficacy', 'O'), ('and', 'O'), ('adverse', 'O'), ('events', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('high', 'O'), ('dose', 'O'), ('dexmedetomidine', 'O'), ('as', 'O'), ('the', 'O'), ('sole', 'O'), ('sedative', 'O'), ('for', 'O'), ('magnetic', 'O'), ('resonance', 'O'), ('imaging', 'O'), ('(', 'O'), ('MRI', 'O'), (')', 'O'), ('studies', 'O'), ('.', 'O'))"
BACKGROUND : Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies .,"(('BACKGROUND', 'O'), (':', 'O'), ('Dexmedetomidine', 'O'), ('has', 'O'), ('been', 'O'), ('used', 'O'), ('at', 'O'), ('our', 'O'), ('institution', 'O'), ('since', 'O'), ('2005', 'O'), ('to', 'O'), ('provide', 'O'), ('sedation', 'O'), ('for', 'O'), ('pediatric', 'O'), ('radiological', 'O'), ('imaging', 'O'), ('studies', 'O'), ('.', 'O'))"
"Over time , an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved .","(('Over', 'O'), ('time', 'O'), (',', 'O'), ('an', 'O'), ('effective', 'O'), ('protocol', 'O'), ('utilizing', 'O'), ('high', 'O'), ('dose', 'O'), ('dexmedetomidine', 'O'), ('as', 'O'), ('the', 'O'), ('sole', 'O'), ('sedative', 'O'), ('agent', 'O'), ('has', 'O'), ('evolved', 'O'), ('.', 'O'))"
"METHODS / MATERIALS : As part of the ongoing Quality Assurance process , data on all sedations are reviewed monthly and protocols modified as needed .","(('METHODS', 'O'), ('/', 'O'), ('MATERIALS', 'O'), (':', 'O'), ('As', 'O'), ('part', 'O'), ('of', 'O'), ('the', 'O'), ('ongoing', 'O'), ('Quality', 'O'), ('Assurance', 'O'), ('process', 'O'), (',', 'O'), ('data', 'O'), ('on', 'O'), ('all', 'O'), ('sedations', 'O'), ('are', 'O'), ('reviewed', 'O'), ('monthly', 'O'), ('and', 'O'), ('protocols', 'O'), ('modified', 'O'), ('as', 'O'), ('needed', 'O'), ('.', 'O'))"
Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007 .,"(('Data', 'O'), ('were', 'O'), ('analyzed', 'O'), ('from', 'O'), ('all', 'O'), ('747', 'O'), ('consecutive', 'O'), ('patients', 'O'), ('who', 'O'), ('received', 'O'), ('dexmedetomidine', 'O'), ('for', 'O'), ('MRI', 'O'), ('sedation', 'O'), ('from', 'O'), ('April', 'O'), ('2005', 'O'), ('to', 'O'), ('April', 'O'), ('2007', 'O'), ('.', 'O'))"
"RESULTS : Since 2005 , the 10 - min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg . kg ( - 1 ) , and the infusion rate increased from 1 to 1 . 5 to 2 microg . kg ( - 1 ) . h ( - 1 ) .","(('RESULTS', 'O'), (':', 'O'), ('Since', 'O'), ('2005', 'O'), (',', 'O'), ('the', 'O'), ('10', 'O'), ('-', 'O'), ('min', 'O'), ('loading', 'O'), ('dose', 'O'), ('of', 'O'), ('our', 'O'), ('dexmedetomidine', 'O'), ('protocol', 'O'), ('increased', 'O'), ('from', 'O'), ('2', 'O'), ('to', 'O'), ('3', 'O'), ('microg', 'O'), ('.', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('infusion', 'O'), ('rate', 'O'), ('increased', 'O'), ('from', 'O'), ('1', 'O'), ('to', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('to', 'O'), ('2', 'O'), ('microg', 'O'), ('.', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'), ('h', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
"The current sedation protocol progressively increased the rate of successful sedation ( able to complete the imaging study ) when using dexmedetomidine alone from 91 . 8 % to 97 . 6 % ( P = 0 . 009 ) , reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min ( P < 0 . 001 ) .","(('The', 'O'), ('current', 'O'), ('sedation', 'O'), ('protocol', 'O'), ('progressively', 'O'), ('increased', 'O'), ('the', 'O'), ('rate', 'O'), ('of', 'O'), ('successful', 'O'), ('sedation', 'O'), ('(', 'O'), ('able', 'O'), ('to', 'O'), ('complete', 'O'), ('the', 'O'), ('imaging', 'O'), ('study', 'O'), (')', 'O'), ('when', 'O'), ('using', 'O'), ('dexmedetomidine', 'O'), ('alone', 'O'), ('from', 'O'), ('91', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('to', 'O'), ('97', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('009', 'O'), (')', 'O'), (',', 'O'), ('reducing', 'O'), ('the', 'O'), ('requirement', 'O'), ('for', 'O'), ('adjuvant', 'O'), ('pentobarbital', 'O'), ('in', 'O'), ('the', 'O'), ('event', 'O'), ('of', 'O'), ('sedation', 'O'), ('failure', 'O'), ('with', 'O'), ('dexmedetomidine', 'O'), ('alone', 'O'), ('and', 'O'), ('decreased', 'O'), ('the', 'O'), ('mean', 'O'), ('recovery', 'O'), ('time', 'O'), ('by', 'O'), ('10', 'O'), ('min', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSION : Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies .,"(('CONCLUSION', 'O'), (':', 'O'), ('Dexmedetomidine', 'O'), ('in', 'O'), ('high', 'O'), ('doses', 'O'), ('provides', 'O'), ('adequate', 'O'), ('sedation', 'O'), ('for', 'O'), ('pediatric', 'O'), ('MRI', 'O'), ('studies', 'O'), ('.', 'O'))"
"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established ' awake ' norms , this deviation is generally within 20 % of norms , and is not associated with adverse sequelae .","(('While', 'O'), ('use', 'O'), ('of', 'O'), ('high', 'O'), ('dose', 'O'), ('dexmedetomidine', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('decreases', 'O'), ('in', 'O'), ('heart', 'O'), ('rate', 'O'), ('and', 'O'), ('blood', 'O'), ('pressure', 'O'), ('outside', 'O'), ('the', 'O'), ('established', 'O'), (""'"", 'O'), ('awake', 'O'), (""'"", 'O'), ('norms', 'O'), (',', 'O'), ('this', 'O'), ('deviation', 'O'), ('is', 'O'), ('generally', 'O'), ('within', 'O'), ('20', 'O'), ('%', 'O'), ('of', 'O'), ('norms', 'O'), (',', 'O'), ('and', 'O'), ('is', 'O'), ('not', 'O'), ('associated', 'O'), ('with', 'O'), ('adverse', 'O'), ('sequelae', 'O'), ('.', 'O'))"
Dexmedetomidine is useful as the sole sedative for pediatric MRI .,"(('Dexmedetomidine', 'O'), ('is', 'O'), ('useful', 'O'), ('as', 'O'), ('the', 'O'), ('sole', 'O'), ('sedative', 'O'), ('for', 'O'), ('pediatric', 'O'), ('MRI', 'B'), ('.', 'O'))"
BACKGROUND : Spontaneous reporting systems for adverse drug reactions ( ADRs ) are handicapped by under - reporting and limited detail on individual cases .,"(('BACKGROUND', 'O'), (':', 'O'), ('Spontaneous', 'O'), ('reporting', 'O'), ('systems', 'O'), ('for', 'O'), ('adverse', 'B'), ('drug', 'I'), ('reactions', 'O'), ('(', 'O'), ('ADRs', 'B'), (')', 'O'), ('are', 'O'), ('handicapped', 'O'), ('by', 'O'), ('under', 'O'), ('-', 'O'), ('reporting', 'O'), ('and', 'O'), ('limited', 'O'), ('detail', 'O'), ('on', 'O'), ('individual', 'O'), ('cases', 'O'), ('.', 'O'))"
We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti - rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients .,"(('We', 'O'), ('report', 'O'), ('an', 'O'), ('investigation', 'O'), ('from', 'O'), ('a', 'O'), ('local', 'O'), ('surveillance', 'O'), ('for', 'O'), ('serious', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reactions', 'O'), ('associated', 'O'), ('with', 'O'), ('disease', 'O'), ('modifying', 'O'), ('anti', 'O'), ('-', 'O'), ('rheumatic', 'O'), ('drugs', 'O'), ('that', 'O'), ('was', 'O'), ('triggered', 'O'), ('by', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('liver', 'B'), ('failure', 'I'), ('in', 'O'), ('two', 'O'), ('of', 'O'), ('our', 'O'), ('patients', 'O'), ('.', 'O'))"
METHODS : Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years .,"(('METHODS', 'O'), (':', 'O'), ('Serious', 'O'), ('ADR', 'O'), ('reports', 'O'), ('have', 'O'), ('been', 'O'), ('solicited', 'O'), ('from', 'O'), ('local', 'O'), ('clinicians', 'O'), ('by', 'O'), ('regular', 'O'), ('postcards', 'O'), ('over', 'O'), ('the', 'O'), ('past', 'O'), ('seven', 'O'), ('years', 'O'), ('.', 'O'))"
Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument .,"(('Two', 'O'), ('clinicians', 'O'), ('reviewed', 'O'), ('structured', 'O'), ('case', 'O'), ('reports', 'O'), ('and', 'O'), ('assessed', 'O'), ('causality', 'O'), ('by', 'O'), ('consensus', 'O'), ('and', 'O'), ('by', 'O'), ('using', 'O'), ('a', 'O'), ('causality', 'O'), ('assessment', 'O'), ('instrument', 'O'), ('.', 'O'))"
RESULTS : Ten cases were identified : eight occurred during surveillance .,"(('RESULTS', 'O'), (':', 'O'), ('Ten', 'O'), ('cases', 'O'), ('were', 'O'), ('identified', 'O'), (':', 'O'), ('eight', 'O'), ('occurred', 'O'), ('during', 'O'), ('surveillance', 'O'), ('.', 'O'))"
"Eight patients were hospitalised , two in hepatic failure - one died after a liver transplant .","(('Eight', 'O'), ('patients', 'O'), ('were', 'O'), ('hospitalised', 'O'), (',', 'O'), ('two', 'O'), ('in', 'O'), ('hepatic', 'B'), ('failure', 'I'), ('-', 'O'), ('one', 'O'), ('died', 'O'), ('after', 'O'), ('a', 'O'), ('liver', 'O'), ('transplant', 'O'), ('.', 'O'))"
All but one event occurred within 6 weeks of treatment .,"(('All', 'O'), ('but', 'O'), ('one', 'O'), ('event', 'O'), ('occurred', 'O'), ('within', 'O'), ('6', 'O'), ('weeks', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O'))"
Five patients were of Black British of African or Caribbean descent .,"(('Five', 'O'), ('patients', 'O'), ('were', 'O'), ('of', 'O'), ('Black', 'O'), ('British', 'O'), ('of', 'O'), ('African', 'O'), ('or', 'O'), ('Caribbean', 'O'), ('descent', 'O'), ('.', 'O'))"
Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six .,"(('Liver', 'O'), ('enzymes', 'O'), ('showed', 'O'), ('a', 'O'), ('hepatocellular', 'O'), ('pattern', 'O'), ('in', 'O'), ('four', 'O'), ('cases', 'O'), ('and', 'O'), ('a', 'O'), ('mixed', 'O'), ('pattern', 'O'), ('in', 'O'), ('six', 'O'), ('.', 'O'))"
"Lithium should be used with extreme caution , especially in patients with mild disturbance of AV conduction .","(('Lithium', 'O'), ('should', 'O'), ('be', 'O'), ('used', 'O'), ('with', 'O'), ('extreme', 'O'), ('caution', 'O'), (',', 'O'), ('especially', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('mild', 'O'), ('disturbance', 'B'), ('of', 'I'), ('AV', 'I'), ('conduction', 'I'), ('.', 'O'))"
Vasoactive intestinal polypeptide ( VIP ) is an immunomodulatory neuropeptide distributed in micturition pathways .,"(('Vasoactive', 'O'), ('intestinal', 'O'), ('polypeptide', 'O'), ('(', 'O'), ('VIP', 'O'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('immunomodulatory', 'O'), ('neuropeptide', 'O'), ('distributed', 'O'), ('in', 'O'), ('micturition', 'O'), ('pathways', 'O'), ('.', 'O'))"
"Four binary comparisons were made : WT control versus CYP treatment ( 48 h ) , VIP ( - / - ) control versus CYP treatment ( 48 h ) , WT control versus VIP ( - / - ) control , and WT with CYP treatment ( 48 h ) versus VIP ( - / - ) with CYP treatment ( 48 h ) .","(('Four', 'O'), ('binary', 'O'), ('comparisons', 'O'), ('were', 'O'), ('made', 'O'), (':', 'O'), ('WT', 'O'), ('control', 'O'), ('versus', 'O'), ('CYP', 'O'), ('treatment', 'O'), ('(', 'O'), ('48', 'O'), ('h', 'O'), (')', 'O'), (',', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('control', 'O'), ('versus', 'O'), ('CYP', 'O'), ('treatment', 'O'), ('(', 'O'), ('48', 'O'), ('h', 'O'), (')', 'O'), (',', 'O'), ('WT', 'O'), ('control', 'O'), ('versus', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('control', 'O'), (',', 'O'), ('and', 'O'), ('WT', 'O'), ('with', 'O'), ('CYP', 'O'), ('treatment', 'O'), ('(', 'O'), ('48', 'O'), ('h', 'O'), (')', 'O'), ('versus', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('with', 'O'), ('CYP', 'O'), ('treatment', 'O'), ('(', 'O'), ('48', 'O'), ('h', 'O'), (')', 'O'), ('.', 'O'))"
The genes presented represent ( 1 ) greater than 1 . 5 - fold change in either direction and ( 2 ) the p value is less than 0 . 05 for the comparison being made .,"(('The', 'O'), ('genes', 'O'), ('presented', 'O'), ('represent', 'O'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('greater', 'O'), ('than', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('-', 'O'), ('fold', 'O'), ('change', 'O'), ('in', 'O'), ('either', 'O'), ('direction', 'O'), ('and', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('the', 'O'), ('p', 'O'), ('value', 'O'), ('is', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), ('for', 'O'), ('the', 'O'), ('comparison', 'O'), ('being', 'O'), ('made', 'O'), ('.', 'O'))"
Several regulated genes were validated using enzyme - linked immunoassays including IL - 1beta and CXCL1 .,"(('Several', 'O'), ('regulated', 'O'), ('genes', 'O'), ('were', 'O'), ('validated', 'O'), ('using', 'O'), ('enzyme', 'O'), ('-', 'O'), ('linked', 'O'), ('immunoassays', 'O'), ('including', 'O'), ('IL', 'O'), ('-', 'O'), ('1beta', 'O'), ('and', 'O'), ('CXCL1', 'O'), ('.', 'O'))"
"CYP treatment significantly ( p < or = 0 . 001 ) increased expression of CXCL1 and IL - 1beta in the urinary bladder of WT and VIP ( - / - ) mice , but expression in VIP ( - / - ) mice with CYP treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .","(('CYP', 'O'), ('treatment', 'O'), ('significantly', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('or', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('increased', 'O'), ('expression', 'O'), ('of', 'O'), ('CXCL1', 'O'), ('and', 'O'), ('IL', 'O'), ('-', 'O'), ('1beta', 'O'), ('in', 'O'), ('the', 'O'), ('urinary', 'O'), ('bladder', 'O'), ('of', 'O'), ('WT', 'O'), ('and', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), (',', 'O'), ('but', 'O'), ('expression', 'O'), ('in', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('with', 'O'), ('CYP', 'O'), ('treatment', 'O'), ('was', 'O'), ('significantly', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('or', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('greater', 'O'), ('(', 'O'), ('4', 'O'), ('.', 'O'), ('2', 'O'), ('-', 'O'), ('to', 'O'), ('13', 'O'), ('-', 'O'), ('fold', 'O'), ('increase', 'O'), (')', 'O'), ('than', 'O'), ('that', 'O'), ('observed', 'O'), ('in', 'O'), ('WT', 'O'), ('urinary', 'O'), ('bladder', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('6', 'O'), ('-', 'O'), ('to', 'O'), ('5', 'O'), ('-', 'O'), ('fold', 'O'), ('increase', 'O'), (')', 'O'), ('.', 'O'))"
"The data suggest that in VIP ( - / - ) mice with bladder inflammation , inflammatory mediators are increased above that observed in WT with CYP .","(('The', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('in', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('with', 'O'), ('bladder', 'B'), ('inflammation', 'I'), (',', 'O'), ('inflammatory', 'O'), ('mediators', 'O'), ('are', 'O'), ('increased', 'O'), ('above', 'O'), ('that', 'O'), ('observed', 'O'), ('in', 'O'), ('WT', 'O'), ('with', 'O'), ('CYP', 'B'), ('.', 'O'))"
This shift in balance may contribute to increased bladder dysfunction in VIP ( - / - ) mice with bladder inflammation and altered neurochemical expression in micturition pathways .,"(('This', 'O'), ('shift', 'O'), ('in', 'O'), ('balance', 'O'), ('may', 'O'), ('contribute', 'O'), ('to', 'O'), ('increased', 'O'), ('bladder', 'B'), ('dysfunction', 'I'), ('in', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('with', 'O'), ('bladder', 'B'), ('inflammation', 'I'), ('and', 'O'), ('altered', 'O'), ('neurochemical', 'O'), ('expression', 'O'), ('in', 'O'), ('micturition', 'O'), ('pathways', 'O'), ('.', 'O'))"
Debrisoquine phenotype and the pharmacokinetics and beta - 2 receptor pharmacodynamics of metoprolol and its enantiomers .,"(('Debrisoquine', 'O'), ('phenotype', 'O'), ('and', 'O'), ('the', 'O'), ('pharmacokinetics', 'O'), ('and', 'O'), ('beta', 'O'), ('-', 'O'), ('2', 'O'), ('receptor', 'O'), ('pharmacodynamics', 'O'), ('of', 'O'), ('metoprolol', 'O'), ('and', 'O'), ('its', 'O'), ('enantiomers', 'O'), ('.', 'O'))"
The metabolism of the cardioselective beta - blocker metoprolol is under genetic control of the debrisoquine / sparteine type .,"(('The', 'O'), ('metabolism', 'O'), ('of', 'O'), ('the', 'O'), ('cardioselective', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('metoprolol', 'O'), ('is', 'O'), ('under', 'O'), ('genetic', 'O'), ('control', 'O'), ('of', 'O'), ('the', 'O'), ('debrisoquine', 'O'), ('/', 'O'), ('sparteine', 'O'), ('type', 'O'), ('.', 'O'))"
"The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher beta - 1 adrenoceptor antagonistic potency of racemic metoprolol in EMs .","(('The', 'O'), ('two', 'O'), ('metabolic', 'O'), ('phenotypes', 'O'), (',', 'O'), ('extensive', 'O'), ('(', 'O'), ('EM', 'O'), (')', 'O'), ('and', 'O'), ('poor', 'O'), ('metabolizers', 'O'), ('(', 'O'), ('PM', 'O'), (')', 'O'), (',', 'O'), ('show', 'O'), ('different', 'O'), ('stereoselective', 'O'), ('metabolism', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('apparently', 'O'), ('higher', 'O'), ('beta', 'O'), ('-', 'O'), ('1', 'O'), ('adrenoceptor', 'O'), ('antagonistic', 'O'), ('potency', 'O'), ('of', 'O'), ('racemic', 'O'), ('metoprolol', 'O'), ('in', 'O'), ('EMs', 'B'), ('.', 'O'))"
We investigated if the latter also applies to the beta - 2 adrenoceptor antagonism by metoprolol .,"(('We', 'O'), ('investigated', 'O'), ('if', 'O'), ('the', 'O'), ('latter', 'O'), ('also', 'O'), ('applies', 'O'), ('to', 'O'), ('the', 'O'), ('beta', 'O'), ('-', 'O'), ('2', 'O'), ('adrenoceptor', 'O'), ('antagonism', 'O'), ('by', 'O'), ('metoprolol', 'O'), ('.', 'O'))"
"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing metoprolol plasma concentrations resulting in half - maximum receptor occupancy .","(('By', 'O'), ('using', 'O'), ('pharmacokinetic', 'O'), ('pharmacodynamic', 'O'), ('modeling', 'O'), ('the', 'O'), ('pharmacodynamics', 'O'), ('of', 'O'), ('racemic', 'O'), ('metoprolol', 'O'), ('and', 'O'), ('the', 'O'), ('active', 'O'), ('S', 'O'), ('-', 'O'), ('isomer', 'O'), (',', 'O'), ('were', 'O'), ('quantitated', 'O'), ('in', 'O'), ('EMs', 'B'), ('and', 'O'), ('PMs', 'B'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('IC50', 'O'), ('values', 'O'), (',', 'O'), ('representing', 'O'), ('metoprolol', 'O'), ('plasma', 'O'), ('concentrations', 'O'), ('resulting', 'O'), ('in', 'O'), ('half', 'O'), ('-', 'O'), ('maximum', 'O'), ('receptor', 'O'), ('occupancy', 'O'), ('.', 'O'))"
Six EMs received 0 . 5 mg of terbutaline s . c . on two different occasions : 1 ) 1 hr after administration of a placebo and 2 ) 1 hr after 150 mg of metoprolol p . o .,"(('Six', 'O'), ('EMs', 'O'), ('received', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('of', 'O'), ('terbutaline', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), ('on', 'O'), ('two', 'O'), ('different', 'O'), ('occasions', 'O'), (':', 'O'), ('1', 'O'), (')', 'O'), ('1', 'O'), ('hr', 'O'), ('after', 'O'), ('administration', 'O'), ('of', 'O'), ('a', 'O'), ('placebo', 'O'), ('and', 'O'), ('2', 'O'), (')', 'O'), ('1', 'O'), ('hr', 'O'), ('after', 'O'), ('150', 'O'), ('mg', 'O'), ('of', 'O'), ('metoprolol', 'O'), ('p', 'O'), ('.', 'O'), ('o', 'O'), ('.', 'O'))"
"Five PMs were studied according to the same protocol , except for a higher terbutaline dose ( 0 . 75 mg ) on day 2 .","(('Five', 'O'), ('PMs', 'O'), ('were', 'O'), ('studied', 'O'), ('according', 'O'), ('to', 'O'), ('the', 'O'), ('same', 'O'), ('protocol', 'O'), (',', 'O'), ('except', 'O'), ('for', 'O'), ('a', 'O'), ('higher', 'O'), ('terbutaline', 'O'), ('dose', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('75', 'O'), ('mg', 'O'), (')', 'O'), ('on', 'O'), ('day', 'O'), ('2', 'O'), ('.', 'O'))"
"Blood samples for the analysis of plasma potassium , terbutaline , metoprolol ( racemic , R - and S - isomer ) , and alpha - hydroxymetoprolol concentrations were taken at regular time intervals , during 8 hr after metoprolol .","(('Blood', 'O'), ('samples', 'O'), ('for', 'O'), ('the', 'O'), ('analysis', 'O'), ('of', 'O'), ('plasma', 'O'), ('potassium', 'O'), (',', 'O'), ('terbutaline', 'O'), (',', 'O'), ('metoprolol', 'O'), ('(', 'O'), ('racemic', 'O'), (',', 'O'), ('R', 'O'), ('-', 'O'), ('and', 'O'), ('S', 'O'), ('-', 'O'), ('isomer', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('alpha', 'O'), ('-', 'O'), ('hydroxymetoprolol', 'O'), ('concentrations', 'O'), ('were', 'O'), ('taken', 'O'), ('at', 'O'), ('regular', 'O'), ('time', 'O'), ('intervals', 'O'), (',', 'O'), ('during', 'O'), ('8', 'O'), ('hr', 'O'), ('after', 'O'), ('metoprolol', 'O'), ('.', 'O'))"
"In PMs , metoprolol increased the terbutaline area under the plasma concentration vs . time curve ( + 67 % ) .","(('In', 'O'), ('PMs', 'B'), (',', 'O'), ('metoprolol', 'O'), ('increased', 'O'), ('the', 'O'), ('terbutaline', 'O'), ('area', 'O'), ('under', 'O'), ('the', 'O'), ('plasma', 'O'), ('concentration', 'O'), ('vs', 'O'), ('.', 'O'), ('time', 'O'), ('curve', 'O'), ('(', 'O'), ('+', 'O'), ('67', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
Higher metoprolol / alpha - hydroxymetoprolol ratios in PMs were predictive for higher R - / S - isomer ratios of unchanged drug .,"(('Higher', 'O'), ('metoprolol', 'O'), ('/', 'O'), ('alpha', 'O'), ('-', 'O'), ('hydroxymetoprolol', 'O'), ('ratios', 'O'), ('in', 'O'), ('PMs', 'O'), ('were', 'O'), ('predictive', 'O'), ('for', 'O'), ('higher', 'O'), ('R', 'O'), ('-', 'O'), ('/', 'O'), ('S', 'O'), ('-', 'O'), ('isomer', 'O'), ('ratios', 'O'), ('of', 'O'), ('unchanged', 'O'), ('drug', 'O'), ('.', 'O'))"
"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )","(('There', 'O'), ('was', 'O'), ('a', 'O'), ('difference', 'O'), ('in', 'O'), ('metoprolol', 'O'), ('potency', 'O'), ('with', 'O'), ('higher', 'O'), ('racemic', 'O'), ('metoprolol', 'O'), ('IC50', 'O'), ('values', 'O'), ('in', 'O'), ('PMs', 'B'), ('(', 'O'), ('72', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('7', 'O'), ('ng', 'O'), ('.', 'O'), ('ml', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('than', 'O'), ('EMs', 'B'), ('(', 'O'), ('42', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('8', 'O'), ('ng', 'O'), ('.', 'O'), ('ml', 'O'), ('-', 'O'), ('1', 'O'), (',', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'), ('(', 'O'), ('ABSTRACT', 'O'), ('TRUNCATED', 'O'), ('AT', 'O'), ('250', 'O'), ('WORDS', 'O'), (')', 'O'))"
The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery : findings in six cases .,"(('The', 'O'), ('hemodynamics', 'O'), ('of', 'O'), ('oxytocin', 'O'), ('and', 'O'), ('other', 'O'), ('vasoactive', 'O'), ('agents', 'O'), ('during', 'O'), ('neuraxial', 'O'), ('anesthesia', 'O'), ('for', 'O'), ('cesarean', 'O'), ('delivery', 'O'), (':', 'O'), ('findings', 'O'), ('in', 'O'), ('six', 'O'), ('cases', 'O'), ('.', 'O'))"
"Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension , particularly when given as a bolus .","(('Oxytocin', 'O'), ('is', 'O'), ('a', 'O'), ('commonly', 'O'), ('used', 'O'), ('uterotonic', 'O'), ('that', 'O'), ('can', 'O'), ('cause', 'O'), ('significant', 'O'), ('and', 'O'), ('even', 'O'), ('fatal', 'O'), ('hypotension', 'B'), (',', 'O'), ('particularly', 'O'), ('when', 'O'), ('given', 'O'), ('as', 'O'), ('a', 'O'), ('bolus', 'O'), ('.', 'O'))"
The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return .,"(('The', 'O'), ('resulting', 'O'), ('hypotension', 'B'), ('can', 'O'), ('be', 'O'), ('produced', 'O'), ('by', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('systemic', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('or', 'O'), ('cardiac', 'O'), ('output', 'O'), ('through', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('venous', 'O'), ('return', 'O'), ('.', 'O'))"
"Pulse power analysis ( also called "" pulse contour analysis "" ) of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time , thereby elucidating the causative factors behind changes in blood pressure .","(('Pulse', 'O'), ('power', 'O'), ('analysis', 'O'), ('(', 'O'), ('also', 'O'), ('called', 'O'), ('""', 'O'), ('pulse', 'O'), ('contour', 'O'), ('analysis', 'O'), ('""', 'O'), (')', 'O'), ('of', 'O'), ('an', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('wave', 'O'), ('form', 'O'), ('allows', 'O'), ('continuous', 'O'), ('evaluation', 'O'), ('of', 'O'), ('systemic', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('and', 'O'), ('cardiac', 'O'), ('output', 'O'), ('in', 'O'), ('real', 'O'), ('time', 'O'), (',', 'O'), ('thereby', 'O'), ('elucidating', 'O'), ('the', 'O'), ('causative', 'O'), ('factors', 'O'), ('behind', 'O'), ('changes', 'O'), ('in', 'O'), ('blood', 'O'), ('pressure', 'O'), ('.', 'O'))"
Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia .,"(('Pulse', 'O'), ('power', 'O'), ('analysis', 'O'), ('was', 'O'), ('conducted', 'O'), ('in', 'O'), ('six', 'O'), ('cases', 'O'), ('of', 'O'), ('cesarean', 'O'), ('delivery', 'O'), ('performed', 'O'), ('under', 'O'), ('neuraxial', 'O'), ('anesthesia', 'O'), ('.', 'O'))"
Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia .,"(('Pulse', 'O'), ('power', 'O'), ('analysis', 'O'), ('may', 'O'), ('be', 'O'), ('helpful', 'O'), ('in', 'O'), ('determining', 'O'), ('the', 'O'), ('etiology', 'O'), ('of', 'O'), ('and', 'O'), ('treating', 'O'), ('hypotension', 'B'), ('during', 'O'), ('cesarean', 'O'), ('delivery', 'O'), ('under', 'O'), ('neuraxial', 'O'), ('anesthesia', 'O'), ('.', 'O'))"
Antithrombin ( 50 or 500 IU / kg / i . v . ) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside ( 50 mg / kg / i . v . ) .,"(('Antithrombin', 'O'), ('(', 'O'), ('50', 'O'), ('or', 'O'), ('500', 'O'), ('IU', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('was', 'O'), ('administered', 'O'), ('to', 'O'), ('rats', 'O'), ('once', 'O'), ('a', 'O'), ('day', 'O'), ('for', 'O'), ('10', 'O'), ('days', 'O'), ('immediately', 'O'), ('after', 'O'), ('the', 'O'), ('injection', 'O'), ('of', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('(', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
Treatment with antithrombin attenuated the puromycin aminonucleoside - induced hematological abnormalities .,"(('Treatment', 'O'), ('with', 'O'), ('antithrombin', 'O'), ('attenuated', 'O'), ('the', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('hematological', 'B'), ('abnormalities', 'I'), ('.', 'O'))"
"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats , while an improvement of the damage was seen in antithrombin - treated rats .","(('Histopathological', 'O'), ('examination', 'O'), ('revealed', 'O'), ('severe', 'O'), ('renal', 'B'), ('damage', 'O'), ('such', 'O'), ('as', 'O'), ('proteinaceous', 'O'), ('casts', 'O'), ('in', 'O'), ('tubuli', 'O'), ('and', 'O'), ('tubular', 'O'), ('expansion', 'O'), ('in', 'O'), ('the', 'O'), ('kidney', 'O'), ('of', 'O'), ('control', 'O'), ('rats', 'O'), (',', 'O'), ('while', 'O'), ('an', 'O'), ('improvement', 'O'), ('of', 'O'), ('the', 'O'), ('damage', 'O'), ('was', 'O'), ('seen', 'O'), ('in', 'O'), ('antithrombin', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('.', 'O'))"
"In addition , antithrombin treatment markedly suppressed puromycin aminonucleoside - induced apoptosis of renal tubular epithelial cells .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('antithrombin', 'O'), ('treatment', 'O'), ('markedly', 'O'), ('suppressed', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('apoptosis', 'O'), ('of', 'O'), ('renal', 'O'), ('tubular', 'O'), ('epithelial', 'O'), ('cells', 'O'), ('.', 'O'))"
"Furthermore , puromycin aminonucleoside - induced increases in renal cytokine content were also decreased .","(('Furthermore', 'O'), (',', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('increases', 'O'), ('in', 'O'), ('renal', 'O'), ('cytokine', 'O'), ('content', 'O'), ('were', 'O'), ('also', 'O'), ('decreased', 'O'), ('.', 'O'))"
Heparin - induced thrombocytopenia after liver transplantation .,"(('Heparin', 'B'), ('-', 'I'), ('induced', 'I'), ('thrombocytopenia', 'I'), ('after', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('.', 'O'))"
BACKGROUND : Unfractionated heparin sodium ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation .,"(('BACKGROUND', 'O'), (':', 'O'), ('Unfractionated', 'O'), ('heparin', 'O'), ('sodium', 'O'), ('(', 'O'), ('UFH', 'O'), (')', 'O'), ('or', 'O'), ('low', 'O'), ('-', 'O'), ('molecular', 'O'), ('weight', 'O'), ('heparin', 'O'), ('(', 'O'), ('LMWH', 'O'), (')', 'O'), ('is', 'O'), ('used', 'O'), ('in', 'O'), ('anticoagulant', 'O'), ('protocols', 'O'), ('at', 'O'), ('several', 'O'), ('institutions', 'O'), ('to', 'O'), ('prevent', 'O'), ('thrombosis', 'B'), ('after', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('.', 'O'))"
PATIENTS AND METHODS : The 32 men and 20 women underwent living donor liver transplantation .,"(('PATIENTS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('The', 'O'), ('32', 'O'), ('men', 'O'), ('and', 'O'), ('20', 'O'), ('women', 'O'), ('underwent', 'O'), ('living', 'O'), ('donor', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('.', 'O'))"
"We started LMWH ( 25 IU / kg / h ) on postoperative day ( POD ) 1 , switching to UFH ( 5000 U / d ) on POD 2 or 3 .","(('We', 'O'), ('started', 'O'), ('LMWH', 'O'), ('(', 'O'), ('25', 'O'), ('IU', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('h', 'O'), (')', 'O'), ('on', 'O'), ('postoperative', 'O'), ('day', 'O'), ('(', 'O'), ('POD', 'O'), (')', 'O'), ('1', 'O'), (',', 'O'), ('switching', 'O'), ('to', 'O'), ('UFH', 'O'), ('(', 'O'), ('5000', 'O'), ('U', 'O'), ('/', 'O'), ('d', 'O'), (')', 'O'), ('on', 'O'), ('POD', 'O'), ('2', 'O'), ('or', 'O'), ('3', 'O'), ('.', 'O'))"
The dose of UFH was changed according to the activated clotting time level .,"(('The', 'O'), ('dose', 'O'), ('of', 'O'), ('UFH', 'O'), ('was', 'O'), ('changed', 'O'), ('according', 'O'), ('to', 'O'), ('the', 'O'), ('activated', 'O'), ('clotting', 'O'), ('time', 'O'), ('level', 'O'), ('.', 'O'))"
Platelet count was measured daily for 3 weeks .,"(('Platelet', 'O'), ('count', 'O'), ('was', 'O'), ('measured', 'O'), ('daily', 'O'), ('for', 'O'), ('3', 'O'), ('weeks', 'O'), ('.', 'O'))"
"RESULTS : The average platelet counts preoperatively , and on POD 7 , 14 , and 21 were 65 , 88 , 149 , and 169 x 10 ( 9 ) / L , respectively .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('average', 'O'), ('platelet', 'O'), ('counts', 'O'), ('preoperatively', 'O'), (',', 'O'), ('and', 'O'), ('on', 'O'), ('POD', 'O'), ('7', 'O'), (',', 'O'), ('14', 'O'), (',', 'O'), ('and', 'O'), ('21', 'O'), ('were', 'O'), ('65', 'O'), (',', 'O'), ('88', 'O'), (',', 'O'), ('149', 'O'), (',', 'O'), ('and', 'O'), ('169', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('9', 'O'), (')', 'O'), ('/', 'O'), ('L', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"In 2 other patients , the platelet count decreased suddenly from 107 x 10 ( 9 ) / L on POD 4 to 65 x 10 ( 9 ) / L on POD 6 and from 76 x 10 ( 9 ) / L on POD 7 to 33 x 10 ( 9 ) / L on POD 9 , respectively .","(('In', 'O'), ('2', 'O'), ('other', 'O'), ('patients', 'O'), (',', 'O'), ('the', 'O'), ('platelet', 'O'), ('count', 'O'), ('decreased', 'O'), ('suddenly', 'O'), ('from', 'O'), ('107', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('9', 'O'), (')', 'O'), ('/', 'O'), ('L', 'O'), ('on', 'O'), ('POD', 'O'), ('4', 'O'), ('to', 'O'), ('65', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('9', 'O'), (')', 'O'), ('/', 'O'), ('L', 'O'), ('on', 'O'), ('POD', 'O'), ('6', 'O'), ('and', 'O'), ('from', 'O'), ('76', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('9', 'O'), (')', 'O'), ('/', 'O'), ('L', 'O'), ('on', 'O'), ('POD', 'O'), ('7', 'O'), ('to', 'O'), ('33', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('9', 'O'), (')', 'O'), ('/', 'O'), ('L', 'O'), ('on', 'O'), ('POD', 'O'), ('9', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
Doxorubicin cardiomyopathy - induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor .,"(('Doxorubicin', 'B'), ('cardiomyopathy', 'I'), ('-', 'O'), ('induced', 'O'), ('inflammation', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('are', 'O'), ('attenuated', 'O'), ('by', 'O'), ('gene', 'O'), ('deletion', 'O'), ('of', 'O'), ('the', 'O'), ('kinin', 'O'), ('B1', 'O'), ('receptor', 'O'), ('.', 'O'))"
"To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced cardiomyopathy .","(('To', 'O'), ('elucidate', 'O'), ('the', 'O'), ('possible', 'O'), ('role', 'O'), ('of', 'O'), ('the', 'O'), ('kinin', 'O'), ('B1', 'O'), ('receptor', 'O'), ('(', 'O'), ('B1R', 'O'), (')', 'O'), ('during', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('DOX', 'B'), ('cardiomyopathy', 'I'), (',', 'O'), ('we', 'O'), ('studied', 'O'), ('B1R', 'O'), ('knockout', 'O'), ('mice', 'O'), ('(', 'O'), ('B1R', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), (')', 'O'), ('by', 'O'), ('investigating', 'O'), ('cardiac', 'O'), ('inflammation', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('after', 'O'), ('induction', 'O'), ('of', 'O'), ('DOX', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
DOX control mice showed cardiac dysfunction measured by pressure - volume loops in vivo .,"(('DOX', 'O'), ('control', 'O'), ('mice', 'O'), ('showed', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('measured', 'O'), ('by', 'O'), ('pressure', 'O'), ('-', 'O'), ('volume', 'O'), ('loops', 'O'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
"Furthermore , mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue .","(('Furthermore', 'O'), (',', 'O'), ('mRNA', 'O'), ('levels', 'O'), ('of', 'O'), ('the', 'O'), ('proinflammatory', 'O'), ('cytokine', 'O'), ('interleukin', 'O'), ('6', 'O'), ('were', 'O'), ('increased', 'O'), ('in', 'O'), ('the', 'O'), ('cardiac', 'O'), ('tissue', 'O'), ('.', 'O'))"
"In DOX B1R ( - / - ) mice , cardiac dysfunction was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .","(('In', 'O'), ('DOX', 'O'), ('B1R', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), (',', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('was', 'O'), ('improved', 'O'), ('compared', 'O'), ('to', 'O'), ('DOX', 'O'), ('control', 'O'), ('mice', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('normalization', 'O'), ('of', 'O'), ('the', 'O'), ('bax', 'O'), ('/', 'O'), ('bcl', 'O'), ('-', 'O'), ('2', 'O'), ('ratio', 'O'), ('and', 'O'), ('interleukin', 'O'), ('6', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('AKT', 'O'), ('activation', 'O'), ('state', 'O'), ('.', 'O'))"
These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('B1R', 'O'), ('is', 'O'), ('detrimental', 'O'), ('in', 'O'), ('DOX', 'B'), ('cardiomyopathy', 'I'), ('in', 'O'), ('that', 'O'), ('it', 'O'), ('mediates', 'O'), ('the', 'O'), ('inflammatory', 'O'), ('response', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('.', 'O'))"
These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy .,"(('These', 'O'), ('insights', 'O'), ('might', 'O'), ('have', 'O'), ('useful', 'O'), ('implications', 'O'), ('for', 'O'), ('future', 'O'), ('studies', 'O'), ('utilizing', 'O'), ('B1R', 'O'), ('antagonists', 'O'), ('for', 'O'), ('treatment', 'O'), ('of', 'O'), ('human', 'O'), ('DOX', 'B'), ('cardiomyopathy', 'I'), ('.', 'O'))"
Penicillin model is a widely used experimental model for epilepsy research .,"(('Penicillin', 'O'), ('model', 'O'), ('is', 'O'), ('a', 'O'), ('widely', 'O'), ('used', 'O'), ('experimental', 'O'), ('model', 'O'), ('for', 'O'), ('epilepsy', 'B'), ('research', 'O'), ('.', 'O'))"
Male Wistar rats were anesthetized with i . p . urethane and connected to an electrocorticogram setup .,"(('Male', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('were', 'O'), ('anesthetized', 'O'), ('with', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('urethane', 'O'), ('and', 'O'), ('connected', 'O'), ('to', 'O'), ('an', 'O'), ('electrocorticogram', 'O'), ('setup', 'O'), ('.', 'O'))"
"Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta , theta ( slow and fast ) , alpha - sigma , beta ( 1 and 2 ) and gamma ( 1 and 2 ) bands .","(('Spectral', 'O'), ('analyses', 'O'), ('were', 'O'), ('conducted', 'O'), ('by', 'O'), ('dividing', 'O'), ('the', 'O'), ('whole', 'O'), ('spectrum', 'O'), ('into', 'O'), ('different', 'O'), ('frequency', 'O'), ('bands', 'O'), ('including', 'O'), ('delta', 'O'), (',', 'O'), ('theta', 'O'), ('(', 'O'), ('slow', 'O'), ('and', 'O'), ('fast', 'O'), (')', 'O'), (',', 'O'), ('alpha', 'O'), ('-', 'O'), ('sigma', 'O'), (',', 'O'), ('beta', 'O'), ('(', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (')', 'O'), ('and', 'O'), ('gamma', 'O'), ('(', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (')', 'O'), ('bands', 'O'), ('.', 'O'))"
"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty - acid oxidation , ATP synthesis , and upregulated JAK / STAT3 pathway .","(('This', 'O'), ('cardioprotection', 'O'), ('is', 'O'), ('accompanied', 'O'), ('by', 'O'), ('decreased', 'O'), ('cardiac', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('and', 'O'), ('triglycerides', 'O'), ('and', 'O'), ('increased', 'O'), ('cardiac', 'O'), ('fatty', 'O'), ('-', 'O'), ('acid', 'O'), ('oxidation', 'O'), (',', 'O'), ('ATP', 'O'), ('synthesis', 'O'), (',', 'O'), ('and', 'O'), ('upregulated', 'O'), ('JAK', 'O'), ('/', 'O'), ('STAT3', 'O'), ('pathway', 'O'), ('.', 'O'))"
", ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .","((',', 'O'), ('(', 'O'), ('5', 'O'), (')', 'O'), ('decreased', 'O'), ('mitochondrial', 'O'), ('AMP', 'O'), ('-', 'O'), ('alpha2', 'O'), ('protein', 'O'), ('kinase', 'O'), (',', 'O'), ('and', 'O'), ('(', 'O'), ('6', 'O'), (')', 'O'), ('86', 'O'), ('%', 'O'), ('drop', 'O'), ('in', 'O'), ('cardiac', 'O'), ('ATP', 'O'), ('levels', 'O'), ('accompanied', 'O'), ('by', 'O'), ('decreased', 'O'), ('ATP', 'O'), ('/', 'O'), ('ADP', 'O'), ('ratio', 'O'), ('after', 'O'), ('doxorubicin', 'O'), ('administration', 'O'), ('.', 'O'))"
Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK / STAT3 pathway .,"(('Decreased', 'O'), ('cardiac', 'O'), ('erythropoietin', 'O'), ('and', 'O'), ('increased', 'O'), ('SOCS3', 'O'), ('further', 'O'), ('downregulated', 'O'), ('the', 'O'), ('cardioprotective', 'O'), ('JAK', 'O'), ('/', 'O'), ('STAT3', 'O'), ('pathway', 'O'), ('.', 'O'))"
Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol .,"(('Severe', 'O'), ('alterations', 'O'), ('in', 'O'), ('the', 'O'), ('structural', 'O'), ('integrity', 'O'), ('of', 'O'), ('the', 'O'), ('sarcolemma', 'O'), ('of', 'O'), ('cardiomyocytes', 'O'), ('have', 'O'), ('been', 'O'), ('demonstrated', 'O'), ('to', 'O'), ('be', 'O'), ('caused', 'O'), ('by', 'O'), ('isoproterenol', 'O'), ('.', 'O'))"
"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin - glycoprotein complex ( DGC ) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins .","(('Taking', 'O'), ('into', 'O'), ('account', 'O'), ('that', 'O'), ('the', 'O'), ('sarcolemmal', 'O'), ('integrity', 'O'), ('is', 'O'), ('stabilized', 'O'), ('by', 'O'), ('the', 'O'), ('dystrophin', 'O'), ('-', 'O'), ('glycoprotein', 'O'), ('complex', 'O'), ('(', 'O'), ('DGC', 'O'), (')', 'O'), ('that', 'O'), ('connects', 'O'), ('actin', 'O'), ('and', 'O'), ('laminin', 'O'), ('in', 'O'), ('contractile', 'O'), ('machinery', 'O'), ('and', 'O'), ('extracellular', 'O'), ('matrix', 'O'), ('and', 'O'), ('by', 'O'), ('integrins', 'O'), (',', 'O'), ('this', 'O'), ('study', 'O'), ('tests', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('isoproterenol', 'O'), ('affects', 'O'), ('sarcolemmal', 'O'), ('stability', 'O'), ('through', 'O'), ('changes', 'O'), ('in', 'O'), ('the', 'O'), ('DGC', 'O'), ('and', 'O'), ('integrins', 'O'), ('.', 'O'))"
We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration .,"(('We', 'O'), ('found', 'O'), ('different', 'O'), ('sensitivity', 'O'), ('of', 'O'), ('the', 'O'), ('DGC', 'O'), ('and', 'O'), ('integrin', 'O'), ('to', 'O'), ('isoproterenol', 'O'), ('subcutaneous', 'O'), ('administration', 'O'), ('.', 'O'))"
Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix .,"(('Immunofluorescent', 'O'), ('staining', 'O'), ('revealed', 'O'), ('that', 'O'), ('dystrophin', 'O'), ('is', 'O'), ('the', 'O'), ('most', 'O'), ('sensitive', 'O'), ('among', 'O'), ('the', 'O'), ('structures', 'O'), ('connecting', 'O'), ('the', 'O'), ('actin', 'O'), ('in', 'O'), ('the', 'O'), ('cardiomyocyte', 'O'), ('cytoskeleton', 'O'), ('and', 'O'), ('the', 'O'), ('extracellular', 'O'), ('matrix', 'O'), ('.', 'O'))"
The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin .,"(('The', 'O'), ('sarcomeric', 'O'), ('actin', 'O'), ('dissolution', 'O'), ('occurred', 'O'), ('after', 'O'), ('the', 'O'), ('reduction', 'O'), ('or', 'O'), ('loss', 'O'), ('of', 'O'), ('dystrophin', 'O'), ('.', 'O'))"
"Subsequently , after lysis of myofilaments , gamma - sarcoglycan , beta - dystroglycan , beta1 - integrin , and laminin alpha - 2 expressions were reduced followed by their breakdown , as epiphenomena of the myocytolytic process .","(('Subsequently', 'O'), (',', 'O'), ('after', 'O'), ('lysis', 'O'), ('of', 'O'), ('myofilaments', 'O'), (',', 'O'), ('gamma', 'O'), ('-', 'O'), ('sarcoglycan', 'O'), (',', 'O'), ('beta', 'O'), ('-', 'O'), ('dystroglycan', 'O'), (',', 'O'), ('beta1', 'O'), ('-', 'O'), ('integrin', 'O'), (',', 'O'), ('and', 'O'), ('laminin', 'O'), ('alpha', 'O'), ('-', 'O'), ('2', 'O'), ('expressions', 'O'), ('were', 'O'), ('reduced', 'O'), ('followed', 'O'), ('by', 'O'), ('their', 'O'), ('breakdown', 'O'), (',', 'O'), ('as', 'O'), ('epiphenomena', 'O'), ('of', 'O'), ('the', 'O'), ('myocytolytic', 'O'), ('process', 'O'), ('.', 'O'))"
"In conclusion , administration of isoproterenol to rats results in primary loss of dystrophin , the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('administration', 'O'), ('of', 'O'), ('isoproterenol', 'O'), ('to', 'O'), ('rats', 'O'), ('results', 'O'), ('in', 'O'), ('primary', 'O'), ('loss', 'O'), ('of', 'O'), ('dystrophin', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('sensitive', 'O'), ('among', 'O'), ('the', 'O'), ('structural', 'O'), ('proteins', 'O'), ('that', 'O'), ('form', 'O'), ('the', 'O'), ('DGC', 'O'), ('that', 'O'), ('connects', 'O'), ('the', 'O'), ('extracellular', 'O'), ('matrix', 'O'), ('and', 'O'), ('the', 'O'), ('cytoskeleton', 'O'), ('in', 'O'), ('cardiomyocyte', 'O'), ('.', 'O'))"
Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives .,"(('Etiologic', 'O'), ('factors', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('liver', 'B'), ('tumors', 'I'), ('associated', 'O'), ('with', 'O'), ('oral', 'O'), ('contraceptives', 'O'), ('.', 'O'))"
"Within the last several years , previously rare liver tumors have been seen in young women using oral contraceptive steroids .","(('Within', 'O'), ('the', 'O'), ('last', 'O'), ('several', 'O'), ('years', 'O'), (',', 'O'), ('previously', 'O'), ('rare', 'O'), ('liver', 'B'), ('tumors', 'I'), ('have', 'O'), ('been', 'O'), ('seen', 'O'), ('in', 'O'), ('young', 'O'), ('women', 'O'), ('using', 'O'), ('oral', 'O'), ('contraceptive', 'O'), ('steroids', 'O'), ('.', 'O'))"
The recent literature contains 44 case reports .,"(('The', 'O'), ('recent', 'O'), ('literature', 'O'), ('contains', 'O'), ('44', 'O'), ('case', 'O'), ('reports', 'O'), ('.', 'O'))"
Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids .,"(('Significant', 'O'), ('statistical', 'O'), ('etiologic', 'O'), ('factors', 'O'), ('include', 'O'), ('prolonged', 'O'), ('uninterrupted', 'O'), ('usage', 'O'), ('of', 'O'), ('oral', 'O'), ('contraceptive', 'O'), ('steroids', 'O'), ('.', 'O'))"
Ifosfamide continuous infusion without mesna .,"(('Ifosfamide', 'O'), ('continuous', 'O'), ('infusion', 'O'), ('without', 'O'), ('mesna', 'O'), ('.', 'O'))"
A phase I trial of a 14 - day cycle .,"(('A', 'O'), ('phase', 'O'), ('I', 'O'), ('trial', 'O'), ('of', 'O'), ('a', 'O'), ('14', 'O'), ('-', 'O'), ('day', 'O'), ('cycle', 'O'), ('.', 'O'))"
Twenty patients received 27 courses of ifosfamide administered as a 24 - hour continuous infusion for 14 days without Mesna .,"(('Twenty', 'O'), ('patients', 'O'), ('received', 'O'), ('27', 'O'), ('courses', 'O'), ('of', 'O'), ('ifosfamide', 'O'), ('administered', 'O'), ('as', 'O'), ('a', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('continuous', 'O'), ('infusion', 'O'), ('for', 'O'), ('14', 'O'), ('days', 'O'), ('without', 'O'), ('Mesna', 'O'), ('.', 'O'))"
The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short - term infusions administered with Mesna .,"(('The', 'O'), ('goal', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('deliver', 'O'), ('a', 'O'), ('dose', 'O'), ('rate', 'O'), ('and', 'O'), ('total', 'O'), ('cumulative', 'O'), ('dose', 'O'), ('of', 'O'), ('ifosfamide', 'O'), ('that', 'O'), ('would', 'O'), ('be', 'O'), ('comparable', 'O'), ('to', 'O'), ('standard', 'O'), ('bolus', 'O'), ('or', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('infusions', 'O'), ('administered', 'O'), ('with', 'O'), ('Mesna', 'O'), ('.', 'O'))"
"Dose escalations proceeded from 200 to 300 , 400 , 450 , 500 , and 550 mg / m2 / d .","(('Dose', 'O'), ('escalations', 'O'), ('proceeded', 'O'), ('from', 'O'), ('200', 'O'), ('to', 'O'), ('300', 'O'), (',', 'O'), ('400', 'O'), (',', 'O'), ('450', 'O'), (',', 'O'), ('500', 'O'), (',', 'O'), ('and', 'O'), ('550', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('/', 'O'), ('d', 'O'), ('.', 'O'))"
"The recommended dose of 500 mg / m2 / d delivers a total dose of 7 g / m2 per cycle , which is comparable to that delivered in clinical practice for bolus or short - term infusion .","(('The', 'O'), ('recommended', 'O'), ('dose', 'O'), ('of', 'O'), ('500', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('/', 'O'), ('d', 'O'), ('delivers', 'O'), ('a', 'O'), ('total', 'O'), ('dose', 'O'), ('of', 'O'), ('7', 'O'), ('g', 'O'), ('/', 'O'), ('m2', 'O'), ('per', 'O'), ('cycle', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('comparable', 'O'), ('to', 'O'), ('that', 'O'), ('delivered', 'O'), ('in', 'O'), ('clinical', 'O'), ('practice', 'O'), ('for', 'O'), ('bolus', 'O'), ('or', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('infusion', 'O'), ('.', 'O'))"
"Because few patients received multiple courses over time , the cumulative effects are indeterminate in the present trial .","(('Because', 'O'), ('few', 'O'), ('patients', 'O'), ('received', 'O'), ('multiple', 'O'), ('courses', 'O'), ('over', 'O'), ('time', 'O'), (',', 'O'), ('the', 'O'), ('cumulative', 'O'), ('effects', 'O'), ('are', 'O'), ('indeterminate', 'O'), ('in', 'O'), ('the', 'O'), ('present', 'O'), ('trial', 'O'), ('.', 'O'))"
The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to 890 per cycle .,"(('The', 'O'), ('protracted', 'O'), ('infusion', 'O'), ('schedule', 'O'), ('for', 'O'), ('ifosfamide', 'O'), ('permits', 'O'), ('convenient', 'O'), ('outpatient', 'O'), ('administration', 'O'), ('without', 'O'), ('Mesna', 'O'), ('and', 'O'), ('reduces', 'O'), ('the', 'O'), ('drug', 'O'), ('cost', 'O'), ('of', 'O'), ('clinical', 'O'), ('usage', 'O'), ('of', 'O'), ('this', 'O'), ('agent', 'O'), ('by', 'O'), ('up', 'O'), ('to', 'O'), ('890', 'O'), ('per', 'O'), ('cycle', 'O'), ('.', 'O'))"
"Clinical activity was demonstrated in a single patient , but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained .","(('Clinical', 'O'), ('activity', 'O'), ('was', 'O'), ('demonstrated', 'O'), ('in', 'O'), ('a', 'O'), ('single', 'O'), ('patient', 'O'), (',', 'O'), ('but', 'O'), ('a', 'O'), ('comparative', 'O'), ('trial', 'O'), ('of', 'O'), ('standard', 'O'), ('bolus', 'O'), ('schedules', 'O'), ('with', 'O'), ('the', 'O'), ('protracted', 'O'), ('infusion', 'O'), ('schedule', 'O'), ('will', 'O'), ('be', 'O'), ('necessary', 'O'), ('to', 'O'), ('determine', 'O'), ('if', 'O'), ('the', 'O'), ('clinical', 'O'), ('effectiveness', 'O'), ('of', 'O'), ('the', 'O'), ('drug', 'O'), ('is', 'O'), ('maintained', 'O'), ('.', 'O'))"
"Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice , especially in older patients with higher seizure thresholds .","(('Suboptimal', 'O'), ('seizure', 'O'), ('duration', 'O'), ('is', 'O'), ('commonly', 'O'), ('encountered', 'O'), ('in', 'O'), ('electroconvulsive', 'O'), ('therapy', 'O'), ('practice', 'O'), (',', 'O'), ('especially', 'O'), ('in', 'O'), ('older', 'O'), ('patients', 'O'), ('with', 'O'), ('higher', 'O'), ('seizure', 'O'), ('thresholds', 'O'), ('.', 'O'))"
"We propose that naturally occurring compounds such as flavonoids , which are present in fruit juices , may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin .","(('We', 'O'), ('propose', 'O'), ('that', 'O'), ('naturally', 'O'), ('occurring', 'O'), ('compounds', 'O'), ('such', 'O'), ('as', 'O'), ('flavonoids', 'O'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('present', 'O'), ('in', 'O'), ('fruit', 'O'), ('juices', 'O'), (',', 'O'), ('may', 'O'), ('increase', 'O'), ('the', 'O'), ('potency', 'O'), ('of', 'O'), ('warfarin', 'O'), ('by', 'O'), ('competing', 'O'), ('for', 'O'), ('the', 'O'), ('enzymes', 'O'), ('that', 'O'), ('normally', 'O'), ('inactivate', 'O'), ('warfarin', 'O'), ('.', 'O'))"
"While traditionally regarded as foodstuffs , consumption of fruit juices should be considered when patients develop adverse drug reactions .","(('While', 'O'), ('traditionally', 'O'), ('regarded', 'O'), ('as', 'O'), ('foodstuffs', 'O'), (',', 'O'), ('consumption', 'O'), ('of', 'O'), ('fruit', 'O'), ('juices', 'O'), ('should', 'O'), ('be', 'O'), ('considered', 'O'), ('when', 'O'), ('patients', 'O'), ('develop', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reactions', 'O'), ('.', 'O'))"
Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride - induced seizures in mice .,"(('Effect', 'O'), ('of', 'O'), ('increasing', 'O'), ('intraperitoneal', 'O'), ('infusion', 'O'), ('rates', 'O'), ('on', 'O'), ('bupropion', 'O'), ('hydrochloride', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
BACKGROUND : It is not known if there is a relationship between input rate and incidence of bupropion - induced seizures .,"(('BACKGROUND', 'O'), (':', 'O'), ('It', 'O'), ('is', 'O'), ('not', 'O'), ('known', 'O'), ('if', 'O'), ('there', 'O'), ('is', 'O'), ('a', 'O'), ('relationship', 'O'), ('between', 'O'), ('input', 'O'), ('rate', 'O'), ('and', 'O'), ('incidence', 'O'), ('of', 'O'), ('bupropion', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('.', 'O'))"
"This is important , since different controlled release formulations of bupropion release the active drug at different rates .","(('This', 'O'), ('is', 'O'), ('important', 'O'), (',', 'O'), ('since', 'O'), ('different', 'O'), ('controlled', 'O'), ('release', 'O'), ('formulations', 'O'), ('of', 'O'), ('bupropion', 'O'), ('release', 'O'), ('the', 'O'), ('active', 'O'), ('drug', 'O'), ('at', 'O'), ('different', 'O'), ('rates', 'O'), ('.', 'O'))"
"METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced convulsions in the Swiss albino mice .","(('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('varying', 'O'), ('the', 'O'), ('intraperitoneal', 'O'), ('infusion', 'O'), ('rates', 'O'), ('of', 'O'), ('bupropion', 'O'), ('HCl', 'O'), ('120', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('a', 'O'), ('known', 'O'), ('convulsive', 'O'), ('dose', 'O'), ('50', 'O'), ('(', 'O'), ('CD50', 'O'), (')', 'O'), (',', 'O'), ('on', 'O'), ('the', 'O'), ('incidence', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('bupropion', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('in', 'O'), ('the', 'O'), ('Swiss', 'O'), ('albino', 'O'), ('mice', 'O'), ('.', 'O'))"
"A total of 69 mice , approximately 7 weeks of age , and weighing 21 . 0 to 29 . 1 g were randomly assigned to bupropion HCl 120 mg / kg treatment by intraperitoneal ( IP ) administration in 7 groups ( 9 to 10 animals per group ) .","(('A', 'O'), ('total', 'O'), ('of', 'O'), ('69', 'O'), ('mice', 'O'), (',', 'O'), ('approximately', 'O'), ('7', 'O'), ('weeks', 'O'), ('of', 'O'), ('age', 'O'), (',', 'O'), ('and', 'O'), ('weighing', 'O'), ('21', 'O'), ('.', 'O'), ('0', 'O'), ('to', 'O'), ('29', 'O'), ('.', 'O'), ('1', 'O'), ('g', 'O'), ('were', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('bupropion', 'O'), ('HCl', 'O'), ('120', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('treatment', 'O'), ('by', 'O'), ('intraperitoneal', 'O'), ('(', 'O'), ('IP', 'O'), (')', 'O'), ('administration', 'O'), ('in', 'O'), ('7', 'O'), ('groups', 'O'), ('(', 'O'), ('9', 'O'), ('to', 'O'), ('10', 'O'), ('animals', 'O'), ('per', 'O'), ('group', 'O'), (')', 'O'), ('.', 'O'))"
"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min , 15 min , 30 min , 60 min , 90 min , 120 min , and 240 min .","(('Bupropion', 'O'), ('HCl', 'O'), ('was', 'O'), ('infused', 'O'), ('through', 'O'), ('a', 'O'), ('surgically', 'O'), ('implanted', 'O'), ('IP', 'O'), ('dosing', 'O'), ('catheter', 'O'), ('with', 'O'), ('infusions', 'O'), ('in', 'O'), ('each', 'O'), ('group', 'O'), ('of', 'O'), ('0', 'O'), ('min', 'O'), (',', 'O'), ('15', 'O'), ('min', 'O'), (',', 'O'), ('30', 'O'), ('min', 'O'), (',', 'O'), ('60', 'O'), ('min', 'O'), (',', 'O'), ('90', 'O'), ('min', 'O'), (',', 'O'), ('120', 'O'), ('min', 'O'), (',', 'O'), ('and', 'O'), ('240', 'O'), ('min', 'O'), ('.', 'O'))"
"The number , time of onset , duration and the intensity of the convulsions or absence of convulsions were recorded .","(('The', 'O'), ('number', 'O'), (',', 'O'), ('time', 'O'), ('of', 'O'), ('onset', 'O'), (',', 'O'), ('duration', 'O'), ('and', 'O'), ('the', 'O'), ('intensity', 'O'), ('of', 'O'), ('the', 'O'), ('convulsions', 'O'), ('or', 'O'), ('absence', 'O'), ('of', 'O'), ('convulsions', 'O'), ('were', 'O'), ('recorded', 'O'), ('.', 'O'))"
RESULTS : The results showed that IP administration of bupropion HCl 120 mg / kg by bolus injection induced convulsions in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .,"(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('results', 'O'), ('showed', 'O'), ('that', 'O'), ('IP', 'O'), ('administration', 'O'), ('of', 'O'), ('bupropion', 'O'), ('HCl', 'O'), ('120', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('by', 'O'), ('bolus', 'O'), ('injection', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('in', 'O'), ('6', 'O'), ('out', 'O'), ('of', 'O'), ('10', 'O'), ('mice', 'O'), ('(', 'O'), ('60', 'O'), ('%', 'O'), ('of', 'O'), ('convulsing', 'O'), ('mice', 'O'), (')', 'O'), ('in', 'O'), ('group', 'O'), ('1', 'O'), ('.', 'O'))"
Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of bupropion HCl 120 mg / kg was associated with a 91 % reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection .,"(('Logistic', 'O'), ('regression', 'O'), ('analysis', 'O'), ('revealed', 'O'), ('that', 'O'), ('infusion', 'O'), ('time', 'O'), ('was', 'O'), ('significant', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0004', 'O'), (';', 'O'), ('odds', 'O'), ('ratio', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('974', 'O'), (')', 'O'), ('and', 'O'), ('increasing', 'O'), ('the', 'O'), ('IP', 'O'), ('infusion', 'O'), ('time', 'O'), ('of', 'O'), ('bupropion', 'O'), ('HCl', 'O'), ('120', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('91', 'O'), ('%', 'O'), ('reduced', 'O'), ('odds', 'O'), ('of', 'O'), ('convulsions', 'O'), ('at', 'O'), ('infusion', 'O'), ('times', 'O'), ('of', 'O'), ('15', 'O'), ('to', 'O'), ('90', 'O'), ('min', 'O'), ('compared', 'O'), ('to', 'O'), ('bolus', 'O'), ('injection', 'O'), ('.', 'O'))"
Further increase in infusion time resulted in further reduction in the odds of convulsions to 99 . 8 % reduction at 240 min .,"(('Further', 'O'), ('increase', 'O'), ('in', 'O'), ('infusion', 'O'), ('time', 'O'), ('resulted', 'O'), ('in', 'O'), ('further', 'O'), ('reduction', 'O'), ('in', 'O'), ('the', 'O'), ('odds', 'O'), ('of', 'O'), ('convulsions', 'O'), ('to', 'O'), ('99', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('reduction', 'O'), ('at', 'O'), ('240', 'O'), ('min', 'O'), ('.', 'O'))"
"CONCLUSION : In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel .","(('CONCLUSION', 'O'), (':', 'O'), ('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('the', 'O'), ('demonstration', 'O'), ('of', 'O'), ('an', 'O'), ('inverse', 'O'), ('relationship', 'O'), ('between', 'O'), ('infusion', 'O'), ('time', 'O'), ('of', 'O'), ('a', 'O'), ('fixed', 'O'), ('and', 'O'), ('convulsive', 'O'), ('dose', 'O'), ('of', 'O'), ('bupropion', 'O'), ('and', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('convulsions', 'O'), ('in', 'O'), ('a', 'O'), ('prospective', 'O'), ('study', 'O'), ('is', 'O'), ('novel', 'O'), ('.', 'O'))"
"Everolimus , a derivative of sirolimus , seems to mediate antileukemia effects .","(('Everolimus', 'O'), (',', 'O'), ('a', 'O'), ('derivative', 'O'), ('of', 'O'), ('sirolimus', 'O'), (',', 'O'), ('seems', 'O'), ('to', 'O'), ('mediate', 'O'), ('antileukemia', 'O'), ('effects', 'O'), ('.', 'O'))"
"With a median follow - up of 26 months , the 2 - year overall survival rate was 47 % .","(('With', 'O'), ('a', 'O'), ('median', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('of', 'O'), ('26', 'O'), ('months', 'O'), (',', 'O'), ('the', 'O'), ('2', 'O'), ('-', 'O'), ('year', 'O'), ('overall', 'O'), ('survival', 'O'), ('rate', 'O'), ('was', 'O'), ('47', 'O'), ('%', 'O'), ('.', 'O'))"
Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas .,"(('Longitudinal', 'O'), ('assessment', 'O'), ('of', 'O'), ('air', 'O'), ('conduction', 'O'), ('audiograms', 'O'), ('in', 'O'), ('a', 'O'), ('phase', 'O'), ('III', 'O'), ('clinical', 'O'), ('trial', 'O'), ('of', 'O'), ('difluoromethylornithine', 'O'), ('and', 'O'), ('sulindac', 'O'), ('for', 'O'), ('prevention', 'O'), ('of', 'O'), ('sporadic', 'O'), ('colorectal', 'B'), ('adenomas', 'I'), ('.', 'O'))"
A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine ( DFMO ) plus sulindac or matched placebos .,"(('A', 'O'), ('phase', 'O'), ('III', 'O'), ('clinical', 'O'), ('trial', 'O'), ('assessed', 'O'), ('the', 'O'), ('recurrence', 'O'), ('of', 'O'), ('adenomatous', 'B'), ('polyps', 'I'), ('after', 'O'), ('treatment', 'O'), ('for', 'O'), ('36', 'O'), ('months', 'O'), ('with', 'O'), ('difluoromethylornithine', 'O'), ('(', 'O'), ('DFMO', 'O'), (')', 'O'), ('plus', 'O'), ('sulindac', 'O'), ('or', 'O'), ('matched', 'O'), ('placebos', 'O'), ('.', 'O'))"
"Temporary hearing loss is a known toxicity of treatment with DFMO , thus a comprehensive approach was developed to analyze serial air conduction audiograms .","(('Temporary', 'B'), ('hearing', 'B'), ('loss', 'I'), ('is', 'O'), ('a', 'O'), ('known', 'O'), ('toxicity', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('DFMO', 'O'), (',', 'O'), ('thus', 'O'), ('a', 'O'), ('comprehensive', 'O'), ('approach', 'O'), ('was', 'O'), ('developed', 'O'), ('to', 'O'), ('analyze', 'O'), ('serial', 'O'), ('air', 'O'), ('conduction', 'O'), ('audiograms', 'O'), ('.', 'O'))"
The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within - subject correlation due to repeated measurements at frequencies .,"(('The', 'O'), ('generalized', 'O'), ('estimating', 'O'), ('equation', 'O'), ('method', 'O'), ('estimated', 'O'), ('the', 'O'), ('mean', 'O'), ('difference', 'O'), ('between', 'O'), ('treatment', 'O'), ('arms', 'O'), ('with', 'O'), ('regard', 'O'), ('to', 'O'), ('change', 'O'), ('in', 'O'), ('air', 'O'), ('conduction', 'O'), ('pure', 'O'), ('tone', 'O'), ('thresholds', 'O'), ('while', 'O'), ('accounting', 'O'), ('for', 'O'), ('within', 'O'), ('-', 'O'), ('subject', 'O'), ('correlation', 'O'), ('due', 'O'), ('to', 'O'), ('repeated', 'O'), ('measurements', 'O'), ('at', 'O'), ('frequencies', 'O'), ('.', 'O'))"
"Based on 290 subjects , there was an average difference of 0 . 50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo ( 95 % confidence interval , - 0 . 64 to 1 . 63 dB ; P = 0 . 39 ) , adjusted for baseline values , age , and frequencies .","(('Based', 'O'), ('on', 'O'), ('290', 'O'), ('subjects', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('an', 'O'), ('average', 'O'), ('difference', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('50', 'O'), ('dB', 'O'), ('between', 'O'), ('subjects', 'O'), ('treated', 'O'), ('with', 'O'), ('DFMO', 'O'), ('plus', 'O'), ('sulindac', 'O'), ('compared', 'O'), ('with', 'O'), ('those', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('64', 'O'), ('to', 'O'), ('1', 'O'), ('.', 'O'), ('63', 'O'), ('dB', 'O'), (';', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('39', 'O'), (')', 'O'), (',', 'O'), ('adjusted', 'O'), ('for', 'O'), ('baseline', 'O'), ('values', 'O'), (',', 'O'), ('age', 'O'), (',', 'O'), ('and', 'O'), ('frequencies', 'O'), ('.', 'O'))"
"In the normal speech range of 500 to 3 , 000 Hz , an estimated difference of 0 . 99 dB ( - 0 . 17 to 2 . 14 dB ; P = 0 . 09 ) was detected .","(('In', 'O'), ('the', 'O'), ('normal', 'O'), ('speech', 'O'), ('range', 'O'), ('of', 'O'), ('500', 'O'), ('to', 'O'), ('3', 'O'), (',', 'O'), ('000', 'O'), ('Hz', 'O'), (',', 'O'), ('an', 'O'), ('estimated', 'O'), ('difference', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('99', 'O'), ('dB', 'O'), ('(', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('17', 'O'), ('to', 'O'), ('2', 'O'), ('.', 'O'), ('14', 'O'), ('dB', 'O'), (';', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('09', 'O'), (')', 'O'), ('was', 'O'), ('detected', 'O'), ('.', 'O'))"
Dose intensity did not add information to models .,"(('Dose', 'O'), ('intensity', 'O'), ('did', 'O'), ('not', 'O'), ('add', 'O'), ('information', 'O'), ('to', 'O'), ('models', 'O'), ('.', 'O'))"
There were 14 of 151 ( 9 . 3 % ) in the DFMO plus sulindac group and 4 of 139 ( 2 . 9 % ) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested ( P = 0 . 02 ) .,"(('There', 'O'), ('were', 'O'), ('14', 'O'), ('of', 'O'), ('151', 'O'), ('(', 'O'), ('9', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('DFMO', 'O'), ('plus', 'O'), ('sulindac', 'O'), ('group', 'O'), ('and', 'O'), ('4', 'O'), ('of', 'O'), ('139', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('who', 'O'), ('experienced', 'O'), ('at', 'O'), ('least', 'O'), ('15', 'O'), ('dB', 'O'), ('hearing', 'O'), ('reduction', 'O'), ('from', 'O'), ('baseline', 'O'), ('in', 'O'), ('2', 'O'), ('or', 'O'), ('more', 'O'), ('consecutive', 'O'), ('frequencies', 'O'), ('across', 'O'), ('the', 'O'), ('entire', 'O'), ('range', 'O'), ('tested', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('02', 'O'), (')', 'O'), ('.', 'O'))"
Follow - up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1 . 08 dB ( - 0 . 81 to 2 . 96 dB ; P = 0 . 26 ) between treatment arms .,"(('Follow', 'O'), ('-', 'O'), ('up', 'O'), ('air', 'O'), ('conduction', 'O'), ('done', 'O'), ('at', 'O'), ('least', 'O'), ('6', 'O'), ('months', 'O'), ('after', 'O'), ('end', 'O'), ('of', 'O'), ('treatment', 'O'), ('showed', 'O'), ('an', 'O'), ('adjusted', 'O'), ('mean', 'O'), ('difference', 'O'), ('in', 'O'), ('hearing', 'O'), ('thresholds', 'O'), ('of', 'O'), ('1', 'O'), ('.', 'O'), ('08', 'O'), ('dB', 'O'), ('(', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('81', 'O'), ('to', 'O'), ('2', 'O'), ('.', 'O'), ('96', 'O'), ('dB', 'O'), (';', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('26', 'O'), (')', 'O'), ('between', 'O'), ('treatment', 'O'), ('arms', 'O'), ('.', 'O'))"
There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('significant', 'O'), ('difference', 'O'), ('in', 'O'), ('the', 'O'), ('proportion', 'O'), ('of', 'O'), ('subjects', 'O'), ('in', 'O'), ('the', 'O'), ('DFMO', 'O'), ('plus', 'O'), ('sulindac', 'O'), ('group', 'O'), ('who', 'O'), ('experienced', 'O'), ('clinically', 'O'), ('significant', 'O'), ('hearing', 'B'), ('loss', 'I'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('.', 'O'))"
There is a < 2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo .,"(('There', 'O'), ('is', 'O'), ('a', 'O'), ('<', 'O'), ('2', 'O'), ('dB', 'O'), ('difference', 'O'), ('in', 'O'), ('mean', 'O'), ('threshold', 'O'), ('for', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('DFMO', 'O'), ('plus', 'O'), ('sulindac', 'O'), ('compared', 'O'), ('with', 'O'), ('those', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('.', 'O'))"
Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment .,"(('Proteinase', 'O'), ('3', 'O'), ('-', 'O'), ('antineutrophil', 'O'), ('cytoplasmic', 'O'), ('antibody', 'O'), ('-', 'O'), ('(', 'O'), ('PR3', 'O'), ('-', 'O'), ('ANCA', 'O'), (')', 'O'), ('positive', 'O'), ('necrotizing', 'B'), ('glomerulonephritis', 'I'), ('after', 'O'), ('restarting', 'O'), ('sulphasalazine', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Proteinase 3 - antineutrophil cytoplasmic antibody ( PR3 - ANCA ) titer was elevated at 183 ELISA units ( EU ) in sera ( normal range less than 10 EU ) , myeloperoxidase - ANCA was negative .","(('Proteinase', 'O'), ('3', 'O'), ('-', 'O'), ('antineutrophil', 'O'), ('cytoplasmic', 'O'), ('antibody', 'O'), ('(', 'O'), ('PR3', 'O'), ('-', 'O'), ('ANCA', 'O'), (')', 'O'), ('titer', 'O'), ('was', 'O'), ('elevated', 'O'), ('at', 'O'), ('183', 'O'), ('ELISA', 'O'), ('units', 'O'), ('(', 'O'), ('EU', 'O'), (')', 'O'), ('in', 'O'), ('sera', 'O'), ('(', 'O'), ('normal', 'O'), ('range', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('EU', 'O'), (')', 'O'), (',', 'O'), ('myeloperoxidase', 'O'), ('-', 'O'), ('ANCA', 'O'), ('was', 'O'), ('negative', 'O'), ('.', 'O'))"
This case suggests that sulphasalazine can induce PR3 - ANCA - positive necrotizing glomerulonephritis .,"(('This', 'O'), ('case', 'O'), ('suggests', 'O'), ('that', 'O'), ('sulphasalazine', 'O'), ('can', 'O'), ('induce', 'O'), ('PR3', 'O'), ('-', 'O'), ('ANCA', 'O'), ('-', 'O'), ('positive', 'O'), ('necrotizing', 'B'), ('glomerulonephritis', 'I'), ('.', 'O'))"
All patients had bilateral symptoms and their levodopa equivalent dosing were analysed .,"(('All', 'O'), ('patients', 'O'), ('had', 'O'), ('bilateral', 'O'), ('symptoms', 'O'), ('and', 'O'), ('their', 'O'), ('levodopa', 'O'), ('equivalent', 'O'), ('dosing', 'O'), ('were', 'O'), ('analysed', 'O'), ('.', 'O'))"
Six patients were operated on in the globus pallidus interna ( GPi ) and four in the subthalamic nucleus ( STN ) .,"(('Six', 'O'), ('patients', 'O'), ('were', 'O'), ('operated', 'O'), ('on', 'O'), ('in', 'O'), ('the', 'O'), ('globus', 'O'), ('pallidus', 'O'), ('interna', 'O'), ('(', 'O'), ('GPi', 'O'), (')', 'O'), ('and', 'O'), ('four', 'O'), ('in', 'O'), ('the', 'O'), ('subthalamic', 'O'), ('nucleus', 'O'), ('(', 'O'), ('STN', 'O'), (')', 'O'), ('.', 'O'))"
Levodopa equivalent daily intake was significantly reduced in the STN group .,"(('Levodopa', 'O'), ('equivalent', 'O'), ('daily', 'O'), ('intake', 'O'), ('was', 'O'), ('significantly', 'O'), ('reduced', 'O'), ('in', 'O'), ('the', 'O'), ('STN', 'O'), ('group', 'O'), ('.', 'O'))"
"Changes in UPDRS , Hoehn _ Yahr and Schwab England ADL scores were similar in both groups .","(('Changes', 'O'), ('in', 'O'), ('UPDRS', 'O'), (',', 'O'), ('Hoehn', 'O'), ('_', 'O'), ('Yahr', 'O'), ('and', 'O'), ('Schwab', 'O'), ('England', 'O'), ('ADL', 'O'), ('scores', 'O'), ('were', 'O'), ('similar', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('.', 'O'))"
Cognitive functions were unchanged in both groups .,"(('Cognitive', 'O'), ('functions', 'O'), ('were', 'O'), ('unchanged', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('.', 'O'))"
"Thirty patients were treated with three 21 - day cycles of bortezomib 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900 , 1 , 200 , or 1 , 500 mg / m ( 2 ) on day 1 .","(('Thirty', 'O'), ('patients', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('three', 'O'), ('21', 'O'), ('-', 'O'), ('day', 'O'), ('cycles', 'O'), ('of', 'O'), ('bortezomib', 'O'), ('1', 'O'), ('.', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('m', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('on', 'O'), ('days', 'O'), ('1', 'O'), (',', 'O'), ('4', 'O'), (',', 'O'), ('8', 'O'), (',', 'O'), ('and', 'O'), ('11', 'O'), ('plus', 'O'), ('dexamethasone', 'O'), ('40', 'O'), ('mg', 'O'), ('on', 'O'), ('the', 'O'), ('day', 'O'), ('of', 'O'), ('bortezomib', 'O'), ('injection', 'O'), ('and', 'O'), ('the', 'O'), ('day', 'O'), ('after', 'O'), ('plus', 'O'), ('cyclophosphamide', 'O'), ('at', 'O'), ('900', 'O'), (',', 'O'), ('1', 'O'), (',', 'O'), ('200', 'O'), (',', 'O'), ('or', 'O'), ('1', 'O'), (',', 'O'), ('500', 'O'), ('mg', 'O'), ('/', 'O'), ('m', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('on', 'O'), ('day', 'O'), ('1', 'O'), ('.', 'O'))"
The maximum tolerated dose of cyclophosphamide was defined as 900 mg / m ( 2 ) .,"(('The', 'O'), ('maximum', 'O'), ('tolerated', 'O'), ('dose', 'O'), ('of', 'O'), ('cyclophosphamide', 'O'), ('was', 'O'), ('defined', 'O'), ('as', 'O'), ('900', 'O'), ('mg', 'O'), ('/', 'O'), ('m', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('.', 'O'))"
"At this dose level , 92 % of patients achieved at least a partial response .","(('At', 'O'), ('this', 'O'), ('dose', 'O'), ('level', 'O'), (',', 'O'), ('92', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('achieved', 'O'), ('at', 'O'), ('least', 'O'), ('a', 'O'), ('partial', 'O'), ('response', 'O'), ('.', 'O'))"
"The overall response rate [ complete response ( CR ) plus partial response ( PR ) ] across all dose levels was 77 % , with a 10 % CR rate .","(('The', 'O'), ('overall', 'O'), ('response', 'O'), ('rate', 'O'), ('[', 'O'), ('complete', 'O'), ('response', 'O'), ('(', 'O'), ('CR', 'O'), (')', 'O'), ('plus', 'O'), ('partial', 'O'), ('response', 'O'), ('(', 'O'), ('PR', 'O'), (')', 'O'), (']', 'O'), ('across', 'O'), ('all', 'O'), ('dose', 'O'), ('levels', 'O'), ('was', 'O'), ('77', 'O'), ('%', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('10', 'O'), ('%', 'O'), ('CR', 'O'), ('rate', 'O'), ('.', 'O'))"
No patient experienced progressive disease .,"(('No', 'O'), ('patient', 'O'), ('experienced', 'O'), ('progressive', 'O'), ('disease', 'O'), ('.', 'O'))"
The hemodynamic effects of captopril and other angiotensin - converting enzyme inhibitors may be mediated by the endogenous opioid system .,"(('The', 'O'), ('hemodynamic', 'O'), ('effects', 'O'), ('of', 'O'), ('captopril', 'O'), ('and', 'O'), ('other', 'O'), ('angiotensin', 'O'), ('-', 'O'), ('converting', 'O'), ('enzyme', 'O'), ('inhibitors', 'O'), ('may', 'O'), ('be', 'O'), ('mediated', 'O'), ('by', 'O'), ('the', 'O'), ('endogenous', 'O'), ('opioid', 'O'), ('system', 'O'), ('.', 'O'))"
"To our knowledge , this is the first reported case of captopril - induced hypotension treated with naloxone .","(('To', 'O'), ('our', 'O'), ('knowledge', 'O'), (',', 'O'), ('this', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('reported', 'O'), ('case', 'O'), ('of', 'O'), ('captopril', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('treated', 'O'), ('with', 'O'), ('naloxone', 'O'), ('.', 'O'))"
Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril .,"(('Our', 'O'), ('experience', 'O'), ('demonstrates', 'O'), ('a', 'O'), ('possible', 'O'), ('role', 'O'), ('of', 'O'), ('naloxone', 'O'), ('in', 'O'), ('the', 'O'), ('reversal', 'O'), ('of', 'O'), ('hypotension', 'B'), ('resulting', 'O'), ('from', 'O'), ('captopril', 'O'), ('.', 'O'))"
Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products .,"(('Identification', 'O'), ('of', 'O'), ('a', 'O'), ('simple', 'O'), ('and', 'O'), ('sensitive', 'O'), ('microplate', 'O'), ('method', 'O'), ('for', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('oversulfated', 'O'), ('chondroitin', 'O'), ('sulfate', 'O'), ('in', 'O'), ('heparin', 'O'), ('products', 'O'), ('.', 'O'))"
Heparin is a commonly implemented anticoagulant used to treat critically ill patients .,"(('Heparin', 'O'), ('is', 'O'), ('a', 'O'), ('commonly', 'O'), ('implemented', 'O'), ('anticoagulant', 'O'), ('used', 'O'), ('to', 'O'), ('treat', 'O'), ('critically', 'O'), ('ill', 'O'), ('patients', 'O'), ('.', 'O'))"
"Using both contaminated heparin products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent hypotension in pigs .","(('Using', 'O'), ('both', 'O'), ('contaminated', 'O'), ('heparin', 'O'), ('products', 'O'), ('and', 'O'), ('the', 'O'), ('synthetically', 'O'), ('produced', 'O'), ('derivative', 'O'), (',', 'O'), ('we', 'O'), ('showed', 'O'), ('that', 'O'), ('the', 'O'), ('OSCS', 'O'), ('produces', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('hypotension', 'B'), ('in', 'O'), ('pigs', 'O'), ('.', 'O'))"
"The no observed effect level ( NOEL ) for this contaminant appears to be approximately 1mg / kg , corresponding to a contamination level of approximately 3 % .","(('The', 'O'), ('no', 'O'), ('observed', 'O'), ('effect', 'O'), ('level', 'O'), ('(', 'O'), ('NOEL', 'O'), (')', 'O'), ('for', 'O'), ('this', 'O'), ('contaminant', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('approximately', 'O'), ('1mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('corresponding', 'O'), ('to', 'O'), ('a', 'O'), ('contamination', 'O'), ('level', 'O'), ('of', 'O'), ('approximately', 'O'), ('3', 'O'), ('%', 'O'), ('.', 'O'))"
"We also demonstrated that OSCS can be identified in heparin products using a simple , inexpensive , commercially available heparin enzyme immunoassay ( EIA ) kit that has a limit of detection of approximately 0 . 1 % , well below the NOEL .","(('We', 'O'), ('also', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('OSCS', 'B'), ('can', 'O'), ('be', 'O'), ('identified', 'O'), ('in', 'O'), ('heparin', 'O'), ('products', 'O'), ('using', 'O'), ('a', 'O'), ('simple', 'O'), (',', 'O'), ('inexpensive', 'O'), (',', 'O'), ('commercially', 'O'), ('available', 'O'), ('heparin', 'O'), ('enzyme', 'O'), ('immunoassay', 'O'), ('(', 'O'), ('EIA', 'O'), (')', 'O'), ('kit', 'O'), ('that', 'O'), ('has', 'O'), ('a', 'O'), ('limit', 'O'), ('of', 'O'), ('detection', 'O'), ('of', 'O'), ('approximately', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), (',', 'O'), ('well', 'O'), ('below', 'O'), ('the', 'O'), ('NOEL', 'O'), ('.', 'O'))"
This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives .,"(('This', 'O'), ('kit', 'O'), ('may', 'O'), ('provide', 'O'), ('a', 'O'), ('useful', 'O'), ('method', 'O'), ('to', 'O'), ('test', 'O'), ('heparin', 'O'), ('products', 'O'), ('for', 'O'), ('contamination', 'O'), ('with', 'O'), ('oversulfated', 'O'), ('GAG', 'O'), ('derivatives', 'O'), ('.', 'O'))"
We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer .,"(('We', 'O'), ('describe', 'O'), ('the', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('woman', 'O'), ('who', 'O'), ('developed', 'O'), ('the', 'O'), ('syndrome', 'O'), ('after', 'O'), ('chemotherapy', 'O'), ('for', 'O'), ('metastatic', 'B'), ('cancer', 'I'), ('.', 'O'))"
She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer .,"(('She', 'O'), ('underwent', 'O'), ('recent', 'O'), ('chemotherapy', 'O'), ('with', 'O'), ('fluorouracil', 'O'), ('for', 'O'), ('metastatic', 'B'), ('colorectal', 'I'), ('cancer', 'I'), ('.', 'O'))"
Coronary angiography revealed no obstructive coronary lesions .,"(('Coronary', 'O'), ('angiography', 'O'), ('revealed', 'O'), ('no', 'O'), ('obstructive', 'B'), ('coronary', 'I'), ('lesions', 'I'), ('.', 'O'))"
The patient was stabilized with medical therapy .,"(('The', 'O'), ('patient', 'O'), ('was', 'O'), ('stabilized', 'O'), ('with', 'O'), ('medical', 'O'), ('therapy', 'O'), ('.', 'O'))"
Four weeks later she remained completely asymptomatic .,"(('Four', 'O'), ('weeks', 'O'), ('later', 'O'), ('she', 'O'), ('remained', 'O'), ('completely', 'O'), ('asymptomatic', 'O'), ('.', 'O'))"
"Using a mouse model , we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate ( PCC ) can reduce hemorrhagic blood volume .","(('Using', 'O'), ('a', 'O'), ('mouse', 'O'), ('model', 'O'), (',', 'O'), ('we', 'O'), ('tested', 'O'), ('whether', 'O'), ('the', 'O'), ('rapid', 'O'), ('reversal', 'O'), ('of', 'O'), ('anticoagulation', 'O'), ('using', 'O'), ('human', 'O'), ('prothrombin', 'O'), ('complex', 'O'), ('concentrate', 'O'), ('(', 'O'), ('PCC', 'O'), (')', 'O'), ('can', 'O'), ('reduce', 'O'), ('hemorrhagic', 'O'), ('blood', 'O'), ('volume', 'O'), ('.', 'O'))"
"Male CD - 1 mice were treated with warfarin ( 2 mg / kg over 24 h ) , resulting in a mean ( + / - s . d . ) International Normalized Ratio of 3 . 5 + / - 0 . 9 .","(('Male', 'O'), ('CD', 'O'), ('-', 'O'), ('1', 'O'), ('mice', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('warfarin', 'O'), ('(', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('over', 'O'), ('24', 'O'), ('h', 'O'), (')', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('a', 'O'), ('mean', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('s', 'O'), ('.', 'O'), ('d', 'O'), ('.', 'O'), (')', 'O'), ('International', 'O'), ('Normalized', 'O'), ('Ratio', 'O'), ('of', 'O'), ('3', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('9', 'O'), ('.', 'O'))"
"First , we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice .","(('First', 'O'), (',', 'O'), ('we', 'O'), ('showed', 'O'), ('that', 'O'), ('an', 'O'), ('intravenous', 'O'), ('administration', 'O'), ('of', 'O'), ('human', 'O'), ('PCC', 'O'), ('rapidly', 'O'), ('reversed', 'O'), ('anticoagulation', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"Forty - five minutes later , the animals were randomly treated with PCC ( 100 U / kg ) or saline i . v . ( n = 12 per group ) .","(('Forty', 'O'), ('-', 'O'), ('five', 'O'), ('minutes', 'O'), ('later', 'O'), (',', 'O'), ('the', 'O'), ('animals', 'O'), ('were', 'O'), ('randomly', 'O'), ('treated', 'O'), ('with', 'O'), ('PCC', 'O'), ('(', 'O'), ('100', 'O'), ('U', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('or', 'O'), ('saline', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('12', 'O'), ('per', 'O'), ('group', 'O'), (')', 'O'), ('.', 'O'))"
"The mean hemorrhagic blood volume was reduced in PCC - treated animals ( 6 . 5 + / - 3 . 1 microL ) compared with saline controls ( 15 . 3 + / - 11 . 2 microL , P = 0 . 015 ) .","(('The', 'O'), ('mean', 'O'), ('hemorrhagic', 'O'), ('blood', 'O'), ('volume', 'O'), ('was', 'O'), ('reduced', 'O'), ('in', 'O'), ('PCC', 'O'), ('-', 'O'), ('treated', 'O'), ('animals', 'O'), ('(', 'O'), ('6', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('1', 'O'), ('microL', 'O'), (')', 'O'), ('compared', 'O'), ('with', 'O'), ('saline', 'O'), ('controls', 'O'), ('(', 'O'), ('15', 'O'), ('.', 'O'), ('3', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('11', 'O'), ('.', 'O'), ('2', 'O'), ('microL', 'O'), (',', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('015', 'O'), (')', 'O'), ('.', 'O'))"
"In contrast , such extensive lesions were never found in the PCC group .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('such', 'O'), ('extensive', 'O'), ('lesions', 'O'), ('were', 'O'), ('never', 'O'), ('found', 'O'), ('in', 'O'), ('the', 'O'), ('PCC', 'B'), ('group', 'O'), ('.', 'O'))"
Long term hormone therapy for perimenopausal and postmenopausal women .,"(('Long', 'O'), ('term', 'O'), ('hormone', 'O'), ('therapy', 'O'), ('for', 'O'), ('perimenopausal', 'O'), ('and', 'O'), ('postmenopausal', 'O'), ('women', 'O'), ('.', 'O'))"
This is an updated version of the original Cochrane review first published in 2005 .,"(('This', 'O'), ('is', 'O'), ('an', 'O'), ('updated', 'O'), ('version', 'O'), ('of', 'O'), ('the', 'O'), ('original', 'O'), ('Cochrane', 'O'), ('review', 'O'), ('first', 'O'), ('published', 'O'), ('in', 'O'), ('2005', 'O'), ('.', 'O'))"
Also relevant non - indexed journals and conference abstracts .,"(('Also', 'O'), ('relevant', 'O'), ('non', 'O'), ('-', 'O'), ('indexed', 'O'), ('journals', 'O'), ('and', 'O'), ('conference', 'O'), ('abstracts', 'O'), ('.', 'O'))"
"SELECTION CRITERIA : Randomised double - blind trials of HT versus placebo , taken for at least one year by perimenopausal or postmenopausal women .","(('SELECTION', 'O'), ('CRITERIA', 'O'), (':', 'O'), ('Randomised', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('trials', 'O'), ('of', 'O'), ('HT', 'O'), ('versus', 'O'), ('placebo', 'O'), (',', 'O'), ('taken', 'O'), ('for', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('year', 'O'), ('by', 'O'), ('perimenopausal', 'O'), ('or', 'O'), ('postmenopausal', 'O'), ('women', 'O'), ('.', 'O'))"
"HT included oestrogens , with or without progestogens , via oral , transdermal , subcutaneous or transnasal routes .","(('HT', 'O'), ('included', 'O'), ('oestrogens', 'O'), (',', 'O'), ('with', 'O'), ('or', 'O'), ('without', 'O'), ('progestogens', 'O'), (',', 'O'), ('via', 'O'), ('oral', 'O'), (',', 'O'), ('transdermal', 'O'), (',', 'O'), ('subcutaneous', 'O'), ('or', 'O'), ('transnasal', 'O'), ('routes', 'O'), ('.', 'O'))"
DATA COLLECTION AND ANALYSIS : Two authors independently assessed trial quality and extracted data .,"(('DATA', 'O'), ('COLLECTION', 'O'), ('AND', 'O'), ('ANALYSIS', 'O'), (':', 'O'), ('Two', 'O'), ('authors', 'O'), ('independently', 'O'), ('assessed', 'O'), ('trial', 'O'), ('quality', 'O'), ('and', 'O'), ('extracted', 'O'), ('data', 'O'), ('.', 'O'))"
"MAIN RESULTS : Nineteen trials involving 41 , 904 women were included .","(('MAIN', 'O'), ('RESULTS', 'O'), (':', 'O'), ('Nineteen', 'O'), ('trials', 'O'), ('involving', 'O'), ('41', 'O'), (',', 'O'), ('904', 'O'), ('women', 'O'), ('were', 'O'), ('included', 'O'), ('.', 'O'))"
"However , this study was not powered to detect differences between groups of younger women .","(('However', 'O'), (',', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('not', 'O'), ('powered', 'O'), ('to', 'O'), ('detect', 'O'), ('differences', 'O'), ('between', 'O'), ('groups', 'O'), ('of', 'O'), ('younger', 'O'), ('women', 'O'), ('.', 'O'))"
AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .,"(('AUTHORS', 'O'), (""'"", 'O'), ('CONCLUSIONS', 'O'), (':', 'O'), ('HT', 'O'), ('is', 'O'), ('not', 'O'), ('indicated', 'O'), ('for', 'O'), ('the', 'O'), ('routine', 'O'), ('management', 'O'), ('of', 'O'), ('chronic', 'B'), ('disease', 'I'), ('.', 'O'))"
"We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .","(('We', 'O'), ('need', 'O'), ('more', 'O'), ('evidence', 'O'), ('on', 'O'), ('the', 'O'), ('safety', 'O'), ('of', 'O'), ('HT', 'O'), ('for', 'O'), ('menopausal', 'O'), ('symptom', 'O'), ('control', 'O'), (',', 'O'), ('though', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('use', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('relatively', 'O'), ('safe', 'O'), ('for', 'O'), ('healthy', 'O'), ('younger', 'O'), ('women', 'O'), ('.', 'O'))"
Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .,"(('Renal', 'B'), ('failure', 'I'), ('developed', 'O'), ('after', 'O'), ('a', 'O'), ('prolonged', 'O'), ('course', 'O'), ('of', 'O'), ('vancomycin', 'O'), ('therapy', 'O'), ('in', 'O'), ('2', 'O'), ('patients', 'O'), ('who', 'O'), ('were', 'O'), ('receiving', 'O'), ('tenofovir', 'O'), ('disoproxil', 'O'), ('fumarate', 'O'), ('as', 'O'), ('part', 'O'), ('of', 'O'), ('an', 'O'), ('antiretroviral', 'O'), ('regimen', 'O'), ('.', 'O'))"
Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin .,"(('Clinicians', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('that', 'O'), ('tenofovir', 'O'), ('may', 'O'), ('raise', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('renal', 'B'), ('failure', 'I'), ('during', 'O'), ('prolonged', 'O'), ('administration', 'O'), ('of', 'O'), ('vancomycin', 'O'), ('.', 'O'))"
"Pyrazinamide can have adverse effects such as hepatic toxicity , hyperuricemia or digestive disorders .","(('Pyrazinamide', 'O'), ('can', 'O'), ('have', 'O'), ('adverse', 'O'), ('effects', 'O'), ('such', 'O'), ('as', 'O'), ('hepatic', 'B'), ('toxicity', 'I'), (',', 'O'), ('hyperuricemia', 'B'), ('or', 'O'), ('digestive', 'B'), ('disorders', 'I'), ('.', 'O'))"
"In rare cases , alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs .","(('In', 'O'), ('rare', 'O'), ('cases', 'O'), (',', 'O'), ('alterations', 'O'), ('in', 'O'), ('taste', 'O'), ('and', 'O'), ('smell', 'O'), ('function', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('for', 'O'), ('pyrazinamide', 'O'), ('when', 'O'), ('combined', 'O'), ('with', 'O'), ('other', 'O'), ('drugs', 'O'), ('.', 'O'))"
The patient presented every day a sensation of smelling something burning 15 min after drug intake .,"(('The', 'O'), ('patient', 'O'), ('presented', 'O'), ('every', 'O'), ('day', 'O'), ('a', 'O'), ('sensation', 'O'), ('of', 'O'), ('smelling', 'O'), ('something', 'O'), ('burning', 'O'), ('15', 'O'), ('min', 'O'), ('after', 'O'), ('drug', 'O'), ('intake', 'O'), ('.', 'O'))"
The case was reported to the Tunisian Centre of Pharmacovigilance .,"(('The', 'O'), ('case', 'O'), ('was', 'O'), ('reported', 'O'), ('to', 'O'), ('the', 'O'), ('Tunisian', 'O'), ('Centre', 'O'), ('of', 'O'), ('Pharmacovigilance', 'O'), ('.', 'O'))"
"However , the involvement of a specific , terminal prostaglandin ( PG ) isomerase has not been evaluated .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('involvement', 'O'), ('of', 'O'), ('a', 'O'), ('specific', 'O'), (',', 'O'), ('terminal', 'O'), ('prostaglandin', 'O'), ('(', 'O'), ('PG', 'O'), (')', 'O'), ('isomerase', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('evaluated', 'O'), ('.', 'O'))"
This was associated with elevated renal mPGES - 1 protein expression and increased urine PGE ( 2 ) excretion .,"(('This', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('elevated', 'O'), ('renal', 'O'), ('mPGES', 'O'), ('-', 'O'), ('1', 'O'), ('protein', 'O'), ('expression', 'O'), ('and', 'O'), ('increased', 'O'), ('urine', 'O'), ('PGE', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('excretion', 'O'), ('.', 'O'))"
"Immunoblotting , immunohistochemistry , and quantitative ( q ) RT - PCR consistently detected a significant decrease in aquaporin - 2 ( AQP2 ) protein expression in both the renal cortex and medulla of lithium - treated + / + mice .","(('Immunoblotting', 'O'), (',', 'O'), ('immunohistochemistry', 'O'), (',', 'O'), ('and', 'O'), ('quantitative', 'O'), ('(', 'O'), ('q', 'O'), (')', 'O'), ('RT', 'O'), ('-', 'O'), ('PCR', 'O'), ('consistently', 'O'), ('detected', 'O'), ('a', 'O'), ('significant', 'O'), ('decrease', 'O'), ('in', 'O'), ('aquaporin', 'O'), ('-', 'O'), ('2', 'O'), ('(', 'O'), ('AQP2', 'O'), (')', 'O'), ('protein', 'O'), ('expression', 'O'), ('in', 'O'), ('both', 'O'), ('the', 'O'), ('renal', 'O'), ('cortex', 'O'), ('and', 'O'), ('medulla', 'O'), ('of', 'O'), ('lithium', 'O'), ('-', 'O'), ('treated', 'O'), ('+', 'O'), ('/', 'O'), ('+', 'O'), ('mice', 'O'), ('.', 'O'))"
This decrease was significantly attenuated in the - / - mice .,"(('This', 'O'), ('decrease', 'O'), ('was', 'O'), ('significantly', 'O'), ('attenuated', 'O'), ('in', 'O'), ('the', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('.', 'O'))"
qRT - PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex .,"(('qRT', 'O'), ('-', 'O'), ('PCR', 'O'), ('detected', 'O'), ('similar', 'O'), ('patterns', 'O'), ('of', 'O'), ('changes', 'O'), ('in', 'O'), ('AQP2', 'O'), ('mRNA', 'O'), ('in', 'O'), ('the', 'O'), ('medulla', 'O'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('the', 'O'), ('cortex', 'O'), ('.', 'O'))"
"Similarly , the total protein abundance of the Na - K - 2Cl cotransporter ( NKCC2 ) in the medulla but not in the cortex of the + / + mice was significantly reduced by lithium treatment .","(('Similarly', 'O'), (',', 'O'), ('the', 'O'), ('total', 'O'), ('protein', 'O'), ('abundance', 'O'), ('of', 'O'), ('the', 'O'), ('Na', 'O'), ('-', 'O'), ('K', 'O'), ('-', 'O'), ('2Cl', 'O'), ('cotransporter', 'O'), ('(', 'O'), ('NKCC2', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('medulla', 'O'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('the', 'O'), ('cortex', 'O'), ('of', 'O'), ('the', 'O'), ('+', 'O'), ('/', 'O'), ('+', 'O'), ('mice', 'O'), ('was', 'O'), ('significantly', 'O'), ('reduced', 'O'), ('by', 'O'), ('lithium', 'O'), ('treatment', 'O'), ('.', 'O'))"
"In contrast , the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the - / - mice .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('the', 'O'), ('dowregulation', 'O'), ('of', 'O'), ('renal', 'O'), ('medullary', 'O'), ('NKCC2', 'O'), ('expression', 'O'), ('was', 'O'), ('significantly', 'O'), ('attenuated', 'O'), ('in', 'O'), ('the', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('.', 'O'))"
Preservation of renal blood flow during hypotension induced with fenoldopam in dogs .,"(('Preservation', 'O'), ('of', 'O'), ('renal', 'O'), ('blood', 'O'), ('flow', 'O'), ('during', 'O'), ('hypotension', 'B'), ('induced', 'O'), ('with', 'O'), ('fenoldopam', 'O'), ('in', 'O'), ('dogs', 'O'), ('.', 'O'))"
The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy .,"(('The', 'O'), ('introduction', 'O'), ('of', 'O'), ('drugs', 'O'), ('that', 'O'), ('could', 'O'), ('induce', 'O'), ('hypotension', 'B'), ('with', 'O'), ('different', 'O'), ('pharmacological', 'O'), ('actions', 'O'), ('would', 'O'), ('be', 'O'), ('advantageous', 'O'), ('because', 'O'), ('side', 'O'), ('effects', 'O'), ('unique', 'O'), ('to', 'O'), ('a', 'O'), ('specific', 'O'), ('drug', 'O'), ('could', 'O'), ('be', 'O'), ('minimized', 'O'), ('by', 'O'), ('selecting', 'O'), ('appropriate', 'O'), ('therapy', 'O'), ('.', 'O'))"
"Specific dopamine - 1 , ( DA1 ) and dopamine - 2 ( DA2 ) receptor agonists are now under clinical investigation .","(('Specific', 'O'), ('dopamine', 'O'), ('-', 'O'), ('1', 'O'), (',', 'O'), ('(', 'O'), ('DA1', 'O'), (')', 'O'), ('and', 'O'), ('dopamine', 'O'), ('-', 'O'), ('2', 'O'), ('(', 'O'), ('DA2', 'O'), (')', 'O'), ('receptor', 'O'), ('agonists', 'O'), ('are', 'O'), ('now', 'O'), ('under', 'O'), ('clinical', 'O'), ('investigation', 'O'), ('.', 'O'))"
Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation .,"(('Fenoldopam', 'O'), ('mesylate', 'O'), ('is', 'O'), ('a', 'O'), ('specific', 'O'), ('DA1', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('that', 'O'), ('lowers', 'O'), ('blood', 'O'), ('pressure', 'O'), ('by', 'O'), ('vasodilatation', 'O'), ('.', 'O'))"
The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested .,"(('The', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('fenoldopam', 'O'), ('could', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('induce', 'O'), ('hypotension', 'B'), ('and', 'O'), ('preserve', 'O'), ('blood', 'O'), ('flow', 'O'), ('to', 'O'), ('the', 'O'), ('kidney', 'O'), ('was', 'O'), ('tested', 'O'), ('.', 'O'))"
"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively , in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia .","(('Systemic', 'O'), ('aortic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('renal', 'O'), ('blood', 'O'), ('flow', 'O'), ('were', 'O'), ('measured', 'O'), ('continuously', 'O'), ('with', 'O'), ('a', 'O'), ('carotid', 'O'), ('arterial', 'O'), ('catheter', 'O'), ('and', 'O'), ('an', 'O'), ('electromagnetic', 'O'), ('flow', 'O'), ('probe', 'O'), ('respectively', 'O'), (',', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('compare', 'O'), ('the', 'O'), ('cardiovascular', 'O'), ('and', 'O'), ('renal', 'O'), ('vascular', 'O'), ('effects', 'O'), ('of', 'O'), ('fenoldopam', 'O'), ('and', 'O'), ('sodium', 'O'), ('nitroprusside', 'O'), ('in', 'O'), ('ten', 'O'), ('dogs', 'O'), ('under', 'O'), ('halothane', 'O'), ('general', 'O'), ('anaesthesia', 'O'), ('.', 'O'))"
Mean arterial pressure was decreased 30 + / - 8 per cent from control with infusion of fenoldopam ( 3 . 4 + / - 2 . 0 micrograms . kg - 1 . min - 1 ) and 34 + / - 4 per cent with infusion of sodium nitroprusside ( 5 . 9 micrograms . kg - 1 . min - 1 ) ( NS ) .,"(('Mean', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('was', 'O'), ('decreased', 'O'), ('30', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('8', 'O'), ('per', 'O'), ('cent', 'O'), ('from', 'O'), ('control', 'O'), ('with', 'O'), ('infusion', 'O'), ('of', 'O'), ('fenoldopam', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('micrograms', 'O'), ('.', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('min', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('and', 'O'), ('34', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('4', 'O'), ('per', 'O'), ('cent', 'O'), ('with', 'O'), ('infusion', 'O'), ('of', 'O'), ('sodium', 'O'), ('nitroprusside', 'O'), ('(', 'O'), ('5', 'O'), ('.', 'O'), ('9', 'O'), ('micrograms', 'O'), ('.', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('min', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('(', 'O'), ('NS', 'O'), (')', 'O'), ('.', 'O'))"
Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced hypotension ( P less than 0 . 01 ) .,"(('Renal', 'O'), ('blood', 'O'), ('flow', 'O'), ('(', 'O'), ('RBF', 'O'), (')', 'O'), ('increased', 'O'), ('during', 'O'), ('fenoldopam', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('11', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('7', 'O'), ('per', 'O'), ('cent', 'O'), ('and', 'O'), ('decreased', 'O'), ('21', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('8', 'O'), ('per', 'O'), ('cent', 'O'), ('during', 'O'), ('sodium', 'O'), ('nitroprusside', 'I'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
Sodium nitroprusside is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension .,"(('Sodium', 'O'), ('nitroprusside', 'O'), ('is', 'O'), ('a', 'O'), ('non', 'O'), ('-', 'O'), ('selective', 'O'), ('arteriolar', 'O'), ('and', 'O'), ('venous', 'O'), ('vasodilator', 'O'), ('that', 'O'), ('can', 'O'), ('produce', 'O'), ('redistribution', 'O'), ('of', 'O'), ('blood', 'O'), ('flow', 'O'), ('away', 'O'), ('from', 'O'), ('the', 'O'), ('kidney', 'O'), ('during', 'O'), ('induced', 'B'), ('hypotension', 'I'), ('.', 'O'))"
Fenoldopam is a selective dopamine - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension .,"(('Fenoldopam', 'O'), ('is', 'O'), ('a', 'O'), ('selective', 'O'), ('dopamine', 'O'), ('-', 'O'), ('1', 'O'), ('(', 'O'), ('DA1', 'O'), (')', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('that', 'O'), ('causes', 'O'), ('vasodilatation', 'O'), ('to', 'O'), ('the', 'O'), ('kidney', 'O'), ('and', 'O'), ('other', 'O'), ('organs', 'O'), ('with', 'O'), ('DA1', 'O'), ('receptors', 'O'), ('and', 'O'), ('preserves', 'O'), ('blood', 'O'), ('flow', 'O'), ('to', 'O'), ('the', 'O'), ('kidney', 'O'), ('during', 'O'), ('induced', 'B'), ('hypotension', 'I'), ('.', 'O'))"
"PURPOSE : We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced seizures .","(('PURPOSE', 'O'), (':', 'O'), ('We', 'O'), ('present', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('patient', 'O'), ('who', 'O'), ('developed', 'O'), ('seizures', 'O'), ('shortly', 'O'), ('after', 'O'), ('initiating', 'O'), ('treatment', 'O'), ('with', 'O'), ('levofloxacin', 'O'), ('and', 'O'), ('to', 'O'), ('discuss', 'O'), ('the', 'O'), ('potential', 'O'), ('drug', 'O'), ('-', 'O'), ('drug', 'O'), ('interactions', 'O'), ('related', 'O'), ('to', 'O'), ('the', 'O'), ('inhibition', 'O'), ('of', 'O'), ('cytochrome', 'O'), ('P450', 'O'), ('(', 'O'), ('CYP', 'O'), (')', 'O'), ('1A2', 'O'), ('in', 'O'), ('this', 'O'), ('case', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('in', 'O'), ('other', 'O'), ('cases', 'O'), (',', 'O'), ('of', 'O'), ('levofloxacin', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('.', 'O'))"
"METHODS : Several biomedical databases were searched including MEDLINE , Cochrane and Ovid .","(('METHODS', 'O'), (':', 'O'), ('Several', 'O'), ('biomedical', 'O'), ('databases', 'O'), ('were', 'O'), ('searched', 'O'), ('including', 'O'), ('MEDLINE', 'O'), (',', 'O'), ('Cochrane', 'O'), ('and', 'O'), ('Ovid', 'O'), ('.', 'O'))"
The main search terms utilized were case report and levofloxacin .,"(('The', 'O'), ('main', 'O'), ('search', 'O'), ('terms', 'O'), ('utilized', 'O'), ('were', 'O'), ('case', 'O'), ('report', 'O'), ('and', 'O'), ('levofloxacin', 'O'), ('.', 'O'))"
The search was limited to studies published in English .,"(('The', 'O'), ('search', 'O'), ('was', 'O'), ('limited', 'O'), ('to', 'O'), ('studies', 'O'), ('published', 'O'), ('in', 'O'), ('English', 'O'), ('.', 'O'))"
RESULTS : Six cases of levofloxacin - induced seizures have been reported in the literature .,"(('RESULTS', 'O'), (':', 'O'), ('Six', 'O'), ('cases', 'O'), ('of', 'O'), ('levofloxacin', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
Drug - drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases .,"(('Drug', 'O'), ('-', 'O'), ('drug', 'O'), ('interactions', 'O'), ('related', 'O'), ('to', 'O'), ('the', 'O'), ('inhibition', 'O'), ('of', 'O'), ('CYP1A2', 'O'), ('by', 'O'), ('levofloxacin', 'O'), ('are', 'O'), ('likely', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('clinical', 'O'), ('outcome', 'O'), ('of', 'O'), ('these', 'O'), ('cases', 'O'), ('.', 'O'))"
CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Clinicians', 'O'), ('are', 'O'), ('exhorted', 'O'), ('to', 'O'), ('pay', 'O'), ('close', 'O'), ('attention', 'O'), ('when', 'O'), ('initiating', 'O'), ('levofloxacin', 'O'), ('therapy', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('medications', 'O'), ('with', 'O'), ('epileptogenic', 'O'), ('properties', 'O'), ('that', 'O'), ('are', 'O'), ('CYP1A2', 'O'), ('substrates', 'O'), ('.', 'O'))"
"Dextran - etodolac conjugates : synthesis , in vitro and in vivo evaluation .","(('Dextran', 'O'), ('-', 'O'), ('etodolac', 'O'), ('conjugates', 'O'), (':', 'O'), ('synthesis', 'O'), (',', 'O'), ('in', 'O'), ('vitro', 'O'), ('and', 'O'), ('in', 'O'), ('vivo', 'O'), ('evaluation', 'O'), ('.', 'O'))"
"Etodolac ( E ) , is a non - narcotic analgesic and antiinflammatory drug .","(('Etodolac', 'O'), ('(', 'O'), ('E', 'O'), (')', 'O'), (',', 'O'), ('is', 'O'), ('a', 'O'), ('non', 'O'), ('-', 'O'), ('narcotic', 'O'), ('analgesic', 'O'), ('and', 'O'), ('antiinflammatory', 'O'), ('drug', 'O'), ('.', 'O'))"
A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac - dextran conjugates ( ED ) to improve its aqueous solubility and reduce gastrointestinal side effects .,"(('A', 'O'), ('biodegradable', 'O'), ('polymer', 'O'), ('dextran', 'O'), ('has', 'O'), ('been', 'O'), ('utilized', 'O'), ('as', 'O'), ('a', 'O'), ('carrier', 'O'), ('for', 'O'), ('synthesis', 'O'), ('of', 'O'), ('etodolac', 'O'), ('-', 'O'), ('dextran', 'O'), ('conjugates', 'O'), ('(', 'O'), ('ED', 'O'), (')', 'O'), ('to', 'O'), ('improve', 'O'), ('its', 'O'), ('aqueous', 'O'), ('solubility', 'O'), ('and', 'O'), ('reduce', 'O'), ('gastrointestinal', 'O'), ('side', 'O'), ('effects', 'O'), ('.', 'O'))"
"An activated moiety , i . e . N - acylimidazole derivative of etodolac ( EAI ) , was condensed with the polysaccharide polymer dextran of different molecular weights ( 40000 , 60000 , 110000 and 200000 ) .","(('An', 'O'), ('activated', 'O'), ('moiety', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('e', 'O'), ('.', 'O'), ('N', 'O'), ('-', 'O'), ('acylimidazole', 'O'), ('derivative', 'O'), ('of', 'O'), ('etodolac', 'O'), ('(', 'O'), ('EAI', 'O'), (')', 'O'), (',', 'O'), ('was', 'O'), ('condensed', 'O'), ('with', 'O'), ('the', 'O'), ('polysaccharide', 'O'), ('polymer', 'O'), ('dextran', 'O'), ('of', 'O'), ('different', 'O'), ('molecular', 'O'), ('weights', 'O'), ('(', 'O'), ('40000', 'O'), (',', 'O'), ('60000', 'O'), (',', 'O'), ('110000', 'O'), ('and', 'O'), ('200000', 'O'), (')', 'O'), ('.', 'O'))"
IR spectral data confirmed formation of ester bonding in the conjugates .,"(('IR', 'O'), ('spectral', 'O'), ('data', 'O'), ('confirmed', 'O'), ('formation', 'O'), ('of', 'O'), ('ester', 'O'), ('bonding', 'O'), ('in', 'O'), ('the', 'O'), ('conjugates', 'O'), ('.', 'O'))"
Etodolac contents were evaluated by UV - spectrophotometric analysis .,"(('Etodolac', 'O'), ('contents', 'O'), ('were', 'O'), ('evaluated', 'O'), ('by', 'O'), ('UV', 'O'), ('-', 'O'), ('spectrophotometric', 'O'), ('analysis', 'O'), ('.', 'O'))"
The molecular weights were determined by measuring viscosity using the Mark - Howink - Sakurada equation .,"(('The', 'O'), ('molecular', 'O'), ('weights', 'O'), ('were', 'O'), ('determined', 'O'), ('by', 'O'), ('measuring', 'O'), ('viscosity', 'O'), ('using', 'O'), ('the', 'O'), ('Mark', 'O'), ('-', 'O'), ('Howink', 'O'), ('-', 'O'), ('Sakurada', 'O'), ('equation', 'O'), ('.', 'O'))"
"In vitro hydrolysis of ED was done in aqueous buffers ( pH 1 . 2 , 7 . 4 , 9 ) and in 80 % ( v / v ) human plasma ( pH 7 . 4 ) .","(('In', 'O'), ('vitro', 'O'), ('hydrolysis', 'O'), ('of', 'O'), ('ED', 'O'), ('was', 'O'), ('done', 'O'), ('in', 'O'), ('aqueous', 'O'), ('buffers', 'O'), ('(', 'O'), ('pH', 'O'), ('1', 'O'), ('.', 'O'), ('2', 'O'), (',', 'O'), ('7', 'O'), ('.', 'O'), ('4', 'O'), (',', 'O'), ('9', 'O'), (')', 'O'), ('and', 'O'), ('in', 'O'), ('80', 'O'), ('%', 'O'), ('(', 'O'), ('v', 'O'), ('/', 'O'), ('v', 'O'), (')', 'O'), ('human', 'O'), ('plasma', 'O'), ('(', 'O'), ('pH', 'O'), ('7', 'O'), ('.', 'O'), ('4', 'O'), (')', 'O'), ('.', 'O'))"
"At pH 9 , a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7 . 4 and 80 % human plasma ( pH 7 . 4 ) , following first - order kinetics .","(('At', 'O'), ('pH', 'O'), ('9', 'O'), (',', 'O'), ('a', 'O'), ('higher', 'O'), ('rate', 'O'), ('of', 'O'), ('etodolac', 'O'), ('release', 'O'), ('from', 'O'), ('ED', 'O'), ('was', 'O'), ('observed', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('aqueous', 'O'), ('buffer', 'O'), ('of', 'O'), ('pH', 'O'), ('7', 'O'), ('.', 'O'), ('4', 'O'), ('and', 'O'), ('80', 'O'), ('%', 'O'), ('human', 'O'), ('plasma', 'O'), ('(', 'O'), ('pH', 'O'), ('7', 'O'), ('.', 'O'), ('4', 'O'), (')', 'O'), (',', 'O'), ('following', 'O'), ('first', 'O'), ('-', 'O'), ('order', 'O'), ('kinetics', 'O'), ('.', 'O'))"
In vivo investigations were performed in animals .,"(('In', 'O'), ('vivo', 'O'), ('investigations', 'O'), ('were', 'O'), ('performed', 'O'), ('in', 'O'), ('animals', 'O'), ('.', 'O'))"
"In comparison to control , E and ED1 - ED4 showed highly significant analgesic and antiinflammatory activities ( p < 0 . 001 ) .","(('In', 'O'), ('comparison', 'O'), ('to', 'O'), ('control', 'O'), (',', 'O'), ('E', 'O'), ('and', 'O'), ('ED1', 'O'), ('-', 'O'), ('ED4', 'O'), ('showed', 'O'), ('highly', 'O'), ('significant', 'O'), ('analgesic', 'O'), ('and', 'O'), ('antiinflammatory', 'O'), ('activities', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
Biological evaluation suggested that conjugates ( ED1 - ED4 ) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug - - etodolac .,"(('Biological', 'O'), ('evaluation', 'O'), ('suggested', 'O'), ('that', 'O'), ('conjugates', 'O'), ('(', 'O'), ('ED1', 'O'), ('-', 'O'), ('ED4', 'O'), (')', 'O'), ('retained', 'O'), ('comparable', 'O'), ('analgesic', 'O'), ('and', 'O'), ('antiinflammatory', 'O'), ('activities', 'O'), ('with', 'O'), ('remarkably', 'O'), ('reduced', 'O'), ('ulcerogenicity', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('their', 'O'), ('parent', 'O'), ('drug', 'O'), ('-', 'O'), ('-', 'O'), ('etodolac', 'O'), ('.', 'O'))"
The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models .,"(('The', 'O'), ('antiarrhythmic', 'O'), ('effect', 'O'), ('and', 'O'), ('possible', 'O'), ('ionic', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('pilocarpine', 'O'), ('on', 'O'), ('animal', 'O'), ('models', 'O'), ('.', 'O'))"
"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig arrhythmia models .","(('This', 'O'), ('study', 'O'), ('was', 'O'), ('designed', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('pilocarpine', 'O'), ('and', 'O'), ('explore', 'O'), ('the', 'O'), ('underlying', 'O'), ('ionic', 'O'), ('mechanism', 'O'), (',', 'O'), ('using', 'O'), ('both', 'O'), ('aconitine', 'O'), ('-', 'O'), ('induced', 'O'), ('rat', 'O'), ('and', 'O'), ('ouabain', 'O'), ('-', 'O'), ('induced', 'O'), ('guinea', 'O'), ('pig', 'O'), ('arrhythmia', 'B'), ('models', 'O'), ('.', 'O'))"
Confocal microscopy was used to measure intracellular free - calcium concentrations ( [ Ca ( 2 + ) ] ( i ) ) in isolated myocytes .,"(('Confocal', 'O'), ('microscopy', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('measure', 'O'), ('intracellular', 'O'), ('free', 'O'), ('-', 'O'), ('calcium', 'O'), ('concentrations', 'O'), ('(', 'O'), ('[', 'O'), ('Ca', 'O'), ('(', 'O'), ('2', 'O'), ('+', 'O'), (')', 'O'), (']', 'O'), ('(', 'O'), ('i', 'O'), (')', 'O'), (')', 'O'), ('in', 'O'), ('isolated', 'O'), ('myocytes', 'O'), ('.', 'O'))"
[ Ca ( 2 + ) ] ( i ) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine .,"(('[', 'O'), ('Ca', 'O'), ('(', 'O'), ('2', 'O'), ('+', 'O'), (')', 'O'), (']', 'O'), ('(', 'O'), ('i', 'O'), (')', 'O'), ('overload', 'O'), ('induced', 'O'), ('by', 'O'), ('aconitine', 'O'), ('or', 'O'), ('ouabain', 'O'), ('was', 'O'), ('reduced', 'O'), ('in', 'O'), ('isolated', 'O'), ('myocytes', 'O'), ('pretreated', 'O'), ('with', 'O'), ('pilocarpine', 'O'), ('.', 'O'))"
"Moreover , M ( 3 ) - muscarinic acetylcholine receptor ( mAChR ) antagonist 4 - DAMP ( 4 - diphenylacetoxy - N - methylpiperidine - methiodide ) partially abolished the beneficial effects of pilocarpine .","(('Moreover', 'O'), (',', 'O'), ('M', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('-', 'O'), ('muscarinic', 'O'), ('acetylcholine', 'O'), ('receptor', 'O'), ('(', 'O'), ('mAChR', 'O'), (')', 'O'), ('antagonist', 'O'), ('4', 'O'), ('-', 'O'), ('DAMP', 'O'), ('(', 'O'), ('4', 'O'), ('-', 'O'), ('diphenylacetoxy', 'O'), ('-', 'O'), ('N', 'O'), ('-', 'O'), ('methylpiperidine', 'O'), ('-', 'O'), ('methiodide', 'O'), (')', 'O'), ('partially', 'O'), ('abolished', 'O'), ('the', 'O'), ('beneficial', 'O'), ('effects', 'O'), ('of', 'O'), ('pilocarpine', 'O'), ('.', 'O'))"
The mechanism may be related to the improvement of Ca ( 2 + ) handling .,"(('The', 'O'), ('mechanism', 'O'), ('may', 'O'), ('be', 'O'), ('related', 'O'), ('to', 'O'), ('the', 'O'), ('improvement', 'O'), ('of', 'O'), ('Ca', 'O'), ('(', 'O'), ('2', 'O'), ('+', 'O'), (')', 'O'), ('handling', 'O'), ('.', 'O'))"
Effect of Hibiscus rosa sinensis on reserpine - induced neurobehavioral and biochemical alterations in rats .,"(('Effect', 'O'), ('of', 'O'), ('Hibiscus', 'O'), ('rosa', 'O'), ('sinensis', 'O'), ('on', 'O'), ('reserpine', 'O'), ('-', 'O'), ('induced', 'O'), ('neurobehavioral', 'O'), ('and', 'O'), ('biochemical', 'O'), ('alterations', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"The rats were treated with intraperitoneal reserpine ( 1 mg / kg , ip ) for 3 days every other day .","(('The', 'O'), ('rats', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('intraperitoneal', 'O'), ('reserpine', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('ip', 'O'), (')', 'O'), ('for', 'O'), ('3', 'O'), ('days', 'O'), ('every', 'O'), ('other', 'O'), ('day', 'O'), ('.', 'O'))"
"On day 5 , vacuous chewing movements and tongue protrusions were counted for 5 min .","(('On', 'O'), ('day', 'O'), ('5', 'O'), (',', 'O'), ('vacuous', 'O'), ('chewing', 'O'), ('movements', 'O'), ('and', 'O'), ('tongue', 'O'), ('protrusions', 'O'), ('were', 'O'), ('counted', 'O'), ('for', 'O'), ('5', 'O'), ('min', 'O'), ('.', 'O'))"
"Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however , coadministration of Hibiscus rosa sinensis roots extract ( 100 , 200 and 300 mg / kg , per orally ) attenuated the effects .","(('Reserpine', 'O'), ('treated', 'O'), ('rats', 'O'), ('significantly', 'O'), ('developed', 'O'), ('vacuous', 'O'), ('chewing', 'O'), ('movements', 'O'), ('and', 'O'), ('tongue', 'O'), ('protrusions', 'O'), ('however', 'O'), (',', 'O'), ('coadministration', 'O'), ('of', 'O'), ('Hibiscus', 'O'), ('rosa', 'O'), ('sinensis', 'O'), ('roots', 'O'), ('extract', 'O'), ('(', 'O'), ('100', 'O'), (',', 'O'), ('200', 'O'), ('and', 'O'), ('300', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('per', 'O'), ('orally', 'O'), (')', 'O'), ('attenuated', 'O'), ('the', 'O'), ('effects', 'O'), ('.', 'O'))"
"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione reductase ( GSH ) , an index of oxidative stress process .","(('Biochemical', 'O'), ('analysis', 'O'), ('of', 'O'), ('brain', 'O'), ('revealed', 'O'), ('that', 'O'), ('the', 'O'), ('reserpine', 'O'), ('treatment', 'O'), ('significantly', 'O'), ('increased', 'O'), ('lipid', 'O'), ('peroxidation', 'O'), ('and', 'O'), ('decreased', 'O'), ('levels', 'O'), ('of', 'O'), ('superoxide', 'O'), ('dismutase', 'O'), ('(', 'O'), ('SOD', 'O'), (')', 'O'), (',', 'O'), ('catalase', 'O'), ('(', 'O'), ('CAT', 'O'), (')', 'O'), ('and', 'O'), ('glutathione', 'O'), ('reductase', 'O'), ('(', 'O'), ('GSH', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('index', 'O'), ('of', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('process', 'O'), ('.', 'O'))"
"Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD , CAT and GSH levels .","(('Coadministration', 'O'), ('of', 'O'), ('extract', 'O'), ('significantly', 'O'), ('reduced', 'O'), ('the', 'O'), ('lipid', 'O'), ('peroxidation', 'O'), ('and', 'O'), ('reversed', 'O'), ('the', 'O'), ('decrease', 'O'), ('in', 'O'), ('brain', 'O'), ('SOD', 'O'), (',', 'O'), ('CAT', 'O'), ('and', 'O'), ('GSH', 'O'), ('levels', 'O'), ('.', 'O'))"
Dynamic response of blood vessel in acute renal failure .,"(('Dynamic', 'O'), ('response', 'O'), ('of', 'O'), ('blood', 'O'), ('vessel', 'O'), ('in', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('.', 'O'))"
"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .","(('In', 'O'), ('this', 'O'), ('study', 'O'), ('we', 'O'), ('postulated', 'O'), ('that', 'O'), ('during', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('induced', 'O'), ('by', 'O'), ('gentamicin', 'O'), ('the', 'O'), ('transient', 'O'), ('or', 'O'), ('dynamic', 'O'), ('response', 'O'), ('of', 'O'), ('blood', 'O'), ('vessels', 'O'), ('could', 'O'), ('be', 'O'), ('affected', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('antioxidants', 'O'), ('can', 'O'), ('prevent', 'O'), ('the', 'O'), ('changes', 'O'), ('in', 'O'), ('dynamic', 'O'), ('responses', 'O'), ('of', 'O'), ('blood', 'O'), ('vessels', 'O'), ('.', 'O'))"
"The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered , but also dynamics of this response , was used in this paper .","(('The', 'O'), ('new', 'O'), ('approach', 'O'), ('to', 'O'), ('ex', 'O'), ('vivo', 'O'), ('blood', 'O'), ('vessel', 'O'), ('experiments', 'O'), ('in', 'O'), ('which', 'O'), ('not', 'O'), ('only', 'O'), ('the', 'O'), ('end', 'O'), ('points', 'O'), ('of', 'O'), ('vessels', 'O'), ('response', 'O'), ('within', 'O'), ('the', 'O'), ('time', 'O'), ('interval', 'O'), ('is', 'O'), ('considered', 'O'), (',', 'O'), ('but', 'O'), ('also', 'O'), ('dynamics', 'O'), ('of', 'O'), ('this', 'O'), ('response', 'O'), (',', 'O'), ('was', 'O'), ('used', 'O'), ('in', 'O'), ('this', 'O'), ('paper', 'O'), ('.', 'O'))"
Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals .,"(('Our', 'O'), ('results', 'O'), ('confirm', 'O'), ('the', 'O'), ('alteration', 'O'), ('in', 'O'), ('dynamic', 'O'), ('response', 'O'), ('of', 'O'), ('blood', 'O'), ('vessels', 'O'), ('during', 'O'), ('the', 'O'), ('change', 'O'), ('of', 'O'), ('pressure', 'O'), ('in', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('treated', 'O'), ('animals', 'O'), ('.', 'O'))"
The beneficial effects of vitamin C administration to gentamicin - treated animals are also confirmed through : lower level of blood urea and creatinine and higher level of potassium .,"(('The', 'O'), ('beneficial', 'O'), ('effects', 'O'), ('of', 'O'), ('vitamin', 'O'), ('C', 'O'), ('administration', 'O'), ('to', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('treated', 'O'), ('animals', 'O'), ('are', 'O'), ('also', 'O'), ('confirmed', 'O'), ('through', 'O'), (':', 'O'), ('lower', 'O'), ('level', 'O'), ('of', 'O'), ('blood', 'O'), ('urea', 'O'), ('and', 'O'), ('creatinine', 'O'), ('and', 'O'), ('higher', 'O'), ('level', 'O'), ('of', 'O'), ('potassium', 'O'), ('.', 'O'))"
The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin - treated animals ( 8 . 07 + / - 1 . 7 s vs . 5 . 64 + / - 0 . 18 s ) .,"(('The', 'O'), ('pressure', 'O'), ('dynamic', 'O'), ('responses', 'O'), ('of', 'O'), ('isolated', 'O'), ('blood', 'O'), ('vessels', 'O'), ('show', 'O'), ('a', 'O'), ('faster', 'O'), ('pressure', 'O'), ('change', 'O'), ('in', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('treated', 'O'), ('animals', 'O'), ('(', 'O'), ('8', 'O'), ('.', 'O'), ('07', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('7', 'O'), ('s', 'O'), ('vs', 'O'), ('.', 'O'), ('5', 'O'), ('.', 'O'), ('64', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('18', 'O'), ('s', 'O'), (')', 'O'), ('.', 'O'))"
Vitamin C administration induced slowdown of pressure change back to the control values .,"(('Vitamin', 'O'), ('C', 'O'), ('administration', 'O'), ('induced', 'O'), ('slowdown', 'O'), ('of', 'O'), ('pressure', 'O'), ('change', 'O'), ('back', 'O'), ('to', 'O'), ('the', 'O'), ('control', 'O'), ('values', 'O'), ('.', 'O'))"
"The pressure dynamic properties , quantitatively defined by comparative pressure dynamic and total pressure dynamic , confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals and beneficial effects of vitamin C administration .","(('The', 'O'), ('pressure', 'O'), ('dynamic', 'O'), ('properties', 'O'), (',', 'O'), ('quantitatively', 'O'), ('defined', 'O'), ('by', 'O'), ('comparative', 'O'), ('pressure', 'O'), ('dynamic', 'O'), ('and', 'O'), ('total', 'O'), ('pressure', 'O'), ('dynamic', 'O'), (',', 'O'), ('confirm', 'O'), ('the', 'O'), ('alteration', 'O'), ('in', 'O'), ('dynamic', 'O'), ('response', 'O'), ('of', 'O'), ('blood', 'O'), ('vessels', 'O'), ('during', 'O'), ('the', 'O'), ('change', 'O'), ('of', 'O'), ('pressure', 'O'), ('in', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('treated', 'O'), ('animals', 'O'), ('and', 'O'), ('beneficial', 'O'), ('effects', 'O'), ('of', 'O'), ('vitamin', 'O'), ('C', 'O'), ('administration', 'O'), ('.', 'O'))"
Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation .,"(('Tacrolimus', 'O'), ('is', 'O'), ('a', 'O'), ('potent', 'O'), ('immunosuppressant', 'O'), ('that', 'O'), ('is', 'O'), ('frequently', 'O'), ('used', 'O'), ('in', 'O'), ('organ', 'O'), ('transplantation', 'O'), ('.', 'O'))"
"However , adverse effects include cardiac toxicity .","(('However', 'O'), (',', 'O'), ('adverse', 'O'), ('effects', 'O'), ('include', 'O'), ('cardiac', 'B'), ('toxicity', 'O'), ('.', 'O'))"
The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography .,"(('The', 'O'), ('hypertrophy', 'B'), ('caused', 'O'), ('no', 'O'), ('clinical', 'O'), ('symptoms', 'O'), ('but', 'O'), ('was', 'O'), ('noted', 'O'), ('because', 'O'), ('of', 'O'), ('elevation', 'O'), ('of', 'O'), ('plasma', 'O'), ('brain', 'O'), ('natriuretic', 'O'), ('peptide', 'O'), ('concentration', 'O'), ('and', 'O'), ('confirmed', 'O'), ('at', 'O'), ('echocardiography', 'O'), ('.', 'O'))"
"The blood tacrolimus concentration was higher than usual at that time ; thus , tacrolimus dosage was reduced .","(('The', 'O'), ('blood', 'O'), ('tacrolimus', 'O'), ('concentration', 'O'), ('was', 'O'), ('higher', 'O'), ('than', 'O'), ('usual', 'O'), ('at', 'O'), ('that', 'O'), ('time', 'O'), (';', 'O'), ('thus', 'O'), (',', 'O'), ('tacrolimus', 'O'), ('dosage', 'O'), ('was', 'O'), ('reduced', 'O'), ('.', 'O'))"
"In patients receiving tacrolimus therapy , blood concentration should be carefully controlled and extreme attention paid to cardiac involvement .","(('In', 'O'), ('patients', 'O'), ('receiving', 'O'), ('tacrolimus', 'O'), ('therapy', 'O'), (',', 'O'), ('blood', 'O'), ('concentration', 'O'), ('should', 'O'), ('be', 'O'), ('carefully', 'O'), ('controlled', 'O'), ('and', 'O'), ('extreme', 'O'), ('attention', 'O'), ('paid', 'O'), ('to', 'O'), ('cardiac', 'B'), ('involvement', 'I'), ('.', 'O'))"
We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced hypotension would preserve long - term associative memory .,"(('We', 'O'), ('tested', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('nimodipine', 'O'), ('(', 'O'), ('NIMO', 'O'), (')', 'O'), ('administered', 'O'), ('at', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('nitroglycerin', 'B'), ('(', 'O'), ('NTG', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('would', 'O'), ('preserve', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('associative', 'O'), ('memory', 'O'), ('.', 'O'))"
METHODS : The passive avoidance ( PA ) paradigm was used to assess memory retention .,"(('METHODS', 'O'), (':', 'O'), ('The', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('(', 'O'), ('PA', 'O'), (')', 'O'), ('paradigm', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('assess', 'O'), ('memory', 'O'), ('retention', 'O'), ('.', 'O'))"
"For PA training , latencies ( seconds ) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered .","(('For', 'O'), ('PA', 'O'), ('training', 'O'), (',', 'O'), ('latencies', 'O'), ('(', 'O'), ('seconds', 'O'), (')', 'O'), ('were', 'O'), ('recorded', 'O'), ('for', 'O'), ('entry', 'O'), ('from', 'O'), ('a', 'O'), ('suspended', 'O'), ('platform', 'O'), ('into', 'O'), ('a', 'O'), ('Plexiglas', 'O'), ('tube', 'O'), ('where', 'O'), ('a', 'O'), ('shock', 'O'), ('was', 'O'), ('automatically', 'O'), ('delivered', 'O'), ('.', 'O'))"
Latencies were recorded 48 h later for a testing trial .,"(('Latencies', 'O'), ('were', 'O'), ('recorded', 'O'), ('48', 'O'), ('h', 'O'), ('later', 'O'), ('for', 'O'), ('a', 'O'), ('testing', 'O'), ('trial', 'O'), ('.', 'O'))"
"Ninety - six Swiss - Webster mice ( 30 - 35 g , 6 - 8 wk ) , were randomized into 6 groups 1 ) saline ( control ) , 2 ) NTG immediately after learning , 3 ) NTG 3 h after learning , 4 ) NTG and NIMO , 5 ) vehicle , and 6 ) NIMO alone .","(('Ninety', 'O'), ('-', 'O'), ('six', 'O'), ('Swiss', 'O'), ('-', 'O'), ('Webster', 'O'), ('mice', 'O'), ('(', 'O'), ('30', 'O'), ('-', 'O'), ('35', 'O'), ('g', 'O'), (',', 'O'), ('6', 'O'), ('-', 'O'), ('8', 'O'), ('wk', 'O'), (')', 'O'), (',', 'O'), ('were', 'O'), ('randomized', 'O'), ('into', 'O'), ('6', 'O'), ('groups', 'O'), ('1', 'O'), (')', 'O'), ('saline', 'O'), ('(', 'O'), ('control', 'O'), (')', 'O'), (',', 'O'), ('2', 'O'), (')', 'O'), ('NTG', 'O'), ('immediately', 'O'), ('after', 'O'), ('learning', 'O'), (',', 'O'), ('3', 'O'), (')', 'O'), ('NTG', 'O'), ('3', 'O'), ('h', 'O'), ('after', 'O'), ('learning', 'O'), (',', 'O'), ('4', 'O'), (')', 'O'), ('NTG', 'O'), ('and', 'O'), ('NIMO', 'O'), (',', 'O'), ('5', 'O'), (')', 'O'), ('vehicle', 'O'), (',', 'O'), ('and', 'O'), ('6', 'O'), (')', 'O'), ('NIMO', 'O'), ('alone', 'O'), ('.', 'O'))"
The extent of hypotension and changes in brain tissue oxygenation ( PbtO ( 2 ) ) and in cerebral blood flow were studied in a separate group of animals .,"(('The', 'O'), ('extent', 'O'), ('of', 'O'), ('hypotension', 'B'), ('and', 'O'), ('changes', 'O'), ('in', 'O'), ('brain', 'O'), ('tissue', 'O'), ('oxygenation', 'O'), ('(', 'O'), ('PbtO', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), (')', 'O'), ('and', 'O'), ('in', 'O'), ('cerebral', 'O'), ('blood', 'O'), ('flow', 'O'), ('were', 'O'), ('studied', 'O'), ('in', 'O'), ('a', 'O'), ('separate', 'O'), ('group', 'O'), ('of', 'O'), ('animals', 'O'), ('.', 'O'))"
RESULTS : All groups exhibited similar training latencies ( 17 . 0 + / - 4 . 6 s ) .,"(('RESULTS', 'O'), (':', 'O'), ('All', 'O'), ('groups', 'O'), ('exhibited', 'O'), ('similar', 'O'), ('training', 'O'), ('latencies', 'O'), ('(', 'O'), ('17', 'O'), ('.', 'O'), ('0', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('4', 'O'), ('.', 'O'), ('6', 'O'), ('s', 'O'), (')', 'O'), ('.', 'O'))"
A Kruskal - Wallis 1 - way analysis of variance indicated a significant difference among the 4 treatment groups ( H = 15 . 34 ; P < 0 . 001 ) .,"(('A', 'O'), ('Kruskal', 'O'), ('-', 'O'), ('Wallis', 'O'), ('1', 'O'), ('-', 'O'), ('way', 'O'), ('analysis', 'O'), ('of', 'O'), ('variance', 'O'), ('indicated', 'O'), ('a', 'O'), ('significant', 'O'), ('difference', 'O'), ('among', 'O'), ('the', 'O'), ('4', 'O'), ('treatment', 'O'), ('groups', 'O'), ('(', 'O'), ('H', 'O'), ('=', 'O'), ('15', 'O'), ('.', 'O'), ('34', 'O'), (';', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
"In a separate group of mice not subjected to behavioral studies , the same dose of NTG ( n = 3 ) and NTG + NIMO ( n = 3 ) caused mean arterial blood pressure to decrease from 85 . 9 + / - 3 . 8 mm Hg sem to 31 . 6 + / - 0 . 8 mm Hg sem and from 86 . 2 + / - 3 . 7 mm Hg sem to 32 . 6 + / - 0 . 2 mm Hg sem , respectively .","(('In', 'O'), ('a', 'O'), ('separate', 'O'), ('group', 'O'), ('of', 'O'), ('mice', 'O'), ('not', 'O'), ('subjected', 'O'), ('to', 'O'), ('behavioral', 'O'), ('studies', 'O'), (',', 'O'), ('the', 'O'), ('same', 'O'), ('dose', 'O'), ('of', 'O'), ('NTG', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('3', 'O'), (')', 'O'), ('and', 'O'), ('NTG', 'O'), ('+', 'O'), ('NIMO', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('3', 'O'), (')', 'O'), ('caused', 'O'), ('mean', 'O'), ('arterial', 'O'), ('blood', 'O'), ('pressure', 'O'), ('to', 'O'), ('decrease', 'O'), ('from', 'O'), ('85', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), ('mm', 'O'), ('Hg', 'O'), ('sem', 'O'), ('to', 'O'), ('31', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('8', 'O'), ('mm', 'O'), ('Hg', 'O'), ('sem', 'O'), ('and', 'O'), ('from', 'O'), ('86', 'O'), ('.', 'O'), ('2', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('7', 'O'), ('mm', 'O'), ('Hg', 'O'), ('sem', 'O'), ('to', 'O'), ('32', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('mm', 'O'), ('Hg', 'O'), ('sem', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
Mean arterial blood pressure in mice treated with NIMO alone decreased from 88 . 1 + / - 3 . 8 mm Hg to 80 . 0 + / - 2 . 9 mm Hg .,"(('Mean', 'O'), ('arterial', 'O'), ('blood', 'O'), ('pressure', 'O'), ('in', 'O'), ('mice', 'O'), ('treated', 'O'), ('with', 'O'), ('NIMO', 'O'), ('alone', 'O'), ('decreased', 'O'), ('from', 'O'), ('88', 'O'), ('.', 'O'), ('1', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), ('mm', 'O'), ('Hg', 'O'), ('to', 'O'), ('80', 'O'), ('.', 'O'), ('0', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('9', 'O'), ('mm', 'O'), ('Hg', 'O'), ('.', 'O'))"
The intergroup difference was statistically significant ( P < 0 . 05 ) .,"(('The', 'O'), ('intergroup', 'O'), ('difference', 'O'), ('was', 'O'), ('statistically', 'O'), ('significant', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"PbtO ( 2 ) decreased from 51 . 7 + / - 4 . 5 mm Hg sem to 33 . 8 + / - 5 . 2 mm Hg sem in the NTG group and from 38 . 6 + / - 6 . 1 mm Hg sem to 25 . 4 + / - 2 . 0 mm Hg sem in the NTG + NIMO groups , respectively .","(('PbtO', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('decreased', 'O'), ('from', 'O'), ('51', 'O'), ('.', 'O'), ('7', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('4', 'O'), ('.', 'O'), ('5', 'O'), ('mm', 'O'), ('Hg', 'O'), ('sem', 'O'), ('to', 'O'), ('33', 'O'), ('.', 'O'), ('8', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('5', 'O'), ('.', 'O'), ('2', 'O'), ('mm', 'O'), ('Hg', 'O'), ('sem', 'O'), ('in', 'O'), ('the', 'O'), ('NTG', 'O'), ('group', 'O'), ('and', 'O'), ('from', 'O'), ('38', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('6', 'O'), ('.', 'O'), ('1', 'O'), ('mm', 'O'), ('Hg', 'O'), ('sem', 'O'), ('to', 'O'), ('25', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('mm', 'O'), ('Hg', 'O'), ('sem', 'O'), ('in', 'O'), ('the', 'O'), ('NTG', 'O'), ('+', 'O'), ('NIMO', 'O'), ('groups', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
There were no significant differences among groups .,"(('There', 'O'), ('were', 'O'), ('no', 'O'), ('significant', 'O'), ('differences', 'O'), ('among', 'O'), ('groups', 'O'), ('.', 'O'))"
"CONCLUSION : In a PA retention paradigm , the injection of NTG immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced hypotension had no effect .","(('CONCLUSION', 'O'), (':', 'O'), ('In', 'O'), ('a', 'O'), ('PA', 'O'), ('retention', 'O'), ('paradigm', 'O'), (',', 'O'), ('the', 'O'), ('injection', 'O'), ('of', 'O'), ('NTG', 'O'), ('immediately', 'O'), ('after', 'O'), ('learning', 'O'), ('produced', 'O'), ('a', 'O'), ('significant', 'O'), ('impairment', 'O'), ('of', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('associative', 'O'), ('memory', 'O'), ('in', 'O'), ('mice', 'O'), (',', 'O'), ('whereas', 'O'), ('delayed', 'O'), ('induced', 'O'), ('hypotension', 'I'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('.', 'O'))"
NIMO attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of hypotension .,"(('NIMO', 'O'), ('attenuated', 'O'), ('the', 'O'), ('disruption', 'O'), ('in', 'O'), ('consolidation', 'O'), ('of', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('memory', 'O'), ('caused', 'O'), ('by', 'O'), ('NTG', 'B'), ('but', 'O'), ('did', 'O'), ('not', 'O'), ('improve', 'O'), ('latency', 'O'), ('in', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension , because there were no differences in the PbtO ( 2 ) indices among groups .","(('The', 'O'), ('observed', 'O'), ('effect', 'O'), ('of', 'O'), ('NIMO', 'O'), ('may', 'O'), ('have', 'O'), ('been', 'O'), ('attributable', 'O'), ('to', 'O'), ('the', 'O'), ('preservation', 'O'), ('of', 'O'), ('calcium', 'O'), ('homeostasis', 'O'), ('during', 'O'), ('hypotension', 'B'), (',', 'O'), ('because', 'O'), ('there', 'O'), ('were', 'O'), ('no', 'O'), ('differences', 'O'), ('in', 'O'), ('the', 'O'), ('PbtO', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('indices', 'O'), ('among', 'O'), ('groups', 'O'), ('.', 'O'))"
AMN082 ( 2 . 5 and 5 mg / kg ) reduces apomorphine - induced rotations in unilateral 6 - hydroxydopamine ( 6 - OHDA ) - lesioned rats .,"(('AMN082', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('and', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('reduces', 'O'), ('apomorphine', 'O'), ('-', 'O'), ('induced', 'O'), ('rotations', 'O'), ('in', 'O'), ('unilateral', 'O'), ('6', 'O'), ('-', 'O'), ('hydroxydopamine', 'I'), ('(', 'O'), ('6', 'O'), ('-', 'O'), ('OHDA', 'O'), (')', 'O'), ('-', 'O'), ('lesioned', 'O'), ('rats', 'O'), ('.', 'O'))"
Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity .,"(('Overall', 'O'), ('these', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('mGlu7', 'O'), ('receptor', 'O'), ('activation', 'O'), ('can', 'O'), ('reverse', 'O'), ('motor', 'B'), ('dysfunction', 'I'), ('associated', 'O'), ('with', 'O'), ('reduced', 'O'), ('dopamine', 'O'), ('activity', 'O'), ('.', 'O'))"
Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies .,"(('Selective', 'O'), ('ligands', 'O'), ('of', 'O'), ('mGlu7', 'O'), ('receptor', 'O'), ('subtypes', 'O'), ('may', 'O'), ('thus', 'O'), ('be', 'O'), ('considered', 'O'), ('as', 'O'), ('promising', 'O'), ('compounds', 'O'), ('for', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('antiparkinsonian', 'O'), ('therapeutic', 'O'), ('strategies', 'O'), ('.', 'O'))"
"Two weeks before his admission , sorafenib had been started .","(('Two', 'O'), ('weeks', 'O'), ('before', 'O'), ('his', 'O'), ('admission', 'O'), (',', 'O'), ('sorafenib', 'O'), ('had', 'O'), ('been', 'O'), ('started', 'O'), ('.', 'O'))"
"However , there was no stenosis in coronary arteries on angiography .","(('However', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('stenosis', 'O'), ('in', 'O'), ('coronary', 'O'), ('arteries', 'O'), ('on', 'O'), ('angiography', 'O'), ('.', 'O'))"
"Cessation of sorafenib and administration of Ca - channel blocker and nitrates ameliorated his symptoms , but relapse occurred after resumption of sorafenib .","(('Cessation', 'O'), ('of', 'O'), ('sorafenib', 'O'), ('and', 'O'), ('administration', 'O'), ('of', 'O'), ('Ca', 'O'), ('-', 'O'), ('channel', 'O'), ('blocker', 'O'), ('and', 'O'), ('nitrates', 'O'), ('ameliorated', 'O'), ('his', 'O'), ('symptoms', 'O'), (',', 'O'), ('but', 'O'), ('relapse', 'O'), ('occurred', 'O'), ('after', 'O'), ('resumption', 'O'), ('of', 'O'), ('sorafenib', 'O'), ('.', 'O'))"
Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival .,"(('Sorafenib', 'O'), ('is', 'O'), ('a', 'O'), ('multikinase', 'O'), ('inhibitor', 'O'), ('that', 'O'), ('targets', 'O'), ('signaling', 'O'), ('pathways', 'O'), ('necessary', 'O'), ('for', 'O'), ('cellular', 'O'), ('proliferation', 'O'), ('and', 'O'), ('survival', 'O'), ('.', 'O'))"
Our report may show an adverse effect on the Rho / ROCK pathway by sorafenib use .,"(('Our', 'O'), ('report', 'O'), ('may', 'O'), ('show', 'O'), ('an', 'O'), ('adverse', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('Rho', 'O'), ('/', 'O'), ('ROCK', 'O'), ('pathway', 'O'), ('by', 'O'), ('sorafenib', 'O'), ('use', 'O'), ('.', 'O'))"
A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB .,"(('A', 'O'), ('novel', 'O'), ('animal', 'O'), ('model', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('ability', 'O'), ('of', 'O'), ('a', 'O'), ('drug', 'O'), ('delivery', 'O'), ('system', 'O'), ('to', 'O'), ('promote', 'O'), ('the', 'O'), ('passage', 'O'), ('through', 'O'), ('the', 'O'), ('BBB', 'O'), ('.', 'O'))"
The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood - brain barrier ( BBB ) and / or to improve the brain localization of a bioactive compound .,"(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('this', 'O'), ('investigation', 'O'), ('was', 'O'), ('to', 'O'), ('explore', 'O'), ('the', 'O'), ('potentiality', 'O'), ('of', 'O'), ('a', 'O'), ('novel', 'O'), ('animal', 'O'), ('model', 'O'), ('to', 'O'), ('be', 'O'), ('used', 'O'), ('for', 'O'), ('the', 'O'), ('in', 'O'), ('vivo', 'O'), ('evaluation', 'O'), ('of', 'O'), ('the', 'O'), ('ability', 'O'), ('of', 'O'), ('a', 'O'), ('drug', 'O'), ('delivery', 'O'), ('system', 'O'), ('to', 'O'), ('promote', 'O'), ('the', 'O'), ('passage', 'O'), ('through', 'O'), ('the', 'O'), ('blood', 'O'), ('-', 'O'), ('brain', 'O'), ('barrier', 'O'), ('(', 'O'), ('BBB', 'O'), (')', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('to', 'O'), ('improve', 'O'), ('the', 'O'), ('brain', 'O'), ('localization', 'O'), ('of', 'O'), ('a', 'O'), ('bioactive', 'O'), ('compound', 'O'), ('.', 'O'))"
"A Tween 80 - coated poly - L - lactid acid nanoparticles was used as a model of colloidal drug delivery system , able to trespass the BBB .","(('A', 'O'), ('Tween', 'O'), ('80', 'O'), ('-', 'O'), ('coated', 'O'), ('poly', 'O'), ('-', 'O'), ('L', 'O'), ('-', 'O'), ('lactid', 'O'), ('acid', 'O'), ('nanoparticles', 'O'), ('was', 'O'), ('used', 'O'), ('as', 'O'), ('a', 'O'), ('model', 'O'), ('of', 'O'), ('colloidal', 'O'), ('drug', 'O'), ('delivery', 'O'), ('system', 'O'), (',', 'O'), ('able', 'O'), ('to', 'O'), ('trespass', 'O'), ('the', 'O'), ('BBB', 'O'), ('.', 'O'))"
"The toxic effects of tacrine - loaded poly - L - lactid acid nanoparticles ( 5mg / kg ) , a saline solution of tacrine ( 5mg / kg ) and an empty colloidal nanoparticle suspension were compared following i . p . administration in LiCl - pre - treated Wistar rats .","(('The', 'O'), ('toxic', 'O'), ('effects', 'O'), ('of', 'O'), ('tacrine', 'O'), ('-', 'O'), ('loaded', 'O'), ('poly', 'O'), ('-', 'O'), ('L', 'O'), ('-', 'O'), ('lactid', 'O'), ('acid', 'O'), ('nanoparticles', 'O'), ('(', 'O'), ('5mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('saline', 'O'), ('solution', 'O'), ('of', 'O'), ('tacrine', 'O'), ('(', 'O'), ('5mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('and', 'O'), ('an', 'O'), ('empty', 'O'), ('colloidal', 'O'), ('nanoparticle', 'O'), ('suspension', 'O'), ('were', 'O'), ('compared', 'O'), ('following', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('administration', 'O'), ('in', 'O'), ('LiCl', 'O'), ('-', 'O'), ('pre', 'O'), ('-', 'O'), ('treated', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('.', 'O'))"
Empty nanoparticles provided similar results to control ( saline - treated ) group of animals .,"(('Empty', 'O'), ('nanoparticles', 'O'), ('provided', 'O'), ('similar', 'O'), ('results', 'O'), ('to', 'O'), ('control', 'O'), ('(', 'O'), ('saline', 'O'), ('-', 'O'), ('treated', 'O'), (')', 'O'), ('group', 'O'), ('of', 'O'), ('animals', 'O'), ('.', 'O'))"
"In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - lithium model of epilepsy in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('the', 'O'), ('evaluation', 'O'), ('of', 'O'), ('time', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('onset', 'O'), ('of', 'O'), ('symptoms', 'O'), ('and', 'O'), ('the', 'O'), ('severity', 'O'), ('of', 'O'), ('neurodegenerative', 'B'), ('processes', 'O'), ('induced', 'O'), ('by', 'O'), ('the', 'O'), ('tacrine', 'O'), ('-', 'O'), ('lithium', 'O'), ('model', 'O'), ('of', 'O'), ('epilepsy', 'B'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), (',', 'O'), ('could', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('evaluate', 'O'), ('preliminarily', 'O'), ('the', 'O'), ('capability', 'O'), ('of', 'O'), ('a', 'O'), ('drug', 'O'), ('delivery', 'O'), ('system', 'O'), ('to', 'O'), ('trespass', 'O'), ('(', 'O'), ('or', 'O'), ('not', 'O'), (')', 'O'), ('the', 'O'), ('BBB', 'O'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
High - dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients .,"(('High', 'O'), ('-', 'O'), ('dose', 'O'), ('tranexamic', 'O'), ('Acid', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('nonischemic', 'B'), ('clinical', 'I'), ('seizures', 'I'), ('in', 'O'), ('cardiac', 'B'), ('surgical', 'I'), ('patients', 'O'), ('.', 'O'))"
"BACKGROUND : In 2 separate centers , we observed a notable increase in the incidence of postoperative convulsive seizures from 1 . 3 % to 3 . 8 % in patients having undergone major cardiac surgical procedures .","(('BACKGROUND', 'O'), (':', 'O'), ('In', 'O'), ('2', 'O'), ('separate', 'O'), ('centers', 'O'), (',', 'O'), ('we', 'O'), ('observed', 'O'), ('a', 'O'), ('notable', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('postoperative', 'B'), ('convulsive', 'I'), ('seizures', 'I'), ('from', 'O'), ('1', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('to', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('in', 'O'), ('patients', 'O'), ('having', 'O'), ('undergone', 'O'), ('major', 'O'), ('cardiac', 'O'), ('surgical', 'O'), ('procedures', 'O'), ('.', 'O'))"
These events were temporally coincident with the initial use of high - dose tranexamic acid ( TXA ) therapy after withdrawal of aprotinin from general clinical usage .,"(('These', 'O'), ('events', 'O'), ('were', 'O'), ('temporally', 'O'), ('coincident', 'O'), ('with', 'O'), ('the', 'O'), ('initial', 'O'), ('use', 'O'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('tranexamic', 'O'), ('acid', 'O'), ('(', 'O'), ('TXA', 'O'), (')', 'O'), ('therapy', 'O'), ('after', 'O'), ('withdrawal', 'O'), ('of', 'O'), ('aprotinin', 'O'), ('from', 'O'), ('general', 'O'), ('clinical', 'O'), ('usage', 'O'), ('.', 'O'))"
The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery .,"(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('this', 'O'), ('review', 'O'), ('was', 'O'), ('to', 'O'), ('perform', 'O'), ('a', 'O'), ('retrospective', 'O'), ('analysis', 'O'), ('to', 'O'), ('examine', 'O'), ('whether', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('relation', 'O'), ('between', 'O'), ('TXA', 'O'), ('usage', 'O'), ('and', 'O'), ('seizures', 'B'), ('after', 'O'), ('cardiac', 'O'), ('surgery', 'O'), ('.', 'O'))"
METHODS : An in - depth chart review was undertaken in all 24 patients who developed perioperative seizures .,"(('METHODS', 'O'), (':', 'O'), ('An', 'O'), ('in', 'O'), ('-', 'O'), ('depth', 'O'), ('chart', 'O'), ('review', 'O'), ('was', 'O'), ('undertaken', 'O'), ('in', 'O'), ('all', 'O'), ('24', 'O'), ('patients', 'O'), ('who', 'O'), ('developed', 'O'), ('perioperative', 'O'), ('seizures', 'O'), ('.', 'O'))"
"Electroencephalographic activity was recorded in 11 of these patients , and all patients had a formal neurological evaluation and brain imaging studies .","(('Electroencephalographic', 'O'), ('activity', 'O'), ('was', 'O'), ('recorded', 'O'), ('in', 'O'), ('11', 'O'), ('of', 'O'), ('these', 'O'), ('patients', 'O'), (',', 'O'), ('and', 'O'), ('all', 'O'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('formal', 'O'), ('neurological', 'O'), ('evaluation', 'O'), ('and', 'O'), ('brain', 'O'), ('imaging', 'O'), ('studies', 'O'), ('.', 'O'))"
"RESULTS : Twenty - one of the 24 patients did not have evidence of new cerebral ischemic injury , but seizures were likely due to ischemic brain injury in 3 patients .","(('RESULTS', 'O'), (':', 'O'), ('Twenty', 'O'), ('-', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('24', 'O'), ('patients', 'O'), ('did', 'O'), ('not', 'O'), ('have', 'O'), ('evidence', 'O'), ('of', 'O'), ('new', 'O'), ('cerebral', 'B'), ('ischemic', 'I'), ('injury', 'I'), (',', 'O'), ('but', 'O'), ('seizures', 'O'), ('were', 'O'), ('likely', 'O'), ('due', 'O'), ('to', 'O'), ('ischemic', 'B'), ('brain', 'I'), ('injury', 'I'), ('in', 'O'), ('3', 'O'), ('patients', 'O'), ('.', 'O'))"
All patients with seizures did not have permanent neurological abnormalities .,"(('All', 'O'), ('patients', 'O'), ('with', 'O'), ('seizures', 'O'), ('did', 'O'), ('not', 'O'), ('have', 'O'), ('permanent', 'O'), ('neurological', 'B'), ('abnormalities', 'I'), ('.', 'O'))"
"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .","(('All', 'O'), ('24', 'O'), ('patients', 'O'), ('with', 'O'), ('seizures', 'O'), ('received', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('TXA', 'O'), ('intraoperatively', 'O'), ('ranging', 'O'), ('from', 'O'), ('61', 'O'), ('to', 'O'), ('259', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('had', 'O'), ('a', 'O'), ('mean', 'O'), ('age', 'O'), ('of', 'O'), ('69', 'O'), ('.', 'O'), ('9', 'O'), ('years', 'O'), (',', 'O'), ('and', 'O'), ('21', 'O'), ('of', 'O'), ('24', 'O'), ('had', 'O'), ('undergone', 'O'), ('open', 'O'), ('chamber', 'O'), ('rather', 'O'), ('than', 'O'), ('coronary', 'O'), ('bypass', 'O'), ('procedures', 'O'), ('.', 'O'))"
All but one patient were managed using cardiopulmonary bypass .,"(('All', 'O'), ('but', 'O'), ('one', 'O'), ('patient', 'O'), ('were', 'O'), ('managed', 'O'), ('using', 'O'), ('cardiopulmonary', 'O'), ('bypass', 'O'), ('.', 'O'))"
CONCLUSION : Our results suggest that use of high - dose TXA in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical seizures in susceptible patients .,"(('CONCLUSION', 'O'), (':', 'O'), ('Our', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('use', 'O'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('TXA', 'O'), ('in', 'O'), ('older', 'O'), ('patients', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('cardiopulmonary', 'O'), ('bypass', 'O'), ('and', 'O'), ('open', 'O'), ('-', 'O'), ('chamber', 'O'), ('cardiac', 'O'), ('surgery', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('clinical', 'O'), ('seizures', 'O'), ('in', 'O'), ('susceptible', 'O'), ('patients', 'O'), ('.', 'O'))"
"Eight patients had cardiac manifestations that were life - threatening in five while taking psychotropic drugs , either phenothiazines or tricyclic antidepressants .","(('Eight', 'O'), ('patients', 'O'), ('had', 'O'), ('cardiac', 'O'), ('manifestations', 'O'), ('that', 'O'), ('were', 'O'), ('life', 'O'), ('-', 'O'), ('threatening', 'O'), ('in', 'O'), ('five', 'O'), ('while', 'O'), ('taking', 'O'), ('psychotropic', 'O'), ('drugs', 'O'), (',', 'O'), ('either', 'O'), ('phenothiazines', 'O'), ('or', 'O'), ('tricyclic', 'O'), ('antidepressants', 'O'), ('.', 'O'))"
Electrocardiographic T and U wave abnormalities were present in most patients .,"(('Electrocardiographic', 'O'), ('T', 'B'), ('and', 'I'), ('U', 'I'), ('wave', 'I'), ('abnormalities', 'I'), ('were', 'O'), ('present', 'O'), ('in', 'O'), ('most', 'O'), ('patients', 'O'), ('.', 'O'))"
Five of the eight patients were 50 years of age or younger ; only one clearly had antecedent heart disease .,"(('Five', 'O'), ('of', 'O'), ('the', 'O'), ('eight', 'O'), ('patients', 'O'), ('were', 'O'), ('50', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('or', 'O'), ('younger', 'O'), (';', 'O'), ('only', 'O'), ('one', 'O'), ('clearly', 'O'), ('had', 'O'), ('antecedent', 'O'), ('heart', 'B'), ('disease', 'I'), ('.', 'O'))"
Mice in the early stage of LP - BM5 MuLV disease were given AZT in their drinking water at 1 . 0 and 2 . 5 mg / ml .,"(('Mice', 'O'), ('in', 'O'), ('the', 'O'), ('early', 'O'), ('stage', 'O'), ('of', 'O'), ('LP', 'B'), ('-', 'I'), ('BM5', 'I'), ('MuLV', 'I'), ('disease', 'I'), ('were', 'O'), ('given', 'O'), ('AZT', 'O'), ('in', 'O'), ('their', 'O'), ('drinking', 'O'), ('water', 'O'), ('at', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('and', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('ml', 'O'), ('.', 'O'))"
"Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected , untreated mice .","(('Colony', 'O'), ('formation', 'O'), ('by', 'O'), ('splenic', 'O'), ('and', 'O'), ('bone', 'O'), ('marrow', 'O'), ('BFUe', 'O'), ('was', 'O'), ('stimulated', 'O'), ('at', 'O'), ('lower', 'O'), ('concentrations', 'O'), ('of', 'O'), ('EPO', 'O'), ('in', 'O'), ('mice', 'O'), ('receiving', 'O'), ('AZT', 'O'), ('for', 'O'), ('15', 'O'), ('d', 'O'), ('than', 'O'), ('for', 'O'), ('infected', 'O'), (',', 'O'), ('untreated', 'O'), ('mice', 'O'), ('.', 'O'))"
"By day 30 , sensitivity of both splenic and bone marrow BFU - e of treated animals returned to that observed from cells of infected untreated animals .","(('By', 'O'), ('day', 'O'), ('30', 'O'), (',', 'O'), ('sensitivity', 'O'), ('of', 'O'), ('both', 'O'), ('splenic', 'O'), ('and', 'O'), ('bone', 'O'), ('marrow', 'O'), ('BFU', 'O'), ('-', 'O'), ('e', 'O'), ('of', 'O'), ('treated', 'O'), ('animals', 'O'), ('returned', 'O'), ('to', 'O'), ('that', 'O'), ('observed', 'O'), ('from', 'O'), ('cells', 'O'), ('of', 'O'), ('infected', 'O'), ('untreated', 'O'), ('animals', 'O'), ('.', 'O'))"
"Sedation depth was titrated using processed electroencephalography with the bispectral index ( BIS ) , and patients were randomized to receive either deep ( BIS , approximately 50 ) or light ( BIS , > or = 80 ) sedation .","(('Sedation', 'O'), ('depth', 'O'), ('was', 'O'), ('titrated', 'O'), ('using', 'O'), ('processed', 'O'), ('electroencephalography', 'O'), ('with', 'O'), ('the', 'O'), ('bispectral', 'O'), ('index', 'O'), ('(', 'O'), ('BIS', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('patients', 'O'), ('were', 'O'), ('randomized', 'O'), ('to', 'O'), ('receive', 'O'), ('either', 'O'), ('deep', 'O'), ('(', 'O'), ('BIS', 'O'), (',', 'O'), ('approximately', 'O'), ('50', 'O'), (')', 'O'), ('or', 'O'), ('light', 'O'), ('(', 'O'), ('BIS', 'O'), (',', 'O'), ('>', 'O'), ('or', 'O'), ('=', 'O'), ('80', 'O'), (')', 'O'), ('sedation', 'O'), ('.', 'O'))"
"RESULTS : From April 2 , 2005 , through October 30 , 2008 , a total of 114 patients were randomized .","(('RESULTS', 'O'), (':', 'O'), ('From', 'O'), ('April', 'O'), ('2', 'O'), (',', 'O'), ('2005', 'O'), (',', 'O'), ('through', 'O'), ('October', 'O'), ('30', 'O'), (',', 'O'), ('2008', 'O'), (',', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('114', 'O'), ('patients', 'O'), ('were', 'O'), ('randomized', 'O'), ('.', 'O'))"
Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis .,"(('Nrf2', 'O'), ('is', 'O'), ('the', 'O'), ('primary', 'O'), ('transcription', 'O'), ('factor', 'O'), ('that', 'O'), ('controls', 'O'), ('the', 'O'), ('antioxidant', 'O'), ('response', 'O'), ('essential', 'O'), ('for', 'O'), ('maintaining', 'O'), ('cellular', 'O'), ('redox', 'O'), ('homeostasis', 'O'), ('.', 'O'))"
"In the animal study , Nrf2 was demonstrated to be crucial in ameliorating streptozotocin - induced renal damage .","(('In', 'O'), ('the', 'O'), ('animal', 'O'), ('study', 'O'), (',', 'O'), ('Nrf2', 'O'), ('was', 'O'), ('demonstrated', 'O'), ('to', 'O'), ('be', 'O'), ('crucial', 'O'), ('in', 'O'), ('ameliorating', 'O'), ('streptozotocin', 'B'), ('-', 'O'), ('induced', 'O'), ('renal', 'B'), ('damage', 'I'), ('.', 'O'))"
This is evident by Nrf2 ( - / - ) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2 ( + / + ) mice .,"(('This', 'O'), ('is', 'O'), ('evident', 'O'), ('by', 'O'), ('Nrf2', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('having', 'O'), ('higher', 'O'), ('ROS', 'O'), ('production', 'O'), ('and', 'O'), ('suffering', 'O'), ('from', 'O'), ('greater', 'O'), ('oxidative', 'O'), ('DNA', 'O'), ('damage', 'O'), ('and', 'O'), ('renal', 'B'), ('injury', 'I'), ('compared', 'O'), ('with', 'O'), ('Nrf2', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('+', 'O'), (')', 'O'), ('mice', 'O'), ('.', 'O'))"
"In human renal mesangial cells , high glucose induced ROS production and activated expression of Nrf2 and its downstream genes .","(('In', 'O'), ('human', 'O'), ('renal', 'O'), ('mesangial', 'O'), ('cells', 'O'), (',', 'O'), ('high', 'O'), ('glucose', 'O'), ('induced', 'O'), ('ROS', 'O'), ('production', 'O'), ('and', 'O'), ('activated', 'O'), ('expression', 'O'), ('of', 'O'), ('Nrf2', 'O'), ('and', 'O'), ('its', 'O'), ('downstream', 'O'), ('genes', 'O'), ('.', 'O'))"
"Furthermore , activation or overexpression of Nrf2 inhibited the promoter activity of TGF - beta1 in a dose - dependent manner , whereas knockdown of Nrf2 by siRNA enhanced TGF - beta1 transcription and fibronectin production .","(('Furthermore', 'O'), (',', 'O'), ('activation', 'O'), ('or', 'O'), ('overexpression', 'O'), ('of', 'O'), ('Nrf2', 'O'), ('inhibited', 'O'), ('the', 'O'), ('promoter', 'O'), ('activity', 'O'), ('of', 'O'), ('TGF', 'O'), ('-', 'O'), ('beta1', 'O'), ('in', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('manner', 'O'), (',', 'O'), ('whereas', 'O'), ('knockdown', 'O'), ('of', 'O'), ('Nrf2', 'O'), ('by', 'O'), ('siRNA', 'O'), ('enhanced', 'O'), ('TGF', 'O'), ('-', 'O'), ('beta1', 'O'), ('transcription', 'O'), ('and', 'O'), ('fibronectin', 'O'), ('production', 'O'), ('.', 'O'))"
Metformin prevents experimental gentamicin - induced nephropathy by a mitochondria - dependent pathway .,"(('Metformin', 'O'), ('prevents', 'O'), ('experimental', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('induced', 'O'), ('nephropathy', 'B'), ('by', 'O'), ('a', 'O'), ('mitochondria', 'O'), ('-', 'O'), ('dependent', 'O'), ('pathway', 'O'), ('.', 'O'))"
The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients .,"(('The', 'O'), ('antidiabetic', 'O'), ('drug', 'O'), ('metformin', 'O'), ('can', 'O'), ('diminish', 'O'), ('apoptosis', 'O'), ('induced', 'O'), ('by', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('in', 'O'), ('endothelial', 'O'), ('cells', 'O'), ('and', 'O'), ('prevent', 'O'), ('vascular', 'B'), ('dysfunction', 'I'), ('even', 'O'), ('in', 'O'), ('nondiabetic', 'O'), ('patients', 'O'), ('.', 'O'))"
Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity .,"(('Here', 'O'), ('we', 'O'), ('tested', 'O'), ('whether', 'O'), ('it', 'O'), ('has', 'O'), ('a', 'O'), ('beneficial', 'O'), ('effect', 'O'), ('in', 'O'), ('a', 'O'), ('rat', 'O'), ('model', 'O'), ('of', 'O'), ('gentamicin', 'B'), ('toxicity', 'I'), ('.', 'O'))"
"Mitochondrial analysis , respiration intensity , levels of reactive oxygen species , permeability transition , and cytochrome c release were assessed 3 and 6 days after gentamicin administration .","(('Mitochondrial', 'O'), ('analysis', 'O'), (',', 'O'), ('respiration', 'O'), ('intensity', 'O'), (',', 'O'), ('levels', 'O'), ('of', 'O'), ('reactive', 'O'), ('oxygen', 'O'), ('species', 'O'), (',', 'O'), ('permeability', 'O'), ('transition', 'O'), (',', 'O'), ('and', 'O'), ('cytochrome', 'O'), ('c', 'O'), ('release', 'O'), ('were', 'O'), ('assessed', 'O'), ('3', 'O'), ('and', 'O'), ('6', 'O'), ('days', 'O'), ('after', 'O'), ('gentamicin', 'O'), ('administration', 'O'), ('.', 'O'))"
Metformin treatment fully blocked gentamicin - mediated acute renal failure .,"(('Metformin', 'O'), ('treatment', 'O'), ('fully', 'O'), ('blocked', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('mediated', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('.', 'O'))"
"This was accompanied by a lower activity of N - acetyl - beta - D - glucosaminidase , together with a decrease of lipid peroxidation and increase of antioxidant systems .","(('This', 'O'), ('was', 'O'), ('accompanied', 'O'), ('by', 'O'), ('a', 'O'), ('lower', 'O'), ('activity', 'O'), ('of', 'O'), ('N', 'O'), ('-', 'O'), ('acetyl', 'O'), ('-', 'O'), ('beta', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('glucosaminidase', 'O'), (',', 'O'), ('together', 'O'), ('with', 'O'), ('a', 'O'), ('decrease', 'O'), ('of', 'O'), ('lipid', 'O'), ('peroxidation', 'O'), ('and', 'O'), ('increase', 'O'), ('of', 'O'), ('antioxidant', 'O'), ('systems', 'O'), ('.', 'O'))"
Metformin also protected the kidney from histological damage 6 days after gentamicin administration .,"(('Metformin', 'O'), ('also', 'O'), ('protected', 'O'), ('the', 'O'), ('kidney', 'O'), ('from', 'O'), ('histological', 'O'), ('damage', 'O'), ('6', 'O'), ('days', 'O'), ('after', 'O'), ('gentamicin', 'O'), ('administration', 'O'), ('.', 'O'))"
These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function .,"(('These', 'O'), ('in', 'O'), ('vivo', 'O'), ('markers', 'O'), ('of', 'O'), ('kidney', 'B'), ('dysfunction', 'I'), ('and', 'O'), ('their', 'O'), ('correction', 'O'), ('by', 'O'), ('metformin', 'O'), ('were', 'O'), ('complemented', 'O'), ('by', 'O'), ('in', 'O'), ('vitro', 'O'), ('studies', 'O'), ('of', 'O'), ('mitochondrial', 'O'), ('function', 'O'), ('.', 'O'))"
"We found that gentamicin treatment depleted respiratory components ( cytochrome c , NADH ) , probably due to the opening of mitochondrial transition pores .","(('We', 'O'), ('found', 'O'), ('that', 'O'), ('gentamicin', 'O'), ('treatment', 'O'), ('depleted', 'O'), ('respiratory', 'O'), ('components', 'O'), ('(', 'O'), ('cytochrome', 'O'), ('c', 'O'), (',', 'O'), ('NADH', 'O'), (')', 'O'), (',', 'O'), ('probably', 'O'), ('due', 'O'), ('to', 'O'), ('the', 'O'), ('opening', 'O'), ('of', 'O'), ('mitochondrial', 'O'), ('transition', 'O'), ('pores', 'O'), ('.', 'O'))"
"These injuries , partly mediated by a rise in reactive oxygen species from the electron transfer chain , were significantly decreased by metformin .","(('These', 'O'), ('injuries', 'O'), (',', 'O'), ('partly', 'O'), ('mediated', 'O'), ('by', 'O'), ('a', 'O'), ('rise', 'O'), ('in', 'O'), ('reactive', 'O'), ('oxygen', 'O'), ('species', 'O'), ('from', 'O'), ('the', 'O'), ('electron', 'O'), ('transfer', 'O'), ('chain', 'O'), (',', 'O'), ('were', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('by', 'O'), ('metformin', 'O'), ('.', 'O'))"
Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .,"(('Risk', 'O'), ('of', 'O'), ('nephropathy', 'B'), ('after', 'O'), ('consumption', 'O'), ('of', 'O'), ('nonionic', 'O'), ('contrast', 'O'), ('media', 'O'), ('by', 'O'), ('children', 'O'), ('undergoing', 'O'), ('cardiac', 'O'), ('angiography', 'O'), (':', 'O'), ('a', 'O'), ('prospective', 'O'), ('study', 'O'), ('.', 'O'))"
"The 80 patients in the study consecutively received either iopromide ( group A , n = 40 ) or iohexol ( group B , n = 40 ) .","(('The', 'O'), ('80', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('study', 'O'), ('consecutively', 'O'), ('received', 'O'), ('either', 'O'), ('iopromide', 'O'), ('(', 'O'), ('group', 'O'), ('A', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('40', 'O'), (')', 'O'), ('or', 'O'), ('iohexol', 'O'), ('(', 'O'), ('group', 'O'), ('B', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('40', 'O'), (')', 'O'), ('.', 'O'))"
"Serum sodium ( Na ) , potassium ( K ) , and creatinine ( Cr ) were measured 24 h before angiography as baseline values , then measured again at 12 - , 24 - , and 48 - h intervals after CM use .","(('Serum', 'O'), ('sodium', 'O'), ('(', 'O'), ('Na', 'O'), (')', 'O'), (',', 'O'), ('potassium', 'O'), ('(', 'O'), ('K', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('creatinine', 'O'), ('(', 'O'), ('Cr', 'O'), (')', 'O'), ('were', 'O'), ('measured', 'O'), ('24', 'O'), ('h', 'O'), ('before', 'O'), ('angiography', 'O'), ('as', 'O'), ('baseline', 'O'), ('values', 'O'), (',', 'O'), ('then', 'O'), ('measured', 'O'), ('again', 'O'), ('at', 'O'), ('12', 'O'), ('-', 'O'), (',', 'O'), ('24', 'O'), ('-', 'O'), (',', 'O'), ('and', 'O'), ('48', 'O'), ('-', 'O'), ('h', 'O'), ('intervals', 'O'), ('after', 'O'), ('CM', 'O'), ('use', 'O'), ('.', 'O'))"
Urine samples for Na and Cr also were checked at the same intervals .,"(('Urine', 'O'), ('samples', 'O'), ('for', 'O'), ('Na', 'O'), ('and', 'O'), ('Cr', 'O'), ('also', 'O'), ('were', 'O'), ('checked', 'O'), ('at', 'O'), ('the', 'O'), ('same', 'O'), ('intervals', 'O'), ('.', 'O'))"
Renal function and hemodynamics during prolonged isoflurane - induced hypotension in humans .,"(('Renal', 'O'), ('function', 'O'), ('and', 'O'), ('hemodynamics', 'O'), ('during', 'O'), ('prolonged', 'O'), ('isoflurane', 'I'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('in', 'O'), ('humans', 'O'), ('.', 'O'))"
The effect of isoflurane - induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects .,"(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('isoflurane', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('on', 'O'), ('glomerular', 'O'), ('function', 'O'), ('and', 'O'), ('renal', 'O'), ('blood', 'O'), ('flow', 'O'), ('was', 'O'), ('investigated', 'O'), ('in', 'O'), ('20', 'O'), ('human', 'O'), ('subjects', 'O'), ('.', 'O'))"
"Glomerular filtration rate ( GFR ) and effective renal plasma flow ( ERPF ) were measured by inulin and para - aminohippurate ( PAH ) clearance , respectively .","(('Glomerular', 'O'), ('filtration', 'O'), ('rate', 'O'), ('(', 'O'), ('GFR', 'O'), (')', 'O'), ('and', 'O'), ('effective', 'O'), ('renal', 'O'), ('plasma', 'O'), ('flow', 'O'), ('(', 'O'), ('ERPF', 'O'), (')', 'O'), ('were', 'O'), ('measured', 'O'), ('by', 'O'), ('inulin', 'O'), ('and', 'O'), ('para', 'O'), ('-', 'O'), ('aminohippurate', 'O'), ('(', 'O'), ('PAH', 'O'), (')', 'O'), ('clearance', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Anesthesia was maintained with fentanyl , nitrous oxide , oxygen , and isoflurane .","(('Anesthesia', 'O'), ('was', 'O'), ('maintained', 'O'), ('with', 'O'), ('fentanyl', 'O'), (',', 'O'), ('nitrous', 'O'), ('oxide', 'O'), (',', 'O'), ('oxygen', 'O'), (',', 'O'), ('and', 'O'), ('isoflurane', 'O'), ('.', 'O'))"
GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension .,"(('GFR', 'O'), ('and', 'O'), ('ERPF', 'O'), ('decreased', 'O'), ('with', 'O'), ('the', 'O'), ('induction', 'O'), ('of', 'O'), ('anesthesia', 'O'), ('but', 'O'), ('not', 'O'), ('significantly', 'O'), ('more', 'O'), ('during', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"Postoperatively , ERPF returned to preoperative values , whereas GFR was higher than preoperative values .","(('Postoperatively', 'O'), (',', 'O'), ('ERPF', 'O'), ('returned', 'O'), ('to', 'O'), ('preoperative', 'O'), ('values', 'O'), (',', 'O'), ('whereas', 'O'), ('GFR', 'O'), ('was', 'O'), ('higher', 'O'), ('than', 'O'), ('preoperative', 'O'), ('values', 'O'), ('.', 'O'))"
"Renal vascular resistance increased during anesthesia but decreased when hypotension was induced , allowing the maintenance of renal blood flow .","(('Renal', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('increased', 'O'), ('during', 'O'), ('anesthesia', 'O'), ('but', 'O'), ('decreased', 'O'), ('when', 'O'), ('hypotension', 'B'), ('was', 'O'), ('induced', 'O'), (',', 'O'), ('allowing', 'O'), ('the', 'O'), ('maintenance', 'O'), ('of', 'O'), ('renal', 'O'), ('blood', 'O'), ('flow', 'O'), ('.', 'O'))"
We conclude that renal compensatory mechanisms are preserved during isoflurane - induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('renal', 'O'), ('compensatory', 'O'), ('mechanisms', 'O'), ('are', 'O'), ('preserved', 'O'), ('during', 'O'), ('isoflurane', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('and', 'O'), ('that', 'O'), ('renal', 'O'), ('function', 'O'), ('and', 'O'), ('hemodynamics', 'O'), ('quickly', 'O'), ('return', 'O'), ('to', 'O'), ('normal', 'O'), ('when', 'O'), ('normotension', 'O'), ('is', 'O'), ('resumed', 'O'), ('.', 'O'))"
A cross - sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys .,"(('A', 'O'), ('cross', 'O'), ('-', 'O'), ('sectional', 'O'), ('evaluation', 'O'), ('of', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('risperidone', 'O'), ('and', 'O'), ('selective', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('inhibitors', 'O'), ('on', 'O'), ('bone', 'O'), ('mineral', 'O'), ('density', 'O'), ('in', 'O'), ('boys', 'O'), ('.', 'O'))"
"METHOD : Medically healthy 7 - to 17 - year - old males chronically treated , in a naturalistic setting , with risperidone were recruited for this cross - sectional study through child psychiatry outpatient clinics between November 2005 and June 2007 .","(('METHOD', 'O'), (':', 'O'), ('Medically', 'O'), ('healthy', 'O'), ('7', 'O'), ('-', 'O'), ('to', 'O'), ('17', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('males', 'O'), ('chronically', 'O'), ('treated', 'O'), (',', 'O'), ('in', 'O'), ('a', 'O'), ('naturalistic', 'O'), ('setting', 'O'), (',', 'O'), ('with', 'O'), ('risperidone', 'O'), ('were', 'O'), ('recruited', 'O'), ('for', 'O'), ('this', 'O'), ('cross', 'O'), ('-', 'O'), ('sectional', 'O'), ('study', 'O'), ('through', 'O'), ('child', 'O'), ('psychiatry', 'O'), ('outpatient', 'O'), ('clinics', 'O'), ('between', 'O'), ('November', 'O'), ('2005', 'O'), ('and', 'O'), ('June', 'O'), ('2007', 'O'), ('.', 'O'))"
Anthropometric measurements and laboratory testing were conducted .,"(('Anthropometric', 'O'), ('measurements', 'O'), ('and', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('were', 'O'), ('conducted', 'O'), ('.', 'O'))"
"The clinical diagnoses were based on chart review , and developmental and treatment history was obtained from the medical record .","(('The', 'O'), ('clinical', 'O'), ('diagnoses', 'O'), ('were', 'O'), ('based', 'O'), ('on', 'O'), ('chart', 'O'), ('review', 'O'), (',', 'O'), ('and', 'O'), ('developmental', 'O'), ('and', 'O'), ('treatment', 'O'), ('history', 'O'), ('was', 'O'), ('obtained', 'O'), ('from', 'O'), ('the', 'O'), ('medical', 'O'), ('record', 'O'), ('.', 'O'))"
"Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography , and areal BMD of the lumbar spine was estimated using dual - energy x - ray absorptiometry .","(('Volumetric', 'O'), ('BMD', 'O'), ('of', 'O'), ('the', 'O'), ('ultradistal', 'O'), ('radius', 'O'), ('was', 'O'), ('measured', 'O'), ('using', 'O'), ('peripheral', 'O'), ('quantitative', 'O'), ('computed', 'O'), ('tomography', 'O'), (',', 'O'), ('and', 'O'), ('areal', 'O'), ('BMD', 'O'), ('of', 'O'), ('the', 'O'), ('lumbar', 'O'), ('spine', 'O'), ('was', 'O'), ('estimated', 'O'), ('using', 'O'), ('dual', 'O'), ('-', 'O'), ('energy', 'O'), ('x', 'O'), ('-', 'O'), ('ray', 'O'), ('absorptiometry', 'O'), ('.', 'O'))"
"As expected , bone mineral content and BMD increased with sexual maturity .","(('As', 'O'), ('expected', 'O'), (',', 'O'), ('bone', 'O'), ('mineral', 'O'), ('content', 'O'), ('and', 'O'), ('BMD', 'B'), ('increased', 'O'), ('with', 'O'), ('sexual', 'O'), ('maturity', 'O'), ('.', 'O'))"
"After adjusting for the stage of sexual development and height and BMI z scores , serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius ( P < . 03 ) .","(('After', 'O'), ('adjusting', 'O'), ('for', 'O'), ('the', 'O'), ('stage', 'O'), ('of', 'O'), ('sexual', 'O'), ('development', 'O'), ('and', 'O'), ('height', 'O'), ('and', 'O'), ('BMI', 'O'), ('z', 'O'), ('scores', 'O'), (',', 'O'), ('serum', 'O'), ('prolactin', 'O'), ('was', 'O'), ('negatively', 'O'), ('associated', 'O'), ('with', 'O'), ('trabecular', 'O'), ('volumetric', 'O'), ('BMD', 'O'), ('at', 'O'), ('the', 'O'), ('ultradistal', 'O'), ('radius', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('.', 'O'), ('03', 'O'), (')', 'O'), ('.', 'O'))"
"Controlling for relevant covariates , we also found treatment with selective serotonin reuptake inhibitors ( SSRIs ) to be associated with lower trabecular BMD at the radius ( P = . 03 ) and BMD z score at the lumbar spine ( P < . 05 ) .","(('Controlling', 'O'), ('for', 'O'), ('relevant', 'O'), ('covariates', 'O'), (',', 'O'), ('we', 'O'), ('also', 'O'), ('found', 'O'), ('treatment', 'O'), ('with', 'O'), ('selective', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('inhibitors', 'O'), ('(', 'O'), ('SSRIs', 'O'), (')', 'O'), ('to', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('lower', 'O'), ('trabecular', 'O'), ('BMD', 'O'), ('at', 'O'), ('the', 'O'), ('radius', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('03', 'O'), (')', 'O'), ('and', 'O'), ('BMD', 'O'), ('z', 'O'), ('score', 'O'), ('at', 'O'), ('the', 'O'), ('lumbar', 'O'), ('spine', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
These findings became more marked when the analysis was restricted to non - Hispanic white patients .,"(('These', 'O'), ('findings', 'O'), ('became', 'O'), ('more', 'O'), ('marked', 'O'), ('when', 'O'), ('the', 'O'), ('analysis', 'O'), ('was', 'O'), ('restricted', 'O'), ('to', 'O'), ('non', 'O'), ('-', 'O'), ('Hispanic', 'O'), ('white', 'O'), ('patients', 'O'), ('.', 'O'))"
Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues .,"(('Future', 'O'), ('research', 'O'), ('should', 'O'), ('evaluate', 'O'), ('the', 'O'), ('longitudinal', 'O'), ('course', 'O'), ('of', 'O'), ('this', 'O'), ('adverse', 'O'), ('event', 'O'), ('to', 'O'), ('determine', 'O'), ('its', 'O'), ('temporal', 'O'), ('stability', 'O'), ('and', 'O'), ('whether', 'O'), ('a', 'O'), ('higher', 'O'), ('fracture', 'B'), ('rate', 'O'), ('ensues', 'O'), ('.', 'O'))"
"However , the pharmacological profiles of these two paradigms are very similar .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('pharmacological', 'O'), ('profiles', 'O'), ('of', 'O'), ('these', 'O'), ('two', 'O'), ('paradigms', 'O'), ('are', 'O'), ('very', 'O'), ('similar', 'O'), ('.', 'O'))"
The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms .,"(('The', 'O'), ('present', 'O'), ('study', 'O'), ('investigated', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('putative', 'O'), ('anxiogenic', 'O'), ('drugs', 'O'), ('on', 'O'), ('LES', 'B'), ('and', 'O'), ('FPS', 'B'), ('and', 'O'), ('aimed', 'O'), ('at', 'O'), ('determining', 'O'), ('the', 'O'), ('sensitivity', 'O'), ('of', 'O'), ('LES', 'O'), ('for', 'O'), ('anxiogenic', 'O'), ('drugs', 'O'), ('and', 'O'), ('to', 'O'), ('potentially', 'O'), ('showing', 'O'), ('a', 'O'), ('pharmacological', 'O'), ('differentiation', 'O'), ('between', 'O'), ('these', 'O'), ('two', 'O'), ('paradigms', 'O'), ('.', 'O'))"
"METHODS : Male Wistar rats received each dose of the alpha ( 2 ) - adrenoceptor antagonist yohimbine ( 0 . 25 - 1 . 0mg / kg ) , the 5 - HT ( 2C ) receptor agonist m - chlorophenylpiperazine ( mCPP , 0 . 5 - 2 . 0mg / kg ) or the GABA ( A ) inverse receptor agonist pentylenetetrazole ( PTZ , 3 - 30mg / kg ) and were subsequently tested in either LES or FPS .","(('METHODS', 'O'), (':', 'O'), ('Male', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('received', 'O'), ('each', 'O'), ('dose', 'O'), ('of', 'O'), ('the', 'O'), ('alpha', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('antagonist', 'O'), ('yohimbine', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('25', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('0mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('(', 'O'), ('2C', 'O'), (')', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('m', 'O'), ('-', 'O'), ('chlorophenylpiperazine', 'O'), ('(', 'O'), ('mCPP', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('0mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('or', 'O'), ('the', 'O'), ('GABA', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), ('inverse', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('pentylenetetrazole', 'O'), ('(', 'O'), ('PTZ', 'O'), (',', 'O'), ('3', 'O'), ('-', 'O'), ('30mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('and', 'O'), ('were', 'O'), ('subsequently', 'O'), ('tested', 'O'), ('in', 'O'), ('either', 'O'), ('LES', 'B'), ('or', 'O'), ('FPS', 'O'), ('.', 'O'))"
"RESULTS : None of the drugs enhanced LES , whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values .","(('RESULTS', 'O'), (':', 'O'), ('None', 'O'), ('of', 'O'), ('the', 'O'), ('drugs', 'O'), ('enhanced', 'O'), ('LES', 'O'), (',', 'O'), ('whereas', 'O'), ('mCPP', 'O'), ('increased', 'O'), ('percentage', 'O'), ('FPS', 'O'), ('and', 'O'), ('yohimbine', 'O'), ('increased', 'O'), ('absolute', 'O'), ('FPS', 'O'), ('values', 'O'), ('.', 'O'))"
"CONCLUSIONS : In contrast to findings in the FPS paradigm , none of the drugs were able to exacerbate the LES response .","(('CONCLUSIONS', 'O'), (':', 'O'), ('In', 'O'), ('contrast', 'O'), ('to', 'O'), ('findings', 'O'), ('in', 'O'), ('the', 'O'), ('FPS', 'O'), ('paradigm', 'O'), (',', 'O'), ('none', 'O'), ('of', 'O'), ('the', 'O'), ('drugs', 'O'), ('were', 'O'), ('able', 'O'), ('to', 'O'), ('exacerbate', 'O'), ('the', 'O'), ('LES', 'O'), ('response', 'O'), ('.', 'O'))"
"Thus , a clear pharmacological differentiation was found between LES and FPS .","(('Thus', 'O'), (',', 'O'), ('a', 'O'), ('clear', 'O'), ('pharmacological', 'O'), ('differentiation', 'O'), ('was', 'O'), ('found', 'O'), ('between', 'O'), ('LES', 'B'), ('and', 'O'), ('FPS', 'B'), ('.', 'O'))"
Rosaceiform dermatitis associated with topical tacrolimus treatment .,"(('Rosaceiform', 'B'), ('dermatitis', 'I'), ('associated', 'O'), ('with', 'O'), ('topical', 'O'), ('tacrolimus', 'O'), ('treatment', 'O'), ('.', 'O'))"
Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis .,"(('Skin', 'O'), ('biopsy', 'O'), ('specimens', 'O'), ('showed', 'O'), ('telangiectasia', 'B'), ('and', 'O'), ('noncaseating', 'O'), ('epithelioid', 'B'), ('granulomatous', 'I'), ('tissue', 'O'), ('formation', 'O'), ('in', 'O'), ('the', 'O'), ('papillary', 'O'), ('to', 'O'), ('mid', 'O'), ('dermis', 'O'), ('.', 'O'))"
"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis , although many cases have not been reported .","(('Continuous', 'O'), ('topical', 'O'), ('use', 'O'), ('of', 'O'), ('immunomodulators', 'O'), ('such', 'O'), ('as', 'O'), ('tacrolimus', 'O'), ('or', 'O'), ('pimecrolimus', 'O'), ('should', 'O'), ('be', 'O'), ('regarded', 'O'), ('as', 'O'), ('a', 'O'), ('potential', 'O'), ('cause', 'O'), ('of', 'O'), ('rosaceiform', 'B'), ('dermatitis', 'I'), (',', 'O'), ('although', 'O'), ('many', 'O'), ('cases', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O'))"
The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i . p . injection of cisplatin ( 5 mg / kg ) .,"(('The', 'O'), ('nephroprotective', 'O'), ('effect', 'O'), ('of', 'O'), ('coenzyme', 'O'), ('Q10', 'O'), ('was', 'O'), ('investigated', 'O'), ('in', 'O'), ('mice', 'O'), ('with', 'O'), ('acute', 'O'), ('renal', 'B'), ('injury', 'I'), ('induced', 'O'), ('by', 'O'), ('a', 'O'), ('single', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('injection', 'O'), ('of', 'O'), ('cisplatin', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('.', 'O'))"
"Coenzyme Q10 treatment ( 10 mg / kg / day , i . p . ) was applied for 6 consecutive days , starting 1 day before cisplatin administration .","(('Coenzyme', 'O'), ('Q10', 'O'), ('treatment', 'O'), ('(', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('day', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('was', 'O'), ('applied', 'O'), ('for', 'O'), ('6', 'O'), ('consecutive', 'O'), ('days', 'O'), (',', 'O'), ('starting', 'O'), ('1', 'O'), ('day', 'O'), ('before', 'O'), ('cisplatin', 'O'), ('administration', 'O'), ('.', 'O'))"
Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin .,"(('Coenzyme', 'O'), ('Q10', 'O'), ('significantly', 'O'), ('reduced', 'O'), ('blood', 'O'), ('urea', 'O'), ('nitrogen', 'O'), ('and', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('levels', 'O'), ('which', 'O'), ('were', 'O'), ('increased', 'O'), ('by', 'O'), ('cisplatin', 'O'), ('.', 'O'))"
"Also , histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment .","(('Also', 'O'), (',', 'O'), ('histopathological', 'O'), ('renal', 'O'), ('tissue', 'O'), ('damage', 'O'), ('mediated', 'O'), ('by', 'O'), ('cisplatin', 'O'), ('was', 'O'), ('ameliorated', 'O'), ('by', 'O'), ('coenzyme', 'O'), ('Q10', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin - induced overexpression of inducible nitric oxide synthase , nuclear factor - kappaB , caspase - 3 and p53 in renal tissue .","(('Immunohistochemical', 'O'), ('analysis', 'O'), ('revealed', 'O'), ('that', 'O'), ('coenzyme', 'O'), ('Q10', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('the', 'O'), ('cisplatin', 'O'), ('-', 'O'), ('induced', 'O'), ('overexpression', 'O'), ('of', 'O'), ('inducible', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('synthase', 'O'), (',', 'O'), ('nuclear', 'O'), ('factor', 'O'), ('-', 'O'), ('kappaB', 'O'), (',', 'O'), ('caspase', 'O'), ('-', 'O'), ('3', 'O'), ('and', 'O'), ('p53', 'O'), ('in', 'O'), ('renal', 'O'), ('tissue', 'O'), ('.', 'O'))"
A case report .,"(('A', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities .,"(('Azathioprine', 'O'), ('withdrawal', 'O'), ('resulted', 'O'), ('after', 'O'), ('7', 'O'), ('weeks', 'O'), ('in', 'O'), ('the', 'O'), ('resolution', 'O'), ('of', 'O'), ('clinical', 'O'), ('and', 'O'), ('biochemical', 'O'), ('abnormalities', 'O'), ('.', 'O'))"
"It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .","(('It', 'O'), ('is', 'O'), ('widely', 'O'), ('believed', 'O'), ('that', 'O'), ('dopamine', 'O'), ('(', 'O'), ('DA', 'O'), (')', 'O'), ('mediates', 'O'), ('methamphetamine', 'O'), ('(', 'O'), ('METH', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('toxicity', 'O'), ('to', 'O'), ('brain', 'O'), ('dopaminergic', 'O'), ('neurons', 'O'), (',', 'O'), ('because', 'O'), ('drugs', 'O'), ('that', 'O'), ('interfere', 'O'), ('with', 'O'), ('DA', 'O'), ('neurotransmission', 'O'), ('decrease', 'O'), ('toxicity', 'O'), (',', 'O'), ('whereas', 'O'), ('drugs', 'O'), ('that', 'O'), ('increase', 'O'), ('DA', 'O'), ('neurotransmission', 'O'), ('enhance', 'O'), ('toxicity', 'O'), ('.', 'O'))"
"However , temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data .","(('However', 'O'), (',', 'O'), ('temperature', 'O'), ('effects', 'O'), ('of', 'O'), ('drugs', 'O'), ('that', 'O'), ('have', 'O'), ('been', 'O'), ('used', 'O'), ('to', 'O'), ('manipulate', 'O'), ('brain', 'O'), ('DA', 'O'), ('neurotransmission', 'O'), ('confound', 'O'), ('interpretation', 'O'), ('of', 'O'), ('the', 'O'), ('data', 'O'), ('.', 'O'))"
CASE : A 49 - year - old patient experienced chest discomfort while swallowing .,"(('CASE', 'O'), (':', 'O'), ('A', 'O'), ('49', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('patient', 'O'), ('experienced', 'O'), ('chest', 'B'), ('discomfort', 'I'), ('while', 'O'), ('swallowing', 'O'), ('.', 'O'))"
"The arrhythmia resolved after therapy with atenolol , but recurred a year later .","(('The', 'O'), ('arrhythmia', 'O'), ('resolved', 'O'), ('after', 'O'), ('therapy', 'O'), ('with', 'O'), ('atenolol', 'O'), (',', 'O'), ('but', 'O'), ('recurred', 'O'), ('a', 'O'), ('year', 'O'), ('later', 'O'), ('.', 'O'))"
The patient noticed that before these episodes he had been using an inhalator of salbutamol .,"(('The', 'O'), ('patient', 'O'), ('noticed', 'O'), ('that', 'O'), ('before', 'O'), ('these', 'O'), ('episodes', 'O'), ('he', 'O'), ('had', 'O'), ('been', 'O'), ('using', 'O'), ('an', 'O'), ('inhalator', 'O'), ('of', 'O'), ('salbutamol', 'O'), ('.', 'O'))"
"After stopping the beta - agonist , and after a week with the atenolol , the arrhythmia disappeared .","(('After', 'O'), ('stopping', 'O'), ('the', 'O'), ('beta', 'O'), ('-', 'O'), ('agonist', 'O'), (',', 'O'), ('and', 'O'), ('after', 'O'), ('a', 'O'), ('week', 'O'), ('with', 'O'), ('the', 'O'), ('atenolol', 'O'), (',', 'O'), ('the', 'O'), ('arrhythmia', 'O'), ('disappeared', 'O'), ('.', 'O'))"
The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin - induced diabetes mellitus .,"(('The', 'O'), ('ability', 'O'), ('of', 'O'), ('insulin', 'O'), ('treatment', 'O'), ('to', 'O'), ('reverse', 'O'), ('or', 'O'), ('prevent', 'O'), ('the', 'O'), ('changes', 'O'), ('in', 'O'), ('urinary', 'O'), ('bladder', 'O'), ('function', 'O'), ('caused', 'O'), ('by', 'O'), ('streptozotocin', 'B'), ('-', 'O'), ('induced', 'I'), ('diabetes', 'I'), ('mellitus', 'I'), ('.', 'O'))"
1 .,"(('1', 'O'), ('.', 'O'))"
2 .,"(('2', 'O'), ('.', 'O'))"
3 .,"(('3', 'O'), ('.', 'O'))"
4 .,"(('4', 'O'), ('.', 'O'))"
5 .,"(('5', 'O'), ('.', 'O'))"
6 .,"(('6', 'O'), ('.', 'O'))"
The data indicate that the effects of streptozotocin - induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment .,"(('The', 'O'), ('data', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('streptozotocin', 'O'), ('-', 'O'), ('induced', 'O'), ('diabetes', 'O'), ('on', 'O'), ('urinary', 'O'), ('bladder', 'O'), ('function', 'O'), ('are', 'O'), ('both', 'O'), ('prevented', 'O'), ('and', 'O'), ('reversed', 'O'), ('by', 'O'), ('insulin', 'O'), ('treatment', 'O'), ('.', 'O'))"
"The inferior colliculus ( IC ) is primarily involved in the processing of auditory information , but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system .","(('The', 'O'), ('inferior', 'O'), ('colliculus', 'O'), ('(', 'O'), ('IC', 'O'), (')', 'O'), ('is', 'O'), ('primarily', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('processing', 'O'), ('of', 'O'), ('auditory', 'O'), ('information', 'O'), (',', 'O'), ('but', 'O'), ('it', 'O'), ('is', 'O'), ('distinguished', 'O'), ('from', 'O'), ('other', 'O'), ('auditory', 'O'), ('nuclei', 'O'), ('in', 'O'), ('the', 'O'), ('brainstem', 'O'), ('by', 'O'), ('its', 'O'), ('connections', 'O'), ('with', 'O'), ('structures', 'O'), ('of', 'O'), ('the', 'O'), ('motor', 'O'), ('system', 'O'), ('.', 'O'))"
"Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing , escape - like behavior , and immobility .","(('Functional', 'O'), ('evidence', 'O'), ('relating', 'O'), ('the', 'O'), ('IC', 'O'), ('to', 'O'), ('motor', 'O'), ('behavior', 'O'), ('derives', 'O'), ('from', 'O'), ('experiments', 'O'), ('showing', 'O'), ('that', 'O'), ('activation', 'O'), ('of', 'O'), ('the', 'O'), ('IC', 'O'), ('by', 'O'), ('electrical', 'O'), ('stimulation', 'O'), ('or', 'O'), ('excitatory', 'O'), ('amino', 'O'), ('acid', 'O'), ('microinjection', 'O'), ('causes', 'O'), ('freezing', 'O'), (',', 'O'), ('escape', 'O'), ('-', 'O'), ('like', 'O'), ('behavior', 'O'), (',', 'O'), ('and', 'O'), ('immobility', 'O'), ('.', 'O'))"
"However , the nature of this immobility is still unclear .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('nature', 'O'), ('of', 'O'), ('this', 'O'), ('immobility', 'O'), ('is', 'O'), ('still', 'O'), ('unclear', 'O'), ('.', 'O'))"
"Accordingly , intracollicular microinjection of NMDA increased the latency to step down the bar .","(('Accordingly', 'O'), (',', 'O'), ('intracollicular', 'O'), ('microinjection', 'O'), ('of', 'O'), ('NMDA', 'O'), ('increased', 'O'), ('the', 'O'), ('latency', 'O'), ('to', 'O'), ('step', 'O'), ('down', 'O'), ('the', 'O'), ('bar', 'O'), ('.', 'O'))"
The condition is treated with intravenous thyroxine ( T4 ) or intravenous tri - iodo - thyronine ( T3 ) .,"(('The', 'O'), ('condition', 'O'), ('is', 'O'), ('treated', 'O'), ('with', 'O'), ('intravenous', 'O'), ('thyroxine', 'O'), ('(', 'O'), ('T4', 'O'), (')', 'O'), ('or', 'O'), ('intravenous', 'O'), ('tri', 'O'), ('-', 'O'), ('iodo', 'O'), ('-', 'O'), ('thyronine', 'O'), ('(', 'O'), ('T3', 'O'), (')', 'O'), ('.', 'O'))"
"Effects of active constituents of Crocus sativus L . , crocin on streptozocin - induced model of sporadic Alzheimer ' s disease in male rats .","(('Effects', 'O'), ('of', 'O'), ('active', 'O'), ('constituents', 'O'), ('of', 'O'), ('Crocus', 'O'), ('sativus', 'O'), ('L', 'O'), ('.', 'O'), (',', 'O'), ('crocin', 'O'), ('on', 'O'), ('streptozocin', 'O'), ('-', 'O'), ('induced', 'O'), ('model', 'O'), ('of', 'O'), ('sporadic', 'B'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('in', 'O'), ('male', 'O'), ('rats', 'O'), ('.', 'O'))"
"BACKGROUND : The involvement of water - soluble carotenoids , crocins , as the main and active components of Crocus sativus L . extract in learning and memory processes has been proposed .","(('BACKGROUND', 'O'), (':', 'O'), ('The', 'O'), ('involvement', 'O'), ('of', 'O'), ('water', 'O'), ('-', 'O'), ('soluble', 'O'), ('carotenoids', 'O'), (',', 'O'), ('crocins', 'O'), (',', 'O'), ('as', 'O'), ('the', 'O'), ('main', 'O'), ('and', 'O'), ('active', 'O'), ('components', 'O'), ('of', 'O'), ('Crocus', 'O'), ('sativus', 'O'), ('L', 'O'), ('.', 'O'), ('extract', 'O'), ('in', 'O'), ('learning', 'O'), ('and', 'O'), ('memory', 'O'), ('processes', 'O'), ('has', 'O'), ('been', 'O'), ('proposed', 'O'), ('.', 'O'))"
"In the present study , the effect of crocins on sporadic Alzheimer ' s disease induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), (',', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('crocins', 'O'), ('on', 'O'), ('sporadic', 'B'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('induced', 'O'), ('by', 'O'), ('intracerebroventricular', 'O'), ('(', 'O'), ('icv', 'O'), (')', 'O'), ('streptozocin', 'O'), ('(', 'O'), ('STZ', 'O'), (')', 'O'), ('in', 'O'), ('male', 'O'), ('rats', 'O'), ('was', 'O'), ('investigated', 'O'), ('.', 'O'))"
"METHODS : Male adult Wistar rats ( n = 90 and 260 - 290 g ) were divided into 1 , control ; 2 and 3 , crocins ( 15 and 30 mg / kg ) ; 4 , STZ ; 5 and 6 , STZ + crocins ( 15 and 30 mg / kg ) groups .","(('METHODS', 'O'), (':', 'O'), ('Male', 'O'), ('adult', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('90', 'O'), ('and', 'O'), ('260', 'O'), ('-', 'O'), ('290', 'O'), ('g', 'O'), (')', 'O'), ('were', 'O'), ('divided', 'O'), ('into', 'O'), ('1', 'O'), (',', 'O'), ('control', 'O'), (';', 'O'), ('2', 'O'), ('and', 'O'), ('3', 'O'), (',', 'O'), ('crocins', 'O'), ('(', 'O'), ('15', 'O'), ('and', 'O'), ('30', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (';', 'O'), ('4', 'O'), (',', 'O'), ('STZ', 'O'), (';', 'O'), ('5', 'O'), ('and', 'O'), ('6', 'O'), (',', 'O'), ('STZ', 'O'), ('+', 'O'), ('crocins', 'O'), ('(', 'O'), ('15', 'O'), ('and', 'O'), ('30', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('groups', 'O'), ('.', 'O'))"
"In Alzheimer ' s disease groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .","(('In', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('groups', 'O'), (',', 'O'), ('rats', 'O'), ('were', 'O'), ('injected', 'O'), ('with', 'O'), ('STZ', 'O'), ('-', 'O'), ('icv', 'O'), ('bilaterally', 'O'), ('(', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('in', 'O'), ('first', 'O'), ('day', 'O'), ('and', 'O'), ('3', 'O'), ('days', 'O'), ('later', 'O'), (',', 'O'), ('a', 'O'), ('similar', 'O'), ('STZ', 'O'), ('-', 'O'), ('icv', 'O'), ('application', 'O'), ('was', 'O'), ('repeated', 'O'), ('.', 'O'))"
"In STZ + crocin animal groups , crocin was applied in doses of 15 and 30 mg / kg , i . p . , one day pre - surgery and continued for three weeks .","(('In', 'O'), ('STZ', 'O'), ('+', 'O'), ('crocin', 'O'), ('animal', 'O'), ('groups', 'O'), (',', 'O'), ('crocin', 'O'), ('was', 'O'), ('applied', 'O'), ('in', 'O'), ('doses', 'O'), ('of', 'O'), ('15', 'O'), ('and', 'O'), ('30', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (',', 'O'), ('one', 'O'), ('day', 'O'), ('pre', 'O'), ('-', 'O'), ('surgery', 'O'), ('and', 'O'), ('continued', 'O'), ('for', 'O'), ('three', 'O'), ('weeks', 'O'), ('.', 'O'))"
Prescription of crocin in each dose was repeated once for two days .,"(('Prescription', 'O'), ('of', 'O'), ('crocin', 'O'), ('in', 'O'), ('each', 'O'), ('dose', 'O'), ('was', 'O'), ('repeated', 'O'), ('once', 'O'), ('for', 'O'), ('two', 'O'), ('days', 'O'), ('.', 'O'))"
"However , the learning and memory performance was assessed using passive avoidance paradigm , and for spatial cognition evaluation , Y - maze task was used .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('learning', 'O'), ('and', 'O'), ('memory', 'O'), ('performance', 'O'), ('was', 'O'), ('assessed', 'O'), ('using', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('paradigm', 'O'), (',', 'O'), ('and', 'O'), ('for', 'O'), ('spatial', 'O'), ('cognition', 'O'), ('evaluation', 'O'), (',', 'O'), ('Y', 'O'), ('-', 'O'), ('maze', 'O'), ('task', 'O'), ('was', 'O'), ('used', 'O'), ('.', 'O'))"
RESULTS : It was found out that crocin ( 30 mg / kg ) - treated STZ - injected rats show higher correct choices and lower errors in Y - maze than vehicle - treated STZ - injected rats .,"(('RESULTS', 'O'), (':', 'O'), ('It', 'O'), ('was', 'O'), ('found', 'O'), ('out', 'O'), ('that', 'O'), ('crocin', 'O'), ('(', 'O'), ('30', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('-', 'O'), ('treated', 'O'), ('STZ', 'O'), ('-', 'O'), ('injected', 'O'), ('rats', 'O'), ('show', 'O'), ('higher', 'O'), ('correct', 'O'), ('choices', 'O'), ('and', 'O'), ('lower', 'O'), ('errors', 'O'), ('in', 'O'), ('Y', 'O'), ('-', 'O'), ('maze', 'O'), ('than', 'O'), ('vehicle', 'O'), ('-', 'O'), ('treated', 'O'), ('STZ', 'O'), ('-', 'O'), ('injected', 'O'), ('rats', 'O'), ('.', 'O'))"
"In addition , the disrupted prepulse inhibition induced by d - amphetamine or phencyclidine was restored by 5 - HT6 receptor antagonist in an animal study using rats .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('the', 'O'), ('disrupted', 'O'), ('prepulse', 'O'), ('inhibition', 'O'), ('induced', 'O'), ('by', 'O'), ('d', 'O'), ('-', 'O'), ('amphetamine', 'O'), ('or', 'O'), ('phencyclidine', 'O'), ('was', 'O'), ('restored', 'O'), ('by', 'O'), ('5', 'O'), ('-', 'O'), ('HT6', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('in', 'O'), ('an', 'O'), ('animal', 'O'), ('study', 'O'), ('using', 'O'), ('rats', 'O'), ('.', 'O'))"
The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients .,"(('The', 'O'), ('age', 'O'), ('and', 'O'), ('sex', 'O'), ('of', 'O'), ('the', 'O'), ('control', 'O'), ('subjects', 'O'), ('did', 'O'), ('not', 'O'), ('differ', 'O'), ('from', 'O'), ('those', 'O'), ('of', 'O'), ('the', 'O'), ('methamphetamine', 'B'), ('dependence', 'I'), ('patients', 'O'), ('.', 'O'))"
"Moreover , this association remained significant after Bonferroni correction .","(('Moreover', 'O'), (',', 'O'), ('this', 'O'), ('association', 'O'), ('remained', 'O'), ('significant', 'O'), ('after', 'O'), ('Bonferroni', 'O'), ('correction', 'O'), ('.', 'O'))"
"In a counterbalanced , placebo - controlled , double - blind study design , healthy subjects were administered a continuous subanesthetic S - ketamine infusion while differences in BOLD responses measured with fMRI were detected .","(('In', 'O'), ('a', 'O'), ('counterbalanced', 'O'), (',', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('study', 'O'), ('design', 'O'), (',', 'O'), ('healthy', 'O'), ('subjects', 'O'), ('were', 'O'), ('administered', 'O'), ('a', 'O'), ('continuous', 'O'), ('subanesthetic', 'O'), ('S', 'O'), ('-', 'O'), ('ketamine', 'O'), ('infusion', 'O'), ('while', 'O'), ('differences', 'O'), ('in', 'O'), ('BOLD', 'O'), ('responses', 'O'), ('measured', 'O'), ('with', 'O'), ('fMRI', 'O'), ('were', 'O'), ('detected', 'O'), ('.', 'O'))"
"During the scanning period , subjects performed continuous overt verbal fluency tasks ( phonological , lexical and semantic ) .","(('During', 'O'), ('the', 'O'), ('scanning', 'O'), ('period', 'O'), (',', 'O'), ('subjects', 'O'), ('performed', 'O'), ('continuous', 'O'), ('overt', 'O'), ('verbal', 'O'), ('fluency', 'O'), ('tasks', 'O'), ('(', 'O'), ('phonological', 'O'), (',', 'O'), ('lexical', 'O'), ('and', 'O'), ('semantic', 'O'), (')', 'O'), ('.', 'O'))"
Ketamine - induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale ( PANSS ) .,"(('Ketamine', 'O'), ('-', 'O'), ('induced', 'O'), ('psychopathological', 'O'), ('symptoms', 'O'), ('were', 'O'), ('assessed', 'O'), ('with', 'O'), ('the', 'O'), ('Positive', 'O'), ('and', 'O'), ('Negative', 'O'), ('Syndrome', 'O'), ('Scale', 'O'), ('(', 'O'), ('PANSS', 'O'), (')', 'O'), ('.', 'O'))"
"Post - hoc t - tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency , while the phonological domain remained unaffected .","(('Post', 'O'), ('-', 'O'), ('hoc', 'O'), ('t', 'O'), ('-', 'O'), ('tests', 'O'), ('revealed', 'O'), ('significant', 'O'), ('differences', 'O'), ('between', 'O'), ('placebo', 'O'), ('and', 'O'), ('ketamine', 'O'), ('for', 'O'), ('the', 'O'), ('amounts', 'O'), ('of', 'O'), ('words', 'O'), ('generated', 'O'), ('during', 'O'), ('lexical', 'O'), ('and', 'O'), ('semantic', 'O'), ('verbal', 'O'), ('fluency', 'O'), (',', 'O'), ('while', 'O'), ('the', 'O'), ('phonological', 'O'), ('domain', 'O'), ('remained', 'O'), ('unaffected', 'O'), ('.', 'O'))"
"Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency , but not for semantic verbal fluency .","(('Ketamine', 'O'), ('led', 'O'), ('to', 'O'), ('enhanced', 'O'), ('cortical', 'O'), ('activations', 'O'), ('in', 'O'), ('supramarginal', 'O'), ('and', 'O'), ('frontal', 'O'), ('brain', 'O'), ('regions', 'O'), ('for', 'O'), ('phonological', 'O'), ('and', 'O'), ('lexical', 'O'), ('verbal', 'O'), ('fluency', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('for', 'O'), ('semantic', 'O'), ('verbal', 'O'), ('fluency', 'O'), ('.', 'O'))"
Long - term prognosis for transplant - free survivors of paracetamol - induced acute liver failure .,"(('Long', 'O'), ('-', 'O'), ('term', 'O'), ('prognosis', 'O'), ('for', 'O'), ('transplant', 'O'), ('-', 'O'), ('free', 'O'), ('survivors', 'O'), ('of', 'O'), ('paracetamol', 'B'), ('-', 'I'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('.', 'O'))"
BACKGROUND : The prognosis for transplant - free survivors of paracetamol - induced acute liver failure remains unknown .,"(('BACKGROUND', 'O'), (':', 'O'), ('The', 'O'), ('prognosis', 'O'), ('for', 'O'), ('transplant', 'O'), ('-', 'O'), ('free', 'O'), ('survivors', 'O'), ('of', 'O'), ('paracetamol', 'B'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('remains', 'O'), ('unknown', 'O'), ('.', 'O'))"
AIM : To examine whether paracetamol - induced acute liver failure increases long - term mortality .,"(('AIM', 'O'), (':', 'O'), ('To', 'O'), ('examine', 'O'), ('whether', 'O'), ('paracetamol', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('increases', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('mortality', 'O'), ('.', 'O'))"
"METHODS : We followed up all transplant - free survivors of paracetamol - induced acute liver injury , hospitalized in a Danish national referral centre during 1984 - 2004 .","(('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('followed', 'O'), ('up', 'O'), ('all', 'O'), ('transplant', 'O'), ('-', 'O'), ('free', 'O'), ('survivors', 'O'), ('of', 'O'), ('paracetamol', 'B'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('injury', 'I'), (',', 'O'), ('hospitalized', 'O'), ('in', 'O'), ('a', 'O'), ('Danish', 'O'), ('national', 'O'), ('referral', 'O'), ('centre', 'O'), ('during', 'O'), ('1984', 'O'), ('-', 'O'), ('2004', 'O'), ('.', 'O'))"
We compared age - specific mortality rates from 1 year post - discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not .,"(('We', 'O'), ('compared', 'O'), ('age', 'O'), ('-', 'O'), ('specific', 'O'), ('mortality', 'O'), ('rates', 'O'), ('from', 'O'), ('1', 'O'), ('year', 'O'), ('post', 'O'), ('-', 'O'), ('discharge', 'O'), ('through', 'O'), ('2008', 'O'), ('between', 'O'), ('those', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('liver', 'B'), ('injury', 'I'), ('led', 'O'), ('to', 'O'), ('an', 'O'), ('acute', 'B'), ('liver', 'B'), ('failure', 'I'), ('and', 'O'), ('those', 'O'), ('in', 'O'), ('whom', 'O'), ('it', 'O'), ('did', 'O'), ('not', 'O'), ('.', 'O'))"
RESULTS : We included 641 patients .,"(('RESULTS', 'O'), (':', 'O'), ('We', 'O'), ('included', 'O'), ('641', 'O'), ('patients', 'O'), ('.', 'O'))"
"On average , age - specific mortality rates were slightly higher for the 101 patients whose paracetamol - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .","(('On', 'O'), ('average', 'O'), (',', 'O'), ('age', 'O'), ('-', 'O'), ('specific', 'O'), ('mortality', 'O'), ('rates', 'O'), ('were', 'O'), ('slightly', 'O'), ('higher', 'O'), ('for', 'O'), ('the', 'O'), ('101', 'O'), ('patients', 'O'), ('whose', 'O'), ('paracetamol', 'O'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('injury', 'I'), ('had', 'O'), ('caused', 'O'), ('an', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('(', 'O'), ('adjusted', 'O'), ('mortality', 'O'), ('rate', 'O'), ('ratio', 'O'), ('=', 'O'), ('1', 'O'), ('.', 'O'), ('70', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('02', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('85', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('association', 'O'), ('was', 'O'), ('age', 'O'), ('-', 'O'), ('dependent', 'O'), (',', 'O'), ('and', 'O'), ('no', 'O'), ('survivors', 'O'), ('of', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('died', 'O'), ('of', 'O'), ('liver', 'B'), ('disease', 'I'), (',', 'O'), ('whereas', 'O'), ('suicides', 'O'), ('were', 'O'), ('frequent', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('.', 'O'))"
These observations speak against long - term effects of acute liver failure .,"(('These', 'O'), ('observations', 'O'), ('speak', 'O'), ('against', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('effects', 'O'), ('of', 'O'), ('acute', 'O'), ('liver', 'I'), ('failure', 'I'), ('.', 'O'))"
CONCLUSIONS : Paracetamol - induced acute liver failure did not affect long - term mortality .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Paracetamol', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('did', 'O'), ('not', 'O'), ('affect', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('mortality', 'O'), ('.', 'O'))"
"Clinical follow - up may be justified by the cause of the liver failure , but not by the liver failure itself .","(('Clinical', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('may', 'O'), ('be', 'O'), ('justified', 'O'), ('by', 'O'), ('the', 'O'), ('cause', 'O'), ('of', 'O'), ('the', 'O'), ('liver', 'B'), ('failure', 'I'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('by', 'O'), ('the', 'O'), ('liver', 'B'), ('failure', 'I'), ('itself', 'O'), ('.', 'O'))"
"Discovery and scale - up syntheses of compound 1 are described in detail , highlighting optimization steps that increased the overall yield of 1 from 10 . 0 % to 30 . 5 % .","(('Discovery', 'O'), ('and', 'O'), ('scale', 'O'), ('-', 'O'), ('up', 'O'), ('syntheses', 'O'), ('of', 'O'), ('compound', 'O'), ('1', 'O'), ('are', 'O'), ('described', 'O'), ('in', 'O'), ('detail', 'O'), (',', 'O'), ('highlighting', 'O'), ('optimization', 'O'), ('steps', 'O'), ('that', 'O'), ('increased', 'O'), ('the', 'O'), ('overall', 'O'), ('yield', 'O'), ('of', 'O'), ('1', 'O'), ('from', 'O'), ('10', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('to', 'O'), ('30', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('.', 'O'))"
"rotation , and MPTP - treated non - human primate model .","(('rotation', 'O'), (',', 'O'), ('and', 'O'), ('MPTP', 'O'), ('-', 'O'), ('treated', 'O'), ('non', 'O'), ('-', 'O'), ('human', 'O'), ('primate', 'O'), ('model', 'O'), ('.', 'O'))"
MATERIAL AND METHODS : Twenty - five Sprague - Dawley rats were implanted DBS electrodes .,"(('MATERIAL', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('Twenty', 'O'), ('-', 'O'), ('five', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('were', 'O'), ('implanted', 'O'), ('DBS', 'O'), ('electrodes', 'O'), ('.', 'O'))"
"In group - 1 ( n = 10 ) hippocampal DBS was off and in the group - 2 ( n = 10 ) hippocampal DBS was on ( 185 Hz , 0 . 5V , 1V , 2V , and 5V for 60 sec ) following penicillin G injection intracortically .","(('In', 'O'), ('group', 'O'), ('-', 'O'), ('1', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('10', 'O'), (')', 'O'), ('hippocampal', 'O'), ('DBS', 'O'), ('was', 'O'), ('off', 'O'), ('and', 'O'), ('in', 'O'), ('the', 'O'), ('group', 'O'), ('-', 'O'), ('2', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('10', 'O'), (')', 'O'), ('hippocampal', 'O'), ('DBS', 'O'), ('was', 'O'), ('on', 'O'), ('(', 'O'), ('185', 'O'), ('Hz', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('5V', 'O'), (',', 'O'), ('1V', 'O'), (',', 'O'), ('2V', 'O'), (',', 'O'), ('and', 'O'), ('5V', 'O'), ('for', 'O'), ('60', 'O'), ('sec', 'O'), (')', 'O'), ('following', 'O'), ('penicillin', 'O'), ('G', 'O'), ('injection', 'O'), ('intracortically', 'O'), ('.', 'O'))"
In the control group hippocampal DBS was on following 8 l saline injection intracortically .,"(('In', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), ('hippocampal', 'O'), ('DBS', 'O'), ('was', 'O'), ('on', 'O'), ('following', 'O'), ('8', 'O'), ('l', 'O'), ('saline', 'O'), ('injection', 'O'), ('intracortically', 'O'), ('.', 'O'))"
"EEG recordings were obtained before and 15 minutes following penicillin - G injection , and at 10th minutes following each stimulus for analysis in terms of frequency , amplitude , and power spectrum .","(('EEG', 'O'), ('recordings', 'O'), ('were', 'O'), ('obtained', 'O'), ('before', 'O'), ('and', 'O'), ('15', 'O'), ('minutes', 'O'), ('following', 'O'), ('penicillin', 'O'), ('-', 'O'), ('G', 'O'), ('injection', 'O'), (',', 'O'), ('and', 'O'), ('at', 'O'), ('10th', 'O'), ('minutes', 'O'), ('following', 'O'), ('each', 'O'), ('stimulus', 'O'), ('for', 'O'), ('analysis', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('frequency', 'O'), (',', 'O'), ('amplitude', 'O'), (',', 'O'), ('and', 'O'), ('power', 'O'), ('spectrum', 'O'), ('.', 'O'))"
"In the control group , hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation .","(('In', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), (',', 'O'), ('hippocampal', 'O'), ('stimulation', 'O'), ('alone', 'O'), ('lead', 'O'), ('only', 'O'), ('to', 'O'), ('diffuse', 'O'), ('slowing', 'O'), ('of', 'O'), ('cerebral', 'O'), ('bioelectrical', 'O'), ('activity', 'O'), ('at', 'O'), ('5V', 'O'), ('stimulation', 'O'), ('.', 'O'))"
These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy .,"(('These', 'O'), ('results', 'O'), ('are', 'O'), ('important', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('defining', 'O'), ('the', 'O'), ('optimal', 'O'), ('parameters', 'O'), ('of', 'O'), ('hippocampal', 'O'), ('DBS', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('epilepsy', 'B'), ('.', 'O'))"
CCNU ( lomustine ) toxicity in dogs : a retrospective study ( 2002 - 07 ) .,"(('CCNU', 'B'), ('(', 'O'), ('lomustine', 'O'), (')', 'O'), ('toxicity', 'O'), ('in', 'O'), ('dogs', 'O'), (':', 'O'), ('a', 'O'), ('retrospective', 'O'), ('study', 'O'), ('(', 'O'), ('2002', 'O'), ('-', 'O'), ('07', 'O'), (')', 'O'), ('.', 'O'))"
DESIGN : The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated .,"(('DESIGN', 'O'), (':', 'O'), ('The', 'O'), ('medical', 'O'), ('records', 'O'), ('of', 'O'), ('206', 'O'), ('dogs', 'O'), ('that', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('CCNU', 'B'), ('at', 'O'), ('the', 'O'), ('Melbourne', 'O'), ('Veterinary', 'O'), ('Specialist', 'O'), ('Centre', 'O'), ('between', 'O'), ('February', 'O'), ('2002', 'O'), ('and', 'O'), ('December', 'O'), ('2007', 'O'), ('were', 'O'), ('retrospectively', 'O'), ('evaluated', 'O'), ('.', 'O'))"
"RESULTS : Of the 206 dogs treated with CCNU , 185 met the inclusion criteria for at least one class of toxicity .","(('RESULTS', 'O'), (':', 'O'), ('Of', 'O'), ('the', 'O'), ('206', 'O'), ('dogs', 'O'), ('treated', 'O'), ('with', 'O'), ('CCNU', 'O'), (',', 'O'), ('185', 'O'), ('met', 'O'), ('the', 'O'), ('inclusion', 'O'), ('criteria', 'O'), ('for', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('class', 'O'), ('of', 'O'), ('toxicity', 'O'), ('.', 'O'))"
"Potential renal toxicity and elevated alanine transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .","(('Potential', 'O'), ('renal', 'O'), ('toxicity', 'O'), ('and', 'O'), ('elevated', 'O'), ('alanine', 'O'), ('transaminase', 'O'), ('(', 'O'), ('ALT', 'O'), (')', 'O'), ('concentration', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('12', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('and', 'O'), ('48', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('of', 'O'), ('dogs', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
The incidence of hepatic failure was 1 . 2 % .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('hepatic', 'B'), ('failure', 'I'), ('was', 'O'), ('1', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('.', 'O'))"
"CONCLUSIONS : CCNU - associated toxicity in dogs is common , but is usually not life threatening .","(('CONCLUSIONS', 'O'), (':', 'O'), ('CCNU', 'O'), ('-', 'O'), ('associated', 'O'), ('toxicity', 'O'), ('in', 'O'), ('dogs', 'O'), ('is', 'O'), ('common', 'O'), (',', 'O'), ('but', 'O'), ('is', 'O'), ('usually', 'O'), ('not', 'O'), ('life', 'O'), ('threatening', 'O'), ('.', 'O'))"
"From present knowledge about the effects of adrenergic eye drops on ocular blood circulation , it is difficult to suggest an association between the two events , which may be coincidental only .","(('From', 'O'), ('present', 'O'), ('knowledge', 'O'), ('about', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('adrenergic', 'O'), ('eye', 'O'), ('drops', 'O'), ('on', 'O'), ('ocular', 'O'), ('blood', 'O'), ('circulation', 'O'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('difficult', 'O'), ('to', 'O'), ('suggest', 'O'), ('an', 'O'), ('association', 'O'), ('between', 'O'), ('the', 'O'), ('two', 'O'), ('events', 'O'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('be', 'O'), ('coincidental', 'O'), ('only', 'O'), ('.', 'O'))"
"Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman immunodeficiency virus ( HIV ) activity .","(('Increased', 'O'), ('extracellular', 'O'), ('concentrations', 'O'), ('of', 'O'), ('uridine', 'O'), ('(', 'O'), ('Urd', 'O'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('reduce', 'O'), (',', 'O'), ('in', 'O'), ('vitro', 'O'), (',', 'O'), ('azidothymidine', 'O'), ('(', 'O'), ('AZT', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('inhibition', 'O'), ('of', 'O'), ('human', 'O'), ('granulocyte', 'O'), ('-', 'O'), ('macrophage', 'O'), ('progenitor', 'O'), ('cells', 'O'), ('without', 'O'), ('impairment', 'O'), ('of', 'O'), ('its', 'O'), ('antihuman', 'O'), ('immunodeficiency', 'I'), ('virus', 'I'), ('(', 'O'), ('HIV', 'B'), (')', 'O'), ('activity', 'O'), ('.', 'O'))"
"This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related toxicity .","(('This', 'O'), ('agent', 'O'), ('inhibits', 'O'), ('Urd', 'O'), ('catabolism', 'O'), ('and', 'O'), (',', 'O'), ('in', 'O'), ('vivo', 'O'), (',', 'O'), ('increases', 'O'), ('the', 'O'), ('plasma', 'O'), ('concentration', 'O'), ('of', 'O'), ('Urd', 'O'), ('in', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('manner', 'O'), (',', 'O'), ('without', 'O'), ('Urd', 'O'), ('-', 'O'), ('related', 'O'), ('toxicity', 'O'), ('.', 'O'))"
"In vitro , at a concentration of 100 mumol / L , BAU possesses minimal anti - HIV activity and has no effect on the ability of AZT to reverse the HIV - induced cytopathic effect in MT4 cells .","(('In', 'O'), ('vitro', 'O'), (',', 'O'), ('at', 'O'), ('a', 'O'), ('concentration', 'O'), ('of', 'O'), ('100', 'O'), ('mumol', 'O'), ('/', 'O'), ('L', 'O'), (',', 'O'), ('BAU', 'O'), ('possesses', 'O'), ('minimal', 'O'), ('anti', 'O'), ('-', 'O'), ('HIV', 'O'), ('activity', 'O'), ('and', 'O'), ('has', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('ability', 'O'), ('of', 'O'), ('AZT', 'O'), ('to', 'O'), ('reverse', 'O'), ('the', 'O'), ('HIV', 'O'), ('-', 'O'), ('induced', 'O'), ('cytopathic', 'O'), ('effect', 'O'), ('in', 'O'), ('MT4', 'O'), ('cells', 'O'), ('.', 'O'))"
The clinical and biochemical implications of these findings are discussed .,"(('The', 'O'), ('clinical', 'O'), ('and', 'O'), ('biochemical', 'O'), ('implications', 'O'), ('of', 'O'), ('these', 'O'), ('findings', 'O'), ('are', 'O'), ('discussed', 'O'), ('.', 'O'))"
"However , correction of the hemodynamic parameters did not improve renal function .","(('However', 'O'), (',', 'O'), ('correction', 'O'), ('of', 'O'), ('the', 'O'), ('hemodynamic', 'O'), ('parameters', 'O'), ('did', 'O'), ('not', 'O'), ('improve', 'O'), ('renal', 'O'), ('function', 'O'), ('.', 'O'))"
"Nociceptive effects induced by intrathecal administration of prostaglandin D2 , E2 , or F2 alpha to conscious mice .","(('Nociceptive', 'O'), ('effects', 'O'), ('induced', 'O'), ('by', 'O'), ('intrathecal', 'O'), ('administration', 'O'), ('of', 'O'), ('prostaglandin', 'O'), ('D2', 'O'), (',', 'O'), ('E2', 'O'), (',', 'O'), ('or', 'O'), ('F2', 'O'), ('alpha', 'O'), ('to', 'O'), ('conscious', 'O'), ('mice', 'O'), ('.', 'O'))"
Similar results were obtained by acetic acid writhing tests .,"(('Similar', 'O'), ('results', 'O'), ('were', 'O'), ('obtained', 'O'), ('by', 'O'), ('acetic', 'O'), ('acid', 'O'), ('writhing', 'O'), ('tests', 'O'), ('.', 'O'))"
This drug was judged to have a favorable effect on the disease course in 7 ( 64 % ) of 11 patients .,"(('This', 'O'), ('drug', 'O'), ('was', 'O'), ('judged', 'O'), ('to', 'O'), ('have', 'O'), ('a', 'O'), ('favorable', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('disease', 'O'), ('course', 'O'), ('in', 'O'), ('7', 'O'), ('(', 'O'), ('64', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('11', 'O'), ('patients', 'O'), ('.', 'O'))"
"Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients , skin softening in 5 , and more normal growth of the affected limb in 2 of 3 children .","(('Improvement', 'O'), ('began', 'O'), ('within', 'O'), ('3', 'O'), ('to', 'O'), ('6', 'O'), ('months', 'O'), ('and', 'O'), ('consisted', 'O'), ('of', 'O'), ('cessation', 'O'), ('of', 'O'), ('active', 'O'), ('cutaneous', 'B'), ('lesions', 'I'), ('in', 'O'), ('all', 'O'), ('7', 'O'), ('patients', 'O'), (',', 'O'), ('skin', 'O'), ('softening', 'O'), ('in', 'O'), ('5', 'O'), (',', 'O'), ('and', 'O'), ('more', 'O'), ('normal', 'O'), ('growth', 'O'), ('of', 'O'), ('the', 'O'), ('affected', 'O'), ('limb', 'O'), ('in', 'O'), ('2', 'O'), ('of', 'O'), ('3', 'O'), ('children', 'O'), ('.', 'O'))"
Joint stiffness and contractures also improved .,"(('Joint', 'O'), ('stiffness', 'O'), ('and', 'O'), ('contractures', 'B'), ('also', 'O'), ('improved', 'O'), ('.', 'O'))"
The dose of D - penicillamine associated with a favorable response was as low as 2 to 5 mg / kg per day given over a period ranging from 15 to 53 months .,"(('The', 'O'), ('dose', 'O'), ('of', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('favorable', 'O'), ('response', 'O'), ('was', 'O'), ('as', 'O'), ('low', 'O'), ('as', 'O'), ('2', 'O'), ('to', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('per', 'O'), ('day', 'O'), ('given', 'O'), ('over', 'O'), ('a', 'O'), ('period', 'O'), ('ranging', 'O'), ('from', 'O'), ('15', 'O'), ('to', 'O'), ('53', 'O'), ('months', 'O'), ('.', 'O'))"
Careful use of epsilon - aminocaproic acid therapy is recommended .,"(('Careful', 'O'), ('use', 'O'), ('of', 'O'), ('epsilon', 'O'), ('-', 'O'), ('aminocaproic', 'O'), ('acid', 'O'), ('therapy', 'O'), ('is', 'O'), ('recommended', 'O'), ('.', 'O'))"
Neither patient had reported previous seizures or seizure - like activity nor was receiving anticonvulsant agents .,"(('Neither', 'O'), ('patient', 'O'), ('had', 'O'), ('reported', 'O'), ('previous', 'O'), ('seizures', 'O'), ('or', 'O'), ('seizure', 'O'), ('-', 'O'), ('like', 'O'), ('activity', 'O'), ('nor', 'O'), ('was', 'O'), ('receiving', 'O'), ('anticonvulsant', 'O'), ('agents', 'O'), ('.', 'O'))"
All seizures were controlled with therapeutic doses of phenytoin .,"(('All', 'O'), ('seizures', 'O'), ('were', 'O'), ('controlled', 'O'), ('with', 'O'), ('therapeutic', 'O'), ('doses', 'O'), ('of', 'O'), ('phenytoin', 'O'), ('.', 'O'))"
Both patients had received maximum doses of other beta - lactam antibiotics without evidence of seizure activity .,"(('Both', 'O'), ('patients', 'O'), ('had', 'O'), ('received', 'O'), ('maximum', 'O'), ('doses', 'O'), ('of', 'O'), ('other', 'O'), ('beta', 'O'), ('-', 'O'), ('lactam', 'O'), ('antibiotics', 'O'), ('without', 'O'), ('evidence', 'O'), ('of', 'O'), ('seizure', 'O'), ('activity', 'O'), ('.', 'O'))"
"The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla , coinciding with the raphe magnus .","(('The', 'O'), ('present', 'O'), ('experiments', 'O'), ('were', 'O'), ('designed', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('the', 'O'), ('midline', 'O'), ('cells', 'O'), ('of', 'O'), ('the', 'O'), ('B3', 'O'), ('serotonin', 'O'), ('neurons', 'O'), ('in', 'O'), ('the', 'O'), ('medulla', 'O'), (',', 'O'), ('coinciding', 'O'), ('with', 'O'), ('the', 'O'), ('raphe', 'O'), ('magnus', 'O'), ('.', 'O'))"
"However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension .","(('However', 'O'), (',', 'O'), ('intraspinal', 'O'), ('injection', 'O'), ('of', 'O'), ('5', 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('DHT', 'O'), ('to', 'O'), ('produce', 'O'), ('a', 'O'), ('more', 'O'), ('selective', 'O'), ('lesion', 'O'), ('of', 'O'), ('only', 'O'), ('descending', 'O'), ('serotonin', 'O'), ('projections', 'O'), ('in', 'O'), ('the', 'O'), ('spinal', 'O'), ('cord', 'O'), ('did', 'O'), ('not', 'O'), ('affect', 'O'), ('this', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"Further , 5 , 7 - DHT lesion of serotonin nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 serotonin cells , did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection .","(('Further', 'O'), (',', 'O'), ('5', 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('DHT', 'O'), ('lesion', 'O'), ('of', 'O'), ('serotonin', 'O'), ('nerves', 'O'), ('travelling', 'O'), ('in', 'O'), ('the', 'O'), ('median', 'O'), ('forebrain', 'O'), ('bundle', 'O'), (',', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('main', 'O'), ('ascending', 'O'), ('pathways', 'O'), ('from', 'O'), ('the', 'O'), ('B3', 'O'), ('serotonin', 'O'), ('cells', 'O'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('affect', 'O'), ('the', 'O'), ('fall', 'O'), ('in', 'O'), ('blood', 'O'), ('pressure', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('midline', 'O'), ('B3', 'O'), ('serotonin', 'O'), ('methyldopa', 'O'), ('injection', 'O'), ('.', 'O'))"
"1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .","(('1', 'O'), ('.', 'O'), ('3', 'O'), ('(', 'O'), ('by', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('micrograms', 'O'), ('/', 'O'), ('ml', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('mean', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('SDM', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('6', 'O'), ('-', 'O'), ('7', 'O'), (')', 'O'), ('.', 'O'))"
"This pharmacological profile is similar to those of mexiletine and tocainide , and all three drugs have central nervous system ( CNS ) stimulant action .","(('This', 'O'), ('pharmacological', 'O'), ('profile', 'O'), ('is', 'O'), ('similar', 'O'), ('to', 'O'), ('those', 'O'), ('of', 'O'), ('mexiletine', 'O'), ('and', 'O'), ('tocainide', 'O'), (',', 'O'), ('and', 'O'), ('all', 'O'), ('three', 'O'), ('drugs', 'O'), ('have', 'O'), ('central', 'O'), ('nervous', 'O'), ('system', 'O'), ('(', 'O'), ('CNS', 'O'), (')', 'O'), ('stimulant', 'O'), ('action', 'O'), ('.', 'O'))"
Continuous ambulatory ECG monitoring during fluorouracil therapy : a prospective study .,"(('Continuous', 'O'), ('ambulatory', 'O'), ('ECG', 'O'), ('monitoring', 'O'), ('during', 'O'), ('fluorouracil', 'O'), ('therapy', 'O'), (':', 'O'), ('a', 'O'), ('prospective', 'O'), ('study', 'O'), ('.', 'O'))"
"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .","(('Although', 'O'), ('there', 'O'), ('have', 'O'), ('been', 'O'), ('anecdotal', 'O'), ('reports', 'O'), ('of', 'O'), ('cardiac', 'B'), ('toxicity', 'I'), ('associated', 'O'), ('with', 'O'), ('fluorouracil', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), (')', 'O'), ('therapy', 'O'), (',', 'O'), ('this', 'O'), ('phenomenon', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('studied', 'O'), ('in', 'O'), ('a', 'O'), ('systematic', 'O'), ('fashion', 'O'), ('.', 'O'))"
We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5 - FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes .,"(('We', 'O'), ('prospectively', 'O'), ('performed', 'O'), ('continuous', 'O'), ('ambulatory', 'O'), ('ECG', 'O'), ('monitoring', 'O'), ('on', 'O'), ('25', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('for', 'O'), ('treatment', 'O'), ('of', 'O'), ('solid', 'B'), ('tumors', 'I'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('ischemic', 'O'), ('ST', 'O'), ('changes', 'O'), ('.', 'O'))"
"Patients were monitored for 23 + / - 4 hours before 5 - FU infusion , and 98 + / - 9 hours during 5 - FU infusion .","(('Patients', 'O'), ('were', 'O'), ('monitored', 'O'), ('for', 'O'), ('23', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('4', 'O'), ('hours', 'O'), ('before', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), (',', 'O'), ('and', 'O'), ('98', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('9', 'O'), ('hours', 'O'), ('during', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('.', 'O'))"
"However , asymptomatic ST changes ( greater than or equal to 1 mm ST deviation ) were common : six of 25 patients ( 24 % ) had ST changes before 5 - FU infusion v 17 ( 68 % ) during 5 - FU infusion ( P less than . 002 ) .","(('However', 'O'), (',', 'O'), ('asymptomatic', 'O'), ('ST', 'O'), ('changes', 'O'), ('(', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('1', 'O'), ('mm', 'O'), ('ST', 'O'), ('deviation', 'O'), (')', 'O'), ('were', 'O'), ('common', 'O'), (':', 'O'), ('six', 'O'), ('of', 'O'), ('25', 'O'), ('patients', 'O'), ('(', 'O'), ('24', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('ST', 'O'), ('changes', 'O'), ('before', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('v', 'O'), ('17', 'O'), ('(', 'O'), ('68', 'O'), ('%', 'O'), (')', 'O'), ('during', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('002', 'O'), (')', 'O'), ('.', 'O'))"
The incidence of ischemic episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('ischemic', 'B'), ('episodes', 'O'), ('per', 'O'), ('patient', 'O'), ('per', 'O'), ('hour', 'O'), ('was', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('02', 'O'), ('prior', 'O'), ('to', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('v', 'O'), ('0', 'O'), ('.', 'O'), ('13', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), ('during', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (';', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('ECG', 'O'), ('changes', 'O'), ('was', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('minutes', 'O'), ('per', 'O'), ('patient', 'O'), ('per', 'O'), ('hour', 'O'), ('before', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('v', 'O'), ('1', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('minutes', 'O'), ('per', 'O'), ('patient', 'O'), ('per', 'O'), ('hour', 'O'), ('during', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
"There were two cases of sudden death , both of which occurred at the end of the chemotherapy course .","(('There', 'O'), ('were', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('sudden', 'B'), ('death', 'O'), (',', 'O'), ('both', 'O'), ('of', 'O'), ('which', 'O'), ('occurred', 'O'), ('at', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('chemotherapy', 'O'), ('course', 'O'), ('.', 'O'))"
The mechanism and clinical significance of these ECG changes remain to be determined .,"(('The', 'O'), ('mechanism', 'O'), ('and', 'O'), ('clinical', 'O'), ('significance', 'O'), ('of', 'O'), ('these', 'O'), ('ECG', 'O'), ('changes', 'O'), ('remain', 'O'), ('to', 'O'), ('be', 'O'), ('determined', 'O'), ('.', 'O'))"
"Nature , time course and dose dependence of zidovudine - related side effects : results from the Multicenter Canadian Azidothymidine Trial .","(('Nature', 'O'), (',', 'O'), ('time', 'O'), ('course', 'O'), ('and', 'O'), ('dose', 'O'), ('dependence', 'O'), ('of', 'O'), ('zidovudine', 'O'), ('-', 'O'), ('related', 'O'), ('side', 'O'), ('effects', 'O'), (':', 'O'), ('results', 'O'), ('from', 'O'), ('the', 'O'), ('Multicenter', 'O'), ('Canadian', 'O'), ('Azidothymidine', 'O'), ('Trial', 'O'), ('.', 'O'))"
"To characterize the nature , time course and dose dependency of zidovudine - related side effects , we undertook a multicenter , prospective , dose - range finding study .","(('To', 'O'), ('characterize', 'O'), ('the', 'O'), ('nature', 'O'), (',', 'O'), ('time', 'O'), ('course', 'O'), ('and', 'O'), ('dose', 'O'), ('dependency', 'O'), ('of', 'O'), ('zidovudine', 'O'), ('-', 'O'), ('related', 'O'), ('side', 'O'), ('effects', 'O'), (',', 'O'), ('we', 'O'), ('undertook', 'O'), ('a', 'O'), ('multicenter', 'O'), (',', 'O'), ('prospective', 'O'), (',', 'O'), ('dose', 'O'), ('-', 'O'), ('range', 'O'), ('finding', 'O'), ('study', 'O'), ('.', 'O'))"
"Our study group consisted of 74 HIV - positive homosexual men belonging to groups II B , III and IV C2 from the Centers for Disease Control ( CDC ) classification of HIV disease .","(('Our', 'O'), ('study', 'O'), ('group', 'O'), ('consisted', 'O'), ('of', 'O'), ('74', 'O'), ('HIV', 'O'), ('-', 'O'), ('positive', 'O'), ('homosexual', 'O'), ('men', 'O'), ('belonging', 'O'), ('to', 'O'), ('groups', 'O'), ('II', 'O'), ('B', 'O'), (',', 'O'), ('III', 'O'), ('and', 'O'), ('IV', 'O'), ('C2', 'O'), ('from', 'O'), ('the', 'O'), ('Centers', 'O'), ('for', 'O'), ('Disease', 'O'), ('Control', 'O'), ('(', 'O'), ('CDC', 'O'), (')', 'O'), ('classification', 'O'), ('of', 'O'), ('HIV', 'B'), ('disease', 'I'), ('.', 'O'))"
"Following a 3 - week observation period , volunteers were treated with zidovudine 600 mg / day for 18 weeks , 900 mg / day for 9 weeks and 1200 mg / day for 9 weeks , followed by a washout period of 6 weeks after which they were re - started on 1200 mg / day or the highest tolerated dose at 8 - hourly intervals .","(('Following', 'O'), ('a', 'O'), ('3', 'O'), ('-', 'O'), ('week', 'O'), ('observation', 'O'), ('period', 'O'), (',', 'O'), ('volunteers', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('zidovudine', 'O'), ('600', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('for', 'O'), ('18', 'O'), ('weeks', 'O'), (',', 'O'), ('900', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('for', 'O'), ('9', 'O'), ('weeks', 'O'), ('and', 'O'), ('1200', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('for', 'O'), ('9', 'O'), ('weeks', 'O'), (',', 'O'), ('followed', 'O'), ('by', 'O'), ('a', 'O'), ('washout', 'O'), ('period', 'O'), ('of', 'O'), ('6', 'O'), ('weeks', 'O'), ('after', 'O'), ('which', 'O'), ('they', 'O'), ('were', 'O'), ('re', 'O'), ('-', 'O'), ('started', 'O'), ('on', 'O'), ('1200', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('or', 'O'), ('the', 'O'), ('highest', 'O'), ('tolerated', 'O'), ('dose', 'O'), ('at', 'O'), ('8', 'O'), ('-', 'O'), ('hourly', 'O'), ('intervals', 'O'), ('.', 'O'))"
Subjects were randomly assigned to 4 - hourly or 8 - hourly regimens within CDC groups while taking 600 and 1200 mg / day .,"(('Subjects', 'O'), ('were', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('4', 'O'), ('-', 'O'), ('hourly', 'O'), ('or', 'O'), ('8', 'O'), ('-', 'O'), ('hourly', 'O'), ('regimens', 'O'), ('within', 'O'), ('CDC', 'O'), ('groups', 'O'), ('while', 'O'), ('taking', 'O'), ('600', 'O'), ('and', 'O'), ('1200', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('.', 'O'))"
Clinical and laboratory evaluations were performed at 3 - week intervals .,"(('Clinical', 'O'), ('and', 'O'), ('laboratory', 'O'), ('evaluations', 'O'), ('were', 'O'), ('performed', 'O'), ('at', 'O'), ('3', 'O'), ('-', 'O'), ('week', 'O'), ('intervals', 'O'), ('.', 'O'))"
"These were generally self - limited , reappearing briefly at each dose increment .","(('These', 'O'), ('were', 'O'), ('generally', 'O'), ('self', 'O'), ('-', 'O'), ('limited', 'O'), (',', 'O'), ('reappearing', 'O'), ('briefly', 'O'), ('at', 'O'), ('each', 'O'), ('dose', 'O'), ('increment', 'O'), ('.', 'O'))"
A decrease in hemoglobin occurred shortly after initiation of therapy .,"(('A', 'O'), ('decrease', 'O'), ('in', 'O'), ('hemoglobin', 'O'), ('occurred', 'O'), ('shortly', 'O'), ('after', 'O'), ('initiation', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O'))"
This was not dose dependent and reversed rapidly upon discontinuation of treatment .,"(('This', 'O'), ('was', 'O'), ('not', 'O'), ('dose', 'O'), ('dependent', 'O'), ('and', 'O'), ('reversed', 'O'), ('rapidly', 'O'), ('upon', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O'))"
"A red blood cell count decrease , a mean cell volume increase and a granulocyte count decrease developed early in a dose - independent fashion , reverting at least partially during the washout phase .","(('A', 'O'), ('red', 'O'), ('blood', 'O'), ('cell', 'O'), ('count', 'O'), ('decrease', 'O'), (',', 'O'), ('a', 'O'), ('mean', 'O'), ('cell', 'O'), ('volume', 'O'), ('increase', 'O'), ('and', 'O'), ('a', 'O'), ('granulocyte', 'O'), ('count', 'O'), ('decrease', 'O'), ('developed', 'O'), ('early', 'O'), ('in', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('independent', 'O'), ('fashion', 'O'), (',', 'O'), ('reverting', 'O'), ('at', 'O'), ('least', 'O'), ('partially', 'O'), ('during', 'O'), ('the', 'O'), ('washout', 'O'), ('phase', 'O'), ('.', 'O'))"
The decrease in reticulocyte count was dose related between 600 and 900 mg / day with no further change when the dose was escalated to 1200 mg / day .,"(('The', 'O'), ('decrease', 'O'), ('in', 'O'), ('reticulocyte', 'O'), ('count', 'O'), ('was', 'O'), ('dose', 'O'), ('related', 'O'), ('between', 'O'), ('600', 'O'), ('and', 'O'), ('900', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('with', 'O'), ('no', 'O'), ('further', 'O'), ('change', 'O'), ('when', 'O'), ('the', 'O'), ('dose', 'O'), ('was', 'O'), ('escalated', 'O'), ('to', 'O'), ('1200', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('.', 'O'))"
This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen ( HBsAg ) and hepatitis B e antigen ( HBeAg ) positive mothers .,"(('This', 'O'), ('program', 'O'), ('consists', 'O'), ('of', 'O'), ('double', 'O'), ('screenings', 'O'), ('of', 'O'), ('pregnant', 'O'), ('women', 'O'), ('and', 'O'), ('prophylactic', 'O'), ('treatment', 'O'), ('to', 'O'), ('the', 'O'), ('infants', 'O'), ('born', 'O'), ('to', 'O'), ('both', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('surface', 'O'), ('antigen', 'O'), ('(', 'O'), ('HBsAg', 'O'), (')', 'O'), ('and', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('e', 'O'), ('antigen', 'O'), ('(', 'O'), ('HBeAg', 'O'), (')', 'O'), ('positive', 'O'), ('mothers', 'O'), ('.', 'O'))"
These infants are treated with two injections of hepatitis B immune globulin ( HBIG ) and at least three injections of plasma derived hepatitis B vaccine .,"(('These', 'O'), ('infants', 'O'), ('are', 'O'), ('treated', 'O'), ('with', 'O'), ('two', 'O'), ('injections', 'O'), ('of', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('immune', 'O'), ('globulin', 'O'), ('(', 'O'), ('HBIG', 'O'), (')', 'O'), ('and', 'O'), ('at', 'O'), ('least', 'O'), ('three', 'O'), ('injections', 'O'), ('of', 'O'), ('plasma', 'O'), ('derived', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('vaccine', 'O'), ('.', 'O'))"
We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987 .,"(('We', 'O'), ('sent', 'O'), ('questionnaires', 'O'), ('about', 'O'), ('the', 'O'), ('numbers', 'O'), ('of', 'O'), ('each', 'O'), ('procedure', 'O'), ('or', 'O'), ('examination', 'O'), ('during', 'O'), ('nine', 'O'), ('months', 'O'), ('of', 'O'), ('investigation', 'O'), ('period', 'O'), ('to', 'O'), ('each', 'O'), ('local', 'O'), ('government', 'O'), ('in', 'O'), ('1986', 'O'), ('and', 'O'), ('1987', 'O'), ('.', 'O'))"
"93 . 4 % pregnant women had the chance to be examined for HBsAg , and the positive rate was 1 . 4 to 1 . 5 % .","(('93', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('pregnant', 'O'), ('women', 'O'), ('had', 'O'), ('the', 'O'), ('chance', 'O'), ('to', 'O'), ('be', 'O'), ('examined', 'O'), ('for', 'O'), ('HBsAg', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('positive', 'O'), ('rate', 'O'), ('was', 'O'), ('1', 'O'), ('.', 'O'), ('4', 'O'), ('to', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('.', 'O'))"
The HBeAg positive rate in HBsAg positive was 23 to 26 % .,"(('The', 'O'), ('HBeAg', 'O'), ('positive', 'O'), ('rate', 'O'), ('in', 'O'), ('HBsAg', 'O'), ('positive', 'O'), ('was', 'O'), ('23', 'O'), ('to', 'O'), ('26', 'O'), ('%', 'O'), ('.', 'O'))"
The HBsAg positive rate in neonates and in infants before two months were 3 % and 2 % respectively .,"(('The', 'O'), ('HBsAg', 'O'), ('positive', 'O'), ('rate', 'O'), ('in', 'O'), ('neonates', 'O'), ('and', 'O'), ('in', 'O'), ('infants', 'O'), ('before', 'O'), ('two', 'O'), ('months', 'O'), ('were', 'O'), ('3', 'O'), ('%', 'O'), ('and', 'O'), ('2', 'O'), ('%', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Some problems may arise , because 27 to 30 % of infants need the fourth vaccination in some restricted areas .","(('Some', 'O'), ('problems', 'O'), ('may', 'O'), ('arise', 'O'), (',', 'O'), ('because', 'O'), ('27', 'O'), ('to', 'O'), ('30', 'O'), ('%', 'O'), ('of', 'O'), ('infants', 'O'), ('need', 'O'), ('the', 'O'), ('fourth', 'O'), ('vaccination', 'O'), ('in', 'O'), ('some', 'O'), ('restricted', 'O'), ('areas', 'O'), ('.', 'O'))"
"The intradermal injection of mu ( morphine , Tyr - D - Ala - Gly - NMe - Phe - Gly - ol and morphiceptin ) , kappa ( trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide ) and delta ( [ D - Pen2 . 5 ] - enkephalin and [ D - Ser2 ] - [ Leu ] enkephalin -","(('The', 'O'), ('intradermal', 'O'), ('injection', 'O'), ('of', 'O'), ('mu', 'O'), ('(', 'O'), ('morphine', 'O'), (',', 'O'), ('Tyr', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('Ala', 'O'), ('-', 'O'), ('Gly', 'O'), ('-', 'O'), ('NMe', 'O'), ('-', 'O'), ('Phe', 'O'), ('-', 'O'), ('Gly', 'O'), ('-', 'O'), ('ol', 'O'), ('and', 'O'), ('morphiceptin', 'O'), (')', 'O'), (',', 'O'), ('kappa', 'O'), ('(', 'O'), ('trans', 'O'), ('-', 'O'), ('3', 'O'), (',', 'O'), ('4', 'O'), ('-', 'O'), ('dichloro', 'O'), ('-', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('N', 'O'), ('[', 'O'), ('2', 'O'), ('-', 'O'), ('(', 'O'), ('1', 'O'), ('-', 'O'), ('pyrrolidinyl', 'O'), (')', 'O'), ('cyclohexyl', 'O'), (']', 'O'), ('benzeneactemide', 'O'), (')', 'O'), ('and', 'O'), ('delta', 'O'), ('(', 'O'), ('[', 'O'), ('D', 'O'), ('-', 'O'), ('Pen2', 'O'), ('.', 'O'), ('5', 'O'), (']', 'O'), ('-', 'O'), ('enkephalin', 'O'), ('and', 'O'), ('[', 'O'), ('D', 'O'), ('-', 'O'), ('Ser2', 'O'), (']', 'O'), ('-', 'O'), ('[', 'O'), ('Leu', 'O'), (']', 'O'), ('enkephalin', 'O'), ('-', 'O'))"
"Thr ) selective opioid - agonists , by themselves , did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat .","(('Thr', 'O'), (')', 'O'), ('selective', 'O'), ('opioid', 'O'), ('-', 'O'), ('agonists', 'O'), (',', 'O'), ('by', 'O'), ('themselves', 'O'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('significantly', 'O'), ('affect', 'O'), ('the', 'O'), ('mechanical', 'O'), ('nociceptive', 'O'), ('threshold', 'O'), ('in', 'O'), ('the', 'O'), ('hindpaw', 'O'), ('of', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
The analgesic effect of the mu - agonist morphine was dose - dependently antagonized by naloxone and prevented by co - injection of pertussis toxin .,"(('The', 'O'), ('analgesic', 'O'), ('effect', 'O'), ('of', 'O'), ('the', 'O'), ('mu', 'O'), ('-', 'O'), ('agonist', 'O'), ('morphine', 'O'), ('was', 'O'), ('dose', 'O'), ('-', 'O'), ('dependently', 'O'), ('antagonized', 'O'), ('by', 'O'), ('naloxone', 'O'), ('and', 'O'), ('prevented', 'O'), ('by', 'O'), ('co', 'O'), ('-', 'O'), ('injection', 'O'), ('of', 'O'), ('pertussis', 'O'), ('toxin', 'O'), ('.', 'O'))"
We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu - opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('the', 'O'), ('analgesic', 'O'), ('action', 'O'), ('of', 'O'), ('opioids', 'O'), ('on', 'O'), ('the', 'O'), ('peripheral', 'O'), ('terminals', 'O'), ('of', 'O'), ('primary', 'O'), ('afferents', 'O'), ('is', 'O'), ('via', 'O'), ('a', 'O'), ('binding', 'O'), ('site', 'O'), ('with', 'O'), ('characteristics', 'O'), ('of', 'O'), ('the', 'O'), ('mu', 'O'), ('-', 'O'), ('opioid', 'O'), ('receptor', 'O'), ('and', 'O'), ('that', 'O'), ('this', 'O'), ('action', 'O'), ('is', 'O'), ('mediated', 'O'), ('by', 'O'), ('inhibition', 'O'), ('of', 'O'), ('the', 'O'), ('cyclic', 'O'), ('adenosine', 'O'), ('monophosphate', 'O'), ('second', 'O'), ('messenger', 'O'), ('system', 'O'), ('.', 'O'))"
"We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon , using male Sprague - Dawley rats anesthetized with ketamine .","(('We', 'O'), ('investigated', 'O'), ('in', 'O'), ('this', 'O'), ('study', 'O'), ('the', 'O'), ('possible', 'O'), ('engagement', 'O'), ('of', 'O'), ('locus', 'O'), ('coeruleus', 'O'), ('of', 'O'), ('the', 'O'), ('pons', 'O'), ('in', 'O'), ('this', 'O'), ('phenomenon', 'O'), (',', 'O'), ('using', 'O'), ('male', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('anesthetized', 'O'), ('with', 'O'), ('ketamine', 'O'), ('.', 'O'))"
"Under proper control of respiration , body temperature and end - tidal CO2 , intravenous administration of fentanyl ( 50 or 100 micrograms / kg ) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles .","(('Under', 'O'), ('proper', 'O'), ('control', 'O'), ('of', 'O'), ('respiration', 'O'), (',', 'O'), ('body', 'O'), ('temperature', 'O'), ('and', 'O'), ('end', 'O'), ('-', 'O'), ('tidal', 'O'), ('CO2', 'O'), (',', 'O'), ('intravenous', 'O'), ('administration', 'O'), ('of', 'O'), ('fentanyl', 'O'), ('(', 'O'), ('50', 'O'), ('or', 'O'), ('100', 'O'), ('micrograms', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('consistently', 'O'), ('promoted', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('electromyographic', 'O'), ('activity', 'O'), ('recorded', 'O'), ('from', 'O'), ('the', 'O'), ('gastrocnemius', 'O'), ('and', 'O'), ('abdominal', 'O'), ('rectus', 'O'), ('muscles', 'O'), ('.', 'O'))"
"Microinjection of fentanyl ( 2 . 5 micrograms / 50 nl ) directly into this pontine nucleus , on the other hand , elicited discernible electromyographic excitation .","(('Microinjection', 'O'), ('of', 'O'), ('fentanyl', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('micrograms', 'O'), ('/', 'O'), ('50', 'O'), ('nl', 'O'), (')', 'O'), ('directly', 'O'), ('into', 'O'), ('this', 'O'), ('pontine', 'O'), ('nucleus', 'O'), (',', 'O'), ('on', 'O'), ('the', 'O'), ('other', 'O'), ('hand', 'O'), (',', 'O'), ('elicited', 'O'), ('discernible', 'O'), ('electromyographic', 'O'), ('excitation', 'O'), ('.', 'O'))"
"Animals ( n = 42 ) were treated intraperitoneally with one of the following six regimens : 1 ) L - MED ( the inactive L - isomer of medetomidine ) , 30 micrograms / kg ; 2 ) D - MED , 10 micrograms / kg ; 3 ) D - MED , 30 micrograms / kg ; 4 ) D - MED [ 30 micrograms / kg ] and the central - acting alpha - 2 antagonist , idazoxan [ 10 mg / kg ] ; 5 ) D - MED [ 30 micrograms / kg","(('Animals', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('42', 'O'), (')', 'O'), ('were', 'O'), ('treated', 'O'), ('intraperitoneally', 'O'), ('with', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('following', 'O'), ('six', 'O'), ('regimens', 'O'), (':', 'O'), ('1', 'O'), (')', 'O'), ('L', 'O'), ('-', 'O'), ('MED', 'O'), ('(', 'O'), ('the', 'O'), ('inactive', 'O'), ('L', 'O'), ('-', 'O'), ('isomer', 'O'), ('of', 'O'), ('medetomidine', 'O'), (')', 'O'), (',', 'O'), ('30', 'O'), ('micrograms', 'O'), ('/', 'O'), ('kg', 'O'), (';', 'O'), ('2', 'O'), (')', 'O'), ('D', 'O'), ('-', 'O'), ('MED', 'O'), (',', 'O'), ('10', 'O'), ('micrograms', 'O'), ('/', 'O'), ('kg', 'O'), (';', 'O'), ('3', 'O'), (')', 'O'), ('D', 'O'), ('-', 'O'), ('MED', 'O'), (',', 'O'), ('30', 'O'), ('micrograms', 'O'), ('/', 'O'), ('kg', 'O'), (';', 'O'), ('4', 'O'), (')', 'O'), ('D', 'O'), ('-', 'O'), ('MED', 'O'), ('[', 'O'), ('30', 'O'), ('micrograms', 'O'), ('/', 'O'), ('kg', 'O'), (']', 'O'), ('and', 'O'), ('the', 'O'), ('central', 'O'), ('-', 'O'), ('acting', 'O'), ('alpha', 'O'), ('-', 'O'), ('2', 'O'), ('antagonist', 'O'), (',', 'O'), ('idazoxan', 'O'), ('[', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (']', 'O'), (';', 'O'), ('5', 'O'), (')', 'O'), ('D', 'O'), ('-', 'O'), ('MED', 'O'), ('[', 'O'), ('30', 'O'), ('micrograms', 'O'), ('/', 'O'), ('kg', 'O'))"
"] and the peripheral - acting alpha - 2 antagonist DG - 5128 [ 10 mg / kg ] , or ; 6 ) saline .","((']', 'O'), ('and', 'O'), ('the', 'O'), ('peripheral', 'O'), ('-', 'O'), ('acting', 'O'), ('alpha', 'O'), ('-', 'O'), ('2', 'O'), ('antagonist', 'O'), ('DG', 'O'), ('-', 'O'), ('5128', 'O'), ('[', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (']', 'O'), (',', 'O'), ('or', 'O'), (';', 'O'), ('6', 'O'), (')', 'O'), ('saline', 'O'), ('.', 'O'))"
Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment .,"(('Baseline', 'O'), ('electromyographic', 'O'), ('activity', 'O'), ('was', 'O'), ('recorded', 'O'), ('from', 'O'), ('the', 'O'), ('gastrocnemius', 'O'), ('muscle', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('drug', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Each rat was then injected with alfentanil ( ALF , 0 . 5 mg / kg sc ) .","(('Each', 'O'), ('rat', 'O'), ('was', 'O'), ('then', 'O'), ('injected', 'O'), ('with', 'O'), ('alfentanil', 'O'), ('(', 'O'), ('ALF', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('sc', 'O'), (')', 'O'), ('.', 'O'))"
ALF injection resulted in a marked increase in hindlimb EMG activity in the L - MED treatment group which was indistinguishable from that seen in animals treated with saline .,"(('ALF', 'O'), ('injection', 'O'), ('resulted', 'O'), ('in', 'O'), ('a', 'O'), ('marked', 'O'), ('increase', 'O'), ('in', 'O'), ('hindlimb', 'O'), ('EMG', 'O'), ('activity', 'O'), ('in', 'O'), ('the', 'O'), ('L', 'O'), ('-', 'O'), ('MED', 'O'), ('treatment', 'O'), ('group', 'O'), ('which', 'O'), ('was', 'O'), ('indistinguishable', 'O'), ('from', 'O'), ('that', 'O'), ('seen', 'O'), ('in', 'O'), ('animals', 'O'), ('treated', 'O'), ('with', 'O'), ('saline', 'O'), ('.', 'O'))"
The small EMG values obtained in the high - dose D - MED group were comparable with those recorded in earlier studies from control animals not given any opiate .,"(('The', 'O'), ('small', 'O'), ('EMG', 'O'), ('values', 'O'), ('obtained', 'O'), ('in', 'O'), ('the', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('D', 'O'), ('-', 'O'), ('MED', 'O'), ('group', 'O'), ('were', 'O'), ('comparable', 'O'), ('with', 'O'), ('those', 'O'), ('recorded', 'O'), ('in', 'O'), ('earlier', 'O'), ('studies', 'O'), ('from', 'O'), ('control', 'O'), ('animals', 'O'), ('not', 'O'), ('given', 'O'), ('any', 'O'), ('opiate', 'O'), ('.', 'O'))"
Some central effects of repeated treatment with fluvoxamine .,"(('Some', 'O'), ('central', 'O'), ('effects', 'O'), ('of', 'O'), ('repeated', 'O'), ('treatment', 'O'), ('with', 'O'), ('fluvoxamine', 'O'), ('.', 'O'))"
"We investigated the effect of repeated treatment with fluvoxamine , a selective serotonin uptake inhibitor , on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the "" behavioral despair "" test .","(('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('repeated', 'O'), ('treatment', 'O'), ('with', 'O'), ('fluvoxamine', 'O'), (',', 'O'), ('a', 'O'), ('selective', 'O'), ('serotonin', 'O'), ('uptake', 'O'), ('inhibitor', 'O'), (',', 'O'), ('on', 'O'), ('behavioral', 'O'), ('effects', 'O'), ('of', 'O'), ('dopaminomimetics', 'O'), ('and', 'O'), ('methoxamine', 'O'), ('and', 'O'), ('on', 'O'), ('the', 'O'), ('animal', 'O'), ('behavior', 'O'), ('in', 'O'), ('the', 'O'), ('""', 'O'), ('behavioral', 'O'), ('despair', 'O'), ('""', 'O'), ('test', 'O'), ('.', 'O'))"
The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine .,"(('The', 'O'), ('stimulation', 'O'), ('of', 'O'), ('locomotor', 'O'), ('activity', 'O'), ('by', 'O'), ('intracerebroventricularly', 'O'), ('administered', 'O'), ('methoxamine', 'O'), ('was', 'O'), ('not', 'O'), ('affected', 'O'), ('by', 'O'), ('repeated', 'O'), ('treatment', 'O'), ('with', 'O'), ('fluvoxamine', 'O'), ('.', 'O'))"
"Given three times fluvoxamine had no effect on the immobilization time in the "" behavioral despair "" test in rats .","(('Given', 'O'), ('three', 'O'), ('times', 'O'), ('fluvoxamine', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('immobilization', 'O'), ('time', 'O'), ('in', 'O'), ('the', 'O'), ('""', 'O'), ('behavioral', 'O'), ('despair', 'O'), ('""', 'O'), ('test', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"The results indicate that fluvoxamine given repeatedly acts differently than citalopram , another selective serotonin uptake inhibitor , and differs also from other antidepressant drugs .","(('The', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('fluvoxamine', 'O'), ('given', 'O'), ('repeatedly', 'O'), ('acts', 'O'), ('differently', 'O'), ('than', 'O'), ('citalopram', 'O'), (',', 'O'), ('another', 'O'), ('selective', 'O'), ('serotonin', 'O'), ('uptake', 'O'), ('inhibitor', 'O'), (',', 'O'), ('and', 'O'), ('differs', 'O'), ('also', 'O'), ('from', 'O'), ('other', 'O'), ('antidepressant', 'O'), ('drugs', 'O'), ('.', 'O'))"
"In contrast , doses of 1 mg / kg BN 52021 given 30 min before or 10 mg / kg administered 5 min before i . v . injection of bupivacaine were ineffective .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('doses', 'O'), ('of', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('BN', 'O'), ('52021', 'O'), ('given', 'O'), ('30', 'O'), ('min', 'O'), ('before', 'O'), ('or', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('administered', 'O'), ('5', 'O'), ('min', 'O'), ('before', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('injection', 'O'), ('of', 'O'), ('bupivacaine', 'O'), ('were', 'O'), ('ineffective', 'O'), ('.', 'O'))"
A partial recovery of bupivacaine - induced ECG alterations was observed after pretreatment of the rats with BN 52021 .,"(('A', 'O'), ('partial', 'O'), ('recovery', 'O'), ('of', 'O'), ('bupivacaine', 'O'), ('-', 'O'), ('induced', 'O'), ('ECG', 'O'), ('alterations', 'O'), ('was', 'O'), ('observed', 'O'), ('after', 'O'), ('pretreatment', 'O'), ('of', 'O'), ('the', 'O'), ('rats', 'O'), ('with', 'O'), ('BN', 'O'), ('52021', 'O'), ('.', 'O'))"
"Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced cardiovascular toxicity .","(('Since', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('BN', 'O'), ('52021', 'O'), (',', 'O'), ('at', 'O'), ('all', 'O'), ('doses', 'O'), ('studied', 'O'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('alter', 'O'), ('MBP', 'O'), ('and', 'O'), ('HR', 'O'), ('at', 'O'), ('the', 'O'), ('doses', 'O'), ('used', 'O'), (',', 'O'), ('the', 'O'), ('bulk', 'O'), ('of', 'O'), ('these', 'O'), ('results', 'O'), ('clearly', 'O'), ('demonstrate', 'O'), ('a', 'O'), ('protective', 'O'), ('action', 'O'), ('of', 'O'), ('BN', 'O'), ('52021', 'O'), (',', 'O'), ('a', 'O'), ('specific', 'O'), ('antagonist', 'O'), ('of', 'O'), ('PAF', 'O'), (',', 'O'), ('against', 'O'), ('bupivacaine', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiovascular', 'B'), ('toxicity', 'I'), ('.', 'O'))"
"Suprofen , a new nonsteroidal anti - inflammatory drug , was marketed in early 1986 as an analgesic agent .","(('Suprofen', 'O'), (',', 'O'), ('a', 'O'), ('new', 'O'), ('nonsteroidal', 'O'), ('anti', 'O'), ('-', 'O'), ('inflammatory', 'O'), ('drug', 'O'), (',', 'O'), ('was', 'O'), ('marketed', 'O'), ('in', 'O'), ('early', 'O'), ('1986', 'O'), ('as', 'O'), ('an', 'O'), ('analgesic', 'O'), ('agent', 'O'), ('.', 'O'))"
"Through August 1986 , a total of 163 cases of this syndrome were reported .","(('Through', 'O'), ('August', 'O'), ('1986', 'O'), (',', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('163', 'O'), ('cases', 'O'), ('of', 'O'), ('this', 'O'), ('syndrome', 'O'), ('were', 'O'), ('reported', 'O'), ('.', 'O'))"
"To elucidate the epidemiology of the syndrome , a case - control study was performed , comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen - exposed control subjects who did not have the syndrome .","(('To', 'O'), ('elucidate', 'O'), ('the', 'O'), ('epidemiology', 'O'), ('of', 'O'), ('the', 'O'), ('syndrome', 'O'), (',', 'O'), ('a', 'O'), ('case', 'O'), ('-', 'O'), ('control', 'O'), ('study', 'O'), ('was', 'O'), ('performed', 'O'), (',', 'O'), ('comparing', 'O'), ('62', 'O'), ('of', 'O'), ('the', 'O'), ('case', 'O'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('the', 'O'), ('spontaneous', 'O'), ('reporting', 'O'), ('system', 'O'), ('to', 'O'), ('185', 'O'), ('suprofen', 'O'), ('-', 'O'), ('exposed', 'O'), ('control', 'O'), ('subjects', 'O'), ('who', 'O'), ('did', 'O'), ('not', 'O'), ('have', 'O'), ('the', 'O'), ('syndrome', 'O'), ('.', 'O'))"
. 5 ) .,"(('.', 'O'), ('5', 'O'), (')', 'O'), ('.', 'O'))"
These were findings that were suggestive but did not reach conventional statistical significance .,"(('These', 'O'), ('were', 'O'), ('findings', 'O'), ('that', 'O'), ('were', 'O'), ('suggestive', 'O'), ('but', 'O'), ('did', 'O'), ('not', 'O'), ('reach', 'O'), ('conventional', 'O'), ('statistical', 'O'), ('significance', 'O'), ('.', 'O'))"
These findings are consistent with the postulated mechanism for this unusual syndrome : acute diffuse crystallization of uric acid in renal tubules .,"(('These', 'O'), ('findings', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('postulated', 'O'), ('mechanism', 'O'), ('for', 'O'), ('this', 'O'), ('unusual', 'O'), ('syndrome', 'O'), (':', 'O'), ('acute', 'O'), ('diffuse', 'O'), ('crystallization', 'O'), ('of', 'O'), ('uric', 'O'), ('acid', 'O'), ('in', 'O'), ('renal', 'O'), ('tubules', 'O'), ('.', 'O'))"
"Unanesthetized adult female , Sprague - Dawley rats were divided in four groups and studied for 15 days .","(('Unanesthetized', 'O'), ('adult', 'O'), ('female', 'O'), (',', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('were', 'O'), ('divided', 'O'), ('in', 'O'), ('four', 'O'), ('groups', 'O'), ('and', 'O'), ('studied', 'O'), ('for', 'O'), ('15', 'O'), ('days', 'O'), ('.', 'O'))"
"Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild DM + gentamicin ) .","(('Group', 'O'), ('1', 'O'), ('(', 'O'), ('P', 'O'), ('alone', 'O'), (')', 'O'), ('received', 'O'), ('P', 'O'), (',', 'O'), ('360', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), (',', 'O'), ('for', 'O'), ('15', 'O'), ('days', 'O'), (';', 'O'), ('Group', 'O'), ('II', 'O'), ('(', 'O'), ('P', 'O'), ('+', 'O'), ('gentamicin', 'O'), (')', 'O'), (';', 'O'), ('Group', 'O'), ('III', 'O'), ('(', 'O'), ('gentamicin', 'O'), ('alone', 'O'), (')', 'O'), ('and', 'O'), ('Group', 'O'), ('IV', 'O'), ('(', 'O'), ('mild', 'O'), ('DM', 'B'), ('+', 'O'), ('gentamicin', 'O'), (')', 'O'), ('.', 'O'))"
"The present studies explored the duration of the loss of righting reflex induced by sub - effective doses of ketamine and morphine , administered simultaneously .","(('The', 'O'), ('present', 'O'), ('studies', 'O'), ('explored', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('loss', 'O'), ('of', 'O'), ('righting', 'O'), ('reflex', 'O'), ('induced', 'O'), ('by', 'O'), ('sub', 'O'), ('-', 'O'), ('effective', 'O'), ('doses', 'O'), ('of', 'O'), ('ketamine', 'O'), ('and', 'O'), ('morphine', 'O'), (',', 'O'), ('administered', 'O'), ('simultaneously', 'O'), ('.', 'O'))"
"There was mutual potentiation between sub - effective doses of ketamine and morphine , but sub - effective doses of ketamine partly antagonized fully - effective doses of morphine .","(('There', 'O'), ('was', 'O'), ('mutual', 'O'), ('potentiation', 'O'), ('between', 'O'), ('sub', 'O'), ('-', 'O'), ('effective', 'O'), ('doses', 'O'), ('of', 'O'), ('ketamine', 'O'), ('and', 'O'), ('morphine', 'O'), (',', 'O'), ('but', 'O'), ('sub', 'O'), ('-', 'O'), ('effective', 'O'), ('doses', 'O'), ('of', 'O'), ('ketamine', 'O'), ('partly', 'O'), ('antagonized', 'O'), ('fully', 'O'), ('-', 'O'), ('effective', 'O'), ('doses', 'O'), ('of', 'O'), ('morphine', 'O'), ('.', 'O'))"
The degree and time course of development of tolerance to daily administration of sub - effective dose combinations of ketamine and morphine were similar .,"(('The', 'O'), ('degree', 'O'), ('and', 'O'), ('time', 'O'), ('course', 'O'), ('of', 'O'), ('development', 'O'), ('of', 'O'), ('tolerance', 'O'), ('to', 'O'), ('daily', 'O'), ('administration', 'O'), ('of', 'O'), ('sub', 'O'), ('-', 'O'), ('effective', 'O'), ('dose', 'O'), ('combinations', 'O'), ('of', 'O'), ('ketamine', 'O'), ('and', 'O'), ('morphine', 'O'), ('were', 'O'), ('similar', 'O'), ('.', 'O'))"
"Rats , tolerant to ketamine - dominant combinations , were cross - tolerant to both drugs , while those tolerant to morphine - dominant combinations were cross - tolerant to morphine but showed either no cross - tolerance or an augmented response to ketamine .","(('Rats', 'O'), (',', 'O'), ('tolerant', 'O'), ('to', 'O'), ('ketamine', 'O'), ('-', 'O'), ('dominant', 'O'), ('combinations', 'O'), (',', 'O'), ('were', 'O'), ('cross', 'O'), ('-', 'O'), ('tolerant', 'O'), ('to', 'O'), ('both', 'O'), ('drugs', 'O'), (',', 'O'), ('while', 'O'), ('those', 'O'), ('tolerant', 'O'), ('to', 'O'), ('morphine', 'O'), ('-', 'O'), ('dominant', 'O'), ('combinations', 'O'), ('were', 'O'), ('cross', 'O'), ('-', 'O'), ('tolerant', 'O'), ('to', 'O'), ('morphine', 'O'), ('but', 'O'), ('showed', 'O'), ('either', 'O'), ('no', 'O'), ('cross', 'O'), ('-', 'O'), ('tolerance', 'O'), ('or', 'O'), ('an', 'O'), ('augmented', 'O'), ('response', 'O'), ('to', 'O'), ('ketamine', 'O'), ('.', 'O'))"
Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects .,"(('Oral', 'O'), ('hydrocortisone', 'O'), ('increases', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('enhances', 'O'), ('pressor', 'O'), ('responsiveness', 'O'), ('in', 'O'), ('normal', 'O'), ('human', 'O'), ('subjects', 'O'), ('.', 'O'))"
"We studied the effects of 1 week of oral hydrocortisone ( 200 mg / day ) on blood pressure , cardiac output , total peripheral resistance , forearm vascular resistance , and norepinephrine spillover to plasma in eight healthy male volunteers .","(('We', 'O'), ('studied', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('1', 'O'), ('week', 'O'), ('of', 'O'), ('oral', 'O'), ('hydrocortisone', 'O'), ('(', 'O'), ('200', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('on', 'O'), ('blood', 'O'), ('pressure', 'O'), (',', 'O'), ('cardiac', 'O'), ('output', 'O'), (',', 'O'), ('total', 'O'), ('peripheral', 'O'), ('resistance', 'O'), (',', 'O'), ('forearm', 'O'), ('vascular', 'O'), ('resistance', 'O'), (',', 'O'), ('and', 'O'), ('norepinephrine', 'O'), ('spillover', 'O'), ('to', 'O'), ('plasma', 'O'), ('in', 'O'), ('eight', 'O'), ('healthy', 'O'), ('male', 'O'), ('volunteers', 'O'), ('.', 'O'))"
"Total peripheral vascular resistance fell from 15 . 1 to 12 . 2 mm Hg / l / min ( SED + / - 1 . 03 , p less than 0 . 05 ) .","(('Total', 'O'), ('peripheral', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('fell', 'O'), ('from', 'O'), ('15', 'O'), ('.', 'O'), ('1', 'O'), ('to', 'O'), ('12', 'O'), ('.', 'O'), ('2', 'O'), ('mm', 'O'), ('Hg', 'O'), ('/', 'O'), ('l', 'O'), ('/', 'O'), ('min', 'O'), ('(', 'O'), ('SED', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('03', 'O'), (',', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"Resting forearm vascular resistance remained unchanged , but the reflex response to the cold pressor test was accentuated , the rise in resistance increasing from 10 . 5 mm Hg / ml / 100 ml / min ( R units ) before treatment to 32 . 6 R units after treatment ( SED + / - 6 . 4 , p less than 0 . 025 ) .","(('Resting', 'O'), ('forearm', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('remained', 'O'), ('unchanged', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('reflex', 'O'), ('response', 'O'), ('to', 'O'), ('the', 'O'), ('cold', 'O'), ('pressor', 'O'), ('test', 'O'), ('was', 'O'), ('accentuated', 'O'), (',', 'O'), ('the', 'O'), ('rise', 'O'), ('in', 'O'), ('resistance', 'O'), ('increasing', 'O'), ('from', 'O'), ('10', 'O'), ('.', 'O'), ('5', 'O'), ('mm', 'O'), ('Hg', 'O'), ('/', 'O'), ('ml', 'O'), ('/', 'O'), ('100', 'O'), ('ml', 'O'), ('/', 'O'), ('min', 'O'), ('(', 'O'), ('R', 'O'), ('units', 'O'), (')', 'O'), ('before', 'O'), ('treatment', 'O'), ('to', 'O'), ('32', 'O'), ('.', 'O'), ('6', 'O'), ('R', 'O'), ('units', 'O'), ('after', 'O'), ('treatment', 'O'), ('(', 'O'), ('SED', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('6', 'O'), ('.', 'O'), ('4', 'O'), (',', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('025', 'O'), (')', 'O'), ('.', 'O'))"
"The rise in forearm vascular resistance accompanying intra - arterial norepinephrine ( 25 , 50 , and 100 ng / min ) was also significantly greater after hydrocortisone , increasing from an average of 14 . 9 + / - 2 . 4 R units before treatment to 35 . 1 + / - 5 . 5 R units after hydrocortisone ( SED + / - 6 . 0 , p less than 0 . 05 ) .","(('The', 'O'), ('rise', 'O'), ('in', 'O'), ('forearm', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('accompanying', 'O'), ('intra', 'O'), ('-', 'O'), ('arterial', 'O'), ('norepinephrine', 'O'), ('(', 'O'), ('25', 'O'), (',', 'O'), ('50', 'O'), (',', 'O'), ('and', 'O'), ('100', 'O'), ('ng', 'O'), ('/', 'O'), ('min', 'O'), (')', 'O'), ('was', 'O'), ('also', 'O'), ('significantly', 'O'), ('greater', 'O'), ('after', 'O'), ('hydrocortisone', 'O'), (',', 'O'), ('increasing', 'O'), ('from', 'O'), ('an', 'O'), ('average', 'O'), ('of', 'O'), ('14', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('4', 'O'), ('R', 'O'), ('units', 'O'), ('before', 'O'), ('treatment', 'O'), ('to', 'O'), ('35', 'O'), ('.', 'O'), ('1', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('5', 'O'), ('.', 'O'), ('5', 'O'), ('R', 'O'), ('units', 'O'), ('after', 'O'), ('hydrocortisone', 'O'), ('(', 'O'), ('SED', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('6', 'O'), ('.', 'O'), ('0', 'O'), (',', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
A shift to the left in the dose - response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment .,"(('A', 'O'), ('shift', 'O'), ('to', 'O'), ('the', 'O'), ('left', 'O'), ('in', 'O'), ('the', 'O'), ('dose', 'O'), ('-', 'O'), ('response', 'O'), ('relation', 'O'), ('and', 'O'), ('fall', 'O'), ('in', 'O'), ('threshold', 'O'), ('suggested', 'O'), ('increased', 'O'), ('sensitivity', 'O'), ('to', 'O'), ('norepinephrine', 'O'), ('after', 'O'), ('treatment', 'O'), ('.', 'O'))"
Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased .,"(('Measurement', 'O'), ('of', 'O'), ('resting', 'O'), ('norepinephrine', 'O'), ('spillover', 'O'), ('rate', 'O'), ('to', 'O'), ('plasma', 'O'), ('and', 'O'), ('norepinephrine', 'O'), ('uptake', 'O'), ('indicated', 'O'), ('that', 'O'), ('overall', 'O'), ('resting', 'O'), ('sympathetic', 'O'), ('nervous', 'O'), ('system', 'O'), ('activity', 'O'), ('was', 'O'), ('not', 'O'), ('increased', 'O'), ('.', 'O'))"
This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium .,"(('This', 'O'), ('reaction', 'O'), ('demonstrates', 'O'), ('that', 'O'), ('nifedipine', 'O'), ('can', 'O'), ('seriously', 'O'), ('potentiate', 'O'), ('the', 'O'), ('toxicity', 'O'), ('of', 'O'), ('magnesium', 'O'), ('.', 'O'))"
Caution should be exercised when these two tocolytics are combined .,"(('Caution', 'O'), ('should', 'O'), ('be', 'O'), ('exercised', 'O'), ('when', 'O'), ('these', 'O'), ('two', 'O'), ('tocolytics', 'O'), ('are', 'O'), ('combined', 'O'), ('.', 'O'))"
Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine .,"(('Chronic', 'O'), ('carbamazepine', 'O'), ('inhibits', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('local', 'B'), ('anesthetic', 'I'), ('seizures', 'I'), ('kindled', 'O'), ('by', 'O'), ('cocaine', 'O'), ('and', 'O'), ('lidocaine', 'O'), ('.', 'O'))"
The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .,"(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('carbamazepine', 'O'), ('(', 'O'), ('CBZ', 'O'), (')', 'O'), ('treatment', 'O'), ('on', 'O'), ('local', 'B'), ('anesthetic', 'I'), ('-', 'I'), ('kindled', 'I'), ('seizures', 'I'), ('and', 'O'), ('lethality', 'O'), ('were', 'O'), ('evaluated', 'O'), ('in', 'O'), ('different', 'O'), ('stages', 'O'), ('of', 'O'), ('the', 'O'), ('kindling', 'O'), ('process', 'O'), ('and', 'O'), ('under', 'O'), ('different', 'O'), ('methods', 'O'), ('of', 'O'), ('CBZ', 'O'), ('administration', 'O'), ('.', 'O'))"
"Chronic oral CBZ inhibited the development of both lidocaine - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic seizures .","(('Chronic', 'O'), ('oral', 'O'), ('CBZ', 'O'), ('inhibited', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('both', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('and', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), (',', 'O'), ('but', 'O'), ('had', 'O'), ('little', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('fully', 'O'), ('developed', 'O'), ('local', 'B'), ('anesthetic', 'I'), ('seizures', 'I'), ('.', 'O'))"
Chronic CBZ also decreased the incidence of seizure - related mortality in the cocaine - injected rats .,"(('Chronic', 'O'), ('CBZ', 'O'), ('also', 'O'), ('decreased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('seizure', 'O'), ('-', 'O'), ('related', 'O'), ('mortality', 'O'), ('in', 'O'), ('the', 'O'), ('cocaine', 'O'), ('-', 'O'), ('injected', 'O'), ('rats', 'O'), ('.', 'O'))"
Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced seizures .,"(('Acute', 'O'), ('CBZ', 'O'), ('over', 'O'), ('a', 'O'), ('range', 'O'), ('of', 'O'), ('doses', 'O'), ('(', 'O'), ('15', 'O'), ('-', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('completed', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('kindled', 'O'), ('or', 'O'), ('acute', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('.', 'O'))"
Repeated i . p . injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled seizures .,"(('Repeated', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('injection', 'O'), ('of', 'O'), ('CBZ', 'O'), ('(', 'O'), ('15', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('also', 'O'), ('was', 'O'), ('without', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('or', 'O'), ('cocaine', 'O'), ('-', 'O'), ('kindled', 'O'), ('seizures', 'O'), ('.', 'O'))"
The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled seizures .,"(('The', 'O'), ('differential', 'O'), ('effects', 'O'), ('of', 'O'), ('CBZ', 'O'), ('depending', 'O'), ('upon', 'O'), ('stage', 'O'), ('of', 'O'), ('seizure', 'O'), ('development', 'O'), ('suggest', 'O'), ('that', 'O'), ('distinct', 'O'), ('mechanisms', 'O'), ('underlie', 'O'), ('the', 'O'), ('development', 'O'), ('versus', 'O'), ('maintenance', 'O'), ('of', 'O'), ('local', 'B'), ('anesthetic', 'I'), ('-', 'I'), ('kindled', 'I'), ('seizures', 'I'), ('.', 'O'))"
"The effectiveness of chronic but not repeated , intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens .","(('The', 'O'), ('effectiveness', 'O'), ('of', 'O'), ('chronic', 'O'), ('but', 'O'), ('not', 'O'), ('repeated', 'O'), (',', 'O'), ('intermittent', 'O'), ('injections', 'O'), ('of', 'O'), ('CBZ', 'O'), ('suggests', 'O'), ('that', 'O'), ('different', 'O'), ('biochemical', 'O'), ('consequences', 'O'), ('result', 'O'), ('from', 'O'), ('the', 'O'), ('different', 'O'), ('treatment', 'O'), ('regimens', 'O'), ('.', 'O'))"
"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data , but remains to be directly evaluated .","(('The', 'O'), ('possible', 'O'), ('utility', 'O'), ('of', 'O'), ('chronic', 'O'), ('CBZ', 'O'), ('in', 'O'), ('preventing', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('toxic', 'O'), ('side', 'O'), ('effects', 'O'), ('in', 'O'), ('human', 'O'), ('cocaine', 'O'), ('users', 'O'), ('is', 'O'), ('suggested', 'O'), ('by', 'O'), ('these', 'O'), ('data', 'O'), (',', 'O'), ('but', 'O'), ('remains', 'O'), ('to', 'O'), ('be', 'O'), ('directly', 'O'), ('evaluated', 'O'), ('.', 'O'))"
"Magnetic resonance imaging of cerebral venous thrombosis secondary to "" low - dose "" birth control pills .","(('Magnetic', 'O'), ('resonance', 'O'), ('imaging', 'O'), ('of', 'O'), ('cerebral', 'B'), ('venous', 'I'), ('thrombosis', 'I'), ('secondary', 'O'), ('to', 'O'), ('""', 'O'), ('low', 'O'), ('-', 'O'), ('dose', 'O'), ('""', 'O'), ('birth', 'O'), ('control', 'O'), ('pills', 'O'), ('.', 'O'))"
The clinical and radiographic features of cerebral deep venous thrombosis in a 21 - year - old white woman are presented .,"(('The', 'O'), ('clinical', 'O'), ('and', 'O'), ('radiographic', 'O'), ('features', 'O'), ('of', 'O'), ('cerebral', 'B'), ('deep', 'I'), ('venous', 'I'), ('thrombosis', 'I'), ('in', 'O'), ('a', 'O'), ('21', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('white', 'O'), ('woman', 'O'), ('are', 'O'), ('presented', 'O'), ('.', 'O'))"
This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes .,"(('This', 'O'), ('nulliparous', 'O'), ('patient', 'O'), ('presented', 'O'), ('with', 'O'), ('relatively', 'O'), ('mild', 'O'), ('clinical', 'O'), ('symptoms', 'O'), ('and', 'O'), ('progressing', 'O'), ('mental', 'O'), ('status', 'O'), ('changes', 'O'), ('.', 'O'))"
"The only known risk factor was "" low - dose "" oral contraceptive pills .","(('The', 'O'), ('only', 'O'), ('known', 'O'), ('risk', 'O'), ('factor', 'O'), ('was', 'O'), ('""', 'O'), ('low', 'O'), ('-', 'O'), ('dose', 'O'), ('""', 'O'), ('oral', 'O'), ('contraceptive', 'O'), ('pills', 'O'), ('.', 'O'))"
"The magnetic resonance image ( MRI ) showed increased signal intensity from the internal cerebral veins , vein of Galen , and straight sinus .","(('The', 'O'), ('magnetic', 'O'), ('resonance', 'O'), ('image', 'O'), ('(', 'O'), ('MRI', 'O'), (')', 'O'), ('showed', 'O'), ('increased', 'O'), ('signal', 'O'), ('intensity', 'O'), ('from', 'O'), ('the', 'O'), ('internal', 'O'), ('cerebral', 'O'), ('veins', 'O'), (',', 'O'), ('vein', 'O'), ('of', 'O'), ('Galen', 'O'), (',', 'O'), ('and', 'O'), ('straight', 'O'), ('sinus', 'O'), ('.', 'O'))"
The diagnosis was confirmed by arterial angiography .,"(('The', 'O'), ('diagnosis', 'O'), ('was', 'O'), ('confirmed', 'O'), ('by', 'O'), ('arterial', 'O'), ('angiography', 'O'), ('.', 'O'))"
Six healthy subjects were given a 0 . 5 mg subcutaneous dose of terbutaline on two occasions : 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally .,"(('Six', 'O'), ('healthy', 'O'), ('subjects', 'O'), ('were', 'O'), ('given', 'O'), ('a', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('subcutaneous', 'O'), ('dose', 'O'), ('of', 'O'), ('terbutaline', 'O'), ('on', 'O'), ('two', 'O'), ('occasions', 'O'), (':', 'O'), ('1', 'O'), ('hour', 'O'), ('after', 'O'), ('oral', 'O'), ('administration', 'O'), ('of', 'O'), ('a', 'O'), ('placebo', 'O'), ('and', 'O'), ('1', 'O'), ('hour', 'O'), ('after', 'O'), ('80', 'O'), ('mg', 'O'), ('oxprenolol', 'O'), ('orally', 'O'), ('.', 'O'))"
"In the 7 - hour period after terbutaline administration , plasma samples were taken for determination of plasma potassium levels and drug concentrations .","(('In', 'O'), ('the', 'O'), ('7', 'O'), ('-', 'O'), ('hour', 'O'), ('period', 'O'), ('after', 'O'), ('terbutaline', 'O'), ('administration', 'O'), (',', 'O'), ('plasma', 'O'), ('samples', 'O'), ('were', 'O'), ('taken', 'O'), ('for', 'O'), ('determination', 'O'), ('of', 'O'), ('plasma', 'O'), ('potassium', 'O'), ('levels', 'O'), ('and', 'O'), ('drug', 'O'), ('concentrations', 'O'), ('.', 'O'))"
The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects .,"(('The', 'O'), ('sigmoid', 'O'), ('Emax', 'O'), ('model', 'O'), ('offered', 'O'), ('a', 'O'), ('good', 'O'), ('description', 'O'), ('of', 'O'), ('the', 'O'), ('relation', 'O'), ('between', 'O'), ('terbutaline', 'O'), ('concentrations', 'O'), ('and', 'O'), ('potassium', 'O'), ('effects', 'O'), ('.', 'O'))"
"Oxprenolol caused decreases of 65 % and 56 % of terbutaline volume of distribution and clearance , respectively , and an increase of 130 % of its AUC .","(('Oxprenolol', 'O'), ('caused', 'O'), ('decreases', 'O'), ('of', 'O'), ('65', 'O'), ('%', 'O'), ('and', 'O'), ('56', 'O'), ('%', 'O'), ('of', 'O'), ('terbutaline', 'O'), ('volume', 'O'), ('of', 'O'), ('distribution', 'O'), ('and', 'O'), ('clearance', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('and', 'O'), ('an', 'O'), ('increase', 'O'), ('of', 'O'), ('130', 'O'), ('%', 'O'), ('of', 'O'), ('its', 'O'), ('AUC', 'O'), ('.', 'O'))"
A dystonia - like syndrome after neuropeptide ( MSH / ACTH ) stimulation of the rat locus ceruleus .,"(('A', 'O'), ('dystonia', 'B'), ('-', 'I'), ('like', 'I'), ('syndrome', 'I'), ('after', 'O'), ('neuropeptide', 'O'), ('(', 'O'), ('MSH', 'O'), ('/', 'O'), ('ACTH', 'O'), (')', 'O'), ('stimulation', 'O'), ('of', 'O'), ('the', 'O'), ('rat', 'O'), ('locus', 'O'), ('ceruleus', 'O'), ('.', 'O'))"
"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia , and information obtained in these studies may be of potential clinical benefit .","(('The', 'O'), ('movement', 'B'), ('disorder', 'I'), ('investigated', 'O'), ('in', 'O'), ('these', 'O'), ('studies', 'O'), ('has', 'O'), ('some', 'O'), ('features', 'O'), ('in', 'O'), ('common', 'O'), ('with', 'O'), ('human', 'O'), ('idiopathic', 'B'), ('dystonia', 'I'), (',', 'O'), ('and', 'O'), ('information', 'O'), ('obtained', 'O'), ('in', 'O'), ('these', 'O'), ('studies', 'O'), ('may', 'O'), ('be', 'O'), ('of', 'O'), ('potential', 'O'), ('clinical', 'O'), ('benefit', 'O'), ('.', 'O'))"
The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE - mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo - cerebellar pathway .,"(('The', 'O'), ('present', 'O'), ('experimental', 'O'), ('results', 'O'), ('indicated', 'O'), ('that', 'O'), ('peptidergic', 'O'), ('stimulation', 'O'), ('of', 'O'), ('the', 'O'), ('LC', 'O'), ('resulted', 'O'), ('in', 'O'), ('a', 'O'), ('NE', 'O'), ('-', 'O'), ('mediated', 'O'), ('inhibition', 'O'), ('of', 'O'), ('cerebellar', 'O'), ('Purkinje', 'O'), ('cells', 'O'), ('located', 'O'), ('at', 'O'), ('terminals', 'O'), ('of', 'O'), ('the', 'O'), ('ceruleo', 'O'), ('-', 'O'), ('cerebellar', 'O'), ('pathway', 'O'), ('.', 'O'))"
"increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .","(('increased', 'O'), ('excitability', 'O'), ('of', 'O'), ('the', 'O'), ('unilateral', 'O'), ('cerebellar', 'O'), ('fastigial', 'O'), ('or', 'O'), ('interpositus', 'O'), ('nuclei', 'O'), (',', 'O'), ('the', 'O'), ('output', 'O'), ('targets', 'O'), ('of', 'O'), ('the', 'O'), ('Purkinje', 'O'), ('cell', 'O'), ('axons', 'O'), (',', 'O'), ('that', 'O'), ('may', 'O'), ('have', 'O'), ('been', 'O'), ('an', 'O'), ('important', 'O'), ('contributing', 'O'), ('factor', 'O'), ('to', 'O'), ('this', 'O'), ('disorder', 'O'), ('.', 'O'))"
These questions are currently being investigated .,"(('These', 'O'), ('questions', 'O'), ('are', 'O'), ('currently', 'O'), ('being', 'O'), ('investigated', 'O'), ('.', 'O'))"
"The present study examines the effect of 6 - day epinephrine treatment ( 100 micrograms / kg per h , s . c . ) on stimulus - induced ( 1 Hz ) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle - and epinephrine - treated rats .","(('The', 'O'), ('present', 'O'), ('study', 'O'), ('examines', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('6', 'O'), ('-', 'O'), ('day', 'O'), ('epinephrine', 'O'), ('treatment', 'O'), ('(', 'O'), ('100', 'O'), ('micrograms', 'O'), ('/', 'O'), ('kg', 'O'), ('per', 'O'), ('h', 'O'), (',', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), ('on', 'O'), ('stimulus', 'O'), ('-', 'O'), ('induced', 'O'), ('(', 'O'), ('1', 'O'), ('Hz', 'O'), (')', 'O'), ('endogenous', 'O'), ('neurotransmitter', 'O'), ('overflow', 'O'), ('from', 'O'), ('the', 'O'), ('isolated', 'O'), ('perfused', 'O'), ('kidney', 'O'), ('of', 'O'), ('vehicle', 'O'), ('-', 'O'), ('and', 'O'), ('epinephrine', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('.', 'O'))"
Renal catecholamine stores and stimulus - induced overflow in the vehicle - treated group consisted of norepinephrine only .,"(('Renal', 'O'), ('catecholamine', 'O'), ('stores', 'O'), ('and', 'O'), ('stimulus', 'O'), ('-', 'O'), ('induced', 'O'), ('overflow', 'O'), ('in', 'O'), ('the', 'O'), ('vehicle', 'O'), ('-', 'O'), ('treated', 'O'), ('group', 'O'), ('consisted', 'O'), ('of', 'O'), ('norepinephrine', 'O'), ('only', 'O'), ('.', 'O'))"
"However , epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40 % of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree .","(('However', 'O'), (',', 'O'), ('epinephrine', 'O'), ('treatment', 'O'), ('resulted', 'O'), ('in', 'O'), ('the', 'O'), ('incorporation', 'O'), ('of', 'O'), ('epinephrine', 'O'), ('into', 'O'), ('renal', 'O'), ('catecholamine', 'O'), ('stores', 'O'), ('such', 'O'), ('that', 'O'), ('approximately', 'O'), ('40', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('catecholamine', 'O'), ('present', 'O'), ('was', 'O'), ('epinephrine', 'O'), ('while', 'O'), ('the', 'O'), ('norepinephrine', 'O'), ('content', 'O'), ('was', 'O'), ('reduced', 'O'), ('by', 'O'), ('a', 'O'), ('similar', 'O'), ('degree', 'O'), ('.', 'O'))"
Total tissue catecholamine content of the kidney on a molar basis was unchanged .,"(('Total', 'O'), ('tissue', 'O'), ('catecholamine', 'O'), ('content', 'O'), ('of', 'O'), ('the', 'O'), ('kidney', 'O'), ('on', 'O'), ('a', 'O'), ('molar', 'O'), ('basis', 'O'), ('was', 'O'), ('unchanged', 'O'), ('.', 'O'))"
Stimulus - induced fractional overflow of neurotransmitter from the epinephrine - treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney .,"(('Stimulus', 'O'), ('-', 'O'), ('induced', 'O'), ('fractional', 'O'), ('overflow', 'O'), ('of', 'O'), ('neurotransmitter', 'O'), ('from', 'O'), ('the', 'O'), ('epinephrine', 'O'), ('-', 'O'), ('treated', 'O'), ('kidneys', 'O'), ('was', 'O'), ('approximately', 'O'), ('twice', 'O'), ('normal', 'O'), ('and', 'O'), ('consisted', 'O'), ('of', 'O'), ('both', 'O'), ('norepinephrine', 'O'), ('and', 'O'), ('epinephrine', 'O'), ('in', 'O'), ('proportions', 'O'), ('similar', 'O'), ('to', 'O'), ('those', 'O'), ('found', 'O'), ('in', 'O'), ('the', 'O'), ('kidney', 'O'), ('.', 'O'))"
This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade .,"(('This', 'O'), ('difference', 'O'), ('in', 'O'), ('fractional', 'O'), ('overflow', 'O'), ('between', 'O'), ('groups', 'O'), ('was', 'O'), ('not', 'O'), ('affected', 'O'), ('by', 'O'), ('neuronal', 'O'), ('and', 'O'), ('extraneuronal', 'O'), ('uptake', 'O'), ('blockade', 'O'), ('.', 'O'))"
Propranolol had no effect on stimulus - induced overflow in either group .,"(('Propranolol', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('stimulus', 'O'), ('-', 'O'), ('induced', 'O'), ('overflow', 'O'), ('in', 'O'), ('either', 'O'), ('group', 'O'), ('.', 'O'))"
Phentolamine increased stimulus - induced overflow in both groups although the increment in overflow was greater in the epinephrine - treated group .,"(('Phentolamine', 'O'), ('increased', 'O'), ('stimulus', 'O'), ('-', 'O'), ('induced', 'O'), ('overflow', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('although', 'O'), ('the', 'O'), ('increment', 'O'), ('in', 'O'), ('overflow', 'O'), ('was', 'O'), ('greater', 'O'), ('in', 'O'), ('the', 'O'), ('epinephrine', 'O'), ('-', 'O'), ('treated', 'O'), ('group', 'O'), ('.', 'O'))"
"In conclusion , chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('chronic', 'O'), ('epinephrine', 'O'), ('treatment', 'O'), ('results', 'O'), ('in', 'O'), ('enhanced', 'O'), ('fractional', 'O'), ('neurotransmitter', 'O'), ('overflow', 'O'), ('.', 'O'))"
"However , neither alterations in prejunctional beta - adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration .","(('However', 'O'), (',', 'O'), ('neither', 'O'), ('alterations', 'O'), ('in', 'O'), ('prejunctional', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('influences', 'O'), ('nor', 'O'), ('alterations', 'O'), ('in', 'O'), ('neuronal', 'O'), ('and', 'O'), ('extraneuronal', 'O'), ('uptake', 'O'), ('mechanisms', 'O'), ('appear', 'O'), ('to', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('this', 'O'), ('alteration', 'O'), ('.', 'O'))"
"Furthermore , data obtained with phentolamine alone do not suggest alpha - adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment .","(('Furthermore', 'O'), (',', 'O'), ('data', 'O'), ('obtained', 'O'), ('with', 'O'), ('phentolamine', 'O'), ('alone', 'O'), ('do', 'O'), ('not', 'O'), ('suggest', 'O'), ('alpha', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('desensitization', 'O'), ('as', 'O'), ('the', 'O'), ('cause', 'O'), ('of', 'O'), ('the', 'O'), ('enhanced', 'O'), ('neurotransmitter', 'O'), ('overflow', 'O'), ('after', 'O'), ('epinephrine', 'O'), ('treatment', 'O'), ('.', 'O'))"
"25 mg / kg , i . v . thiopental produced anesthesia without altering respiratory rate , increased GABA , decreased glutamate , and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem .","(('25', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('thiopental', 'O'), ('produced', 'O'), ('anesthesia', 'O'), ('without', 'O'), ('altering', 'O'), ('respiratory', 'O'), ('rate', 'O'), (',', 'O'), ('increased', 'O'), ('GABA', 'O'), (',', 'O'), ('decreased', 'O'), ('glutamate', 'O'), (',', 'O'), ('and', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('aspartate', 'O'), ('or', 'O'), ('glycine', 'O'), ('levels', 'O'), ('compared', 'O'), ('to', 'O'), ('controls', 'O'), ('in', 'O'), ('rat', 'O'), ('cortex', 'O'), ('and', 'O'), ('brain', 'O'), ('stem', 'O'), ('.', 'O'))"
Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental .,"(('Pretreatment', 'O'), ('of', 'O'), ('rats', 'O'), ('with', 'O'), ('thiosemicarbazide', 'O'), ('for', 'O'), ('30', 'O'), ('minutes', 'O'), ('abolished', 'O'), ('the', 'O'), ('anesthetic', 'O'), ('action', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('the', 'O'), ('respiratory', 'O'), ('depressant', 'O'), ('action', 'O'), ('of', 'O'), ('thiopental', 'O'), ('.', 'O'))"
"50 mg / kg , i . v . thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .","(('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('thiopental', 'O'), ('produced', 'O'), ('respiratory', 'O'), ('arrest', 'O'), ('with', 'O'), ('further', 'O'), ('increase', 'O'), ('in', 'O'), ('GABA', 'O'), ('and', 'O'), ('decrease', 'O'), ('in', 'O'), ('glutamate', 'O'), ('again', 'O'), ('in', 'O'), ('cortex', 'O'), ('and', 'O'), ('brain', 'O'), ('stem', 'O'), ('without', 'O'), ('affecting', 'O'), ('any', 'O'), ('of', 'O'), ('the', 'O'), ('amino', 'O'), ('acids', 'O'), ('studied', 'O'), ('in', 'O'), ('four', 'O'), ('regions', 'O'), ('of', 'O'), ('rat', 'O'), ('brain', 'O'), ('.', 'O'))"
The effects of diazepam on cardiovascular function were assessed in conscious rats .,"(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('diazepam', 'O'), ('on', 'O'), ('cardiovascular', 'O'), ('function', 'O'), ('were', 'O'), ('assessed', 'O'), ('in', 'O'), ('conscious', 'O'), ('rats', 'O'), ('.', 'O'))"
Intravenous administration of diazepam ( 1 - 30 mg kg - 1 ) produced a dose - dependent decrease in both the mean arterial pressure and the heart rate .,"(('Intravenous', 'O'), ('administration', 'O'), ('of', 'O'), ('diazepam', 'O'), ('(', 'O'), ('1', 'O'), ('-', 'O'), ('30', 'O'), ('mg', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('produced', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('decrease', 'O'), ('in', 'O'), ('both', 'O'), ('the', 'O'), ('mean', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('and', 'O'), ('the', 'O'), ('heart', 'O'), ('rate', 'O'), ('.', 'O'))"
Chlorthalidone ( 50 mg daily ) was given for 14 days .,"(('Chlorthalidone', 'O'), ('(', 'O'), ('50', 'O'), ('mg', 'O'), ('daily', 'O'), (')', 'O'), ('was', 'O'), ('given', 'O'), ('for', 'O'), ('14', 'O'), ('days', 'O'), ('.', 'O'))"
Six patients received a normal - sodium diet and four a low - sodium ( 17 mmol / day ) diet .,"(('Six', 'O'), ('patients', 'O'), ('received', 'O'), ('a', 'O'), ('normal', 'O'), ('-', 'O'), ('sodium', 'O'), ('diet', 'O'), ('and', 'O'), ('four', 'O'), ('a', 'O'), ('low', 'O'), ('-', 'O'), ('sodium', 'O'), ('(', 'O'), ('17', 'O'), ('mmol', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('diet', 'O'), ('.', 'O'))"
All patients had a normal initial total body potassium ( 40K ) .,"(('All', 'O'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('normal', 'O'), ('initial', 'O'), ('total', 'O'), ('body', 'O'), ('potassium', 'O'), ('(', 'O'), ('40K', 'O'), (')', 'O'), ('.', 'O'))"
"The electrolyte balances , weight , bromide space , plasma renin activity , and aldosterone secretion rate were measured .","(('The', 'O'), ('electrolyte', 'O'), ('balances', 'O'), (',', 'O'), ('weight', 'O'), (',', 'O'), ('bromide', 'O'), ('space', 'O'), (',', 'O'), ('plasma', 'O'), ('renin', 'O'), ('activity', 'O'), (',', 'O'), ('and', 'O'), ('aldosterone', 'O'), ('secretion', 'O'), ('rate', 'O'), ('were', 'O'), ('measured', 'O'), ('.', 'O'))"
"In both groups a potassium deficit developed , with proportionally larger losses from the extracellular than from the intracellular compartment .","(('In', 'O'), ('both', 'O'), ('groups', 'O'), ('a', 'O'), ('potassium', 'O'), ('deficit', 'O'), ('developed', 'O'), (',', 'O'), ('with', 'O'), ('proportionally', 'O'), ('larger', 'O'), ('losses', 'O'), ('from', 'O'), ('the', 'O'), ('extracellular', 'O'), ('than', 'O'), ('from', 'O'), ('the', 'O'), ('intracellular', 'O'), ('compartment', 'O'), ('.', 'O'))"
"In the normal - sodium group the highest mean potassium deficit was 176 mmol on day 9 , after which some potassium was regained ; in the low - sodium group the highest deficit was 276 mmol on day 13 .","(('In', 'O'), ('the', 'O'), ('normal', 'O'), ('-', 'O'), ('sodium', 'O'), ('group', 'O'), ('the', 'O'), ('highest', 'O'), ('mean', 'O'), ('potassium', 'O'), ('deficit', 'O'), ('was', 'O'), ('176', 'O'), ('mmol', 'O'), ('on', 'O'), ('day', 'O'), ('9', 'O'), (',', 'O'), ('after', 'O'), ('which', 'O'), ('some', 'O'), ('potassium', 'O'), ('was', 'O'), ('regained', 'O'), (';', 'O'), ('in', 'O'), ('the', 'O'), ('low', 'O'), ('-', 'O'), ('sodium', 'O'), ('group', 'O'), ('the', 'O'), ('highest', 'O'), ('deficit', 'O'), ('was', 'O'), ('276', 'O'), ('mmol', 'O'), ('on', 'O'), ('day', 'O'), ('13', 'O'), ('.', 'O'))"
The normal - sodium group showed an immediate but temporary rise of the renin and aldosterone levels ; in the low - sodium group renin and aldosterone increased more slowly but remained elevated .,"(('The', 'O'), ('normal', 'O'), ('-', 'O'), ('sodium', 'O'), ('group', 'O'), ('showed', 'O'), ('an', 'O'), ('immediate', 'O'), ('but', 'O'), ('temporary', 'O'), ('rise', 'O'), ('of', 'O'), ('the', 'O'), ('renin', 'O'), ('and', 'O'), ('aldosterone', 'O'), ('levels', 'O'), (';', 'O'), ('in', 'O'), ('the', 'O'), ('low', 'O'), ('-', 'O'), ('sodium', 'O'), ('group', 'O'), ('renin', 'O'), ('and', 'O'), ('aldosterone', 'O'), ('increased', 'O'), ('more', 'O'), ('slowly', 'O'), ('but', 'O'), ('remained', 'O'), ('elevated', 'O'), ('.', 'O'))"
"It is concluded that dietary sodium restriction increases diuretic - induced potassium loss , presumably by an increased activity of the renin - angiotensin - aldosterone system , while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion .","(('It', 'O'), ('is', 'O'), ('concluded', 'O'), ('that', 'O'), ('dietary', 'O'), ('sodium', 'O'), ('restriction', 'O'), ('increases', 'O'), ('diuretic', 'O'), ('-', 'O'), ('induced', 'O'), ('potassium', 'O'), ('loss', 'O'), (',', 'O'), ('presumably', 'O'), ('by', 'O'), ('an', 'O'), ('increased', 'O'), ('activity', 'O'), ('of', 'O'), ('the', 'O'), ('renin', 'O'), ('-', 'O'), ('angiotensin', 'O'), ('-', 'O'), ('aldosterone', 'O'), ('system', 'O'), (',', 'O'), ('while', 'O'), ('sodium', 'O'), ('delivery', 'O'), ('to', 'O'), ('the', 'O'), ('distal', 'O'), ('renal', 'O'), ('tubules', 'O'), ('remains', 'O'), ('sufficiently', 'O'), ('high', 'O'), ('to', 'O'), ('allow', 'O'), ('increased', 'O'), ('potassium', 'O'), ('secretion', 'O'), ('.', 'O'))"
Drugs with affinity for other 5 - HT receptors or weak affinity were ineffective .,"(('Drugs', 'O'), ('with', 'O'), ('affinity', 'O'), ('for', 'O'), ('other', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('receptors', 'O'), ('or', 'O'), ('weak', 'O'), ('affinity', 'O'), ('were', 'O'), ('ineffective', 'O'), ('.', 'O'))"
Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium .,"(('Glycopyrronium', 'O'), ('requirements', 'O'), ('for', 'O'), ('antagonism', 'O'), ('of', 'O'), ('the', 'O'), ('muscarinic', 'O'), ('side', 'O'), ('effects', 'O'), ('of', 'O'), ('edrophonium', 'O'), ('.', 'O'))"
"We have compared , in 60 adult patients , the cardiovascular effects of glycopyrronium 5 micrograms kg - 1 and 10 micrograms kg - 1 given either simultaneously or 1 min before edrophonium 1 mg kg - 1 .","(('We', 'O'), ('have', 'O'), ('compared', 'O'), (',', 'O'), ('in', 'O'), ('60', 'O'), ('adult', 'O'), ('patients', 'O'), (',', 'O'), ('the', 'O'), ('cardiovascular', 'O'), ('effects', 'O'), ('of', 'O'), ('glycopyrronium', 'O'), ('5', 'O'), ('micrograms', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('and', 'O'), ('10', 'O'), ('micrograms', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('given', 'O'), ('either', 'O'), ('simultaneously', 'O'), ('or', 'O'), ('1', 'O'), ('min', 'O'), ('before', 'O'), ('edrophonium', 'O'), ('1', 'O'), ('mg', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'))"
Significant differences between the four groups were detected ( P less than 0 . 001 ) .,"(('Significant', 'O'), ('differences', 'O'), ('between', 'O'), ('the', 'O'), ('four', 'O'), ('groups', 'O'), ('were', 'O'), ('detected', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
Both groups receiving 10 micrograms kg - 1 showed increases in heart rate of up to 30 beat min - 1 ( 95 % confidence limits 28 - 32 beat min - 1 ) .,"(('Both', 'O'), ('groups', 'O'), ('receiving', 'O'), ('10', 'O'), ('micrograms', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('showed', 'O'), ('increases', 'O'), ('in', 'O'), ('heart', 'O'), ('rate', 'O'), ('of', 'O'), ('up', 'O'), ('to', 'O'), ('30', 'O'), ('beat', 'O'), ('min', 'O'), ('-', 'O'), ('1', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('limits', 'O'), ('28', 'O'), ('-', 'O'), ('32', 'O'), ('beat', 'O'), ('min', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
This low dose of glycopyrronium provided good control of oropharyngeal secretions .,"(('This', 'O'), ('low', 'O'), ('dose', 'O'), ('of', 'O'), ('glycopyrronium', 'O'), ('provided', 'O'), ('good', 'O'), ('control', 'O'), ('of', 'O'), ('oropharyngeal', 'O'), ('secretions', 'O'), ('.', 'O'))"
"Selective injection of iopentol , iohexol and metrizoate into the left coronary artery of the dog .","(('Selective', 'O'), ('injection', 'O'), ('of', 'O'), ('iopentol', 'O'), (',', 'O'), ('iohexol', 'O'), ('and', 'O'), ('metrizoate', 'O'), ('into', 'O'), ('the', 'O'), ('left', 'O'), ('coronary', 'O'), ('artery', 'O'), ('of', 'O'), ('the', 'O'), ('dog', 'O'), ('.', 'O'))"
Induction of ventricular fibrillation and decrease of aortic pressure .,"(('Induction', 'O'), ('of', 'O'), ('ventricular', 'B'), ('fibrillation', 'I'), ('and', 'O'), ('decrease', 'O'), ('of', 'O'), ('aortic', 'O'), ('pressure', 'O'), ('.', 'O'))"
"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol , iohexol and metrizoate in doses of 4 ml , 8 ml and 16 ml .","(('In', 'O'), ('twenty', 'O'), ('beagle', 'O'), ('dogs', 'O'), ('selective', 'O'), ('injections', 'O'), ('were', 'O'), ('made', 'O'), ('into', 'O'), ('the', 'O'), ('left', 'O'), ('coronary', 'O'), ('artery', 'O'), ('with', 'O'), ('iopentol', 'O'), (',', 'O'), ('iohexol', 'O'), ('and', 'O'), ('metrizoate', 'O'), ('in', 'O'), ('doses', 'O'), ('of', 'O'), ('4', 'O'), ('ml', 'O'), (',', 'O'), ('8', 'O'), ('ml', 'O'), ('and', 'O'), ('16', 'O'), ('ml', 'O'), ('.', 'O'))"
"Thirty - six iopentol injections , 35 iohexol injections and 37 metrizoate injections were made .","(('Thirty', 'O'), ('-', 'O'), ('six', 'O'), ('iopentol', 'O'), ('injections', 'O'), (',', 'O'), ('35', 'O'), ('iohexol', 'O'), ('injections', 'O'), ('and', 'O'), ('37', 'O'), ('metrizoate', 'O'), ('injections', 'O'), ('were', 'O'), ('made', 'O'), ('.', 'O'))"
Frequencies of ventricular fibrillation were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .,"(('Frequencies', 'O'), ('of', 'O'), ('ventricular', 'B'), ('fibrillation', 'I'), ('were', 'O'), ('significantly', 'O'), ('lower', 'O'), ('(', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('after', 'O'), ('iopentol', 'O'), ('(', 'O'), ('0', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('iohexol', 'O'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), ('than', 'O'), ('after', 'O'), ('metrizoate', 'O'), ('(', 'O'), ('22', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses .,"(('Iopentol', 'O'), ('and', 'O'), ('iohexol', 'O'), ('also', 'O'), ('produced', 'O'), ('significantly', 'O'), ('less', 'O'), ('decrease', 'O'), ('in', 'O'), ('aortic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('than', 'O'), ('metrizoate', 'O'), ('at', 'O'), ('the', 'O'), ('different', 'O'), ('doses', 'O'), ('.', 'O'))"
Thyroid function and urine - concentrating ability during lithium treatment .,"(('Thyroid', 'O'), ('function', 'O'), ('and', 'O'), ('urine', 'O'), ('-', 'O'), ('concentrating', 'O'), ('ability', 'O'), ('during', 'O'), ('lithium', 'O'), ('treatment', 'O'), ('.', 'O'))"
We measured serum thyroxine and urine - concentrating ability ( Umax ) in response to desmopressin ( DDAVP ) in 85 patients receiving lithium .,"(('We', 'O'), ('measured', 'O'), ('serum', 'O'), ('thyroxine', 'O'), ('and', 'O'), ('urine', 'O'), ('-', 'O'), ('concentrating', 'O'), ('ability', 'O'), ('(', 'O'), ('Umax', 'O'), (')', 'O'), ('in', 'O'), ('response', 'O'), ('to', 'O'), ('desmopressin', 'O'), ('(', 'O'), ('DDAVP', 'O'), (')', 'O'), ('in', 'O'), ('85', 'O'), ('patients', 'O'), ('receiving', 'O'), ('lithium', 'O'), ('.', 'O'))"
It is concluded that the dominant mechanisms by which lithium exerts these two effects are different .,"(('It', 'O'), ('is', 'O'), ('concluded', 'O'), ('that', 'O'), ('the', 'O'), ('dominant', 'O'), ('mechanisms', 'O'), ('by', 'O'), ('which', 'O'), ('lithium', 'O'), ('exerts', 'O'), ('these', 'O'), ('two', 'O'), ('effects', 'O'), ('are', 'O'), ('different', 'O'), ('.', 'O'))"
Remodelling of nerve structure in experimental isoniazid neuropathy in the rat .,"(('Remodelling', 'O'), ('of', 'O'), ('nerve', 'O'), ('structure', 'O'), ('in', 'O'), ('experimental', 'O'), ('isoniazid', 'B'), ('neuropathy', 'I'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
The neuropathy caused by a single dose of isoniazid in rats was studied with a computer - assisted morphometric method .,"(('The', 'O'), ('neuropathy', 'B'), ('caused', 'O'), ('by', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('isoniazid', 'O'), ('in', 'O'), ('rats', 'O'), ('was', 'O'), ('studied', 'O'), ('with', 'O'), ('a', 'O'), ('computer', 'O'), ('-', 'O'), ('assisted', 'O'), ('morphometric', 'O'), ('method', 'O'), ('.', 'O'))"
"Scatter diagrams of the g ratio ( quotient fibre diameter / axon diameter ) define regenerating fibres as a distinct population , distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre .","(('Scatter', 'O'), ('diagrams', 'O'), ('of', 'O'), ('the', 'O'), ('g', 'O'), ('ratio', 'O'), ('(', 'O'), ('quotient', 'O'), ('fibre', 'O'), ('diameter', 'O'), ('/', 'O'), ('axon', 'O'), ('diameter', 'O'), (')', 'O'), ('define', 'O'), ('regenerating', 'O'), ('fibres', 'O'), ('as', 'O'), ('a', 'O'), ('distinct', 'O'), ('population', 'O'), (',', 'O'), ('distinguishable', 'O'), ('from', 'O'), ('the', 'O'), ('surviving', 'O'), ('fibres', 'O'), ('by', 'O'), ('reduced', 'O'), ('sheath', 'O'), ('thickness', 'O'), ('and', 'O'), ('reduced', 'O'), ('axon', 'O'), ('calibre', 'O'), ('.', 'O'))"
"There was also evidence of a subtle direct toxic effect on the entire fibre population , causing axon shrinkage masked by readjustment of the myelin sheath .","(('There', 'O'), ('was', 'O'), ('also', 'O'), ('evidence', 'O'), ('of', 'O'), ('a', 'O'), ('subtle', 'O'), ('direct', 'O'), ('toxic', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('entire', 'O'), ('fibre', 'O'), ('population', 'O'), (',', 'O'), ('causing', 'O'), ('axon', 'O'), ('shrinkage', 'O'), ('masked', 'O'), ('by', 'O'), ('readjustment', 'O'), ('of', 'O'), ('the', 'O'), ('myelin', 'O'), ('sheath', 'O'), ('.', 'O'))"
One hundred fifty - five subjects participated .,"(('One', 'O'), ('hundred', 'O'), ('fifty', 'O'), ('-', 'O'), ('five', 'O'), ('subjects', 'O'), ('participated', 'O'), ('.', 'O'))"
"Medications were given four times daily ; the azelastine groups received 0 . 5 , 1 . 0 , or 2 . 0 mg in the morning and evening with placebo in the early and late afternoon ; the chlorpheniramine group received 4 . 0 mg four times daily .","(('Medications', 'O'), ('were', 'O'), ('given', 'O'), ('four', 'O'), ('times', 'O'), ('daily', 'O'), (';', 'O'), ('the', 'O'), ('azelastine', 'O'), ('groups', 'O'), ('received', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), (',', 'O'), ('or', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('in', 'O'), ('the', 'O'), ('morning', 'O'), ('and', 'O'), ('evening', 'O'), ('with', 'O'), ('placebo', 'O'), ('in', 'O'), ('the', 'O'), ('early', 'O'), ('and', 'O'), ('late', 'O'), ('afternoon', 'O'), (';', 'O'), ('the', 'O'), ('chlorpheniramine', 'O'), ('group', 'O'), ('received', 'O'), ('4', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('four', 'O'), ('times', 'O'), ('daily', 'O'), ('.', 'O'))"
Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4 - week treatment period while subjects received study medications .,"(('Daily', 'O'), ('subject', 'O'), ('symptom', 'O'), ('cards', 'O'), ('were', 'O'), ('completed', 'O'), ('during', 'O'), ('a', 'O'), ('screening', 'O'), ('period', 'O'), ('to', 'O'), ('assess', 'O'), ('pretreatment', 'O'), ('symptoms', 'O'), ('and', 'O'), ('during', 'O'), ('a', 'O'), ('4', 'O'), ('-', 'O'), ('week', 'O'), ('treatment', 'O'), ('period', 'O'), ('while', 'O'), ('subjects', 'O'), ('received', 'O'), ('study', 'O'), ('medications', 'O'), ('.', 'O'))"
"Individual symptoms , total symptoms , and major symptoms were compared to determine efficacy of medication .","(('Individual', 'O'), ('symptoms', 'O'), (',', 'O'), ('total', 'O'), ('symptoms', 'O'), (',', 'O'), ('and', 'O'), ('major', 'O'), ('symptoms', 'O'), ('were', 'O'), ('compared', 'O'), ('to', 'O'), ('determine', 'O'), ('efficacy', 'O'), ('of', 'O'), ('medication', 'O'), ('.', 'O'))"
"Elicited , volunteered , and observed adverse experiences were recorded for each subject and compared among groups .","(('Elicited', 'O'), (',', 'O'), ('volunteered', 'O'), (',', 'O'), ('and', 'O'), ('observed', 'O'), ('adverse', 'O'), ('experiences', 'O'), ('were', 'O'), ('recorded', 'O'), ('for', 'O'), ('each', 'O'), ('subject', 'O'), ('and', 'O'), ('compared', 'O'), ('among', 'O'), ('groups', 'O'), ('.', 'O'))"
"Vital signs , body weights , serum chemistry values , complete blood cell counts , urine studies , and electrocardiograms were obtained for each subject and compared among groups .","(('Vital', 'O'), ('signs', 'O'), (',', 'O'), ('body', 'O'), ('weights', 'O'), (',', 'O'), ('serum', 'O'), ('chemistry', 'O'), ('values', 'O'), (',', 'O'), ('complete', 'O'), ('blood', 'O'), ('cell', 'O'), ('counts', 'O'), (',', 'O'), ('urine', 'O'), ('studies', 'O'), (',', 'O'), ('and', 'O'), ('electrocardiograms', 'O'), ('were', 'O'), ('obtained', 'O'), ('for', 'O'), ('each', 'O'), ('subject', 'O'), ('and', 'O'), ('compared', 'O'), ('among', 'O'), ('groups', 'O'), ('.', 'O'))"
Symptoms relief in the group receiving the highest concentration of azelastine ( 2 . 0 mg twice daily ) was statistically greater than in the placebo group during all weeks of the study .,"(('Symptoms', 'O'), ('relief', 'O'), ('in', 'O'), ('the', 'O'), ('group', 'O'), ('receiving', 'O'), ('the', 'O'), ('highest', 'O'), ('concentration', 'O'), ('of', 'O'), ('azelastine', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (')', 'O'), ('was', 'O'), ('statistically', 'O'), ('greater', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('during', 'O'), ('all', 'O'), ('weeks', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study .,"(('Lower', 'O'), ('doses', 'O'), ('of', 'O'), ('azelastine', 'O'), ('were', 'O'), ('statistically', 'O'), ('more', 'O'), ('effective', 'O'), ('than', 'O'), ('placebo', 'O'), ('only', 'O'), ('during', 'O'), ('portions', 'O'), ('of', 'O'), ('the', 'O'), ('first', 'O'), ('3', 'O'), ('weeks', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
"In contrast , although the chlorpheniramine group did have fewer symptoms than the placebo group during the study , the difference never reached statistical significance during any week of the study .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('chlorpheniramine', 'O'), ('group', 'O'), ('did', 'O'), ('have', 'O'), ('fewer', 'O'), ('symptoms', 'O'), ('than', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('during', 'O'), ('the', 'O'), ('study', 'O'), (',', 'O'), ('the', 'O'), ('difference', 'O'), ('never', 'O'), ('reached', 'O'), ('statistical', 'O'), ('significance', 'O'), ('during', 'O'), ('any', 'O'), ('week', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
There were no serious side effects in any of the treatment groups .,"(('There', 'O'), ('were', 'O'), ('no', 'O'), ('serious', 'O'), ('side', 'O'), ('effects', 'O'), ('in', 'O'), ('any', 'O'), ('of', 'O'), ('the', 'O'), ('treatment', 'O'), ('groups', 'O'), ('.', 'O'))"
Association with HLA - B35 and Cw4 antigens .,"(('Association', 'O'), ('with', 'O'), ('HLA', 'O'), ('-', 'O'), ('B35', 'O'), ('and', 'O'), ('Cw4', 'O'), ('antigens', 'O'), ('.', 'O'))"
"A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .","(('A', 'O'), ('strong', 'O'), ('association', 'O'), ('has', 'O'), ('been', 'O'), ('found', 'O'), ('between', 'O'), ('nephritis', 'B'), ('and', 'O'), ('dermatitis', 'B'), ('due', 'O'), ('to', 'O'), ('Tiopronin', 'O'), ('(', 'O'), ('a', 'O'), ('D', 'O'), ('-', 'O'), ('Penicillamine', 'O'), ('like', 'O'), ('compound', 'O'), (')', 'O'), ('and', 'O'), ('class', 'O'), ('I', 'O'), ('antigens', 'O'), ('B35', 'O'), ('-', 'O'), ('Cw4', 'O'), (',', 'O'), ('and', 'O'), ('between', 'O'), ('dermatitis', 'B'), ('due', 'O'), ('to', 'O'), ('gold', 'O'), ('thiosulphate', 'O'), ('and', 'O'), ('B35', 'O'), ('.', 'O'))"
"Three days post lesion , most rats circled predominantly contralaterally to the lesion .","(('Three', 'O'), ('days', 'O'), ('post', 'O'), ('lesion', 'O'), (',', 'O'), ('most', 'O'), ('rats', 'O'), ('circled', 'O'), ('predominantly', 'O'), ('contralaterally', 'O'), ('to', 'O'), ('the', 'O'), ('lesion', 'O'), ('.', 'O'))"
"It consists of microangiopathic hemolytic anemia , thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10 % of patients treated with this agent .","(('It', 'O'), ('consists', 'O'), ('of', 'O'), ('microangiopathic', 'B'), ('hemolytic', 'I'), ('anemia', 'I'), (',', 'O'), ('thrombocytopenia', 'B'), ('and', 'O'), ('progressive', 'O'), ('renal', 'B'), ('failure', 'I'), ('associated', 'O'), ('with', 'O'), ('mitomycin', 'O'), ('C', 'O'), ('treatment', 'O'), ('and', 'O'), ('affects', 'O'), ('about', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('this', 'O'), ('agent', 'O'), ('.', 'O'))"
The mechanism of action is postulated as mitomycin C - induced endothelial cell damage .,"(('The', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('is', 'O'), ('postulated', 'O'), ('as', 'O'), ('mitomycin', 'O'), ('C', 'O'), ('-', 'O'), ('induced', 'O'), ('endothelial', 'O'), ('cell', 'O'), ('damage', 'O'), ('.', 'O'))"
Intraperitoneal ketanserin administration at doses of 0 . 63 and 2 . 5 mg / kg prevented the alfentanil - induced increase in electromyographic activity compared with animals pretreated with saline .,"(('Intraperitoneal', 'O'), ('ketanserin', 'O'), ('administration', 'O'), ('at', 'O'), ('doses', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('63', 'O'), ('and', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('prevented', 'O'), ('the', 'O'), ('alfentanil', 'O'), ('-', 'O'), ('induced', 'O'), ('increase', 'O'), ('in', 'O'), ('electromyographic', 'O'), ('activity', 'O'), ('compared', 'O'), ('with', 'O'), ('animals', 'O'), ('pretreated', 'O'), ('with', 'O'), ('saline', 'O'), ('.', 'O'))"
Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60 - min recording period than did animals that received ketanserin alone .,"(('Rats', 'O'), ('that', 'O'), ('received', 'O'), ('ketanserin', 'O'), ('and', 'O'), ('alfentanil', 'O'), ('exhibited', 'O'), ('less', 'O'), ('rearing', 'O'), ('and', 'O'), ('exploratory', 'O'), ('behavior', 'O'), ('at', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('60', 'O'), ('-', 'O'), ('min', 'O'), ('recording', 'O'), ('period', 'O'), ('than', 'O'), ('did', 'O'), ('animals', 'O'), ('that', 'O'), ('received', 'O'), ('ketanserin', 'O'), ('alone', 'O'), ('.', 'O'))"
Antagonism of diazepam - induced sedative effects by Ro15 - 1788 in patients after surgery under lumbar epidural block .,"(('Antagonism', 'O'), ('of', 'O'), ('diazepam', 'O'), ('-', 'O'), ('induced', 'O'), ('sedative', 'O'), ('effects', 'O'), ('by', 'O'), ('Ro15', 'O'), ('-', 'O'), ('1788', 'O'), ('in', 'O'), ('patients', 'O'), ('after', 'O'), ('surgery', 'O'), ('under', 'O'), ('lumbar', 'O'), ('epidural', 'I'), ('block', 'O'), ('.', 'O'))"
A double - blind placebo - controlled investigation of efficacy and safety .,"(('A', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('investigation', 'O'), ('of', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('.', 'O'))"
"The aim of this study was to assess the efficacy of Ro15 - 1788 and a placebo in reversing diazepam - induced effects after surgery under epidural block , and to evaluate the local tolerance and general safety of Ro15 - 1788 .","(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('efficacy', 'O'), ('of', 'O'), ('Ro15', 'O'), ('-', 'O'), ('1788', 'O'), ('and', 'O'), ('a', 'O'), ('placebo', 'O'), ('in', 'O'), ('reversing', 'O'), ('diazepam', 'O'), ('-', 'O'), ('induced', 'O'), ('effects', 'O'), ('after', 'O'), ('surgery', 'O'), ('under', 'O'), ('epidural', 'O'), ('block', 'O'), (',', 'O'), ('and', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('local', 'O'), ('tolerance', 'O'), ('and', 'O'), ('general', 'O'), ('safety', 'O'), ('of', 'O'), ('Ro15', 'O'), ('-', 'O'), ('1788', 'O'), ('.', 'O'))"
Fifty - seven patients were sedated with diazepam for surgery under epidural anaesthesia .,"(('Fifty', 'O'), ('-', 'O'), ('seven', 'O'), ('patients', 'O'), ('were', 'O'), ('sedated', 'O'), ('with', 'O'), ('diazepam', 'O'), ('for', 'O'), ('surgery', 'O'), ('under', 'O'), ('epidural', 'O'), ('anaesthesia', 'O'), ('.', 'O'))"
Antagonism of diazepam - induced effects by Ro15 - 1788 was investigated postoperatively in a double - blind placebo - controlled trial .,"(('Antagonism', 'O'), ('of', 'O'), ('diazepam', 'O'), ('-', 'O'), ('induced', 'O'), ('effects', 'O'), ('by', 'O'), ('Ro15', 'O'), ('-', 'O'), ('1788', 'O'), ('was', 'O'), ('investigated', 'O'), ('postoperatively', 'O'), ('in', 'O'), ('a', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('trial', 'O'), ('.', 'O'))"
The Ro15 - 1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug .,"(('The', 'O'), ('Ro15', 'O'), ('-', 'O'), ('1788', 'O'), ('group', 'O'), ('showed', 'O'), ('a', 'O'), ('significant', 'O'), ('improvement', 'O'), ('in', 'O'), ('the', 'O'), ('performance', 'O'), ('test', 'O'), ('up', 'O'), ('to', 'O'), ('120', 'O'), ('min', 'O'), ('after', 'O'), ('administration', 'O'), ('of', 'O'), ('the', 'O'), ('drug', 'O'), ('.', 'O'))"
There was no evidence of reaction at the injection site .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('evidence', 'O'), ('of', 'O'), ('reaction', 'O'), ('at', 'O'), ('the', 'O'), ('injection', 'O'), ('site', 'O'), ('.', 'O'))"
"Male F344 rats , 5 weeks of age , were maintained on diet containing 1 % or 2 % BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations ( w / v ) for 52 weeks .","(('Male', 'O'), ('F344', 'O'), ('rats', 'O'), (',', 'O'), ('5', 'O'), ('weeks', 'O'), ('of', 'O'), ('age', 'O'), (',', 'O'), ('were', 'O'), ('maintained', 'O'), ('on', 'O'), ('diet', 'O'), ('containing', 'O'), ('1', 'O'), ('%', 'O'), ('or', 'O'), ('2', 'O'), ('%', 'O'), ('BHA', 'O'), ('by', 'O'), ('weight', 'O'), ('and', 'O'), ('simultaneously', 'O'), ('on', 'O'), ('drinking', 'O'), ('water', 'O'), ('supplemented', 'O'), ('with', 'O'), ('RA', 'O'), ('at', 'O'), ('various', 'O'), ('concentrations', 'O'), ('(', 'O'), ('w', 'O'), ('/', 'O'), ('v', 'O'), (')', 'O'), ('for', 'O'), ('52', 'O'), ('weeks', 'O'), ('.', 'O'))"
RA alone did not induce hyperplastic changes in the forestomach .,"(('RA', 'O'), ('alone', 'O'), ('did', 'O'), ('not', 'O'), ('induce', 'O'), ('hyperplastic', 'O'), ('changes', 'O'), ('in', 'O'), ('the', 'O'), ('forestomach', 'O'), ('.', 'O'))"
Data on dose dependency or incidence concerning this side effect were not known .,"(('Data', 'O'), ('on', 'O'), ('dose', 'O'), ('dependency', 'O'), ('or', 'O'), ('incidence', 'O'), ('concerning', 'O'), ('this', 'O'), ('side', 'O'), ('effect', 'O'), ('were', 'O'), ('not', 'O'), ('known', 'O'), ('.', 'O'))"
We have initiated a prospective study to obtain some more data on these subjects .,"(('We', 'O'), ('have', 'O'), ('initiated', 'O'), ('a', 'O'), ('prospective', 'O'), ('study', 'O'), ('to', 'O'), ('obtain', 'O'), ('some', 'O'), ('more', 'O'), ('data', 'O'), ('on', 'O'), ('these', 'O'), ('subjects', 'O'), ('.', 'O'))"
"Forty - four MMC - treated patients were studied , 37 of them could be evaluated .","(('Forty', 'O'), ('-', 'O'), ('four', 'O'), ('MMC', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), ('were', 'O'), ('studied', 'O'), (',', 'O'), ('37', 'O'), ('of', 'O'), ('them', 'O'), ('could', 'O'), ('be', 'O'), ('evaluated', 'O'), ('.', 'O'))"
"All patients were studied by repeated physical examinations , chest X - rays , electro - and echocardiography and radionuclide left ventricular ejection fraction ( EF ) determinations .","(('All', 'O'), ('patients', 'O'), ('were', 'O'), ('studied', 'O'), ('by', 'O'), ('repeated', 'O'), ('physical', 'O'), ('examinations', 'O'), (',', 'O'), ('chest', 'O'), ('X', 'O'), ('-', 'O'), ('rays', 'O'), (',', 'O'), ('electro', 'O'), ('-', 'O'), ('and', 'O'), ('echocardiography', 'O'), ('and', 'O'), ('radionuclide', 'O'), ('left', 'O'), ('ventricular', 'O'), ('ejection', 'O'), ('fraction', 'O'), ('(', 'O'), ('EF', 'O'), (')', 'O'), ('determinations', 'O'), ('.', 'O'))"
The results were evaluated per cumulative dose level .,"(('The', 'O'), ('results', 'O'), ('were', 'O'), ('evaluated', 'O'), ('per', 'O'), ('cumulative', 'O'), ('dose', 'O'), ('level', 'O'), ('.', 'O'))"
One of the patients developed cardiac failure after 30 mg m - 2 MMC and only 150 mg m - 2 doxorubicin .,"(('One', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('developed', 'O'), ('cardiac', 'B'), ('failure', 'I'), ('after', 'O'), ('30', 'O'), ('mg', 'O'), ('m', 'O'), ('-', 'O'), ('2', 'O'), ('MMC', 'O'), ('and', 'O'), ('only', 'O'), ('150', 'O'), ('mg', 'O'), ('m', 'O'), ('-', 'O'), ('2', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
The cardiac failure was predicted by a drop in EF determined during a cold pressor test .,"(('The', 'O'), ('cardiac', 'B'), ('failure', 'I'), ('was', 'O'), ('predicted', 'O'), ('by', 'O'), ('a', 'O'), ('drop', 'O'), ('in', 'O'), ('EF', 'O'), ('determined', 'O'), ('during', 'O'), ('a', 'O'), ('cold', 'O'), ('pressor', 'O'), ('test', 'O'), ('.', 'O'))"
The literature on this subject was also reviewed .,"(('The', 'O'), ('literature', 'O'), ('on', 'O'), ('this', 'O'), ('subject', 'O'), ('was', 'O'), ('also', 'O'), ('reviewed', 'O'), ('.', 'O'))"
The incidence is likely to be less than 10 % even for this risk group .,"(('The', 'O'), ('incidence', 'O'), ('is', 'O'), ('likely', 'O'), ('to', 'O'), ('be', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('even', 'O'), ('for', 'O'), ('this', 'O'), ('risk', 'O'), ('group', 'O'), ('.', 'O'))"
Reversible cerebral lesions associated with tiazofurin usage : MR demonstration .,"(('Reversible', 'O'), ('cerebral', 'B'), ('lesions', 'I'), ('associated', 'O'), ('with', 'O'), ('tiazofurin', 'O'), ('usage', 'O'), (':', 'O'), ('MR', 'O'), ('demonstration', 'O'), ('.', 'O'))"
Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation .,"(('Tiazofurin', 'O'), ('is', 'O'), ('an', 'O'), ('experimental', 'O'), ('chemotherapeutic', 'O'), ('agent', 'O'), ('currently', 'O'), ('undergoing', 'O'), ('clinical', 'O'), ('evaluation', 'O'), ('.', 'O'))"
We report our results with magnetic resonance ( MR ) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug .,"(('We', 'O'), ('report', 'O'), ('our', 'O'), ('results', 'O'), ('with', 'O'), ('magnetic', 'O'), ('resonance', 'O'), ('(', 'O'), ('MR', 'O'), (')', 'O'), ('in', 'O'), ('demonstrating', 'O'), ('reversible', 'O'), ('cerebral', 'B'), ('abnormalities', 'I'), ('concurrent', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('this', 'O'), ('drug', 'O'), ('.', 'O'))"
The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography .,"(('The', 'O'), ('abnormalities', 'O'), ('on', 'O'), ('MR', 'O'), ('were', 'O'), ('correlated', 'O'), ('with', 'O'), ('findings', 'O'), ('on', 'O'), ('CT', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('with', 'O'), ('cerebral', 'O'), ('angiography', 'O'), ('.', 'O'))"
The utility of MR in the evaluation of patients receiving this new agent is illustrated .,"(('The', 'O'), ('utility', 'O'), ('of', 'O'), ('MR', 'O'), ('in', 'O'), ('the', 'O'), ('evaluation', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('this', 'O'), ('new', 'O'), ('agent', 'O'), ('is', 'O'), ('illustrated', 'O'), ('.', 'O'))"
"Rats were pretreated with saline or nicotine ( 1 . 5 mg / kg per day ) by subcutaneously implanting each animal with an Alzet osmotic mini - pump which continuously released saline or nicotine for 1 , 5 and 14 days .","(('Rats', 'O'), ('were', 'O'), ('pretreated', 'O'), ('with', 'O'), ('saline', 'O'), ('or', 'O'), ('nicotine', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('per', 'O'), ('day', 'O'), (')', 'O'), ('by', 'O'), ('subcutaneously', 'O'), ('implanting', 'O'), ('each', 'O'), ('animal', 'O'), ('with', 'O'), ('an', 'O'), ('Alzet', 'O'), ('osmotic', 'O'), ('mini', 'O'), ('-', 'O'), ('pump', 'O'), ('which', 'O'), ('continuously', 'O'), ('released', 'O'), ('saline', 'O'), ('or', 'O'), ('nicotine', 'O'), ('for', 'O'), ('1', 'O'), (',', 'O'), ('5', 'O'), ('and', 'O'), ('14', 'O'), ('days', 'O'), ('.', 'O'))"
"At the end of each pretreatment period , animals were used for ( i ) determining their locomotor response to acutely injected nicotine ( 0 . 2 mg / kg , s . c . ) and ( ii ) measuring the density of L - [ 3H ] nicotine and [ 3H ] spiperone binding sites in the striatum .","(('At', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('each', 'O'), ('pretreatment', 'O'), ('period', 'O'), (',', 'O'), ('animals', 'O'), ('were', 'O'), ('used', 'O'), ('for', 'O'), ('(', 'O'), ('i', 'O'), (')', 'O'), ('determining', 'O'), ('their', 'O'), ('locomotor', 'O'), ('response', 'O'), ('to', 'O'), ('acutely', 'O'), ('injected', 'O'), ('nicotine', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), ('and', 'O'), ('(', 'O'), ('ii', 'O'), (')', 'O'), ('measuring', 'O'), ('the', 'O'), ('density', 'O'), ('of', 'O'), ('L', 'O'), ('-', 'O'), ('[', 'O'), ('3H', 'O'), (']', 'O'), ('nicotine', 'O'), ('and', 'O'), ('[', 'O'), ('3H', 'O'), (']', 'O'), ('spiperone', 'O'), ('binding', 'O'), ('sites', 'O'), ('in', 'O'), ('the', 'O'), ('striatum', 'O'), ('.', 'O'))"
"We observed no changes in nicotine - induced locomotor response , striatal L - [ 3H ] nicotine and [ 3H ] spiperone binding in the animals pretreated with nicotine for 1 day .","(('We', 'O'), ('observed', 'O'), ('no', 'O'), ('changes', 'O'), ('in', 'O'), ('nicotine', 'O'), ('-', 'O'), ('induced', 'O'), ('locomotor', 'O'), ('response', 'O'), (',', 'O'), ('striatal', 'O'), ('L', 'O'), ('-', 'O'), ('[', 'O'), ('3H', 'O'), (']', 'O'), ('nicotine', 'O'), ('and', 'O'), ('[', 'O'), ('3H', 'O'), (']', 'O'), ('spiperone', 'O'), ('binding', 'O'), ('in', 'O'), ('the', 'O'), ('animals', 'O'), ('pretreated', 'O'), ('with', 'O'), ('nicotine', 'O'), ('for', 'O'), ('1', 'O'), ('day', 'O'), ('.', 'O'))"
"In rats which were pretreated with nicotine for 5 days , there was a significant increase in the nicotine - stimulated locomotor response which was associated with an increase in the number of L - [ 3H ] nicotine binding sites and also with an elevated dopamine ( DA ) level in the striatum .","(('In', 'O'), ('rats', 'O'), ('which', 'O'), ('were', 'O'), ('pretreated', 'O'), ('with', 'O'), ('nicotine', 'O'), ('for', 'O'), ('5', 'O'), ('days', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('significant', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('nicotine', 'O'), ('-', 'O'), ('stimulated', 'O'), ('locomotor', 'O'), ('response', 'O'), ('which', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('L', 'O'), ('-', 'O'), ('[', 'O'), ('3H', 'O'), (']', 'O'), ('nicotine', 'O'), ('binding', 'O'), ('sites', 'O'), ('and', 'O'), ('also', 'O'), ('with', 'O'), ('an', 'O'), ('elevated', 'O'), ('dopamine', 'O'), ('(', 'O'), ('DA', 'O'), (')', 'O'), ('level', 'O'), ('in', 'O'), ('the', 'O'), ('striatum', 'O'), ('.', 'O'))"
The number of striatal [ 3H ] spiperone binding sites was not affected .,"(('The', 'O'), ('number', 'O'), ('of', 'O'), ('striatal', 'O'), ('[', 'O'), ('3H', 'O'), (']', 'O'), ('spiperone', 'O'), ('binding', 'O'), ('sites', 'O'), ('was', 'O'), ('not', 'O'), ('affected', 'O'), ('.', 'O'))"
"In animals pretreated with nicotine for 14 days , the nicotine - induced locomotor response remained to be potentiated .","(('In', 'O'), ('animals', 'O'), ('pretreated', 'O'), ('with', 'O'), ('nicotine', 'O'), ('for', 'O'), ('14', 'O'), ('days', 'O'), (',', 'O'), ('the', 'O'), ('nicotine', 'O'), ('-', 'O'), ('induced', 'O'), ('locomotor', 'O'), ('response', 'O'), ('remained', 'O'), ('to', 'O'), ('be', 'O'), ('potentiated', 'O'), ('.', 'O'))"
"However , this response was correlated with an elevated number of striatal [ 3H ] spiperone binding sites , whereas the number of striatal L - [ 3H ] nicotine binding sites and the striatal DA level were normal .","(('However', 'O'), (',', 'O'), ('this', 'O'), ('response', 'O'), ('was', 'O'), ('correlated', 'O'), ('with', 'O'), ('an', 'O'), ('elevated', 'O'), ('number', 'O'), ('of', 'O'), ('striatal', 'O'), ('[', 'O'), ('3H', 'O'), (']', 'O'), ('spiperone', 'O'), ('binding', 'O'), ('sites', 'O'), (',', 'O'), ('whereas', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('striatal', 'O'), ('L', 'O'), ('-', 'O'), ('[', 'O'), ('3H', 'O'), (']', 'O'), ('nicotine', 'O'), ('binding', 'O'), ('sites', 'O'), ('and', 'O'), ('the', 'O'), ('striatal', 'O'), ('DA', 'O'), ('level', 'O'), ('were', 'O'), ('normal', 'O'), ('.', 'O'))"
Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium / potassium ratio .,"(('Timolol', 'O'), ('also', 'O'), ('reduced', 'O'), ('the', 'O'), ('rise', 'O'), ('in', 'O'), ('plasma', 'O'), ('aldosterone', 'O'), ('and', 'O'), ('urine', 'O'), ('potassium', 'O'), ('excretion', 'O'), ('following', 'O'), ('bendrofluazide', 'O'), ('and', 'O'), ('increased', 'O'), ('the', 'O'), ('urine', 'O'), ('sodium', 'O'), ('/', 'O'), ('potassium', 'O'), ('ratio', 'O'), ('.', 'O'))"
There was no evidence of a shift of potassium from the intracellular to the extracellular space .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('evidence', 'O'), ('of', 'O'), ('a', 'O'), ('shift', 'O'), ('of', 'O'), ('potassium', 'O'), ('from', 'O'), ('the', 'O'), ('intracellular', 'O'), ('to', 'O'), ('the', 'O'), ('extracellular', 'O'), ('space', 'O'), ('.', 'O'))"
A brief review of the literature on similar cases is presented .,"(('A', 'O'), ('brief', 'O'), ('review', 'O'), ('of', 'O'), ('the', 'O'), ('literature', 'O'), ('on', 'O'), ('similar', 'O'), ('cases', 'O'), ('is', 'O'), ('presented', 'O'), ('.', 'O'))"
Cardiac transplantation : improved quality of survival with a modified immunosuppressive protocol .,"(('Cardiac', 'O'), ('transplantation', 'O'), (':', 'O'), ('improved', 'O'), ('quality', 'O'), ('of', 'O'), ('survival', 'O'), ('with', 'O'), ('a', 'O'), ('modified', 'O'), ('immunosuppressive', 'O'), ('protocol', 'O'), ('.', 'O'))"
The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients .,"(('The', 'O'), ('effects', 'O'), ('on', 'O'), ('renal', 'O'), ('function', 'O'), ('on', 'O'), ('two', 'O'), ('different', 'O'), ('immunosuppressive', 'O'), ('protocols', 'O'), ('were', 'O'), ('evaluated', 'O'), ('retrospectively', 'O'), ('in', 'O'), ('two', 'O'), ('subsequent', 'O'), ('groups', 'O'), ('of', 'O'), ('heart', 'O'), ('transplant', 'O'), ('recipients', 'O'), ('.', 'O'))"
"In group I , cyclosporine was given before the procedure at a loading dose of 17 . 5 mg / kg and then continued after the procedure to keep a whole blood level about 1000 ng / ml .","(('In', 'O'), ('group', 'O'), ('I', 'O'), (',', 'O'), ('cyclosporine', 'O'), ('was', 'O'), ('given', 'O'), ('before', 'O'), ('the', 'O'), ('procedure', 'O'), ('at', 'O'), ('a', 'O'), ('loading', 'O'), ('dose', 'O'), ('of', 'O'), ('17', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('and', 'O'), ('then', 'O'), ('continued', 'O'), ('after', 'O'), ('the', 'O'), ('procedure', 'O'), ('to', 'O'), ('keep', 'O'), ('a', 'O'), ('whole', 'O'), ('blood', 'O'), ('level', 'O'), ('about', 'O'), ('1000', 'O'), ('ng', 'O'), ('/', 'O'), ('ml', 'O'), ('.', 'O'))"
"In group II , cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine , which was used for the first postoperative week .","(('In', 'O'), ('group', 'O'), ('II', 'O'), (',', 'O'), ('cyclosporine', 'O'), ('was', 'O'), ('started', 'O'), ('only', 'O'), ('after', 'O'), ('the', 'O'), ('procedure', 'O'), ('at', 'O'), ('a', 'O'), ('lower', 'O'), ('dosage', 'O'), ('and', 'O'), ('was', 'O'), ('complemented', 'O'), ('by', 'O'), ('azathioprine', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('used', 'O'), ('for', 'O'), ('the', 'O'), ('first', 'O'), ('postoperative', 'O'), ('week', 'O'), ('.', 'O'))"
Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels .,"(('Group', 'O'), ('II', 'O'), ('showed', 'O'), ('a', 'O'), ('better', 'O'), ('perioperative', 'O'), ('renal', 'O'), ('function', 'O'), ('as', 'O'), ('determined', 'O'), ('by', 'O'), ('serum', 'O'), ('blood', 'O'), ('urea', 'O'), ('nitrogen', 'O'), ('and', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('levels', 'O'), ('.', 'O'))"
"Despite this improvement in late renal function , group II still shows a slow rise in serum creatinine .","(('Despite', 'O'), ('this', 'O'), ('improvement', 'O'), ('in', 'O'), ('late', 'O'), ('renal', 'O'), ('function', 'O'), (',', 'O'), ('group', 'O'), ('II', 'O'), ('still', 'O'), ('shows', 'O'), ('a', 'O'), ('slow', 'O'), ('rise', 'O'), ('in', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('.', 'O'))"
Ethopropazine and benztropine in neuroleptic - induced parkinsonism .,"(('Ethopropazine', 'O'), ('and', 'O'), ('benztropine', 'O'), ('in', 'O'), ('neuroleptic', 'B'), ('-', 'O'), ('induced', 'O'), ('parkinsonism', 'B'), ('.', 'O'))"
Quinidine phenylethylbarbiturate - induced fulminant hepatitis in a pregnant woman .,"(('Quinidine', 'O'), ('phenylethylbarbiturate', 'O'), ('-', 'O'), ('induced', 'O'), ('fulminant', 'B'), ('hepatitis', 'I'), ('in', 'O'), ('a', 'O'), ('pregnant', 'O'), ('woman', 'O'), ('.', 'O'))"
A case report .,"(('A', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
We report the case of a 19 - year - old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1 - month administration of quinidine phenylethylbarbiturate .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('19', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('Laotian', 'O'), ('patient', 'O'), ('affected', 'O'), ('by', 'O'), ('fulminant', 'B'), ('hepatitis', 'I'), ('during', 'O'), ('the', 'O'), ('third', 'O'), ('trimester', 'O'), ('of', 'O'), ('her', 'O'), ('pregnancy', 'O'), ('after', 'O'), ('a', 'O'), ('1', 'O'), ('-', 'O'), ('month', 'O'), ('administration', 'O'), ('of', 'O'), ('quinidine', 'O'), ('phenylethylbarbiturate', 'O'), ('.', 'O'))"
"After delivery , the patient underwent orthotopic liver transplantation .","(('After', 'O'), ('delivery', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('underwent', 'O'), ('orthotopic', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('.', 'O'))"
The patient was in good condition 16 months after liver transplantation .,"(('The', 'O'), ('patient', 'O'), ('was', 'O'), ('in', 'O'), ('good', 'O'), ('condition', 'O'), ('16', 'O'), ('months', 'O'), ('after', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('.', 'O'))"
Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient .,"(('Quinidine', 'O'), ('itself', 'O'), ('or', 'O'), ('phenylethylbarbiturate', 'O'), ('may', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('fulminant', 'B'), ('hepatitis', 'I'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('.', 'O'))"
"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10 - propargyl - 5 , 8 - dideazafolic acid ( CB 3717 ) .","(('Recent', 'O'), ('preclinical', 'O'), ('and', 'O'), ('clinical', 'O'), ('studies', 'O'), ('with', 'O'), ('the', 'O'), ('thymidylate', 'O'), ('synthase', 'O'), ('inhibitor', 'O'), ('N10', 'O'), ('-', 'O'), ('propargyl', 'O'), ('-', 'O'), ('5', 'O'), (',', 'O'), ('8', 'O'), ('-', 'O'), ('dideazafolic', 'O'), ('acid', 'O'), ('(', 'O'), ('CB', 'O'), ('3717', 'O'), (')', 'O'), ('.', 'O'))"
Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates .,"(('Recent', 'O'), ('preclinical', 'O'), ('studies', 'O'), ('have', 'O'), ('focused', 'O'), ('on', 'O'), ('the', 'O'), ('intracellular', 'O'), ('formation', 'O'), ('of', 'O'), ('CB', 'O'), ('3717', 'O'), ('polyglutamates', 'O'), ('.', 'O'))"
"Following a 12 - hour exposure of L1210 cells to 50 microM [ 3H ] CB 3717 , 30 % of the extractable radioactivity could be accounted for as CB 3717 tetra - and pentaglutamate , as determined by high - pressure liquid chromatography ( HPLC ) analyses .","(('Following', 'O'), ('a', 'O'), ('12', 'O'), ('-', 'O'), ('hour', 'O'), ('exposure', 'O'), ('of', 'O'), ('L1210', 'O'), ('cells', 'O'), ('to', 'O'), ('50', 'O'), ('microM', 'O'), ('[', 'O'), ('3H', 'O'), (']', 'O'), ('CB', 'O'), ('3717', 'O'), (',', 'O'), ('30', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('extractable', 'O'), ('radioactivity', 'O'), ('could', 'O'), ('be', 'O'), ('accounted', 'O'), ('for', 'O'), ('as', 'O'), ('CB', 'O'), ('3717', 'O'), ('tetra', 'O'), ('-', 'O'), ('and', 'O'), ('pentaglutamate', 'O'), (',', 'O'), ('as', 'O'), ('determined', 'O'), ('by', 'O'), ('high', 'O'), ('-', 'O'), ('pressure', 'O'), ('liquid', 'O'), ('chromatography', 'O'), ('(', 'O'), ('HPLC', 'O'), (')', 'O'), ('analyses', 'O'), ('.', 'O'))"
"In early clinical studies with CB 3717 , activity has been seen in breast cancer , ovarian cancer , hepatoma , and mesothelioma .","(('In', 'O'), ('early', 'O'), ('clinical', 'O'), ('studies', 'O'), ('with', 'O'), ('CB', 'O'), ('3717', 'O'), (',', 'O'), ('activity', 'O'), ('has', 'O'), ('been', 'O'), ('seen', 'O'), ('in', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('ovarian', 'B'), ('cancer', 'I'), (',', 'O'), ('hepatoma', 'B'), (',', 'O'), ('and', 'O'), ('mesothelioma', 'B'), ('.', 'O'))"
This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions .,"(('This', 'O'), ('latter', 'O'), ('effect', 'O'), ('is', 'O'), ('thought', 'O'), ('to', 'O'), ('be', 'O'), ('due', 'O'), ('to', 'O'), ('drug', 'O'), ('precipitation', 'O'), ('within', 'O'), ('the', 'O'), ('renal', 'O'), ('tubule', 'O'), ('as', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('the', 'O'), ('poor', 'O'), ('solubility', 'O'), ('of', 'O'), ('CB', 'O'), ('3717', 'O'), ('under', 'O'), ('acidic', 'O'), ('conditions', 'O'), ('.', 'O'))"
"In an attempt to overcome this problem , a clinical trial of CB 3717 administered with alkaline diuresis is under way .","(('In', 'O'), ('an', 'O'), ('attempt', 'O'), ('to', 'O'), ('overcome', 'O'), ('this', 'O'), ('problem', 'O'), (',', 'O'), ('a', 'O'), ('clinical', 'O'), ('trial', 'O'), ('of', 'O'), ('CB', 'O'), ('3717', 'O'), ('administered', 'O'), ('with', 'O'), ('alkaline', 'O'), ('diuresis', 'O'), ('is', 'O'), ('under', 'O'), ('way', 'O'), ('.', 'O'))"
Evidence of antitumor activity has been seen in 3 patients .,"(('Evidence', 'O'), ('of', 'O'), ('antitumor', 'O'), ('activity', 'O'), ('has', 'O'), ('been', 'O'), ('seen', 'O'), ('in', 'O'), ('3', 'O'), ('patients', 'O'), ('.', 'O'))"
Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved .,"(('Pharmacokinetic', 'O'), ('investigations', 'O'), ('have', 'O'), ('shown', 'O'), ('that', 'O'), ('alkaline', 'O'), ('diuresis', 'O'), ('does', 'O'), ('not', 'O'), ('alter', 'O'), ('CB', 'O'), ('3717', 'O'), ('plasma', 'O'), ('levels', 'O'), ('or', 'O'), ('urinary', 'O'), ('excretion', 'O'), ('and', 'O'), ('that', 'O'), ('satisfactory', 'O'), ('urinary', 'O'), ('alkalinization', 'O'), ('can', 'O'), ('be', 'O'), ('readily', 'O'), ('achieved', 'O'), ('.', 'O'))"
Type B hepatitis after needle - stick exposure : prevention with hepatitis B immune globulin .,"(('Type', 'B'), ('B', 'I'), ('hepatitis', 'I'), ('after', 'O'), ('needle', 'O'), ('-', 'O'), ('stick', 'O'), ('exposure', 'O'), (':', 'O'), ('prevention', 'O'), ('with', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('immune', 'O'), ('globulin', 'O'), ('.', 'O'))"
Final report of the Veterans Administration Cooperative Study .,"(('Final', 'O'), ('report', 'O'), ('of', 'O'), ('the', 'O'), ('Veterans', 'O'), ('Administration', 'O'), ('Cooperative', 'O'), ('Study', 'O'), ('.', 'O'))"
"Clinical hepatitis developed in 1 . 4 % of HBIG and in 5 . 9 % of ISG recipients ( P = 0 . 016 ) , and seroconversion ( anti - HBs ) occurred in 5 . 6 % and 20 . 7 % of them respectively ( P less than 0 . 001 ) .","(('Clinical', 'B'), ('hepatitis', 'I'), ('developed', 'O'), ('in', 'O'), ('1', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('of', 'O'), ('HBIG', 'O'), ('and', 'O'), ('in', 'O'), ('5', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), ('of', 'O'), ('ISG', 'B'), ('recipients', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('016', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('seroconversion', 'O'), ('(', 'O'), ('anti', 'O'), ('-', 'O'), ('HBs', 'O'), (')', 'O'), ('occurred', 'O'), ('in', 'O'), ('5', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('and', 'O'), ('20', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), ('of', 'O'), ('them', 'O'), ('respectively', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
Mild and transient side - effects were noted in 3 . 0 % of ISG and in 3 . 2 % of HBIG recipients .,"(('Mild', 'O'), ('and', 'O'), ('transient', 'O'), ('side', 'O'), ('-', 'O'), ('effects', 'O'), ('were', 'O'), ('noted', 'O'), ('in', 'O'), ('3', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('of', 'O'), ('ISG', 'B'), ('and', 'O'), ('in', 'O'), ('3', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('of', 'O'), ('HBIG', 'O'), ('recipients', 'O'), ('.', 'O'))"
Available donor sera were examined for DNA polymerase ( DNAP ) and e antigen and antibody ( HBeAg ; anti - HBE ) .,"(('Available', 'O'), ('donor', 'O'), ('sera', 'O'), ('were', 'O'), ('examined', 'O'), ('for', 'O'), ('DNA', 'O'), ('polymerase', 'O'), ('(', 'O'), ('DNAP', 'O'), (')', 'O'), ('and', 'O'), ('e', 'O'), ('antigen', 'O'), ('and', 'O'), ('antibody', 'O'), ('(', 'O'), ('HBeAg', 'O'), (';', 'O'), ('anti', 'O'), ('-', 'O'), ('HBE', 'O'), (')', 'O'), ('.', 'O'))"
Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg - positive donors .,"(('Both', 'O'), ('DNAP', 'O'), ('and', 'O'), ('HBeAg', 'O'), ('showed', 'O'), ('a', 'O'), ('highly', 'O'), ('statistically', 'O'), ('significant', 'O'), ('correlation', 'O'), ('with', 'O'), ('the', 'O'), ('infectivity', 'O'), ('of', 'O'), ('HBsAg', 'O'), ('-', 'O'), ('positive', 'O'), ('donors', 'O'), ('.', 'O'))"
The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included .,"(('The', 'O'), ('efficacy', 'O'), ('of', 'O'), ('ISG', 'O'), ('in', 'O'), ('preventing', 'O'), ('type', 'B'), ('B', 'I'), ('hepatitis', 'I'), ('cannot', 'O'), ('be', 'O'), ('ascertained', 'O'), ('because', 'O'), ('a', 'O'), ('true', 'O'), ('placebo', 'O'), ('group', 'O'), ('was', 'O'), ('not', 'O'), ('included', 'O'), ('.', 'O'))"
Production of autochthonous prostate cancer in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and testosterone .,"(('Production', 'O'), ('of', 'O'), ('autochthonous', 'B'), ('prostate', 'I'), ('cancer', 'I'), ('in', 'O'), ('Lobund', 'O'), ('-', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('by', 'O'), ('treatments', 'O'), ('with', 'O'), ('N', 'O'), ('-', 'O'), ('nitroso', 'O'), ('-', 'O'), ('N', 'O'), ('-', 'O'), ('methylurea', 'O'), ('and', 'O'), ('testosterone', 'O'), ('.', 'O'))"
The incubation periods averaged 10 . 6 months .,"(('The', 'O'), ('incubation', 'O'), ('periods', 'O'), ('averaged', 'O'), ('10', 'O'), ('.', 'O'), ('6', 'O'), ('months', 'O'), ('.', 'O'))"
"In L - W rats , TP acted as a tumor enhancement agent , with primary emphasis on the development of prostate cancer .","(('In', 'O'), ('L', 'O'), ('-', 'O'), ('W', 'O'), ('rats', 'O'), (',', 'O'), ('TP', 'O'), ('acted', 'O'), ('as', 'O'), ('a', 'O'), ('tumor', 'B'), ('enhancement', 'O'), ('agent', 'O'), (',', 'O'), ('with', 'O'), ('primary', 'O'), ('emphasis', 'O'), ('on', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('.', 'O'))"
Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients .,"(('Relative', 'O'), ('efficacy', 'O'), ('and', 'O'), ('toxicity', 'O'), ('of', 'O'), ('netilmicin', 'O'), ('and', 'O'), ('tobramycin', 'O'), ('in', 'O'), ('oncology', 'B'), ('patients', 'O'), ('.', 'O'))"
We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections .,"(('We', 'O'), ('prospectively', 'O'), ('compared', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('of', 'O'), ('netilmicin', 'O'), ('sulfate', 'O'), ('or', 'O'), ('tobramycin', 'O'), ('sulfate', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('piperacillin', 'O'), ('sodium', 'O'), ('in', 'O'), ('118', 'O'), ('immunocompromised', 'B'), ('patients', 'O'), ('with', 'O'), ('presumed', 'O'), ('severe', 'O'), ('infections', 'O'), ('.', 'O'))"
The two treatment regimens were equally efficacious .,"(('The', 'O'), ('two', 'O'), ('treatment', 'O'), ('regimens', 'O'), ('were', 'O'), ('equally', 'O'), ('efficacious', 'O'), ('.', 'O'))"
"Of those evaluated with posttherapy audiograms , three of four netilmicin and piperacillin - treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin - treated patients .","(('Of', 'O'), ('those', 'O'), ('evaluated', 'O'), ('with', 'O'), ('posttherapy', 'O'), ('audiograms', 'O'), (',', 'O'), ('three', 'O'), ('of', 'O'), ('four', 'O'), ('netilmicin', 'O'), ('and', 'O'), ('piperacillin', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), ('had', 'O'), ('auditory', 'O'), ('thresholds', 'O'), ('return', 'O'), ('to', 'O'), ('baseline', 'O'), ('compared', 'O'), ('with', 'O'), ('one', 'O'), ('of', 'O'), ('nine', 'O'), ('tobramycin', 'O'), ('and', 'O'), ('piperacillin', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), ('.', 'O'))"
The number of greater than or equal to 15 - dB increases in auditory threshold as a proportion of total greater than or equal to 15 - dB changes ( increases and decreases ) was significantly lower in netilmicin and piperacillin - vs tobramycin and piperacillin - treated patients ( 18 of 78 vs 67 of 115 ) .,"(('The', 'O'), ('number', 'O'), ('of', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('15', 'O'), ('-', 'O'), ('dB', 'O'), ('increases', 'O'), ('in', 'O'), ('auditory', 'O'), ('threshold', 'O'), ('as', 'O'), ('a', 'O'), ('proportion', 'O'), ('of', 'O'), ('total', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('15', 'O'), ('-', 'O'), ('dB', 'O'), ('changes', 'O'), ('(', 'O'), ('increases', 'O'), ('and', 'O'), ('decreases', 'O'), (')', 'O'), ('was', 'O'), ('significantly', 'O'), ('lower', 'O'), ('in', 'O'), ('netilmicin', 'O'), ('and', 'O'), ('piperacillin', 'O'), ('-', 'O'), ('vs', 'O'), ('tobramycin', 'O'), ('and', 'O'), ('piperacillin', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), ('(', 'O'), ('18', 'O'), ('of', 'O'), ('78', 'O'), ('vs', 'O'), ('67', 'O'), ('of', 'O'), ('115', 'O'), (')', 'O'), ('.', 'O'))"
Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis ( volume and specific gravity ) and by measurement of the two urinary enzymes .,"(('Proximal', 'B'), ('tubular', 'I'), ('damage', 'I'), ('caused', 'O'), ('by', 'O'), ('HCBD', 'B'), ('and', 'O'), ('papillary', 'B'), ('damage', 'I'), ('caused', 'O'), ('by', 'O'), ('BEA', 'B'), ('were', 'O'), ('distinguished', 'O'), ('both', 'O'), ('by', 'O'), ('conventional', 'O'), ('urinalysis', 'O'), ('(', 'O'), ('volume', 'O'), ('and', 'O'), ('specific', 'O'), ('gravity', 'O'), (')', 'O'), ('and', 'O'), ('by', 'O'), ('measurement', 'O'), ('of', 'O'), ('the', 'O'), ('two', 'O'), ('urinary', 'O'), ('enzymes', 'O'), ('.', 'O'))"
Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N - acetyl - beta - glucosaminidase showed a sustained elevation in papillary damage .,"(('Alkaline', 'O'), ('phosphatase', 'O'), ('and', 'O'), ('glucose', 'O'), ('were', 'O'), ('markedly', 'O'), ('and', 'O'), ('transiently', 'O'), ('elevated', 'O'), ('in', 'O'), ('proximal', 'B'), ('tubular', 'I'), ('damage', 'I'), ('and', 'O'), ('N', 'O'), ('-', 'O'), ('acetyl', 'O'), ('-', 'O'), ('beta', 'O'), ('-', 'O'), ('glucosaminidase', 'O'), ('showed', 'O'), ('a', 'O'), ('sustained', 'O'), ('elevation', 'O'), ('in', 'O'), ('papillary', 'B'), ('damage', 'I'), ('.', 'O'))"
It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage .,"(('It', 'O'), ('is', 'O'), ('concluded', 'O'), ('that', 'O'), ('both', 'O'), ('selective', 'O'), ('urinary', 'O'), ('enzymes', 'O'), ('and', 'O'), ('the', 'O'), ('molecular', 'O'), ('weight', 'O'), ('pattern', 'O'), ('of', 'O'), ('urinary', 'O'), ('proteins', 'O'), ('can', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('provide', 'O'), ('diagnostic', 'O'), ('information', 'O'), ('about', 'O'), ('the', 'O'), ('possible', 'O'), ('site', 'O'), ('of', 'O'), ('renal', 'B'), ('damage', 'I'), ('.', 'O'))"
"Aspirin or salicylate ingestion had occurred in only one of the 20 cases ( 5 % ) , and paracetamol ( acetaminophen ) had been administered in only six of the cases ( 30 % ) .","(('Aspirin', 'O'), ('or', 'O'), ('salicylate', 'O'), ('ingestion', 'O'), ('had', 'O'), ('occurred', 'O'), ('in', 'O'), ('only', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('20', 'O'), ('cases', 'O'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('paracetamol', 'O'), ('(', 'O'), ('acetaminophen', 'O'), (')', 'O'), ('had', 'O'), ('been', 'O'), ('administered', 'O'), ('in', 'O'), ('only', 'O'), ('six', 'O'), ('of', 'O'), ('the', 'O'), ('cases', 'O'), ('(', 'O'), ('30', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
"In Australia , the pediatric usage of aspirin has been extremely low for the past 25 years ( less than 1 % of total dosage units sold ) , with paracetamol ( acetaminophen ) dominating the pediatric analgesic and antipyretic market .","(('In', 'O'), ('Australia', 'O'), (',', 'O'), ('the', 'O'), ('pediatric', 'O'), ('usage', 'O'), ('of', 'O'), ('aspirin', 'O'), ('has', 'O'), ('been', 'O'), ('extremely', 'O'), ('low', 'O'), ('for', 'O'), ('the', 'O'), ('past', 'O'), ('25', 'O'), ('years', 'O'), ('(', 'O'), ('less', 'O'), ('than', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('total', 'O'), ('dosage', 'O'), ('units', 'O'), ('sold', 'O'), (')', 'O'), (',', 'O'), ('with', 'O'), ('paracetamol', 'O'), ('(', 'O'), ('acetaminophen', 'O'), (')', 'O'), ('dominating', 'O'), ('the', 'O'), ('pediatric', 'O'), ('analgesic', 'O'), ('and', 'O'), ('antipyretic', 'O'), ('market', 'O'), ('.', 'O'))"
The role of cyclosporine ( CSA ) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats .,"(('The', 'O'), ('role', 'O'), ('of', 'O'), ('cyclosporine', 'O'), ('(', 'O'), ('CSA', 'O'), (')', 'O'), ('alone', 'O'), ('or', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('various', 'O'), ('chemotherapeutics', 'O'), ('in', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('renal', 'B'), ('toxicity', 'O'), ('was', 'O'), ('evaluated', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
Administration of 20 mg / kg / day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man .,"(('Administration', 'O'), ('of', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('day', 'O'), ('CSA', 'O'), ('for', 'O'), ('4', 'O'), ('weeks', 'O'), ('caused', 'O'), ('renal', 'O'), ('functional', 'O'), ('and', 'O'), ('structural', 'O'), ('changes', 'O'), ('similar', 'O'), ('to', 'O'), ('those', 'O'), ('reported', 'O'), ('in', 'O'), ('man', 'O'), ('.', 'O'))"
Plasma potassium concentrations were on average 1 mmol / L lower during the chlorthalidone phase compared to amiloride therapy .,"(('Plasma', 'O'), ('potassium', 'O'), ('concentrations', 'O'), ('were', 'O'), ('on', 'O'), ('average', 'O'), ('1', 'O'), ('mmol', 'O'), ('/', 'O'), ('L', 'O'), ('lower', 'O'), ('during', 'O'), ('the', 'O'), ('chlorthalidone', 'O'), ('phase', 'O'), ('compared', 'O'), ('to', 'O'), ('amiloride', 'O'), ('therapy', 'O'), ('.', 'O'))"
"Blood pressure and volume states as assessed by bodyweight , plasma renin and noradrenaline ( norepinephrine ) concentrations were similar on the 2 regimens .","(('Blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('volume', 'O'), ('states', 'O'), ('as', 'O'), ('assessed', 'O'), ('by', 'O'), ('bodyweight', 'O'), (',', 'O'), ('plasma', 'O'), ('renin', 'O'), ('and', 'O'), ('noradrenaline', 'O'), ('(', 'O'), ('norepinephrine', 'O'), (')', 'O'), ('concentrations', 'O'), ('were', 'O'), ('similar', 'O'), ('on', 'O'), ('the', 'O'), ('2', 'O'), ('regimens', 'O'), ('.', 'O'))"
The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs .,"(('The', 'O'), ('reaction', 'O'), ('was', 'O'), ('specific', 'O'), ('to', 'O'), ('trihexyphenidyl', 'O'), ('and', 'O'), ('not', 'O'), ('to', 'O'), ('other', 'O'), ('anticholinergic', 'O'), ('drugs', 'O'), ('.', 'O'))"
This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect .,"(('This', 'O'), ('antidyskinetic', 'O'), ('drug', 'O'), ('is', 'O'), ('widely', 'O'), ('used', 'O'), ('in', 'O'), ('clinical', 'O'), ('psychiatric', 'O'), ('practice', 'O'), ('and', 'O'), ('physicians', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('this', 'O'), ('side', 'O'), ('effect', 'O'), ('.', 'O'))"
This was successfully reversed by naloxone .,"(('This', 'O'), ('was', 'O'), ('successfully', 'O'), ('reversed', 'O'), ('by', 'O'), ('naloxone', 'O'), ('.', 'O'))"
The mechanisms possibly implicated in this accident are discussed .,"(('The', 'O'), ('mechanisms', 'O'), ('possibly', 'O'), ('implicated', 'O'), ('in', 'O'), ('this', 'O'), ('accident', 'O'), ('are', 'O'), ('discussed', 'O'), ('.', 'O'))"
The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats .,"(('The', 'O'), ('mitotic', 'O'), ('inhibition', 'O'), ('and', 'O'), ('the', 'O'), ('production', 'O'), ('of', 'O'), ('micronuclei', 'O'), ('normally', 'O'), ('observed', 'O'), ('after', 'O'), ('partial', 'O'), ('hepatectomy', 'I'), ('in', 'O'), ('DEN', 'O'), ('treated', 'O'), ('rats', 'O'), ('were', 'O'), ('also', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('in', 'O'), ('DEN', 'O'), ('+', 'O'), ('PB', 'O'), ('treated', 'O'), ('rats', 'O'), ('.', 'O'))"
"When the treatment last only 2 weeks , the presence of PB did not change significantly the last parameters .","(('When', 'O'), ('the', 'O'), ('treatment', 'O'), ('last', 'O'), ('only', 'O'), ('2', 'O'), ('weeks', 'O'), (',', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('PB', 'B'), ('did', 'O'), ('not', 'O'), ('change', 'O'), ('significantly', 'O'), ('the', 'O'), ('last', 'O'), ('parameters', 'O'), ('.', 'O'))"
"In DEN + PB treated rats , the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone .","(('In', 'O'), ('DEN', 'O'), ('+', 'O'), ('PB', 'O'), ('treated', 'O'), ('rats', 'O'), (',', 'O'), ('the', 'O'), ('survival', 'O'), ('was', 'O'), ('prolonged', 'O'), ('and', 'O'), ('the', 'O'), ('tumor', 'B'), ('incidence', 'O'), ('decreased', 'O'), ('as', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('results', 'O'), ('obtained', 'O'), ('by', 'O'), ('DEN', 'O'), ('alone', 'O'), ('.', 'O'))"
Biochemical investigations are in progress to obtain more information about this ' paradoxical ' PB effect .,"(('Biochemical', 'O'), ('investigations', 'O'), ('are', 'O'), ('in', 'O'), ('progress', 'O'), ('to', 'O'), ('obtain', 'O'), ('more', 'O'), ('information', 'O'), ('about', 'O'), ('this', 'O'), (""'"", 'O'), ('paradoxical', 'O'), (""'"", 'O'), ('PB', 'B'), ('effect', 'O'), ('.', 'O'))"
The case of a 40 - year - old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported .,"(('The', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('40', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('patient', 'O'), ('who', 'O'), ('underwent', 'O'), ('an', 'O'), ('unsuccessful', 'O'), ('cadaver', 'O'), ('kidney', 'O'), ('transplantation', 'O'), ('and', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('ethambutol', 'O'), ('and', 'O'), ('isoniazid', 'O'), ('is', 'O'), ('reported', 'O'), ('.', 'O'))"
Ethambutol was stopped and only small improvement of the visual acuity followed .,"(('Ethambutol', 'O'), ('was', 'O'), ('stopped', 'O'), ('and', 'O'), ('only', 'O'), ('small', 'O'), ('improvement', 'O'), ('of', 'O'), ('the', 'O'), ('visual', 'O'), ('acuity', 'O'), ('followed', 'O'), ('.', 'O'))"
"Isoniazid was discontinued later , followed by a dramatic improvement in the visual acuity .","(('Isoniazid', 'O'), ('was', 'O'), ('discontinued', 'O'), ('later', 'O'), (',', 'O'), ('followed', 'O'), ('by', 'O'), ('a', 'O'), ('dramatic', 'O'), ('improvement', 'O'), ('in', 'O'), ('the', 'O'), ('visual', 'O'), ('acuity', 'O'), ('.', 'O'))"
The hazards of optic nerve toxicity due to ethambutol are known .,"(('The', 'O'), ('hazards', 'O'), ('of', 'O'), ('optic', 'B'), ('nerve', 'I'), ('toxicity', 'I'), ('due', 'O'), ('to', 'O'), ('ethambutol', 'O'), ('are', 'O'), ('known', 'O'), ('.', 'O'))"
We emphasize the potential danger in the use of ethambutol and isoniazid .,"(('We', 'O'), ('emphasize', 'O'), ('the', 'O'), ('potential', 'O'), ('danger', 'O'), ('in', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('ethambutol', 'O'), ('and', 'O'), ('isoniazid', 'O'), ('.', 'O'))"
A prospective study of adverse reactions associated with vancomycin therapy .,"(('A', 'O'), ('prospective', 'O'), ('study', 'O'), ('of', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('associated', 'O'), ('with', 'O'), ('vancomycin', 'O'), ('therapy', 'O'), ('.', 'O'))"
A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16 - month period .,"(('A', 'O'), ('prospective', 'O'), ('evaluation', 'O'), ('of', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('of', 'O'), ('vancomycin', 'O'), ('was', 'O'), ('conducted', 'O'), ('in', 'O'), ('54', 'O'), ('consecutive', 'O'), ('patients', 'O'), ('over', 'O'), ('a', 'O'), ('16', 'O'), ('-', 'O'), ('month', 'O'), ('period', 'O'), ('.', 'O'))"
Vancomycin was curative in 95 % of 43 patients with proven infection .,"(('Vancomycin', 'O'), ('was', 'O'), ('curative', 'O'), ('in', 'O'), ('95', 'O'), ('%', 'O'), ('of', 'O'), ('43', 'O'), ('patients', 'O'), ('with', 'O'), ('proven', 'O'), ('infection', 'O'), ('.', 'O'))"
Drugs were ceased in six patients because of adverse reactions ; in three of these vancomycin was considered the likely cause .,"(('Drugs', 'O'), ('were', 'O'), ('ceased', 'O'), ('in', 'O'), ('six', 'O'), ('patients', 'O'), ('because', 'O'), ('of', 'O'), ('adverse', 'O'), ('reactions', 'O'), (';', 'O'), ('in', 'O'), ('three', 'O'), ('of', 'O'), ('these', 'O'), ('vancomycin', 'O'), ('was', 'O'), ('considered', 'O'), ('the', 'O'), ('likely', 'O'), ('cause', 'O'), ('.', 'O'))"
"We conclude that vancomycin , administered appropriately , constitutes safe , effective therapy for infections caused by susceptible bacteria .","(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('vancomycin', 'O'), (',', 'O'), ('administered', 'O'), ('appropriately', 'O'), (',', 'O'), ('constitutes', 'O'), ('safe', 'O'), (',', 'O'), ('effective', 'O'), ('therapy', 'O'), ('for', 'O'), ('infections', 'O'), ('caused', 'O'), ('by', 'O'), ('susceptible', 'O'), ('bacteria', 'O'), ('.', 'O'))"
"In 42 of these patients , data were examined for factors associated with clinical outcome .","(('In', 'O'), ('42', 'O'), ('of', 'O'), ('these', 'O'), ('patients', 'O'), (',', 'O'), ('data', 'O'), ('were', 'O'), ('examined', 'O'), ('for', 'O'), ('factors', 'O'), ('associated', 'O'), ('with', 'O'), ('clinical', 'O'), ('outcome', 'O'), ('.', 'O'))"
"Variables evaluated included patient weight , age , sex , serum creatinine level , creatinine clearance , duration of therapy , total dose , mean daily dose , organism minimum inhibitory concentration ( MIC ) , mean peak levels , mean trough levels , mean area under the serum concentration - time curve ( AUC ) , total AUC , mean AUC greater than MIC , total AUC greater than MIC , mean Schumacher ' s intensity factor ( IF ) , total IF , In ( mean maximum concentration [ Cmax ] / MIC ) .","(('Variables', 'O'), ('evaluated', 'O'), ('included', 'O'), ('patient', 'O'), ('weight', 'O'), (',', 'O'), ('age', 'O'), (',', 'O'), ('sex', 'O'), (',', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('level', 'O'), (',', 'O'), ('creatinine', 'O'), ('clearance', 'O'), (',', 'O'), ('duration', 'O'), ('of', 'O'), ('therapy', 'O'), (',', 'O'), ('total', 'O'), ('dose', 'O'), (',', 'O'), ('mean', 'O'), ('daily', 'O'), ('dose', 'O'), (',', 'O'), ('organism', 'O'), ('minimum', 'O'), ('inhibitory', 'O'), ('concentration', 'O'), ('(', 'O'), ('MIC', 'O'), (')', 'O'), (',', 'O'), ('mean', 'O'), ('peak', 'O'), ('levels', 'O'), (',', 'O'), ('mean', 'O'), ('trough', 'O'), ('levels', 'O'), (',', 'O'), ('mean', 'O'), ('area', 'O'), ('under', 'O'), ('the', 'O'), ('serum', 'O'), ('concentration', 'O'), ('-', 'O'), ('time', 'O'), ('curve', 'O'), ('(', 'O'), ('AUC', 'O'), (')', 'O'), (',', 'O'), ('total', 'O'), ('AUC', 'O'), (',', 'O'), ('mean', 'O'), ('AUC', 'O'), ('greater', 'O'), ('than', 'O'), ('MIC', 'O'), (',', 'O'), ('total', 'O'), ('AUC', 'O'), ('greater', 'O'), ('than', 'O'), ('MIC', 'O'), (',', 'O'), ('mean', 'O'), ('Schumacher', 'O'), (""'"", 'O'), ('s', 'O'), ('intensity', 'O'), ('factor', 'O'), ('(', 'O'), ('IF', 'O'), (')', 'O'), (',', 'O'), ('total', 'O'), ('IF', 'O'), (',', 'O'), ('In', 'O'), ('(', 'O'), ('mean', 'O'), ('maximum', 'O'), ('concentration', 'O'), ('[', 'O'), ('Cmax', 'O'), (']', 'O'), ('/', 'O'), ('MIC', 'O'), (')', 'O'), ('.', 'O'))"
Model - dependent pharmacokinetic parameters were calculated by computer based on a one - compartment model .,"(('Model', 'O'), ('-', 'O'), ('dependent', 'O'), ('pharmacokinetic', 'O'), ('parameters', 'O'), ('were', 'O'), ('calculated', 'O'), ('by', 'O'), ('computer', 'O'), ('based', 'O'), ('on', 'O'), ('a', 'O'), ('one', 'O'), ('-', 'O'), ('compartment', 'O'), ('model', 'O'), ('.', 'O'))"
"In contrast , a stepwise discriminant function analysis identified only duration of therapy ( P less than . 001 ) as an important factor .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('a', 'O'), ('stepwise', 'O'), ('discriminant', 'O'), ('function', 'O'), ('analysis', 'O'), ('identified', 'O'), ('only', 'O'), ('duration', 'O'), ('of', 'O'), ('therapy', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('as', 'O'), ('an', 'O'), ('important', 'O'), ('factor', 'O'), ('.', 'O'))"
"When examined individually , mean IF , MIC , total dose , mean daily dose , and ln ( mean Cmax / MIC ) correlated significantly ( P less than . 05 ) with cure .","(('When', 'O'), ('examined', 'O'), ('individually', 'O'), (',', 'O'), ('mean', 'O'), ('IF', 'O'), (',', 'O'), ('MIC', 'O'), (',', 'O'), ('total', 'O'), ('dose', 'O'), (',', 'O'), ('mean', 'O'), ('daily', 'O'), ('dose', 'O'), (',', 'O'), ('and', 'O'), ('ln', 'O'), ('(', 'O'), ('mean', 'O'), ('Cmax', 'O'), ('/', 'O'), ('MIC', 'O'), (')', 'O'), ('correlated', 'O'), ('significantly', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('with', 'O'), ('cure', 'O'), ('.', 'O'))"
"In contrast , a simultaneous multivariable analysis identified IF , MIC , and total dose according to one model and ln ( mean Cmax / MIC ) according to a second statistical model of parameters selected to have the greatest prospective value .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('a', 'O'), ('simultaneous', 'O'), ('multivariable', 'O'), ('analysis', 'O'), ('identified', 'O'), ('IF', 'O'), (',', 'O'), ('MIC', 'O'), (',', 'O'), ('and', 'O'), ('total', 'O'), ('dose', 'O'), ('according', 'O'), ('to', 'O'), ('one', 'O'), ('model', 'O'), ('and', 'O'), ('ln', 'O'), ('(', 'O'), ('mean', 'O'), ('Cmax', 'O'), ('/', 'O'), ('MIC', 'O'), (')', 'O'), ('according', 'O'), ('to', 'O'), ('a', 'O'), ('second', 'O'), ('statistical', 'O'), ('model', 'O'), ('of', 'O'), ('parameters', 'O'), ('selected', 'O'), ('to', 'O'), ('have', 'O'), ('the', 'O'), ('greatest', 'O'), ('prospective', 'O'), ('value', 'O'), ('.', 'O'))"
"Based on Bayes ' theorem and the first model , the predictive accuracy of identifying patients not cured increased from 0 . 19 to 0 . 83 .","(('Based', 'O'), ('on', 'O'), ('Bayes', 'O'), (""'"", 'O'), ('theorem', 'O'), ('and', 'O'), ('the', 'O'), ('first', 'O'), ('model', 'O'), (',', 'O'), ('the', 'O'), ('predictive', 'O'), ('accuracy', 'O'), ('of', 'O'), ('identifying', 'O'), ('patients', 'O'), ('not', 'O'), ('cured', 'O'), ('increased', 'O'), ('from', 'O'), ('0', 'O'), ('.', 'O'), ('19', 'O'), ('to', 'O'), ('0', 'O'), ('.', 'O'), ('83', 'O'), ('.', 'O'))"
"For the second model , the predictive accuracy increased from 0 . 19 to 0 . 50 . ( ABSTRACT TRUNCATED AT 250 WORDS )","(('For', 'O'), ('the', 'O'), ('second', 'O'), ('model', 'O'), (',', 'O'), ('the', 'O'), ('predictive', 'O'), ('accuracy', 'O'), ('increased', 'O'), ('from', 'O'), ('0', 'O'), ('.', 'O'), ('19', 'O'), ('to', 'O'), ('0', 'O'), ('.', 'O'), ('50', 'O'), ('.', 'O'), ('(', 'O'), ('ABSTRACT', 'O'), ('TRUNCATED', 'O'), ('AT', 'O'), ('250', 'O'), ('WORDS', 'O'), (')', 'O'))"
Dose - related beneficial and adverse effects of dietary corticosterone on organophosphorus - induced delayed neuropathy in chickens .,"(('Dose', 'O'), ('-', 'O'), ('related', 'O'), ('beneficial', 'O'), ('and', 'O'), ('adverse', 'O'), ('effects', 'O'), ('of', 'O'), ('dietary', 'O'), ('corticosterone', 'O'), ('on', 'O'), ('organophosphorus', 'O'), ('-', 'O'), ('induced', 'O'), ('delayed', 'B'), ('neuropathy', 'I'), ('in', 'O'), ('chickens', 'O'), ('.', 'O'))"
"Tri - ortho - tolyl phosphate ( TOTP ) , 360 mg / kg , po , and 0 , 0 ' - diisopropyl phosphorofluoridate ( DFP ) , 1 mg / kg sc , were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone .","(('Tri', 'O'), ('-', 'O'), ('ortho', 'O'), ('-', 'O'), ('tolyl', 'O'), ('phosphate', 'O'), ('(', 'O'), ('TOTP', 'O'), (')', 'O'), (',', 'O'), ('360', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('po', 'O'), (',', 'O'), ('and', 'O'), ('0', 'O'), (',', 'O'), ('0', 'O'), (""'"", 'O'), ('-', 'O'), ('diisopropyl', 'O'), ('phosphorofluoridate', 'O'), ('(', 'O'), ('DFP', 'O'), (')', 'O'), (',', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('sc', 'O'), (',', 'O'), ('were', 'O'), ('administered', 'O'), ('to', 'O'), ('adult', 'O'), ('White', 'O'), ('Leghorn', 'O'), ('chickens', 'O'), ('24', 'O'), ('hr', 'O'), ('after', 'O'), ('they', 'O'), ('were', 'O'), ('placed', 'O'), ('on', 'O'), ('diets', 'O'), ('containing', 'O'), ('0', 'O'), ('to', 'O'), ('300', 'O'), ('ppm', 'O'), ('corticosterone', 'O'), ('.', 'O'))"
Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared .,"(('Supplemented', 'O'), ('diets', 'O'), ('were', 'O'), ('continued', 'O'), ('until', 'O'), ('clinical', 'O'), ('signs', 'O'), ('and', 'O'), ('lesions', 'O'), ('of', 'O'), ('delayed', 'B'), ('neuropathy', 'I'), ('appeared', 'O'), ('.', 'O'))"
"Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced neuropathy , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .","(('Although', 'O'), ('low', 'O'), ('concentrations', 'O'), ('(', 'O'), ('less', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('50', 'O'), ('ppm', 'O'), (')', 'O'), ('of', 'O'), ('corticosterone', 'O'), ('had', 'O'), ('beneficial', 'O'), ('effects', 'O'), ('on', 'O'), ('TOTP', 'O'), ('-', 'O'), ('induced', 'O'), ('neuropathy', 'B'), (',', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('200', 'O'), ('ppm', 'O'), ('exacerbated', 'O'), ('clinical', 'O'), ('signs', 'O'), ('in', 'O'), ('chickens', 'O'), ('given', 'O'), ('either', 'O'), ('TOTP', 'O'), ('or', 'O'), ('DFP', 'O'), ('.', 'O'))"
Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase .,"(('Chickens', 'O'), ('given', 'O'), ('200', 'O'), ('ppm', 'O'), ('corticosterone', 'O'), ('without', 'O'), ('TOTP', 'O'), ('or', 'O'), ('DFP', 'O'), ('had', 'O'), ('significantly', 'O'), ('elevated', 'O'), ('activity', 'O'), ('of', 'O'), ('plasma', 'O'), ('cholinesterase', 'O'), ('and', 'O'), ('significantly', 'O'), ('inhibited', 'O'), ('activity', 'O'), ('of', 'O'), ('liver', 'O'), ('carboxylesterase', 'O'), ('.', 'O'))"
"The use of amiodarone has , however , been limited due to its serious side - effects .","(('The', 'O'), ('use', 'O'), ('of', 'O'), ('amiodarone', 'O'), ('has', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('been', 'O'), ('limited', 'O'), ('due', 'O'), ('to', 'O'), ('its', 'O'), ('serious', 'O'), ('side', 'O'), ('-', 'O'), ('effects', 'O'), ('.', 'O'))"
Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels .,"(('Patients', 'O'), ('receiving', 'O'), ('amiodarone', 'O'), ('should', 'O'), ('be', 'O'), ('regularly', 'O'), ('screened', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('hepatic', 'O'), ('enzyme', 'O'), ('levels', 'O'), ('.', 'O'))"
"Conventional LW rats , implanted with testosterone at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic tumors .","(('Conventional', 'O'), ('LW', 'O'), ('rats', 'O'), (',', 'O'), ('implanted', 'O'), ('with', 'O'), ('testosterone', 'O'), ('at', 'O'), ('age', 'O'), ('4', 'O'), ('months', 'O'), (',', 'O'), ('developed', 'O'), ('a', 'O'), ('higher', 'O'), ('incidence', 'O'), ('of', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('after', 'O'), ('an', 'O'), ('average', 'O'), ('interval', 'O'), ('of', 'O'), ('14', 'O'), ('months', 'O'), (':', 'O'), ('24', 'O'), ('%', 'O'), ('had', 'O'), ('developed', 'O'), ('gross', 'O'), ('tumors', 'B'), (',', 'O'), ('and', 'O'), ('40', 'O'), ('%', 'O'), ('when', 'O'), ('it', 'O'), ('included', 'O'), ('microscopic', 'O'), ('tumors', 'B'), ('.', 'O'))"
"Preliminary results indicate that testosterone - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed prostate cancer after intervals of 6 - 12 months .","(('Preliminary', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('testosterone', 'O'), ('-', 'O'), ('treated', 'O'), ('LW', 'O'), ('rats', 'O'), ('that', 'O'), ('were', 'O'), ('fed', 'O'), ('the', 'O'), ('same', 'O'), ('diet', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('supplemented', 'O'), ('with', 'O'), ('corn', 'O'), ('oil', 'O'), ('up', 'O'), ('to', 'O'), ('20', 'O'), ('%', 'O'), ('fat', 'O'), (',', 'O'), ('developed', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('after', 'O'), ('intervals', 'O'), ('of', 'O'), ('6', 'O'), ('-', 'O'), ('12', 'O'), ('months', 'O'), ('.', 'O'))"
Aged GF Sprague - Dawley ( SD ) rats have not developed prostate cancer spontaneously .,"(('Aged', 'O'), ('GF', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('(', 'O'), ('SD', 'O'), (')', 'O'), ('rats', 'O'), ('have', 'O'), ('not', 'O'), ('developed', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('spontaneously', 'O'), ('.', 'O'))"
Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer .,"(('Experimental', 'O'), ('designs', 'O'), ('should', 'O'), ('consider', 'O'), ('genetic', 'O'), ('susceptibility', 'O'), ('as', 'O'), ('a', 'O'), ('basic', 'O'), ('prerequisite', 'O'), ('for', 'O'), ('studies', 'O'), ('on', 'O'), ('experimental', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('.', 'O'))"
Time course alterations of QTC interval due to hypaque 76 .,"(('Time', 'O'), ('course', 'O'), ('alterations', 'O'), ('of', 'O'), ('QTC', 'O'), ('interval', 'O'), ('due', 'O'), ('to', 'O'), ('hypaque', 'O'), ('76', 'O'), ('.', 'O'))"
"Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one , three , five and ten minutes after injection of hypaque 76 .","(('Sequential', 'O'), ('measurement', 'O'), ('of', 'O'), ('QT', 'O'), ('interval', 'O'), ('during', 'O'), ('left', 'O'), ('ventricular', 'O'), ('angiography', 'O'), ('was', 'O'), ('made', 'O'), ('30', 'O'), ('seconds', 'O'), ('and', 'O'), ('one', 'O'), (',', 'O'), ('three', 'O'), (',', 'O'), ('five', 'O'), ('and', 'O'), ('ten', 'O'), ('minutes', 'O'), ('after', 'O'), ('injection', 'O'), ('of', 'O'), ('hypaque', 'O'), ('76', 'O'), ('.', 'O'))"
The subjects were ten patients found to have normal left ventricles and coronary arteries .,"(('The', 'O'), ('subjects', 'O'), ('were', 'O'), ('ten', 'O'), ('patients', 'O'), ('found', 'O'), ('to', 'O'), ('have', 'O'), ('normal', 'O'), ('left', 'O'), ('ventricles', 'O'), ('and', 'O'), ('coronary', 'O'), ('arteries', 'O'), ('.', 'O'))"
Rat extraocular muscle regeneration .,"(('Rat', 'O'), ('extraocular', 'O'), ('muscle', 'O'), ('regeneration', 'O'), ('.', 'O'))"
Repair of local anesthetic - induced damage .,"(('Repair', 'O'), ('of', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('-', 'O'), ('induced', 'O'), ('damage', 'O'), ('.', 'O'))"
"Local anesthetics that are commonly used in ophthalmic surgery ( 0 . 75 % bupivacaine hydrochloride , 2 . 0 % mepivacaine hydrochloride , and 2 . 0 % lidocaine hydrochloride plus 1 : 100 , 000 epinephrine ) were injected into the retrobulbar area of rat eyes .","(('Local', 'O'), ('anesthetics', 'O'), ('that', 'O'), ('are', 'O'), ('commonly', 'O'), ('used', 'O'), ('in', 'O'), ('ophthalmic', 'O'), ('surgery', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('75', 'O'), ('%', 'O'), ('bupivacaine', 'O'), ('hydrochloride', 'O'), (',', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('mepivacaine', 'O'), ('hydrochloride', 'O'), (',', 'O'), ('and', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('lidocaine', 'O'), ('hydrochloride', 'O'), ('plus', 'O'), ('1', 'O'), (':', 'O'), ('100', 'O'), (',', 'O'), ('000', 'O'), ('epinephrine', 'O'), (')', 'O'), ('were', 'O'), ('injected', 'O'), ('into', 'O'), ('the', 'O'), ('retrobulbar', 'O'), ('area', 'O'), ('of', 'O'), ('rat', 'O'), ('eyes', 'O'), ('.', 'O'))"
Controls were injected with physiological saline .,"(('Controls', 'O'), ('were', 'O'), ('injected', 'O'), ('with', 'O'), ('physiological', 'O'), ('saline', 'O'), ('.', 'O'))"
All three anesthetics produced massive degeneration of the extraocular muscles .,"(('All', 'O'), ('three', 'O'), ('anesthetics', 'O'), ('produced', 'O'), ('massive', 'O'), ('degeneration', 'B'), ('of', 'I'), ('the', 'I'), ('extraocular', 'I'), ('muscles', 'I'), ('.', 'O'))"
"In addition to muscle damage , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus epinephrine .","(('In', 'O'), ('addition', 'O'), ('to', 'O'), ('muscle', 'O'), ('damage', 'O'), (',', 'O'), ('severe', 'O'), ('damage', 'O'), ('was', 'O'), ('also', 'O'), ('seen', 'O'), ('in', 'O'), ('harderian', 'O'), ('glands', 'O'), (',', 'O'), ('especially', 'O'), ('after', 'O'), ('exposure', 'O'), ('to', 'O'), ('mepivacaine', 'O'), ('and', 'O'), ('lidocaine', 'O'), ('plus', 'O'), ('epinephrine', 'O'), ('.', 'O'))"
Gentamicin nephropathy in a neonate .,"(('Gentamicin', 'B'), ('nephropathy', 'I'), ('in', 'O'), ('a', 'O'), ('neonate', 'O'), ('.', 'O'))"
The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin ( 5 mg / kg / day ) and penicillin are presented .,"(('The', 'O'), ('clinical', 'O'), ('and', 'O'), ('autopsy', 'O'), ('findings', 'O'), ('in', 'O'), ('a', 'O'), ('premature', 'O'), ('baby', 'O'), ('who', 'O'), ('died', 'O'), ('of', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('after', 'O'), ('therapy', 'O'), ('with', 'O'), ('gentamicin', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('and', 'O'), ('penicillin', 'O'), ('are', 'O'), ('presented', 'O'), ('.', 'O'))"
"Numerous periodic acid Schiff ( PAS ) positive , diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules .","(('Numerous', 'O'), ('periodic', 'O'), ('acid', 'O'), ('Schiff', 'O'), ('(', 'O'), ('PAS', 'O'), (')', 'O'), ('positive', 'O'), (',', 'O'), ('diastase', 'O'), ('resistant', 'O'), ('cytoplasmic', 'O'), ('inclusion', 'O'), ('bodies', 'O'), ('which', 'O'), ('appeared', 'O'), ('as', 'O'), ('myelin', 'O'), ('figures', 'O'), ('in', 'O'), ('cytosegresomes', 'O'), ('under', 'O'), ('the', 'O'), ('electron', 'O'), ('microscope', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('the', 'O'), ('proximal', 'O'), ('convoluted', 'O'), ('tubules', 'O'), ('.', 'O'))"
The pathological changes induced by gentamicin in the human neonatal kidneys have not been previously reported .,"(('The', 'O'), ('pathological', 'O'), ('changes', 'O'), ('induced', 'O'), ('by', 'O'), ('gentamicin', 'O'), ('in', 'O'), ('the', 'O'), ('human', 'O'), ('neonatal', 'O'), ('kidneys', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('previously', 'O'), ('reported', 'O'), ('.', 'O'))"
Induction by paracetamol of bladder and liver tumours in the rat .,"(('Induction', 'O'), ('by', 'O'), ('paracetamol', 'O'), ('of', 'O'), ('bladder', 'B'), ('and', 'I'), ('liver', 'I'), ('tumours', 'I'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
Effects on hepatocyte fine structure .,"(('Effects', 'O'), ('on', 'O'), ('hepatocyte', 'O'), ('fine', 'O'), ('structure', 'O'), ('.', 'O'))"
Groups of male and female inbred Leeds strain rats were fed diets containing either 0 . 5 % or 1 . 0 % paracetamol by weight for up to 18 months .,"(('Groups', 'O'), ('of', 'O'), ('male', 'O'), ('and', 'O'), ('female', 'O'), ('inbred', 'O'), ('Leeds', 'O'), ('strain', 'O'), ('rats', 'O'), ('were', 'O'), ('fed', 'O'), ('diets', 'O'), ('containing', 'O'), ('either', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('or', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('paracetamol', 'O'), ('by', 'O'), ('weight', 'O'), ('for', 'O'), ('up', 'O'), ('to', 'O'), ('18', 'O'), ('months', 'O'), ('.', 'O'))"
"At the 1 . 0 % dosage level , 20 % of rats of both sexes developed neoplastic nodules of the liver , a statistically significant incidence .","(('At', 'O'), ('the', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('dosage', 'O'), ('level', 'O'), (',', 'O'), ('20', 'O'), ('%', 'O'), ('of', 'O'), ('rats', 'O'), ('of', 'O'), ('both', 'O'), ('sexes', 'O'), ('developed', 'O'), ('neoplastic', 'B'), ('nodules', 'I'), ('of', 'I'), ('the', 'I'), ('liver', 'I'), (',', 'O'), ('a', 'O'), ('statistically', 'O'), ('significant', 'O'), ('incidence', 'O'), ('.', 'O'))"
"These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration , the latter also being observed in the low dosage male rats .","(('These', 'O'), ('rats', 'O'), ('also', 'O'), ('showed', 'O'), ('gross', 'O'), ('enlargement', 'O'), ('of', 'O'), ('their', 'O'), ('livers', 'O'), ('and', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('foci', 'O'), ('of', 'O'), ('cellular', 'O'), ('alteration', 'O'), (',', 'O'), ('the', 'O'), ('latter', 'O'), ('also', 'O'), ('being', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('low', 'O'), ('dosage', 'O'), ('male', 'O'), ('rats', 'O'), ('.', 'O'))"
"However , significant yields of bladder tumours were only obtained from low dosage females and high dosage males .","(('However', 'O'), (',', 'O'), ('significant', 'O'), ('yields', 'O'), ('of', 'O'), ('bladder', 'B'), ('tumours', 'I'), ('were', 'O'), ('only', 'O'), ('obtained', 'O'), ('from', 'O'), ('low', 'O'), ('dosage', 'O'), ('females', 'O'), ('and', 'O'), ('high', 'O'), ('dosage', 'O'), ('males', 'O'), ('.', 'O'))"
A low yield of tumours at various other sites also arose following paracetamol feeding .,"(('A', 'O'), ('low', 'O'), ('yield', 'O'), ('of', 'O'), ('tumours', 'B'), ('at', 'O'), ('various', 'O'), ('other', 'O'), ('sites', 'O'), ('also', 'O'), ('arose', 'O'), ('following', 'O'), ('paracetamol', 'O'), ('feeding', 'O'), ('.', 'O'))"
Report of two cases .,"(('Report', 'O'), ('of', 'O'), ('two', 'O'), ('cases', 'O'), ('.', 'O'))"
"Very rarely , the toxic neurological manifestations of this drug are of cerebral origin .","(('Very', 'O'), ('rarely', 'O'), (',', 'O'), ('the', 'O'), ('toxic', 'O'), ('neurological', 'O'), ('manifestations', 'O'), ('of', 'O'), ('this', 'O'), ('drug', 'O'), ('are', 'O'), ('of', 'O'), ('cerebral', 'O'), ('origin', 'O'), ('.', 'O'))"
Both had brain surgery before DPH treatment .,"(('Both', 'O'), ('had', 'O'), ('brain', 'O'), ('surgery', 'O'), ('before', 'O'), ('DPH', 'O'), ('treatment', 'O'), ('.', 'O'))"
It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs .,"(('It', 'O'), ('is', 'O'), ('assumed', 'O'), ('that', 'O'), ('patients', 'O'), ('with', 'O'), ('some', 'O'), ('cerebral', 'B'), ('damage', 'I'), ('are', 'O'), ('liable', 'O'), ('to', 'O'), ('manifest', 'O'), ('DPH', 'B'), ('toxicity', 'I'), ('as', 'O'), ('focal', 'O'), ('neurological', 'O'), ('signs', 'O'), ('.', 'O'))"
"Tiapride had no effect on levodopa - induced early morning of "" off - period "" segmental dystonia .","(('Tiapride', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('early', 'O'), ('morning', 'O'), ('of', 'O'), ('""', 'O'), ('off', 'O'), ('-', 'O'), ('period', 'O'), ('""', 'O'), ('segmental', 'B'), ('dystonia', 'I'), ('.', 'O'))"
Quinidine hepatitis .,"(('Quinidine', 'B'), ('hepatitis', 'I'), ('.', 'O'))"
"Long - term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT , lactic acid dehydrogenase , and alkaline phosphatase .","(('Long', 'O'), ('-', 'O'), ('term', 'O'), ('administration', 'O'), ('of', 'O'), ('quinidine', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('persistent', 'O'), ('elevation', 'O'), ('of', 'O'), ('serum', 'O'), ('concentrations', 'O'), ('of', 'O'), ('SGOT', 'O'), (',', 'O'), ('lactic', 'O'), ('acid', 'O'), ('dehydrogenase', 'O'), (',', 'O'), ('and', 'O'), ('alkaline', 'O'), ('phosphatase', 'O'), ('.', 'O'))"
Liver biopsy showed active hepatitis .,"(('Liver', 'O'), ('biopsy', 'O'), ('showed', 'O'), ('active', 'O'), ('hepatitis', 'B'), ('.', 'O'))"
Discontinuance of quinidine therapy led to normalization of liver function tests .,"(('Discontinuance', 'O'), ('of', 'O'), ('quinidine', 'O'), ('therapy', 'O'), ('led', 'O'), ('to', 'O'), ('normalization', 'O'), ('of', 'O'), ('liver', 'O'), ('function', 'O'), ('tests', 'O'), ('.', 'O'))"
"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT , alkaline phosphatase , and lactic acid dehydrogenase values .","(('A', 'O'), ('challenge', 'O'), ('dose', 'O'), ('of', 'O'), ('quinidine', 'O'), ('caused', 'O'), ('clinical', 'O'), ('symptoms', 'O'), ('and', 'O'), ('abrupt', 'O'), ('elevation', 'O'), ('of', 'O'), ('SGOT', 'O'), (',', 'O'), ('alkaline', 'O'), ('phosphatase', 'O'), (',', 'O'), ('and', 'O'), ('lactic', 'O'), ('acid', 'O'), ('dehydrogenase', 'O'), ('values', 'O'), ('.', 'O'))"
"This report also suggests that , even after long - term administration , the hepatic toxicity is reversible .","(('This', 'O'), ('report', 'O'), ('also', 'O'), ('suggests', 'O'), ('that', 'O'), (',', 'O'), ('even', 'O'), ('after', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('administration', 'O'), (',', 'O'), ('the', 'O'), ('hepatic', 'O'), ('toxicity', 'O'), ('is', 'O'), ('reversible', 'O'), ('.', 'O'))"
Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed .,"(('Previous', 'O'), ('reports', 'O'), ('of', 'O'), ('these', 'O'), ('phenomena', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('recent', 'O'), ('studies', 'O'), ('of', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('heparin', 'O'), ('are', 'O'), ('reviewed', 'O'), ('.', 'O'))"
"Appropriate treatment consists of discontinuation of heparin , and anticoagulation with sodium warfarin if necessary .","(('Appropriate', 'O'), ('treatment', 'O'), ('consists', 'O'), ('of', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('heparin', 'O'), (',', 'O'), ('and', 'O'), ('anticoagulation', 'O'), ('with', 'O'), ('sodium', 'O'), ('warfarin', 'O'), ('if', 'O'), ('necessary', 'O'), ('.', 'O'))"
Vascular procedures are performed as indicated .,"(('Vascular', 'O'), ('procedures', 'O'), ('are', 'O'), ('performed', 'O'), ('as', 'O'), ('indicated', 'O'), ('.', 'O'))"
"Pharmacology of GYKI - 41 099 ( chlorpropanol , Tobanum ) a new potent beta - adrenergic antagonist .","(('Pharmacology', 'O'), ('of', 'O'), ('GYKI', 'O'), ('-', 'O'), ('41', 'O'), ('099', 'O'), ('(', 'O'), ('chlorpropanol', 'O'), (',', 'O'), ('Tobanum', 'O'), (')', 'O'), ('a', 'O'), ('new', 'O'), ('potent', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenergic', 'O'), ('antagonist', 'O'), ('.', 'O'))"
"The compound GYKI - 41 099 , as a beta - adrenergic antagonist , is 3 - 8 times more potent than propranolol in vitro and in vivo .","(('The', 'O'), ('compound', 'O'), ('GYKI', 'O'), ('-', 'O'), ('41', 'O'), ('099', 'O'), (',', 'O'), ('as', 'O'), ('a', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenergic', 'O'), ('antagonist', 'O'), (',', 'O'), ('is', 'O'), ('3', 'O'), ('-', 'O'), ('8', 'O'), ('times', 'O'), ('more', 'O'), ('potent', 'O'), ('than', 'O'), ('propranolol', 'O'), ('in', 'O'), ('vitro', 'O'), ('and', 'O'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats .,"(('Its', 'O'), ('antiarrhythmic', 'O'), ('effectiveness', 'O'), ('surpasses', 'O'), ('that', 'O'), ('of', 'O'), ('propranolol', 'O'), ('and', 'O'), ('pindolol', 'O'), ('inhibiting', 'O'), ('the', 'O'), ('ouabain', 'B'), ('arrhythmia', 'I'), ('in', 'O'), ('dogs', 'O'), ('and', 'O'), ('cats', 'O'), ('.', 'O'))"
GYKI - 41 900 has a negligible cardiodepressant activity ; it is not cardioselective .,"(('GYKI', 'O'), ('-', 'O'), ('41', 'O'), ('900', 'O'), ('has', 'O'), ('a', 'O'), ('negligible', 'O'), ('cardiodepressant', 'O'), ('activity', 'O'), (';', 'O'), ('it', 'O'), ('is', 'O'), ('not', 'O'), ('cardioselective', 'O'), ('.', 'O'))"
The compound shows a rapid and long lasting effect .,"(('The', 'O'), ('compound', 'O'), ('shows', 'O'), ('a', 'O'), ('rapid', 'O'), ('and', 'O'), ('long', 'O'), ('lasting', 'O'), ('effect', 'O'), ('.', 'O'))"
There was a prolonged elimination of the radioactivity after the injection of 14C - 41 099 to rats and dogs .,"(('There', 'O'), ('was', 'O'), ('a', 'O'), ('prolonged', 'O'), ('elimination', 'O'), ('of', 'O'), ('the', 'O'), ('radioactivity', 'O'), ('after', 'O'), ('the', 'O'), ('injection', 'O'), ('of', 'O'), ('14C', 'O'), ('-', 'O'), ('41', 'O'), ('099', 'O'), ('to', 'O'), ('rats', 'O'), ('and', 'O'), ('dogs', 'O'), ('.', 'O'))"
The half life of the unlabeled substance in humans was more than 10 hours .,"(('The', 'O'), ('half', 'O'), ('life', 'O'), ('of', 'O'), ('the', 'O'), ('unlabeled', 'O'), ('substance', 'O'), ('in', 'O'), ('humans', 'O'), ('was', 'O'), ('more', 'O'), ('than', 'O'), ('10', 'O'), ('hours', 'O'), ('.', 'O'))"
The trial is single - blind .,"(('The', 'O'), ('trial', 'O'), ('is', 'O'), ('single', 'O'), ('-', 'O'), ('blind', 'O'), ('.', 'O'))"
"23 582 patient - years of observation have been completed so far , 10 684 on active drugs and 12 898 on placebos .","(('23', 'O'), ('582', 'O'), ('patient', 'O'), ('-', 'O'), ('years', 'O'), ('of', 'O'), ('observation', 'O'), ('have', 'O'), ('been', 'O'), ('completed', 'O'), ('so', 'O'), ('far', 'O'), (',', 'O'), ('10', 'O'), ('684', 'O'), ('on', 'O'), ('active', 'O'), ('drugs', 'O'), ('and', 'O'), ('12', 'O'), ('898', 'O'), ('on', 'O'), ('placebos', 'O'), ('.', 'O'))"
No corneal disease is known to have occurred in the propranolol group .,"(('No', 'O'), ('corneal', 'B'), ('disease', 'I'), ('is', 'O'), ('known', 'O'), ('to', 'O'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('propranolol', 'O'), ('group', 'O'), ('.', 'O'))"
"Mean serum potassium level fell , and urea and uric acid levels rose , in men and women taking bendrofluazide .","(('Mean', 'O'), ('serum', 'O'), ('potassium', 'O'), ('level', 'O'), ('fell', 'O'), (',', 'O'), ('and', 'O'), ('urea', 'O'), ('and', 'O'), ('uric', 'O'), ('acid', 'O'), ('levels', 'O'), ('rose', 'O'), (',', 'O'), ('in', 'O'), ('men', 'O'), ('and', 'O'), ('women', 'O'), ('taking', 'O'), ('bendrofluazide', 'O'), ('.', 'O'))"
"In the propranolol group , serum potassium and uric acid levels rose in both sexes , but the urea level rose significantly in women only .","(('In', 'O'), ('the', 'O'), ('propranolol', 'O'), ('group', 'O'), (',', 'O'), ('serum', 'O'), ('potassium', 'O'), ('and', 'O'), ('uric', 'O'), ('acid', 'O'), ('levels', 'O'), ('rose', 'O'), ('in', 'O'), ('both', 'O'), ('sexes', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('urea', 'O'), ('level', 'O'), ('rose', 'O'), ('significantly', 'O'), ('in', 'O'), ('women', 'O'), ('only', 'O'), ('.', 'O'))"
A 3 mg / kg ( i . p . ) dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min .,"(('A', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('(', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('dose', 'O'), ('induced', 'O'), ('this', 'O'), ('response', 'O'), ('in', 'O'), ('all', 'O'), ('of', 'O'), ('the', 'O'), ('mice', 'O'), ('tested', 'O'), ('and', 'O'), ('the', 'O'), ('peak', 'O'), ('response', 'O'), ('of', 'O'), ('73', 'O'), ('jerks', 'O'), ('per', 'O'), ('min', 'O'), ('was', 'O'), ('observed', 'O'), ('between', 'O'), ('27', 'O'), ('and', 'O'), ('45', 'O'), ('min', 'O'), ('.', 'O'))"
Increasing the brain serotonin levels by the administration of 5 - hydroxytryptophan ( 80 - 160 mg / kg ) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect .,"(('Increasing', 'O'), ('the', 'O'), ('brain', 'O'), ('serotonin', 'O'), ('levels', 'O'), ('by', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('5', 'O'), ('-', 'O'), ('hydroxytryptophan', 'O'), ('(', 'O'), ('80', 'O'), ('-', 'O'), ('160', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('a', 'O'), ('peripheral', 'O'), ('decarboxylase', 'O'), ('inhibitor', 'O'), ('resulted', 'O'), ('in', 'O'), ('an', 'O'), ('inhibition', 'O'), ('of', 'O'), ('the', 'O'), ('muscimol', 'O'), ('effect', 'O'), ('.', 'O'))"
"However , in a similar experiment l - dopa ( 80 - 160 mg / kg ) was without effect .","(('However', 'O'), (',', 'O'), ('in', 'O'), ('a', 'O'), ('similar', 'O'), ('experiment', 'O'), ('l', 'O'), ('-', 'O'), ('dopa', 'O'), ('(', 'O'), ('80', 'O'), ('-', 'O'), ('160', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('was', 'O'), ('without', 'O'), ('effect', 'O'), ('.', 'O'))"
"In doses of 3 - 10 mg / kg , the serotonin receptor agonist MK - 212 caused a dose - dependent blockade of the response of muscimol .","(('In', 'O'), ('doses', 'O'), ('of', 'O'), ('3', 'O'), ('-', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('the', 'O'), ('serotonin', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('MK', 'O'), ('-', 'O'), ('212', 'O'), ('caused', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('blockade', 'O'), ('of', 'O'), ('the', 'O'), ('response', 'O'), ('of', 'O'), ('muscimol', 'O'), ('.', 'O'))"
"While ( - ) - baclofen ( 1 - 3 mg / kg ) proved to be an effective antagonist of muscimol , its ( + ) - isomer ( 5 - 20 mg / kg ) lacked this property .","(('While', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('baclofen', 'O'), ('(', 'O'), ('1', 'O'), ('-', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('proved', 'O'), ('to', 'O'), ('be', 'O'), ('an', 'O'), ('effective', 'O'), ('antagonist', 'O'), ('of', 'O'), ('muscimol', 'O'), (',', 'O'), ('its', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('-', 'O'), ('isomer', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('lacked', 'O'), ('this', 'O'), ('property', 'O'), ('.', 'O'))"
Adverse interaction between beta - adrenergic blocking drugs and verapamil - - report of three cases .,"(('Adverse', 'O'), ('interaction', 'O'), ('between', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenergic', 'O'), ('blocking', 'O'), ('drugs', 'O'), ('and', 'O'), ('verapamil', 'O'), ('-', 'O'), ('-', 'O'), ('report', 'O'), ('of', 'O'), ('three', 'O'), ('cases', 'O'), ('.', 'O'))"
This clinical picture resolved completely with cessation of the combined therapy .,"(('This', 'O'), ('clinical', 'O'), ('picture', 'O'), ('resolved', 'O'), ('completely', 'O'), ('with', 'O'), ('cessation', 'O'), ('of', 'O'), ('the', 'O'), ('combined', 'O'), ('therapy', 'O'), ('.', 'O'))"
"Baseline left ventricular function , assessed by cardiac catheterisation or nuclear angiography , was normal in two patients and only mildly reduced in the other .","(('Baseline', 'O'), ('left', 'O'), ('ventricular', 'O'), ('function', 'O'), (',', 'O'), ('assessed', 'O'), ('by', 'O'), ('cardiac', 'O'), ('catheterisation', 'O'), ('or', 'O'), ('nuclear', 'O'), ('angiography', 'O'), (',', 'O'), ('was', 'O'), ('normal', 'O'), ('in', 'O'), ('two', 'O'), ('patients', 'O'), ('and', 'O'), ('only', 'O'), ('mildly', 'O'), ('reduced', 'O'), ('in', 'O'), ('the', 'O'), ('other', 'O'), ('.', 'O'))"
Simultaneously administration of beta - adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution .,"(('Simultaneously', 'O'), ('administration', 'O'), ('of', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenergic', 'O'), ('blocking', 'O'), ('drugs', 'O'), ('and', 'O'), ('verapamil', 'O'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('profound', 'O'), ('adverse', 'O'), ('interactions', 'O'), ('and', 'O'), ('should', 'O'), ('only', 'O'), ('be', 'O'), ('administered', 'O'), ('with', 'O'), ('great', 'O'), ('caution', 'O'), ('.', 'O'))"
Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states .,"(('Comparison', 'O'), ('of', 'O'), ('the', 'O'), ('effectiveness', 'O'), ('of', 'O'), ('ranitidine', 'O'), ('and', 'O'), ('cimetidine', 'O'), ('in', 'O'), ('inhibiting', 'O'), ('acid', 'O'), ('secretion', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('gastric', 'B'), ('hypersecretory', 'I'), ('states', 'I'), ('.', 'O'))"
The H2 - histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short - and long - term basis in 22 patients with gastric acid hypersecretory states .,"(('The', 'O'), ('H2', 'O'), ('-', 'O'), ('histamine', 'O'), ('receptor', 'O'), ('antagonists', 'O'), ('ranitidine', 'O'), ('and', 'O'), ('cimetidine', 'O'), ('were', 'O'), ('compared', 'O'), ('for', 'O'), ('their', 'O'), ('abilities', 'O'), ('to', 'O'), ('control', 'O'), ('gastric', 'B'), ('acid', 'I'), ('hypersecretion', 'I'), ('on', 'O'), ('a', 'O'), ('short', 'O'), ('-', 'O'), ('and', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('basis', 'O'), ('in', 'O'), ('22', 'O'), ('patients', 'O'), ('with', 'O'), ('gastric', 'B'), ('acid', 'I'), ('hypersecretory', 'I'), ('states', 'I'), ('.', 'O'))"
The rates of onset of the action of cimetidine and ranitidine were the same .,"(('The', 'O'), ('rates', 'O'), ('of', 'O'), ('onset', 'O'), ('of', 'O'), ('the', 'O'), ('action', 'O'), ('of', 'O'), ('cimetidine', 'O'), ('and', 'O'), ('ranitidine', 'O'), ('were', 'O'), ('the', 'O'), ('same', 'O'), ('.', 'O'))"
"The actions of both drugs were increased by anticholinergic agents , and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion .","(('The', 'O'), ('actions', 'O'), ('of', 'O'), ('both', 'O'), ('drugs', 'O'), ('were', 'O'), ('increased', 'O'), ('by', 'O'), ('anticholinergic', 'O'), ('agents', 'O'), (',', 'O'), ('and', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('close', 'O'), ('correlation', 'O'), ('between', 'O'), ('the', 'O'), ('daily', 'O'), ('maintenance', 'O'), ('dose', 'O'), ('of', 'O'), ('each', 'O'), ('drug', 'O'), ('needed', 'O'), ('to', 'O'), ('control', 'O'), ('acid', 'O'), ('secretion', 'O'), ('.', 'O'))"
"However , ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed ( 1 . 2 g per day for ranitidine and 3 . 6 g per day for cimetidine ) .","(('However', 'O'), (',', 'O'), ('ranitidine', 'O'), ('was', 'O'), ('threefold', 'O'), ('more', 'O'), ('potent', 'O'), ('than', 'O'), ('cimetidine', 'O'), ('both', 'O'), ('in', 'O'), ('acute', 'O'), ('inhibition', 'O'), ('studies', 'O'), ('and', 'O'), ('in', 'O'), ('the', 'O'), ('median', 'O'), ('maintenance', 'O'), ('dose', 'O'), ('needed', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('2', 'O'), ('g', 'O'), ('per', 'O'), ('day', 'O'), ('for', 'O'), ('ranitidine', 'O'), ('and', 'O'), ('3', 'O'), ('.', 'O'), ('6', 'O'), ('g', 'O'), ('per', 'O'), ('day', 'O'), ('for', 'O'), ('cimetidine', 'O'), (')', 'O'), ('.', 'O'))"
"Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .","(('Treatment', 'O'), ('with', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('cimetidine', 'O'), ('(', 'O'), ('one', 'O'), ('to', 'O'), ('60', 'O'), ('months', 'O'), (';', 'O'), ('median', 'O'), (',', 'O'), ('11', 'O'), ('months', 'O'), (')', 'O'), ('or', 'O'), ('ranitidine', 'O'), ('(', 'O'), ('two', 'O'), ('to', 'O'), ('31', 'O'), ('months', 'O'), (';', 'O'), ('median', 'O'), (',', 'O'), ('14', 'O'), ('months', 'O'), (')', 'O'), ('was', 'O'), ('not', 'O'), ('associated', 'O'), ('with', 'O'), ('hepatic', 'B'), ('or', 'O'), ('hematologic', 'O'), ('toxicity', 'O'), ('or', 'O'), ('alterations', 'O'), ('of', 'O'), ('serum', 'O'), ('gastrin', 'O'), ('concentrations', 'O'), (',', 'O'), ('but', 'O'), ('ranitidine', 'O'), ('therapy', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('significantly', 'O'), ('lower', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('level', 'O'), ('than', 'O'), ('seen', 'O'), ('with', 'O'), ('cimetidine', 'O'), ('therapy', 'O'), ('.', 'O'))"
The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states .,"(('The', 'O'), ('results', 'O'), ('show', 'O'), ('that', 'O'), ('both', 'O'), ('drugs', 'O'), ('can', 'O'), ('adequately', 'O'), ('inhibit', 'O'), ('acid', 'O'), ('secretion', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('gastric', 'B'), ('hypersecretory', 'I'), ('states', 'O'), ('.', 'O'))"
"Both are safe at high doses , but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine .","(('Both', 'O'), ('are', 'O'), ('safe', 'O'), ('at', 'O'), ('high', 'O'), ('doses', 'O'), (',', 'O'), ('but', 'O'), ('ranitidine', 'O'), ('is', 'O'), ('threefold', 'O'), ('more', 'O'), ('potent', 'O'), ('and', 'O'), ('does', 'O'), ('not', 'O'), ('cause', 'O'), ('the', 'O'), ('antiandrogen', 'O'), ('side', 'O'), ('effects', 'O'), ('frequently', 'O'), ('seen', 'O'), ('with', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('cimetidine', 'O'), ('.', 'O'))"
Epileptogenic properties of enflurane and their clinical interpretation .,"(('Epileptogenic', 'O'), ('properties', 'O'), ('of', 'O'), ('enflurane', 'O'), ('and', 'O'), ('their', 'O'), ('clinical', 'O'), ('interpretation', 'O'), ('.', 'O'))"
Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported .,"(('Three', 'O'), ('cases', 'O'), ('of', 'O'), ('EEG', 'O'), ('changes', 'O'), ('induced', 'O'), ('by', 'O'), ('single', 'O'), ('exposure', 'O'), ('to', 'O'), ('enflurane', 'O'), ('anesthesia', 'O'), ('are', 'O'), ('reported', 'O'), ('.', 'O'))"
"In one patient , enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures .","(('In', 'O'), ('one', 'O'), ('patient', 'O'), (',', 'O'), ('enflurane', 'O'), ('administered', 'O'), ('during', 'O'), ('a', 'O'), ('donor', 'O'), ('nephrectomy', 'O'), ('resulted', 'O'), ('in', 'O'), ('unexpected', 'O'), ('partial', 'O'), ('motor', 'B'), ('seizures', 'O'), ('.', 'O'))"
"Until the cause of the seizures was correctly identified , the patient was inappropriately treated with anticonvulsants .","(('Until', 'O'), ('the', 'O'), ('cause', 'O'), ('of', 'O'), ('the', 'O'), ('seizures', 'O'), ('was', 'O'), ('correctly', 'O'), ('identified', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('was', 'O'), ('inappropriately', 'O'), ('treated', 'O'), ('with', 'O'), ('anticonvulsants', 'O'), ('.', 'O'))"
"Two other patients suffered from partial , complex and generalized seizures uncontrolled by medication .","(('Two', 'O'), ('other', 'O'), ('patients', 'O'), ('suffered', 'O'), ('from', 'O'), ('partial', 'O'), (',', 'O'), ('complex', 'I'), ('and', 'I'), ('generalized', 'I'), ('seizures', 'O'), ('uncontrolled', 'O'), ('by', 'O'), ('medication', 'O'), ('.', 'O'))"
Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG .,"(('Previous', 'O'), ('exposures', 'O'), ('to', 'O'), ('enflurane', 'O'), ('have', 'O'), ('to', 'O'), ('be', 'O'), ('disclosed', 'O'), ('to', 'O'), ('avoid', 'O'), ('mistakes', 'O'), ('in', 'O'), ('clinical', 'O'), ('interpretation', 'O'), ('of', 'O'), ('the', 'O'), ('EEG', 'O'), ('.', 'O'))"
Development of isoproterenol - induced cardiac hypertrophy .,"(('Development', 'O'), ('of', 'O'), ('isoproterenol', 'B'), ('-', 'O'), ('induced', 'O'), ('cardiac', 'B'), ('hypertrophy', 'I'), ('.', 'O'))"
The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( ISO ) ( 0 . 3 mg / kg body weight ) .,"(('The', 'O'), ('development', 'O'), ('of', 'O'), ('cardiac', 'B'), ('hypertrophy', 'I'), ('was', 'O'), ('studied', 'O'), ('in', 'O'), ('adult', 'O'), ('female', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('following', 'O'), ('daily', 'O'), ('subcutaneous', 'O'), ('injections', 'O'), ('of', 'O'), ('isoproterenol', 'O'), ('(', 'O'), ('ISO', 'O'), (')', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('body', 'O'), ('weight', 'O'), (')', 'O'), ('.', 'O'))"
"A time course was established for the change in tissue mass , RNA and DNA content , as well as hydroxyproline content .","(('A', 'O'), ('time', 'O'), ('course', 'O'), ('was', 'O'), ('established', 'O'), ('for', 'O'), ('the', 'O'), ('change', 'O'), ('in', 'O'), ('tissue', 'O'), ('mass', 'O'), (',', 'O'), ('RNA', 'O'), ('and', 'O'), ('DNA', 'O'), ('content', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('hydroxyproline', 'O'), ('content', 'O'), ('.', 'O'))"
Heart weight increased 44 % after 8 days of treatment with a half time of 3 . 4 days .,"(('Heart', 'O'), ('weight', 'O'), ('increased', 'O'), ('44', 'O'), ('%', 'O'), ('after', 'O'), ('8', 'O'), ('days', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('a', 'O'), ('half', 'O'), ('time', 'O'), ('of', 'O'), ('3', 'O'), ('.', 'O'), ('4', 'O'), ('days', 'O'), ('.', 'O'))"
Ventricular RNA content was elevated 26 % after 24 h of a single injection and reached a maximal level following 8 days of therapy .,"(('Ventricular', 'O'), ('RNA', 'O'), ('content', 'O'), ('was', 'O'), ('elevated', 'O'), ('26', 'O'), ('%', 'O'), ('after', 'O'), ('24', 'O'), ('h', 'O'), ('of', 'O'), ('a', 'O'), ('single', 'O'), ('injection', 'O'), ('and', 'O'), ('reached', 'O'), ('a', 'O'), ('maximal', 'O'), ('level', 'O'), ('following', 'O'), ('8', 'O'), ('days', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O'))"
The half time for RNA accumulation was 2 . 0 days .,"(('The', 'O'), ('half', 'O'), ('time', 'O'), ('for', 'O'), ('RNA', 'O'), ('accumulation', 'O'), ('was', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('days', 'O'), ('.', 'O'))"
The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46 % after 4 days of therapy .,"(('The', 'O'), ('total', 'O'), ('content', 'O'), ('of', 'O'), ('hydroxyproline', 'O'), ('remained', 'O'), ('stable', 'O'), ('during', 'O'), ('the', 'O'), ('first', 'O'), ('2', 'O'), ('days', 'O'), ('of', 'O'), ('treatment', 'O'), ('but', 'O'), ('increased', 'O'), ('46', 'O'), ('%', 'O'), ('after', 'O'), ('4', 'O'), ('days', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O'))"
Ventricular DNA content was unchanged during the early stage ( 1 - 4 days ) of hypertrophic growth but increased to a new steady - state level 19 % above the controls after 8 days of treatment .,"(('Ventricular', 'O'), ('DNA', 'O'), ('content', 'O'), ('was', 'O'), ('unchanged', 'O'), ('during', 'O'), ('the', 'O'), ('early', 'O'), ('stage', 'O'), ('(', 'O'), ('1', 'O'), ('-', 'O'), ('4', 'O'), ('days', 'O'), (')', 'O'), ('of', 'O'), ('hypertrophic', 'B'), ('growth', 'O'), ('but', 'O'), ('increased', 'O'), ('to', 'O'), ('a', 'O'), ('new', 'O'), ('steady', 'O'), ('-', 'O'), ('state', 'O'), ('level', 'O'), ('19', 'O'), ('%', 'O'), ('above', 'O'), ('the', 'O'), ('controls', 'O'), ('after', 'O'), ('8', 'O'), ('days', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O'))"
Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy .,"(('Intraventricular', 'O'), ('pressures', 'O'), ('and', 'O'), ('coronary', 'O'), ('flow', 'O'), ('measures', 'O'), ('were', 'O'), ('similar', 'O'), ('for', 'O'), ('control', 'O'), ('and', 'O'), ('experimental', 'O'), ('animals', 'O'), ('following', 'O'), ('4', 'O'), ('days', 'O'), ('of', 'O'), ('developed', 'B'), ('hypertrophy', 'B'), ('.', 'O'))"
"However , dP / dt in the ISO - treated hearts was slightly but significantly ( P less than 0 . 05 ) elevated .","(('However', 'O'), (',', 'O'), ('dP', 'O'), ('/', 'O'), ('dt', 'O'), ('in', 'O'), ('the', 'O'), ('ISO', 'O'), ('-', 'O'), ('treated', 'O'), ('hearts', 'O'), ('was', 'O'), ('slightly', 'O'), ('but', 'O'), ('significantly', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('elevated', 'O'), ('.', 'O'))"
These data indicate that the adaptive response to ISO shows an early hypertrophic phase ( 1 - 4 days ) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA .,"(('These', 'O'), ('data', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('adaptive', 'O'), ('response', 'O'), ('to', 'O'), ('ISO', 'O'), ('shows', 'O'), ('an', 'O'), ('early', 'O'), ('hypertrophic', 'O'), ('phase', 'O'), ('(', 'O'), ('1', 'O'), ('-', 'O'), ('4', 'O'), ('days', 'O'), (')', 'O'), ('characterized', 'O'), ('by', 'O'), ('a', 'O'), ('substantial', 'O'), ('increase', 'O'), ('in', 'O'), ('RNA', 'O'), ('content', 'O'), ('and', 'O'), ('cardiac', 'O'), ('mass', 'O'), ('in', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('changes', 'O'), ('in', 'O'), ('DNA', 'O'), ('.', 'O'))"
Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis .,"(('Multiple', 'O'), ('side', 'O'), ('effects', 'O'), ('of', 'O'), ('penicillamine', 'O'), ('therapy', 'O'), ('in', 'O'), ('one', 'O'), ('patient', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('.', 'O'))"
A patient who had developed all 5 is now described .,"(('A', 'O'), ('patient', 'O'), ('who', 'O'), ('had', 'O'), ('developed', 'O'), ('all', 'O'), ('5', 'O'), ('is', 'O'), ('now', 'O'), ('described', 'O'), ('.', 'O'))"
Obsolete but dangerous antacid preparations .,"(('Obsolete', 'O'), ('but', 'O'), ('dangerous', 'O'), ('antacid', 'O'), ('preparations', 'O'), ('.', 'O'))"
The powders had been obtained from pharmacists unknown to the patients ' medical practitioners .,"(('The', 'O'), ('powders', 'O'), ('had', 'O'), ('been', 'O'), ('obtained', 'O'), ('from', 'O'), ('pharmacists', 'O'), ('unknown', 'O'), ('to', 'O'), ('the', 'O'), ('patients', 'O'), (""'"", 'O'), ('medical', 'O'), ('practitioners', 'O'), ('.', 'O'))"
"It is suggested that these preparations were responsible for the patient ' s problems , and that such powders should no longer be freely obtainable .","(('It', 'O'), ('is', 'O'), ('suggested', 'O'), ('that', 'O'), ('these', 'O'), ('preparations', 'O'), ('were', 'O'), ('responsible', 'O'), ('for', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('problems', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('such', 'O'), ('powders', 'O'), ('should', 'O'), ('no', 'O'), ('longer', 'O'), ('be', 'O'), ('freely', 'O'), ('obtainable', 'O'), ('.', 'O'))"
Doxorubicin cardiomyopathy in children with left - sided Wilms tumor .,"(('Doxorubicin', 'B'), ('cardiomyopathy', 'I'), ('in', 'O'), ('children', 'O'), ('with', 'O'), ('left', 'B'), ('-', 'I'), ('sided', 'I'), ('Wilms', 'B'), ('tumor', 'I'), ('.', 'O'))"
Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin .,"(('Two', 'O'), ('children', 'O'), ('with', 'O'), ('Wilms', 'B'), ('tumor', 'I'), ('of', 'I'), ('the', 'O'), ('left', 'O'), ('kidney', 'O'), ('experienced', 'O'), ('severe', 'O'), ('anthracycline', 'B'), ('cardiomyopathy', 'I'), ('after', 'O'), ('irradiation', 'O'), ('to', 'O'), ('the', 'O'), ('tumor', 'B'), ('bed', 'O'), ('and', 'O'), ('conventional', 'O'), ('dosage', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
The cardiomyopathy is attributed 1 ) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2 ) to the interaction of doxorubicin and irradiation on cardiac muscle .,"(('The', 'O'), ('cardiomyopathy', 'B'), ('is', 'O'), ('attributed', 'O'), ('1', 'O'), (')', 'O'), ('to', 'O'), ('the', 'O'), ('fact', 'O'), ('that', 'O'), ('radiation', 'O'), ('fields', 'O'), ('for', 'O'), ('left', 'B'), ('Wilms', 'I'), ('tumor', 'I'), ('include', 'O'), ('the', 'O'), ('lower', 'O'), ('portion', 'O'), ('of', 'O'), ('the', 'O'), ('heart', 'O'), ('and', 'O'), ('2', 'O'), (')', 'O'), ('to', 'O'), ('the', 'O'), ('interaction', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('and', 'O'), ('irradiation', 'O'), ('on', 'O'), ('cardiac', 'O'), ('muscle', 'O'), ('.', 'O'))"
It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation .,"(('It', 'O'), ('is', 'O'), ('recommended', 'O'), ('that', 'O'), ('doxorubicin', 'O'), ('dosage', 'O'), ('be', 'O'), ('sharply', 'O'), ('restricted', 'O'), ('in', 'O'), ('children', 'O'), ('with', 'O'), ('Wilms', 'B'), ('tumor', 'I'), ('of', 'I'), ('the', 'I'), ('left', 'I'), ('kidney', 'I'), ('who', 'O'), ('receive', 'O'), ('postoperative', 'O'), ('irradiation', 'O'), ('.', 'O'))"
Effects of calcitonin on rat extrapyramidal motor system : behavioral and biochemical data .,"(('Effects', 'O'), ('of', 'O'), ('calcitonin', 'O'), ('on', 'O'), ('rat', 'O'), ('extrapyramidal', 'O'), ('motor', 'O'), ('system', 'O'), (':', 'O'), ('behavioral', 'O'), ('and', 'O'), ('biochemical', 'O'), ('data', 'O'), ('.', 'O'))"
"The effects of i . v . c . injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system , were investigated in male rats .","(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), ('injection', 'O'), ('of', 'O'), ('human', 'O'), ('and', 'O'), ('salmon', 'O'), ('calcitonin', 'O'), ('on', 'O'), ('biochemical', 'O'), ('and', 'O'), ('behavioral', 'O'), ('parameters', 'O'), ('related', 'O'), ('to', 'O'), ('the', 'O'), ('extrapyramidal', 'O'), ('motor', 'O'), ('system', 'O'), (',', 'O'), ('were', 'O'), ('investigated', 'O'), ('in', 'O'), ('male', 'O'), ('rats', 'O'), ('.', 'O'))"
Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity .,"(('Moreover', 'O'), ('calcitonin', 'O'), ('induced', 'O'), ('a', 'O'), ('significant', 'O'), ('decrease', 'O'), ('in', 'O'), ('nigral', 'O'), ('GAD', 'O'), ('activity', 'O'), ('but', 'O'), ('no', 'O'), ('change', 'O'), ('in', 'O'), ('striatal', 'O'), ('DA', 'O'), ('and', 'O'), ('DOPAC', 'O'), ('concentration', 'O'), ('or', 'O'), ('GAD', 'O'), ('activity', 'O'), ('.', 'O'))"
The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA - related behavioral messages of striatal origin .,"(('The', 'O'), ('results', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('view', 'O'), ('of', 'O'), ('a', 'O'), ('primary', 'O'), ('action', 'O'), ('of', 'O'), ('calcitonin', 'O'), ('on', 'O'), ('the', 'O'), ('striatonigral', 'O'), ('GABAergic', 'O'), ('pathway', 'O'), ('mediating', 'O'), ('the', 'O'), ('DA', 'O'), ('-', 'O'), ('related', 'O'), ('behavioral', 'O'), ('messages', 'O'), ('of', 'O'), ('striatal', 'O'), ('origin', 'O'), ('.', 'O'))"
"Naloxazone pretreatment modifies cardiorespiratory , temperature , and behavioral effects of morphine .","(('Naloxazone', 'O'), ('pretreatment', 'O'), ('modifies', 'O'), ('cardiorespiratory', 'O'), (',', 'O'), ('temperature', 'O'), (',', 'O'), ('and', 'O'), ('behavioral', 'O'), ('effects', 'O'), ('of', 'O'), ('morphine', 'O'), ('.', 'O'))"
"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone , an antagonist of high - affinity mu 1 opioid receptors .","(('Behavioral', 'O'), ('and', 'O'), ('cardiorespiratory', 'O'), ('responses', 'O'), ('to', 'O'), ('a', 'O'), ('lethal', 'O'), ('dose', 'O'), ('of', 'O'), ('morphine', 'O'), ('were', 'O'), ('evaluated', 'O'), ('in', 'O'), ('rats', 'O'), ('pretreated', 'O'), ('with', 'O'), ('saline', 'O'), ('or', 'O'), ('naloxazone', 'O'), (',', 'O'), ('an', 'O'), ('antagonist', 'O'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('affinity', 'O'), ('mu', 'O'), ('1', 'O'), ('opioid', 'O'), ('receptors', 'O'), ('.', 'O'))"
Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine .,"(('Results', 'O'), ('indicate', 'O'), ('that', 'O'), ('subpopulations', 'O'), ('of', 'O'), ('mu', 'O'), ('receptors', 'O'), ('may', 'O'), ('mediate', 'O'), ('selective', 'O'), ('behavioral', 'O'), ('and', 'O'), ('cardiorespiratory', 'O'), ('responses', 'O'), ('to', 'O'), ('morphine', 'O'), ('.', 'O'))"
"Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam , but NH4Ac treatment alone had no effect .","(('Pretreatment', 'O'), ('with', 'O'), ('ammonium', 'O'), ('acetate', 'O'), ('(', 'O'), ('NH4Ac', 'O'), (')', 'O'), ('(', 'O'), ('6', 'O'), ('mmol', 'O'), ('/', 'O'), ('kg', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), ('approximately', 'O'), ('doubled', 'O'), ('the', 'O'), ('time', 'O'), ('morphine', 'O'), ('-', 'O'), ('treated', 'O'), ('mice', 'O'), ('remained', 'O'), ('on', 'O'), ('a', 'O'), ('hot', 'O'), ('surface', 'O'), ('and', 'O'), ('similarly', 'O'), ('increased', 'O'), ('muscular', 'B'), ('incoordination', 'I'), ('by', 'O'), ('diazepam', 'O'), (',', 'O'), ('but', 'O'), ('NH4Ac', 'O'), ('treatment', 'O'), ('alone', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('.', 'O'))"
Experiments in vitro showed that acetylcholine - induced catecholamine release from bovine adrenal medulla is depressed as much as 50 % by 0 . 3 mM NH4Ac and KCl - induced contractions of guinea - pig ileum were inhibited 20 % by 5 mM NH4Ac .,"(('Experiments', 'O'), ('in', 'O'), ('vitro', 'O'), ('showed', 'O'), ('that', 'O'), ('acetylcholine', 'O'), ('-', 'O'), ('induced', 'O'), ('catecholamine', 'O'), ('release', 'O'), ('from', 'O'), ('bovine', 'O'), ('adrenal', 'O'), ('medulla', 'O'), ('is', 'O'), ('depressed', 'O'), ('as', 'O'), ('much', 'O'), ('as', 'O'), ('50', 'O'), ('%', 'O'), ('by', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('mM', 'O'), ('NH4Ac', 'O'), ('and', 'O'), ('KCl', 'O'), ('-', 'O'), ('induced', 'O'), ('contractions', 'O'), ('of', 'O'), ('guinea', 'O'), ('-', 'O'), ('pig', 'O'), ('ileum', 'O'), ('were', 'O'), ('inhibited', 'O'), ('20', 'O'), ('%', 'O'), ('by', 'O'), ('5', 'O'), ('mM', 'O'), ('NH4Ac', 'O'), ('.', 'O'))"
These results suggested that ammonia blocks calcium channels .,"(('These', 'O'), ('results', 'O'), ('suggested', 'O'), ('that', 'O'), ('ammonia', 'O'), ('blocks', 'O'), ('calcium', 'O'), ('channels', 'O'), ('.', 'O'))"
Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept .,"(('Parallels', 'O'), ('in', 'O'), ('the', 'O'), ('actions', 'O'), ('of', 'O'), ('NH4Ac', 'O'), ('and', 'O'), ('the', 'O'), ('calcium', 'O'), ('channel', 'O'), ('blocker', 'O'), ('verapamil', 'O'), ('support', 'O'), ('this', 'O'), ('concept', 'O'), ('.', 'O'))"
"MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg / m2 , each administered at 0 hr ( = injection of IF ) , 4 hr and 8 hr p . i .","(('MESNA', 'O'), ('was', 'O'), ('given', 'O'), ('orally', 'O'), ('on', 'O'), ('the', 'O'), ('days', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('IF', 'B'), ('in', 'O'), ('3', 'O'), ('doses', 'O'), ('of', 'O'), ('840', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), (',', 'O'), ('each', 'O'), ('administered', 'O'), ('at', 'O'), ('0', 'O'), ('hr', 'O'), ('(', 'O'), ('=', 'O'), ('injection', 'O'), ('of', 'O'), ('IF', 'B'), (')', 'O'), (',', 'O'), ('4', 'O'), ('hr', 'O'), ('and', 'O'), ('8', 'O'), ('hr', 'O'), ('p', 'O'), ('.', 'O'), ('i', 'O'), ('.', 'O'))"
Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria .,"(('Out', 'O'), ('of', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('88', 'O'), ('courses', 'O'), ('of', 'O'), ('this', 'O'), ('treatment', 'O'), ('we', 'O'), ('observed', 'O'), ('10', 'O'), ('episodes', 'O'), ('of', 'O'), ('asymptomatic', 'O'), ('microscopic', 'O'), ('haematuria', 'B'), ('and', 'O'), ('no', 'O'), ('episodes', 'O'), ('of', 'O'), ('gross', 'O'), ('haematuria', 'B'), ('.', 'O'))"
In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions ( total 31 % ) .,"(('In', 'O'), ('this', 'O'), ('group', 'O'), ('of', 'O'), ('45', 'O'), ('patients', 'O'), ('under', 'O'), ('protection', 'O'), ('with', 'O'), ('MESNA', 'O'), ('there', 'O'), ('were', 'O'), ('5', 'O'), ('complete', 'O'), ('remissions', 'O'), ('and', 'O'), ('9', 'O'), ('partial', 'O'), ('remissions', 'O'), ('(', 'O'), ('total', 'O'), ('31', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures ( raised fluid intake and forced diuresis ) .,"(('A', 'O'), ('further', 'O'), ('group', 'O'), ('of', 'O'), ('25', 'O'), ('patients', 'O'), ('under', 'O'), ('polychemotherapy', 'O'), ('with', 'O'), ('IF', 'B'), ('were', 'O'), ('treated', 'O'), ('by', 'O'), ('conventional', 'O'), ('prophylactic', 'O'), ('measures', 'O'), ('(', 'O'), ('raised', 'O'), ('fluid', 'O'), ('intake', 'O'), ('and', 'O'), ('forced', 'O'), ('diuresis', 'O'), (')', 'O'), ('.', 'O'))"
There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment .,"(('There', 'O'), ('were', 'O'), ('no', 'O'), ('appreciable', 'O'), ('differences', 'O'), ('between', 'O'), ('the', 'O'), ('MESNA', 'O'), ('series', 'O'), ('and', 'O'), ('the', 'O'), ('conventional', 'O'), ('prophylaxis', 'O'), ('series', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('either', 'O'), ('haematological', 'O'), ('or', 'O'), ('systemic', 'O'), ('toxicity', 'O'), ('of', 'O'), ('the', 'O'), ('cytostatic', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Our results support the view that MESNA , given orally in conjunction with combined cytostatic regimens which include IF , simplifies the treatment and provides optimum protection for the urinary epithelium .","(('Our', 'O'), ('results', 'O'), ('support', 'O'), ('the', 'O'), ('view', 'O'), ('that', 'O'), ('MESNA', 'O'), (',', 'O'), ('given', 'O'), ('orally', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('combined', 'O'), ('cytostatic', 'O'), ('regimens', 'O'), ('which', 'O'), ('include', 'O'), ('IF', 'O'), (',', 'O'), ('simplifies', 'O'), ('the', 'O'), ('treatment', 'O'), ('and', 'O'), ('provides', 'O'), ('optimum', 'O'), ('protection', 'O'), ('for', 'O'), ('the', 'O'), ('urinary', 'O'), ('epithelium', 'O'), ('.', 'O'))"
Protection with oral MESNA is particularly suitable for outpatients .,"(('Protection', 'O'), ('with', 'O'), ('oral', 'O'), ('MESNA', 'O'), ('is', 'O'), ('particularly', 'O'), ('suitable', 'O'), ('for', 'O'), ('outpatients', 'O'), ('.', 'O'))"
"When the carbamazepine was discontinued , two of the children returned to their former state very quickly , two had the minor motor seizures resolve in 3 and 6 months , and one had the seizures persist .","(('When', 'O'), ('the', 'O'), ('carbamazepine', 'O'), ('was', 'O'), ('discontinued', 'O'), (',', 'O'), ('two', 'O'), ('of', 'O'), ('the', 'O'), ('children', 'O'), ('returned', 'O'), ('to', 'O'), ('their', 'O'), ('former', 'O'), ('state', 'O'), ('very', 'O'), ('quickly', 'O'), (',', 'O'), ('two', 'O'), ('had', 'O'), ('the', 'O'), ('minor', 'O'), ('motor', 'O'), ('seizures', 'O'), ('resolve', 'O'), ('in', 'O'), ('3', 'O'), ('and', 'O'), ('6', 'O'), ('months', 'O'), (',', 'O'), ('and', 'O'), ('one', 'O'), ('had', 'O'), ('the', 'O'), ('seizures', 'O'), ('persist', 'O'), ('.', 'O'))"
The other children are doing well on other anticonvulsants .,"(('The', 'O'), ('other', 'O'), ('children', 'O'), ('are', 'O'), ('doing', 'O'), ('well', 'O'), ('on', 'O'), ('other', 'O'), ('anticonvulsants', 'O'), ('.', 'O'))"
Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats .,"(('Effect', 'O'), ('of', 'O'), ('prostaglandin', 'O'), ('synthetase', 'O'), ('inhibitors', 'O'), ('on', 'O'), ('experimentally', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .","(('To', 'O'), ('investigate', 'O'), ('the', 'O'), ('relationship', 'O'), ('of', 'O'), ('prostaglandins', 'O'), ('(', 'O'), ('PGs', 'O'), (')', 'O'), ('to', 'O'), ('seizure', 'O'), ('induction', 'O'), (',', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('six', 'O'), ('PG', 'O'), ('synthetase', 'O'), ('inhibitors', 'O'), ('on', 'O'), ('convulsions', 'O'), ('induced', 'O'), ('by', 'O'), ('flurothyl', 'O'), (',', 'O'), ('picrotoxin', 'O'), (',', 'O'), ('pentetrazol', 'O'), ('(', 'O'), ('PTZ', 'O'), (')', 'O'), (',', 'O'), ('electroshock', 'O'), ('or', 'O'), ('bicuculline', 'O'), ('were', 'O'), ('evaluated', 'O'), ('.', 'O'))"
"Ibuprofen , sulindac , mefenamic acid , and low dose meclofenamic acid increased the latency - to - onset in the flurothyl and / or PTZ models ; the electroshock , picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents .","(('Ibuprofen', 'O'), (',', 'O'), ('sulindac', 'O'), (',', 'O'), ('mefenamic', 'O'), ('acid', 'O'), (',', 'O'), ('and', 'O'), ('low', 'O'), ('dose', 'O'), ('meclofenamic', 'O'), ('acid', 'O'), ('increased', 'O'), ('the', 'O'), ('latency', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('onset', 'O'), ('in', 'O'), ('the', 'O'), ('flurothyl', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('PTZ', 'O'), ('models', 'O'), (';', 'O'), ('the', 'O'), ('electroshock', 'O'), (',', 'O'), ('picrotoxin', 'O'), ('and', 'O'), ('bicuculline', 'O'), ('models', 'O'), ('were', 'O'), ('not', 'O'), ('significantly', 'O'), ('affected', 'O'), ('by', 'O'), ('any', 'O'), ('of', 'O'), ('the', 'O'), ('pretreatment', 'O'), ('agents', 'O'), ('.', 'O'))"
"These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .","(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('PGs', 'O'), ('are', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('mechanism', 'O'), ('(', 'O'), ('s', 'O'), (')', 'O'), ('underlying', 'O'), ('fluorthyl', 'O'), ('-', 'O'), ('and', 'O'), ('PTZ', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('picrotoxin', 'O'), ('-', 'O'), (',', 'O'), ('electroshock', 'O'), ('-', 'O'), (',', 'O'), ('or', 'O'), ('bicuculline', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('.', 'O'))"
Acute changes of blood ammonia may predict short - term adverse effects of valproic acid .,"(('Acute', 'O'), ('changes', 'O'), ('of', 'O'), ('blood', 'O'), ('ammonia', 'O'), ('may', 'O'), ('predict', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('adverse', 'O'), ('effects', 'O'), ('of', 'O'), ('valproic', 'O'), ('acid', 'O'), ('.', 'O'))"
"A standardized loading dose of VPA was administered , and venous blood was sampled at 0 , 1 , 2 , 3 , and 4 hours .","(('A', 'O'), ('standardized', 'O'), ('loading', 'O'), ('dose', 'O'), ('of', 'O'), ('VPA', 'O'), ('was', 'O'), ('administered', 'O'), (',', 'O'), ('and', 'O'), ('venous', 'O'), ('blood', 'O'), ('was', 'O'), ('sampled', 'O'), ('at', 'O'), ('0', 'O'), (',', 'O'), ('1', 'O'), (',', 'O'), ('2', 'O'), (',', 'O'), ('3', 'O'), (',', 'O'), ('and', 'O'), ('4', 'O'), ('hours', 'O'), ('.', 'O'))"
"By measuring VPA - induced changes of blood NH3 content , it may be possible to identify patients at higher risk of obtundation when VPA is given chronically .","(('By', 'O'), ('measuring', 'O'), ('VPA', 'O'), ('-', 'O'), ('induced', 'O'), ('changes', 'O'), ('of', 'O'), ('blood', 'O'), ('NH3', 'O'), ('content', 'O'), (',', 'O'), ('it', 'O'), ('may', 'O'), ('be', 'O'), ('possible', 'O'), ('to', 'O'), ('identify', 'O'), ('patients', 'O'), ('at', 'O'), ('higher', 'O'), ('risk', 'O'), ('of', 'O'), ('obtundation', 'O'), ('when', 'O'), ('VPA', 'O'), ('is', 'O'), ('given', 'O'), ('chronically', 'O'), ('.', 'O'))"
The possibility of reproducing the same renal abnormality with captopril was examined in SHR .,"(('The', 'O'), ('possibility', 'O'), ('of', 'O'), ('reproducing', 'O'), ('the', 'O'), ('same', 'O'), ('renal', 'B'), ('abnormality', 'I'), ('with', 'O'), ('captopril', 'O'), ('was', 'O'), ('examined', 'O'), ('in', 'O'), ('SHR', 'O'), ('.', 'O'))"
Oral administration of captopril at 100 mg / kg for 14 days failed to aggravate proteinuria pre - existing in SHR .,"(('Oral', 'O'), ('administration', 'O'), ('of', 'O'), ('captopril', 'O'), ('at', 'O'), ('100', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('for', 'O'), ('14', 'O'), ('days', 'O'), ('failed', 'O'), ('to', 'O'), ('aggravate', 'O'), ('proteinuria', 'B'), ('pre', 'O'), ('-', 'O'), ('existing', 'O'), ('in', 'O'), ('SHR', 'O'), ('.', 'O'))"
"Also , captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR .","(('Also', 'O'), (',', 'O'), ('captopril', 'O'), ('treatment', 'O'), ('failed', 'O'), ('to', 'O'), ('potentiate', 'O'), ('or', 'O'), ('facilitate', 'O'), ('development', 'O'), ('of', 'O'), ('massive', 'O'), ('proteinuria', 'B'), ('invoked', 'O'), ('by', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('in', 'O'), ('SHR', 'O'), ('.', 'O'))"
"Captopril had little or no demonstrable effects on serum electrolyte concentrations , excretion of urine , sodium and potassium , endogenous creatinine clearance , body weight , and food and water consumption .","(('Captopril', 'O'), ('had', 'O'), ('little', 'O'), ('or', 'O'), ('no', 'O'), ('demonstrable', 'O'), ('effects', 'O'), ('on', 'O'), ('serum', 'O'), ('electrolyte', 'O'), ('concentrations', 'O'), (',', 'O'), ('excretion', 'O'), ('of', 'O'), ('urine', 'O'), (',', 'O'), ('sodium', 'O'), ('and', 'O'), ('potassium', 'O'), (',', 'O'), ('endogenous', 'O'), ('creatinine', 'O'), ('clearance', 'O'), (',', 'O'), ('body', 'O'), ('weight', 'O'), (',', 'O'), ('and', 'O'), ('food', 'O'), ('and', 'O'), ('water', 'O'), ('consumption', 'O'), ('.', 'O'))"
"However , ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR .","(('However', 'O'), (',', 'O'), ('ketone', 'O'), ('bodies', 'O'), ('were', 'O'), ('consistently', 'O'), ('present', 'O'), ('in', 'O'), ('urine', 'O'), ('and', 'O'), ('several', 'O'), ('lethalities', 'O'), ('occurred', 'O'), ('during', 'O'), ('multiple', 'O'), ('dosing', 'O'), ('of', 'O'), ('captopril', 'O'), ('in', 'O'), ('SHR', 'O'), ('.', 'O'))"
Complete heart block following a single dose of trazodone .,"(('Complete', 'B'), ('heart', 'I'), ('block', 'I'), ('following', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('trazodone', 'O'), ('.', 'O'))"
"Forty minutes after receiving a single starting dose of trazodone , a patient developed complete heart block .","(('Forty', 'O'), ('minutes', 'O'), ('after', 'O'), ('receiving', 'O'), ('a', 'O'), ('single', 'O'), ('starting', 'O'), ('dose', 'O'), ('of', 'O'), ('trazodone', 'O'), (',', 'O'), ('a', 'O'), ('patient', 'O'), ('developed', 'O'), ('complete', 'O'), ('heart', 'B'), ('block', 'I'), ('.', 'O'))"
"The case illustrates that , despite the results of earlier studies , trazodone ' s effect on cardiac conduction may be severe in individuals at risk for conduction delay .","(('The', 'O'), ('case', 'O'), ('illustrates', 'O'), ('that', 'O'), (',', 'O'), ('despite', 'O'), ('the', 'O'), ('results', 'O'), ('of', 'O'), ('earlier', 'O'), ('studies', 'O'), (',', 'O'), ('trazodone', 'O'), (""'"", 'O'), ('s', 'O'), ('effect', 'O'), ('on', 'O'), ('cardiac', 'O'), ('conduction', 'O'), ('may', 'O'), ('be', 'O'), ('severe', 'O'), ('in', 'O'), ('individuals', 'O'), ('at', 'O'), ('risk', 'O'), ('for', 'O'), ('conduction', 'B'), ('delay', 'I'), ('.', 'O'))"
Known causes of movement disorders were eliminated after evaluation .,"(('Known', 'O'), ('causes', 'O'), ('of', 'O'), ('movement', 'B'), ('disorders', 'I'), ('were', 'O'), ('eliminated', 'O'), ('after', 'O'), ('evaluation', 'O'), ('.', 'O'))"
Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders .,"(('Phenobarbital', 'O'), ('should', 'O'), ('be', 'O'), ('added', 'O'), ('to', 'O'), ('the', 'O'), ('list', 'O'), ('of', 'O'), ('anticonvulsant', 'O'), ('drugs', 'O'), ('that', 'O'), ('can', 'O'), ('cause', 'O'), ('movement', 'B'), ('disorders', 'I'), ('.', 'O'))"
The pineal indolamines exhibited mixed actions .,"(('The', 'O'), ('pineal', 'O'), ('indolamines', 'O'), ('exhibited', 'O'), ('mixed', 'O'), ('actions', 'O'), ('.', 'O'))"
"Serotonin and N - acetyl serotonin which augmented ketamine DOC , did not do so in the absence of the pineal gland , whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick .","(('Serotonin', 'O'), ('and', 'O'), ('N', 'O'), ('-', 'O'), ('acetyl', 'O'), ('serotonin', 'O'), ('which', 'O'), ('augmented', 'O'), ('ketamine', 'O'), ('DOC', 'O'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('do', 'O'), ('so', 'O'), ('in', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('the', 'O'), ('pineal', 'O'), ('gland', 'O'), (',', 'O'), ('whereas', 'O'), ('melatonin', 'O'), ('potentiated', 'O'), ('the', 'O'), ('ketamine', 'O'), ('DOC', 'O'), ('in', 'O'), ('both', 'O'), ('the', 'O'), ('intact', 'O'), ('and', 'O'), ('pinealectomized', 'O'), ('chick', 'O'), ('.', 'O'))"
"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent ; furthermore , melatonin did not augment the ketamine DOC whereas dopamine continued to do so .","(('Ketamine', 'O'), ('was', 'O'), ('more', 'O'), ('potent', 'O'), ('in', 'O'), ('the', 'O'), ('hypophysectomized', 'O'), ('chick', 'O'), ('and', 'O'), ('the', 'O'), ('circadian', 'O'), ('rhythm', 'O'), ('noted', 'O'), ('in', 'O'), ('the', 'O'), ('intact', 'O'), ('chick', 'O'), ('was', 'O'), ('absent', 'O'), (';', 'O'), ('furthermore', 'O'), (',', 'O'), ('melatonin', 'O'), ('did', 'O'), ('not', 'O'), ('augment', 'O'), ('the', 'O'), ('ketamine', 'O'), ('DOC', 'O'), ('whereas', 'O'), ('dopamine', 'O'), ('continued', 'O'), ('to', 'O'), ('do', 'O'), ('so', 'O'), ('.', 'O'))"
This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood - brain barrier in the young chick and the intact barrier in the rat .,"(('This', 'O'), ('study', 'O'), ('did', 'O'), ('not', 'O'), ('demonstrate', 'O'), ('a', 'O'), ('species', 'O'), ('difference', 'O'), ('regarding', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('the', 'O'), ('amines', 'O'), ('on', 'O'), ('the', 'O'), ('pineal', 'O'), ('in', 'O'), ('spite', 'O'), ('of', 'O'), ('the', 'O'), ('immature', 'O'), ('blood', 'O'), ('-', 'O'), ('brain', 'O'), ('barrier', 'O'), ('in', 'O'), ('the', 'O'), ('young', 'O'), ('chick', 'O'), ('and', 'O'), ('the', 'O'), ('intact', 'O'), ('barrier', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
"In addition , these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('these', 'O'), ('data', 'O'), ('indicate', 'O'), ('a', 'O'), ('direct', 'O'), ('role', 'O'), ('of', 'O'), ('the', 'O'), ('pituitary', 'O'), ('in', 'O'), ('the', 'O'), ('augmentation', 'O'), ('of', 'O'), ('ketamine', 'O'), ('DOC', 'O'), ('induced', 'O'), ('by', 'O'), ('melatonin', 'O'), ('.', 'O'))"
Sixty - two patients with a heparin - induced thrombocytopenia are reported .,"(('Sixty', 'O'), ('-', 'O'), ('two', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('heparin', 'B'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'I'), ('are', 'O'), ('reported', 'O'), ('.', 'O'))"
Immunologic testing has demonstrated the presence of a heparin - dependent platelet membrane antibody .,"(('Immunologic', 'O'), ('testing', 'O'), ('has', 'O'), ('demonstrated', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('a', 'O'), ('heparin', 'O'), ('-', 'O'), ('dependent', 'O'), ('platelet', 'O'), ('membrane', 'O'), ('antibody', 'O'), ('.', 'O'))"
"Specific risk factors have not been identified ; therefore , all patients receiving heparin should be monitored .","(('Specific', 'O'), ('risk', 'O'), ('factors', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('identified', 'O'), (';', 'O'), ('therefore', 'O'), (',', 'O'), ('all', 'O'), ('patients', 'O'), ('receiving', 'O'), ('heparin', 'O'), ('should', 'O'), ('be', 'O'), ('monitored', 'O'), ('.', 'O'))"
"Management consists of cessation of heparin , platelet anti - aggregating agents , and alternate forms of anticoagulation when indicated .","(('Management', 'O'), ('consists', 'O'), ('of', 'O'), ('cessation', 'O'), ('of', 'O'), ('heparin', 'O'), (',', 'O'), ('platelet', 'O'), ('anti', 'O'), ('-', 'O'), ('aggregating', 'O'), ('agents', 'O'), (',', 'O'), ('and', 'O'), ('alternate', 'O'), ('forms', 'O'), ('of', 'O'), ('anticoagulation', 'O'), ('when', 'O'), ('indicated', 'O'), ('.', 'O'))"
The toxicity of Renografin 76 % was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .,"(('The', 'O'), ('toxicity', 'O'), ('of', 'O'), ('Renografin', 'O'), ('76', 'O'), ('%', 'O'), ('was', 'O'), ('compared', 'O'), ('with', 'O'), ('that', 'O'), ('of', 'O'), ('Hypaque', 'O'), ('76', 'O'), ('%', 'O'), ('by', 'O'), ('selective', 'O'), ('injection', 'O'), ('of', 'O'), ('each', 'O'), ('into', 'O'), ('the', 'O'), ('right', 'O'), ('coronary', 'O'), ('artery', 'O'), ('of', 'O'), ('dogs', 'O'), ('.', 'O'))"
"Renografin contains the chelating agents sodium citrate and disodium edetate , while Hypaque contains calcium disodium edetate and no sodium citrate .","(('Renografin', 'O'), ('contains', 'O'), ('the', 'O'), ('chelating', 'O'), ('agents', 'O'), ('sodium', 'O'), ('citrate', 'O'), ('and', 'O'), ('disodium', 'O'), ('edetate', 'O'), (',', 'O'), ('while', 'O'), ('Hypaque', 'O'), ('contains', 'O'), ('calcium', 'O'), ('disodium', 'O'), ('edetate', 'O'), ('and', 'O'), ('no', 'O'), ('sodium', 'O'), ('citrate', 'O'), ('.', 'O'))"
The loading dose was 800 mg / day for 6 weeks and the maintenance dose was 600 mg / day .,"(('The', 'O'), ('loading', 'O'), ('dose', 'O'), ('was', 'O'), ('800', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('for', 'O'), ('6', 'O'), ('weeks', 'O'), ('and', 'O'), ('the', 'O'), ('maintenance', 'O'), ('dose', 'O'), ('was', 'O'), ('600', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('.', 'O'))"
One or more adverse drug reactions occurred in 51 % of patients .,"(('One', 'O'), ('or', 'O'), ('more', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('51', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O'))"
Adverse effects forced a reduction in the dose of amiodarone in 41 % and discontinuation of amiodarone in 10 % of patients .,"(('Adverse', 'O'), ('effects', 'O'), ('forced', 'O'), ('a', 'O'), ('reduction', 'O'), ('in', 'O'), ('the', 'O'), ('dose', 'O'), ('of', 'O'), ('amiodarone', 'O'), ('in', 'O'), ('41', 'O'), ('%', 'O'), ('and', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('amiodarone', 'O'), ('in', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O'))"
Why may epsilon - aminocaproic acid ( EACA ) induce myopathy in man ?,"(('Why', 'O'), ('may', 'O'), ('epsilon', 'O'), ('-', 'O'), ('aminocaproic', 'O'), ('acid', 'O'), ('(', 'O'), ('EACA', 'O'), (')', 'O'), ('induce', 'O'), ('myopathy', 'B'), ('in', 'O'), ('man', 'O'), ('?', 'O'))"
Report of a case and literature review .,"(('Report', 'O'), ('of', 'O'), ('a', 'O'), ('case', 'O'), ('and', 'O'), ('literature', 'O'), ('review', 'O'), ('.', 'O'))"
Pathogenetic hypotheses are discussed .,"(('Pathogenetic', 'O'), ('hypotheses', 'O'), ('are', 'O'), ('discussed', 'O'), ('.', 'O'))"
"It is often combined with caffeine in diet preparations and "" look - alike "" pills .","(('It', 'O'), ('is', 'O'), ('often', 'O'), ('combined', 'O'), ('with', 'O'), ('caffeine', 'O'), ('in', 'O'), ('diet', 'O'), ('preparations', 'O'), ('and', 'O'), ('""', 'O'), ('look', 'O'), ('-', 'O'), ('alike', 'O'), ('""', 'O'), ('pills', 'O'), ('.', 'O'))"
An acute elevation in blood pressure may be a contributing factor .,"(('An', 'O'), ('acute', 'O'), ('elevation', 'O'), ('in', 'O'), ('blood', 'O'), ('pressure', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('contributing', 'O'), ('factor', 'O'), ('.', 'O'))"
Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months .,"(('Sulindac', 'O'), ('was', 'O'), ('substituted', 'O'), ('for', 'O'), ('naproxen', 'O'), ('and', 'O'), ('no', 'O'), ('further', 'O'), ('adverse', 'O'), ('renal', 'O'), ('effects', 'O'), ('occurred', 'O'), ('over', 'O'), ('the', 'O'), ('next', 'O'), ('12', 'O'), ('months', 'O'), ('.', 'O'))"
"To quantify the effects of gentamicin , kanamycin and netilmicin on renal protein reabsorption and accumulation , these drugs were administered to rats intraperitoneally ( 30 mg / kg / day ) for 7 , 14 or 21 days .","(('To', 'O'), ('quantify', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('gentamicin', 'O'), (',', 'O'), ('kanamycin', 'O'), ('and', 'O'), ('netilmicin', 'O'), ('on', 'O'), ('renal', 'O'), ('protein', 'O'), ('reabsorption', 'O'), ('and', 'O'), ('accumulation', 'O'), (',', 'O'), ('these', 'O'), ('drugs', 'O'), ('were', 'O'), ('administered', 'O'), ('to', 'O'), ('rats', 'O'), ('intraperitoneally', 'O'), ('(', 'O'), ('30', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('for', 'O'), ('7', 'O'), (',', 'O'), ('14', 'O'), ('or', 'O'), ('21', 'O'), ('days', 'O'), ('.', 'O'))"
"Scanning electron microscopy of the glomerular endothelia , urinary measurements of sodium , potassium , endogenous lysozyme , N - acetyl - beta - D - glucosaminidase ( NAG ) as well as clearance and accumulation experiments after i . v . administration of egg - white lysozyme and measurements of inulin clearance ( GFR ) were done in each treatment group .","(('Scanning', 'O'), ('electron', 'O'), ('microscopy', 'O'), ('of', 'O'), ('the', 'O'), ('glomerular', 'O'), ('endothelia', 'O'), (',', 'O'), ('urinary', 'O'), ('measurements', 'O'), ('of', 'O'), ('sodium', 'O'), (',', 'O'), ('potassium', 'O'), (',', 'O'), ('endogenous', 'O'), ('lysozyme', 'O'), (',', 'O'), ('N', 'O'), ('-', 'O'), ('acetyl', 'O'), ('-', 'O'), ('beta', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('glucosaminidase', 'O'), ('(', 'O'), ('NAG', 'O'), (')', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('clearance', 'O'), ('and', 'O'), ('accumulation', 'O'), ('experiments', 'O'), ('after', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('administration', 'O'), ('of', 'O'), ('egg', 'O'), ('-', 'O'), ('white', 'O'), ('lysozyme', 'O'), ('and', 'O'), ('measurements', 'O'), ('of', 'O'), ('inulin', 'O'), ('clearance', 'O'), ('(', 'O'), ('GFR', 'O'), (')', 'O'), ('were', 'O'), ('done', 'O'), ('in', 'O'), ('each', 'O'), ('treatment', 'O'), ('group', 'O'), ('.', 'O'))"
"Gentamicin administration decreased diameter , density and shape of endothelial fenestrae .","(('Gentamicin', 'O'), ('administration', 'O'), ('decreased', 'O'), ('diameter', 'O'), (',', 'O'), ('density', 'O'), ('and', 'O'), ('shape', 'O'), ('of', 'O'), ('endothelial', 'O'), ('fenestrae', 'O'), ('.', 'O'))"
Kanamycin and netilmicin appeared to have no effect at the dose used .,"(('Kanamycin', 'O'), ('and', 'O'), ('netilmicin', 'O'), ('appeared', 'O'), ('to', 'O'), ('have', 'O'), ('no', 'O'), ('effect', 'O'), ('at', 'O'), ('the', 'O'), ('dose', 'O'), ('used', 'O'), ('.', 'O'))"
All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium .,"(('All', 'O'), ('three', 'O'), ('aminoglycosides', 'O'), ('decreased', 'O'), ('GFR', 'O'), ('and', 'O'), ('increased', 'O'), ('urinary', 'O'), ('excretion', 'O'), ('of', 'O'), ('sodium', 'O'), ('and', 'O'), ('potassium', 'O'), ('.', 'O'))"
While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i . v . administration of egg - white lysozyme netilmicin had no effect .,"(('While', 'O'), ('gentamicin', 'O'), ('and', 'O'), ('kanamycin', 'O'), ('decreased', 'O'), ('the', 'O'), ('percentage', 'O'), ('reabsorption', 'O'), ('and', 'O'), ('accumulation', 'O'), ('of', 'O'), ('lysozyme', 'O'), ('after', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('administration', 'O'), ('of', 'O'), ('egg', 'O'), ('-', 'O'), ('white', 'O'), ('lysozyme', 'O'), ('netilmicin', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('.', 'O'))"
"Daily excretion of total protein , endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin .","(('Daily', 'O'), ('excretion', 'O'), ('of', 'O'), ('total', 'O'), ('protein', 'O'), (',', 'O'), ('endogenous', 'O'), ('lysozyme', 'O'), ('and', 'O'), ('NAG', 'O'), ('increased', 'O'), ('only', 'O'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('kanamycin', 'O'), ('and', 'O'), ('gentamicin', 'O'), ('.', 'O'))"
"When the androgens were withdrawn , the patient ' s physical changes , symptoms , sleep study , and supraglottic resistance all returned to normal .","(('When', 'O'), ('the', 'O'), ('androgens', 'O'), ('were', 'O'), ('withdrawn', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('physical', 'O'), ('changes', 'O'), (',', 'O'), ('symptoms', 'O'), (',', 'O'), ('sleep', 'O'), ('study', 'O'), (',', 'O'), ('and', 'O'), ('supraglottic', 'O'), ('resistance', 'O'), ('all', 'O'), ('returned', 'O'), ('to', 'O'), ('normal', 'O'), ('.', 'O'))"
Our report provides direct evidence for this role .,"(('Our', 'O'), ('report', 'O'), ('provides', 'O'), ('direct', 'O'), ('evidence', 'O'), ('for', 'O'), ('this', 'O'), ('role', 'O'), ('.', 'O'))"
Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep .,"(('Structural', 'O'), ('and', 'O'), ('functional', 'O'), ('measurements', 'O'), ('indicate', 'O'), ('that', 'O'), ('androgens', 'O'), ('exert', 'O'), ('a', 'O'), ('permissive', 'O'), ('or', 'O'), ('necessary', 'O'), ('action', 'O'), ('on', 'O'), ('the', 'O'), ('structural', 'O'), ('configuration', 'O'), ('of', 'O'), ('the', 'O'), ('oropharynx', 'O'), ('that', 'O'), ('predisposes', 'O'), ('to', 'O'), ('obstruction', 'B'), ('during', 'O'), ('sleep', 'O'), ('.', 'O'))"
10 monkeys ( macaques ) received adriamycin by monthly intravenous injections at 12 mg / m2 ( 1 mg / kg ) .,"(('10', 'O'), ('monkeys', 'O'), ('(', 'O'), ('macaques', 'O'), (')', 'O'), ('received', 'O'), ('adriamycin', 'O'), ('by', 'O'), ('monthly', 'O'), ('intravenous', 'O'), ('injections', 'O'), ('at', 'O'), ('12', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('.', 'O'))"
"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man , and that leukemia may be a consequence of prolonged treatment with this drug .","(('Our', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('adriamycin', 'O'), ('is', 'O'), ('a', 'O'), ('more', 'O'), ('potent', 'O'), ('cardiotoxin', 'O'), ('in', 'O'), ('monkeys', 'O'), ('than', 'O'), ('in', 'O'), ('man', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('leukemia', 'B'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('consequence', 'O'), ('of', 'O'), ('prolonged', 'O'), ('treatment', 'O'), ('with', 'O'), ('this', 'O'), ('drug', 'O'), ('.', 'O'))"
Sixty - three percent of these infants had tricuspid valve involvement .,"(('Sixty', 'O'), ('-', 'O'), ('three', 'O'), ('percent', 'O'), ('of', 'O'), ('these', 'O'), ('infants', 'O'), ('had', 'O'), ('tricuspid', 'B'), ('valve', 'I'), ('involvement', 'I'), ('.', 'O'))"
Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy .,"(('Lithium', 'O'), ('carbonate', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('factor', 'O'), ('in', 'O'), ('the', 'O'), ('increasing', 'O'), ('incidence', 'O'), ('of', 'O'), ('congenital', 'B'), ('heart', 'I'), ('disease', 'I'), ('when', 'O'), ('taken', 'O'), ('during', 'O'), ('early', 'O'), ('pregnancy', 'O'), ('.', 'O'))"
"Generally , the dose - response curves were bell - shaped .","(('Generally', 'O'), (',', 'O'), ('the', 'O'), ('dose', 'O'), ('-', 'O'), ('response', 'O'), ('curves', 'O'), ('were', 'O'), ('bell', 'O'), ('-', 'O'), ('shaped', 'O'), ('.', 'O'))"
The mechanisms underlying the activity of aniracetam and its ' therapeutic window ' are unknown .,"(('The', 'O'), ('mechanisms', 'O'), ('underlying', 'O'), ('the', 'O'), ('activity', 'O'), ('of', 'O'), ('aniracetam', 'O'), ('and', 'O'), ('its', 'O'), (""'"", 'O'), ('therapeutic', 'O'), ('window', 'O'), (""'"", 'O'), ('are', 'O'), ('unknown', 'O'), ('.', 'O'))"
"Piracetam , another pyrrolidinone derivative was used for comparison .","(('Piracetam', 'O'), (',', 'O'), ('another', 'O'), ('pyrrolidinone', 'O'), ('derivative', 'O'), ('was', 'O'), ('used', 'O'), ('for', 'O'), ('comparison', 'O'), ('.', 'O'))"
It was active only in six of nine tests and had about one - tenth the potency of aniracetam .,"(('It', 'O'), ('was', 'O'), ('active', 'O'), ('only', 'O'), ('in', 'O'), ('six', 'O'), ('of', 'O'), ('nine', 'O'), ('tests', 'O'), ('and', 'O'), ('had', 'O'), ('about', 'O'), ('one', 'O'), ('-', 'O'), ('tenth', 'O'), ('the', 'O'), ('potency', 'O'), ('of', 'O'), ('aniracetam', 'O'), ('.', 'O'))"
The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process .,"(('The', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('aniracetam', 'O'), ('improves', 'O'), ('cognitive', 'O'), ('functions', 'O'), ('which', 'O'), ('are', 'O'), ('impaired', 'O'), ('by', 'O'), ('different', 'O'), ('procedure', 'O'), ('and', 'O'), ('in', 'O'), ('different', 'O'), ('phases', 'O'), ('of', 'O'), ('the', 'O'), ('learning', 'O'), ('and', 'O'), ('memory', 'O'), ('process', 'O'), ('.', 'O'))"
Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats .,"(('Effect', 'O'), ('of', 'O'), ('calcium', 'O'), ('chloride', 'O'), ('on', 'O'), ('gross', 'O'), ('behavioural', 'O'), ('changes', 'O'), ('produced', 'O'), ('by', 'O'), ('carbachol', 'O'), ('and', 'O'), ('eserine', 'O'), ('in', 'O'), ('cats', 'O'), ('.', 'O'))"
Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine .,"(('Calcium', 'O'), ('chloride', 'O'), ('depressed', 'O'), ('or', 'O'), ('almost', 'O'), ('completely', 'O'), ('abolished', 'O'), ('the', 'O'), ('vocalization', 'O'), ('and', 'O'), ('fighting', 'O'), ('due', 'O'), ('to', 'O'), ('carbachol', 'O'), ('and', 'O'), ('eserine', 'O'), ('.', 'O'))"
Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites .,"(('Calcium', 'O'), ('chloride', 'O'), ('inhibited', 'O'), ('the', 'O'), ('vocalization', 'O'), ('and', 'O'), ('fighting', 'O'), ('produced', 'O'), ('by', 'O'), ('carbachol', 'O'), ('and', 'O'), ('eserine', 'O'), ('most', 'O'), ('probably', 'O'), ('by', 'O'), ('a', 'O'), ('nonspecific', 'O'), ('stabilizing', 'O'), ('action', 'O'), ('on', 'O'), ('central', 'O'), ('muscarinic', 'O'), ('cholinoceptive', 'O'), ('sites', 'O'), ('.', 'O'))"
These results further support the view that calcium ions in excess have an atropine - like action also in the central nervous system .,"(('These', 'O'), ('results', 'O'), ('further', 'O'), ('support', 'O'), ('the', 'O'), ('view', 'O'), ('that', 'O'), ('calcium', 'O'), ('ions', 'O'), ('in', 'O'), ('excess', 'O'), ('have', 'O'), ('an', 'O'), ('atropine', 'O'), ('-', 'O'), ('like', 'O'), ('action', 'O'), ('also', 'O'), ('in', 'O'), ('the', 'O'), ('central', 'O'), ('nervous', 'O'), ('system', 'O'), ('.', 'O'))"
Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs .,"(('Thiazide', 'O'), ('diuretics', 'O'), ('are', 'O'), ('widely', 'O'), ('accepted', 'O'), ('as', 'O'), ('the', 'O'), ('cornerstone', 'O'), ('of', 'O'), ('antihypertensive', 'O'), ('treatment', 'O'), ('programs', 'O'), ('.', 'O'))"
"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg , 150 mg and 200 mg daily until blood pressure normalized .","(('Initial', 'O'), ('dose', 'O'), ('was', 'O'), ('50', 'O'), ('mg', 'O'), ('and', 'O'), ('the', 'O'), ('dose', 'O'), ('was', 'O'), ('increased', 'O'), ('at', 'O'), ('monthly', 'O'), ('intervals', 'O'), ('to', 'O'), ('100', 'O'), ('mg', 'O'), (',', 'O'), ('150', 'O'), ('mg', 'O'), ('and', 'O'), ('200', 'O'), ('mg', 'O'), ('daily', 'O'), ('until', 'O'), ('blood', 'O'), ('pressure', 'O'), ('normalized', 'O'), ('.', 'O'))"
"The serum K during the control period was 4 . 5 + / - 0 . 2 mEq / l an on 50 , 100 , 150 and 200 mg HCTZ daily 3 . 9 + / - 0 . 3 , 3 . 4 + / - 0 . 2 , 2 . 9 + / - 0 . 2 , and 2 . 4 + / - 0 . 3 mEq / l , respectively .","(('The', 'O'), ('serum', 'O'), ('K', 'O'), ('during', 'O'), ('the', 'O'), ('control', 'O'), ('period', 'O'), ('was', 'O'), ('4', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('mEq', 'O'), ('/', 'O'), ('l', 'O'), ('an', 'O'), ('on', 'O'), ('50', 'O'), (',', 'O'), ('100', 'O'), (',', 'O'), ('150', 'O'), ('and', 'O'), ('200', 'O'), ('mg', 'O'), ('HCTZ', 'O'), ('daily', 'O'), ('3', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), (',', 'O'), ('3', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), (',', 'O'), ('2', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), (',', 'O'), ('and', 'O'), ('2', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('mEq', 'O'), ('/', 'O'), ('l', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Corresponding figures for whole body K were 4107 + / - 208 , 3722 + / - 319 , 3628 + / - 257 , 3551 + / - 336 , and 3269 + / - 380 mEq , respectively .","(('Corresponding', 'O'), ('figures', 'O'), ('for', 'O'), ('whole', 'O'), ('body', 'O'), ('K', 'O'), ('were', 'O'), ('4107', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('208', 'O'), (',', 'O'), ('3722', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('319', 'O'), (',', 'O'), ('3628', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('257', 'O'), (',', 'O'), ('3551', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('336', 'O'), (',', 'O'), ('and', 'O'), ('3269', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('380', 'O'), ('mEq', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
In 13 patients we observed the effects of HCTZ therapy ( 100 mg daily ) on the occurrence of PVC ' s during rest as well as during static and dynamic exercise .,"(('In', 'O'), ('13', 'O'), ('patients', 'O'), ('we', 'O'), ('observed', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('HCTZ', 'O'), ('therapy', 'O'), ('(', 'O'), ('100', 'O'), ('mg', 'O'), ('daily', 'O'), (')', 'O'), ('on', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('PVC', 'B'), (""'"", 'O'), ('s', 'O'), ('during', 'O'), ('rest', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('during', 'O'), ('static', 'O'), ('and', 'O'), ('dynamic', 'O'), ('exercise', 'O'), ('.', 'O'))"
"During rest we observed 0 . 6 + / - 0 . 08 PVC beats / min + / - SEM and during static and dynamic exercise 0 . 6 + / - 0 . 06 and 0 . 8 + / - 0 . 15 , respectively .","(('During', 'O'), ('rest', 'O'), ('we', 'O'), ('observed', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('08', 'O'), ('PVC', 'O'), ('beats', 'O'), ('/', 'O'), ('min', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('SEM', 'O'), ('and', 'O'), ('during', 'O'), ('static', 'O'), ('and', 'O'), ('dynamic', 'O'), ('exercise', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('06', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'), ('8', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('15', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Corresponding figures during HCTZ therapy 100 mg daily were 1 . 4 + / - 0 . 1 , 3 . 6 + / - 0 . 7 and 5 . 7 4 / - 0 . 8 , respectively .","(('Corresponding', 'O'), ('figures', 'O'), ('during', 'O'), ('HCTZ', 'O'), ('therapy', 'O'), ('100', 'O'), ('mg', 'O'), ('daily', 'O'), ('were', 'O'), ('1', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), (',', 'O'), ('3', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('7', 'O'), ('and', 'O'), ('5', 'O'), ('.', 'O'), ('7', 'O'), ('4', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('8', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"The occurrence of PVC ' s correlated significantly with the fall in serum K + observed r = 0 . 72 , p less than 0 . 001 .","(('The', 'O'), ('occurrence', 'O'), ('of', 'O'), ('PVC', 'B'), (""'"", 'I'), ('s', 'I'), ('correlated', 'O'), ('significantly', 'O'), ('with', 'O'), ('the', 'O'), ('fall', 'O'), ('in', 'O'), ('serum', 'O'), ('K', 'O'), ('+', 'O'), ('observed', 'O'), ('r', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('72', 'O'), (',', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), ('.', 'O'))"
"A correlation was found between serum acid protease activity and prothrombin time , and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase , which showed a sharp early peak and then a fall .","(('A', 'O'), ('correlation', 'O'), ('was', 'O'), ('found', 'O'), ('between', 'O'), ('serum', 'O'), ('acid', 'O'), ('protease', 'O'), ('activity', 'O'), ('and', 'O'), ('prothrombin', 'O'), ('time', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('increase', 'O'), ('in', 'O'), ('cathepsin', 'O'), ('D', 'O'), ('activity', 'O'), ('was', 'O'), ('sustained', 'O'), ('over', 'O'), ('several', 'O'), ('days', 'O'), ('compared', 'O'), ('with', 'O'), ('aspartate', 'O'), ('aminotransferase', 'O'), (',', 'O'), ('which', 'O'), ('showed', 'O'), ('a', 'O'), ('sharp', 'O'), ('early', 'O'), ('peak', 'O'), ('and', 'O'), ('then', 'O'), ('a', 'O'), ('fall', 'O'), ('.', 'O'))"
"Circulating lysosomal proteases can damage other organs , and measurement of their activity may therefore be of added value in assessing prognosis in this condition .","(('Circulating', 'O'), ('lysosomal', 'O'), ('proteases', 'O'), ('can', 'O'), ('damage', 'O'), ('other', 'O'), ('organs', 'O'), (',', 'O'), ('and', 'O'), ('measurement', 'O'), ('of', 'O'), ('their', 'O'), ('activity', 'O'), ('may', 'O'), ('therefore', 'O'), ('be', 'O'), ('of', 'O'), ('added', 'O'), ('value', 'O'), ('in', 'O'), ('assessing', 'O'), ('prognosis', 'O'), ('in', 'O'), ('this', 'O'), ('condition', 'O'), ('.', 'O'))"
Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement .,"(('Serial', 'O'), ('liver', 'O'), ('biopsies', 'O'), ('showed', 'O'), ('the', 'O'), ('development', 'O'), ('and', 'O'), ('resolution', 'O'), ('of', 'O'), ('intense', 'O'), ('sinusoidal', 'O'), ('engorgement', 'I'), ('.', 'O'))"
"Although this disease was clinically reversible , some subintimal fibrosis about the terminal hepatic veins persisted .","(('Although', 'O'), ('this', 'O'), ('disease', 'O'), ('was', 'O'), ('clinically', 'O'), ('reversible', 'O'), (',', 'O'), ('some', 'O'), ('subintimal', 'O'), ('fibrosis', 'I'), ('about', 'O'), ('the', 'O'), ('terminal', 'O'), ('hepatic', 'O'), ('veins', 'O'), ('persisted', 'O'), ('.', 'O'))"
Chlorpropamide - induced optic neuropathy .,"(('Chlorpropamide', 'B'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('.', 'O'))"
Plasma apolipoprotein A - I tended to increase ( 40 % increase at day 5 ) .,"(('Plasma', 'O'), ('apolipoprotein', 'O'), ('A', 'O'), ('-', 'O'), ('I', 'O'), ('tended', 'O'), ('to', 'O'), ('increase', 'O'), ('(', 'O'), ('40', 'O'), ('%', 'O'), ('increase', 'O'), ('at', 'O'), ('day', 'O'), ('5', 'O'), (')', 'O'), ('.', 'O'))"
The plasma concentration of HDL followed the same pattern .,"(('The', 'O'), ('plasma', 'O'), ('concentration', 'O'), ('of', 'O'), ('HDL', 'O'), ('followed', 'O'), ('the', 'O'), ('same', 'O'), ('pattern', 'O'), ('.', 'O'))"
Plasma VLDL and LDL increased at a later stage ( day 9 ) .,"(('Plasma', 'O'), ('VLDL', 'O'), ('and', 'O'), ('LDL', 'O'), ('increased', 'O'), ('at', 'O'), ('a', 'O'), ('later', 'O'), ('stage', 'O'), ('(', 'O'), ('day', 'O'), ('9', 'O'), (')', 'O'), ('.', 'O'))"
Plasma apolipoprotein A - I was found not only in HDL ( 1 . 063 - 1 . 210 g / ml ) but also in the LDL density class ( 1 . 025 - 1 . 050 g / ml ) .,"(('Plasma', 'O'), ('apolipoprotein', 'O'), ('A', 'O'), ('-', 'O'), ('I', 'O'), ('was', 'O'), ('found', 'O'), ('not', 'O'), ('only', 'O'), ('in', 'O'), ('HDL', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('063', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('210', 'O'), ('g', 'O'), ('/', 'O'), ('ml', 'O'), (')', 'O'), ('but', 'O'), ('also', 'O'), ('in', 'O'), ('the', 'O'), ('LDL', 'O'), ('density', 'O'), ('class', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('025', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('050', 'O'), ('g', 'O'), ('/', 'O'), ('ml', 'O'), (')', 'O'), ('.', 'O'))"
These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL .,"(('These', 'O'), ('observations', 'O'), ('indicate', 'O'), ('that', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('alters', 'O'), ('plasma', 'O'), ('lipoproteins', 'O'), ('by', 'O'), ('lowering', 'O'), ('VLDL', 'O'), ('and', 'O'), ('increasing', 'O'), ('HDL', 'O'), ('.', 'O'))"
"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .","(('Any', 'O'), ('other', 'O'), ('suspected', 'O'), ('cases', 'O'), ('of', 'O'), ('ocular', 'O'), ('toxicity', 'O'), ('associated', 'O'), ('with', 'O'), ('topically', 'O'), ('applied', 'O'), ('chloramphenicol', 'O'), ('should', 'O'), ('be', 'O'), ('reported', 'O'), ('to', 'O'), ('the', 'O'), ('National', 'O'), ('Registry', 'O'), ('of', 'O'), ('Drug', 'O'), ('-', 'O'), ('Induced', 'O'), ('Ocular', 'O'), ('Side', 'O'), ('Effects', 'O'), (',', 'O'), ('Oregon', 'O'), ('Health', 'O'), ('Sciences', 'O'), ('University', 'O'), (',', 'O'), ('Portland', 'O'), (',', 'O'), ('OR', 'O'), ('97201', 'O'), ('.', 'O'))"
Midazolam compared with thiopentone as an induction agent .,"(('Midazolam', 'O'), ('compared', 'O'), ('with', 'O'), ('thiopentone', 'O'), ('as', 'O'), ('an', 'O'), ('induction', 'O'), ('agent', 'O'), ('.', 'O'))"
"On the whole , the differences between midazolam and thiopentone had no apparent clinical consequences .","(('On', 'O'), ('the', 'O'), ('whole', 'O'), (',', 'O'), ('the', 'O'), ('differences', 'O'), ('between', 'O'), ('midazolam', 'O'), ('and', 'O'), ('thiopentone', 'O'), ('had', 'O'), ('no', 'O'), ('apparent', 'O'), ('clinical', 'O'), ('consequences', 'O'), ('.', 'O'))"
Midazolam is a new alternative agent for induction in combination anaesthesia .,"(('Midazolam', 'O'), ('is', 'O'), ('a', 'O'), ('new', 'O'), ('alternative', 'O'), ('agent', 'O'), ('for', 'O'), ('induction', 'O'), ('in', 'O'), ('combination', 'O'), ('anaesthesia', 'O'), ('.', 'O'))"
Extrapyramidal side effects and oral haloperidol : an analysis of explanatory patient and treatment characteristics .,"(('Extrapyramidal', 'B'), ('side', 'I'), ('effects', 'O'), ('and', 'O'), ('oral', 'O'), ('haloperidol', 'O'), (':', 'O'), ('an', 'O'), ('analysis', 'O'), ('of', 'O'), ('explanatory', 'O'), ('patient', 'O'), ('and', 'O'), ('treatment', 'O'), ('characteristics', 'O'), ('.', 'O'))"
The incidence of extrapyramidal side effects ( EPS ) was evaluated in 98 patients treated with haloperidol .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('extrapyramidal', 'B'), ('side', 'I'), ('effects', 'O'), ('(', 'O'), ('EPS', 'B'), (')', 'O'), ('was', 'O'), ('evaluated', 'O'), ('in', 'O'), ('98', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('haloperidol', 'O'), ('.', 'O'))"
The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('parkinsonism', 'B'), ('was', 'O'), ('higher', 'O'), ('at', 'O'), ('higher', 'O'), ('doses', 'O'), ('of', 'O'), ('haloperidol', 'O'), ('and', 'O'), ('in', 'O'), ('younger', 'O'), ('patients', 'O'), ('.', 'O'))"
Prophylactic antiparkinsonian medication was effective in younger but not in older patients .,"(('Prophylactic', 'O'), ('antiparkinsonian', 'O'), ('medication', 'O'), ('was', 'O'), ('effective', 'O'), ('in', 'O'), ('younger', 'O'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('older', 'O'), ('patients', 'O'), ('.', 'O'))"
"However , these medications were more effective in both young and old patients when given after parkinsonism developed .","(('However', 'O'), (',', 'O'), ('these', 'O'), ('medications', 'O'), ('were', 'O'), ('more', 'O'), ('effective', 'O'), ('in', 'O'), ('both', 'O'), ('young', 'O'), ('and', 'O'), ('old', 'O'), ('patients', 'O'), ('when', 'O'), ('given', 'O'), ('after', 'O'), ('parkinsonism', 'B'), ('developed', 'O'), ('.', 'O'))"
The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol .,"(('The', 'O'), ('present', 'O'), ('study', 'O'), ('points', 'O'), ('to', 'O'), ('patient', 'O'), ('characteristics', 'O'), ('that', 'O'), ('may', 'O'), ('be', 'O'), ('of', 'O'), ('significance', 'O'), ('in', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('EPS', 'B'), ('due', 'O'), ('to', 'O'), ('haloperidol', 'O'), ('.', 'O'))"
Deaths from local anesthetic - induced convulsions in mice .,"(('Deaths', 'O'), ('from', 'O'), ('local', 'O'), ('anesthetic', 'I'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
Median convulsant ( CD50 ) and median lethal ( LD50 ) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic - induced convulsions .,"(('Median', 'O'), ('convulsant', 'O'), ('(', 'O'), ('CD50', 'O'), (')', 'O'), ('and', 'O'), ('median', 'O'), ('lethal', 'O'), ('(', 'O'), ('LD50', 'O'), (')', 'O'), ('doses', 'O'), ('of', 'O'), ('three', 'O'), ('representative', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('were', 'O'), ('determined', 'O'), ('in', 'O'), ('adult', 'O'), ('mice', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('threat', 'O'), ('to', 'O'), ('life', 'O'), ('of', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'O'), ('.', 'O'))"
"The CD50 and LD50 , respectively , were 57 . 7 and 58 . 7 mg / kg for bupivacaine , 111 . 0 and 133 . 1 mg / kg for lidocaine , and 243 . 4 and 266 . 5 mg / kg for chloroprocaine .","(('The', 'O'), ('CD50', 'O'), ('and', 'O'), ('LD50', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('were', 'O'), ('57', 'O'), ('.', 'O'), ('7', 'O'), ('and', 'O'), ('58', 'O'), ('.', 'O'), ('7', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('for', 'O'), ('bupivacaine', 'O'), (',', 'O'), ('111', 'O'), ('.', 'O'), ('0', 'O'), ('and', 'O'), ('133', 'O'), ('.', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('for', 'O'), ('lidocaine', 'O'), (',', 'O'), ('and', 'O'), ('243', 'O'), ('.', 'O'), ('4', 'O'), ('and', 'O'), ('266', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('for', 'O'), ('chloroprocaine', 'O'), ('.', 'O'))"
"When given intraperitoneally , bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine .","(('When', 'O'), ('given', 'O'), ('intraperitoneally', 'O'), (',', 'O'), ('bupivacaine', 'O'), ('thus', 'O'), ('was', 'O'), ('only', 'O'), ('about', 'O'), ('twice', 'O'), ('as', 'O'), ('toxic', 'O'), ('as', 'O'), ('lidocaine', 'O'), ('and', 'O'), ('four', 'O'), ('times', 'O'), ('as', 'O'), ('toxic', 'O'), ('as', 'O'), ('chloroprocaine', 'O'), ('.', 'O'))"
"A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .","(('A', 'O'), ('CD50', 'O'), ('dose', 'O'), ('of', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('(', 'O'), ('causing', 'O'), ('convulsions', 'O'), ('in', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('mice', 'O'), (')', 'O'), ('was', 'O'), ('fatal', 'O'), ('in', 'O'), ('90', 'O'), ('%', 'O'), ('of', 'O'), ('bupivacaine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), (',', 'O'), ('in', 'O'), ('57', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('chloroprocaine', 'O'), ('group', 'O'), (',', 'O'), ('and', 'O'), ('in', 'O'), ('6', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('lidocaine', 'O'), ('group', 'O'), ('.', 'O'))"
The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated .,"(('The', 'O'), ('narrow', 'O'), ('gap', 'O'), ('between', 'O'), ('convulsant', 'O'), ('and', 'O'), ('lethal', 'O'), ('doses', 'O'), ('of', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('indicates', 'O'), ('that', 'O'), ('untreated', 'O'), ('convulsions', 'O'), ('present', 'O'), ('much', 'O'), ('more', 'O'), ('of', 'O'), ('a', 'O'), ('threat', 'O'), ('to', 'O'), ('life', 'O'), ('than', 'O'), ('heretofore', 'O'), ('appreciated', 'O'), ('.', 'O'))"
Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments .,"(('Results', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('similarity', 'O'), ('to', 'O'), ('pharmacological', 'O'), ('effects', 'O'), ('of', 'O'), ('other', 'O'), ('antidepressive', 'O'), ('treatments', 'O'), ('.', 'O'))"
Indomethacin was first given four weeks prior to the onset of symptoms .,"(('Indomethacin', 'O'), ('was', 'O'), ('first', 'O'), ('given', 'O'), ('four', 'O'), ('weeks', 'O'), ('prior', 'O'), ('to', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('symptoms', 'O'), ('.', 'O'))"
"Fortunately , this seems to be a very rare complication .","(('Fortunately', 'O'), (',', 'O'), ('this', 'O'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('very', 'O'), ('rare', 'O'), ('complication', 'O'), ('.', 'O'))"
Dose - effect and structure - function relationships in doxorubicin cardiomyopathy .,"(('Dose', 'O'), ('-', 'O'), ('effect', 'O'), ('and', 'O'), ('structure', 'O'), ('-', 'O'), ('function', 'O'), ('relationships', 'O'), ('in', 'O'), ('doxorubicin', 'B'), ('cardiomyopathy', 'I'), ('.', 'O'))"
We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR .,"(('We', 'O'), ('measured', 'O'), ('the', 'O'), ('degree', 'O'), ('of', 'O'), ('morphologic', 'O'), ('damage', 'O'), ('by', 'O'), ('ultrastructural', 'O'), ('examination', 'O'), ('of', 'O'), ('endomyocardial', 'O'), ('biopsy', 'O'), ('and', 'O'), ('the', 'O'), ('degree', 'O'), ('of', 'O'), ('performance', 'O'), ('abnormally', 'O'), ('by', 'O'), ('right', 'O'), ('heart', 'O'), ('catheterization', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('DXR', 'O'), ('.', 'O'))"
Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg / m2 .,"(('Morphologic', 'O'), ('damage', 'O'), ('was', 'O'), ('variable', 'O'), ('but', 'O'), ('was', 'O'), ('proportional', 'O'), ('to', 'O'), ('the', 'O'), ('total', 'O'), ('cumulative', 'O'), ('DXR', 'O'), ('dose', 'O'), ('between', 'O'), ('100', 'O'), ('and', 'O'), ('600', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('.', 'O'))"
"Performance abnormalities correlated weakly with dose , exhibited a curvilinear relationship , and had a "" threshold "" for expression .","(('Performance', 'B'), ('abnormalities', 'I'), ('correlated', 'O'), ('weakly', 'O'), ('with', 'O'), ('dose', 'O'), (',', 'O'), ('exhibited', 'O'), ('a', 'O'), ('curvilinear', 'O'), ('relationship', 'O'), (',', 'O'), ('and', 'O'), ('had', 'O'), ('a', 'O'), ('""', 'O'), ('threshold', 'O'), ('""', 'O'), ('for', 'O'), ('expression', 'O'), ('.', 'O'))"
"Catheterization abnormalities correlated well with morphologic damage ( r = 0 . 57 to 0 . 78 ) in a subgroup of patients in whom exercise hemodynamics were measured , and this relationship also exhibited a curvilinear , threshold configuration .","(('Catheterization', 'B'), ('abnormalities', 'I'), ('correlated', 'O'), ('well', 'O'), ('with', 'O'), ('morphologic', 'O'), ('damage', 'O'), ('(', 'O'), ('r', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('57', 'O'), ('to', 'O'), ('0', 'O'), ('.', 'O'), ('78', 'O'), (')', 'O'), ('in', 'O'), ('a', 'O'), ('subgroup', 'O'), ('of', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('exercise', 'O'), ('hemodynamics', 'O'), ('were', 'O'), ('measured', 'O'), (',', 'O'), ('and', 'O'), ('this', 'O'), ('relationship', 'O'), ('also', 'O'), ('exhibited', 'O'), ('a', 'O'), ('curvilinear', 'O'), (',', 'O'), ('threshold', 'O'), ('configuration', 'O'), ('.', 'O'))"
Response to conventional therapy has been disappointing .,"(('Response', 'O'), ('to', 'O'), ('conventional', 'O'), ('therapy', 'O'), ('has', 'O'), ('been', 'O'), ('disappointing', 'O'), ('.', 'O'))"
Cranial decompression was carried out .,"(('Cranial', 'O'), ('decompression', 'O'), ('was', 'O'), ('carried', 'O'), ('out', 'O'), ('.', 'O'))"
A justification of the need for further evaluation of cranial decompression in such patients is presented .,"(('A', 'O'), ('justification', 'O'), ('of', 'O'), ('the', 'O'), ('need', 'O'), ('for', 'O'), ('further', 'O'), ('evaluation', 'O'), ('of', 'O'), ('cranial', 'O'), ('decompression', 'O'), ('in', 'O'), ('such', 'O'), ('patients', 'O'), ('is', 'O'), ('presented', 'O'), ('.', 'O'))"
Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone ( LH ) .,"(('Various', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('male', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('received', 'O'), ('digoxin', 'O'), ('on', 'O'), ('a', 'O'), ('longterm', 'O'), ('basis', 'O'), ('have', 'O'), ('increased', 'O'), ('levels', 'O'), ('of', 'O'), ('serum', 'O'), ('estrogen', 'O'), ('and', 'O'), ('decreased', 'O'), ('levels', 'O'), ('of', 'O'), ('plasma', 'O'), ('testosterone', 'O'), ('and', 'O'), ('luteinizing', 'O'), ('hormone', 'O'), ('(', 'O'), ('LH', 'O'), (')', 'O'), ('.', 'O'))"
"This study was undertaken to investigate the links between the long - term administration of digoxin therapy and sexual behavior , and the effect of digoxin on plasma levels of estradiol , testosterone , and LH .","(('This', 'O'), ('study', 'O'), ('was', 'O'), ('undertaken', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('links', 'O'), ('between', 'O'), ('the', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('administration', 'O'), ('of', 'O'), ('digoxin', 'O'), ('therapy', 'O'), ('and', 'O'), ('sexual', 'O'), ('behavior', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('digoxin', 'O'), ('on', 'O'), ('plasma', 'O'), ('levels', 'O'), ('of', 'O'), ('estradiol', 'O'), (',', 'O'), ('testosterone', 'O'), (',', 'O'), ('and', 'O'), ('LH', 'O'), ('.', 'O'))"
The patients of the study and control group ( without digoxin ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the rheumatic heart disease patients .,"(('The', 'O'), ('patients', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('and', 'O'), ('control', 'O'), ('group', 'O'), ('(', 'O'), ('without', 'O'), ('digoxin', 'O'), (')', 'O'), ('were', 'O'), ('of', 'O'), ('similar', 'O'), ('cardiac', 'O'), ('functional', 'O'), ('capacity', 'O'), ('and', 'O'), ('age', 'O'), ('(', 'O'), ('25', 'O'), ('-', 'O'), ('40', 'O'), ('years', 'O'), (')', 'O'), ('and', 'O'), ('were', 'O'), ('randomly', 'O'), ('selected', 'O'), ('from', 'O'), ('the', 'O'), ('rheumatic', 'B'), ('heart', 'I'), ('disease', 'I'), ('patients', 'O'), ('.', 'O'))"
"A subjective assessment of sexual behavior in the study and control groups was carried out , using parameters such as sexual desire , sexual excitement , and frequency of sexual relations .","(('A', 'O'), ('subjective', 'O'), ('assessment', 'O'), ('of', 'O'), ('sexual', 'O'), ('behavior', 'O'), ('in', 'O'), ('the', 'O'), ('study', 'O'), ('and', 'O'), ('control', 'O'), ('groups', 'O'), ('was', 'O'), ('carried', 'O'), ('out', 'O'), (',', 'O'), ('using', 'O'), ('parameters', 'O'), ('such', 'O'), ('as', 'O'), ('sexual', 'O'), ('desire', 'O'), (',', 'O'), ('sexual', 'O'), ('excitement', 'O'), (',', 'O'), ('and', 'O'), ('frequency', 'O'), ('of', 'O'), ('sexual', 'O'), ('relations', 'O'), ('.', 'O'))"
Personal interviews and a questionnaire were also used for the evaluation of sexual behavior .,"(('Personal', 'O'), ('interviews', 'O'), ('and', 'O'), ('a', 'O'), ('questionnaire', 'O'), ('were', 'O'), ('also', 'O'), ('used', 'O'), ('for', 'O'), ('the', 'O'), ('evaluation', 'O'), ('of', 'O'), ('sexual', 'O'), ('behavior', 'O'), ('.', 'O'))"
"The findings support the reports concerning digoxin effect on plasma estradiol , testosterone , and LH .","(('The', 'O'), ('findings', 'O'), ('support', 'O'), ('the', 'O'), ('reports', 'O'), ('concerning', 'O'), ('digoxin', 'O'), ('effect', 'O'), ('on', 'O'), ('plasma', 'O'), ('estradiol', 'O'), (',', 'O'), ('testosterone', 'O'), (',', 'O'), ('and', 'O'), ('LH', 'O'), ('.', 'O'))"
The differences in the means were significant .,"(('The', 'O'), ('differences', 'O'), ('in', 'O'), ('the', 'O'), ('means', 'O'), ('were', 'O'), ('significant', 'O'), ('.', 'O'))"
Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically .,"(('Young', 'O'), ('women', 'O'), ('on', 'O'), ('replacement', 'O'), ('estrogens', 'O'), ('for', 'O'), ('ovarian', 'B'), ('failure', 'I'), ('after', 'O'), ('cancer', 'B'), ('therapy', 'O'), ('may', 'O'), ('also', 'O'), ('have', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('endometrial', 'B'), ('carcinoma', 'I'), ('and', 'O'), ('should', 'O'), ('be', 'O'), ('examined', 'O'), ('periodically', 'O'), ('.', 'O'))"
Long - term lithium treatment and the kidney .,"(('Long', 'O'), ('-', 'O'), ('term', 'O'), ('lithium', 'O'), ('treatment', 'O'), ('and', 'O'), ('the', 'O'), ('kidney', 'O'), ('.', 'O'))"
Interim report on fifty patients .,"(('Interim', 'O'), ('report', 'O'), ('on', 'O'), ('fifty', 'O'), ('patients', 'O'), ('.', 'O'))"
This is a report on the first part of our study of the effects of long - term lithium treatment on the kidney .,"(('This', 'O'), ('is', 'O'), ('a', 'O'), ('report', 'O'), ('on', 'O'), ('the', 'O'), ('first', 'O'), ('part', 'O'), ('of', 'O'), ('our', 'O'), ('study', 'O'), ('of', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('lithium', 'O'), ('treatment', 'O'), ('on', 'O'), ('the', 'O'), ('kidney', 'O'), ('.', 'O'))"
"Creatinine clearance , maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long - term lithium for more than one year .","(('Creatinine', 'O'), ('clearance', 'O'), (',', 'O'), ('maximum', 'O'), ('urinary', 'O'), ('osmolality', 'O'), ('and', 'O'), ('24', 'O'), ('hour', 'O'), ('urine', 'O'), ('volume', 'O'), ('have', 'O'), ('been', 'O'), ('tested', 'O'), ('in', 'O'), ('50', 'O'), ('affectively', 'O'), ('ill', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('been', 'O'), ('on', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('lithium', 'O'), ('for', 'O'), ('more', 'O'), ('than', 'O'), ('one', 'O'), ('year', 'O'), ('.', 'O'))"
"These findings have been compared with norms and with values of the same tests from screening prior to lithium , available for most of our patients .","(('These', 'O'), ('findings', 'O'), ('have', 'O'), ('been', 'O'), ('compared', 'O'), ('with', 'O'), ('norms', 'O'), ('and', 'O'), ('with', 'O'), ('values', 'O'), ('of', 'O'), ('the', 'O'), ('same', 'O'), ('tests', 'O'), ('from', 'O'), ('screening', 'O'), ('prior', 'O'), ('to', 'O'), ('lithium', 'O'), (',', 'O'), ('available', 'O'), ('for', 'O'), ('most', 'O'), ('of', 'O'), ('our', 'O'), ('patients', 'O'), ('.', 'O'))"
No evidence was found for any reduction of glomerular filtration during lithium treatment .,"(('No', 'O'), ('evidence', 'O'), ('was', 'O'), ('found', 'O'), ('for', 'O'), ('any', 'O'), ('reduction', 'O'), ('of', 'O'), ('glomerular', 'O'), ('filtration', 'O'), ('during', 'O'), ('lithium', 'O'), ('treatment', 'O'), ('.', 'O'))"
Low clearance values found in several patients could be accounted for by their age and their pre - lithium values .,"(('Low', 'O'), ('clearance', 'O'), ('values', 'O'), ('found', 'O'), ('in', 'O'), ('several', 'O'), ('patients', 'O'), ('could', 'O'), ('be', 'O'), ('accounted', 'O'), ('for', 'O'), ('by', 'O'), ('their', 'O'), ('age', 'O'), ('and', 'O'), ('their', 'O'), ('pre', 'O'), ('-', 'O'), ('lithium', 'O'), ('values', 'O'), ('.', 'O'))"
Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients .,"(('Urinary', 'B'), ('concentration', 'I'), ('defect', 'I'), ('appeared', 'O'), ('frequent', 'O'), ('but', 'O'), ('the', 'O'), ('extent', 'O'), ('of', 'O'), ('the', 'O'), ('impairment', 'O'), ('is', 'O'), ('difficult', 'O'), ('to', 'O'), ('assess', 'O'), ('because', 'O'), ('of', 'O'), ('the', 'O'), ('uncertainty', 'O'), ('about', 'O'), ('the', 'O'), ('norms', 'O'), ('applicable', 'O'), ('to', 'O'), ('this', 'O'), ('group', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O'))"
"The concentration defect appeared reversible , at least in part .","(('The', 'O'), ('concentration', 'O'), ('defect', 'O'), ('appeared', 'O'), ('reversible', 'O'), (',', 'O'), ('at', 'O'), ('least', 'O'), ('in', 'O'), ('part', 'O'), ('.', 'O'))"
An attempt is made to draw practical conclusions from the preliminary findings .,"(('An', 'O'), ('attempt', 'O'), ('is', 'O'), ('made', 'O'), ('to', 'O'), ('draw', 'O'), ('practical', 'O'), ('conclusions', 'O'), ('from', 'O'), ('the', 'O'), ('preliminary', 'O'), ('findings', 'O'), ('.', 'O'))"
"Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .","(('Cyclosporin', 'O'), ('A', 'O'), ('(', 'O'), ('CsA', 'O'), (';', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('and', 'O'), ('Fujimycine', 'O'), ('(', 'O'), ('FK506', 'O'), (';', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('the', 'O'), ('related', 'O'), ('macrolide', 'O'), ('immunosuppressant', 'O'), ('rapamycin', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('caused', 'O'), ('a', 'O'), ('reduction', 'O'), ('of', 'O'), ('glomerular', 'O'), ('filtration', 'O'), ('rate', 'O'), (',', 'O'), ('degenerative', 'B'), ('changes', 'I'), ('of', 'I'), ('proximal', 'O'), ('tubular', 'O'), ('epithelium', 'O'), (',', 'O'), ('and', 'O'), ('hypertrophy', 'B'), ('of', 'I'), ('the', 'I'), ('juxtaglomerular', 'I'), ('apparatus', 'I'), ('in', 'O'), ('male', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('when', 'O'), ('given', 'O'), ('for', 'O'), ('10', 'O'), ('days', 'O'), ('.', 'O'))"
The molecular mechanisms of CsA and FK506 toxicity were investigated .,"(('The', 'O'), ('molecular', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('CsA', 'O'), ('and', 'O'), ('FK506', 'O'), ('toxicity', 'O'), ('were', 'O'), ('investigated', 'O'), ('.', 'O'))"
"Cyclophilin A and FK506 - binding protein , the main intracytoplasmic receptors for CsA and FK506 , respectively , were each detected in renal tissue extract .","(('Cyclophilin', 'O'), ('A', 'O'), ('and', 'O'), ('FK506', 'O'), ('-', 'O'), ('binding', 'O'), ('protein', 'O'), (',', 'O'), ('the', 'O'), ('main', 'O'), ('intracytoplasmic', 'O'), ('receptors', 'O'), ('for', 'O'), ('CsA', 'O'), ('and', 'O'), ('FK506', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('were', 'O'), ('each', 'O'), ('detected', 'O'), ('in', 'O'), ('renal', 'O'), ('tissue', 'O'), ('extract', 'O'), ('.', 'O'))"
"In the kidney , high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506 , but not by rapamycin .","(('In', 'O'), ('the', 'O'), ('kidney', 'O'), (',', 'O'), ('high', 'O'), ('levels', 'O'), ('of', 'O'), ('immunoreactive', 'O'), ('and', 'O'), ('enzymatically', 'O'), ('active', 'O'), ('calcineurin', 'O'), ('were', 'O'), ('found', 'O'), ('which', 'O'), ('were', 'O'), ('inhibited', 'O'), ('by', 'O'), ('the', 'O'), ('immunosuppressants', 'O'), ('CsA', 'O'), ('and', 'O'), ('FK506', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('by', 'O'), ('rapamycin', 'O'), ('.', 'O'))"
"Finally , specific immunophilin - drug - calcineurin complexes formed only in the presence of CsA and FK506 , but not rapamycin .","(('Finally', 'O'), (',', 'O'), ('specific', 'O'), ('immunophilin', 'O'), ('-', 'O'), ('drug', 'O'), ('-', 'O'), ('calcineurin', 'O'), ('complexes', 'O'), ('formed', 'O'), ('only', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('CsA', 'O'), ('and', 'O'), ('FK506', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('rapamycin', 'O'), ('.', 'O'))"
Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients .,"(('Carboplatin', 'O'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('cause', 'O'), ('acute', 'O'), ('renal', 'B'), ('failure', 'I'), ('when', 'O'), ('administered', 'O'), ('in', 'O'), ('high', 'O'), ('doses', 'O'), ('to', 'O'), ('adult', 'O'), ('patients', 'O'), ('.', 'O'))"
Possible contributing factors are discussed .,"(('Possible', 'O'), ('contributing', 'O'), ('factors', 'O'), ('are', 'O'), ('discussed', 'O'), ('.', 'O'))"
Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol .,"(('Clinical', 'O'), ('evaluation', 'O'), ('on', 'O'), ('combined', 'O'), ('administration', 'O'), ('of', 'O'), ('oral', 'O'), ('prostacyclin', 'O'), ('analogue', 'O'), ('beraprost', 'O'), ('and', 'O'), ('phosphodiesterase', 'O'), ('inhibitor', 'O'), ('cilostazol', 'O'), ('.', 'O'))"
"Among various oral antiplatelets , a combination of a novel prostacyclin analogue beraprost ( BPT ) and a potent phosphodiesterase inhibitor cilostazol ( CLZ ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP ( cyclic adenosine 3 ' , 5 ' - monophosphate ) .","(('Among', 'O'), ('various', 'O'), ('oral', 'O'), ('antiplatelets', 'O'), (',', 'O'), ('a', 'O'), ('combination', 'O'), ('of', 'O'), ('a', 'O'), ('novel', 'O'), ('prostacyclin', 'O'), ('analogue', 'O'), ('beraprost', 'O'), ('(', 'O'), ('BPT', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('potent', 'O'), ('phosphodiesterase', 'O'), ('inhibitor', 'O'), ('cilostazol', 'O'), ('(', 'O'), ('CLZ', 'O'), (')', 'O'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('untoward', 'O'), ('clinical', 'O'), ('effects', 'O'), ('due', 'O'), ('to', 'O'), ('possible', 'O'), ('synergistic', 'O'), ('elevation', 'O'), ('of', 'O'), ('intracellular', 'O'), ('cAMP', 'O'), ('(', 'O'), ('cyclic', 'O'), ('adenosine', 'O'), ('3', 'O'), (""'"", 'O'), (',', 'O'), ('5', 'O'), (""'"", 'O'), ('-', 'O'), ('monophosphate', 'O'), (')', 'O'), ('.', 'O'))"
"Thereby , a clinical study of the combined administration of the two agents was attempted .","(('Thereby', 'O'), (',', 'O'), ('a', 'O'), ('clinical', 'O'), ('study', 'O'), ('of', 'O'), ('the', 'O'), ('combined', 'O'), ('administration', 'O'), ('of', 'O'), ('the', 'O'), ('two', 'O'), ('agents', 'O'), ('was', 'O'), ('attempted', 'O'), ('.', 'O'))"
"Twelve healthy volunteers were assigned to take BPT / CLZ in the following schedule ; BPT : 40 micrograms at day 1 and 120 micrograms t . i . d . from day 7 to 14 , CLZ : 200 mg t . i . d . from day 3 to 14 .","(('Twelve', 'O'), ('healthy', 'O'), ('volunteers', 'O'), ('were', 'O'), ('assigned', 'O'), ('to', 'O'), ('take', 'O'), ('BPT', 'O'), ('/', 'O'), ('CLZ', 'O'), ('in', 'O'), ('the', 'O'), ('following', 'O'), ('schedule', 'O'), (';', 'O'), ('BPT', 'O'), (':', 'O'), ('40', 'O'), ('micrograms', 'O'), ('at', 'O'), ('day', 'O'), ('1', 'O'), ('and', 'O'), ('120', 'O'), ('micrograms', 'O'), ('t', 'O'), ('.', 'O'), ('i', 'O'), ('.', 'O'), ('d', 'O'), ('.', 'O'), ('from', 'O'), ('day', 'O'), ('7', 'O'), ('to', 'O'), ('14', 'O'), (',', 'O'), ('CLZ', 'O'), (':', 'O'), ('200', 'O'), ('mg', 'O'), ('t', 'O'), ('.', 'O'), ('i', 'O'), ('.', 'O'), ('d', 'O'), ('.', 'O'), ('from', 'O'), ('day', 'O'), ('3', 'O'), ('to', 'O'), ('14', 'O'), ('.', 'O'))"
"Throughout the observation period , no significant alteration in vital signs was observed .","(('Throughout', 'O'), ('the', 'O'), ('observation', 'O'), ('period', 'O'), (',', 'O'), ('no', 'O'), ('significant', 'O'), ('alteration', 'O'), ('in', 'O'), ('vital', 'O'), ('signs', 'O'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
"All of these symptoms , probably caused by the vasodilating effect of the two agents , were of mild degree and no special treatment was required .","(('All', 'O'), ('of', 'O'), ('these', 'O'), ('symptoms', 'O'), (',', 'O'), ('probably', 'O'), ('caused', 'O'), ('by', 'O'), ('the', 'O'), ('vasodilating', 'O'), ('effect', 'O'), ('of', 'O'), ('the', 'O'), ('two', 'O'), ('agents', 'O'), (',', 'O'), ('were', 'O'), ('of', 'O'), ('mild', 'O'), ('degree', 'O'), ('and', 'O'), ('no', 'O'), ('special', 'O'), ('treatment', 'O'), ('was', 'O'), ('required', 'O'), ('.', 'O'))"
Intraplatelet cAMP content was gradually but significantly increased to 9 . 84 + / - 4 . 59 pmol per 10 ( 9 ) platelets at day 14 in comparison with the initial value ( 6 . 87 + / - 2 . 25 pmol ) .,"(('Intraplatelet', 'O'), ('cAMP', 'O'), ('content', 'O'), ('was', 'O'), ('gradually', 'O'), ('but', 'O'), ('significantly', 'O'), ('increased', 'O'), ('to', 'O'), ('9', 'O'), ('.', 'O'), ('84', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('4', 'O'), ('.', 'O'), ('59', 'O'), ('pmol', 'O'), ('per', 'O'), ('10', 'O'), ('(', 'O'), ('9', 'O'), (')', 'O'), ('platelets', 'O'), ('at', 'O'), ('day', 'O'), ('14', 'O'), ('in', 'O'), ('comparison', 'O'), ('with', 'O'), ('the', 'O'), ('initial', 'O'), ('value', 'O'), ('(', 'O'), ('6', 'O'), ('.', 'O'), ('87', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('25', 'O'), ('pmol', 'O'), (')', 'O'), ('.', 'O'))"
The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted .,"(('The', 'O'), ('platelet', 'O'), ('aggregability', 'O'), ('was', 'O'), ('significantly', 'O'), ('suppressed', 'O'), ('at', 'O'), ('various', 'O'), ('time', 'O'), ('intervals', 'O'), ('but', 'O'), ('no', 'O'), ('additive', 'O'), ('or', 'O'), ('synergistic', 'O'), ('inhibitory', 'O'), ('effect', 'O'), ('by', 'O'), ('the', 'O'), ('combined', 'O'), ('administration', 'O'), ('was', 'O'), ('noted', 'O'), ('.', 'O'))"
"In conclusion , the combined administration of BPT / CLZ is safe at doses used in the study , though the beneficial clinical effect of the combined administration has yet to be elucidated .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('the', 'O'), ('combined', 'O'), ('administration', 'O'), ('of', 'O'), ('BPT', 'O'), ('/', 'O'), ('CLZ', 'O'), ('is', 'O'), ('safe', 'O'), ('at', 'O'), ('doses', 'O'), ('used', 'O'), ('in', 'O'), ('the', 'O'), ('study', 'O'), (',', 'O'), ('though', 'O'), ('the', 'O'), ('beneficial', 'O'), ('clinical', 'O'), ('effect', 'O'), ('of', 'O'), ('the', 'O'), ('combined', 'O'), ('administration', 'O'), ('has', 'O'), ('yet', 'O'), ('to', 'O'), ('be', 'O'), ('elucidated', 'O'), ('.', 'O'))"
Pravastatin - associated myopathy .,"(('Pravastatin', 'B'), ('-', 'O'), ('associated', 'O'), ('myopathy', 'B'), ('.', 'O'))"
Report of a case .,"(('Report', 'O'), ('of', 'O'), ('a', 'O'), ('case', 'O'), ('.', 'O'))"
"A case of acute inflammatory myopathy associated with the use of pravastatin , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .","(('A', 'O'), ('case', 'O'), ('of', 'O'), ('acute', 'B'), ('inflammatory', 'I'), ('myopathy', 'I'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('pravastatin', 'O'), (',', 'O'), ('a', 'O'), ('new', 'O'), ('hydrophilic', 'O'), ('3', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('-', 'O'), ('3', 'O'), ('methylglutaril', 'O'), ('coenzyme', 'O'), ('A', 'O'), ('reductase', 'O'), ('inhibitor', 'O'), (',', 'O'), ('is', 'O'), ('reported', 'O'), ('.', 'O'))"
He assumed pravastatin ( 20 mg / day ) because of hypercholesterolemia .,"(('He', 'O'), ('assumed', 'O'), ('pravastatin', 'O'), ('(', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('because', 'O'), ('of', 'O'), ('hypercholesterolemia', 'B'), ('.', 'O'))"
He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation .,"(('He', 'O'), ('was', 'O'), ('admitted', 'O'), ('with', 'O'), ('acute', 'B'), ('myopathy', 'B'), ('of', 'I'), ('the', 'I'), ('lower', 'I'), ('limbs', 'I'), ('which', 'O'), ('resolved', 'O'), ('in', 'O'), ('a', 'O'), ('few', 'O'), ('days', 'O'), ('after', 'O'), ('pravastatin', 'O'), ('discontinuation', 'O'), ('.', 'O'))"
Muscle biopsy ( left gastrocnemius ) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4 + lymphocytes .,"(('Muscle', 'O'), ('biopsy', 'O'), ('(', 'O'), ('left', 'O'), ('gastrocnemius', 'O'), (')', 'O'), ('revealed', 'O'), ('a', 'O'), ('perimysial', 'O'), ('and', 'O'), ('endomysial', 'O'), ('inflammatory', 'O'), ('infiltrate', 'O'), ('with', 'O'), ('a', 'O'), ('prevalence', 'O'), ('of', 'O'), ('CD4', 'O'), ('+', 'O'), ('lymphocytes', 'O'), ('.', 'O'))"
"While lovastatin and simvastatin have been associated with toxic myopathy , pravastatin - associated myopathy could represent a distinct , inflammatory entity .","(('While', 'O'), ('lovastatin', 'O'), ('and', 'O'), ('simvastatin', 'O'), ('have', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('toxic', 'B'), ('myopathy', 'I'), (',', 'O'), ('pravastatin', 'O'), ('-', 'O'), ('associated', 'O'), ('myopathy', 'B'), ('could', 'O'), ('represent', 'O'), ('a', 'O'), ('distinct', 'O'), (',', 'O'), ('inflammatory', 'O'), ('entity', 'O'), ('.', 'O'))"
"The effect of L - dopa was correlated with a decrease in blood and brain ammonia , an increase in brain dopamine , and an increase in renal excretion of ammonia and urea .","(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), ('was', 'O'), ('correlated', 'O'), ('with', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('blood', 'O'), ('and', 'O'), ('brain', 'O'), ('ammonia', 'O'), (',', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('brain', 'O'), ('dopamine', 'O'), (',', 'O'), ('and', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('renal', 'O'), ('excretion', 'O'), ('of', 'O'), ('ammonia', 'O'), ('and', 'O'), ('urea', 'O'), ('.', 'O'))"
Possible causal mechanisms are discussed .,"(('Possible', 'O'), ('causal', 'O'), ('mechanisms', 'O'), ('are', 'O'), ('discussed', 'O'), ('.', 'O'))"
Halogenated anesthetics form liver adducts and antigens that cross - react with halothane - induced antibodies .,"(('Halogenated', 'O'), ('anesthetics', 'O'), ('form', 'O'), ('liver', 'O'), ('adducts', 'O'), ('and', 'O'), ('antigens', 'O'), ('that', 'O'), ('cross', 'O'), ('-', 'O'), ('react', 'O'), ('with', 'O'), ('halothane', 'O'), ('-', 'O'), ('induced', 'O'), ('antibodies', 'O'), ('.', 'O'))"
"Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type hepatic injury both alone and following previous exposure to halothane .","(('Two', 'O'), ('halogenated', 'O'), ('anesthetics', 'O'), (',', 'O'), ('enflurane', 'O'), ('and', 'O'), ('isoflurane', 'O'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('allergic', 'B'), ('-', 'I'), ('type', 'I'), ('hepatic', 'I'), ('injury', 'I'), ('both', 'O'), ('alone', 'O'), ('and', 'O'), ('following', 'O'), ('previous', 'O'), ('exposure', 'O'), ('to', 'O'), ('halothane', 'O'), ('.', 'O'))"
Halothane hepatitis appears to involve an aberrant immune response .,"(('Halothane', 'B'), ('hepatitis', 'I'), ('appears', 'O'), ('to', 'O'), ('involve', 'O'), ('an', 'O'), ('aberrant', 'O'), ('immune', 'O'), ('response', 'O'), ('.', 'O'))"
An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on halothane hepatitis patients .,"(('An', 'O'), ('antibody', 'O'), ('response', 'O'), ('to', 'O'), ('a', 'O'), ('protein', 'O'), ('-', 'O'), ('bound', 'O'), ('biotransformation', 'O'), ('product', 'O'), ('(', 'O'), ('trifluoroacetyl', 'O'), ('adduct', 'O'), (')', 'O'), ('has', 'O'), ('been', 'O'), ('detected', 'O'), ('on', 'O'), ('halothane', 'B'), ('hepatitis', 'I'), ('patients', 'O'), ('.', 'O'))"
This study was performed to determine cross - reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane .,"(('This', 'O'), ('study', 'O'), ('was', 'O'), ('performed', 'O'), ('to', 'O'), ('determine', 'O'), ('cross', 'O'), ('-', 'O'), ('reactivity', 'O'), ('between', 'O'), ('enflurane', 'O'), ('and', 'O'), ('isoflurane', 'O'), ('with', 'O'), ('the', 'O'), ('hypersensitivity', 'B'), ('induced', 'O'), ('by', 'O'), ('halothane', 'O'), ('.', 'O'))"
"The subcellular and lobular production of hepatic neoantigens recognized by halothane - induced antibodies following enflurane and isoflurane , and the biochemical nature of these neoantigens was investigated in two animal models .","(('The', 'O'), ('subcellular', 'O'), ('and', 'O'), ('lobular', 'O'), ('production', 'O'), ('of', 'O'), ('hepatic', 'O'), ('neoantigens', 'O'), ('recognized', 'O'), ('by', 'O'), ('halothane', 'O'), ('-', 'O'), ('induced', 'O'), ('antibodies', 'O'), ('following', 'O'), ('enflurane', 'O'), ('and', 'O'), ('isoflurane', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('biochemical', 'O'), ('nature', 'O'), ('of', 'O'), ('these', 'O'), ('neoantigens', 'O'), ('was', 'O'), ('investigated', 'O'), ('in', 'O'), ('two', 'O'), ('animal', 'O'), ('models', 'O'), ('.', 'O'))"
Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver .,"(('Enflurane', 'O'), ('administration', 'O'), ('resulted', 'O'), ('in', 'O'), ('neoantigens', 'O'), ('detected', 'O'), ('in', 'O'), ('both', 'O'), ('the', 'O'), ('microsomal', 'O'), ('and', 'O'), ('cytosolic', 'O'), ('fraction', 'O'), ('of', 'O'), ('liver', 'O'), ('homogenates', 'O'), ('and', 'O'), ('in', 'O'), ('the', 'O'), ('centrilobular', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('liver', 'O'), ('.', 'O'))"
"In the same liver , biochemical analysis detected fluorinated liver adducts that were up to 20 - fold greater in guinea pigs than in rats .","(('In', 'O'), ('the', 'O'), ('same', 'O'), ('liver', 'O'), (',', 'O'), ('biochemical', 'O'), ('analysis', 'O'), ('detected', 'O'), ('fluorinated', 'O'), ('liver', 'O'), ('adducts', 'O'), ('that', 'O'), ('were', 'O'), ('up', 'O'), ('to', 'O'), ('20', 'O'), ('-', 'O'), ('fold', 'O'), ('greater', 'O'), ('in', 'O'), ('guinea', 'O'), ('pigs', 'O'), ('than', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .,"(('This', 'O'), ('supports', 'O'), ('and', 'O'), ('extends', 'O'), ('previous', 'O'), ('evidence', 'O'), ('for', 'O'), ('a', 'O'), ('mechanism', 'O'), ('by', 'O'), ('which', 'O'), ('enflurane', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('isoflurane', 'O'), ('could', 'O'), ('produce', 'O'), ('a', 'O'), ('hypersensitivity', 'B'), ('condition', 'I'), ('similar', 'O'), ('to', 'O'), ('that', 'O'), ('of', 'O'), ('halothane', 'B'), ('hepatitis', 'I'), ('either', 'O'), ('alone', 'O'), ('or', 'O'), ('subsequent', 'O'), ('to', 'O'), ('halothane', 'O'), ('administration', 'O'), ('.', 'O'))"
The guinea pig would appear to be a useful model for further investigations of the immunological response to these antigens .,"(('The', 'O'), ('guinea', 'O'), ('pig', 'O'), ('would', 'O'), ('appear', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('useful', 'O'), ('model', 'O'), ('for', 'O'), ('further', 'O'), ('investigations', 'O'), ('of', 'O'), ('the', 'O'), ('immunological', 'O'), ('response', 'O'), ('to', 'O'), ('these', 'O'), ('antigens', 'O'), ('.', 'O'))"
Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops .,"(('Cholinergic', 'B'), ('toxicity', 'I'), ('resulting', 'O'), ('from', 'O'), ('ocular', 'O'), ('instillation', 'O'), ('of', 'O'), ('echothiophate', 'O'), ('iodide', 'O'), ('eye', 'O'), ('drops', 'O'), ('.', 'O'))"
"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops , presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis .","(('A', 'O'), ('patient', 'O'), ('developed', 'O'), ('a', 'O'), ('severe', 'O'), ('cholinergic', 'B'), ('syndrome', 'I'), ('from', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('echothiophate', 'O'), ('iodide', 'O'), ('ophthalmic', 'O'), ('drops', 'O'), (',', 'O'), ('presented', 'O'), ('with', 'O'), ('profound', 'O'), ('muscle', 'B'), ('weakness', 'I'), ('and', 'O'), ('was', 'O'), ('initially', 'O'), ('given', 'O'), ('the', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('myasthenia', 'B'), ('gravis', 'I'), ('.', 'O'))"
Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops .,"(('Red', 'O'), ('blood', 'O'), ('cell', 'O'), ('and', 'O'), ('serum', 'O'), ('cholinesterase', 'O'), ('levels', 'O'), ('were', 'O'), ('severely', 'O'), ('depressed', 'O'), ('and', 'O'), ('symptoms', 'O'), ('resolved', 'O'), ('spontaneously', 'O'), ('following', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('the', 'O'), ('eye', 'O'), ('drops', 'O'), ('.', 'O'))"
Little information exists concerning adverse effects of flumazenil in children .,"(('Little', 'O'), ('information', 'O'), ('exists', 'O'), ('concerning', 'O'), ('adverse', 'O'), ('effects', 'O'), ('of', 'O'), ('flumazenil', 'O'), ('in', 'O'), ('children', 'O'), ('.', 'O'))"
Phase I trial of 13 - cis - retinoic acid in children with neuroblastoma following bone marrow transplantation .,"(('Phase', 'O'), ('I', 'O'), ('trial', 'O'), ('of', 'O'), ('13', 'O'), ('-', 'O'), ('cis', 'O'), ('-', 'O'), ('retinoic', 'O'), ('acid', 'O'), ('in', 'O'), ('children', 'O'), ('with', 'O'), ('neuroblastoma', 'B'), ('following', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplantation', 'O'), ('.', 'O'))"
PURPOSE : Treatment of neuroblastoma cell lines with 13 - cis - retinoic acid ( cis - RA ) can cause sustained inhibition of proliferation .,"(('PURPOSE', 'O'), (':', 'O'), ('Treatment', 'O'), ('of', 'O'), ('neuroblastoma', 'B'), ('cell', 'O'), ('lines', 'O'), ('with', 'O'), ('13', 'O'), ('-', 'O'), ('cis', 'O'), ('-', 'O'), ('retinoic', 'O'), ('acid', 'O'), ('(', 'O'), ('cis', 'O'), ('-', 'O'), ('RA', 'O'), (')', 'O'), ('can', 'O'), ('cause', 'O'), ('sustained', 'O'), ('inhibition', 'O'), ('of', 'O'), ('proliferation', 'O'), ('.', 'O'))"
"Since cis - RA has demonstrated clinical responses in neuroblastoma patients , it may be effective in preventing relapse after cytotoxic therapy .","(('Since', 'O'), ('cis', 'O'), ('-', 'O'), ('RA', 'O'), ('has', 'O'), ('demonstrated', 'O'), ('clinical', 'O'), ('responses', 'O'), ('in', 'O'), ('neuroblastoma', 'B'), ('patients', 'O'), (',', 'O'), ('it', 'O'), ('may', 'O'), ('be', 'O'), ('effective', 'O'), ('in', 'O'), ('preventing', 'O'), ('relapse', 'O'), ('after', 'O'), ('cytotoxic', 'O'), ('therapy', 'O'), ('.', 'O'))"
"PATIENTS AND METHODS : Fifty - one assessable patients , 2 to 12 years of age , were treated with oral cis - RA administered in two equally divided doses daily for 2 weeks , followed by a 2 - week rest period , for up to 12 courses .","(('PATIENTS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('Fifty', 'O'), ('-', 'O'), ('one', 'O'), ('assessable', 'O'), ('patients', 'O'), (',', 'O'), ('2', 'O'), ('to', 'O'), ('12', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), (',', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('oral', 'O'), ('cis', 'O'), ('-', 'O'), ('RA', 'O'), ('administered', 'O'), ('in', 'O'), ('two', 'O'), ('equally', 'O'), ('divided', 'O'), ('doses', 'O'), ('daily', 'O'), ('for', 'O'), ('2', 'O'), ('weeks', 'O'), (',', 'O'), ('followed', 'O'), ('by', 'O'), ('a', 'O'), ('2', 'O'), ('-', 'O'), ('week', 'O'), ('rest', 'O'), ('period', 'O'), (',', 'O'), ('for', 'O'), ('up', 'O'), ('to', 'O'), ('12', 'O'), ('courses', 'O'), ('.', 'O'))"
The dose was escalated from 100 to 200 mg / m2 / d until dose - limiting toxicity ( DLT ) was observed .,"(('The', 'O'), ('dose', 'O'), ('was', 'O'), ('escalated', 'O'), ('from', 'O'), ('100', 'O'), ('to', 'O'), ('200', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('/', 'O'), ('d', 'O'), ('until', 'O'), ('dose', 'O'), ('-', 'O'), ('limiting', 'O'), ('toxicity', 'O'), ('(', 'O'), ('DLT', 'B'), (')', 'O'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
A single intrapatient dose escalation was permitted .,"(('A', 'O'), ('single', 'O'), ('intrapatient', 'O'), ('dose', 'O'), ('escalation', 'O'), ('was', 'O'), ('permitted', 'O'), ('.', 'O'))"
RESULTS : The MTD of cis - RA was 160 mg / m2 / d .,"(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('MTD', 'O'), ('of', 'O'), ('cis', 'O'), ('-', 'O'), ('RA', 'O'), ('was', 'O'), ('160', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('/', 'O'), ('d', 'O'), ('.', 'O'))"
Serum levels of 7 . 4 + / - 3 . 0 mumol / L ( peak ) and 4 . 0 + / - 2 . 8 mumol / L ( trough ) at the MTD were maintained during 14 days of therapy .,"(('Serum', 'O'), ('levels', 'O'), ('of', 'O'), ('7', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('0', 'O'), ('mumol', 'O'), ('/', 'O'), ('L', 'O'), ('(', 'O'), ('peak', 'O'), (')', 'O'), ('and', 'O'), ('4', 'O'), ('.', 'O'), ('0', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('8', 'O'), ('mumol', 'O'), ('/', 'O'), ('L', 'O'), ('(', 'O'), ('trough', 'O'), (')', 'O'), ('at', 'O'), ('the', 'O'), ('MTD', 'O'), ('were', 'O'), ('maintained', 'O'), ('during', 'O'), ('14', 'O'), ('days', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O'))"
The DLT correlated with serum levels > or = 10 mumol / L .,"(('The', 'O'), ('DLT', 'O'), ('correlated', 'O'), ('with', 'O'), ('serum', 'O'), ('levels', 'O'), ('>', 'O'), ('or', 'O'), ('=', 'O'), ('10', 'O'), ('mumol', 'O'), ('/', 'O'), ('L', 'O'), ('.', 'O'))"
CONCLUSION : The MTD of cis - RA given on this intermittent schedule was 160 mg / m2 / d .,"(('CONCLUSION', 'O'), (':', 'O'), ('The', 'O'), ('MTD', 'O'), ('of', 'O'), ('cis', 'O'), ('-', 'O'), ('RA', 'O'), ('given', 'O'), ('on', 'O'), ('this', 'O'), ('intermittent', 'O'), ('schedule', 'O'), ('was', 'O'), ('160', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('/', 'O'), ('d', 'O'), ('.', 'O'))"
Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose .,"(('Serum', 'O'), ('levels', 'O'), ('known', 'O'), ('to', 'O'), ('be', 'O'), ('effective', 'O'), ('against', 'O'), ('neuroblastoma', 'B'), ('in', 'O'), ('vitro', 'O'), ('were', 'O'), ('achieved', 'O'), ('at', 'O'), ('this', 'O'), ('dose', 'O'), ('.', 'O'))"
Monitoring of serum calcium and cis - RA levels is indicated in future trials .,"(('Monitoring', 'O'), ('of', 'O'), ('serum', 'O'), ('calcium', 'O'), ('and', 'O'), ('cis', 'O'), ('-', 'O'), ('RA', 'O'), ('levels', 'O'), ('is', 'O'), ('indicated', 'O'), ('in', 'O'), ('future', 'O'), ('trials', 'O'), ('.', 'O'))"
"Plasma extracts were analyzed by a highly sensitive high - performance liquid chromatographic method for the direct determination of malondialdehyde , oxypurines , and nucleosides .","(('Plasma', 'O'), ('extracts', 'O'), ('were', 'O'), ('analyzed', 'O'), ('by', 'O'), ('a', 'O'), ('highly', 'O'), ('sensitive', 'O'), ('high', 'O'), ('-', 'O'), ('performance', 'O'), ('liquid', 'O'), ('chromatographic', 'O'), ('method', 'O'), ('for', 'O'), ('the', 'O'), ('direct', 'O'), ('determination', 'O'), ('of', 'O'), ('malondialdehyde', 'O'), (',', 'O'), ('oxypurines', 'O'), (',', 'O'), ('and', 'O'), ('nucleosides', 'O'), ('.', 'O'))"
"The present data indicate that the determination of malondialdehyde , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )","(('The', 'O'), ('present', 'O'), ('data', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('determination', 'O'), ('of', 'O'), ('malondialdehyde', 'O'), (',', 'O'), ('oxypurines', 'O'), (',', 'O'), ('and', 'O'), ('nucleosides', 'O'), ('in', 'O'), ('peripheral', 'O'), ('blood', 'O'), (',', 'O'), ('may', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('monitor', 'O'), ('the', 'O'), ('metabolic', 'O'), ('alterations', 'O'), ('of', 'O'), ('tissues', 'O'), ('occurring', 'O'), ('during', 'O'), ('ischemic', 'O'), ('phenomena', 'O'), ('.', 'O'), ('(', 'O'), ('ABSTRACT', 'O'), ('TRUNCATED', 'O'), ('AT', 'O'), ('250', 'O'), ('WORDS', 'O'), (')', 'O'))"
Acute renal toxicity of doxorubicin ( adriamycin ) - loaded cyanoacrylate nanoparticles .,"(('Acute', 'O'), ('renal', 'O'), ('toxicity', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('adriamycin', 'O'), (')', 'O'), ('-', 'O'), ('loaded', 'O'), ('cyanoacrylate', 'O'), ('nanoparticles', 'O'), ('.', 'O'))"
Acute doxorubicin - loaded nanoparticle ( DXNP ) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis .,"(('Acute', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('loaded', 'O'), ('nanoparticle', 'O'), ('(', 'O'), ('DXNP', 'O'), (')', 'O'), ('renal', 'O'), ('toxicity', 'O'), ('was', 'O'), ('explored', 'O'), ('in', 'O'), ('both', 'O'), ('normal', 'O'), ('rats', 'O'), ('and', 'O'), ('rats', 'O'), ('with', 'O'), ('experimental', 'O'), ('glomerulonephritis', 'B'), ('.', 'O'))"
"In normal rats , 2 / 6 rats given free doxorubicin ( DX ) ( 5 mg / kg ) died within one week , whereas all control animals and all rats having received free NP or DXNP survived .","(('In', 'O'), ('normal', 'O'), ('rats', 'O'), (',', 'O'), ('2', 'O'), ('/', 'O'), ('6', 'O'), ('rats', 'O'), ('given', 'O'), ('free', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('DX', 'O'), (')', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('died', 'O'), ('within', 'O'), ('one', 'O'), ('week', 'O'), (',', 'O'), ('whereas', 'O'), ('all', 'O'), ('control', 'O'), ('animals', 'O'), ('and', 'O'), ('all', 'O'), ('rats', 'O'), ('having', 'O'), ('received', 'O'), ('free', 'O'), ('NP', 'O'), ('or', 'O'), ('DXNP', 'O'), ('survived', 'O'), ('.', 'O'))"
A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX .,"(('A', 'O'), ('3', 'O'), ('times', 'O'), ('higher', 'O'), ('proteinuria', 'B'), ('appeared', 'O'), ('in', 'O'), ('animals', 'O'), ('treated', 'O'), ('with', 'O'), ('DXNP', 'O'), ('than', 'O'), ('in', 'O'), ('those', 'O'), ('treated', 'O'), ('with', 'O'), ('DX', 'O'), ('.', 'O'))"
Free NP did not provoke any proteinuria .,"(('Free', 'O'), ('NP', 'O'), ('did', 'O'), ('not', 'O'), ('provoke', 'O'), ('any', 'O'), ('proteinuria', 'B'), ('.', 'O'))"
"Two hr post - injection , DXNP was 2 . 7 times more concentrated in kidneys than free DX ( p < 0 . 025 ) .","(('Two', 'O'), ('hr', 'O'), ('post', 'O'), ('-', 'O'), ('injection', 'O'), (',', 'O'), ('DXNP', 'O'), ('was', 'O'), ('2', 'O'), ('.', 'O'), ('7', 'O'), ('times', 'O'), ('more', 'O'), ('concentrated', 'O'), ('in', 'O'), ('kidneys', 'O'), ('than', 'O'), ('free', 'O'), ('DX', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('025', 'O'), (')', 'O'), ('.', 'O'))"
"In rats with immune experimental glomerulonephritis , 5 / 6 rats given DX died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .","(('In', 'O'), ('rats', 'O'), ('with', 'O'), ('immune', 'O'), ('experimental', 'O'), ('glomerulonephritis', 'B'), (',', 'O'), ('5', 'O'), ('/', 'O'), ('6', 'O'), ('rats', 'O'), ('given', 'O'), ('DX', 'O'), ('died', 'O'), ('within', 'O'), ('7', 'O'), ('days', 'O'), (',', 'O'), ('in', 'O'), ('contrast', 'O'), ('to', 'O'), ('animals', 'O'), ('treated', 'O'), ('by', 'O'), ('DXNP', 'O'), (',', 'O'), ('NP', 'O'), (',', 'O'), ('or', 'O'), ('untreated', 'O'), (',', 'O'), ('which', 'O'), ('all', 'O'), ('survived', 'O'), ('.', 'O'))"
Rats treated by unloaded NP behaved as controls .,"(('Rats', 'O'), ('treated', 'O'), ('by', 'O'), ('unloaded', 'O'), ('NP', 'O'), ('behaved', 'O'), ('as', 'O'), ('controls', 'O'), ('.', 'O'))"
"These results demonstrate that , in these experimental conditions , DXNP killed less animals than free DX , despite of an enhanced renal toxicity of the former .","(('These', 'O'), ('results', 'O'), ('demonstrate', 'O'), ('that', 'O'), (',', 'O'), ('in', 'O'), ('these', 'O'), ('experimental', 'O'), ('conditions', 'O'), (',', 'O'), ('DXNP', 'O'), ('killed', 'O'), ('less', 'O'), ('animals', 'O'), ('than', 'O'), ('free', 'O'), ('DX', 'O'), (',', 'O'), ('despite', 'O'), ('of', 'O'), ('an', 'O'), ('enhanced', 'O'), ('renal', 'O'), ('toxicity', 'O'), ('of', 'O'), ('the', 'O'), ('former', 'O'), ('.', 'O'))"
"In normal conscious rats investigated by continuous cystometry , intravesically instilled prostaglandin ( PG ) E2 facilitated micturition and increased basal intravesical pressure .","(('In', 'O'), ('normal', 'O'), ('conscious', 'O'), ('rats', 'O'), ('investigated', 'O'), ('by', 'O'), ('continuous', 'O'), ('cystometry', 'O'), (',', 'O'), ('intravesically', 'O'), ('instilled', 'O'), ('prostaglandin', 'O'), ('(', 'O'), ('PG', 'O'), (')', 'O'), ('E2', 'O'), ('facilitated', 'O'), ('micturition', 'O'), ('and', 'O'), ('increased', 'O'), ('basal', 'O'), ('intravesical', 'O'), ('pressure', 'O'), ('.', 'O'))"
"The effect was attenuated by both the NK1 receptor selective antagonist RP 67 , 580 and the NK2 receptor selective antagonist SR 48 , 968 , given intra - arterially , suggesting that it was mediated by stimulation of both NK1 and NK2 receptors .","(('The', 'O'), ('effect', 'O'), ('was', 'O'), ('attenuated', 'O'), ('by', 'O'), ('both', 'O'), ('the', 'O'), ('NK1', 'O'), ('receptor', 'O'), ('selective', 'O'), ('antagonist', 'O'), ('RP', 'O'), ('67', 'O'), (',', 'O'), ('580', 'O'), ('and', 'O'), ('the', 'O'), ('NK2', 'O'), ('receptor', 'O'), ('selective', 'O'), ('antagonist', 'O'), ('SR', 'O'), ('48', 'O'), (',', 'O'), ('968', 'O'), (',', 'O'), ('given', 'O'), ('intra', 'O'), ('-', 'O'), ('arterially', 'O'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('it', 'O'), ('was', 'O'), ('mediated', 'O'), ('by', 'O'), ('stimulation', 'O'), ('of', 'O'), ('both', 'O'), ('NK1', 'O'), ('and', 'O'), ('NK2', 'O'), ('receptors', 'O'), ('.', 'O'))"
"Intra - arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex , indicating that the PG had a direct contractant effect on the detrusor smooth muscle .","(('Intra', 'O'), ('-', 'O'), ('arterially', 'O'), ('given', 'O'), ('PGE2', 'O'), ('produced', 'O'), ('a', 'O'), ('distinct', 'O'), ('increase', 'O'), ('in', 'O'), ('bladder', 'O'), ('pressure', 'O'), ('before', 'O'), ('initiating', 'O'), ('a', 'O'), ('micturition', 'O'), ('reflex', 'O'), (',', 'O'), ('indicating', 'O'), ('that', 'O'), ('the', 'O'), ('PG', 'O'), ('had', 'O'), ('a', 'O'), ('direct', 'O'), ('contractant', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('detrusor', 'O'), ('smooth', 'O'), ('muscle', 'O'), ('.', 'O'))"
"The effect of intra - arterial PGE2 could not be blocked by intra - arterial RP 67 , 580 or SR 48 , 968 , which opens the possibility that the micturition reflex elicited by intra - arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically .","(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('intra', 'O'), ('-', 'O'), ('arterial', 'O'), ('PGE2', 'O'), ('could', 'O'), ('not', 'O'), ('be', 'O'), ('blocked', 'O'), ('by', 'O'), ('intra', 'O'), ('-', 'O'), ('arterial', 'O'), ('RP', 'O'), ('67', 'O'), (',', 'O'), ('580', 'O'), ('or', 'O'), ('SR', 'O'), ('48', 'O'), (',', 'O'), ('968', 'O'), (',', 'O'), ('which', 'O'), ('opens', 'O'), ('the', 'O'), ('possibility', 'O'), ('that', 'O'), ('the', 'O'), ('micturition', 'O'), ('reflex', 'O'), ('elicited', 'O'), ('by', 'O'), ('intra', 'O'), ('-', 'O'), ('arterial', 'O'), ('PGE2', 'O'), ('was', 'O'), ('mediated', 'O'), ('by', 'O'), ('pathways', 'O'), ('other', 'O'), ('than', 'O'), ('the', 'O'), ('reflex', 'O'), ('initiated', 'O'), ('when', 'O'), ('the', 'O'), ('PG', 'O'), ('was', 'O'), ('given', 'O'), ('intravesically', 'O'), ('.', 'O'))"
"The present results thus suggest that intra - arterial PGE2 , given near the bladder , may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor .","(('The', 'O'), ('present', 'O'), ('results', 'O'), ('thus', 'O'), ('suggest', 'O'), ('that', 'O'), ('intra', 'O'), ('-', 'O'), ('arterial', 'O'), ('PGE2', 'O'), (',', 'O'), ('given', 'O'), ('near', 'O'), ('the', 'O'), ('bladder', 'O'), (',', 'O'), ('may', 'O'), ('initiate', 'O'), ('micturition', 'O'), ('in', 'O'), ('the', 'O'), ('normal', 'O'), ('rat', 'O'), ('chiefly', 'O'), ('by', 'O'), ('directly', 'O'), ('contracting', 'O'), ('the', 'O'), ('smooth', 'O'), ('muscle', 'O'), ('of', 'O'), ('the', 'O'), ('detrusor', 'O'), ('.', 'O'))"
"However , when given intravesically , PGE2 may stimulate micturition by releasing tachykinins from nerves in and / or immediately below the urothelium .","(('However', 'O'), (',', 'O'), ('when', 'O'), ('given', 'O'), ('intravesically', 'O'), (',', 'O'), ('PGE2', 'O'), ('may', 'O'), ('stimulate', 'O'), ('micturition', 'O'), ('by', 'O'), ('releasing', 'O'), ('tachykinins', 'O'), ('from', 'O'), ('nerves', 'O'), ('in', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('immediately', 'O'), ('below', 'O'), ('the', 'O'), ('urothelium', 'O'), ('.', 'O'))"
"These tachykinins , in turn , initiate a micturition reflex by stimulating NK1 and NK2 receptors .","(('These', 'O'), ('tachykinins', 'O'), (',', 'O'), ('in', 'O'), ('turn', 'O'), (',', 'O'), ('initiate', 'O'), ('a', 'O'), ('micturition', 'O'), ('reflex', 'O'), ('by', 'O'), ('stimulating', 'O'), ('NK1', 'O'), ('and', 'O'), ('NK2', 'O'), ('receptors', 'O'), ('.', 'O'))"
A case report .,"(('A', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
A seventy - eight - year - old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained - release verapamil with concomitant use of metoprolol .,"(('A', 'O'), ('seventy', 'O'), ('-', 'O'), ('eight', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('presented', 'O'), ('with', 'O'), ('complete', 'B'), ('heart', 'I'), ('block', 'I'), ('and', 'O'), ('refractory', 'B'), ('hypotension', 'I'), ('two', 'O'), ('days', 'O'), ('after', 'O'), ('a', 'O'), ('therapeutic', 'O'), ('dose', 'O'), ('of', 'O'), ('sustained', 'O'), ('-', 'O'), ('release', 'O'), ('verapamil', 'O'), ('with', 'O'), ('concomitant', 'O'), ('use', 'O'), ('of', 'O'), ('metoprolol', 'O'), ('.', 'O'))"
"However , shortly after the use of intravenous calcium chloride , the refractory hypotension and complete heart block resolved .","(('However', 'O'), (',', 'O'), ('shortly', 'O'), ('after', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('intravenous', 'O'), ('calcium', 'O'), ('chloride', 'O'), (',', 'O'), ('the', 'O'), ('refractory', 'O'), ('hypotension', 'B'), ('and', 'O'), ('complete', 'B'), ('heart', 'I'), ('block', 'I'), ('resolved', 'O'), ('.', 'O'))"
Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients .,"(('Protective', 'O'), ('effect', 'O'), ('of', 'O'), ('misoprostol', 'O'), ('on', 'O'), ('indomethacin', 'B'), ('induced', 'O'), ('renal', 'B'), ('dysfunction', 'I'), ('in', 'O'), ('elderly', 'O'), ('patients', 'O'), ('.', 'O'))"
OBJECTIVE : To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('the', 'O'), ('possible', 'O'), ('protective', 'O'), ('effects', 'O'), ('of', 'O'), ('misoprostol', 'O'), ('on', 'O'), ('renal', 'O'), ('function', 'O'), ('in', 'O'), ('hospitalized', 'O'), ('elderly', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('indomethacin', 'O'), ('.', 'O'))"
"METHODS : Forty - five hospitalized elderly patients ( > 65 years old ) who required therapy with nonsteroidal antiinflammatory drugs ( NSAID ) were randomly assigned to receive either indomethacin , 150 mg / day ( Group A ) , or indomethacin 150 mg / day plus misoprostol at 0 . 6 mg / day ( Group B ) .","(('METHODS', 'O'), (':', 'O'), ('Forty', 'O'), ('-', 'O'), ('five', 'O'), ('hospitalized', 'O'), ('elderly', 'O'), ('patients', 'O'), ('(', 'O'), ('>', 'O'), ('65', 'O'), ('years', 'O'), ('old', 'O'), (')', 'O'), ('who', 'O'), ('required', 'O'), ('therapy', 'O'), ('with', 'O'), ('nonsteroidal', 'O'), ('antiinflammatory', 'O'), ('drugs', 'O'), ('(', 'O'), ('NSAID', 'O'), (')', 'O'), ('were', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('receive', 'O'), ('either', 'O'), ('indomethacin', 'O'), (',', 'O'), ('150', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('(', 'O'), ('Group', 'O'), ('A', 'O'), (')', 'O'), (',', 'O'), ('or', 'O'), ('indomethacin', 'O'), ('150', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('plus', 'O'), ('misoprostol', 'O'), ('at', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('(', 'O'), ('Group', 'O'), ('B', 'O'), (')', 'O'), ('.', 'O'))"
"Laboratory variables of renal function [ serum creatinine , blood urea nitrogen ( BUN ) and electrolytes ] were evaluated before initiation of therapy and every 2 days , until termination of the study ( a period of at least 6 days ) .","(('Laboratory', 'O'), ('variables', 'O'), ('of', 'O'), ('renal', 'O'), ('function', 'O'), ('[', 'O'), ('serum', 'O'), ('creatinine', 'O'), (',', 'O'), ('blood', 'O'), ('urea', 'O'), ('nitrogen', 'O'), ('(', 'O'), ('BUN', 'O'), (')', 'O'), ('and', 'O'), ('electrolytes', 'O'), (']', 'O'), ('were', 'O'), ('evaluated', 'O'), ('before', 'O'), ('initiation', 'O'), ('of', 'O'), ('therapy', 'O'), ('and', 'O'), ('every', 'O'), ('2', 'O'), ('days', 'O'), (',', 'O'), ('until', 'O'), ('termination', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('(', 'O'), ('a', 'O'), ('period', 'O'), ('of', 'O'), ('at', 'O'), ('least', 'O'), ('6', 'O'), ('days', 'O'), (')', 'O'), ('.', 'O'))"
"RESULTS : Forty - two patients completed the study , 22 in Group A and 20 in Group B .","(('RESULTS', 'O'), (':', 'O'), ('Forty', 'O'), ('-', 'O'), ('two', 'O'), ('patients', 'O'), ('completed', 'O'), ('the', 'O'), ('study', 'O'), (',', 'O'), ('22', 'O'), ('in', 'O'), ('Group', 'O'), ('A', 'O'), ('and', 'O'), ('20', 'O'), ('in', 'O'), ('Group', 'O'), ('B', 'O'), ('.', 'O'))"
"BUN and creatinine increased by > 50 % of baseline levels in 54 and 45 % of Group A patients , respectively , compared to only 20 and 10 % of Group B patients ( p < 0 . 05 ) .","(('BUN', 'O'), ('and', 'O'), ('creatinine', 'O'), ('increased', 'O'), ('by', 'O'), ('>', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('baseline', 'O'), ('levels', 'O'), ('in', 'O'), ('54', 'O'), ('and', 'O'), ('45', 'O'), ('%', 'O'), ('of', 'O'), ('Group', 'O'), ('A', 'O'), ('patients', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('compared', 'O'), ('to', 'O'), ('only', 'O'), ('20', 'O'), ('and', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('Group', 'O'), ('B', 'O'), ('patients', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"Potassium ( K ) increment of 0 . 6 mEq / l or more was observed in 50 % of Group A , but in only 15 % of Group B patients ( p < 0 . 05 ) .","(('Potassium', 'O'), ('(', 'O'), ('K', 'O'), (')', 'O'), ('increment', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('mEq', 'O'), ('/', 'O'), ('l', 'O'), ('or', 'O'), ('more', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('Group', 'O'), ('A', 'O'), (',', 'O'), ('but', 'O'), ('in', 'O'), ('only', 'O'), ('15', 'O'), ('%', 'O'), ('of', 'O'), ('Group', 'O'), ('B', 'O'), ('patients', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"The mean increments in BUN , creatinine , and K were reduced by 63 , 80 , and 42 % , respectively , in Group B patients compared to Group A . Response to treatment did not differ significantly between the 2 groups .","(('The', 'O'), ('mean', 'O'), ('increments', 'O'), ('in', 'O'), ('BUN', 'O'), (',', 'O'), ('creatinine', 'O'), (',', 'O'), ('and', 'O'), ('K', 'O'), ('were', 'O'), ('reduced', 'O'), ('by', 'O'), ('63', 'O'), (',', 'O'), ('80', 'O'), (',', 'O'), ('and', 'O'), ('42', 'O'), ('%', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('in', 'O'), ('Group', 'O'), ('B', 'O'), ('patients', 'O'), ('compared', 'O'), ('to', 'O'), ('Group', 'O'), ('A', 'O'), ('.', 'O'), ('Response', 'O'), ('to', 'O'), ('treatment', 'O'), ('did', 'O'), ('not', 'O'), ('differ', 'O'), ('significantly', 'O'), ('between', 'O'), ('the', 'O'), ('2', 'O'), ('groups', 'O'), ('.', 'O'))"
CONCLUSION : Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction .,"(('CONCLUSION', 'O'), (':', 'O'), ('Hospitalized', 'O'), ('elderly', 'O'), ('patients', 'O'), ('are', 'O'), ('at', 'O'), ('risk', 'O'), ('for', 'O'), ('developing', 'O'), ('indomethacin', 'B'), ('related', 'O'), ('renal', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
"Dextromethorphan ( DM ) , the dextrorotatory isomer of 3 - hydroxy - N - methylmorphinan , is the main ingredient in a number of widely available , over - the - counter antitussives .","(('Dextromethorphan', 'O'), ('(', 'O'), ('DM', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('dextrorotatory', 'O'), ('isomer', 'O'), ('of', 'O'), ('3', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('-', 'O'), ('N', 'O'), ('-', 'O'), ('methylmorphinan', 'O'), (',', 'O'), ('is', 'O'), ('the', 'O'), ('main', 'O'), ('ingredient', 'O'), ('in', 'O'), ('a', 'O'), ('number', 'O'), ('of', 'O'), ('widely', 'O'), ('available', 'O'), (',', 'O'), ('over', 'O'), ('-', 'O'), ('the', 'O'), ('-', 'O'), ('counter', 'O'), ('antitussives', 'O'), ('.', 'O'))"
Initial studies ( Bornstein 1968 ) showed that it possessed no respiratory suppressant effects and no addiction liability .,"(('Initial', 'O'), ('studies', 'O'), ('(', 'O'), ('Bornstein', 'O'), ('1968', 'O'), (')', 'O'), ('showed', 'O'), ('that', 'O'), ('it', 'O'), ('possessed', 'O'), ('no', 'O'), ('respiratory', 'O'), ('suppressant', 'O'), ('effects', 'O'), ('and', 'O'), ('no', 'O'), ('addiction', 'O'), ('liability', 'O'), ('.', 'O'))"
"Subsequently , however , several articles reporting abuse of this drug have appeared in the literature .","(('Subsequently', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('several', 'O'), ('articles', 'O'), ('reporting', 'O'), ('abuse', 'O'), ('of', 'O'), ('this', 'O'), ('drug', 'O'), ('have', 'O'), ('appeared', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
There have also been two reported fatalities from DM overdoses ( Fleming 1986 ) .,"(('There', 'O'), ('have', 'O'), ('also', 'O'), ('been', 'O'), ('two', 'O'), ('reported', 'O'), ('fatalities', 'O'), ('from', 'O'), ('DM', 'B'), ('overdoses', 'O'), ('(', 'O'), ('Fleming', 'O'), ('1986', 'O'), (')', 'O'), ('.', 'O'))"
"However , there are no reports describing the effects of chronic abuse .","(('However', 'O'), (',', 'O'), ('there', 'O'), ('are', 'O'), ('no', 'O'), ('reports', 'O'), ('describing', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('chronic', 'O'), ('abuse', 'O'), ('.', 'O'))"
This report describes a case of cognitive deterioration resulting from prolonged use of DM .,"(('This', 'O'), ('report', 'O'), ('describes', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('cognitive', 'B'), ('deterioration', 'I'), ('resulting', 'O'), ('from', 'O'), ('prolonged', 'O'), ('use', 'O'), ('of', 'O'), ('DM', 'O'), ('.', 'O'))"
"A hemodynamic , volumetric , and metabolic study in patients without heart failure .","(('A', 'O'), ('hemodynamic', 'O'), (',', 'O'), ('volumetric', 'O'), (',', 'O'), ('and', 'O'), ('metabolic', 'O'), ('study', 'O'), ('in', 'O'), ('patients', 'O'), ('without', 'O'), ('heart', 'B'), ('failure', 'I'), ('.', 'O'))"
"Because the protocol was long and involved interventions which might affect the determinations , we also studied in nine patients using an identical protocol except that ouabain administration was omitted .","(('Because', 'O'), ('the', 'O'), ('protocol', 'O'), ('was', 'O'), ('long', 'O'), ('and', 'O'), ('involved', 'O'), ('interventions', 'O'), ('which', 'O'), ('might', 'O'), ('affect', 'O'), ('the', 'O'), ('determinations', 'O'), (',', 'O'), ('we', 'O'), ('also', 'O'), ('studied', 'O'), ('in', 'O'), ('nine', 'O'), ('patients', 'O'), ('using', 'O'), ('an', 'O'), ('identical', 'O'), ('protocol', 'O'), ('except', 'O'), ('that', 'O'), ('ouabain', 'O'), ('administration', 'O'), ('was', 'O'), ('omitted', 'O'), ('.', 'O'))"
"Left ventricular end - diastolic pressure and left ventricular end - diastolic volume fell in each patient given ouabain , even though they were initially elevated in only two patients .","(('Left', 'O'), ('ventricular', 'O'), ('end', 'O'), ('-', 'O'), ('diastolic', 'O'), ('pressure', 'O'), ('and', 'O'), ('left', 'O'), ('ventricular', 'O'), ('end', 'O'), ('-', 'O'), ('diastolic', 'O'), ('volume', 'O'), ('fell', 'O'), ('in', 'O'), ('each', 'O'), ('patient', 'O'), ('given', 'O'), ('ouabain', 'O'), (',', 'O'), ('even', 'O'), ('though', 'O'), ('they', 'O'), ('were', 'O'), ('initially', 'O'), ('elevated', 'O'), ('in', 'O'), ('only', 'O'), ('two', 'O'), ('patients', 'O'), ('.', 'O'))"
Left ventricular end - diastolic pressure fell from 11 . 5 + / - 1 . 4 ( mean + / - SE ) to 5 . 6 + / - 0 . 9 mm Hg ( P less than 0 . 001 ) and left ventricular end - diastolic volume fell from 100 + / - 17 to 82 + / - 12 ml / m2 ( P less than 0 . 01 ) 1 h after ouabain infusion was completed .,"(('Left', 'O'), ('ventricular', 'O'), ('end', 'O'), ('-', 'O'), ('diastolic', 'O'), ('pressure', 'O'), ('fell', 'O'), ('from', 'O'), ('11', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('4', 'O'), ('(', 'O'), ('mean', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('SE', 'O'), (')', 'O'), ('to', 'O'), ('5', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('9', 'O'), ('mm', 'O'), ('Hg', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('and', 'O'), ('left', 'O'), ('ventricular', 'O'), ('end', 'O'), ('-', 'O'), ('diastolic', 'O'), ('volume', 'O'), ('fell', 'O'), ('from', 'O'), ('100', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('17', 'O'), ('to', 'O'), ('82', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('12', 'O'), ('ml', 'O'), ('/', 'O'), ('m2', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('1', 'O'), ('h', 'O'), ('after', 'O'), ('ouabain', 'O'), ('infusion', 'O'), ('was', 'O'), ('completed', 'O'), ('.', 'O'))"
The maximum velocity of contractile element shortening increased from 1 . 68 + / - 0 . 11 ml / s to 2 . 18 + / - 0 . 21 muscle - lengths / s ( P less than 0 . 05 ) and is consistent with an increase in contractility .,"(('The', 'O'), ('maximum', 'O'), ('velocity', 'O'), ('of', 'O'), ('contractile', 'O'), ('element', 'O'), ('shortening', 'O'), ('increased', 'O'), ('from', 'O'), ('1', 'O'), ('.', 'O'), ('68', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('11', 'O'), ('ml', 'O'), ('/', 'O'), ('s', 'O'), ('to', 'O'), ('2', 'O'), ('.', 'O'), ('18', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('21', 'O'), ('muscle', 'O'), ('-', 'O'), ('lengths', 'O'), ('/', 'O'), ('s', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('and', 'O'), ('is', 'O'), ('consistent', 'O'), ('with', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('contractility', 'O'), ('.', 'O'))"
No significant change in these parameters occurred in the control patients .,"(('No', 'O'), ('significant', 'O'), ('change', 'O'), ('in', 'O'), ('these', 'O'), ('parameters', 'O'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('patients', 'O'), ('.', 'O'))"
No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients .,"(('No', 'O'), ('significant', 'O'), ('change', 'O'), ('in', 'O'), ('myocardial', 'O'), ('oxygen', 'O'), ('consumption', 'O'), ('occurred', 'O'), ('after', 'O'), ('ouabain', 'O'), ('administration', 'O'), ('but', 'O'), ('this', 'O'), ('may', 'O'), ('be', 'O'), ('related', 'O'), ('to', 'O'), ('a', 'O'), ('greater', 'O'), ('decrease', 'O'), ('in', 'O'), ('mean', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('in', 'O'), ('the', 'O'), ('ouabain', 'O'), ('patients', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('patients', 'O'), ('.', 'O'))"
"Though this fall would be associated with a decrease in wall tension , and , therefore , of myocardial oxygen consumption , it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption .","(('Though', 'O'), ('this', 'O'), ('fall', 'O'), ('would', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('wall', 'O'), ('tension', 'O'), (',', 'O'), ('and', 'O'), (',', 'O'), ('therefore', 'O'), (',', 'O'), ('of', 'O'), ('myocardial', 'O'), ('oxygen', 'O'), ('consumption', 'O'), (',', 'O'), ('it', 'O'), ('may', 'O'), ('not', 'O'), ('be', 'O'), ('of', 'O'), ('sufficient', 'O'), ('magnitude', 'O'), ('to', 'O'), ('prevent', 'O'), ('a', 'O'), ('net', 'O'), ('increase', 'O'), ('in', 'O'), ('myocardial', 'O'), ('oxygen', 'O'), ('consumption', 'O'), ('.', 'O'))"
"Nevertheless , compensatory mechanisms prevent a deterioration of resting myocardial metabolism .","(('Nevertheless', 'O'), (',', 'O'), ('compensatory', 'O'), ('mechanisms', 'O'), ('prevent', 'O'), ('a', 'O'), ('deterioration', 'O'), ('of', 'O'), ('resting', 'O'), ('myocardial', 'O'), ('metabolism', 'O'), ('.', 'O'))"
"The purpose of this study was to determine whether glucocorticoid treatment can directly affect the outflow facility of isolated , perfusion - cultured human eyes .","(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('determine', 'O'), ('whether', 'O'), ('glucocorticoid', 'O'), ('treatment', 'O'), ('can', 'O'), ('directly', 'O'), ('affect', 'O'), ('the', 'O'), ('outflow', 'O'), ('facility', 'O'), ('of', 'O'), ('isolated', 'O'), (',', 'O'), ('perfusion', 'O'), ('-', 'O'), ('cultured', 'O'), ('human', 'O'), ('eyes', 'O'), ('.', 'O'))"
"METHODS : The anterior segments of human donor eyes from regional eye banks were placed in a constant flow , variable pressure perfusion culture system .","(('METHODS', 'O'), (':', 'O'), ('The', 'O'), ('anterior', 'O'), ('segments', 'O'), ('of', 'O'), ('human', 'O'), ('donor', 'O'), ('eyes', 'O'), ('from', 'O'), ('regional', 'O'), ('eye', 'O'), ('banks', 'O'), ('were', 'O'), ('placed', 'O'), ('in', 'O'), ('a', 'O'), ('constant', 'O'), ('flow', 'O'), (',', 'O'), ('variable', 'O'), ('pressure', 'O'), ('perfusion', 'O'), ('culture', 'O'), ('system', 'O'), ('.', 'O'))"
Paired eyes were perfused in serum - free media with or without 10 ( - 7 ) M dexamethasone for 12 days .,"(('Paired', 'O'), ('eyes', 'O'), ('were', 'O'), ('perfused', 'O'), ('in', 'O'), ('serum', 'O'), ('-', 'O'), ('free', 'O'), ('media', 'O'), ('with', 'O'), ('or', 'O'), ('without', 'O'), ('10', 'O'), ('(', 'O'), ('-', 'O'), ('7', 'O'), (')', 'O'), ('M', 'O'), ('dexamethasone', 'O'), ('for', 'O'), ('12', 'O'), ('days', 'O'), ('.', 'O'))"
Intraocular pressure was monitored daily .,"(('Intraocular', 'O'), ('pressure', 'O'), ('was', 'O'), ('monitored', 'O'), ('daily', 'O'), ('.', 'O'))"
"After incubation , the eyes were morphologically characterized by light microscopy , transmission and scanning electron microscopy , and scanning laser confocal microscopy .","(('After', 'O'), ('incubation', 'O'), (',', 'O'), ('the', 'O'), ('eyes', 'O'), ('were', 'O'), ('morphologically', 'O'), ('characterized', 'O'), ('by', 'O'), ('light', 'O'), ('microscopy', 'O'), (',', 'O'), ('transmission', 'O'), ('and', 'O'), ('scanning', 'O'), ('electron', 'O'), ('microscopy', 'O'), (',', 'O'), ('and', 'O'), ('scanning', 'O'), ('laser', 'O'), ('confocal', 'O'), ('microscopy', 'O'), ('.', 'O'))"
RESULTS : A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17 . 5 + / - 3 . 8 mm Hg after 12 days of dexamethasone exposure .,"(('RESULTS', 'O'), (':', 'O'), ('A', 'O'), ('significant', 'O'), ('increase', 'O'), ('in', 'O'), ('intraocular', 'O'), ('pressure', 'O'), ('developed', 'O'), ('in', 'O'), ('13', 'O'), ('of', 'O'), ('the', 'O'), ('44', 'O'), ('pairs', 'O'), ('of', 'O'), ('eyes', 'O'), ('perfused', 'O'), ('with', 'O'), ('dexamethasone', 'O'), ('with', 'O'), ('an', 'O'), ('average', 'O'), ('pressure', 'O'), ('rise', 'O'), ('of', 'O'), ('17', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), ('mm', 'O'), ('Hg', 'O'), ('after', 'O'), ('12', 'O'), ('days', 'O'), ('of', 'O'), ('dexamethasone', 'O'), ('exposure', 'O'), ('.', 'O'))"
"The contralateral control eyes , which did not receive dexamethasone , maintained a stable intraocular pressure during the same period .","(('The', 'O'), ('contralateral', 'O'), ('control', 'O'), ('eyes', 'O'), (',', 'O'), ('which', 'O'), ('did', 'O'), ('not', 'O'), ('receive', 'O'), ('dexamethasone', 'O'), (',', 'O'), ('maintained', 'O'), ('a', 'O'), ('stable', 'O'), ('intraocular', 'O'), ('pressure', 'O'), ('during', 'O'), ('the', 'O'), ('same', 'O'), ('period', 'O'), ('.', 'O'))"
The outflow pathway of the untreated eyes appeared morphologically normal .,"(('The', 'O'), ('outflow', 'O'), ('pathway', 'O'), ('of', 'O'), ('the', 'O'), ('untreated', 'O'), ('eyes', 'O'), ('appeared', 'O'), ('morphologically', 'O'), ('normal', 'O'), ('.', 'O'))"
"The dexamethasone - treated nonresponder eyes appeared to be morphologically similar to the untreated eyes , although several subtle dexamethasone - induced morphologic changes were evident .","(('The', 'O'), ('dexamethasone', 'O'), ('-', 'O'), ('treated', 'O'), ('nonresponder', 'O'), ('eyes', 'O'), ('appeared', 'O'), ('to', 'O'), ('be', 'O'), ('morphologically', 'O'), ('similar', 'O'), ('to', 'O'), ('the', 'O'), ('untreated', 'O'), ('eyes', 'O'), (',', 'O'), ('although', 'O'), ('several', 'O'), ('subtle', 'O'), ('dexamethasone', 'O'), ('-', 'O'), ('induced', 'O'), ('morphologic', 'O'), ('changes', 'O'), ('were', 'O'), ('evident', 'O'), ('.', 'O'))"
Auditory disturbance associated with interscalene brachial plexus block .,"(('Auditory', 'B'), ('disturbance', 'I'), ('associated', 'O'), ('with', 'O'), ('interscalene', 'B'), ('brachial', 'I'), ('plexus', 'I'), ('block', 'I'), ('.', 'O'))"
We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block ( IBPB ) .,"(('We', 'O'), ('performed', 'O'), ('an', 'O'), ('audiometric', 'O'), ('study', 'O'), ('in', 'O'), ('20', 'O'), ('patients', 'O'), ('who', 'O'), ('underwent', 'O'), ('surgery', 'O'), ('of', 'O'), ('the', 'O'), ('shoulder', 'O'), ('region', 'O'), ('under', 'O'), ('an', 'O'), ('interscalene', 'O'), ('brachial', 'O'), ('plexus', 'O'), ('block', 'O'), ('(', 'O'), ('IBPB', 'O'), (')', 'O'), ('.', 'O'))"
Bupivacaine 0 . 75 % with adrenaline was given followed by a 24 - hr continuous infusion of 0 . 25 % bupivacaine .,"(('Bupivacaine', 'O'), ('0', 'O'), ('.', 'O'), ('75', 'O'), ('%', 'O'), ('with', 'O'), ('adrenaline', 'O'), ('was', 'O'), ('given', 'O'), ('followed', 'O'), ('by', 'O'), ('a', 'O'), ('24', 'O'), ('-', 'O'), ('hr', 'O'), ('continuous', 'O'), ('infusion', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('25', 'O'), ('%', 'O'), ('bupivacaine', 'O'), ('.', 'O'))"
"Three audiometric threshold measurements ( 0 . 25 - 18 kHz ) were made : the first before IBPB , the second 2 - 6 h after surgery and the third on the first day after operation .","(('Three', 'O'), ('audiometric', 'O'), ('threshold', 'O'), ('measurements', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('25', 'O'), ('-', 'O'), ('18', 'O'), ('kHz', 'O'), (')', 'O'), ('were', 'O'), ('made', 'O'), (':', 'O'), ('the', 'O'), ('first', 'O'), ('before', 'O'), ('IBPB', 'O'), (',', 'O'), ('the', 'O'), ('second', 'O'), ('2', 'O'), ('-', 'O'), ('6', 'O'), ('h', 'O'), ('after', 'O'), ('surgery', 'O'), ('and', 'O'), ('the', 'O'), ('third', 'O'), ('on', 'O'), ('the', 'O'), ('first', 'O'), ('day', 'O'), ('after', 'O'), ('operation', 'O'), ('.', 'O'))"
"In four patients hearing impairment on the side of the block was demonstrated after operation , in three measurements on the day of surgery and in one on the following day .","(('In', 'O'), ('four', 'O'), ('patients', 'O'), ('hearing', 'B'), ('impairment', 'I'), ('on', 'O'), ('the', 'O'), ('side', 'O'), ('of', 'O'), ('the', 'O'), ('block', 'O'), ('was', 'O'), ('demonstrated', 'O'), ('after', 'O'), ('operation', 'O'), (',', 'O'), ('in', 'O'), ('three', 'O'), ('measurements', 'O'), ('on', 'O'), ('the', 'O'), ('day', 'O'), ('of', 'O'), ('surgery', 'O'), ('and', 'O'), ('in', 'O'), ('one', 'O'), ('on', 'O'), ('the', 'O'), ('following', 'O'), ('day', 'O'), ('.', 'O'))"
The frequencies at which the impairment occurred varied between patients ; in one only low frequencies ( 0 . 25 - 0 . 5 kHz ) were involved .,"(('The', 'O'), ('frequencies', 'O'), ('at', 'O'), ('which', 'O'), ('the', 'O'), ('impairment', 'O'), ('occurred', 'O'), ('varied', 'O'), ('between', 'O'), ('patients', 'O'), (';', 'O'), ('in', 'O'), ('one', 'O'), ('only', 'O'), ('low', 'O'), ('frequencies', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('25', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('kHz', 'O'), (')', 'O'), ('were', 'O'), ('involved', 'O'), ('.', 'O'))"
The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine .,"(('The', 'O'), ('maximum', 'O'), ('change', 'O'), ('in', 'O'), ('threshold', 'O'), ('was', 'O'), ('35', 'O'), ('dB', 'O'), ('at', 'O'), ('6', 'O'), ('kHz', 'O'), ('measured', 'O'), ('at', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('continuous', 'O'), ('infusion', 'O'), ('of', 'O'), ('bupivacaine', 'O'), ('.', 'O'))"
This patient had hearing threshold changes ( 15 - 20 dB ) at 6 - 10 kHz on the opposite side also .,"(('This', 'O'), ('patient', 'O'), ('had', 'O'), ('hearing', 'O'), ('threshold', 'O'), ('changes', 'O'), ('(', 'O'), ('15', 'O'), ('-', 'O'), ('20', 'O'), ('dB', 'O'), (')', 'O'), ('at', 'O'), ('6', 'O'), ('-', 'O'), ('10', 'O'), ('kHz', 'O'), ('on', 'O'), ('the', 'O'), ('opposite', 'O'), ('side', 'O'), ('also', 'O'), ('.', 'O'))"
The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and zidovudine in patients with HIV - 1 infection and 200 - 500 CD4 cells / mm3 .,"(('The', 'O'), ('safety', 'O'), ('and', 'O'), ('efficacy', 'O'), ('of', 'O'), ('combination', 'O'), ('N', 'O'), ('-', 'O'), ('butyl', 'O'), ('-', 'O'), ('deoxynojirimycin', 'O'), ('(', 'O'), ('SC', 'O'), ('-', 'O'), ('48334', 'O'), (')', 'O'), ('and', 'O'), ('zidovudine', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('HIV', 'B'), ('-', 'I'), ('1', 'I'), ('infection', 'I'), ('and', 'O'), ('200', 'O'), ('-', 'O'), ('500', 'O'), ('CD4', 'O'), ('cells', 'O'), ('/', 'O'), ('mm3', 'O'), ('.', 'O'))"
"We conducted a double - blind , randomized phase II study to evaluate the safety and activity of combination therapy with N - butyl - deoxynojirimycin ( SC - 48334 ) ( an alpha - glucosidase I inhibitor ) and zidovudine versus zidovudine alone .","(('We', 'O'), ('conducted', 'O'), ('a', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('randomized', 'O'), ('phase', 'O'), ('II', 'O'), ('study', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('safety', 'O'), ('and', 'O'), ('activity', 'O'), ('of', 'O'), ('combination', 'O'), ('therapy', 'O'), ('with', 'O'), ('N', 'O'), ('-', 'O'), ('butyl', 'O'), ('-', 'O'), ('deoxynojirimycin', 'O'), ('(', 'O'), ('SC', 'O'), ('-', 'O'), ('48334', 'O'), (')', 'O'), ('(', 'O'), ('an', 'O'), ('alpha', 'O'), ('-', 'O'), ('glucosidase', 'O'), ('I', 'O'), ('inhibitor', 'O'), (')', 'O'), ('and', 'O'), ('zidovudine', 'O'), ('versus', 'O'), ('zidovudine', 'O'), ('alone', 'O'), ('.', 'O'))"
Patients with 200 to 500 CD4 cells / mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC - 48334 ( 1000 mg every 8 h ) and zidovudine ( 100 mg every 8 h ) or zidovudine and placebo .,"(('Patients', 'O'), ('with', 'O'), ('200', 'O'), ('to', 'O'), ('500', 'O'), ('CD4', 'O'), ('cells', 'O'), ('/', 'O'), ('mm3', 'O'), ('who', 'O'), ('tolerated', 'O'), ('<', 'O'), ('or', 'O'), ('=', 'O'), ('12', 'O'), ('weeks', 'O'), ('of', 'O'), ('prior', 'O'), ('zidovudine', 'O'), ('therapy', 'O'), ('received', 'O'), ('SC', 'O'), ('-', 'O'), ('48334', 'O'), ('(', 'O'), ('1000', 'O'), ('mg', 'O'), ('every', 'O'), ('8', 'O'), ('h', 'O'), (')', 'O'), ('and', 'O'), ('zidovudine', 'O'), ('(', 'O'), ('100', 'O'), ('mg', 'O'), ('every', 'O'), ('8', 'O'), ('h', 'O'), (')', 'O'), ('or', 'O'), ('zidovudine', 'O'), ('and', 'O'), ('placebo', 'O'), ('.', 'O'))"
"Sixty patients received combination therapy and 58 , zidovudine and placebo .","(('Sixty', 'O'), ('patients', 'O'), ('received', 'O'), ('combination', 'O'), ('therapy', 'O'), ('and', 'O'), ('58', 'O'), (',', 'O'), ('zidovudine', 'O'), ('and', 'O'), ('placebo', 'O'), ('.', 'O'))"
"Twenty - three patients ( 38 % ) and 15 ( 26 % ) , in the combination and zidovudine groups , respectively , discontinued therapy ( p = 0 . 15 ) .","(('Twenty', 'O'), ('-', 'O'), ('three', 'O'), ('patients', 'O'), ('(', 'O'), ('38', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('15', 'O'), ('(', 'O'), ('26', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('combination', 'O'), ('and', 'O'), ('zidovudine', 'O'), ('groups', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('discontinued', 'O'), ('therapy', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('15', 'O'), (')', 'O'), ('.', 'O'))"
The mean SC - 48334 steady - state trough level ( 4 . 04 + / - 0 . 99 micrograms / ml ) was below the in vitro inhibitory concentration for human immunodeficiency virus ( HIV ) .,"(('The', 'O'), ('mean', 'O'), ('SC', 'O'), ('-', 'O'), ('48334', 'O'), ('steady', 'O'), ('-', 'O'), ('state', 'O'), ('trough', 'O'), ('level', 'O'), ('(', 'O'), ('4', 'O'), ('.', 'O'), ('04', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('99', 'O'), ('micrograms', 'O'), ('/', 'O'), ('ml', 'O'), (')', 'O'), ('was', 'O'), ('below', 'O'), ('the', 'O'), ('in', 'O'), ('vitro', 'O'), ('inhibitory', 'O'), ('concentration', 'O'), ('for', 'O'), ('human', 'B'), ('immunodeficiency', 'I'), ('virus', 'I'), ('(', 'O'), ('HIV', 'B'), (')', 'O'), ('.', 'O'))"
"The mean increase in CD4 cells at week 4 was 73 . 8 cells / mm3 and 52 . 4 cells / mm3 for the combination and zidovudine groups , respectively ( p > 0 . 36 ) .","(('The', 'O'), ('mean', 'O'), ('increase', 'O'), ('in', 'O'), ('CD4', 'O'), ('cells', 'O'), ('at', 'O'), ('week', 'O'), ('4', 'O'), ('was', 'O'), ('73', 'O'), ('.', 'O'), ('8', 'O'), ('cells', 'O'), ('/', 'O'), ('mm3', 'O'), ('and', 'O'), ('52', 'O'), ('.', 'O'), ('4', 'O'), ('cells', 'O'), ('/', 'O'), ('mm3', 'O'), ('for', 'O'), ('the', 'O'), ('combination', 'O'), ('and', 'O'), ('zidovudine', 'O'), ('groups', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('p', 'O'), ('>', 'O'), ('0', 'O'), ('.', 'O'), ('36', 'O'), (')', 'O'), ('.', 'O'))"
"For patients with prior zidovudine therapy , the mean change in CD4 cells in the combination and zidovudine groups was 63 . 7 cells / mm3 and 4 . 9 cells / mm3 at week 8 and 6 . 8 cells / mm3 and - 45 . 1 cells / mm3 at week 16 , respectively .","(('For', 'O'), ('patients', 'O'), ('with', 'O'), ('prior', 'O'), ('zidovudine', 'O'), ('therapy', 'O'), (',', 'O'), ('the', 'O'), ('mean', 'O'), ('change', 'O'), ('in', 'O'), ('CD4', 'O'), ('cells', 'O'), ('in', 'O'), ('the', 'O'), ('combination', 'O'), ('and', 'O'), ('zidovudine', 'O'), ('groups', 'O'), ('was', 'O'), ('63', 'O'), ('.', 'O'), ('7', 'O'), ('cells', 'O'), ('/', 'O'), ('mm3', 'O'), ('and', 'O'), ('4', 'O'), ('.', 'O'), ('9', 'O'), ('cells', 'O'), ('/', 'O'), ('mm3', 'O'), ('at', 'O'), ('week', 'O'), ('8', 'O'), ('and', 'O'), ('6', 'O'), ('.', 'O'), ('8', 'O'), ('cells', 'O'), ('/', 'O'), ('mm3', 'O'), ('and', 'O'), ('-', 'O'), ('45', 'O'), ('.', 'O'), ('1', 'O'), ('cells', 'O'), ('/', 'O'), ('mm3', 'O'), ('at', 'O'), ('week', 'O'), ('16', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six ( 40 % ) and two ( 11 % ) at week 4 ( p = 0 . 10 ) and five ( 45 % ) and two ( 14 % ) at week 24 ( p = 0 . 08 ) , respectively .","(('The', 'O'), ('number', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('suppression', 'O'), ('of', 'O'), ('HIV', 'O'), ('p24', 'O'), ('antigenemia', 'O'), ('in', 'O'), ('the', 'O'), ('combination', 'O'), ('and', 'O'), ('zidovudine', 'O'), ('groups', 'O'), ('was', 'O'), ('six', 'O'), ('(', 'O'), ('40', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('two', 'O'), ('(', 'O'), ('11', 'O'), ('%', 'O'), (')', 'O'), ('at', 'O'), ('week', 'O'), ('4', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('10', 'O'), (')', 'O'), ('and', 'O'), ('five', 'O'), ('(', 'O'), ('45', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('two', 'O'), ('(', 'O'), ('14', 'O'), ('%', 'O'), (')', 'O'), ('at', 'O'), ('week', 'O'), ('24', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('08', 'O'), (')', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"The long - term use of nondepolarizing neuromuscular blocking agents ( ND - NMBA ) has recently been implicated as a cause of prolonged muscle weakness , although the site of the lesion and the predisposing factors have been unclear .","(('The', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('use', 'O'), ('of', 'O'), ('nondepolarizing', 'O'), ('neuromuscular', 'O'), ('blocking', 'O'), ('agents', 'O'), ('(', 'O'), ('ND', 'O'), ('-', 'O'), ('NMBA', 'O'), (')', 'O'), ('has', 'O'), ('recently', 'O'), ('been', 'O'), ('implicated', 'O'), ('as', 'O'), ('a', 'O'), ('cause', 'O'), ('of', 'O'), ('prolonged', 'O'), ('muscle', 'B'), ('weakness', 'I'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('site', 'O'), ('of', 'O'), ('the', 'O'), ('lesion', 'O'), ('and', 'O'), ('the', 'O'), ('predisposing', 'O'), ('factors', 'O'), ('have', 'O'), ('been', 'O'), ('unclear', 'O'), ('.', 'O'))"
We report 3 patients ( age 37 - 52 years ) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND - NMBAs .,"(('We', 'O'), ('report', 'O'), ('3', 'O'), ('patients', 'O'), ('(', 'O'), ('age', 'O'), ('37', 'O'), ('-', 'O'), ('52', 'O'), ('years', 'O'), (')', 'O'), ('with', 'O'), ('acute', 'B'), ('respiratory', 'I'), ('insufficiency', 'I'), ('who', 'O'), ('developed', 'O'), ('prolonged', 'B'), ('weakness', 'B'), ('following', 'O'), ('the', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('ND', 'O'), ('-', 'O'), ('NMBAs', 'O'), ('.', 'O'))"
Two patients also received intravenous corticosteroids .,"(('Two', 'O'), ('patients', 'O'), ('also', 'O'), ('received', 'O'), ('intravenous', 'O'), ('corticosteroids', 'O'), ('.', 'O'))"
"Electrophysiologic studies revealed low amplitude compound motor action potentials , normal sensory studies , and fibrillations .","(('Electrophysiologic', 'O'), ('studies', 'O'), ('revealed', 'O'), ('low', 'O'), ('amplitude', 'O'), ('compound', 'O'), ('motor', 'O'), ('action', 'O'), ('potentials', 'O'), (',', 'O'), ('normal', 'O'), ('sensory', 'O'), ('studies', 'O'), (',', 'O'), ('and', 'O'), ('fibrillations', 'O'), ('.', 'O'))"
Repetitive stimulation at 2 Hz showed a decremental response in 2 patients .,"(('Repetitive', 'O'), ('stimulation', 'O'), ('at', 'O'), ('2', 'O'), ('Hz', 'O'), ('showed', 'O'), ('a', 'O'), ('decremental', 'O'), ('response', 'O'), ('in', 'O'), ('2', 'O'), ('patients', 'O'), ('.', 'O'))"
The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng / mL .,"(('The', 'O'), ('serum', 'O'), ('vecuronium', 'O'), ('level', 'O'), ('measured', 'O'), ('in', 'O'), ('1', 'O'), ('patient', 'O'), ('14', 'O'), ('days', 'O'), ('after', 'O'), ('the', 'O'), ('drug', 'O'), ('had', 'O'), ('been', 'O'), ('discontinued', 'O'), ('was', 'O'), ('172', 'O'), ('ng', 'O'), ('/', 'O'), ('mL', 'O'), ('.', 'O'))"
Failure of ancrod in the treatment of heparin - induced arterial thrombosis .,"(('Failure', 'O'), ('of', 'O'), ('ancrod', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('heparin', 'B'), ('-', 'I'), ('induced', 'I'), ('arterial', 'B'), ('thrombosis', 'I'), ('.', 'O'))"
The morbidity and mortality associated with heparin - induced thrombosis remain high despite numerous empirical therapies .,"(('The', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), ('associated', 'O'), ('with', 'O'), ('heparin', 'B'), ('-', 'I'), ('induced', 'I'), ('thrombosis', 'I'), ('remain', 'O'), ('high', 'O'), ('despite', 'O'), ('numerous', 'O'), ('empirical', 'O'), ('therapies', 'O'), ('.', 'O'))"
The authors present a case of failure of ancrod treatment in a patient with heparin - induced thrombosis .,"(('The', 'O'), ('authors', 'O'), ('present', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('failure', 'O'), ('of', 'O'), ('ancrod', 'O'), ('treatment', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('heparin', 'B'), ('-', 'I'), ('induced', 'I'), ('thrombosis', 'I'), ('.', 'O'))"
"The oxytocin should be given only in Ringers lactate or , alternately , in Ringers lactate and a 5 per cent dextrose and water solutions .","(('The', 'O'), ('oxytocin', 'O'), ('should', 'O'), ('be', 'O'), ('given', 'O'), ('only', 'O'), ('in', 'O'), ('Ringers', 'O'), ('lactate', 'O'), ('or', 'O'), (',', 'O'), ('alternately', 'O'), (',', 'O'), ('in', 'O'), ('Ringers', 'O'), ('lactate', 'O'), ('and', 'O'), ('a', 'O'), ('5', 'O'), ('per', 'O'), ('cent', 'O'), ('dextrose', 'O'), ('and', 'O'), ('water', 'O'), ('solutions', 'O'), ('.', 'O'))"
The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases .,"(('The', 'O'), ('urinary', 'O'), ('output', 'O'), ('should', 'O'), ('be', 'O'), ('monitored', 'O'), ('and', 'O'), ('the', 'O'), ('oxytocin', 'O'), ('administration', 'O'), ('discontinued', 'O'), ('and', 'O'), ('the', 'O'), ('serum', 'O'), ('electrolytes', 'O'), ('checked', 'O'), ('if', 'O'), ('the', 'O'), ('urinary', 'O'), ('output', 'O'), ('decreases', 'O'), ('.', 'O'))"
The oxytocin should not be administered in excess of 36 hours .,"(('The', 'O'), ('oxytocin', 'O'), ('should', 'O'), ('not', 'O'), ('be', 'O'), ('administered', 'O'), ('in', 'O'), ('excess', 'O'), ('of', 'O'), ('36', 'O'), ('hours', 'O'), ('.', 'O'))"
If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance .,"(('If', 'O'), ('the', 'O'), ('patient', 'O'), ('has', 'O'), ('not', 'O'), ('aborted', 'O'), ('by', 'O'), ('then', 'O'), ('the', 'O'), ('oxytocin', 'O'), ('should', 'O'), ('be', 'O'), ('discontinued', 'O'), ('for', 'O'), ('10', 'O'), ('to', 'O'), ('12', 'O'), ('hours', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('perform', 'O'), ('electrolyte', 'O'), ('determinations', 'O'), ('and', 'O'), ('correct', 'O'), ('any', 'O'), ('electrolyte', 'O'), ('imbalance', 'O'), ('.', 'O'))"
Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different .,"(('Concomitant', 'O'), ('assay', 'O'), ('of', 'O'), ('cellular', 'O'), ('mediated', 'O'), ('immunity', 'O'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('using', 'O'), ('skin', 'O'), ('test', 'O'), ('antigen', 'O'), ('and', 'O'), ('a', 'O'), ('lymphokine', 'O'), ('in', 'O'), ('vitro', 'O'), ('test', 'O'), ('provided', 'O'), ('results', 'O'), ('that', 'O'), ('were', 'O'), ('different', 'O'), ('.', 'O'))"
This last finding may be related to time of testing and / or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte .,"(('This', 'O'), ('last', 'O'), ('finding', 'O'), ('may', 'O'), ('be', 'O'), ('related', 'O'), ('to', 'O'), ('time', 'O'), ('of', 'O'), ('testing', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('endogenous', 'O'), ('serum', 'O'), ('binding', 'O'), ('of', 'O'), ('rifampin', 'O'), ('which', 'O'), ('could', 'O'), ('have', 'O'), ('inhibited', 'O'), ('mitogen', 'O'), ('activity', 'O'), ('for', 'O'), ('the', 'O'), ('lymphocyte', 'O'), ('.', 'O'))"
KF17837 : a novel selective adenosine A2A receptor antagonist with anticataleptic activity .,"(('KF17837', 'O'), (':', 'O'), ('a', 'O'), ('novel', 'O'), ('selective', 'O'), ('adenosine', 'O'), ('A2A', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('with', 'O'), ('anticataleptic', 'O'), ('activity', 'O'), ('.', 'O'))"
KF17837 is a novel selective adenosine A2A receptor antagonist .,"(('KF17837', 'O'), ('is', 'O'), ('a', 'O'), ('novel', 'O'), ('selective', 'O'), ('adenosine', 'O'), ('A2A', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('.', 'O'))"
"These anticataleptic effects were exhibited dose dependently at doses from 0 . 625 and 2 . 5 mg / kg p . o . , respectively .","(('These', 'O'), ('anticataleptic', 'O'), ('effects', 'O'), ('were', 'O'), ('exhibited', 'O'), ('dose', 'O'), ('dependently', 'O'), ('at', 'O'), ('doses', 'O'), ('from', 'O'), ('0', 'O'), ('.', 'O'), ('625', 'O'), ('and', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('p', 'O'), ('.', 'O'), ('o', 'O'), ('.', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Moreover , KF17837 ( 0 . 625 mg / kg p . o . ) potentiated the anticataleptic effects of a subthreshold dose of L - 3 , 4 - dihydroxyphenylalanine ( L - DOPA ; 25 mg / kg i . p . ) plus benserazide ( 6 . 25 mg / kg i . p . ) .","(('Moreover', 'O'), (',', 'O'), ('KF17837', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('625', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('p', 'O'), ('.', 'O'), ('o', 'O'), ('.', 'O'), (')', 'O'), ('potentiated', 'O'), ('the', 'O'), ('anticataleptic', 'O'), ('effects', 'O'), ('of', 'O'), ('a', 'O'), ('subthreshold', 'O'), ('dose', 'O'), ('of', 'O'), ('L', 'O'), ('-', 'O'), ('3', 'O'), (',', 'O'), ('4', 'O'), ('-', 'O'), ('dihydroxyphenylalanine', 'O'), ('(', 'O'), ('L', 'O'), ('-', 'O'), ('DOPA', 'O'), (';', 'O'), ('25', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('plus', 'O'), ('benserazide', 'O'), ('(', 'O'), ('6', 'O'), ('.', 'O'), ('25', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists .,"(('These', 'O'), ('results', 'O'), ('suggested', 'O'), ('that', 'O'), ('KF17837', 'O'), ('is', 'O'), ('a', 'O'), ('centrally', 'O'), ('active', 'O'), ('adenosine', 'O'), ('A2A', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('and', 'O'), ('that', 'O'), ('the', 'O'), ('dopaminergic', 'O'), ('function', 'O'), ('of', 'O'), ('the', 'O'), ('nigrostriatal', 'O'), ('pathway', 'O'), ('is', 'O'), ('potentiated', 'O'), ('by', 'O'), ('adenosine', 'O'), ('A2A', 'O'), ('receptor', 'O'), ('antagonists', 'O'), ('.', 'O'))"
"Furthermore , KF17837 may be a useful drug in the treatment of parkinsonism .","(('Furthermore', 'O'), (',', 'O'), ('KF17837', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('useful', 'O'), ('drug', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('parkinsonism', 'B'), ('.', 'O'))"
They were then treated chronically with L - DOPA / benserazide 50 / 12 . 5 mg / kg given orally daily for 2 months .,"(('They', 'O'), ('were', 'O'), ('then', 'O'), ('treated', 'O'), ('chronically', 'O'), ('with', 'O'), ('L', 'O'), ('-', 'O'), ('DOPA', 'O'), ('/', 'O'), ('benserazide', 'O'), ('50', 'O'), ('/', 'O'), ('12', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('given', 'O'), ('orally', 'O'), ('daily', 'O'), ('for', 'O'), ('2', 'O'), ('months', 'O'), ('.', 'O'))"
All patients were receiving high - dose ifosfamide as part of their bone marrow transplant procedure .,"(('All', 'O'), ('patients', 'O'), ('were', 'O'), ('receiving', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('ifosfamide', 'O'), ('as', 'O'), ('part', 'O'), ('of', 'O'), ('their', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplant', 'O'), ('procedure', 'O'), ('.', 'O'))"
The incidence may be dose and infusion - time related .,"(('The', 'O'), ('incidence', 'O'), ('may', 'O'), ('be', 'O'), ('dose', 'O'), ('and', 'O'), ('infusion', 'O'), ('-', 'O'), ('time', 'O'), ('related', 'O'), ('.', 'O'))"
Patients anxious about this experience respond well to support and education about this occurrence .,"(('Patients', 'O'), ('anxious', 'O'), ('about', 'O'), ('this', 'O'), ('experience', 'O'), ('respond', 'O'), ('well', 'O'), ('to', 'O'), ('support', 'O'), ('and', 'O'), ('education', 'O'), ('about', 'O'), ('this', 'O'), ('occurrence', 'O'), ('.', 'O'))"
Optimal pharmacologic management of disturbed patients is unclear .,"(('Optimal', 'O'), ('pharmacologic', 'O'), ('management', 'O'), ('of', 'O'), ('disturbed', 'O'), ('patients', 'O'), ('is', 'O'), ('unclear', 'O'), ('.', 'O'))"
Photodistributed nifedipine - induced facial telangiectasia .,"(('Photodistributed', 'O'), ('nifedipine', 'O'), ('-', 'O'), ('induced', 'O'), ('facial', 'B'), ('telangiectasia', 'I'), ('.', 'O'))"
"Five months after starting nifedipine ( Adalat ) , two patients developed photodistributed facial telangiectasia , which became more noticeable with time .","(('Five', 'O'), ('months', 'O'), ('after', 'O'), ('starting', 'O'), ('nifedipine', 'O'), ('(', 'O'), ('Adalat', 'O'), (')', 'O'), (',', 'O'), ('two', 'O'), ('patients', 'O'), ('developed', 'O'), ('photodistributed', 'B'), ('facial', 'I'), ('telangiectasia', 'I'), (',', 'O'), ('which', 'O'), ('became', 'O'), ('more', 'O'), ('noticeable', 'O'), ('with', 'O'), ('time', 'O'), ('.', 'O'))"
Both patients reported a significant cosmetic improvement after discontinuing the drug .,"(('Both', 'O'), ('patients', 'O'), ('reported', 'O'), ('a', 'O'), ('significant', 'O'), ('cosmetic', 'O'), ('improvement', 'O'), ('after', 'O'), ('discontinuing', 'O'), ('the', 'O'), ('drug', 'O'), ('.', 'O'))"
"One commenced the closely related drug amlodipine 3 years later , with recurrence of telangiectasia .","(('One', 'O'), ('commenced', 'O'), ('the', 'O'), ('closely', 'O'), ('related', 'O'), ('drug', 'O'), ('amlodipine', 'O'), ('3', 'O'), ('years', 'O'), ('later', 'O'), (',', 'O'), ('with', 'O'), ('recurrence', 'O'), ('of', 'O'), ('telangiectasia', 'B'), ('.', 'O'))"
The photodistribution of the telangiectasia suggests a significant drug / light interaction .,"(('The', 'O'), ('photodistribution', 'O'), ('of', 'O'), ('the', 'O'), ('telangiectasia', 'B'), ('suggests', 'O'), ('a', 'O'), ('significant', 'O'), ('drug', 'O'), ('/', 'O'), ('light', 'O'), ('interaction', 'O'), ('.', 'O'))"
Penicillamine - induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis .,"(('Penicillamine', 'O'), ('-', 'O'), ('induced', 'O'), ('rapidly', 'O'), ('progressive', 'O'), ('glomerulonephritis', 'B'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('.', 'O'))"
Light microscopy study showed severe glomerulonephritis with crescent formation in 60 % of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole .,"(('Light', 'O'), ('microscopy', 'O'), ('study', 'O'), ('showed', 'O'), ('severe', 'O'), ('glomerulonephritis', 'B'), ('with', 'O'), ('crescent', 'O'), ('formation', 'O'), ('in', 'O'), ('60', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('glomeruli', 'O'), ('and', 'O'), ('infiltration', 'O'), ('of', 'O'), ('inflammatory', 'O'), ('cells', 'O'), ('in', 'O'), ('the', 'O'), ('wall', 'O'), ('of', 'O'), ('an', 'O'), ('arteriole', 'O'), ('.', 'O'))"
"Immunofluorescence revealed scanty granular IgG , IgA and C3 deposits along the capillary walls and mesangium .","(('Immunofluorescence', 'O'), ('revealed', 'O'), ('scanty', 'O'), ('granular', 'O'), ('IgG', 'O'), (',', 'O'), ('IgA', 'O'), ('and', 'O'), ('C3', 'O'), ('deposits', 'O'), ('along', 'O'), ('the', 'O'), ('capillary', 'O'), ('walls', 'O'), ('and', 'O'), ('mesangium', 'O'), ('.', 'O'))"
"The patient was treated with steroid pulse , plasmapheresis , cyclophosphamide and antiplatelet agents .","(('The', 'O'), ('patient', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('steroid', 'O'), ('pulse', 'O'), (',', 'O'), ('plasmapheresis', 'O'), (',', 'O'), ('cyclophosphamide', 'O'), ('and', 'O'), ('antiplatelet', 'O'), ('agents', 'O'), ('.', 'O'))"
A complete recovery of renal function was achieved in a few weeks .,"(('A', 'O'), ('complete', 'O'), ('recovery', 'O'), ('of', 'O'), ('renal', 'O'), ('function', 'O'), ('was', 'O'), ('achieved', 'O'), ('in', 'O'), ('a', 'O'), ('few', 'O'), ('weeks', 'O'), ('.', 'O'))"
The prompt discontinuation of D - penicillamine and vigorous treatment measures could allow for a good prognosis as in this case .,"(('The', 'O'), ('prompt', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('and', 'O'), ('vigorous', 'O'), ('treatment', 'O'), ('measures', 'O'), ('could', 'O'), ('allow', 'O'), ('for', 'O'), ('a', 'O'), ('good', 'O'), ('prognosis', 'O'), ('as', 'O'), ('in', 'O'), ('this', 'O'), ('case', 'O'), ('.', 'O'))"
We described the special clinical course of the patient .,"(('We', 'O'), ('described', 'O'), ('the', 'O'), ('special', 'O'), ('clinical', 'O'), ('course', 'O'), ('of', 'O'), ('the', 'O'), ('patient', 'O'), ('.', 'O'))"
All cases were retrospectively sampled from three different hospitals in Copenhagen .,"(('All', 'O'), ('cases', 'O'), ('were', 'O'), ('retrospectively', 'O'), ('sampled', 'O'), ('from', 'O'), ('three', 'O'), ('different', 'O'), ('hospitals', 'O'), ('in', 'O'), ('Copenhagen', 'O'), ('.', 'O'))"
The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations .,"(('The', 'O'), ('possible', 'O'), ('mechanisms', 'O'), ('are', 'O'), ('discussed', 'O'), ('and', 'O'), ('treatment', 'O'), ('proposals', 'O'), ('given', 'O'), ('suggesting', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('more', 'O'), ('efficacious', 'O'), ('opioids', 'O'), ('with', 'O'), ('less', 'O'), ('excitatory', 'O'), ('potency', 'O'), ('in', 'O'), ('these', 'O'), ('situations', 'O'), ('.', 'O'))"
Liposomal daunorubicin in advanced Kaposi ' s sarcoma : a phase II study .,"(('Liposomal', 'O'), ('daunorubicin', 'O'), ('in', 'O'), ('advanced', 'B'), ('Kaposi', 'B'), (""'"", 'I'), ('s', 'I'), ('sarcoma', 'I'), (':', 'O'), ('a', 'O'), ('phase', 'O'), ('II', 'O'), ('study', 'O'), ('.', 'O'))"
Eleven homosexual men with advanced Kaposi ' s sarcoma were entered in the trial .,"(('Eleven', 'O'), ('homosexual', 'O'), ('men', 'O'), ('with', 'O'), ('advanced', 'O'), ('Kaposi', 'B'), (""'"", 'I'), ('s', 'I'), ('sarcoma', 'I'), ('were', 'O'), ('entered', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('.', 'O'))"
Ten subjects were evaluated .,"(('Ten', 'O'), ('subjects', 'O'), ('were', 'O'), ('evaluated', 'O'), ('.', 'O'))"
"A partial response was achieved in four , of whom two subsequently relapsed .","(('A', 'O'), ('partial', 'O'), ('response', 'O'), ('was', 'O'), ('achieved', 'O'), ('in', 'O'), ('four', 'O'), (',', 'O'), ('of', 'O'), ('whom', 'O'), ('two', 'O'), ('subsequently', 'O'), ('relapsed', 'O'), ('.', 'O'))"
"Stabilization of Kaposi ' s sarcoma occurred in the remaining six , maintained until the end of the trial period in four .","(('Stabilization', 'O'), ('of', 'O'), ('Kaposi', 'B'), (""'"", 'I'), ('s', 'I'), ('sarcoma', 'I'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('remaining', 'O'), ('six', 'O'), (',', 'O'), ('maintained', 'O'), ('until', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('trial', 'O'), ('period', 'O'), ('in', 'O'), ('four', 'O'), ('.', 'O'))"
"The drug was generally well tolerated , with few mild symptoms of toxicity .","(('The', 'O'), ('drug', 'O'), ('was', 'O'), ('generally', 'O'), ('well', 'O'), ('tolerated', 'O'), (',', 'O'), ('with', 'O'), ('few', 'O'), ('mild', 'O'), ('symptoms', 'O'), ('of', 'O'), ('toxicity', 'O'), ('.', 'O'))"
"In this small patient sample , liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi ' s sarcoma .","(('In', 'O'), ('this', 'O'), ('small', 'O'), ('patient', 'O'), ('sample', 'O'), (',', 'O'), ('liposomal', 'O'), ('daunorubicin', 'O'), ('was', 'O'), ('an', 'O'), ('effective', 'O'), ('and', 'O'), ('well', 'O'), ('tolerated', 'O'), ('agent', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('Kaposi', 'B'), (""'"", 'I'), ('s', 'I'), ('sarcoma', 'I'), ('.', 'O'))"
Long - term effects of vincristine on the peripheral nervous system .,"(('Long', 'O'), ('-', 'O'), ('term', 'O'), ('effects', 'O'), ('of', 'O'), ('vincristine', 'O'), ('on', 'O'), ('the', 'O'), ('peripheral', 'O'), ('nervous', 'O'), ('system', 'O'), ('.', 'O'))"
"Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed , four to 77 months ( median 34 months ) after vincristine treatment .","(('Physical', 'O'), ('and', 'O'), ('quantitative', 'O'), ('sensory', 'O'), ('examination', 'O'), ('with', 'O'), ('determination', 'O'), ('of', 'O'), ('vibratory', 'O'), ('perception', 'O'), ('and', 'O'), ('thermal', 'O'), ('discrimination', 'O'), ('thresholds', 'O'), ('were', 'O'), ('performed', 'O'), (',', 'O'), ('four', 'O'), ('to', 'O'), ('77', 'O'), ('months', 'O'), ('(', 'O'), ('median', 'O'), ('34', 'O'), ('months', 'O'), (')', 'O'), ('after', 'O'), ('vincristine', 'O'), ('treatment', 'O'), ('.', 'O'))"
In 13 of these 27 patients symptoms were still present at the time of examination .,"(('In', 'O'), ('13', 'O'), ('of', 'O'), ('these', 'O'), ('27', 'O'), ('patients', 'O'), ('symptoms', 'O'), ('were', 'O'), ('still', 'O'), ('present', 'O'), ('at', 'O'), ('the', 'O'), ('time', 'O'), ('of', 'O'), ('examination', 'O'), ('.', 'O'))"
In these patients sensory signs and symptoms predominated .,"(('In', 'O'), ('these', 'O'), ('patients', 'O'), ('sensory', 'O'), ('signs', 'O'), ('and', 'O'), ('symptoms', 'O'), ('predominated', 'O'), ('.', 'O'))"
In the other 14 patients symptoms had been present in the past .,"(('In', 'O'), ('the', 'O'), ('other', 'O'), ('14', 'O'), ('patients', 'O'), ('symptoms', 'O'), ('had', 'O'), ('been', 'O'), ('present', 'O'), ('in', 'O'), ('the', 'O'), ('past', 'O'), ('.', 'O'))"
Symptoms persisted maximally 40 months since cessation of therapy .,"(('Symptoms', 'O'), ('persisted', 'O'), ('maximally', 'O'), ('40', 'O'), ('months', 'O'), ('since', 'O'), ('cessation', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O'))"
There was no age difference between patients with and without complaints at the time of examination .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('age', 'O'), ('difference', 'O'), ('between', 'O'), ('patients', 'O'), ('with', 'O'), ('and', 'O'), ('without', 'O'), ('complaints', 'O'), ('at', 'O'), ('the', 'O'), ('time', 'O'), ('of', 'O'), ('examination', 'O'), ('.', 'O'))"
Normal reflexes were found in two third of patients .,"(('Normal', 'O'), ('reflexes', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('two', 'O'), ('third', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O'))"
Neuropathic complaints were not very troublesome on the long term .,"(('Neuropathic', 'B'), ('complaints', 'O'), ('were', 'O'), ('not', 'O'), ('very', 'O'), ('troublesome', 'O'), ('on', 'O'), ('the', 'O'), ('long', 'O'), ('term', 'O'), ('.', 'O'))"
It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good .,"(('It', 'O'), ('is', 'O'), ('concluded', 'O'), ('that', 'O'), ('with', 'O'), ('the', 'O'), ('above', 'O'), ('mentioned', 'O'), ('vincristine', 'O'), ('dose', 'O'), ('schedule', 'O'), ('signs', 'O'), ('and', 'O'), ('symptoms', 'O'), ('of', 'O'), ('vincristine', 'B'), ('neuropathy', 'I'), ('are', 'O'), ('reversible', 'O'), ('for', 'O'), ('a', 'O'), ('great', 'O'), ('deal', 'O'), ('and', 'O'), ('prognosis', 'O'), ('is', 'O'), ('fairly', 'O'), ('good', 'O'), ('.', 'O'))"
"Special reference is made to their clinical presentation , which may be totally asymptomatic .","(('Special', 'O'), ('reference', 'O'), ('is', 'O'), ('made', 'O'), ('to', 'O'), ('their', 'O'), ('clinical', 'O'), ('presentation', 'O'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('be', 'O'), ('totally', 'O'), ('asymptomatic', 'O'), ('.', 'O'))"
"Liver - function tests are of little diagnostic value , but valuable information may be obtained from both liver scanning and hepatic angiography .","(('Liver', 'O'), ('-', 'O'), ('function', 'O'), ('tests', 'O'), ('are', 'O'), ('of', 'O'), ('little', 'O'), ('diagnostic', 'O'), ('value', 'O'), (',', 'O'), ('but', 'O'), ('valuable', 'O'), ('information', 'O'), ('may', 'O'), ('be', 'O'), ('obtained', 'O'), ('from', 'O'), ('both', 'O'), ('liver', 'O'), ('scanning', 'O'), ('and', 'O'), ('hepatic', 'O'), ('angiography', 'O'), ('.', 'O'))"
Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced seizures .,"(('Loss', 'O'), ('of', 'O'), ('glutamate', 'O'), ('decarboxylase', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('following', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('.', 'O'))"
In situ hybridization methods were used to determine if glutamic acid decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to seizure - induced damage in a model of chronic seizures .,"(('In', 'O'), ('situ', 'O'), ('hybridization', 'O'), ('methods', 'O'), ('were', 'O'), ('used', 'O'), ('to', 'O'), ('determine', 'O'), ('if', 'O'), ('glutamic', 'O'), ('acid', 'O'), ('decarboxylase', 'O'), ('(', 'O'), ('GAD', 'O'), (')', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('within', 'O'), ('the', 'O'), ('hilus', 'O'), ('of', 'O'), ('the', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('are', 'O'), ('vulnerable', 'O'), ('to', 'O'), ('seizure', 'O'), ('-', 'O'), ('induced', 'O'), ('damage', 'O'), ('in', 'O'), ('a', 'O'), ('model', 'O'), ('of', 'O'), ('chronic', 'O'), ('seizures', 'O'), ('.', 'O'))"
"Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced seizures .","(('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('were', 'O'), ('injected', 'O'), ('intraperitoneally', 'O'), ('with', 'O'), ('pilocarpine', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('hippocampal', 'O'), ('formation', 'O'), ('was', 'O'), ('studied', 'O'), ('histologically', 'O'), ('at', 'O'), ('1', 'O'), (',', 'O'), ('2', 'O'), (',', 'O'), ('4', 'O'), (',', 'O'), ('and', 'O'), ('8', 'O'), ('week', 'O'), ('intervals', 'O'), ('after', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('.', 'O'))"
"In situ hybridization histochemistry , using a digoxigenin - labeled GAD cRNA probe , demonstrated a substantial decrease in the number of GAD mRNA - containing neurons in the hilus of the dentate gyrus in the pilocarpine - treated rats as compared to controls at all time intervals .","(('In', 'O'), ('situ', 'O'), ('hybridization', 'O'), ('histochemistry', 'O'), (',', 'O'), ('using', 'O'), ('a', 'O'), ('digoxigenin', 'O'), ('-', 'O'), ('labeled', 'O'), ('GAD', 'O'), ('cRNA', 'O'), ('probe', 'O'), (',', 'O'), ('demonstrated', 'O'), ('a', 'O'), ('substantial', 'O'), ('decrease', 'O'), ('in', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('GAD', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('in', 'O'), ('the', 'O'), ('hilus', 'O'), ('of', 'O'), ('the', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('in', 'O'), ('the', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('controls', 'O'), ('at', 'O'), ('all', 'O'), ('time', 'O'), ('intervals', 'O'), ('.', 'O'))"
"Additional neuronanatomical studies , including cresyl violet staining , neuronal degeneration methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels .","(('Additional', 'O'), ('neuronanatomical', 'O'), ('studies', 'O'), (',', 'O'), ('including', 'O'), ('cresyl', 'O'), ('violet', 'O'), ('staining', 'O'), (',', 'O'), ('neuronal', 'B'), ('degeneration', 'I'), ('methods', 'O'), (',', 'O'), ('and', 'O'), ('histochemical', 'O'), ('localization', 'O'), ('of', 'O'), ('glial', 'O'), ('fibrillary', 'O'), ('acidic', 'O'), ('protein', 'O'), (',', 'O'), ('suggested', 'O'), ('that', 'O'), ('the', 'O'), ('decrease', 'O'), ('in', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('GAD', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('was', 'O'), ('related', 'O'), ('to', 'O'), ('neuronal', 'O'), ('loss', 'O'), ('rather', 'O'), ('than', 'O'), ('to', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('GAD', 'O'), ('mRNA', 'O'), ('levels', 'O'), ('.', 'O'))"
The loss of GAD mRNA - containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer .,"(('The', 'O'), ('loss', 'O'), ('of', 'O'), ('GAD', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('in', 'O'), ('the', 'O'), ('hilus', 'O'), ('contrasted', 'O'), ('with', 'O'), ('the', 'O'), ('relative', 'O'), ('preservation', 'O'), ('of', 'O'), ('labeled', 'O'), ('putative', 'O'), ('basket', 'O'), ('cells', 'O'), ('along', 'O'), ('the', 'O'), ('inner', 'O'), ('margin', 'O'), ('of', 'O'), ('the', 'O'), ('granule', 'O'), ('cell', 'O'), ('layer', 'O'), ('.', 'O'))"
Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA - containing neurons in the hilus of both groups of experimental animals .,"(('Quantitative', 'O'), ('analyses', 'O'), ('of', 'O'), ('labeled', 'O'), ('neurons', 'O'), ('in', 'O'), ('three', 'O'), ('regions', 'O'), ('of', 'O'), ('the', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('in', 'O'), ('the', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), ('week', 'O'), ('groups', 'O'), ('showed', 'O'), ('statistically', 'O'), ('significant', 'O'), ('decreases', 'O'), ('in', 'O'), ('the', 'O'), ('mean', 'O'), ('number', 'O'), ('of', 'O'), ('GAD', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('in', 'O'), ('the', 'O'), ('hilus', 'O'), ('of', 'O'), ('both', 'O'), ('groups', 'O'), ('of', 'O'), ('experimental', 'O'), ('animals', 'O'), ('.', 'O'))"
"No significant differences were found in the molecular layer or the granule cell layer , which included labeled neurons along the lower margin of the granule cell layer .","(('No', 'O'), ('significant', 'O'), ('differences', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('the', 'O'), ('molecular', 'O'), ('layer', 'O'), ('or', 'O'), ('the', 'O'), ('granule', 'O'), ('cell', 'O'), ('layer', 'O'), (',', 'O'), ('which', 'O'), ('included', 'O'), ('labeled', 'O'), ('neurons', 'O'), ('along', 'O'), ('the', 'O'), ('lower', 'O'), ('margin', 'O'), ('of', 'O'), ('the', 'O'), ('granule', 'O'), ('cell', 'O'), ('layer', 'O'), ('.', 'O'))"
"The results indicate that , in this model , a subpopulation of GAD mRNA - containing neurons within the dentate gyrus is selectively vulnerable to seizure - induced damage .","(('The', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), (',', 'O'), ('in', 'O'), ('this', 'O'), ('model', 'O'), (',', 'O'), ('a', 'O'), ('subpopulation', 'O'), ('of', 'O'), ('GAD', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('within', 'O'), ('the', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('is', 'O'), ('selectively', 'O'), ('vulnerable', 'O'), ('to', 'O'), ('seizure', 'O'), ('-', 'O'), ('induced', 'O'), ('damage', 'O'), ('.', 'O'))"
Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons .,"(('Such', 'O'), ('differential', 'O'), ('vulnerability', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('another', 'O'), ('indication', 'O'), ('of', 'O'), ('the', 'O'), ('heterogeneity', 'O'), ('of', 'O'), ('GABA', 'O'), ('neurons', 'O'), ('.', 'O'))"
Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function .,"(('Effects', 'O'), ('of', 'O'), ('deliberate', 'B'), ('hypotension', 'I'), ('induced', 'O'), ('by', 'O'), ('labetalol', 'O'), ('with', 'O'), ('isoflurane', 'O'), ('on', 'O'), ('neuropsychological', 'O'), ('function', 'O'), ('.', 'O'))"
The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients .,"(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('deliberate', 'B'), ('hypotension', 'I'), ('on', 'O'), ('brain', 'O'), ('function', 'O'), ('measured', 'O'), ('by', 'O'), ('neuropsychological', 'O'), ('tests', 'O'), ('was', 'O'), ('studied', 'O'), ('in', 'O'), ('41', 'O'), ('adult', 'O'), ('patients', 'O'), ('.', 'O'))"
Seventeen patients without hypotension served as a control group .,"(('Seventeen', 'O'), ('patients', 'O'), ('without', 'O'), ('hypotension', 'B'), ('served', 'O'), ('as', 'O'), ('a', 'O'), ('control', 'O'), ('group', 'O'), ('.', 'O'))"
The tests were performed preoperatively and 2 days postoperatively .,"(('The', 'O'), ('tests', 'O'), ('were', 'O'), ('performed', 'O'), ('preoperatively', 'O'), ('and', 'O'), ('2', 'O'), ('days', 'O'), ('postoperatively', 'O'), ('.', 'O'))"
There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value .,"(('There', 'O'), ('were', 'O'), ('no', 'O'), ('statistically', 'O'), ('significant', 'O'), ('differences', 'O'), ('between', 'O'), ('the', 'O'), ('groups', 'O'), ('in', 'O'), ('any', 'O'), ('of', 'O'), ('the', 'O'), ('tests', 'O'), ('in', 'O'), ('the', 'O'), ('changes', 'O'), ('from', 'O'), ('preoperative', 'O'), ('value', 'O'), ('to', 'O'), ('postoperative', 'O'), ('value', 'O'), ('.', 'O'))"
The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .,"(('The', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('hypotension', 'B'), ('induced', 'O'), ('by', 'O'), ('labetalol', 'O'), ('with', 'O'), ('isoflurane', 'O'), ('has', 'O'), ('no', 'O'), ('significant', 'O'), ('harmful', 'O'), ('effects', 'O'), ('on', 'O'), ('mental', 'O'), ('functions', 'O'), ('compared', 'O'), ('to', 'O'), ('normotensive', 'O'), ('anaesthesia', 'O'), ('.', 'O'))"
Apparent cure of rheumatoid arthritis by bone marrow transplantation .,"(('Apparent', 'O'), ('cure', 'O'), ('of', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('by', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplantation', 'O'), ('.', 'O'))"
This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis .,"(('This', 'O'), ('experience', 'O'), ('raises', 'O'), ('the', 'O'), ('question', 'O'), ('of', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('BMT', 'O'), ('itself', 'O'), ('as', 'O'), ('a', 'O'), ('therapeutic', 'O'), ('option', 'O'), ('for', 'O'), ('patients', 'O'), ('with', 'O'), ('uncontrolled', 'O'), ('destructive', 'B'), ('synovitis', 'I'), ('.', 'O'))"
We report a case of combined levomepromazine - fluvoxamine treatment - induced seizures .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('combined', 'O'), ('levomepromazine', 'O'), ('-', 'O'), ('fluvoxamine', 'O'), ('treatment', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('.', 'O'))"
It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity .,"(('It', 'O'), ('seems', 'O'), ('that', 'O'), ('combined', 'O'), ('treatment', 'O'), ('of', 'O'), ('fluvoxamine', 'O'), ('with', 'O'), ('phenothiazines', 'O'), ('may', 'O'), ('possess', 'O'), ('proconvulsive', 'O'), ('activity', 'O'), ('.', 'O'))"
This article reports two cases of this complication and reviews all reported cases to date .,"(('This', 'O'), ('article', 'O'), ('reports', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('this', 'O'), ('complication', 'O'), ('and', 'O'), ('reviews', 'O'), ('all', 'O'), ('reported', 'O'), ('cases', 'O'), ('to', 'O'), ('date', 'O'), ('.', 'O'))"
"In these patients , no other acute side effects of pentamidine were observed .","(('In', 'O'), ('these', 'O'), ('patients', 'O'), (',', 'O'), ('no', 'O'), ('other', 'O'), ('acute', 'O'), ('side', 'O'), ('effects', 'O'), ('of', 'O'), ('pentamidine', 'O'), ('were', 'O'), ('observed', 'O'), ('.', 'O'))"
Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia .,"(('Efficacy', 'O'), ('and', 'O'), ('tolerability', 'O'), ('of', 'O'), ('lovastatin', 'O'), ('in', 'O'), ('3390', 'O'), ('women', 'O'), ('with', 'O'), ('moderate', 'B'), ('hypercholesterolemia', 'B'), ('.', 'O'))"
OBJECTIVE : To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('of', 'O'), ('lovastatin', 'O'), ('in', 'O'), ('women', 'O'), ('with', 'O'), ('moderate', 'B'), ('hypercholesterolemia', 'B'), ('.', 'O'))"
"DESIGN : The Expanded Clinical Evaluation of Lovastatin ( EXCEL ) Study , a multicenter , double - blind , diet - and placebo - controlled trial , in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily , or 20 or 40 mg twice daily for 48 weeks .","(('DESIGN', 'O'), (':', 'O'), ('The', 'O'), ('Expanded', 'O'), ('Clinical', 'O'), ('Evaluation', 'O'), ('of', 'O'), ('Lovastatin', 'O'), ('(', 'O'), ('EXCEL', 'O'), (')', 'O'), ('Study', 'O'), (',', 'O'), ('a', 'O'), ('multicenter', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('diet', 'O'), ('-', 'O'), ('and', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('trial', 'O'), (',', 'O'), ('in', 'O'), ('which', 'O'), ('participants', 'O'), ('were', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('receive', 'O'), ('placebo', 'O'), ('or', 'O'), ('lovastatin', 'O'), ('at', 'O'), ('doses', 'O'), ('of', 'O'), ('20', 'O'), ('or', 'O'), ('40', 'O'), ('mg', 'O'), ('once', 'O'), ('daily', 'O'), (',', 'O'), ('or', 'O'), ('20', 'O'), ('or', 'O'), ('40', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), ('for', 'O'), ('48', 'O'), ('weeks', 'O'), ('.', 'O'))"
SETTING : Ambulatory patients recruited by 362 participating centers throughout the United States .,"(('SETTING', 'O'), (':', 'O'), ('Ambulatory', 'O'), ('patients', 'O'), ('recruited', 'O'), ('by', 'O'), ('362', 'O'), ('participating', 'O'), ('centers', 'O'), ('throughout', 'O'), ('the', 'O'), ('United', 'O'), ('States', 'O'), ('.', 'O'))"
PATIENTS : Women ( n = 3390 ) from the total cohort of 8245 volunteers .,"(('PATIENTS', 'O'), (':', 'O'), ('Women', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('3390', 'O'), (')', 'O'), ('from', 'O'), ('the', 'O'), ('total', 'O'), ('cohort', 'O'), ('of', 'O'), ('8245', 'O'), ('volunteers', 'O'), ('.', 'O'))"
"MEASUREMENTS : Plasma total , low - density lipoprotein ( LDL ) , and high - density lipoprotein ( HDL ) cholesterol , and triglycerides ; and laboratory and clinical evidence of adverse events monitored periodically throughout the study .","(('MEASUREMENTS', 'O'), (':', 'O'), ('Plasma', 'O'), ('total', 'O'), (',', 'O'), ('low', 'O'), ('-', 'O'), ('density', 'O'), ('lipoprotein', 'O'), ('(', 'O'), ('LDL', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('high', 'O'), ('-', 'O'), ('density', 'O'), ('lipoprotein', 'O'), ('(', 'O'), ('HDL', 'O'), (')', 'O'), ('cholesterol', 'O'), (',', 'O'), ('and', 'O'), ('triglycerides', 'O'), (';', 'O'), ('and', 'O'), ('laboratory', 'O'), ('and', 'O'), ('clinical', 'O'), ('evidence', 'O'), ('of', 'O'), ('adverse', 'O'), ('events', 'O'), ('monitored', 'O'), ('periodically', 'O'), ('throughout', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
"RESULTS : Among women , lovastatin ( 20 to 80 mg / d ) produced sustained ( 12 - to 48 - week ) , dose - related changes ( P < 0 . 001 ) : decreases in LDL cholesterol ( 24 % to 40 % ) and triglycerides ( 9 % to 18 % ) , and increases in HDL cholesterol ( 6 . 7 % to 8 . 6 % ) .","(('RESULTS', 'O'), (':', 'O'), ('Among', 'O'), ('women', 'O'), (',', 'O'), ('lovastatin', 'O'), ('(', 'O'), ('20', 'O'), ('to', 'O'), ('80', 'O'), ('mg', 'O'), ('/', 'O'), ('d', 'O'), (')', 'O'), ('produced', 'O'), ('sustained', 'O'), ('(', 'O'), ('12', 'O'), ('-', 'O'), ('to', 'O'), ('48', 'O'), ('-', 'O'), ('week', 'O'), (')', 'O'), (',', 'O'), ('dose', 'O'), ('-', 'O'), ('related', 'O'), ('changes', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (':', 'O'), ('decreases', 'O'), ('in', 'O'), ('LDL', 'O'), ('cholesterol', 'O'), ('(', 'O'), ('24', 'O'), ('%', 'O'), ('to', 'O'), ('40', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('triglycerides', 'O'), ('(', 'O'), ('9', 'O'), ('%', 'O'), ('to', 'O'), ('18', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('increases', 'O'), ('in', 'O'), ('HDL', 'O'), ('cholesterol', 'O'), ('(', 'O'), ('6', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), ('to', 'O'), ('8', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
"Depending on the dose , from 82 % to 95 % of lovastatin - treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4 . 14 mmol / L ( 160 mg / dL ) , and 40 % to 87 % achieved the goal of 3 . 36 mmol / L ( 130 mg / dL ) .","(('Depending', 'O'), ('on', 'O'), ('the', 'O'), ('dose', 'O'), (',', 'O'), ('from', 'O'), ('82', 'O'), ('%', 'O'), ('to', 'O'), ('95', 'O'), ('%', 'O'), ('of', 'O'), ('lovastatin', 'O'), ('-', 'O'), ('treated', 'O'), ('women', 'O'), ('achieved', 'O'), ('the', 'O'), ('National', 'O'), ('Cholesterol', 'O'), ('Education', 'O'), ('Program', 'O'), ('goal', 'O'), ('of', 'O'), ('LDL', 'O'), ('cholesterol', 'O'), ('levels', 'O'), ('less', 'O'), ('than', 'O'), ('4', 'O'), ('.', 'O'), ('14', 'O'), ('mmol', 'O'), ('/', 'O'), ('L', 'O'), ('(', 'O'), ('160', 'O'), ('mg', 'O'), ('/', 'O'), ('dL', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('40', 'O'), ('%', 'O'), ('to', 'O'), ('87', 'O'), ('%', 'O'), ('achieved', 'O'), ('the', 'O'), ('goal', 'O'), ('of', 'O'), ('3', 'O'), ('.', 'O'), ('36', 'O'), ('mmol', 'O'), ('/', 'O'), ('L', 'O'), ('(', 'O'), ('130', 'O'), ('mg', 'O'), ('/', 'O'), ('dL', 'O'), (')', 'O'), ('.', 'O'))"
Successive transaminase elevations greater than three times the upper limit of normal occurred in 0 . 1 % of women and were dose dependent above the 20 - mg dose .,"(('Successive', 'O'), ('transaminase', 'O'), ('elevations', 'O'), ('greater', 'O'), ('than', 'O'), ('three', 'O'), ('times', 'O'), ('the', 'O'), ('upper', 'O'), ('limit', 'O'), ('of', 'O'), ('normal', 'O'), ('occurred', 'O'), ('in', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('women', 'O'), ('and', 'O'), ('were', 'O'), ('dose', 'O'), ('dependent', 'O'), ('above', 'O'), ('the', 'O'), ('20', 'O'), ('-', 'O'), ('mg', 'O'), ('dose', 'O'), ('.', 'O'))"
Estrogen - replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin .,"(('Estrogen', 'O'), ('-', 'O'), ('replacement', 'O'), ('therapy', 'O'), ('appeared', 'O'), ('to', 'O'), ('have', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('either', 'O'), ('the', 'O'), ('efficacy', 'O'), ('or', 'O'), ('safety', 'O'), ('profile', 'O'), ('of', 'O'), ('lovastatin', 'O'), ('.', 'O'))"
CONCLUSION : Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women .,"(('CONCLUSION', 'O'), (':', 'O'), ('Lovastatin', 'O'), ('is', 'O'), ('highly', 'O'), ('effective', 'O'), ('and', 'O'), ('generally', 'O'), ('well', 'O'), ('tolerated', 'O'), ('as', 'O'), ('therapy', 'O'), ('for', 'O'), ('primary', 'B'), ('hypercholesterolemia', 'I'), ('in', 'O'), ('women', 'O'), ('.', 'O'))"
Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed .,"(('Five', 'O'), ('patients', 'O'), ('with', 'O'), ('cancer', 'B'), ('who', 'O'), ('developed', 'O'), ('acute', 'B'), ('renal', 'B'), ('failure', 'I'), ('that', 'O'), ('followed', 'O'), ('treatment', 'O'), ('with', 'O'), ('ciprofloxacin', 'O'), ('are', 'O'), ('described', 'O'), ('and', 'O'), ('an', 'O'), ('additional', 'O'), ('15', 'O'), ('cases', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('are', 'O'), ('reviewed', 'O'), ('.', 'O'))"
"Other than elevation of serum creatinine levels , characteristic clinical manifestations and abnormal laboratory findings are not frequently present .","(('Other', 'O'), ('than', 'O'), ('elevation', 'O'), ('of', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('levels', 'O'), (',', 'O'), ('characteristic', 'O'), ('clinical', 'O'), ('manifestations', 'O'), ('and', 'O'), ('abnormal', 'O'), ('laboratory', 'O'), ('findings', 'O'), ('are', 'O'), ('not', 'O'), ('frequently', 'O'), ('present', 'O'), ('.', 'O'))"
"Definitive diagnosis requires performance of renal biopsy , although this is not always feasible .","(('Definitive', 'O'), ('diagnosis', 'O'), ('requires', 'O'), ('performance', 'O'), ('of', 'O'), ('renal', 'O'), ('biopsy', 'O'), (',', 'O'), ('although', 'O'), ('this', 'O'), ('is', 'O'), ('not', 'O'), ('always', 'O'), ('feasible', 'O'), ('.', 'O'))"
An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin - induced acute renal failure .,"(('An', 'O'), ('improvement', 'O'), ('in', 'O'), ('renal', 'O'), ('function', 'O'), ('that', 'O'), ('followed', 'O'), ('the', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('the', 'O'), ('offending', 'O'), ('antibiotic', 'O'), ('supports', 'O'), ('the', 'O'), ('presumptive', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('ciprofloxacin', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('.', 'O'))"
"A palpable venous cord was present in 23 % ( 14 of 62 ) of patients in the diazepam group , compared with 2 % ( 1 of 60 patients ) in the midazolam group ( p < 0 . 002 ) .","(('A', 'O'), ('palpable', 'O'), ('venous', 'O'), ('cord', 'O'), ('was', 'O'), ('present', 'O'), ('in', 'O'), ('23', 'O'), ('%', 'O'), ('(', 'O'), ('14', 'O'), ('of', 'O'), ('62', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('diazepam', 'O'), ('group', 'O'), (',', 'O'), ('compared', 'O'), ('with', 'O'), ('2', 'O'), ('%', 'O'), ('(', 'O'), ('1', 'O'), ('of', 'O'), ('60', 'O'), ('patients', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('midazolam', 'O'), ('group', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('002', 'O'), (')', 'O'), ('.', 'O'))"
Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha - benzene hexachloride .,"(('Changes', 'O'), ('in', 'O'), ('peroxisomes', 'O'), ('in', 'O'), ('preneoplastic', 'O'), ('liver', 'O'), ('and', 'O'), ('hepatoma', 'B'), ('of', 'O'), ('mice', 'O'), ('induced', 'O'), ('by', 'O'), ('alpha', 'O'), ('-', 'O'), ('benzene', 'O'), ('hexachloride', 'O'), ('.', 'O'))"
"At the 16th week of carcinogen feeding , hyperplastic nodules appeared and advanced to further stages .","(('At', 'O'), ('the', 'O'), ('16th', 'O'), ('week', 'O'), ('of', 'O'), ('carcinogen', 'O'), ('feeding', 'O'), (',', 'O'), ('hyperplastic', 'B'), ('nodules', 'O'), ('appeared', 'O'), ('and', 'O'), ('advanced', 'O'), ('to', 'O'), ('further', 'O'), ('stages', 'O'), ('.', 'O'))"
A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes .,"(('A', 'O'), ('majority', 'O'), ('of', 'O'), ('the', 'O'), ('nodules', 'O'), ('showed', 'O'), ('a', 'O'), ('considerable', 'O'), ('number', 'O'), ('of', 'O'), ('peroxisomes', 'O'), ('and', 'O'), ('the', 'O'), ('inductive', 'O'), ('proliferation', 'O'), ('of', 'O'), ('peroxisomes', 'O'), ('.', 'O'))"
"Within the nodules , foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared .","(('Within', 'O'), ('the', 'O'), ('nodules', 'O'), (',', 'O'), ('foci', 'O'), ('of', 'O'), ('proliferation', 'O'), ('of', 'O'), ('the', 'O'), ('cells', 'O'), ('that', 'O'), ('showed', 'O'), ('no', 'O'), ('inducibility', 'O'), ('of', 'O'), ('proliferation', 'O'), ('of', 'O'), ('peroxisomes', 'O'), ('appeared', 'O'), ('.', 'O'))"
No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl - alpha - p - chlorophenoxyisobutyrate unlike in the case of rats .,"(('No', 'O'), ('abnormal', 'O'), ('matrical', 'O'), ('inclusions', 'O'), ('of', 'O'), ('peroxisomes', 'O'), ('were', 'O'), ('formed', 'O'), ('in', 'O'), ('the', 'O'), ('cells', 'O'), ('of', 'O'), ('hyperplastic', 'B'), ('nodules', 'O'), ('by', 'O'), ('ethyl', 'O'), ('-', 'O'), ('alpha', 'O'), ('-', 'O'), ('p', 'O'), ('-', 'O'), ('chlorophenoxyisobutyrate', 'O'), ('unlike', 'O'), ('in', 'O'), ('the', 'O'), ('case', 'O'), ('of', 'O'), ('rats', 'O'), ('.', 'O'))"
METHODS : Male SHR ( aged 6 weeks ) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet .,"(('METHODS', 'O'), (':', 'O'), ('Male', 'O'), ('SHR', 'O'), ('(', 'O'), ('aged', 'O'), ('6', 'O'), ('weeks', 'O'), (')', 'O'), ('that', 'O'), ('had', 'O'), ('been', 'O'), ('treated', 'O'), ('from', 'O'), ('conception', 'O'), ('onward', 'O'), ('with', 'O'), ('either', 'O'), ('captopril', 'O'), ('or', 'O'), ('vehicle', 'O'), ('remained', 'O'), ('on', 'O'), ('a', 'O'), ('basal', 'O'), ('sodium', 'O'), ('chloride', 'O'), ('diet', 'O'), ('or', 'O'), ('were', 'O'), ('fed', 'O'), ('a', 'O'), ('high', 'O'), ('sodium', 'O'), ('chloride', 'O'), ('diet', 'O'), ('.', 'O'))"
"After 2 weeks , the rats were subjected to ganglionic blockade and 2 days later , an infusion of clonidine .","(('After', 'O'), ('2', 'O'), ('weeks', 'O'), (',', 'O'), ('the', 'O'), ('rats', 'O'), ('were', 'O'), ('subjected', 'O'), ('to', 'O'), ('ganglionic', 'O'), ('blockade', 'O'), ('and', 'O'), ('2', 'O'), ('days', 'O'), ('later', 'O'), (',', 'O'), ('an', 'O'), ('infusion', 'O'), ('of', 'O'), ('clonidine', 'O'), ('.', 'O'))"
RESULTS : Lifetime captopril treatment significantly lowered mean arterial pressure in both groups .,"(('RESULTS', 'O'), (':', 'O'), ('Lifetime', 'O'), ('captopril', 'O'), ('treatment', 'O'), ('significantly', 'O'), ('lowered', 'O'), ('mean', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('.', 'O'))"
Infusion of the central nervous system alpha2 - adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high ( compared with the basal ) sodium chloride diet .,"(('Infusion', 'O'), ('of', 'O'), ('the', 'O'), ('central', 'O'), ('nervous', 'O'), ('system', 'O'), ('alpha2', 'O'), ('-', 'O'), ('adrenergic', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('clonidine', 'O'), ('also', 'O'), ('resulted', 'O'), ('in', 'O'), ('a', 'O'), ('greater', 'O'), ('reduction', 'O'), ('in', 'O'), ('MAP', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('of', 'O'), ('SHR', 'O'), ('that', 'O'), ('were', 'O'), ('fed', 'O'), ('the', 'O'), ('high', 'O'), ('(', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('basal', 'O'), (')', 'O'), ('sodium', 'O'), ('chloride', 'O'), ('diet', 'O'), ('.', 'O'))"
"CONCLUSIONS : In both lifetime captopril - treated and control SHR , the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet .","(('CONCLUSIONS', 'O'), (':', 'O'), ('In', 'O'), ('both', 'O'), ('lifetime', 'O'), ('captopril', 'O'), ('-', 'O'), ('treated', 'O'), ('and', 'O'), ('control', 'O'), ('SHR', 'O'), (',', 'O'), ('the', 'O'), ('sympathetic', 'O'), ('nervous', 'O'), ('system', 'O'), ('contributes', 'O'), ('to', 'O'), ('the', 'O'), ('pressor', 'O'), ('effects', 'O'), ('of', 'O'), ('a', 'O'), ('high', 'O'), ('sodium', 'O'), ('chloride', 'O'), ('diet', 'O'), ('.', 'O'))"
"Cardiac function was assessed in long - term survivors of malignant bone tumors who were treated according to Rosen ' s T5 or T10 protocol , both including doxorubicin .","(('Cardiac', 'O'), ('function', 'O'), ('was', 'O'), ('assessed', 'O'), ('in', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('survivors', 'O'), ('of', 'O'), ('malignant', 'B'), ('bone', 'I'), ('tumors', 'I'), ('who', 'O'), ('were', 'O'), ('treated', 'O'), ('according', 'O'), ('to', 'O'), ('Rosen', 'O'), (""'"", 'O'), ('s', 'O'), ('T5', 'O'), ('or', 'O'), ('T10', 'O'), ('protocol', 'O'), (',', 'O'), ('both', 'O'), ('including', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
"Thirty - one patients , age 10 - 45 years ( median age 17 . 8 years ) were evaluated 2 . 3 - 14 . 1 years ( median 8 . 9 years ) following completion of treatment .","(('Thirty', 'O'), ('-', 'O'), ('one', 'O'), ('patients', 'O'), (',', 'O'), ('age', 'O'), ('10', 'O'), ('-', 'O'), ('45', 'O'), ('years', 'O'), ('(', 'O'), ('median', 'O'), ('age', 'O'), ('17', 'O'), ('.', 'O'), ('8', 'O'), ('years', 'O'), (')', 'O'), ('were', 'O'), ('evaluated', 'O'), ('2', 'O'), ('.', 'O'), ('3', 'O'), ('-', 'O'), ('14', 'O'), ('.', 'O'), ('1', 'O'), ('years', 'O'), ('(', 'O'), ('median', 'O'), ('8', 'O'), ('.', 'O'), ('9', 'O'), ('years', 'O'), (')', 'O'), ('following', 'O'), ('completion', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O'))"
Cumulative doses of doxorubicin were 225 - 550 mg / m2 ( median dose 360 ) .,"(('Cumulative', 'O'), ('doses', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('were', 'O'), ('225', 'O'), ('-', 'O'), ('550', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('(', 'O'), ('median', 'O'), ('dose', 'O'), ('360', 'O'), (')', 'O'), ('.', 'O'))"
"The evaluation consisted of a history , physical examination , electrocardiogram ( ECG ) , signal averaged ECG , 24 - hour ambulatory ECG , echocardiography and radionuclide angiography .","(('The', 'O'), ('evaluation', 'O'), ('consisted', 'O'), ('of', 'O'), ('a', 'O'), ('history', 'O'), (',', 'O'), ('physical', 'O'), ('examination', 'O'), (',', 'O'), ('electrocardiogram', 'O'), ('(', 'O'), ('ECG', 'O'), (')', 'O'), (',', 'O'), ('signal', 'O'), ('averaged', 'O'), ('ECG', 'O'), (',', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('ambulatory', 'O'), ('ECG', 'O'), (',', 'O'), ('echocardiography', 'O'), ('and', 'O'), ('radionuclide', 'O'), ('angiography', 'O'), ('.', 'O'))"
The incidence of cardiac abnormalities increased with length of follow - up ( P < or = . 05 ) .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('cardiac', 'B'), ('abnormalities', 'I'), ('increased', 'O'), ('with', 'O'), ('length', 'O'), ('of', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('or', 'O'), ('=', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status , except for heart rate variability .","(('No', 'O'), ('correlation', 'O'), ('could', 'O'), ('be', 'O'), ('demonstrated', 'O'), ('between', 'O'), ('cumulative', 'O'), ('dose', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('and', 'O'), ('cardiac', 'O'), ('status', 'O'), (',', 'O'), ('except', 'O'), ('for', 'O'), ('heart', 'O'), ('rate', 'O'), ('variability', 'O'), ('.', 'O'))"
"When adjusted to body surface area , the left ventricular posterior wall thickness ( LVPW index ) was decreased in all patients .","(('When', 'O'), ('adjusted', 'O'), ('to', 'O'), ('body', 'O'), ('surface', 'O'), ('area', 'O'), (',', 'O'), ('the', 'O'), ('left', 'O'), ('ventricular', 'O'), ('posterior', 'O'), ('wall', 'O'), ('thickness', 'O'), ('(', 'O'), ('LVPW', 'O'), ('index', 'O'), (')', 'O'), ('was', 'O'), ('decreased', 'O'), ('in', 'O'), ('all', 'O'), ('patients', 'O'), ('.', 'O'))"
Life - long cardiac follow - up in these patients is warranted .,"(('Life', 'O'), ('-', 'O'), ('long', 'O'), ('cardiac', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('is', 'O'), ('warranted', 'O'), ('.', 'O'))"
"Thus , caffeine ( 3 . 3 mg / kg ) versus placebo was tested in 48 healthy men ( aged 20 to 35 years ) selected after screening on 2 separate occasions .","(('Thus', 'O'), (',', 'O'), ('caffeine', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('versus', 'O'), ('placebo', 'O'), ('was', 'O'), ('tested', 'O'), ('in', 'O'), ('48', 'O'), ('healthy', 'O'), ('men', 'O'), ('(', 'O'), ('aged', 'O'), ('20', 'O'), ('to', 'O'), ('35', 'O'), ('years', 'O'), (')', 'O'), ('selected', 'O'), ('after', 'O'), ('screening', 'O'), ('on', 'O'), ('2', 'O'), ('separate', 'O'), ('occasions', 'O'), ('.', 'O'))"
Participants were then tested on 2 occasions after 12 - hour abstinence from caffeine in each of 2 protocols ; this required a total of 4 laboratory visits .,"(('Participants', 'O'), ('were', 'O'), ('then', 'O'), ('tested', 'O'), ('on', 'O'), ('2', 'O'), ('occasions', 'O'), ('after', 'O'), ('12', 'O'), ('-', 'O'), ('hour', 'O'), ('abstinence', 'O'), ('from', 'O'), ('caffeine', 'O'), ('in', 'O'), ('each', 'O'), ('of', 'O'), ('2', 'O'), ('protocols', 'O'), (';', 'O'), ('this', 'O'), ('required', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('4', 'O'), ('laboratory', 'O'), ('visits', 'O'), ('.', 'O'))"
"Caffeine - induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls ( + 8 . 4 vs + 3 . 8 mm Hg , p < 0 . 0001 ) , and were attributable to larger changes in impedance - derived measures of systemic vascular resistance ( + 135 vs + 45 dynes . s . cm - 5 , p < 0 . 004 ) .","(('Caffeine', 'O'), ('-', 'O'), ('induced', 'O'), ('changes', 'O'), ('in', 'O'), ('diastolic', 'O'), ('BP', 'O'), ('were', 'O'), ('2', 'O'), ('to', 'O'), ('3', 'O'), ('times', 'O'), ('larger', 'O'), ('in', 'O'), ('borderline', 'O'), ('subjects', 'O'), ('than', 'O'), ('in', 'O'), ('controls', 'O'), ('(', 'O'), ('+', 'O'), ('8', 'O'), ('.', 'O'), ('4', 'O'), ('vs', 'O'), ('+', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), ('mm', 'O'), ('Hg', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('0001', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('were', 'O'), ('attributable', 'O'), ('to', 'O'), ('larger', 'O'), ('changes', 'O'), ('in', 'O'), ('impedance', 'O'), ('-', 'O'), ('derived', 'O'), ('measures', 'O'), ('of', 'O'), ('systemic', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('(', 'O'), ('+', 'O'), ('135', 'O'), ('vs', 'O'), ('+', 'O'), ('45', 'O'), ('dynes', 'O'), ('.', 'O'), ('s', 'O'), ('.', 'O'), ('cm', 'O'), ('-', 'O'), ('5', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('004', 'O'), (')', 'O'), ('.', 'O'))"
These findings were consistent and reached significance in both protocols .,"(('These', 'O'), ('findings', 'O'), ('were', 'O'), ('consistent', 'O'), ('and', 'O'), ('reached', 'O'), ('significance', 'O'), ('in', 'O'), ('both', 'O'), ('protocols', 'O'), ('.', 'O'))"
The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96 % .,"(('The', 'O'), ('percentage', 'O'), ('of', 'O'), ('borderline', 'O'), ('subjects', 'O'), ('in', 'O'), ('whom', 'O'), ('diastolic', 'O'), ('BP', 'O'), ('changes', 'O'), ('exceeded', 'O'), ('the', 'O'), ('median', 'O'), ('control', 'O'), ('response', 'O'), ('was', 'O'), ('96', 'O'), ('%', 'O'), ('.', 'O'))"
"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression , as well as hinder accurate diagnosis and treatment .","(('We', 'O'), ('suspect', 'O'), ('that', 'O'), ('the', 'O'), ('potential', 'O'), ('for', 'O'), ('caffeine', 'O'), ('to', 'O'), ('stabilize', 'O'), ('high', 'O'), ('resistance', 'O'), ('states', 'O'), ('in', 'O'), ('susceptible', 'O'), ('persons', 'O'), ('suggests', 'O'), ('that', 'O'), ('its', 'O'), ('use', 'O'), ('may', 'O'), ('facilitate', 'O'), ('their', 'O'), ('disease', 'O'), ('progression', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('hinder', 'O'), ('accurate', 'O'), ('diagnosis', 'O'), ('and', 'O'), ('treatment', 'O'), ('.', 'O'))"
Absence of effect of sertraline on time - based sensitization of cognitive impairment with haloperidol .,"(('Absence', 'O'), ('of', 'O'), ('effect', 'O'), ('of', 'O'), ('sertraline', 'O'), ('on', 'O'), ('time', 'O'), ('-', 'O'), ('based', 'O'), ('sensitization', 'O'), ('of', 'O'), ('cognitive', 'B'), ('impairment', 'I'), ('with', 'O'), ('haloperidol', 'O'), ('.', 'O'))"
"This double - blind , randomized , placebo - controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects .","(('This', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('study', 'O'), ('evaluated', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('haloperidol', 'O'), ('alone', 'O'), ('and', 'O'), ('haloperidol', 'O'), ('plus', 'O'), ('sertraline', 'O'), ('on', 'O'), ('cognitive', 'O'), ('and', 'O'), ('psychomotor', 'O'), ('function', 'O'), ('in', 'O'), ('24', 'O'), ('healthy', 'O'), ('male', 'O'), ('subjects', 'O'), ('.', 'O'))"
METHOD : All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25 .,"(('METHOD', 'O'), (':', 'O'), ('All', 'O'), ('subjects', 'O'), ('received', 'O'), ('placebo', 'O'), ('on', 'O'), ('Day', 'O'), ('1', 'O'), ('and', 'O'), ('haloperidol', 'O'), ('2', 'O'), ('mg', 'O'), ('on', 'O'), ('Days', 'O'), ('2', 'O'), ('and', 'O'), ('25', 'O'), ('.', 'O'))"
"From Days 9 to 25 , subjects were randomly assigned to either sertraline ( 12 subjects ) or placebo ( 12 subjects ) ; the sertraline dose was titrated from 50 to 200 mg / day from Days 9 to 16 , and remained at 200 mg / day for the final 10 days of the drug administration period .","(('From', 'O'), ('Days', 'O'), ('9', 'O'), ('to', 'O'), ('25', 'O'), (',', 'O'), ('subjects', 'O'), ('were', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('either', 'O'), ('sertraline', 'O'), ('(', 'O'), ('12', 'O'), ('subjects', 'O'), (')', 'O'), ('or', 'O'), ('placebo', 'O'), ('(', 'O'), ('12', 'O'), ('subjects', 'O'), (')', 'O'), (';', 'O'), ('the', 'O'), ('sertraline', 'O'), ('dose', 'O'), ('was', 'O'), ('titrated', 'O'), ('from', 'O'), ('50', 'O'), ('to', 'O'), ('200', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('from', 'O'), ('Days', 'O'), ('9', 'O'), ('to', 'O'), ('16', 'O'), (',', 'O'), ('and', 'O'), ('remained', 'O'), ('at', 'O'), ('200', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('for', 'O'), ('the', 'O'), ('final', 'O'), ('10', 'O'), ('days', 'O'), ('of', 'O'), ('the', 'O'), ('drug', 'O'), ('administration', 'O'), ('period', 'O'), ('.', 'O'))"
"Cognitive function testing was performed before dosing and over a 24 - hour period after dosing on Days 1 , 2 , and 25 .","(('Cognitive', 'O'), ('function', 'O'), ('testing', 'O'), ('was', 'O'), ('performed', 'O'), ('before', 'O'), ('dosing', 'O'), ('and', 'O'), ('over', 'O'), ('a', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('period', 'O'), ('after', 'O'), ('dosing', 'O'), ('on', 'O'), ('Days', 'O'), ('1', 'O'), (',', 'O'), ('2', 'O'), (',', 'O'), ('and', 'O'), ('25', 'O'), ('.', 'O'))"
"When single - dose haloperidol was given again 25 days later , greater impairment with earlier onset was noted in several tests in both treatment groups , suggesting enhancement of this effect .","(('When', 'O'), ('single', 'O'), ('-', 'O'), ('dose', 'O'), ('haloperidol', 'O'), ('was', 'O'), ('given', 'O'), ('again', 'O'), ('25', 'O'), ('days', 'O'), ('later', 'O'), (',', 'O'), ('greater', 'O'), ('impairment', 'O'), ('with', 'O'), ('earlier', 'O'), ('onset', 'O'), ('was', 'O'), ('noted', 'O'), ('in', 'O'), ('several', 'O'), ('tests', 'O'), ('in', 'O'), ('both', 'O'), ('treatment', 'O'), ('groups', 'O'), (',', 'O'), ('suggesting', 'O'), ('enhancement', 'O'), ('of', 'O'), ('this', 'O'), ('effect', 'O'), ('.', 'O'))"
There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('indication', 'O'), ('that', 'O'), ('sertraline', 'O'), ('exacerbated', 'O'), ('the', 'O'), ('impairment', 'O'), ('produced', 'O'), ('by', 'O'), ('haloperidol', 'O'), ('since', 'O'), ('an', 'O'), ('equivalent', 'O'), ('effect', 'O'), ('also', 'O'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('.', 'O'))"
Three subjects ( 2 on sertraline and 1 on placebo ) withdrew from the study because of side effects .,"(('Three', 'O'), ('subjects', 'O'), ('(', 'O'), ('2', 'O'), ('on', 'O'), ('sertraline', 'O'), ('and', 'O'), ('1', 'O'), ('on', 'O'), ('placebo', 'O'), (')', 'O'), ('withdrew', 'O'), ('from', 'O'), ('the', 'O'), ('study', 'O'), ('because', 'O'), ('of', 'O'), ('side', 'O'), ('effects', 'O'), ('.', 'O'))"
Ten subjects in each group reported side effects related to treatment .,"(('Ten', 'O'), ('subjects', 'O'), ('in', 'O'), ('each', 'O'), ('group', 'O'), ('reported', 'O'), ('side', 'O'), ('effects', 'O'), ('related', 'O'), ('to', 'O'), ('treatment', 'O'), ('.', 'O'))"
The side effect profiles of sertraline and of placebo were similar .,"(('The', 'O'), ('side', 'O'), ('effect', 'O'), ('profiles', 'O'), ('of', 'O'), ('sertraline', 'O'), ('and', 'O'), ('of', 'O'), ('placebo', 'O'), ('were', 'O'), ('similar', 'O'), ('.', 'O'))"
CONCLUSION : Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration .,"(('CONCLUSION', 'O'), (':', 'O'), ('Haloperidol', 'O'), ('produced', 'O'), ('a', 'O'), ('clear', 'O'), ('profile', 'O'), ('of', 'O'), ('cognitive', 'B'), ('impairment', 'I'), ('that', 'O'), ('was', 'O'), ('not', 'O'), ('worsened', 'O'), ('by', 'O'), ('concomitant', 'O'), ('sertraline', 'O'), ('administration', 'O'), ('.', 'O'))"
A case report .,"(('A', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
Chemotherapy of advanced inoperable non - small cell lung cancer with paclitaxel : a phase II trial .,"(('Chemotherapy', 'O'), ('of', 'O'), ('advanced', 'B'), ('inoperable', 'I'), ('non', 'I'), ('-', 'I'), ('small', 'I'), ('cell', 'I'), ('lung', 'I'), ('cancer', 'I'), ('with', 'O'), ('paclitaxel', 'O'), (':', 'O'), ('a', 'O'), ('phase', 'O'), ('II', 'O'), ('trial', 'O'), ('.', 'O'))"
"Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably ovarian and breast carcinoma .","(('Paclitaxel', 'O'), ('(', 'O'), ('Taxol', 'O'), (';', 'O'), ('Bristol', 'O'), ('-', 'O'), ('Myers', 'O'), ('Squibb', 'O'), ('Company', 'O'), (',', 'O'), ('Princeton', 'O'), (',', 'O'), ('NJ', 'O'), (')', 'O'), ('has', 'O'), ('demonstrated', 'O'), ('significant', 'O'), ('antineoplastic', 'O'), ('activity', 'O'), ('against', 'O'), ('different', 'O'), ('tumor', 'B'), ('types', 'O'), (',', 'O'), ('notably', 'O'), ('ovarian', 'B'), ('and', 'I'), ('breast', 'I'), ('carcinoma', 'I'), ('.', 'O'))"
"The 58 patients treated ( 41 men and 17 women ) had a median age of 59 years ( age range , 25 to 75 ) and a performance status of 0 through 2 .","(('The', 'O'), ('58', 'O'), ('patients', 'O'), ('treated', 'O'), ('(', 'O'), ('41', 'O'), ('men', 'O'), ('and', 'O'), ('17', 'O'), ('women', 'O'), (')', 'O'), ('had', 'O'), ('a', 'O'), ('median', 'O'), ('age', 'O'), ('of', 'O'), ('59', 'O'), ('years', 'O'), ('(', 'O'), ('age', 'O'), ('range', 'O'), (',', 'O'), ('25', 'O'), ('to', 'O'), ('75', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('performance', 'O'), ('status', 'O'), ('of', 'O'), ('0', 'O'), ('through', 'O'), ('2', 'O'), ('.', 'O'))"
Paclitaxel 225 mg / m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication .,"(('Paclitaxel', 'O'), ('225', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('was', 'O'), ('infused', 'O'), ('over', 'O'), ('3', 'O'), ('hours', 'O'), ('every', 'O'), ('3', 'O'), ('weeks', 'O'), ('with', 'O'), ('standard', 'O'), ('prophylactic', 'O'), ('premedication', 'O'), ('.', 'O'))"
"Of 50 patients evaluable for response , 12 ( 24 % ) had partial remission , 26 ( 52 % ) had no change , and 12 had disease progression ( 24 % ) .","(('Of', 'O'), ('50', 'O'), ('patients', 'O'), ('evaluable', 'O'), ('for', 'O'), ('response', 'O'), (',', 'O'), ('12', 'O'), ('(', 'O'), ('24', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('partial', 'O'), ('remission', 'O'), (',', 'O'), ('26', 'O'), ('(', 'O'), ('52', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('no', 'O'), ('change', 'O'), (',', 'O'), ('and', 'O'), ('12', 'O'), ('had', 'O'), ('disease', 'O'), ('progression', 'O'), ('(', 'O'), ('24', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
Grade 1 or 2 polyneuropathy affected 56 % of patients while only one ( 2 % ) experienced severe polyneuropathy .,"(('Grade', 'O'), ('1', 'O'), ('or', 'O'), ('2', 'O'), ('polyneuropathy', 'B'), ('affected', 'O'), ('56', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('while', 'O'), ('only', 'O'), ('one', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('experienced', 'O'), ('severe', 'O'), ('polyneuropathy', 'B'), ('.', 'O'))"
"Similarly , grade 1 or 2 myalgia / arthralgia was observed in 63 . 2 % of patients , but only 14 . 3 % experienced grade 3 or 4 .","(('Similarly', 'O'), (',', 'O'), ('grade', 'O'), ('1', 'O'), ('or', 'O'), ('2', 'O'), ('myalgia', 'B'), ('/', 'O'), ('arthralgia', 'B'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('63', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), (',', 'O'), ('but', 'O'), ('only', 'O'), ('14', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('experienced', 'O'), ('grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('.', 'O'))"
"Paclitaxel is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity .","(('Paclitaxel', 'O'), ('is', 'O'), ('thus', 'O'), ('an', 'O'), ('active', 'O'), ('single', 'O'), ('agent', 'O'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('population', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('3', 'O'), ('-', 'O'), ('hour', 'O'), ('infusion', 'O'), ('proving', 'O'), ('comparably', 'O'), ('effective', 'O'), ('to', 'O'), ('a', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('infusion', 'O'), ('and', 'O'), ('superior', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('hematologic', 'O'), ('and', 'O'), ('nonhematologic', 'O'), ('toxicity', 'O'), ('.', 'O'))"
Paclitaxel combined with carboplatin in the first - line treatment of advanced ovarian cancer .,"(('Paclitaxel', 'O'), ('combined', 'O'), ('with', 'O'), ('carboplatin', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('-', 'O'), ('line', 'O'), ('treatment', 'O'), ('of', 'O'), ('advanced', 'B'), ('ovarian', 'I'), ('cancer', 'I'), ('.', 'O'))"
"In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .","(('In', 'O'), ('a', 'O'), ('phase', 'O'), ('I', 'O'), ('study', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('maximum', 'O'), ('tolerated', 'O'), ('dose', 'O'), ('of', 'O'), ('paclitaxel', 'O'), ('(', 'O'), ('Taxol', 'O'), (';', 'O'), ('Bristol', 'O'), ('-', 'O'), ('Myers', 'O'), ('Squibb', 'O'), ('Company', 'O'), (',', 'O'), ('Princeton', 'O'), (',', 'O'), ('NJ', 'O'), (')', 'O'), ('given', 'O'), ('as', 'O'), ('a', 'O'), ('3', 'O'), ('-', 'O'), ('hour', 'O'), ('infusion', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('carboplatin', 'O'), ('administered', 'O'), ('every', 'O'), ('21', 'O'), ('days', 'O'), ('to', 'O'), ('women', 'O'), ('with', 'O'), ('advanced', 'B'), ('ovarian', 'I'), ('cancer', 'I'), (',', 'O'), ('paclitaxel', 'O'), ('doses', 'O'), ('were', 'O'), ('escalated', 'O'), ('as', 'O'), ('follows', 'O'), (':', 'O'), ('level', 'O'), ('1', 'O'), (',', 'O'), ('135', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), (';', 'O'), ('level', 'O'), ('2', 'O'), (',', 'O'), ('160', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), (';', 'O'), ('level', 'O'), ('3', 'O'), (',', 'O'), ('185', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), (';', 'O'), ('and', 'O'), ('level', 'O'), ('4', 'O'), (',', 'O'), ('210', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('.', 'O'))"
The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration - time curve ( AUC ) of 5 using the Calvert formula .,"(('The', 'O'), ('fixed', 'O'), ('dose', 'O'), ('of', 'O'), ('carboplatin', 'O'), ('at', 'O'), ('levels', 'O'), ('1', 'O'), ('through', 'O'), ('4', 'O'), ('was', 'O'), ('given', 'O'), ('to', 'O'), ('achieve', 'O'), ('an', 'O'), ('area', 'O'), ('under', 'O'), ('the', 'O'), ('concentration', 'O'), ('-', 'O'), ('time', 'O'), ('curve', 'O'), ('(', 'O'), ('AUC', 'O'), (')', 'O'), ('of', 'O'), ('5', 'O'), ('using', 'O'), ('the', 'O'), ('Calvert', 'O'), ('formula', 'O'), ('.', 'O'))"
"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7 . 5 , respectively , combined with a fixed paclitaxel dose of 185 mg / m2 .","(('In', 'O'), ('levels', 'O'), ('5', 'O'), ('and', 'O'), ('6', 'O'), ('the', 'O'), ('carboplatin', 'O'), ('dose', 'O'), ('was', 'O'), ('targeted', 'O'), ('at', 'O'), ('AUCs', 'O'), ('of', 'O'), ('6', 'O'), ('and', 'O'), ('7', 'O'), ('.', 'O'), ('5', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('combined', 'O'), ('with', 'O'), ('a', 'O'), ('fixed', 'O'), ('paclitaxel', 'O'), ('dose', 'O'), ('of', 'O'), ('185', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('.', 'O'))"
"To date , 30 previously untreated patients , all with a good performance status ( Eastern Cooperative Oncology Group 0 to 2 ) have been entered into this ongoing study .","(('To', 'O'), ('date', 'O'), (',', 'O'), ('30', 'O'), ('previously', 'O'), ('untreated', 'O'), ('patients', 'O'), (',', 'O'), ('all', 'O'), ('with', 'O'), ('a', 'O'), ('good', 'O'), ('performance', 'O'), ('status', 'O'), ('(', 'O'), ('Eastern', 'O'), ('Cooperative', 'O'), ('Oncology', 'O'), ('Group', 'O'), ('0', 'O'), ('to', 'O'), ('2', 'O'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('entered', 'O'), ('into', 'O'), ('this', 'O'), ('ongoing', 'O'), ('study', 'O'), ('.', 'O'))"
"So far , 14 patients are evaluable for response ; of these , eight ( 57 % ) showed objective ( complete or partial ) response and disease stabilized in six patients .","(('So', 'O'), ('far', 'O'), (',', 'O'), ('14', 'O'), ('patients', 'O'), ('are', 'O'), ('evaluable', 'O'), ('for', 'O'), ('response', 'O'), (';', 'O'), ('of', 'O'), ('these', 'O'), (',', 'O'), ('eight', 'O'), ('(', 'O'), ('57', 'O'), ('%', 'O'), (')', 'O'), ('showed', 'O'), ('objective', 'O'), ('(', 'O'), ('complete', 'O'), ('or', 'O'), ('partial', 'O'), (')', 'O'), ('response', 'O'), ('and', 'O'), ('disease', 'O'), ('stabilized', 'O'), ('in', 'O'), ('six', 'O'), ('patients', 'O'), ('.', 'O'))"
No patient had disease progression .,"(('No', 'O'), ('patient', 'O'), ('had', 'O'), ('disease', 'O'), ('progression', 'O'), ('.', 'O'))"
We conclude that the combination of paclitaxel 185 mg / m2 administered as a 3 - hour infusion followed immediately by a 1 - hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21 - day schedule in the outpatient setting .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('the', 'O'), ('combination', 'O'), ('of', 'O'), ('paclitaxel', 'O'), ('185', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('administered', 'O'), ('as', 'O'), ('a', 'O'), ('3', 'O'), ('-', 'O'), ('hour', 'O'), ('infusion', 'O'), ('followed', 'O'), ('immediately', 'O'), ('by', 'O'), ('a', 'O'), ('1', 'O'), ('-', 'O'), ('hour', 'O'), ('infusion', 'O'), ('of', 'O'), ('carboplatin', 'O'), ('at', 'O'), ('an', 'O'), ('AUC', 'O'), ('of', 'O'), ('6', 'O'), ('can', 'O'), ('be', 'O'), ('administered', 'O'), ('safely', 'O'), ('in', 'O'), ('a', 'O'), ('21', 'O'), ('-', 'O'), ('day', 'O'), ('schedule', 'O'), ('in', 'O'), ('the', 'O'), ('outpatient', 'O'), ('setting', 'O'), ('.', 'O'))"
The recommended dose for phase III studies is paclitaxel 185 mg / m2 and carboplatin AUC 6 .,"(('The', 'O'), ('recommended', 'O'), ('dose', 'O'), ('for', 'O'), ('phase', 'O'), ('III', 'O'), ('studies', 'O'), ('is', 'O'), ('paclitaxel', 'O'), ('185', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('and', 'O'), ('carboplatin', 'O'), ('AUC', 'O'), ('6', 'O'), ('.', 'O'))"
Effects of acute steroid administration on ventilatory and peripheral muscles in rats .,"(('Effects', 'O'), ('of', 'O'), ('acute', 'O'), ('steroid', 'O'), ('administration', 'O'), ('on', 'O'), ('ventilatory', 'O'), ('and', 'O'), ('peripheral', 'O'), ('muscles', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids .,"(('Occasional', 'O'), ('case', 'O'), ('reports', 'O'), ('have', 'O'), ('shown', 'O'), ('that', 'O'), ('acute', 'B'), ('myopathy', 'I'), ('may', 'O'), ('occur', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('massive', 'O'), ('doses', 'O'), ('of', 'O'), ('corticosteroids', 'O'), ('.', 'O'))"
The mechanism of this myopathy is poorly understood .,"(('The', 'O'), ('mechanism', 'O'), ('of', 'O'), ('this', 'O'), ('myopathy', 'B'), ('is', 'O'), ('poorly', 'O'), ('understood', 'O'), ('.', 'O'))"
"Therefore , 60 male rats were randomly assigned to receive daily injection of saline ( C ) , methylprednisolone ( M ) , or triamcinolone ( T ) 80 mg / kg / d for 5 d .","(('Therefore', 'O'), (',', 'O'), ('60', 'O'), ('male', 'O'), ('rats', 'O'), ('were', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('receive', 'O'), ('daily', 'O'), ('injection', 'O'), ('of', 'O'), ('saline', 'O'), ('(', 'O'), ('C', 'O'), (')', 'O'), (',', 'O'), ('methylprednisolone', 'O'), ('(', 'O'), ('M', 'O'), (')', 'O'), (',', 'O'), ('or', 'O'), ('triamcinolone', 'O'), ('(', 'O'), ('T', 'O'), (')', 'O'), ('80', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('d', 'O'), ('for', 'O'), ('5', 'O'), ('d', 'O'), ('.', 'O'))"
"In the 45 remaining animals , diaphragm contractility and histopathologic features of several muscles were studied .","(('In', 'O'), ('the', 'O'), ('45', 'O'), ('remaining', 'O'), ('animals', 'O'), (',', 'O'), ('diaphragm', 'O'), ('contractility', 'O'), ('and', 'O'), ('histopathologic', 'O'), ('features', 'O'), ('of', 'O'), ('several', 'O'), ('muscles', 'O'), ('were', 'O'), ('studied', 'O'), ('.', 'O'))"
Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment .,"(('Weights', 'O'), ('of', 'O'), ('respiratory', 'O'), ('and', 'O'), ('peripheral', 'O'), ('muscles', 'O'), ('were', 'O'), ('similarly', 'O'), ('decreased', 'O'), ('after', 'O'), ('steroid', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Maximal twitches of the diaphragm were lower in the C group ( 653 + / - 174 g / cm ( 2 ) ) than in the M group ( 837 + / - 171 g / cm ( 2 ) ; p < 0 . 05 ) and the T group ( 765 + / - 145 g / cm ( 2 ) , NS ) .","(('Maximal', 'O'), ('twitches', 'O'), ('of', 'O'), ('the', 'O'), ('diaphragm', 'O'), ('were', 'O'), ('lower', 'O'), ('in', 'O'), ('the', 'O'), ('C', 'O'), ('group', 'O'), ('(', 'O'), ('653', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('174', 'O'), ('g', 'O'), ('/', 'O'), ('cm', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), (')', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('M', 'O'), ('group', 'O'), ('(', 'O'), ('837', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('171', 'O'), ('g', 'O'), ('/', 'O'), ('cm', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), (';', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('and', 'O'), ('the', 'O'), ('T', 'O'), ('group', 'O'), ('(', 'O'), ('765', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('145', 'O'), ('g', 'O'), ('/', 'O'), ('cm', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), (',', 'O'), ('NS', 'O'), (')', 'O'), ('.', 'O'))"
Steroid treatment also induced a leftward shift of the force - frequency curve at 25 and 50 Hz when compared with saline treatment ( p < 0 . 05 ) .,"(('Steroid', 'O'), ('treatment', 'O'), ('also', 'O'), ('induced', 'O'), ('a', 'O'), ('leftward', 'O'), ('shift', 'O'), ('of', 'O'), ('the', 'O'), ('force', 'O'), ('-', 'O'), ('frequency', 'O'), ('curve', 'O'), ('at', 'O'), ('25', 'O'), ('and', 'O'), ('50', 'O'), ('Hz', 'O'), ('when', 'O'), ('compared', 'O'), ('with', 'O'), ('saline', 'O'), ('treatment', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that muscle atrophy was considerably less pronounced in PF animals than in T - treated animals .","(('Finally', 'O'), (',', 'O'), ('a', 'O'), ('pair', 'O'), ('-', 'O'), ('fed', 'O'), ('(', 'O'), ('PF', 'O'), (')', 'O'), ('study', 'O'), (',', 'O'), ('performed', 'O'), ('in', 'O'), ('18', 'O'), ('rats', 'O'), ('(', 'O'), ('C', 'O'), (',', 'O'), ('T', 'O'), (',', 'O'), ('and', 'O'), ('PF', 'O'), (')', 'O'), (',', 'O'), ('showed', 'O'), ('that', 'O'), ('muscle', 'B'), ('atrophy', 'I'), ('was', 'O'), ('considerably', 'O'), ('less', 'O'), ('pronounced', 'O'), ('in', 'O'), ('PF', 'O'), ('animals', 'O'), ('than', 'O'), ('in', 'O'), ('T', 'O'), ('-', 'O'), ('treated', 'O'), ('animals', 'O'), ('.', 'O'))"
"Mesna is generally administered by the intravenous route , although experience with oral delivery of the drug has increased .","(('Mesna', 'O'), ('is', 'O'), ('generally', 'O'), ('administered', 'O'), ('by', 'O'), ('the', 'O'), ('intravenous', 'O'), ('route', 'O'), (',', 'O'), ('although', 'O'), ('experience', 'O'), ('with', 'O'), ('oral', 'O'), ('delivery', 'O'), ('of', 'O'), ('the', 'O'), ('drug', 'O'), ('has', 'O'), ('increased', 'O'), ('.', 'O'))"
The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access .,"(('The', 'O'), ('continuous', 'O'), ('subcutaneous', 'O'), ('administration', 'O'), ('of', 'O'), ('mesna', 'O'), ('has', 'O'), ('the', 'O'), ('advantage', 'O'), ('of', 'O'), ('not', 'O'), ('requiring', 'O'), ('intravenous', 'O'), ('access', 'O'), ('.', 'O'))"
"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe , practical , and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting .","(('Limited', 'O'), ('clinical', 'O'), ('experience', 'O'), ('with', 'O'), ('continuous', 'O'), ('subcutaneous', 'O'), ('mesna', 'O'), ('administration', 'O'), ('suggests', 'O'), ('it', 'O'), ('is', 'O'), ('a', 'O'), ('safe', 'O'), (',', 'O'), ('practical', 'O'), (',', 'O'), ('and', 'O'), ('economic', 'O'), ('method', 'O'), ('of', 'O'), ('drug', 'O'), ('delivery', 'O'), ('that', 'O'), ('permits', 'O'), ('ifosfamide', 'O'), ('to', 'O'), ('be', 'O'), ('administered', 'O'), ('successfully', 'O'), ('in', 'O'), ('the', 'O'), ('outpatient', 'O'), ('setting', 'O'), ('.', 'O'))"
"Fifty - four patients , aged 27 - 90 years , who were given lignocaine 5 % in 6 . 8 % glucose solution for spinal anaesthesia were studied .","(('Fifty', 'O'), ('-', 'O'), ('four', 'O'), ('patients', 'O'), (',', 'O'), ('aged', 'O'), ('27', 'O'), ('-', 'O'), ('90', 'O'), ('years', 'O'), (',', 'O'), ('who', 'O'), ('were', 'O'), ('given', 'O'), ('lignocaine', 'O'), ('5', 'O'), ('%', 'O'), ('in', 'O'), ('6', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('glucose', 'O'), ('solution', 'O'), ('for', 'O'), ('spinal', 'O'), ('anaesthesia', 'O'), ('were', 'O'), ('studied', 'O'), ('.', 'O'))"
Adequate spontaneous respiration was re - established in an average period of ten minutes after the injection .,"(('Adequate', 'O'), ('spontaneous', 'O'), ('respiration', 'O'), ('was', 'O'), ('re', 'O'), ('-', 'O'), ('established', 'O'), ('in', 'O'), ('an', 'O'), ('average', 'O'), ('period', 'O'), ('of', 'O'), ('ten', 'O'), ('minutes', 'O'), ('after', 'O'), ('the', 'O'), ('injection', 'O'), ('.', 'O'))"
In 12 patients biochemical genetic examinations confirmed the presence of an atypical serum cholinesterase .,"(('In', 'O'), ('12', 'O'), ('patients', 'O'), ('biochemical', 'O'), ('genetic', 'O'), ('examinations', 'O'), ('confirmed', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('an', 'O'), ('atypical', 'O'), ('serum', 'O'), ('cholinesterase', 'O'), ('.', 'O'))"
In three patients none of the usual variants were found .,"(('In', 'O'), ('three', 'O'), ('patients', 'O'), ('none', 'O'), ('of', 'O'), ('the', 'O'), ('usual', 'O'), ('variants', 'O'), ('were', 'O'), ('found', 'O'), ('.', 'O'))"
It is therefore supposed that other unknown variants of serum cholinesterase exist which cannot hydrolyze succinylcholine .,"(('It', 'O'), ('is', 'O'), ('therefore', 'O'), ('supposed', 'O'), ('that', 'O'), ('other', 'O'), ('unknown', 'O'), ('variants', 'O'), ('of', 'O'), ('serum', 'O'), ('cholinesterase', 'O'), ('exist', 'O'), ('which', 'O'), ('cannot', 'O'), ('hydrolyze', 'O'), ('succinylcholine', 'O'), ('.', 'O'))"
"Deoxycholic acid conjugation , transport capacity , and metabolism were compared in control and ethinyl estradiol - treated rats .","(('Deoxycholic', 'O'), ('acid', 'O'), ('conjugation', 'O'), (',', 'O'), ('transport', 'O'), ('capacity', 'O'), (',', 'O'), ('and', 'O'), ('metabolism', 'O'), ('were', 'O'), ('compared', 'O'), ('in', 'O'), ('control', 'O'), ('and', 'O'), ('ethinyl', 'O'), ('estradiol', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('.', 'O'))"
"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid , and both were decreased by ethinyl estradiol treatment .","(('Control', 'O'), ('rats', 'O'), ('were', 'O'), ('found', 'O'), ('to', 'O'), ('have', 'O'), ('a', 'O'), ('lower', 'O'), ('capacity', 'O'), ('to', 'O'), ('transport', 'O'), ('deoxycholic', 'O'), ('acid', 'O'), ('than', 'O'), ('taurodeoxycholic', 'O'), ('acid', 'O'), (',', 'O'), ('and', 'O'), ('both', 'O'), ('were', 'O'), ('decreased', 'O'), ('by', 'O'), ('ethinyl', 'O'), ('estradiol', 'O'), ('treatment', 'O'), ('.', 'O'))"
"During [ 24 - 14C ] sodium deoxycholate infusion , [ 14C ] biliary bile acid secretion increased , but bile flow did not change significantly in either control or ethinyl estradiol - treated rats .","(('During', 'O'), ('[', 'O'), ('24', 'O'), ('-', 'O'), ('14C', 'O'), (']', 'O'), ('sodium', 'O'), ('deoxycholate', 'O'), ('infusion', 'O'), (',', 'O'), ('[', 'O'), ('14C', 'O'), (']', 'O'), ('biliary', 'O'), ('bile', 'O'), ('acid', 'O'), ('secretion', 'O'), ('increased', 'O'), (',', 'O'), ('but', 'O'), ('bile', 'O'), ('flow', 'O'), ('did', 'O'), ('not', 'O'), ('change', 'O'), ('significantly', 'O'), ('in', 'O'), ('either', 'O'), ('control', 'O'), ('or', 'O'), ('ethinyl', 'O'), ('estradiol', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('.', 'O'))"
"Ethinyl estradiol - treated animals excreted significantly less 14C as taurocholic acid than did control animals , consistent with an impairment of 7alpha - hydroxylation of taurodeoxycholic acid .","(('Ethinyl', 'O'), ('estradiol', 'O'), ('-', 'O'), ('treated', 'O'), ('animals', 'O'), ('excreted', 'O'), ('significantly', 'O'), ('less', 'O'), ('14C', 'O'), ('as', 'O'), ('taurocholic', 'O'), ('acid', 'O'), ('than', 'O'), ('did', 'O'), ('control', 'O'), ('animals', 'O'), (',', 'O'), ('consistent', 'O'), ('with', 'O'), ('an', 'O'), ('impairment', 'O'), ('of', 'O'), ('7alpha', 'O'), ('-', 'O'), ('hydroxylation', 'O'), ('of', 'O'), ('taurodeoxycholic', 'O'), ('acid', 'O'), ('.', 'O'))"
"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid , but did result in an increase in sulfation of taurodeoxycholic acid from 1 . 5 % in controls to nearly 4 . 0 % ( P less than 0 . 01 ) .","(('Ethinyl', 'O'), ('estradiol', 'O'), ('treatment', 'O'), ('did', 'O'), ('not', 'O'), ('impair', 'O'), ('conjugation', 'O'), ('of', 'O'), ('deoxycholic', 'O'), ('acid', 'O'), (',', 'O'), ('but', 'O'), ('did', 'O'), ('result', 'O'), ('in', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('sulfation', 'O'), ('of', 'O'), ('taurodeoxycholic', 'O'), ('acid', 'O'), ('from', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('in', 'O'), ('controls', 'O'), ('to', 'O'), ('nearly', 'O'), ('4', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species .,"(('These', 'O'), ('results', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('the', 'O'), ('rat', 'O'), ('has', 'O'), ('a', 'O'), ('poorer', 'O'), ('tolerance', 'O'), ('for', 'O'), ('deoxycholic', 'O'), ('acid', 'O'), ('than', 'O'), ('do', 'O'), ('certain', 'O'), ('other', 'O'), ('species', 'O'), ('.', 'O'))"
"Furthermore , the rat converts deoxycholic acid , a poor choleretic , to taurocholic acid , a good choleretic .","(('Furthermore', 'O'), (',', 'O'), ('the', 'O'), ('rat', 'O'), ('converts', 'O'), ('deoxycholic', 'O'), ('acid', 'O'), (',', 'O'), ('a', 'O'), ('poor', 'O'), ('choleretic', 'O'), (',', 'O'), ('to', 'O'), ('taurocholic', 'O'), ('acid', 'O'), (',', 'O'), ('a', 'O'), ('good', 'O'), ('choleretic', 'O'), ('.', 'O'))"
"When this conversion is impaired with ethinyl estradiol treatment , sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid .","(('When', 'O'), ('this', 'O'), ('conversion', 'O'), ('is', 'O'), ('impaired', 'O'), ('with', 'O'), ('ethinyl', 'O'), ('estradiol', 'O'), ('treatment', 'O'), (',', 'O'), ('sulfation', 'O'), ('may', 'O'), ('be', 'O'), ('an', 'O'), ('important', 'O'), ('alternate', 'O'), ('pathway', 'O'), ('for', 'O'), ('excretion', 'O'), ('of', 'O'), ('this', 'O'), ('potentially', 'O'), ('harmful', 'O'), ('bile', 'O'), ('acid', 'O'), ('.', 'O'))"
"Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .","(('Recently', 'O'), (',', 'O'), ('we', 'O'), ('demonstrated', 'O'), ('the', 'O'), ('hepatoprotective', 'O'), ('effects', 'O'), ('of', 'O'), ('nicotinic', 'O'), ('acid', 'O'), ('amide', 'O'), (',', 'O'), ('a', 'O'), ('selective', 'O'), ('inhibitor', 'O'), ('of', 'O'), ('poly', 'O'), ('(', 'O'), ('ADP', 'O'), ('-', 'O'), ('ribose', 'O'), (')', 'O'), ('polymerase', 'O'), ('(', 'O'), ('PARP', 'O'), (';', 'O'), ('EC', 'O'), ('2', 'O'), ('.', 'O'), ('4', 'O'), ('.', 'O'), ('2', 'O'), ('.', 'O'), ('30', 'O'), (')', 'O'), ('on', 'O'), ('mice', 'O'), ('suffering', 'O'), ('from', 'O'), ('acetaminophen', 'B'), ('(', 'O'), ('AAP', 'B'), (')', 'I'), ('-', 'I'), ('hepatitis', 'I'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('the', 'O'), ('AAP', 'B'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('injury', 'I'), ('involves', 'O'), ('a', 'O'), ('step', 'O'), ('which', 'O'), ('depends', 'O'), ('on', 'O'), ('adenoribosylation', 'O'), ('.', 'O'))"
"The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals .","(('The', 'O'), ('present', 'O'), ('study', 'O'), ('investigates', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('a', 'O'), ('diet', 'O'), ('free', 'O'), ('of', 'O'), ('precursors', 'O'), ('of', 'O'), ('NAD', 'O'), (',', 'O'), ('the', 'O'), ('substrate', 'O'), ('on', 'O'), ('which', 'O'), ('PARP', 'O'), ('acts', 'O'), (',', 'O'), ('in', 'O'), ('female', 'O'), ('NMRI', 'O'), ('mice', 'O'), ('with', 'O'), ('AAP', 'B'), ('hepatitis', 'I'), ('and', 'O'), ('evaluates', 'O'), ('the', 'O'), ('influence', 'O'), ('of', 'O'), ('simultaneous', 'O'), ('ethanol', 'O'), ('consumption', 'O'), ('in', 'O'), ('these', 'O'), ('animals', 'O'), ('.', 'O'))"
"While AAP caused a 117 - fold elevation of serum transaminase activities in mice kept on a standard laboratory diet , which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide ( NAA ) , adverse effects were noted in animals fed a diet free of precursors of NAD .","(('While', 'O'), ('AAP', 'O'), ('caused', 'O'), ('a', 'O'), ('117', 'O'), ('-', 'O'), ('fold', 'O'), ('elevation', 'O'), ('of', 'O'), ('serum', 'O'), ('transaminase', 'O'), ('activities', 'O'), ('in', 'O'), ('mice', 'O'), ('kept', 'O'), ('on', 'O'), ('a', 'O'), ('standard', 'O'), ('laboratory', 'O'), ('diet', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('significantly', 'O'), ('exacerbated', 'O'), ('by', 'O'), ('ethanol', 'O'), ('and', 'O'), ('inhibited', 'O'), ('by', 'O'), ('nicotinic', 'O'), ('acid', 'O'), ('amide', 'O'), ('(', 'O'), ('NAA', 'O'), (')', 'O'), (',', 'O'), ('adverse', 'O'), ('effects', 'O'), ('were', 'O'), ('noted', 'O'), ('in', 'O'), ('animals', 'O'), ('fed', 'O'), ('a', 'O'), ('diet', 'O'), ('free', 'O'), ('of', 'O'), ('precursors', 'O'), ('of', 'O'), ('NAD', 'O'), ('.', 'O'))"
"In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the liver damage was inhibited by 50 % by ethanol .","(('In', 'O'), ('these', 'O'), ('animals', 'O'), (',', 'O'), ('only', 'O'), ('minor', 'O'), ('increases', 'O'), ('of', 'O'), ('serum', 'O'), ('transaminase', 'O'), ('activities', 'O'), ('were', 'O'), ('measured', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('AAP', 'O'), (',', 'O'), ('and', 'O'), ('unlike', 'O'), ('the', 'O'), ('exacerbation', 'O'), ('caused', 'O'), ('by', 'O'), ('ethanol', 'O'), ('in', 'O'), ('mice', 'O'), ('on', 'O'), ('a', 'O'), ('standard', 'O'), ('diet', 'O'), (',', 'O'), ('the', 'O'), ('liver', 'B'), ('damage', 'O'), ('was', 'O'), ('inhibited', 'O'), ('by', 'O'), ('50', 'O'), ('%', 'O'), ('by', 'O'), ('ethanol', 'O'), ('.', 'O'))"
"A further 64 % reduction of hepatitis was observed , when NAA was given to ethanol / AAP - mice .","(('A', 'O'), ('further', 'O'), ('64', 'O'), ('%', 'O'), ('reduction', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('was', 'O'), ('observed', 'O'), (',', 'O'), ('when', 'O'), ('NAA', 'O'), ('was', 'O'), ('given', 'O'), ('to', 'O'), ('ethanol', 'O'), ('/', 'O'), ('AAP', 'O'), ('-', 'O'), ('mice', 'O'), ('.', 'O'))"
Our results provide evidence that the AAP - induced hepatitis and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme ' s substrate NAD .,"(('Our', 'O'), ('results', 'O'), ('provide', 'O'), ('evidence', 'O'), ('that', 'O'), ('the', 'O'), ('AAP', 'B'), ('-', 'O'), ('induced', 'O'), ('hepatitis', 'B'), ('and', 'O'), ('its', 'O'), ('exacerbation', 'O'), ('by', 'O'), ('ethanol', 'O'), ('can', 'O'), ('either', 'O'), ('be', 'O'), ('reduced', 'O'), ('by', 'O'), ('end', 'O'), ('-', 'O'), ('product', 'O'), ('inhibition', 'O'), ('of', 'O'), ('PARP', 'O'), ('by', 'O'), ('NAA', 'O'), ('or', 'O'), ('by', 'O'), ('dietary', 'O'), ('depletion', 'O'), ('of', 'O'), ('the', 'O'), ('enzyme', 'O'), (""'"", 'O'), ('s', 'O'), ('substrate', 'O'), ('NAD', 'O'), ('.', 'O'))"
We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic .,"(('We', 'O'), ('see', 'O'), ('the', 'O'), ('main', 'O'), ('application', 'O'), ('of', 'O'), ('NAA', 'O'), ('as', 'O'), ('for', 'O'), ('the', 'O'), ('combinational', 'O'), ('use', 'O'), ('in', 'O'), ('pharmaceutical', 'O'), ('preparations', 'O'), ('of', 'O'), ('acetaminophen', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('avoid', 'O'), ('hepatic', 'B'), ('damage', 'I'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('this', 'O'), ('widely', 'O'), ('used', 'O'), ('analgesic', 'O'), ('.', 'O'))"
Effect of calcium chloride and 4 - aminopyridine therapy on desipramine toxicity in rats .,"(('Effect', 'O'), ('of', 'O'), ('calcium', 'O'), ('chloride', 'O'), ('and', 'O'), ('4', 'O'), ('-', 'O'), ('aminopyridine', 'O'), ('therapy', 'O'), ('on', 'O'), ('desipramine', 'B'), ('toxicity', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues .,"(('Recent', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('tricyclic', 'O'), ('antidepressants', 'O'), ('inhibit', 'O'), ('calcium', 'O'), ('influx', 'O'), ('in', 'O'), ('some', 'O'), ('tissues', 'O'), ('.', 'O'))"
This study addressed the potential role of calcium channel blockade in tricyclic antidepressant - induced hypotension .,"(('This', 'O'), ('study', 'O'), ('addressed', 'O'), ('the', 'O'), ('potential', 'O'), ('role', 'O'), ('of', 'O'), ('calcium', 'O'), ('channel', 'O'), ('blockade', 'O'), ('in', 'O'), ('tricyclic', 'O'), ('antidepressant', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('.', 'O'))"
CaCl2 and 4 - aminopyridine .,"(('CaCl2', 'O'), ('and', 'O'), ('4', 'O'), ('-', 'O'), ('aminopyridine', 'O'), ('.', 'O'))"
"Fifteen min later , animals received CaCl2 , NaHCO3 , or saline .","(('Fifteen', 'O'), ('min', 'O'), ('later', 'O'), (',', 'O'), ('animals', 'O'), ('received', 'O'), ('CaCl2', 'O'), (',', 'O'), ('NaHCO3', 'O'), (',', 'O'), ('or', 'O'), ('saline', 'O'), ('.', 'O'))"
"In a second experiment , rats received tricyclic antidepressant desipramine IP followed in 15 min by 4 - aminopyridine or saline .","(('In', 'O'), ('a', 'O'), ('second', 'O'), ('experiment', 'O'), (',', 'O'), ('rats', 'O'), ('received', 'O'), ('tricyclic', 'O'), ('antidepressant', 'O'), ('desipramine', 'O'), ('IP', 'O'), ('followed', 'O'), ('in', 'O'), ('15', 'O'), ('min', 'O'), ('by', 'O'), ('4', 'O'), ('-', 'O'), ('aminopyridine', 'O'), ('or', 'O'), ('saline', 'O'), ('.', 'O'))"
RESULTS : NaHCO3 briefly ( 5 min ) reversed hypotension and QRS prolongation .,"(('RESULTS', 'O'), (':', 'O'), ('NaHCO3', 'O'), ('briefly', 'O'), ('(', 'O'), ('5', 'O'), ('min', 'O'), (')', 'O'), ('reversed', 'O'), ('hypotension', 'B'), ('and', 'O'), ('QRS', 'O'), ('prolongation', 'O'), ('.', 'O'))"
CaCl2 and 4 - aminopyridine failed to improve blood pressure .,"(('CaCl2', 'O'), ('and', 'O'), ('4', 'O'), ('-', 'O'), ('aminopyridine', 'O'), ('failed', 'O'), ('to', 'O'), ('improve', 'O'), ('blood', 'O'), ('pressure', 'O'), ('.', 'O'))"
CONCLUSION : The administration of CaCl2 or 4 - aminopyridine did not reverse tricyclic antidepressant - induced hypotension in rats .,"(('CONCLUSION', 'O'), (':', 'O'), ('The', 'O'), ('administration', 'O'), ('of', 'O'), ('CaCl2', 'O'), ('or', 'O'), ('4', 'O'), ('-', 'O'), ('aminopyridine', 'O'), ('did', 'O'), ('not', 'O'), ('reverse', 'O'), ('tricyclic', 'O'), ('antidepressant', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity .,"(('CaCl2', 'O'), ('therapy', 'O'), ('may', 'O'), ('possibly', 'O'), ('worsen', 'O'), ('both', 'O'), ('cardiovascular', 'B'), ('and', 'I'), ('central', 'I'), ('nervous', 'I'), ('system', 'I'), ('toxicity', 'I'), ('.', 'O'))"
These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant - induced hypotension .,"(('These', 'O'), ('findings', 'O'), ('do', 'O'), ('not', 'O'), ('support', 'O'), ('a', 'O'), ('role', 'O'), ('for', 'O'), ('calcium', 'O'), ('channel', 'O'), ('inhibition', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('tricyclic', 'B'), ('antidepressant', 'I'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"OBJECTIVE : To compare the antihypertensive efficacy of a new angiotensin II antagonist , valsartan , with a reference therapy , amlodipine .","(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('compare', 'O'), ('the', 'O'), ('antihypertensive', 'O'), ('efficacy', 'O'), ('of', 'O'), ('a', 'O'), ('new', 'O'), ('angiotensin', 'O'), ('II', 'O'), ('antagonist', 'O'), (',', 'O'), ('valsartan', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('reference', 'O'), ('therapy', 'O'), (',', 'O'), ('amlodipine', 'O'), ('.', 'O'))"
"After 8 weeks of therapy , in patients whose blood pressure remained uncontrolled , 5 mg amlodipine was added to the initial therapy .","(('After', 'O'), ('8', 'O'), ('weeks', 'O'), ('of', 'O'), ('therapy', 'O'), (',', 'O'), ('in', 'O'), ('patients', 'O'), ('whose', 'O'), ('blood', 'O'), ('pressure', 'O'), ('remained', 'O'), ('uncontrolled', 'O'), (',', 'O'), ('5', 'O'), ('mg', 'O'), ('amlodipine', 'O'), ('was', 'O'), ('added', 'O'), ('to', 'O'), ('the', 'O'), ('initial', 'O'), ('therapy', 'O'), ('.', 'O'))"
"Patients were assessed at 4 , 8 , and 12 weeks .","(('Patients', 'O'), ('were', 'O'), ('assessed', 'O'), ('at', 'O'), ('4', 'O'), (',', 'O'), ('8', 'O'), (',', 'O'), ('and', 'O'), ('12', 'O'), ('weeks', 'O'), ('.', 'O'))"
The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks .,"(('The', 'O'), ('primary', 'O'), ('efficacy', 'O'), ('variable', 'O'), ('was', 'O'), ('change', 'O'), ('from', 'O'), ('baseline', 'O'), ('in', 'O'), ('mean', 'O'), ('sitting', 'O'), ('diastolic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('at', 'O'), ('8', 'O'), ('weeks', 'O'), ('.', 'O'))"
Secondary variables included change in sitting systolic blood pressure and responder rates .,"(('Secondary', 'O'), ('variables', 'O'), ('included', 'O'), ('change', 'O'), ('in', 'O'), ('sitting', 'O'), ('systolic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('responder', 'O'), ('rates', 'O'), ('.', 'O'))"
"RESULTS : Both valsartan and amlodipine were effective at lowering blood pressure at 4 , 8 , and 12 weeks .","(('RESULTS', 'O'), (':', 'O'), ('Both', 'O'), ('valsartan', 'O'), ('and', 'O'), ('amlodipine', 'O'), ('were', 'O'), ('effective', 'O'), ('at', 'O'), ('lowering', 'O'), ('blood', 'O'), ('pressure', 'O'), ('at', 'O'), ('4', 'O'), (',', 'O'), ('8', 'O'), (',', 'O'), ('and', 'O'), ('12', 'O'), ('weeks', 'O'), ('.', 'O'))"
"Similar decreases were observed in both groups , with no statistically significant differences between the groups for any variable analyzed .","(('Similar', 'O'), ('decreases', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), (',', 'O'), ('with', 'O'), ('no', 'O'), ('statistically', 'O'), ('significant', 'O'), ('differences', 'O'), ('between', 'O'), ('the', 'O'), ('groups', 'O'), ('for', 'O'), ('any', 'O'), ('variable', 'O'), ('analyzed', 'O'), ('.', 'O'))"
"For the primary variable the difference was 0 . 5 mm Hg in favor of valsartan ( p = 0 . 68 ; 95 % confidence interval , - 2 . 7 to 1 . 7 ) .","(('For', 'O'), ('the', 'O'), ('primary', 'O'), ('variable', 'O'), ('the', 'O'), ('difference', 'O'), ('was', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mm', 'O'), ('Hg', 'O'), ('in', 'O'), ('favor', 'O'), ('of', 'O'), ('valsartan', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('68', 'O'), (';', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('7', 'O'), ('to', 'O'), ('1', 'O'), ('.', 'O'), ('7', 'O'), (')', 'O'), ('.', 'O'))"
Responder rates at 8 weeks were 66 . 7 % for valsartan and 60 . 2 % for amlodipine ( p = 0 . 39 ) .,"(('Responder', 'O'), ('rates', 'O'), ('at', 'O'), ('8', 'O'), ('weeks', 'O'), ('were', 'O'), ('66', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), ('for', 'O'), ('valsartan', 'O'), ('and', 'O'), ('60', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('for', 'O'), ('amlodipine', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('39', 'O'), (')', 'O'), ('.', 'O'))"
Both treatments were well tolerated .,"(('Both', 'O'), ('treatments', 'O'), ('were', 'O'), ('well', 'O'), ('tolerated', 'O'), ('.', 'O'))"
"The incidence of drug - related dependent edema was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .","(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('drug', 'O'), ('-', 'O'), ('related', 'O'), ('dependent', 'B'), ('edema', 'I'), ('was', 'O'), ('somewhat', 'O'), ('higher', 'O'), ('in', 'O'), ('the', 'O'), ('amlodipine', 'O'), ('group', 'O'), (',', 'O'), ('particularly', 'O'), ('at', 'O'), ('a', 'O'), ('dose', 'O'), ('of', 'O'), ('10', 'O'), ('mg', 'O'), ('per', 'O'), ('day', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('for', 'O'), ('80', 'O'), ('mg', 'O'), ('valsartan', 'O'), (';', 'O'), ('3', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('for', 'O'), ('5', 'O'), ('mg', 'O'), ('amlodipine', 'O'), (';', 'O'), ('0', 'O'), ('%', 'O'), ('for', 'O'), ('valsartan', 'O'), ('plus', 'O'), ('5', 'O'), ('mg', 'O'), ('amlodipine', 'O'), (';', 'O'), ('14', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('for', 'O'), ('10', 'O'), ('mg', 'O'), ('amlodipine', 'O'), (')', 'O'), ('.', 'O'))"
"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class , dihydropyridine calcium antagonists .","(('The', 'O'), ('results', 'O'), ('also', 'O'), ('show', 'O'), ('valsartan', 'O'), ('to', 'O'), ('be', 'O'), ('well', 'O'), ('tolerated', 'O'), ('and', 'O'), ('suggest', 'O'), ('that', 'O'), ('it', 'O'), ('is', 'O'), ('not', 'O'), ('associated', 'O'), ('with', 'O'), ('side', 'O'), ('effects', 'O'), ('characteristic', 'O'), ('of', 'O'), ('this', 'O'), ('comparator', 'O'), ('class', 'O'), (',', 'O'), ('dihydropyridine', 'O'), ('calcium', 'O'), ('antagonists', 'O'), ('.', 'O'))"
The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor ( MAOI ) and a specific serotonin reuptake inhibitor .,"(('The', 'O'), ('most', 'O'), ('common', 'O'), ('cause', 'O'), ('of', 'O'), ('this', 'O'), ('syndrome', 'O'), ('is', 'O'), ('an', 'O'), ('interaction', 'O'), ('between', 'O'), ('a', 'O'), ('monoamine', 'O'), ('oxidase', 'O'), ('inhibitor', 'O'), ('(', 'O'), ('MAOI', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('specific', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('inhibitor', 'O'), ('.', 'O'))"
Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine .,"(('Venlafaxine', 'O'), ('is', 'O'), ('a', 'O'), ('new', 'O'), ('antidepressant', 'O'), ('agent', 'O'), ('that', 'O'), ('inhibits', 'O'), ('the', 'O'), ('reuptake', 'O'), ('of', 'O'), ('serotonin', 'O'), ('and', 'O'), ('norepinephrine', 'O'), ('.', 'O'))"
He had been well until the morning of presentation when he took 1 / 2 tab of venlafaxine .,"(('He', 'O'), ('had', 'O'), ('been', 'O'), ('well', 'O'), ('until', 'O'), ('the', 'O'), ('morning', 'O'), ('of', 'O'), ('presentation', 'O'), ('when', 'O'), ('he', 'O'), ('took', 'O'), ('1', 'O'), ('/', 'O'), ('2', 'O'), ('tab', 'O'), ('of', 'O'), ('venlafaxine', 'O'), ('.', 'O'))"
His pupils were 7 mm and sluggishly reactive to light .,"(('His', 'O'), ('pupils', 'O'), ('were', 'O'), ('7', 'O'), ('mm', 'O'), ('and', 'O'), ('sluggishly', 'O'), ('reactive', 'O'), ('to', 'O'), ('light', 'O'), ('.', 'O'))"
"Vital signs were : blood pressure 120 / 67 mm Hg , heart rate 127 / min , respiratory rate 28 / min , and temperature 97 F .","(('Vital', 'O'), ('signs', 'O'), ('were', 'O'), (':', 'O'), ('blood', 'O'), ('pressure', 'O'), ('120', 'O'), ('/', 'O'), ('67', 'O'), ('mm', 'O'), ('Hg', 'O'), (',', 'O'), ('heart', 'O'), ('rate', 'O'), ('127', 'O'), ('/', 'O'), ('min', 'O'), (',', 'O'), ('respiratory', 'O'), ('rate', 'O'), ('28', 'O'), ('/', 'O'), ('min', 'O'), (',', 'O'), ('and', 'O'), ('temperature', 'O'), ('97', 'O'), ('F', 'O'), ('.', 'O'))"
His subsequent course was remarkable for non - immune thrombocytopenia which resolved .,"(('His', 'O'), ('subsequent', 'O'), ('course', 'O'), ('was', 'O'), ('remarkable', 'O'), ('for', 'O'), ('non', 'B'), ('-', 'I'), ('immune', 'I'), ('thrombocytopenia', 'I'), ('which', 'O'), ('resolved', 'O'), ('.', 'O'))"
His mental status normalized and he was transferred to a psychiatry ward .,"(('His', 'O'), ('mental', 'O'), ('status', 'O'), ('normalized', 'O'), ('and', 'O'), ('he', 'O'), ('was', 'O'), ('transferred', 'O'), ('to', 'O'), ('a', 'O'), ('psychiatry', 'O'), ('ward', 'O'), ('.', 'O'))"
Cyclophosphamide associated bladder cancer - - a highly aggressive disease : analysis of 12 cases .,"(('Cyclophosphamide', 'B'), ('associated', 'I'), ('bladder', 'B'), ('cancer', 'I'), ('-', 'O'), ('-', 'O'), ('a', 'O'), ('highly', 'O'), ('aggressive', 'O'), ('disease', 'O'), (':', 'O'), ('analysis', 'O'), ('of', 'O'), ('12', 'O'), ('cases', 'O'), ('.', 'O'))"
MATERIALS AND METHODS : The medical records of 6 men and 6 women ( mean age 55 years ) with cyclophosphamide associated bladder cancer were reviewed .,"(('MATERIALS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('The', 'O'), ('medical', 'O'), ('records', 'O'), ('of', 'O'), ('6', 'O'), ('men', 'O'), ('and', 'O'), ('6', 'O'), ('women', 'O'), ('(', 'O'), ('mean', 'O'), ('age', 'O'), ('55', 'O'), ('years', 'O'), (')', 'O'), ('with', 'O'), ('cyclophosphamide', 'B'), ('associated', 'O'), ('bladder', 'B'), ('cancer', 'I'), ('were', 'O'), ('reviewed', 'O'), ('.', 'O'))"
RESULTS : All tumors were grade 3 or 4 transitional cell carcinoma .,"(('RESULTS', 'O'), (':', 'O'), ('All', 'O'), ('tumors', 'B'), ('were', 'O'), ('grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('transitional', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('.', 'O'))"
Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease .,"(('Of', 'O'), ('the', 'O'), ('5', 'O'), ('patients', 'O'), ('initially', 'O'), ('treated', 'O'), ('with', 'O'), ('endoscopic', 'O'), ('resection', 'O'), ('alone', 'O'), ('only', 'O'), ('1', 'O'), ('is', 'O'), ('alive', 'O'), ('without', 'O'), ('disease', 'O'), ('.', 'O'))"
Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months .,"(('Of', 'O'), ('the', 'O'), ('6', 'O'), ('patients', 'O'), ('who', 'O'), ('underwent', 'O'), ('early', 'O'), ('cystectomy', 'O'), ('4', 'O'), ('were', 'O'), ('alive', 'O'), ('at', 'O'), ('24', 'O'), ('to', 'O'), ('111', 'O'), ('months', 'O'), ('.', 'O'))"
The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later .,"(('The', 'O'), ('remaining', 'O'), ('patient', 'O'), ('with', 'O'), ('extensive', 'B'), ('cancer', 'B'), ('underwent', 'O'), ('partial', 'O'), ('cystectomy', 'O'), ('for', 'O'), ('palliation', 'O'), ('and', 'O'), ('died', 'O'), ('3', 'O'), ('months', 'O'), ('later', 'O'), ('.', 'O'))"
CONCLUSIONS : Cyclophosphamide associated bladder tumor is an aggressive disease .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Cyclophosphamide', 'B'), ('associated', 'I'), ('bladder', 'B'), ('tumor', 'I'), ('is', 'O'), ('an', 'O'), ('aggressive', 'O'), ('disease', 'O'), ('.', 'O'))"
"However , long - term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease , even when noninvasive .","(('However', 'O'), (',', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('survival', 'O'), ('is', 'O'), ('possible', 'O'), ('when', 'O'), ('radical', 'O'), ('cystectomy', 'O'), ('is', 'O'), ('performed', 'O'), ('for', 'O'), ('bladder', 'B'), ('tumors', 'I'), ('with', 'O'), ('any', 'O'), ('sign', 'O'), ('of', 'O'), ('invasion', 'O'), ('and', 'O'), ('for', 'O'), ('recurrent', 'O'), ('high', 'O'), ('grade', 'O'), ('disease', 'O'), (',', 'O'), ('even', 'O'), ('when', 'O'), ('noninvasive', 'O'), ('.', 'O'))"
A phase I clinical study of the antipurine antifolate lometrexol ( DDATHF ) given with oral folic acid .,"(('A', 'O'), ('phase', 'O'), ('I', 'O'), ('clinical', 'O'), ('study', 'O'), ('of', 'O'), ('the', 'O'), ('antipurine', 'O'), ('antifolate', 'O'), ('lometrexol', 'O'), ('(', 'O'), ('DDATHF', 'O'), (')', 'O'), ('given', 'O'), ('with', 'O'), ('oral', 'O'), ('folic', 'O'), ('acid', 'O'), ('.', 'O'))"
"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase ( GARFT ) , an enzyme essential for de novo purine synthesis .","(('Lometrexol', 'O'), ('is', 'O'), ('an', 'O'), ('antifolate', 'O'), ('which', 'O'), ('inhibits', 'O'), ('glycinamide', 'O'), ('ribonucleotide', 'O'), ('formyltransferase', 'O'), ('(', 'O'), ('GARFT', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('enzyme', 'O'), ('essential', 'O'), ('for', 'O'), ('de', 'O'), ('novo', 'O'), ('purine', 'O'), ('synthesis', 'O'), ('.', 'O'))"
"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs , notably methotrexate .","(('Extensive', 'O'), ('experimental', 'O'), ('and', 'O'), ('limited', 'O'), ('clinical', 'O'), ('data', 'O'), ('have', 'O'), ('shown', 'O'), ('that', 'O'), ('lometrexol', 'O'), ('has', 'O'), ('activity', 'O'), ('against', 'O'), ('tumours', 'B'), ('which', 'O'), ('are', 'O'), ('refractory', 'O'), ('to', 'O'), ('other', 'O'), ('drugs', 'O'), (',', 'O'), ('notably', 'O'), ('methotrexate', 'O'), ('.', 'O'))"
"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration , i . e . for 7 days prior to and 7 days following a single bolus dose .","(('Preclinical', 'O'), ('murine', 'O'), ('studies', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('the', 'O'), ('toxicity', 'O'), ('of', 'O'), ('lometrexol', 'O'), ('can', 'O'), ('be', 'O'), ('prevented', 'O'), ('by', 'O'), ('low', 'O'), ('dose', 'O'), ('folic', 'O'), ('acid', 'O'), ('administration', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('e', 'O'), ('.', 'O'), ('for', 'O'), ('7', 'O'), ('days', 'O'), ('prior', 'O'), ('to', 'O'), ('and', 'O'), ('7', 'O'), ('days', 'O'), ('following', 'O'), ('a', 'O'), ('single', 'O'), ('bolus', 'O'), ('dose', 'O'), ('.', 'O'))"
This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation .,"(('This', 'O'), ('observation', 'O'), ('prompted', 'O'), ('a', 'O'), ('Phase', 'O'), ('I', 'O'), ('clinical', 'O'), ('study', 'O'), ('of', 'O'), ('lometrexol', 'O'), ('given', 'O'), ('with', 'O'), ('folic', 'O'), ('acid', 'O'), ('supplementation', 'O'), ('which', 'O'), ('has', 'O'), ('confirmed', 'O'), ('that', 'O'), ('the', 'O'), ('toxicity', 'O'), ('of', 'O'), ('lometrexol', 'O'), ('can', 'O'), ('be', 'O'), ('markedly', 'O'), ('reduced', 'O'), ('by', 'O'), ('folic', 'O'), ('acid', 'O'), ('supplementation', 'O'), ('.', 'O'))"
There was no clear relationship between clinical toxicity and the extent of plasma folate elevation .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('clear', 'O'), ('relationship', 'O'), ('between', 'O'), ('clinical', 'O'), ('toxicity', 'O'), ('and', 'O'), ('the', 'O'), ('extent', 'O'), ('of', 'O'), ('plasma', 'O'), ('folate', 'O'), ('elevation', 'O'), ('.', 'O'))"
Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance .,"(('Associated', 'O'), ('studies', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('lometrexol', 'O'), ('plasma', 'O'), ('pharmacokinetics', 'O'), ('were', 'O'), ('not', 'O'), ('altered', 'O'), ('by', 'O'), ('folic', 'O'), ('acid', 'O'), ('administration', 'O'), ('indicating', 'O'), ('that', 'O'), ('supplementation', 'O'), ('is', 'O'), ('unlikely', 'O'), ('to', 'O'), ('reduce', 'O'), ('toxicity', 'O'), ('by', 'O'), ('enhancing', 'O'), ('lometrexol', 'O'), ('plasma', 'O'), ('clearance', 'O'), ('.', 'O'))"
The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor .,"(('The', 'O'), ('work', 'O'), ('described', 'O'), ('in', 'O'), ('this', 'O'), ('report', 'O'), ('has', 'O'), ('identified', 'O'), ('for', 'O'), ('the', 'O'), ('first', 'O'), ('time', 'O'), ('a', 'O'), ('clinically', 'O'), ('acceptable', 'O'), ('schedule', 'O'), ('for', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('a', 'O'), ('GARFT', 'O'), ('inhibitor', 'O'), ('.', 'O'))"
This information will facilitate the future evaluation of this class of compounds in cancer therapy .,"(('This', 'O'), ('information', 'O'), ('will', 'O'), ('facilitate', 'O'), ('the', 'O'), ('future', 'O'), ('evaluation', 'O'), ('of', 'O'), ('this', 'O'), ('class', 'O'), ('of', 'O'), ('compounds', 'O'), ('in', 'O'), ('cancer', 'B'), ('therapy', 'O'), ('.', 'O'))"
Pemoline induced acute choreoathetosis : case report and review of the literature .,"(('Pemoline', 'O'), ('induced', 'O'), ('acute', 'O'), ('choreoathetosis', 'B'), (':', 'O'), ('case', 'O'), ('report', 'O'), ('and', 'O'), ('review', 'O'), ('of', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
Pemoline has not been commonly associated in the literature as a cause of acute movement disorders .,"(('Pemoline', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('commonly', 'O'), ('associated', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('as', 'O'), ('a', 'O'), ('cause', 'O'), ('of', 'O'), ('acute', 'O'), ('movement', 'B'), ('disorders', 'I'), ('.', 'O'))"
The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis .,"(('The', 'O'), ('following', 'O'), ('case', 'O'), ('describes', 'O'), ('two', 'O'), ('children', 'O'), ('acutely', 'O'), ('poisoned', 'O'), ('with', 'O'), ('pemoline', 'O'), ('who', 'O'), ('experienced', 'O'), ('profound', 'O'), ('choreoathetosis', 'B'), ('.', 'O'))"
"CASE REPORT : Two , 3 - year - old male , identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets .","(('CASE', 'O'), ('REPORT', 'O'), (':', 'O'), ('Two', 'O'), (',', 'O'), ('3', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('male', 'O'), (',', 'O'), ('identical', 'O'), ('twin', 'O'), ('siblings', 'O'), ('presented', 'O'), ('to', 'O'), ('the', 'O'), ('emergency', 'O'), ('department', 'O'), ('after', 'O'), ('found', 'O'), ('playing', 'O'), ('with', 'O'), ('a', 'O'), ('an', 'O'), ('empty', 'O'), ('bottle', 'O'), ('of', 'O'), ('pemoline', 'O'), ('originally', 'O'), ('containing', 'O'), ('59', 'O'), ('tablets', 'O'), ('.', 'O'))"
This was their first day of pemoline therapy .,"(('This', 'O'), ('was', 'O'), ('their', 'O'), ('first', 'O'), ('day', 'O'), ('of', 'O'), ('pemoline', 'O'), ('therapy', 'O'), ('.', 'O'))"
The children gave no history of prior movement disorders and there was no family history of movement disorders .,"(('The', 'O'), ('children', 'O'), ('gave', 'O'), ('no', 'O'), ('history', 'O'), ('of', 'O'), ('prior', 'O'), ('movement', 'B'), ('disorders', 'I'), ('and', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('family', 'O'), ('history', 'O'), ('of', 'O'), ('movement', 'B'), ('disorders', 'I'), ('.', 'O'))"
"Despite treatment , the children continued to have choreoathetosis for approximately 24 hours .","(('Despite', 'O'), ('treatment', 'O'), (',', 'O'), ('the', 'O'), ('children', 'O'), ('continued', 'O'), ('to', 'O'), ('have', 'O'), ('choreoathetosis', 'B'), ('for', 'O'), ('approximately', 'O'), ('24', 'O'), ('hours', 'O'), ('.', 'O'))"
"Forty - eight hours after admission , the children appeared to be at their baseline and were discharged home .","(('Forty', 'O'), ('-', 'O'), ('eight', 'O'), ('hours', 'O'), ('after', 'O'), ('admission', 'O'), (',', 'O'), ('the', 'O'), ('children', 'O'), ('appeared', 'O'), ('to', 'O'), ('be', 'O'), ('at', 'O'), ('their', 'O'), ('baseline', 'O'), ('and', 'O'), ('were', 'O'), ('discharged', 'O'), ('home', 'O'), ('.', 'O'))"
CONCLUSION : Pemoline associated movement disorder has been rarely reported in the acute toxicology literature .,"(('CONCLUSION', 'O'), (':', 'O'), ('Pemoline', 'O'), ('associated', 'O'), ('movement', 'B'), ('disorder', 'I'), ('has', 'O'), ('been', 'O'), ('rarely', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('acute', 'O'), ('toxicology', 'O'), ('literature', 'O'), ('.', 'O'))"
Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve .,"(('Effect', 'O'), ('of', 'O'), ('myopic', 'B'), ('excimer', 'O'), ('laser', 'O'), ('photorefractive', 'O'), ('keratectomy', 'I'), ('on', 'O'), ('the', 'O'), ('electrophysiologic', 'O'), ('function', 'O'), ('of', 'O'), ('the', 'O'), ('retina', 'O'), ('and', 'O'), ('optic', 'O'), ('nerve', 'O'), ('.', 'O'))"
PURPOSE : To assess by electrophysiologic testing the effect of photorefractive keratectomy ( PRK ) on the retina and optic nerve .,"(('PURPOSE', 'O'), (':', 'O'), ('To', 'O'), ('assess', 'O'), ('by', 'O'), ('electrophysiologic', 'O'), ('testing', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('photorefractive', 'O'), ('keratectomy', 'I'), ('(', 'O'), ('PRK', 'O'), (')', 'O'), ('on', 'O'), ('the', 'O'), ('retina', 'O'), ('and', 'O'), ('optic', 'O'), ('nerve', 'O'), ('.', 'O'))"
"SETTING : Eye Clinic , S .","(('SETTING', 'O'), (':', 'O'), ('Eye', 'O'), ('Clinic', 'O'), (',', 'O'), ('S', 'O'), ('.', 'O'))"
"Salvatore Hospital , L ' Aquila University , Italy .","(('Salvatore', 'O'), ('Hospital', 'O'), (',', 'O'), ('L', 'O'), (""'"", 'O'), ('Aquila', 'O'), ('University', 'O'), (',', 'O'), ('Italy', 'O'), ('.', 'O'))"
METHODS : Standard pattern electroretinograms ( P - ERGs ) and standard pattern visual evoked potentials ( P - VEPs ) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5 . 00 and 15 . 00 diopters ( D ) ( mean 8 . 00 D ) .,"(('METHODS', 'O'), (':', 'O'), ('Standard', 'O'), ('pattern', 'O'), ('electroretinograms', 'O'), ('(', 'O'), ('P', 'O'), ('-', 'O'), ('ERGs', 'O'), (')', 'O'), ('and', 'O'), ('standard', 'O'), ('pattern', 'O'), ('visual', 'O'), ('evoked', 'O'), ('potentials', 'O'), ('(', 'O'), ('P', 'O'), ('-', 'O'), ('VEPs', 'O'), (')', 'O'), ('were', 'O'), ('done', 'O'), ('in', 'O'), ('25', 'O'), ('eyes', 'O'), ('of', 'O'), ('25', 'O'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('myopic', 'B'), ('PRK', 'I'), ('for', 'O'), ('an', 'O'), ('attempted', 'O'), ('correction', 'O'), ('between', 'O'), ('5', 'O'), ('.', 'O'), ('00', 'O'), ('and', 'O'), ('15', 'O'), ('.', 'O'), ('00', 'O'), ('diopters', 'O'), ('(', 'O'), ('D', 'O'), (')', 'O'), ('(', 'O'), ('mean', 'O'), ('8', 'O'), ('.', 'O'), ('00', 'O'), ('D', 'O'), (')', 'O'), ('.', 'O'))"
"Testing was done preoperatively and 3 , 6 , 12 , and 18 months postoperatively .","(('Testing', 'O'), ('was', 'O'), ('done', 'O'), ('preoperatively', 'O'), ('and', 'O'), ('3', 'O'), (',', 'O'), ('6', 'O'), (',', 'O'), ('12', 'O'), (',', 'O'), ('and', 'O'), ('18', 'O'), ('months', 'O'), ('postoperatively', 'O'), ('.', 'O'))"
The contralateral eyes served as controls .,"(('The', 'O'), ('contralateral', 'O'), ('eyes', 'O'), ('served', 'O'), ('as', 'O'), ('controls', 'O'), ('.', 'O'))"
RESULTS : No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively .,"(('RESULTS', 'O'), (':', 'O'), ('No', 'O'), ('statistically', 'O'), ('significant', 'O'), ('differences', 'O'), ('were', 'O'), ('seen', 'O'), ('between', 'O'), ('treated', 'O'), ('and', 'O'), ('control', 'O'), ('eyes', 'O'), ('nor', 'O'), ('between', 'O'), ('treated', 'O'), ('eyes', 'O'), ('preoperatively', 'O'), ('and', 'O'), ('postoperatively', 'O'), ('.', 'O'))"
CONCLUSION : Myopic excimer laser PRK did not seem to affect the posterior segment .,"(('CONCLUSION', 'O'), (':', 'O'), ('Myopic', 'B'), ('excimer', 'O'), ('laser', 'O'), ('PRK', 'O'), ('did', 'O'), ('not', 'O'), ('seem', 'O'), ('to', 'O'), ('affect', 'O'), ('the', 'O'), ('posterior', 'O'), ('segment', 'O'), ('.', 'O'))"
Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure .,"(('Neutrophil', 'O'), ('superoxide', 'O'), ('and', 'O'), ('hydrogen', 'O'), ('peroxide', 'O'), ('production', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('.', 'O'))"
This defect persisted when zymosan opsonized by control serum was used ( P < 0 . 05 ) .,"(('This', 'O'), ('defect', 'O'), ('persisted', 'O'), ('when', 'O'), ('zymosan', 'O'), ('opsonized', 'O'), ('by', 'O'), ('control', 'O'), ('serum', 'O'), ('was', 'O'), ('used', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen , adriamycin , carbon tetrachloride , chloroform and galactosamine .","(('Cholesteryl', 'O'), ('hemisuccinate', 'O'), ('treatment', 'O'), ('protects', 'O'), ('rodents', 'O'), ('from', 'O'), ('the', 'O'), ('toxic', 'O'), ('effects', 'O'), ('of', 'O'), ('acetaminophen', 'O'), (',', 'O'), ('adriamycin', 'O'), (',', 'O'), ('carbon', 'O'), ('tetrachloride', 'O'), (',', 'O'), ('chloroform', 'O'), ('and', 'O'), ('galactosamine', 'O'), ('.', 'O'))"
"To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced toxicity .","(('To', 'O'), ('further', 'O'), ('our', 'O'), ('understanding', 'O'), ('of', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('CS', 'O'), ('cytoprotection', 'O'), (',', 'O'), ('we', 'O'), ('examined', 'O'), ('in', 'O'), ('rats', 'O'), ('and', 'O'), ('mice', 'O'), ('the', 'O'), ('protective', 'O'), ('abilities', 'O'), ('of', 'O'), ('CS', 'O'), ('and', 'O'), ('the', 'O'), ('non', 'O'), ('-', 'O'), ('hydrolyzable', 'O'), ('ether', 'O'), ('form', 'O'), ('of', 'O'), ('CS', 'O'), (',', 'O'), ('gamma', 'O'), ('-', 'O'), ('cholesteryloxybutyric', 'O'), ('acid', 'O'), (',', 'O'), ('tris', 'O'), ('salt', 'O'), ('(', 'O'), ('CSE', 'O'), (')', 'O'), ('against', 'O'), ('acetaminophen', 'O'), ('-', 'O'), (',', 'O'), ('adriamycin', 'O'), ('-', 'O'), (',', 'O'), ('carbon', 'O'), ('tetrachloride', 'O'), ('-', 'O'), (',', 'O'), ('chloroform', 'O'), ('-', 'O'), ('and', 'O'), ('galactosamine', 'O'), ('-', 'O'), ('induced', 'O'), ('toxicity', 'O'), ('.', 'O'))"
"The results of these studies demonstrated that CS - mediated protection is not selective for a particular species , organ system or toxic chemical .","(('The', 'O'), ('results', 'O'), ('of', 'O'), ('these', 'O'), ('studies', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('CS', 'O'), ('-', 'O'), ('mediated', 'O'), ('protection', 'O'), ('is', 'O'), ('not', 'O'), ('selective', 'O'), ('for', 'O'), ('a', 'O'), ('particular', 'O'), ('species', 'O'), (',', 'O'), ('organ', 'O'), ('system', 'O'), ('or', 'O'), ('toxic', 'O'), ('chemical', 'O'), ('.', 'O'))"
Maximal CS - mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult .,"(('Maximal', 'O'), ('CS', 'O'), ('-', 'O'), ('mediated', 'O'), ('protection', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('experimental', 'O'), ('animals', 'O'), ('pretreated', 'O'), ('24', 'O'), ('h', 'O'), ('prior', 'O'), ('to', 'O'), ('the', 'O'), ('toxic', 'O'), ('insult', 'O'), ('.', 'O'))"
These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death .,"(('These', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('CS', 'O'), ('intervenes', 'O'), ('in', 'O'), ('a', 'O'), ('critical', 'O'), ('cellular', 'O'), ('event', 'O'), ('that', 'O'), ('is', 'O'), ('an', 'O'), ('important', 'O'), ('common', 'O'), ('pathway', 'O'), ('to', 'O'), ('toxic', 'O'), ('cell', 'O'), ('death', 'O'), ('.', 'O'))"
"However , based on the data presented , we can not exclude the possibility that CS administration inhibits chemical bioactivation .","(('However', 'O'), (',', 'O'), ('based', 'O'), ('on', 'O'), ('the', 'O'), ('data', 'O'), ('presented', 'O'), (',', 'O'), ('we', 'O'), ('can', 'O'), ('not', 'O'), ('exclude', 'O'), ('the', 'O'), ('possibility', 'O'), ('that', 'O'), ('CS', 'O'), ('administration', 'O'), ('inhibits', 'O'), ('chemical', 'O'), ('bioactivation', 'O'), ('.', 'O'))"
"Our findings do suggest that CS - mediated protection is dependent on the action of the intact anionic CS molecule ( non - hydrolyzable CSE was as protective as CS ) , whose mechanism has yet to be defined .","(('Our', 'O'), ('findings', 'O'), ('do', 'O'), ('suggest', 'O'), ('that', 'O'), ('CS', 'O'), ('-', 'O'), ('mediated', 'O'), ('protection', 'O'), ('is', 'O'), ('dependent', 'O'), ('on', 'O'), ('the', 'O'), ('action', 'O'), ('of', 'O'), ('the', 'O'), ('intact', 'O'), ('anionic', 'O'), ('CS', 'O'), ('molecule', 'O'), ('(', 'O'), ('non', 'O'), ('-', 'O'), ('hydrolyzable', 'O'), ('CSE', 'O'), ('was', 'O'), ('as', 'O'), ('protective', 'O'), ('as', 'O'), ('CS', 'O'), (')', 'O'), (',', 'O'), ('whose', 'O'), ('mechanism', 'O'), ('has', 'O'), ('yet', 'O'), ('to', 'O'), ('be', 'O'), ('defined', 'O'), ('.', 'O'))"
The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls .,"(('The', 'O'), ('drug', 'O'), ('was', 'O'), ('given', 'O'), ('to', 'O'), ('two', 'O'), ('groups', 'O'), ('consisting', 'O'), ('of', 'O'), ('castrated', 'O'), ('and', 'O'), ('noncastrated', 'O'), ('rats', 'O'), ('and', 'O'), ('compared', 'O'), ('to', 'O'), ('two', 'O'), ('groups', 'O'), ('of', 'O'), ('castrated', 'O'), ('and', 'O'), ('noncastrated', 'O'), ('controls', 'O'), ('.', 'O'))"
Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days .,"(('Prolactin', 'O'), ('levels', 'O'), ('were', 'O'), ('measured', 'O'), ('and', 'O'), ('the', 'O'), ('uteri', 'O'), ('of', 'O'), ('the', 'O'), ('rats', 'O'), ('were', 'O'), ('removed', 'O'), ('for', 'O'), ('histopathological', 'O'), ('analysis', 'O'), ('at', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('98', 'O'), ('days', 'O'), ('.', 'O'))"
"SETTING : Marmara University School of Medicine , Department of Histology and Embryology , Zeynep Kamil Women and Children ' s Hospital .","(('SETTING', 'O'), (':', 'O'), ('Marmara', 'O'), ('University', 'O'), ('School', 'O'), ('of', 'O'), ('Medicine', 'O'), (',', 'O'), ('Department', 'O'), ('of', 'O'), ('Histology', 'O'), ('and', 'O'), ('Embryology', 'O'), (',', 'O'), ('Zeynep', 'O'), ('Kamil', 'O'), ('Women', 'O'), ('and', 'O'), ('Children', 'O'), (""'"", 'O'), ('s', 'O'), ('Hospital', 'O'), ('.', 'O'))"
"MAIN OUTCOME MEASURES : Serum prolactin levels , uterine histopathology .","(('MAIN', 'O'), ('OUTCOME', 'O'), ('MEASURES', 'O'), (':', 'O'), ('Serum', 'O'), ('prolactin', 'O'), ('levels', 'O'), (',', 'O'), ('uterine', 'O'), ('histopathology', 'O'), ('.', 'O'))"
RESULTS : The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups .,"(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('prolactin', 'O'), ('levels', 'O'), ('of', 'O'), ('castrated', 'O'), ('and', 'O'), ('noncastrated', 'O'), ('groups', 'O'), ('treated', 'O'), ('with', 'O'), ('fluoxetine', 'O'), ('were', 'O'), ('statistically', 'O'), ('significantly', 'O'), ('higher', 'O'), ('when', 'O'), ('compared', 'O'), ('to', 'O'), ('their', 'O'), ('respective', 'O'), ('control', 'O'), ('groups', 'O'), ('.', 'O'))"
CONCLUSION : It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma .,"(('CONCLUSION', 'O'), (':', 'O'), ('It', 'O'), ('was', 'O'), ('suggested', 'O'), ('that', 'O'), ('high', 'O'), ('serum', 'O'), ('prolactin', 'O'), ('levels', 'O'), ('cause', 'O'), ('degeneration', 'B'), ('of', 'I'), ('myometrial', 'I'), ('cells', 'I'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('ovarian', 'O'), ('steroids', 'O'), ('that', 'O'), ('results', 'O'), ('in', 'O'), ('a', 'O'), ('myometrial', 'O'), ('invasion', 'O'), ('by', 'O'), ('endometrial', 'O'), ('stroma', 'O'), ('.', 'O'))"
"Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced seizures in mice .","(('Several', 'O'), ('structurally', 'O'), ('related', 'O'), ('metabolites', 'O'), ('of', 'O'), ('progesterone', 'O'), ('(', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('pregnane', 'O'), ('-', 'O'), ('20', 'O'), ('-', 'O'), ('ones', 'O'), (')', 'O'), ('and', 'O'), ('deoxycorticosterone', 'O'), ('(', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('pregnane', 'O'), ('-', 'O'), ('21', 'O'), ('-', 'O'), ('diol', 'O'), ('-', 'O'), ('20', 'O'), ('-', 'O'), ('ones', 'O'), (')', 'O'), ('and', 'O'), ('their', 'O'), ('3', 'O'), ('beta', 'O'), ('-', 'O'), ('epimers', 'O'), ('were', 'O'), ('evaluated', 'O'), ('for', 'O'), ('protective', 'O'), ('activity', 'O'), ('against', 'O'), ('pilocarpine', 'O'), ('-', 'O'), (',', 'O'), ('kainic', 'O'), ('acid', 'O'), ('-', 'O'), ('and', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('aspartate', 'O'), ('(', 'O'), ('NMDA', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"The corresponding epimers with the 3 - hydroxy group in the beta - position were also effective but less potent ( ED50 values , 33 . 8 - 63 . 5 , i . p . ) .","(('The', 'O'), ('corresponding', 'O'), ('epimers', 'O'), ('with', 'O'), ('the', 'O'), ('3', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('group', 'O'), ('in', 'O'), ('the', 'O'), ('beta', 'O'), ('-', 'O'), ('position', 'O'), ('were', 'O'), ('also', 'O'), ('effective', 'O'), ('but', 'O'), ('less', 'O'), ('potent', 'O'), ('(', 'O'), ('ED50', 'O'), ('values', 'O'), (',', 'O'), ('33', 'O'), ('.', 'O'), ('8', 'O'), ('-', 'O'), ('63', 'O'), ('.', 'O'), ('5', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .","(('Although', 'O'), ('the', 'O'), ('neuroactive', 'O'), ('steroids', 'O'), ('were', 'O'), ('considerably', 'O'), ('less', 'O'), ('potent', 'O'), ('than', 'O'), ('the', 'O'), ('benzodiazepine', 'O'), ('clonazepam', 'O'), ('in', 'O'), ('protecting', 'O'), ('against', 'O'), ('pilocarpine', 'B'), ('seizures', 'O'), (',', 'O'), ('steroids', 'O'), ('with', 'O'), ('the', 'O'), ('5', 'O'), ('alpha', 'O'), (',', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('configuration', 'O'), ('had', 'O'), ('comparable', 'O'), ('or', 'O'), ('higher', 'O'), ('protective', 'O'), ('index', 'O'), ('values', 'O'), ('(', 'O'), ('TD50', 'O'), ('for', 'O'), ('motor', 'B'), ('impairment', 'I'), ('divided', 'O'), ('by', 'O'), ('ED50', 'O'), ('for', 'O'), ('seizure', 'B'), ('protection', 'O'), (')', 'O'), ('than', 'O'), ('clonazepam', 'O'), (',', 'O'), ('indicating', 'O'), ('that', 'O'), ('some', 'O'), ('neuroactive', 'O'), ('steroids', 'O'), ('may', 'O'), ('have', 'O'), ('lower', 'O'), ('relative', 'O'), ('toxicity', 'O'), ('.', 'O'))"
"Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .","(('Steroids', 'O'), ('with', 'O'), ('the', 'O'), ('5', 'O'), ('alpha', 'O'), (',', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('or', 'O'), ('5', 'O'), ('beta', 'O'), (',', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('configurations', 'O'), ('also', 'O'), ('produced', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('delay', 'O'), ('in', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('limbic', 'B'), ('seizures', 'I'), ('induced', 'O'), ('by', 'O'), ('kainic', 'O'), ('acid', 'O'), ('(', 'O'), ('32', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('did', 'O'), ('not', 'O'), ('completely', 'O'), ('protect', 'O'), ('against', 'O'), ('the', 'O'), ('seizures', 'O'), ('.', 'O'))"
"The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA seizures or lethality .","(('The', 'O'), ('steroids', 'O'), ('also', 'O'), ('caused', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('delay', 'O'), ('in', 'O'), ('NMDA', 'O'), ('(', 'O'), ('257', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('lethality', 'O'), (',', 'O'), ('but', 'O'), ('did', 'O'), ('not', 'O'), ('completely', 'O'), ('protect', 'O'), ('against', 'O'), ('NMDA', 'B'), ('seizures', 'O'), ('or', 'O'), ('lethality', 'O'), ('.', 'O'))"
"Furthermore , the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6 , nor did its hepatic levels at days 1 , 3 , 5 , or 7 after PAN injection .","(('Furthermore', 'O'), (',', 'O'), ('the', 'O'), ('Ao', 'O'), ('mRNA', 'O'), ('levels', 'O'), ('did', 'O'), ('not', 'O'), ('change', 'O'), ('in', 'O'), ('any', 'O'), ('of', 'O'), ('the', 'O'), ('extrahepatic', 'O'), ('tissues', 'O'), ('studied', 'O'), ('on', 'O'), ('day', 'O'), ('6', 'O'), (',', 'O'), ('nor', 'O'), ('did', 'O'), ('its', 'O'), ('hepatic', 'O'), ('levels', 'O'), ('at', 'O'), ('days', 'O'), ('1', 'O'), (',', 'O'), ('3', 'O'), (',', 'O'), ('5', 'O'), (',', 'O'), ('or', 'O'), ('7', 'O'), ('after', 'O'), ('PAN', 'O'), ('injection', 'O'), ('.', 'O'))"
"Risperidone , a benzisoxazole derivative antipsychotic , has high serotonin 5 - HT2 receptor blockade and dose - related D2 receptor blockade .","(('Risperidone', 'O'), (',', 'O'), ('a', 'O'), ('benzisoxazole', 'O'), ('derivative', 'O'), ('antipsychotic', 'O'), (',', 'O'), ('has', 'O'), ('high', 'O'), ('serotonin', 'O'), ('5', 'O'), ('-', 'O'), ('HT2', 'O'), ('receptor', 'O'), ('blockade', 'O'), ('and', 'O'), ('dose', 'O'), ('-', 'O'), ('related', 'O'), ('D2', 'O'), ('receptor', 'O'), ('blockade', 'O'), ('.', 'O'))"
The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine .,"(('The', 'O'), ('syndrome', 'O'), ('reversed', 'O'), ('after', 'O'), ('discontinuing', 'O'), ('risperidone', 'O'), ('and', 'O'), ('starting', 'O'), ('treatment', 'O'), ('with', 'O'), ('dantrolene', 'O'), ('and', 'O'), ('bromocriptine', 'O'), ('.', 'O'))"
"The inhibitory effect of carteolol was almost comparable to that of propranolol , but was weaker than that of biperiden .","(('The', 'O'), ('inhibitory', 'O'), ('effect', 'O'), ('of', 'O'), ('carteolol', 'O'), ('was', 'O'), ('almost', 'O'), ('comparable', 'O'), ('to', 'O'), ('that', 'O'), ('of', 'O'), ('propranolol', 'O'), (',', 'O'), ('but', 'O'), ('was', 'O'), ('weaker', 'O'), ('than', 'O'), ('that', 'O'), ('of', 'O'), ('biperiden', 'O'), ('.', 'O'))"
Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine - induced stereotypy and locomotor activity in rats .,"(('Carteolol', 'O'), ('did', 'O'), ('not', 'O'), ('antagonize', 'O'), ('the', 'O'), ('inhibitory', 'O'), ('effects', 'O'), ('of', 'O'), ('haloperidol', 'O'), ('on', 'O'), ('apomorphine', 'O'), ('-', 'O'), ('induced', 'O'), ('stereotypy', 'O'), ('and', 'O'), ('locomotor', 'O'), ('activity', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"In addition , carteolol did not evoke 5 - HT1A receptor - stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5 - hydroxytryptophan - induced head twitch in rats .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('carteolol', 'O'), ('did', 'O'), ('not', 'O'), ('evoke', 'O'), ('5', 'O'), ('-', 'O'), ('HT1A', 'O'), ('receptor', 'O'), ('-', 'O'), ('stimulating', 'O'), ('behavioral', 'O'), ('signs', 'O'), ('such', 'O'), ('as', 'O'), ('flat', 'O'), ('body', 'O'), ('posture', 'O'), ('and', 'O'), ('forepaw', 'O'), ('treading', 'O'), ('and', 'O'), ('did', 'O'), ('not', 'O'), ('inhibit', 'O'), ('5', 'O'), ('-', 'O'), ('hydroxytryptophan', 'O'), ('-', 'O'), ('induced', 'O'), ('head', 'O'), ('twitch', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"Finally , carteolol did not inhibit physostigmine - induced lethality in rats .","(('Finally', 'O'), (',', 'O'), ('carteolol', 'O'), ('did', 'O'), ('not', 'O'), ('inhibit', 'O'), ('physostigmine', 'O'), ('-', 'O'), ('induced', 'O'), ('lethality', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
BACKGROUND : Increased attention has been focused recently on the estrogenic effects of tamoxifen .,"(('BACKGROUND', 'O'), (':', 'O'), ('Increased', 'O'), ('attention', 'O'), ('has', 'O'), ('been', 'O'), ('focused', 'O'), ('recently', 'O'), ('on', 'O'), ('the', 'O'), ('estrogenic', 'O'), ('effects', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('.', 'O'))"
Review of the literature reveals an association between tamoxifen use and gynecologic tumors .,"(('Review', 'O'), ('of', 'O'), ('the', 'O'), ('literature', 'O'), ('reveals', 'O'), ('an', 'O'), ('association', 'O'), ('between', 'O'), ('tamoxifen', 'O'), ('use', 'O'), ('and', 'O'), ('gynecologic', 'B'), ('tumors', 'I'), ('.', 'O'))"
CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor - positive breast carcinoma .,"(('CASE', 'O'), (':', 'O'), ('A', 'O'), ('52', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('postmenopausal', 'O'), ('woman', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('tamoxifen', 'O'), ('for', 'O'), ('stage', 'B'), ('II', 'I'), ('estrogen', 'I'), ('receptor', 'I'), ('-', 'I'), ('positive', 'I'), ('breast', 'B'), ('carcinoma', 'I'), ('.', 'O'))"
Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use .,"(('Her', 'O'), ('aspartate', 'O'), ('transaminase', 'O'), ('and', 'O'), ('alanine', 'O'), ('transaminase', 'O'), ('levels', 'O'), ('increase', 'O'), ('markedly', 'O'), ('after', 'O'), ('6', 'O'), ('months', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('use', 'O'), ('.', 'O'))"
It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation .,"(('It', 'O'), ('is', 'O'), ('generally', 'O'), ('assumed', 'O'), ('that', 'O'), ('DNA', 'O'), ('elongation', 'O'), ('is', 'O'), ('stopped', 'O'), ('by', 'O'), ('the', 'O'), ('insertion', 'O'), ('of', 'O'), ('AZT', 'O'), ('into', 'O'), ('the', 'O'), ('chain', 'O'), ('in', 'O'), ('place', 'O'), ('of', 'O'), ('thymidine', 'O'), ('thus', 'O'), ('preventing', 'O'), ('the', 'O'), ('phosphate', 'O'), ('hydroxyl', 'O'), ('linkages', 'O'), ('and', 'O'), ('therefore', 'O'), ('suppresses', 'O'), ('hemopoietic', 'O'), ('progenitor', 'O'), ('cell', 'O'), ('proliferation', 'O'), ('in', 'O'), ('an', 'O'), ('early', 'O'), ('stage', 'O'), ('of', 'O'), ('differentiation', 'O'), ('.', 'O'))"
"CBA / Ca male mice started on AZT 0 . 75 mg / ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0 . 5 mg / ml H2O for a group , another group removed from AZT to see recovery , and third group remained on 0 . 75 mg .","(('CBA', 'O'), ('/', 'O'), ('Ca', 'O'), ('male', 'O'), ('mice', 'O'), ('started', 'O'), ('on', 'O'), ('AZT', 'O'), ('0', 'O'), ('.', 'O'), ('75', 'O'), ('mg', 'O'), ('/', 'O'), ('ml', 'O'), ('H2O', 'O'), ('at', 'O'), ('84', 'O'), ('days', 'O'), ('of', 'O'), ('age', 'O'), ('and', 'O'), ('kept', 'O'), ('on', 'O'), ('it', 'O'), ('for', 'O'), ('687', 'O'), ('days', 'O'), ('when', 'O'), ('dosage', 'O'), ('reduced', 'O'), ('to', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('ml', 'O'), ('H2O', 'O'), ('for', 'O'), ('a', 'O'), ('group', 'O'), (',', 'O'), ('another', 'O'), ('group', 'O'), ('removed', 'O'), ('from', 'O'), ('AZT', 'O'), ('to', 'O'), ('see', 'O'), ('recovery', 'O'), (',', 'O'), ('and', 'O'), ('third', 'O'), ('group', 'O'), ('remained', 'O'), ('on', 'O'), ('0', 'O'), ('.', 'O'), ('75', 'O'), ('mg', 'O'), ('.', 'O'))"
At 687 days mice that had been on 0 . 75 mg had average platelet counts of 2 . 5 x 10 ( 6 ) .,"(('At', 'O'), ('687', 'O'), ('days', 'O'), ('mice', 'O'), ('that', 'O'), ('had', 'O'), ('been', 'O'), ('on', 'O'), ('0', 'O'), ('.', 'O'), ('75', 'O'), ('mg', 'O'), ('had', 'O'), ('average', 'O'), ('platelet', 'O'), ('counts', 'O'), ('of', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('6', 'O'), (')', 'O'), ('.', 'O'))"
A variety of histological patterns was observed .,"(('A', 'O'), ('variety', 'O'), ('of', 'O'), ('histological', 'O'), ('patterns', 'O'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine .,"(('Biphasic', 'O'), ('response', 'O'), ('of', 'O'), ('the', 'O'), ('SA', 'O'), ('node', 'O'), ('of', 'O'), ('the', 'O'), ('dog', 'O'), ('heart', 'O'), ('in', 'O'), ('vivo', 'O'), ('to', 'O'), ('selective', 'O'), ('administration', 'O'), ('of', 'O'), ('ketamine', 'O'), ('.', 'O'))"
Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery .,"(('Effect', 'O'), ('of', 'O'), ('ketamine', 'O'), ('on', 'O'), ('the', 'O'), ('SA', 'O'), ('node', 'O'), ('of', 'O'), ('the', 'O'), ('dog', 'O'), ('heart', 'O'), ('was', 'O'), ('studied', 'O'), ('in', 'O'), ('vivo', 'O'), ('using', 'O'), ('a', 'O'), ('selective', 'O'), ('perfusion', 'O'), ('technique', 'O'), ('of', 'O'), ('the', 'O'), ('SA', 'O'), ('node', 'O'), ('artery', 'O'), ('.', 'O'))"
This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery .,"(('This', 'O'), ('may', 'O'), ('indicate', 'O'), ('that', 'O'), ('an', 'O'), ('activation', 'O'), ('of', 'O'), ('the', 'O'), ('peripheral', 'O'), ('adrenergic', 'O'), ('mechanism', 'O'), ('plays', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('induction', 'O'), ('of', 'O'), ('the', 'O'), ('excitatory', 'O'), ('effect', 'O'), ('of', 'O'), ('ketamine', 'O'), ('injected', 'O'), ('in', 'O'), ('the', 'O'), ('SA', 'O'), ('node', 'O'), ('artery', 'O'), ('.', 'O'))"
Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat pituitary tumors may mediate estrogen - initiated tumor angiogenesis .,"(('Over', 'O'), ('expression', 'O'), ('of', 'O'), ('vascular', 'O'), ('endothelial', 'O'), ('growth', 'O'), ('factor', 'O'), ('and', 'O'), ('its', 'O'), ('receptor', 'O'), ('during', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('estrogen', 'O'), ('-', 'O'), ('induced', 'O'), ('rat', 'O'), ('pituitary', 'B'), ('tumors', 'I'), ('may', 'O'), ('mediate', 'O'), ('estrogen', 'O'), ('-', 'O'), ('initiated', 'O'), ('tumor', 'B'), ('angiogenesis', 'O'), ('.', 'O'))"
"Estrogens , which have been associated with several types of human and animal cancers , can induce tumor angiogenesis in the pituitary of Fischer 344 rats .","(('Estrogens', 'O'), (',', 'O'), ('which', 'O'), ('have', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('several', 'O'), ('types', 'O'), ('of', 'O'), ('human', 'O'), ('and', 'O'), ('animal', 'O'), ('cancers', 'B'), (',', 'O'), ('can', 'O'), ('induce', 'O'), ('tumor', 'B'), ('angiogenesis', 'O'), ('in', 'O'), ('the', 'O'), ('pituitary', 'O'), ('of', 'O'), ('Fischer', 'O'), ('344', 'O'), ('rats', 'O'), ('.', 'O'))"
"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .","(('To', 'O'), ('elucidate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('estrogen', 'O'), ('in', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('tumor', 'B'), ('angiogenesis', 'O'), ('in', 'O'), ('the', 'O'), ('pituitary', 'O'), ('of', 'O'), ('female', 'O'), ('rats', 'O'), (',', 'O'), ('the', 'O'), ('density', 'O'), ('of', 'O'), ('blood', 'O'), ('vessels', 'O'), ('was', 'O'), ('analysed', 'O'), ('using', 'O'), ('factor', 'O'), ('VIII', 'O'), ('related', 'O'), ('antigen', 'O'), ('(', 'O'), ('FVIIIRAg', 'O'), (')', 'O'), ('immunohistochemistry', 'O'), ('and', 'O'), ('the', 'O'), ('expression', 'O'), ('of', 'O'), ('vascular', 'O'), ('endothelial', 'O'), ('growth', 'O'), ('factor', 'O'), ('/', 'O'), ('vascular', 'O'), ('permeability', 'O'), ('factor', 'O'), ('(', 'O'), ('VEGF', 'O'), ('/', 'O'), ('VPF', 'O'), (')', 'O'), ('was', 'O'), ('examined', 'O'), ('by', 'O'), ('Western', 'O'), ('blot', 'O'), ('and', 'O'), ('immunohistochemical', 'O'), ('analysis', 'O'), ('.', 'O'))"
The expression of VEGF receptor ( VEGFR - 2 / Flk - 1 / KDR ) was also examined by immunohistochemistry .,"(('The', 'O'), ('expression', 'O'), ('of', 'O'), ('VEGF', 'O'), ('receptor', 'O'), ('(', 'O'), ('VEGFR', 'O'), ('-', 'O'), ('2', 'O'), ('/', 'O'), ('Flk', 'O'), ('-', 'O'), ('1', 'O'), ('/', 'O'), ('KDR', 'O'), (')', 'O'), ('was', 'O'), ('also', 'O'), ('examined', 'O'), ('by', 'O'), ('immunohistochemistry', 'O'), ('.', 'O'))"
"The results demonstrated that 17beta - estradiol ( E2 ) induces neovascularization , as well as the growth and enlargement of blood vessels after 7 days of exposure .","(('The', 'O'), ('results', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('17beta', 'O'), ('-', 'O'), ('estradiol', 'O'), ('(', 'O'), ('E2', 'O'), (')', 'O'), ('induces', 'O'), ('neovascularization', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('the', 'O'), ('growth', 'O'), ('and', 'O'), ('enlargement', 'O'), ('of', 'O'), ('blood', 'O'), ('vessels', 'O'), ('after', 'O'), ('7', 'O'), ('days', 'O'), ('of', 'O'), ('exposure', 'O'), ('.', 'O'))"
The high tumor angiogenic potential was associated with an elevated VEGF / VPF protein expression in the E2 exposed pituitary of ovariectomized ( OVEX ) rats .,"(('The', 'O'), ('high', 'O'), ('tumor', 'B'), ('angiogenic', 'O'), ('potential', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('elevated', 'O'), ('VEGF', 'O'), ('/', 'O'), ('VPF', 'O'), ('protein', 'O'), ('expression', 'O'), ('in', 'O'), ('the', 'O'), ('E2', 'O'), ('exposed', 'O'), ('pituitary', 'O'), ('of', 'O'), ('ovariectomized', 'O'), ('(', 'O'), ('OVEX', 'O'), (')', 'O'), ('rats', 'O'), ('.', 'O'))"
"VEGF / VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin ( UEA1 ) binding studies , indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non - endothelial cells .","(('VEGF', 'O'), ('/', 'O'), ('VPF', 'O'), ('and', 'O'), ('FVIIIRAg', 'O'), ('immunohistochemistry', 'O'), ('and', 'O'), ('endothelial', 'O'), ('specific', 'O'), ('lectin', 'O'), ('(', 'O'), ('UEA1', 'O'), (')', 'O'), ('binding', 'O'), ('studies', 'O'), (',', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('elevation', 'O'), ('of', 'O'), ('VEGF', 'O'), ('protein', 'O'), ('expression', 'O'), ('initially', 'O'), ('occurred', 'O'), ('in', 'O'), ('both', 'O'), ('blood', 'O'), ('vessels', 'O'), ('and', 'O'), ('non', 'O'), ('-', 'O'), ('endothelial', 'O'), ('cells', 'O'), ('.', 'O'))"
"After 15 days of E2 exposure , VEGF / VPF protein expression , in the non - endothelial cell population , sharply declined and was restricted to the blood vessels .","(('After', 'O'), ('15', 'O'), ('days', 'O'), ('of', 'O'), ('E2', 'O'), ('exposure', 'O'), (',', 'O'), ('VEGF', 'O'), ('/', 'O'), ('VPF', 'O'), ('protein', 'O'), ('expression', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('non', 'O'), ('-', 'O'), ('endothelial', 'O'), ('cell', 'O'), ('population', 'O'), (',', 'O'), ('sharply', 'O'), ('declined', 'O'), ('and', 'O'), ('was', 'O'), ('restricted', 'O'), ('to', 'O'), ('the', 'O'), ('blood', 'O'), ('vessels', 'O'), ('.', 'O'))"
The function of non - endothelial - derived VEGF is not clear .,"(('The', 'O'), ('function', 'O'), ('of', 'O'), ('non', 'O'), ('-', 'O'), ('endothelial', 'O'), ('-', 'O'), ('derived', 'O'), ('VEGF', 'O'), ('is', 'O'), ('not', 'O'), ('clear', 'O'), ('.', 'O'))"
"Furthermore , immunohistochemical studies demonstrated that VEGFR - 2 ( flk - 1 / KDR ) , expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure .","(('Furthermore', 'O'), (',', 'O'), ('immunohistochemical', 'O'), ('studies', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('VEGFR', 'O'), ('-', 'O'), ('2', 'O'), ('(', 'O'), ('flk', 'O'), ('-', 'O'), ('1', 'O'), ('/', 'O'), ('KDR', 'O'), (')', 'O'), (',', 'O'), ('expression', 'O'), ('was', 'O'), ('elevated', 'O'), ('significantly', 'O'), ('in', 'O'), ('the', 'O'), ('endothelial', 'O'), ('cells', 'O'), ('of', 'O'), ('microblood', 'O'), ('vessels', 'O'), ('after', 'O'), ('7', 'O'), ('days', 'O'), ('of', 'O'), ('E2', 'O'), ('exposure', 'O'), ('.', 'O'))"
These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('over', 'O'), ('expression', 'O'), ('of', 'O'), ('VEGF', 'O'), ('and', 'O'), ('its', 'O'), ('receptor', 'O'), ('(', 'O'), ('VEGFR', 'O'), ('-', 'O'), ('2', 'O'), (')', 'O'), ('may', 'O'), ('play', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('initial', 'O'), ('step', 'O'), ('of', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('estrogen', 'O'), ('induced', 'O'), ('tumor', 'B'), ('angiogenesis', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('pituitary', 'O'), ('.', 'O'))"
"NIK - 247 , tacrine and E - 2020 all strongly inhibited acetylcholinesterase ( AChE ) in human red blood cells ( IC50s = 1 . 0 x 10 ( - 6 ) , 2 . 9 x 10 ( - 7 ) and 3 . 7 x 10 ( - 8 ) M , respectively ) .","(('NIK', 'O'), ('-', 'O'), ('247', 'O'), (',', 'O'), ('tacrine', 'O'), ('and', 'O'), ('E', 'O'), ('-', 'O'), ('2020', 'O'), ('all', 'O'), ('strongly', 'O'), ('inhibited', 'O'), ('acetylcholinesterase', 'O'), ('(', 'O'), ('AChE', 'O'), (')', 'O'), ('in', 'O'), ('human', 'O'), ('red', 'O'), ('blood', 'O'), ('cells', 'O'), ('(', 'O'), ('IC50s', 'O'), ('=', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('-', 'O'), ('6', 'O'), (')', 'O'), (',', 'O'), ('2', 'O'), ('.', 'O'), ('9', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('-', 'O'), ('7', 'O'), (')', 'O'), ('and', 'O'), ('3', 'O'), ('.', 'O'), ('7', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('-', 'O'), ('8', 'O'), (')', 'O'), ('M', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O'))"
"In addition , NIK - 247 and tacrine , but not E - 2020 , strongly inhibited butyrylcholinestrase ( BuChE ) in human serum .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('NIK', 'O'), ('-', 'O'), ('247', 'O'), ('and', 'O'), ('tacrine', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('E', 'O'), ('-', 'O'), ('2020', 'O'), (',', 'O'), ('strongly', 'O'), ('inhibited', 'O'), ('butyrylcholinestrase', 'O'), ('(', 'O'), ('BuChE', 'O'), (')', 'O'), ('in', 'O'), ('human', 'O'), ('serum', 'O'), ('.', 'O'))"
All three drugs produced mixed inhibition of AChE activity .,"(('All', 'O'), ('three', 'O'), ('drugs', 'O'), ('produced', 'O'), ('mixed', 'O'), ('inhibition', 'O'), ('of', 'O'), ('AChE', 'O'), ('activity', 'O'), ('.', 'O'))"
"Moreover , the inhibitory effect of NIK - 247 on AChE was reversible .","(('Moreover', 'O'), (',', 'O'), ('the', 'O'), ('inhibitory', 'O'), ('effect', 'O'), ('of', 'O'), ('NIK', 'O'), ('-', 'O'), ('247', 'O'), ('on', 'O'), ('AChE', 'B'), ('was', 'O'), ('reversible', 'O'), ('.', 'O'))"
The three compounds at 1 and 3 mg / kg p . o . did not significantly decrease spontaneous movement by rats .,"(('The', 'O'), ('three', 'O'), ('compounds', 'O'), ('at', 'O'), ('1', 'O'), ('and', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('p', 'O'), ('.', 'O'), ('o', 'O'), ('.', 'O'), ('did', 'O'), ('not', 'O'), ('significantly', 'O'), ('decrease', 'O'), ('spontaneous', 'O'), ('movement', 'O'), ('by', 'O'), ('rats', 'O'), ('.', 'O'))"
The findings suggest that NIK - 247 may be a useful drug for the treatment of Alzheimer ' s disease .,"(('The', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('NIK', 'O'), ('-', 'O'), ('247', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('useful', 'O'), ('drug', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
"The therapeutic use of selective DA D1 receptor agonists such as SKF - 82958 ( 6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide ) and A - 77636 ( [ 1R , 3S ] 3 - [ 1 ' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 -","(('The', 'O'), ('therapeutic', 'O'), ('use', 'O'), ('of', 'O'), ('selective', 'O'), ('DA', 'O'), ('D1', 'O'), ('receptor', 'O'), ('agonists', 'O'), ('such', 'O'), ('as', 'O'), ('SKF', 'O'), ('-', 'O'), ('82958', 'O'), ('(', 'O'), ('6', 'O'), ('-', 'O'), ('chloro', 'O'), ('-', 'O'), ('7', 'O'), (',', 'O'), ('8', 'O'), ('-', 'O'), ('dihydroxy', 'O'), ('-', 'O'), ('3', 'O'), ('-', 'O'), ('allyl', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('phenyl', 'O'), ('-', 'O'), ('2', 'O'), (',', 'O'), ('3', 'O'), (',', 'O'), ('4', 'O'), (',', 'O'), ('5', 'O'), ('-', 'O'), ('tetrahydro', 'O'), ('-', 'O'), ('1H', 'O'), ('-', 'O'), ('3', 'O'), ('-', 'O'), ('benzaze', 'O'), ('pine', 'O'), ('hydrobromide', 'O'), (')', 'O'), ('and', 'O'), ('A', 'O'), ('-', 'O'), ('77636', 'O'), ('(', 'O'), ('[', 'O'), ('1R', 'O'), (',', 'O'), ('3S', 'O'), (']', 'O'), ('3', 'O'), ('-', 'O'), ('[', 'O'), ('1', 'O'), (""'"", 'O'), ('-', 'O'), ('admantyl', 'O'), (']', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('aminomethyl', 'O'), ('-', 'O'), ('3', 'O'), (',', 'O'), ('4', 'O'), ('-', 'O'), ('dihydro', 'O'), ('-', 'O'), ('5', 'O'), (',', 'O'), ('6', 'O'), ('-', 'O'))"
"dihydroxy - 1H - 2 - benzo pyran hydrochloride ) seems limited because of their duration of action , which is too short for SKF - 82958 ( < 1 hr ) and too long for A - 77636 ( > 20 hr , leading to behavioral tolerance ) .","(('dihydroxy', 'O'), ('-', 'O'), ('1H', 'O'), ('-', 'O'), ('2', 'O'), ('-', 'O'), ('benzo', 'O'), ('pyran', 'O'), ('hydrochloride', 'O'), (')', 'O'), ('seems', 'O'), ('limited', 'O'), ('because', 'O'), ('of', 'O'), ('their', 'O'), ('duration', 'O'), ('of', 'O'), ('action', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('too', 'O'), ('short', 'O'), ('for', 'O'), ('SKF', 'O'), ('-', 'O'), ('82958', 'O'), ('(', 'O'), ('<', 'O'), ('1', 'O'), ('hr', 'O'), (')', 'O'), ('and', 'O'), ('too', 'O'), ('long', 'O'), ('for', 'O'), ('A', 'O'), ('-', 'O'), ('77636', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('hr', 'O'), (',', 'O'), ('leading', 'O'), ('to', 'O'), ('behavioral', 'O'), ('tolerance', 'O'), (')', 'O'), ('.', 'O'))"
"7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .","(('7', 'O'), (',', 'O'), ('11b', 'O'), ('-', 'O'), ('hexahydro', 'O'), ('-', 'O'), ('2', 'O'), ('-', 'O'), ('propyl', 'O'), ('-', 'O'), ('3', 'O'), ('-', 'O'), ('thia', 'O'), ('-', 'O'), ('5', 'O'), ('-', 'O'), ('+', 'O'), ('+', 'O'), ('+', 'O'), ('azacyclopent', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('ena', 'O'), ('[', 'O'), ('c', 'O'), (']', 'O'), ('phenathrene', 'O'), ('-', 'O'), ('9', 'O'), ('-', 'O'), ('10', 'O'), ('-', 'O'), ('diol', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('selective', 'O'), ('and', 'O'), ('full', 'O'), ('DA', 'O'), ('D1', 'O'), ('-', 'O'), ('like', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('with', 'O'), ('an', 'O'), ('intermediate', 'O'), ('duration', 'O'), ('of', 'O'), ('action', 'O'), ('.', 'O'))"
"Levodopa and the DA D2 - like receptor agonist , LY - 171555 ( [ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride ) were also used for comparison .","(('Levodopa', 'O'), ('and', 'O'), ('the', 'O'), ('DA', 'O'), ('D2', 'O'), ('-', 'O'), ('like', 'O'), ('receptor', 'O'), ('agonist', 'O'), (',', 'O'), ('LY', 'O'), ('-', 'O'), ('171555', 'O'), ('(', 'O'), ('[', 'O'), ('4aR', 'O'), ('-', 'O'), ('trans', 'O'), (']', 'O'), ('-', 'O'), ('4', 'O'), (',', 'O'), ('4a', 'O'), (',', 'O'), ('5', 'O'), (',', 'O'), ('6', 'O'), (',', 'O'), ('7', 'O'), (',', 'O'), ('8', 'O'), (',', 'O'), ('8a', 'O'), (',', 'O'), ('9', 'O'), ('-', 'O'), ('o', 'O'), ('-', 'O'), ('dihydro', 'O'), ('-', 'O'), ('5n', 'O'), ('-', 'O'), ('propyl', 'O'), ('-', 'O'), ('2H', 'O'), ('-', 'O'), ('pyrazo', 'O'), ('lo', 'O'), ('-', 'O'), ('3', 'O'), ('-', 'O'), ('4', 'O'), ('-', 'O'), ('quinoline', 'O'), ('hydrochloride', 'O'), (')', 'O'), ('were', 'O'), ('also', 'O'), ('used', 'O'), ('for', 'O'), ('comparison', 'O'), ('.', 'O'))"
Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus ( referred to as the basal ganglia output ) compared with levodopa and selective DA D2 receptor agonist .,"(('Selective', 'O'), ('stimulation', 'O'), ('of', 'O'), ('the', 'O'), ('DA', 'O'), ('D1', 'O'), ('receptor', 'O'), ('may', 'O'), ('provide', 'O'), ('better', 'O'), ('integration', 'O'), ('of', 'O'), ('neural', 'O'), ('inputs', 'O'), ('transmitted', 'O'), ('to', 'O'), ('the', 'O'), ('internal', 'O'), ('segment', 'O'), ('of', 'O'), ('the', 'O'), ('globus', 'O'), ('pallidus', 'O'), ('(', 'O'), ('referred', 'O'), ('to', 'O'), ('as', 'O'), ('the', 'O'), ('basal', 'O'), ('ganglia', 'O'), ('output', 'O'), (')', 'O'), ('compared', 'O'), ('with', 'O'), ('levodopa', 'O'), ('and', 'O'), ('selective', 'O'), ('DA', 'O'), ('D2', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('.', 'O'))"
This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure - like events following high - frequency stimulation in hippocampal slices .,"(('This', 'O'), ('expression', 'O'), ('may', 'O'), ('represent', 'O'), ('an', 'O'), ('endogenous', 'O'), ('damping', 'O'), ('mechanism', 'O'), ('since', 'O'), ('NPY', 'O'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('block', 'O'), ('seizure', 'O'), ('-', 'O'), ('like', 'O'), ('events', 'O'), ('following', 'O'), ('high', 'O'), ('-', 'O'), ('frequency', 'O'), ('stimulation', 'O'), ('in', 'O'), ('hippocampal', 'O'), ('slices', 'O'), ('.', 'O'))"
We report peroxidase - antiperoxidase immunostaining for NPY in several brain regions in this model .,"(('We', 'O'), ('report', 'O'), ('peroxidase', 'O'), ('-', 'O'), ('antiperoxidase', 'O'), ('immunostaining', 'O'), ('for', 'O'), ('NPY', 'O'), ('in', 'O'), ('several', 'O'), ('brain', 'O'), ('regions', 'O'), ('in', 'O'), ('this', 'O'), ('model', 'O'), ('.', 'O'))"
"PILO - injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals , in the dentate gyrus inner molecular layer and , in a few cases , within presumed granule cells .","(('PILO', 'O'), ('-', 'O'), ('injected', 'O'), ('animals', 'O'), ('exhibited', 'O'), ('NPY', 'O'), ('immunoreactivity', 'O'), ('in', 'O'), ('the', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('mossy', 'O'), ('fibre', 'O'), ('terminals', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('inner', 'O'), ('molecular', 'O'), ('layer', 'O'), ('and', 'O'), (',', 'O'), ('in', 'O'), ('a', 'O'), ('few', 'O'), ('cases', 'O'), (',', 'O'), ('within', 'O'), ('presumed', 'O'), ('granule', 'O'), ('cells', 'O'), ('.', 'O'))"
"NPY immunoreactivity was also dramatically changed in the entorhinal cortex , amygdala and sensorimotor areas .","(('NPY', 'O'), ('immunoreactivity', 'O'), ('was', 'O'), ('also', 'O'), ('dramatically', 'O'), ('changed', 'O'), ('in', 'O'), ('the', 'O'), ('entorhinal', 'O'), ('cortex', 'O'), (',', 'O'), ('amygdala', 'O'), ('and', 'O'), ('sensorimotor', 'O'), ('areas', 'O'), ('.', 'O'))"
"In addition , PILO injected animals exhibited a reduction in the number of NPY - immunoreactive interneurons compared with controls .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('PILO', 'O'), ('injected', 'O'), ('animals', 'O'), ('exhibited', 'O'), ('a', 'O'), ('reduction', 'O'), ('in', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('NPY', 'O'), ('-', 'O'), ('immunoreactive', 'O'), ('interneurons', 'O'), ('compared', 'O'), ('with', 'O'), ('controls', 'O'), ('.', 'O'))"
"However , the significance of this changed synthesis of NPY remains to be determined .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('significance', 'O'), ('of', 'O'), ('this', 'O'), ('changed', 'O'), ('synthesis', 'O'), ('of', 'O'), ('NPY', 'O'), ('remains', 'O'), ('to', 'O'), ('be', 'O'), ('determined', 'O'), ('.', 'O'))"
"All patients were examined preoperatively and 39 were examined at six months ; 27 of the patients were also examined at one year , and 11 at two years .","(('All', 'O'), ('patients', 'O'), ('were', 'O'), ('examined', 'O'), ('preoperatively', 'O'), ('and', 'O'), ('39', 'O'), ('were', 'O'), ('examined', 'O'), ('at', 'O'), ('six', 'O'), ('months', 'O'), (';', 'O'), ('27', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('were', 'O'), ('also', 'O'), ('examined', 'O'), ('at', 'O'), ('one', 'O'), ('year', 'O'), (',', 'O'), ('and', 'O'), ('11', 'O'), ('at', 'O'), ('two', 'O'), ('years', 'O'), ('.', 'O'))"
"confidence interval , 29 to 59 percent ) .","(('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('29', 'O'), ('to', 'O'), ('59', 'O'), ('percent', 'O'), (')', 'O'), ('.', 'O'))"
Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery .,"(('Approximately', 'O'), ('half', 'O'), ('the', 'O'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('been', 'O'), ('dependent', 'O'), ('on', 'O'), ('assistance', 'O'), ('in', 'O'), ('activities', 'O'), ('of', 'O'), ('daily', 'O'), ('living', 'O'), ('in', 'O'), ('the', 'O'), ('off', 'O'), ('period', 'O'), ('before', 'O'), ('surgery', 'O'), ('became', 'O'), ('independent', 'O'), ('after', 'O'), ('surgery', 'O'), ('.', 'O'))"
"The complications of surgery were generally well tolerated , and there were no significant changes in the use of medication .","(('The', 'O'), ('complications', 'O'), ('of', 'O'), ('surgery', 'O'), ('were', 'O'), ('generally', 'O'), ('well', 'O'), ('tolerated', 'O'), (',', 'O'), ('and', 'O'), ('there', 'O'), ('were', 'O'), ('no', 'O'), ('significant', 'O'), ('changes', 'O'), ('in', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('medication', 'O'), ('.', 'O'))"
"Much of the benefit is sustained at two years , although some improvements , such as those on the ipsilateral side and in axial symptoms , wane within the first year .","(('Much', 'O'), ('of', 'O'), ('the', 'O'), ('benefit', 'O'), ('is', 'O'), ('sustained', 'O'), ('at', 'O'), ('two', 'O'), ('years', 'O'), (',', 'O'), ('although', 'O'), ('some', 'O'), ('improvements', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('those', 'O'), ('on', 'O'), ('the', 'O'), ('ipsilateral', 'O'), ('side', 'O'), ('and', 'O'), ('in', 'O'), ('axial', 'O'), ('symptoms', 'O'), (',', 'O'), ('wane', 'O'), ('within', 'O'), ('the', 'O'), ('first', 'O'), ('year', 'O'), ('.', 'O'))"
The on - period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy .,"(('The', 'O'), ('on', 'O'), ('-', 'O'), ('period', 'O'), ('symptoms', 'O'), ('that', 'O'), ('are', 'O'), ('resistant', 'O'), ('to', 'O'), ('dopaminergic', 'O'), ('therapy', 'O'), ('do', 'O'), ('not', 'O'), ('respond', 'O'), ('to', 'O'), ('pallidotomy', 'O'), ('.', 'O'))"
Clarithromycin is a relatively new macrolide antibiotic that offers twice - daily dosing .,"(('Clarithromycin', 'O'), ('is', 'O'), ('a', 'O'), ('relatively', 'O'), ('new', 'O'), ('macrolide', 'O'), ('antibiotic', 'O'), ('that', 'O'), ('offers', 'O'), ('twice', 'O'), ('-', 'O'), ('daily', 'O'), ('dosing', 'O'), ('.', 'O'))"
It differs from erythromycin only in the methylation of the hydroxyl group at position 6 .,"(('It', 'O'), ('differs', 'O'), ('from', 'O'), ('erythromycin', 'O'), ('only', 'O'), ('in', 'O'), ('the', 'O'), ('methylation', 'O'), ('of', 'O'), ('the', 'O'), ('hydroxyl', 'O'), ('group', 'O'), ('at', 'O'), ('position', 'O'), ('6', 'O'), ('.', 'O'))"
The entire procedure was repeated during glyceryl trinitrate infusion ( Nitrolingual 1 microg / kg / min for 120 min ) .,"(('The', 'O'), ('entire', 'O'), ('procedure', 'O'), ('was', 'O'), ('repeated', 'O'), ('during', 'O'), ('glyceryl', 'O'), ('trinitrate', 'O'), ('infusion', 'O'), ('(', 'O'), ('Nitrolingual', 'O'), ('1', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('min', 'O'), ('for', 'O'), ('120', 'O'), ('min', 'O'), (')', 'O'), ('.', 'O'))"
RESULTS : Prostigmine - morphine provocation caused significant increases in the time to peak activity ( Tmax ) over the hepatic hilum ( HH : 34 . 33 + / - 5 . 05 vs . 22 . 77 + / - 3 . 26 ) and the common bile duct ( CBD : 60 . 44 + / - 5 . 99 vs . 40 . 0 + / - 2 . 88 ) and in the half - time of excretion ( T1 / 2 ) over the liver parenchyma ( LP : 120 . 04 + / - 16 .,"(('RESULTS', 'O'), (':', 'O'), ('Prostigmine', 'O'), ('-', 'O'), ('morphine', 'O'), ('provocation', 'O'), ('caused', 'O'), ('significant', 'O'), ('increases', 'O'), ('in', 'O'), ('the', 'O'), ('time', 'O'), ('to', 'O'), ('peak', 'O'), ('activity', 'O'), ('(', 'O'), ('Tmax', 'O'), (')', 'O'), ('over', 'O'), ('the', 'O'), ('hepatic', 'O'), ('hilum', 'O'), ('(', 'O'), ('HH', 'O'), (':', 'O'), ('34', 'O'), ('.', 'O'), ('33', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('5', 'O'), ('.', 'O'), ('05', 'O'), ('vs', 'O'), ('.', 'O'), ('22', 'O'), ('.', 'O'), ('77', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('26', 'O'), (')', 'O'), ('and', 'O'), ('the', 'O'), ('common', 'O'), ('bile', 'O'), ('duct', 'O'), ('(', 'O'), ('CBD', 'O'), (':', 'O'), ('60', 'O'), ('.', 'O'), ('44', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('5', 'O'), ('.', 'O'), ('99', 'O'), ('vs', 'O'), ('.', 'O'), ('40', 'O'), ('.', 'O'), ('0', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('88', 'O'), (')', 'O'), ('and', 'O'), ('in', 'O'), ('the', 'O'), ('half', 'O'), ('-', 'O'), ('time', 'O'), ('of', 'O'), ('excretion', 'O'), ('(', 'O'), ('T1', 'O'), ('/', 'O'), ('2', 'O'), (')', 'O'), ('over', 'O'), ('the', 'O'), ('liver', 'O'), ('parenchyma', 'O'), ('(', 'O'), ('LP', 'O'), (':', 'O'), ('120', 'O'), ('.', 'O'), ('04', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('16', 'O'), ('.', 'O'))"
Glyceryl trinitrate infusion completely normalized the prostigmine - morphine - induced alterations in these quantitative parameters ( TmaX over the LP : 11 . 33 + / - 1 . 13 ; over the HH : 18 . 88 + / - 1 . 48 ; and over the CBD : 36 . 22 + / - 1 . 92 ; and T1 / 2 over the LP : 28 . 21 + / - 1 . 83 ; over the HH : 33 . 42 + / - 3 . 10 ; and over the CBD : 41 . 66 + / -,"(('Glyceryl', 'O'), ('trinitrate', 'O'), ('infusion', 'O'), ('completely', 'O'), ('normalized', 'O'), ('the', 'O'), ('prostigmine', 'O'), ('-', 'O'), ('morphine', 'O'), ('-', 'O'), ('induced', 'O'), ('alterations', 'O'), ('in', 'O'), ('these', 'O'), ('quantitative', 'O'), ('parameters', 'O'), ('(', 'O'), ('TmaX', 'O'), ('over', 'O'), ('the', 'O'), ('LP', 'O'), (':', 'O'), ('11', 'O'), ('.', 'O'), ('33', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('13', 'O'), (';', 'O'), ('over', 'O'), ('the', 'O'), ('HH', 'O'), (':', 'O'), ('18', 'O'), ('.', 'O'), ('88', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('48', 'O'), (';', 'O'), ('and', 'O'), ('over', 'O'), ('the', 'O'), ('CBD', 'O'), (':', 'O'), ('36', 'O'), ('.', 'O'), ('22', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('92', 'O'), (';', 'O'), ('and', 'O'), ('T1', 'O'), ('/', 'O'), ('2', 'O'), ('over', 'O'), ('the', 'O'), ('LP', 'O'), (':', 'O'), ('28', 'O'), ('.', 'O'), ('21', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('83', 'O'), (';', 'O'), ('over', 'O'), ('the', 'O'), ('HH', 'O'), (':', 'O'), ('33', 'O'), ('.', 'O'), ('42', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('10', 'O'), (';', 'O'), ('and', 'O'), ('over', 'O'), ('the', 'O'), ('CBD', 'O'), (':', 'O'), ('41', 'O'), ('.', 'O'), ('66', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'))"
") , suggesting an effective sphincter - relaxing effect of glyceryl trinitrate .","((')', 'O'), (',', 'O'), ('suggesting', 'O'), ('an', 'O'), ('effective', 'O'), ('sphincter', 'O'), ('-', 'O'), ('relaxing', 'O'), ('effect', 'O'), ('of', 'O'), ('glyceryl', 'O'), ('trinitrate', 'O'), ('.', 'O'))"
Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D - penicillamine .,"(('Four', 'O'), ('patients', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('developed', 'O'), ('heavy', 'O'), ('proteinuria', 'B'), ('after', 'O'), ('five', 'O'), ('to', 'O'), ('12', 'O'), ('months', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('.', 'O'))"
"Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase , or no departure from normal .","(('Light', 'O'), ('microscopy', 'O'), ('of', 'O'), ('renal', 'O'), ('biopsy', 'O'), ('samples', 'O'), ('showed', 'O'), ('minimal', 'O'), ('glomerular', 'O'), ('capillary', 'O'), ('wall', 'O'), ('thickening', 'O'), ('and', 'O'), ('mesangial', 'O'), ('matrix', 'O'), ('increase', 'O'), (',', 'O'), ('or', 'O'), ('no', 'O'), ('departure', 'O'), ('from', 'O'), ('normal', 'O'), ('.', 'O'))"
"Electron microscopy , however , revealed subepithelial electron - dense deposits , fusion of epithelial cell foot processes , and evidence of mesangial cell hyperactivity .","(('Electron', 'O'), ('microscopy', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('revealed', 'O'), ('subepithelial', 'O'), ('electron', 'O'), ('-', 'O'), ('dense', 'O'), ('deposits', 'O'), (',', 'O'), ('fusion', 'O'), ('of', 'O'), ('epithelial', 'O'), ('cell', 'O'), ('foot', 'O'), ('processes', 'O'), (',', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('mesangial', 'B'), ('cell', 'I'), ('hyperactivity', 'I'), ('.', 'O'))"
Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3 .,"(('Immunofluorescence', 'O'), ('microscopy', 'O'), ('demonstrated', 'O'), ('granular', 'O'), ('capillary', 'O'), ('wall', 'O'), ('deposits', 'O'), ('of', 'O'), ('IgG', 'O'), ('and', 'O'), ('C3', 'O'), ('.', 'O'))"
It is tentatively concluded that complement was activated by the classical pathway .,"(('It', 'O'), ('is', 'O'), ('tentatively', 'O'), ('concluded', 'O'), ('that', 'O'), ('complement', 'O'), ('was', 'O'), ('activated', 'O'), ('by', 'O'), ('the', 'O'), ('classical', 'O'), ('pathway', 'O'), ('.', 'O'))"
It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called ' migraine generator ' .,"(('It', 'O'), ('was', 'O'), ('suggested', 'O'), ('that', 'O'), ('this', 'O'), ('brain', 'O'), ('stem', 'O'), ('activation', 'O'), ('is', 'O'), ('inherent', 'O'), ('to', 'O'), ('the', 'O'), ('migraine', 'B'), ('attack', 'O'), ('itself', 'O'), ('and', 'O'), ('represents', 'O'), ('the', 'O'), ('so', 'O'), ('called', 'O'), (""'"", 'O'), ('migraine', 'B'), ('generator', 'O'), (""'"", 'O'), ('.', 'O'))"
"Increases of regional cerebral blood flow ( rCBF ) were found bilaterally in the insula , in the anterior cingulate cortex , the cavernous sinus and the cerebellum .","(('Increases', 'O'), ('of', 'O'), ('regional', 'O'), ('cerebral', 'O'), ('blood', 'O'), ('flow', 'O'), ('(', 'O'), ('rCBF', 'O'), (')', 'O'), ('were', 'O'), ('found', 'O'), ('bilaterally', 'O'), ('in', 'O'), ('the', 'O'), ('insula', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('anterior', 'O'), ('cingulate', 'O'), ('cortex', 'O'), (',', 'O'), ('the', 'O'), ('cavernous', 'O'), ('sinus', 'O'), ('and', 'O'), ('the', 'O'), ('cerebellum', 'O'), ('.', 'O'))"
Value of methylprednisolone in prevention of the arthralgia - myalgia syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .,"(('Value', 'O'), ('of', 'O'), ('methylprednisolone', 'O'), ('in', 'O'), ('prevention', 'O'), ('of', 'O'), ('the', 'O'), ('arthralgia', 'B'), ('-', 'I'), ('myalgia', 'I'), ('syndrome', 'I'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('total', 'O'), ('dose', 'O'), ('infusion', 'O'), ('of', 'O'), ('iron', 'O'), ('dextran', 'O'), (':', 'O'), ('a', 'O'), ('double', 'O'), ('blind', 'O'), ('randomized', 'O'), ('trial', 'O'), ('.', 'O'))"
The safety and efficacy of total dose infusion ( TDI ) of iron dextran has been well documented .,"(('The', 'O'), ('safety', 'O'), ('and', 'O'), ('efficacy', 'O'), ('of', 'O'), ('total', 'O'), ('dose', 'O'), ('infusion', 'O'), ('(', 'O'), ('TDI', 'O'), (')', 'O'), ('of', 'O'), ('iron', 'O'), ('dextran', 'O'), ('has', 'O'), ('been', 'O'), ('well', 'O'), ('documented', 'O'), ('.', 'O'))"
"In 40 % of treated patients , an arthralgia - myalgia syndrome develops .","(('In', 'O'), ('40', 'O'), ('%', 'O'), ('of', 'O'), ('treated', 'O'), ('patients', 'O'), (',', 'O'), ('an', 'O'), ('arthralgia', 'B'), ('-', 'I'), ('myalgia', 'I'), ('syndrome', 'I'), ('develops', 'O'), ('.', 'O'))"
"The purpose of this randomized , double - blind , prospective study was to investigate whether intravenous ( i . v . ) administration of methylprednisolone ( MP ) prevents this complication .","(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('this', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('prospective', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('investigate', 'O'), ('whether', 'O'), ('intravenous', 'O'), ('(', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('administration', 'O'), ('of', 'O'), ('methylprednisolone', 'O'), ('(', 'O'), ('MP', 'O'), (')', 'O'), ('prevents', 'O'), ('this', 'O'), ('complication', 'O'), ('.', 'O'))"
"Sixty - five patients , 34 women and 31 men , ages 36 to 80 years , received either normal saline before and after TDI ( group 1 ) , 125 mg i . v . MP before and saline after TDI ( group 2 ) , or 125 mg i . v . MP before and after TDI ( group 3 ) .","(('Sixty', 'O'), ('-', 'O'), ('five', 'O'), ('patients', 'O'), (',', 'O'), ('34', 'O'), ('women', 'O'), ('and', 'O'), ('31', 'O'), ('men', 'O'), (',', 'O'), ('ages', 'O'), ('36', 'O'), ('to', 'O'), ('80', 'O'), ('years', 'O'), (',', 'O'), ('received', 'O'), ('either', 'O'), ('normal', 'O'), ('saline', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('TDI', 'O'), ('(', 'O'), ('group', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('125', 'O'), ('mg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('MP', 'O'), ('before', 'O'), ('and', 'O'), ('saline', 'O'), ('after', 'O'), ('TDI', 'O'), ('(', 'O'), ('group', 'O'), ('2', 'O'), (')', 'O'), (',', 'O'), ('or', 'O'), ('125', 'O'), ('mg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('MP', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('TDI', 'O'), ('(', 'O'), ('group', 'O'), ('3', 'O'), (')', 'O'), ('.', 'O'))"
Patients were observed for 72 hours and reactions were recorded and graded according to severity .,"(('Patients', 'O'), ('were', 'O'), ('observed', 'O'), ('for', 'O'), ('72', 'O'), ('hours', 'O'), ('and', 'O'), ('reactions', 'O'), ('were', 'O'), ('recorded', 'O'), ('and', 'O'), ('graded', 'O'), ('according', 'O'), ('to', 'O'), ('severity', 'O'), ('.', 'O'))"
"Fifty - eight percent of group 1 patients , 33 % of group 2 , and 26 % of group 3 had reactions to TDI .","(('Fifty', 'O'), ('-', 'O'), ('eight', 'O'), ('percent', 'O'), ('of', 'O'), ('group', 'O'), ('1', 'O'), ('patients', 'O'), (',', 'O'), ('33', 'O'), ('%', 'O'), ('of', 'O'), ('group', 'O'), ('2', 'O'), (',', 'O'), ('and', 'O'), ('26', 'O'), ('%', 'O'), ('of', 'O'), ('group', 'O'), ('3', 'O'), ('had', 'O'), ('reactions', 'O'), ('to', 'O'), ('TDI', 'O'), ('.', 'O'))"
"The severity of reactions ( minimal , mild , and moderate , respectively ) was as follows : group 1 - - 6 , 6 , and 2 ; group 2 - - 1 , 5 , and 0 ; group 3 - - 5 , 1 , and 0 .","(('The', 'O'), ('severity', 'O'), ('of', 'O'), ('reactions', 'O'), ('(', 'O'), ('minimal', 'O'), (',', 'O'), ('mild', 'O'), (',', 'O'), ('and', 'O'), ('moderate', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('was', 'O'), ('as', 'O'), ('follows', 'O'), (':', 'O'), ('group', 'O'), ('1', 'O'), ('-', 'O'), ('-', 'O'), ('6', 'O'), (',', 'O'), ('6', 'O'), (',', 'O'), ('and', 'O'), ('2', 'O'), (';', 'O'), ('group', 'O'), ('2', 'O'), ('-', 'O'), ('-', 'O'), ('1', 'O'), (',', 'O'), ('5', 'O'), (',', 'O'), ('and', 'O'), ('0', 'O'), (';', 'O'), ('group', 'O'), ('3', 'O'), ('-', 'O'), ('-', 'O'), ('5', 'O'), (',', 'O'), ('1', 'O'), (',', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'))"
Data were analyzed by the two - sided Fisher ' s exact test using 95 % confidence intervals with the approximation of Woolf .,"(('Data', 'O'), ('were', 'O'), ('analyzed', 'O'), ('by', 'O'), ('the', 'O'), ('two', 'O'), ('-', 'O'), ('sided', 'O'), ('Fisher', 'O'), (""'"", 'O'), ('s', 'O'), ('exact', 'O'), ('test', 'O'), ('using', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('intervals', 'O'), ('with', 'O'), ('the', 'O'), ('approximation', 'O'), ('of', 'O'), ('Woolf', 'O'), ('.', 'O'))"
These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia - myalgia syndrome .,"(('These', 'O'), ('data', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('administration', 'O'), ('of', 'O'), ('MP', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('TDI', 'O'), ('reduces', 'O'), ('the', 'O'), ('frequency', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('the', 'O'), ('arthralgia', 'B'), ('-', 'I'), ('myalgia', 'I'), ('syndrome', 'I'), ('.', 'O'))"
We conclude that 125 mg i . v . MP should be given routinely before and after TDI of iron dextran .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('125', 'O'), ('mg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('MP', 'O'), ('should', 'O'), ('be', 'O'), ('given', 'O'), ('routinely', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('TDI', 'O'), ('of', 'O'), ('iron', 'O'), ('dextran', 'O'), ('.', 'O'))"
"After discontinuing cisapride , the QT interval returned to normal and symptoms did not recur .","(('After', 'O'), ('discontinuing', 'O'), ('cisapride', 'O'), (',', 'O'), ('the', 'O'), ('QT', 'O'), ('interval', 'O'), ('returned', 'O'), ('to', 'O'), ('normal', 'O'), ('and', 'O'), ('symptoms', 'O'), ('did', 'O'), ('not', 'O'), ('recur', 'O'), ('.', 'O'))"
"We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4 , including diltiazem .","(('We', 'O'), ('suggest', 'O'), ('that', 'O'), ('caution', 'O'), ('be', 'O'), ('taken', 'O'), ('when', 'O'), ('cisapride', 'O'), ('is', 'O'), ('prescribed', 'O'), ('with', 'O'), ('any', 'O'), ('potent', 'O'), ('inhibitor', 'O'), ('of', 'O'), ('CYP3A4', 'O'), (',', 'O'), ('including', 'O'), ('diltiazem', 'O'), ('.', 'O'))"
Single photon emission tomography with i . v . 133Xe was used to measure the rCBF changes .,"(('Single', 'O'), ('photon', 'O'), ('emission', 'O'), ('tomography', 'O'), ('with', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('133Xe', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('measure', 'O'), ('the', 'O'), ('rCBF', 'O'), ('changes', 'O'), ('.', 'O'))"
PATIENTS AND METHODS : A total of 329 patients enrolled in the study at 24 centers .,"(('PATIENTS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('A', 'O'), ('total', 'O'), ('of', 'O'), ('329', 'O'), ('patients', 'O'), ('enrolled', 'O'), ('in', 'O'), ('the', 'O'), ('study', 'O'), ('at', 'O'), ('24', 'O'), ('centers', 'O'), ('.', 'O'))"
All patients had a pre - therapy Gram ' s stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy .,"(('All', 'O'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('pre', 'O'), ('-', 'O'), ('therapy', 'O'), ('Gram', 'O'), (""'"", 'O'), ('s', 'O'), ('stain', 'O'), ('and', 'O'), ('culture', 'O'), ('of', 'O'), ('sinus', 'O'), ('exudate', 'O'), ('obtained', 'O'), ('by', 'O'), ('antral', 'O'), ('puncture', 'O'), ('or', 'O'), ('nasal', 'O'), ('endoscopy', 'O'), ('.', 'O'))"
Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results .,"(('Clinical', 'O'), ('response', 'O'), ('was', 'O'), ('assessed', 'O'), ('on', 'O'), ('the', 'O'), ('basis', 'O'), ('of', 'O'), ('signs', 'O'), ('and', 'O'), ('symptoms', 'O'), ('and', 'O'), ('sinus', 'O'), ('radiograph', 'O'), ('or', 'O'), ('computed', 'O'), ('tomography', 'O'), ('results', 'O'), ('.', 'O'))"
Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre - therapy pathogen ( s ) .,"(('Microbiologic', 'O'), ('cure', 'O'), ('rates', 'O'), ('were', 'O'), ('determined', 'O'), ('on', 'O'), ('the', 'O'), ('basis', 'O'), ('of', 'O'), ('presumed', 'O'), ('plus', 'O'), ('documented', 'O'), ('eradication', 'O'), ('of', 'O'), ('the', 'O'), ('pre', 'O'), ('-', 'O'), ('therapy', 'O'), ('pathogen', 'O'), ('(', 'O'), ('s', 'O'), (')', 'O'), ('.', 'O'))"
"RESULTS : The most common pathogens were Haemophilus influenzae , Streptococcus pneumoniae , Staphylococcus aureus , and Moraxella catarrhalis .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('pathogens', 'O'), ('were', 'O'), ('Haemophilus', 'O'), ('influenzae', 'O'), (',', 'O'), ('Streptococcus', 'O'), ('pneumoniae', 'O'), (',', 'O'), ('Staphylococcus', 'O'), ('aureus', 'O'), (',', 'O'), ('and', 'O'), ('Moraxella', 'B'), ('catarrhalis', 'I'), ('.', 'O'))"
"Of 300 clinically evaluable patients , 175 ( 58 % ) were cured and 90 ( 30 % ) were improved at the post - therapy evaluation , resulting in a clinical success rate of 88 % .","(('Of', 'O'), ('300', 'O'), ('clinically', 'O'), ('evaluable', 'O'), ('patients', 'O'), (',', 'O'), ('175', 'O'), ('(', 'O'), ('58', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('cured', 'O'), ('and', 'O'), ('90', 'O'), ('(', 'O'), ('30', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('improved', 'O'), ('at', 'O'), ('the', 'O'), ('post', 'O'), ('-', 'O'), ('therapy', 'O'), ('evaluation', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('a', 'O'), ('clinical', 'O'), ('success', 'O'), ('rate', 'O'), ('of', 'O'), ('88', 'O'), ('%', 'O'), ('.', 'O'))"
Thirty - five patients ( 12 % ) clinically failed treatment .,"(('Thirty', 'O'), ('-', 'O'), ('five', 'O'), ('patients', 'O'), ('(', 'O'), ('12', 'O'), ('%', 'O'), (')', 'O'), ('clinically', 'O'), ('failed', 'O'), ('treatment', 'O'), ('.', 'O'))"
The microbiologic eradication rate ( presumed plus documented ) among 138 microbiologically evaluable patients was 92 % .,"(('The', 'O'), ('microbiologic', 'O'), ('eradication', 'O'), ('rate', 'O'), ('(', 'O'), ('presumed', 'O'), ('plus', 'O'), ('documented', 'O'), (')', 'O'), ('among', 'O'), ('138', 'O'), ('microbiologically', 'O'), ('evaluable', 'O'), ('patients', 'O'), ('was', 'O'), ('92', 'O'), ('%', 'O'), ('.', 'O'))"
Microbiologic eradication rates ( presumed plus documented ) of the most common pathogens ranged from 93 % ( M . catarrhalis ) to 100 % ( S . pneumoniae ) at the post - therapy visit .,"(('Microbiologic', 'O'), ('eradication', 'O'), ('rates', 'O'), ('(', 'O'), ('presumed', 'O'), ('plus', 'O'), ('documented', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('pathogens', 'O'), ('ranged', 'O'), ('from', 'O'), ('93', 'O'), ('%', 'O'), ('(', 'O'), ('M', 'O'), ('.', 'O'), ('catarrhalis', 'O'), (')', 'O'), ('to', 'O'), ('100', 'O'), ('%', 'O'), ('(', 'O'), ('S', 'O'), ('.', 'O'), ('pneumoniae', 'O'), (')', 'O'), ('at', 'O'), ('the', 'O'), ('post', 'O'), ('-', 'O'), ('therapy', 'O'), ('visit', 'O'), ('.', 'O'))"
All but one of the 265 patients who were cured or improved at post - therapy returned for a long - term follow - up visit ; 243 ( 92 % ) remained well 4 to 6 weeks after therapy ; and 21 ( 8 % ) had a relapse of symptoms .,"(('All', 'O'), ('but', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('265', 'O'), ('patients', 'O'), ('who', 'O'), ('were', 'O'), ('cured', 'O'), ('or', 'O'), ('improved', 'O'), ('at', 'O'), ('post', 'O'), ('-', 'O'), ('therapy', 'O'), ('returned', 'O'), ('for', 'O'), ('a', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('visit', 'O'), (';', 'O'), ('243', 'O'), ('(', 'O'), ('92', 'O'), ('%', 'O'), (')', 'O'), ('remained', 'O'), ('well', 'O'), ('4', 'O'), ('to', 'O'), ('6', 'O'), ('weeks', 'O'), ('after', 'O'), ('therapy', 'O'), (';', 'O'), ('and', 'O'), ('21', 'O'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('a', 'O'), ('relapse', 'O'), ('of', 'O'), ('symptoms', 'O'), ('.', 'O'))"
Adverse events considered to be related to levofloxacin administration were reported by 29 patients ( 9 % ) .,"(('Adverse', 'O'), ('events', 'O'), ('considered', 'O'), ('to', 'O'), ('be', 'O'), ('related', 'O'), ('to', 'O'), ('levofloxacin', 'O'), ('administration', 'O'), ('were', 'O'), ('reported', 'O'), ('by', 'O'), ('29', 'O'), ('patients', 'O'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case - control study .,"(('Iatrogenic', 'O'), ('risks', 'O'), ('of', 'O'), ('endometrial', 'B'), ('carcinoma', 'I'), ('after', 'O'), ('treatment', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('in', 'O'), ('a', 'O'), ('large', 'O'), ('French', 'O'), ('case', 'O'), ('-', 'O'), ('control', 'O'), ('study', 'O'), ('.', 'O'))"
F d ration Nationale des Centres de Lutte Contre le Cancer ( FNCLCC ) .,"(('F', 'O'), ('d', 'O'), ('ration', 'O'), ('Nationale', 'O'), ('des', 'O'), ('Centres', 'O'), ('de', 'O'), ('Lutte', 'O'), ('Contre', 'I'), ('le', 'O'), ('Cancer', 'I'), ('(', 'O'), ('FNCLCC', 'O'), (')', 'O'), ('.', 'O'))"
"Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer , its endometrial iatrogenic effects must be carefully examined .","(('Since', 'O'), ('tamoxifen', 'O'), ('is', 'O'), ('widely', 'O'), ('used', 'O'), ('in', 'O'), ('breast', 'B'), ('cancer', 'I'), ('treatment', 'O'), ('and', 'O'), ('has', 'O'), ('been', 'O'), ('proposed', 'O'), ('for', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('its', 'O'), ('endometrial', 'O'), ('iatrogenic', 'O'), ('effects', 'O'), ('must', 'O'), ('be', 'O'), ('carefully', 'O'), ('examined', 'O'), ('.', 'O'))"
We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case - control study .,"(('We', 'O'), ('have', 'O'), ('investigated', 'O'), ('the', 'O'), ('association', 'O'), ('between', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('and', 'O'), ('tamoxifen', 'O'), ('use', 'O'), ('or', 'O'), ('other', 'O'), ('treatments', 'O'), ('in', 'O'), ('women', 'O'), ('treated', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('-', 'O'), ('control', 'O'), ('study', 'O'), ('.', 'O'))"
"Cases of endometrial cancer diagnosed after breast cancer ( n = 135 ) and 467 controls matched for age , year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included .","(('Cases', 'O'), ('of', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('diagnosed', 'O'), ('after', 'O'), ('breast', 'B'), ('cancer', 'I'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('135', 'O'), (')', 'O'), ('and', 'O'), ('467', 'O'), ('controls', 'O'), ('matched', 'O'), ('for', 'O'), ('age', 'O'), (',', 'O'), ('year', 'O'), ('of', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('hospital', 'O'), ('and', 'O'), ('survival', 'O'), ('time', 'O'), ('with', 'O'), ('an', 'O'), ('intact', 'O'), ('uterus', 'O'), ('were', 'O'), ('included', 'O'), ('.', 'O'))"
"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .","(('Women', 'O'), ('who', 'O'), ('had', 'O'), ('received', 'O'), ('tamoxifen', 'O'), ('were', 'O'), ('significantly', 'O'), ('more', 'O'), ('likely', 'O'), ('to', 'O'), ('have', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('diagnosed', 'O'), ('than', 'O'), ('those', 'O'), ('who', 'O'), ('had', 'O'), ('not', 'O'), ('(', 'O'), ('crude', 'O'), ('relative', 'O'), ('risk', 'O'), ('=', 'O'), ('4', 'O'), ('.', 'O'), ('9', 'O'), (',', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0001', 'O'), (')', 'O'), ('.', 'O'))"
"Univariate and adjusted analyses showed that the risk increased with the length of treatment ( p = 0 . 0001 ) or the cumulative dose of tamoxifen received ( p = 0 . 0001 ) , irrespective of the daily dose .","(('Univariate', 'O'), ('and', 'O'), ('adjusted', 'O'), ('analyses', 'O'), ('showed', 'O'), ('that', 'O'), ('the', 'O'), ('risk', 'O'), ('increased', 'O'), ('with', 'O'), ('the', 'O'), ('length', 'O'), ('of', 'O'), ('treatment', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0001', 'O'), (')', 'O'), ('or', 'O'), ('the', 'O'), ('cumulative', 'O'), ('dose', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('received', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0001', 'O'), (')', 'O'), (',', 'O'), ('irrespective', 'O'), ('of', 'O'), ('the', 'O'), ('daily', 'O'), ('dose', 'O'), ('.', 'O'))"
"Women who had undergone pelvic radiotherapy also had a higher risk ( crude relative risk = 7 . 8 , p = 0 . 0001 ) .","(('Women', 'O'), ('who', 'O'), ('had', 'O'), ('undergone', 'O'), ('pelvic', 'O'), ('radiotherapy', 'O'), ('also', 'O'), ('had', 'O'), ('a', 'O'), ('higher', 'O'), ('risk', 'O'), ('(', 'O'), ('crude', 'O'), ('relative', 'O'), ('risk', 'O'), ('=', 'O'), ('7', 'O'), ('.', 'O'), ('8', 'O'), (',', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0001', 'O'), (')', 'O'), ('.', 'O'))"
"After adjusting for confounding factors , the risk was higher for tamoxifen users ( p = 0 . 0012 ) , treatment for more than 3 years ( all p < 0 . 03 ) and pelvic radiotherapy ( p = 0 . 012 ) .","(('After', 'O'), ('adjusting', 'O'), ('for', 'O'), ('confounding', 'O'), ('factors', 'O'), (',', 'O'), ('the', 'O'), ('risk', 'O'), ('was', 'O'), ('higher', 'O'), ('for', 'O'), ('tamoxifen', 'O'), ('users', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0012', 'O'), (')', 'O'), (',', 'O'), ('treatment', 'O'), ('for', 'O'), ('more', 'O'), ('than', 'O'), ('3', 'O'), ('years', 'O'), ('(', 'O'), ('all', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), (')', 'O'), ('and', 'O'), ('pelvic', 'O'), ('radiotherapy', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('012', 'O'), (')', 'O'), ('.', 'O'))"
Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment .,"(('Women', 'O'), ('who', 'O'), ('had', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('and', 'O'), ('had', 'O'), ('received', 'O'), ('tamoxifen', 'O'), ('had', 'O'), ('more', 'O'), ('advanced', 'O'), ('disease', 'O'), ('and', 'O'), ('poorer', 'O'), ('prognosis', 'O'), ('than', 'O'), ('those', 'O'), ('with', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('who', 'O'), ('had', 'O'), ('not', 'O'), ('received', 'O'), ('this', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Our results suggest a causal role of tamoxifen in endometrial cancer , particularly when used as currently proposed for breast cancer prevention .","(('Our', 'O'), ('results', 'O'), ('suggest', 'O'), ('a', 'O'), ('causal', 'O'), ('role', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('in', 'O'), ('endometrial', 'B'), ('cancer', 'I'), (',', 'O'), ('particularly', 'O'), ('when', 'O'), ('used', 'O'), ('as', 'O'), ('currently', 'O'), ('proposed', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('prevention', 'O'), ('.', 'O'))"
Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer .,"(('Pelvic', 'O'), ('radiotherapy', 'O'), ('may', 'O'), ('be', 'O'), ('an', 'O'), ('additional', 'O'), ('iatrogenic', 'O'), ('factor', 'O'), ('for', 'O'), ('women', 'O'), ('with', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment .,"(('Women', 'O'), ('who', 'O'), ('receive', 'O'), ('tamoxifen', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('should', 'O'), ('be', 'O'), ('offered', 'O'), ('gynaecological', 'O'), ('surveillance', 'O'), ('during', 'O'), ('and', 'O'), ('after', 'O'), ('treatment', 'O'), ('.', 'O'))"
A long - term evaluation of the risk - benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted .,"(('A', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('evaluation', 'O'), ('of', 'O'), ('the', 'O'), ('risk', 'O'), ('-', 'O'), ('benefit', 'O'), ('ratio', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('as', 'O'), ('a', 'O'), ('preventive', 'O'), ('treatment', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('is', 'O'), ('clearly', 'O'), ('warranted', 'O'), ('.', 'O'))"
Contribution of the glycine site of NMDA receptors in rostral and intermediate - caudal parts of the striatum to the regulation of muscle tone in rats .,"(('Contribution', 'O'), ('of', 'O'), ('the', 'O'), ('glycine', 'O'), ('site', 'O'), ('of', 'O'), ('NMDA', 'O'), ('receptors', 'O'), ('in', 'O'), ('rostral', 'O'), ('and', 'O'), ('intermediate', 'O'), ('-', 'O'), ('caudal', 'O'), ('parts', 'O'), ('of', 'O'), ('the', 'O'), ('striatum', 'O'), ('to', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('muscle', 'O'), ('tone', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone .,"(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('contribution', 'O'), ('of', 'O'), ('the', 'O'), ('glycine', 'O'), ('site', 'O'), ('of', 'O'), ('NMDA', 'O'), ('receptors', 'O'), ('in', 'O'), ('the', 'O'), ('striatum', 'O'), ('to', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('muscle', 'O'), ('tone', 'O'), ('.', 'O'))"
"Muscle tone was examined using a combined mechanoand electromyographic method , which measured simultaneously the muscle resistance ( MMG ) of the rat ' s hind foot to passive extension and flexion in the ankle joint and the electromyographic activity ( EMG ) of the antagonistic muscles of that joint : gastrocnemius and tibialis anterior .","(('Muscle', 'O'), ('tone', 'O'), ('was', 'O'), ('examined', 'O'), ('using', 'O'), ('a', 'O'), ('combined', 'O'), ('mechanoand', 'O'), ('electromyographic', 'O'), ('method', 'O'), (',', 'O'), ('which', 'O'), ('measured', 'O'), ('simultaneously', 'O'), ('the', 'O'), ('muscle', 'O'), ('resistance', 'O'), ('(', 'O'), ('MMG', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('rat', 'O'), (""'"", 'O'), ('s', 'O'), ('hind', 'O'), ('foot', 'O'), ('to', 'O'), ('passive', 'O'), ('extension', 'O'), ('and', 'O'), ('flexion', 'O'), ('in', 'O'), ('the', 'O'), ('ankle', 'O'), ('joint', 'O'), ('and', 'O'), ('the', 'O'), ('electromyographic', 'O'), ('activity', 'O'), ('(', 'O'), ('EMG', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('antagonistic', 'O'), ('muscles', 'O'), ('of', 'O'), ('that', 'O'), ('joint', 'O'), (':', 'O'), ('gastrocnemius', 'O'), ('and', 'O'), ('tibialis', 'O'), ('anterior', 'O'), ('.', 'O'))"
"5 , 7 - DCKA injected bilaterally in a dose of 4 . 5 microg / 0 . 5 microl into the intermediate - caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone .","(('5', 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('DCKA', 'O'), ('injected', 'O'), ('bilaterally', 'O'), ('in', 'O'), ('a', 'O'), ('dose', 'O'), ('of', 'O'), ('4', 'O'), ('.', 'O'), ('5', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), ('into', 'O'), ('the', 'O'), ('intermediate', 'O'), ('-', 'O'), ('caudal', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('striatum', 'O'), ('of', 'O'), ('rats', 'O'), ('not', 'O'), ('pretreated', 'O'), ('with', 'O'), ('haloperidol', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('muscle', 'O'), ('tone', 'O'), ('.', 'O'))"
The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug .,"(('The', 'O'), ('present', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('blockade', 'O'), ('of', 'O'), ('the', 'O'), ('glycine', 'O'), ('site', 'O'), ('of', 'O'), ('NMDA', 'O'), ('receptors', 'O'), ('in', 'O'), ('the', 'O'), ('rostral', 'O'), ('part', 'O'), ('of', 'O'), ('the', 'O'), ('striatum', 'O'), ('may', 'O'), ('be', 'O'), ('mainly', 'O'), ('responsible', 'O'), ('for', 'O'), ('the', 'O'), ('antiparkinsonian', 'O'), ('action', 'O'), ('of', 'O'), ('this', 'O'), ('drug', 'O'), ('.', 'O'))"
Carboplatin toxic effects on the peripheral nervous system of the rat .,"(('Carboplatin', 'O'), ('toxic', 'O'), ('effects', 'O'), ('on', 'O'), ('the', 'O'), ('peripheral', 'O'), ('nervous', 'O'), ('system', 'O'), ('of', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
MATERIALS AND METHODS : Two different schedules of CBDCA administration ( 10 mg / kg and 15 mg / kg i . p . twice a week for nine times ) were evaluated in Wistar rats .,"(('MATERIALS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('Two', 'O'), ('different', 'O'), ('schedules', 'O'), ('of', 'O'), ('CBDCA', 'O'), ('administration', 'O'), ('(', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('and', 'O'), ('15', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('twice', 'O'), ('a', 'O'), ('week', 'O'), ('for', 'O'), ('nine', 'O'), ('times', 'O'), (')', 'O'), ('were', 'O'), ('evaluated', 'O'), ('in', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('.', 'O'))"
"The dorsal root ganglia sensory neurons and , to a lesser extent , satellite cells showed the same changes as those induced by CDDP , mainly affecting the nucleus and nucleolus of ganglionic sensory neurons .","(('The', 'O'), ('dorsal', 'O'), ('root', 'O'), ('ganglia', 'O'), ('sensory', 'O'), ('neurons', 'O'), ('and', 'O'), (',', 'O'), ('to', 'O'), ('a', 'O'), ('lesser', 'O'), ('extent', 'O'), (',', 'O'), ('satellite', 'O'), ('cells', 'O'), ('showed', 'O'), ('the', 'O'), ('same', 'O'), ('changes', 'O'), ('as', 'O'), ('those', 'O'), ('induced', 'O'), ('by', 'O'), ('CDDP', 'O'), (',', 'O'), ('mainly', 'O'), ('affecting', 'O'), ('the', 'O'), ('nucleus', 'O'), ('and', 'O'), ('nucleolus', 'O'), ('of', 'O'), ('ganglionic', 'O'), ('sensory', 'O'), ('neurons', 'O'), ('.', 'O'))"
"Moreover , significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment .","(('Moreover', 'O'), (',', 'O'), ('significant', 'O'), ('amounts', 'O'), ('of', 'O'), ('platinum', 'O'), ('were', 'O'), ('detected', 'O'), ('in', 'O'), ('the', 'O'), ('dorsal', 'O'), ('root', 'O'), ('ganglia', 'O'), ('and', 'O'), ('kidney', 'O'), ('after', 'O'), ('CBDCA', 'O'), ('treatment', 'O'), ('.', 'O'))"
This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system .,"(('This', 'O'), ('model', 'O'), ('can', 'O'), ('be', 'O'), ('used', 'O'), ('alone', 'O'), ('or', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('other', 'O'), ('drugs', 'O'), ('to', 'O'), ('explore', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('CBDCA', 'O'), ('on', 'O'), ('the', 'O'), ('peripheral', 'O'), ('nervous', 'O'), ('system', 'O'), ('.', 'O'))"
RESULTS : In diarrhoea - predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups .,"(('RESULTS', 'O'), (':', 'O'), ('In', 'O'), ('diarrhoea', 'B'), ('-', 'O'), ('predominant', 'O'), ('patients', 'O'), ('significant', 'O'), ('differences', 'O'), ('in', 'O'), ('contraction', 'O'), ('characteristics', 'O'), ('were', 'O'), ('observed', 'O'), ('between', 'O'), ('the', 'O'), ('cisapride', 'O'), ('and', 'O'), ('placebo', 'O'), ('groups', 'O'), ('.', 'O'))"
"In cisapride - treated diarrhoea - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ;","(('In', 'O'), ('cisapride', 'O'), ('-', 'O'), ('treated', 'O'), ('diarrhoea', 'B'), ('-', 'O'), ('predominant', 'I'), ('patients', 'O'), ('the', 'O'), ('mean', 'O'), ('contraction', 'O'), ('amplitude', 'O'), ('was', 'O'), ('higher', 'O'), ('(', 'O'), ('29', 'O'), ('.', 'O'), ('3', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('2', 'O'), ('versus', 'O'), ('24', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('6', 'O'), ('mm', 'O'), ('Hg', 'O'), (',', 'O'), ('cisapride', 'O'), ('versus', 'O'), ('placebo', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (';', 'O'), ('pretreatment', 'O'), (',', 'O'), ('25', 'O'), ('.', 'O'), ('7', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('6', 'O'), ('.', 'O'), ('0', 'O'), ('mm', 'O'), ('Hg', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('mean', 'O'), ('contraction', 'O'), ('duration', 'O'), ('longer', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('versus', 'O'), ('3', 'O'), ('.', 'O'), ('0', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('sec', 'O'), (',', 'O'), ('cisapride', 'O'), ('versus', 'O'), ('placebo', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (';', 'O'))"
"pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .","(('pretreatment', 'O'), (',', 'O'), ('3', 'O'), ('.', 'O'), ('1', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('sec', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('mean', 'O'), ('contraction', 'O'), ('frequency', 'O'), ('lower', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('versus', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('4', 'O'), ('cont', 'O'), ('.', 'O'), ('/', 'O'), ('min', 'O'), (',', 'O'), ('cisapride', 'O'), ('versus', 'O'), ('placebo', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (';', 'O'), ('pretreatment', 'O'), (',', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('1', 'O'), ('cont', 'O'), ('.', 'O'), ('/', 'O'), ('min', 'O'), (']', 'O'), ('than', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('.', 'O'))"
Symptoms were assessed by using a visual analogue scale before and after treatment .,"(('Symptoms', 'O'), ('were', 'O'), ('assessed', 'O'), ('by', 'O'), ('using', 'O'), ('a', 'O'), ('visual', 'O'), ('analogue', 'O'), ('scale', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('treatment', 'O'), ('.', 'O'))"
Prevention of breast cancer with tamoxifen : preliminary findings from the Italian randomised trial among hysterectomised women .,"(('Prevention', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('with', 'O'), ('tamoxifen', 'O'), (':', 'O'), ('preliminary', 'O'), ('findings', 'O'), ('from', 'O'), ('the', 'O'), ('Italian', 'O'), ('randomised', 'O'), ('trial', 'O'), ('among', 'O'), ('hysterectomised', 'B'), ('women', 'O'), ('.', 'O'))"
Italian Tamoxifen Prevention Study .,"(('Italian', 'O'), ('Tamoxifen', 'O'), ('Prevention', 'O'), ('Study', 'O'), ('.', 'O'))"
"BACKGROUND : Tamoxifen is a candidate chemopreventive agent in breast cancer , although the drug may be associated with the development of endometrial cancer .","(('BACKGROUND', 'O'), (':', 'O'), ('Tamoxifen', 'O'), ('is', 'O'), ('a', 'O'), ('candidate', 'O'), ('chemopreventive', 'O'), ('agent', 'O'), ('in', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('drug', 'O'), ('may', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('.', 'O'))"
Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive .,"(('Therefore', 'O'), ('we', 'O'), ('did', 'O'), ('a', 'O'), ('trial', 'O'), ('in', 'O'), ('hysterectomised', 'B'), ('women', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('as', 'O'), ('a', 'O'), ('chemopreventive', 'O'), ('.', 'O'))"
"METHODS : In October , 1992 , we started a double - blind placebo - controlled , randomised trial of tamoxifen in women ( mainly in Italy ) who did not have breast cancer and who had had a hysterectomy .","(('METHODS', 'O'), (':', 'O'), ('In', 'O'), ('October', 'O'), (',', 'O'), ('1992', 'O'), (',', 'O'), ('we', 'O'), ('started', 'O'), ('a', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), (',', 'O'), ('randomised', 'O'), ('trial', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('in', 'O'), ('women', 'O'), ('(', 'O'), ('mainly', 'O'), ('in', 'O'), ('Italy', 'O'), (')', 'O'), ('who', 'O'), ('did', 'O'), ('not', 'O'), ('have', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('who', 'O'), ('had', 'O'), ('had', 'O'), ('a', 'O'), ('hysterectomy', 'B'), ('.', 'O'))"
"Women were randomised to receive tamoxifen 20 mg per day or placebo , both orally for 5 years .","(('Women', 'O'), ('were', 'O'), ('randomised', 'O'), ('to', 'O'), ('receive', 'O'), ('tamoxifen', 'O'), ('20', 'O'), ('mg', 'O'), ('per', 'O'), ('day', 'O'), ('or', 'O'), ('placebo', 'O'), (',', 'O'), ('both', 'O'), ('orally', 'O'), ('for', 'O'), ('5', 'O'), ('years', 'O'), ('.', 'O'))"
The original plan was to follow the intervention phase by 5 years ' follow - up .,"(('The', 'O'), ('original', 'O'), ('plan', 'O'), ('was', 'O'), ('to', 'O'), ('follow', 'O'), ('the', 'O'), ('intervention', 'O'), ('phase', 'O'), ('by', 'O'), ('5', 'O'), ('years', 'O'), (""'"", 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('.', 'O'))"
"In June , 1997 , the trialists and the data - monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study .","(('In', 'O'), ('June', 'O'), (',', 'O'), ('1997', 'O'), (',', 'O'), ('the', 'O'), ('trialists', 'O'), ('and', 'O'), ('the', 'O'), ('data', 'O'), ('-', 'O'), ('monitoring', 'O'), ('committee', 'O'), ('decided', 'O'), ('to', 'O'), ('end', 'O'), ('recruitment', 'O'), ('primarily', 'O'), ('because', 'O'), ('of', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('women', 'O'), ('dropping', 'O'), ('out', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
"Recruitment ended on July 11 , 1997 , and the study will continue as planned .","(('Recruitment', 'O'), ('ended', 'O'), ('on', 'O'), ('July', 'O'), ('11', 'O'), (',', 'O'), ('1997', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('study', 'O'), ('will', 'O'), ('continue', 'O'), ('as', 'O'), ('planned', 'O'), ('.', 'O'))"
The primary endpoints are the occurrence of and deaths from breast cancer .,"(('The', 'O'), ('primary', 'O'), ('endpoints', 'O'), ('are', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('and', 'O'), ('deaths', 'O'), ('from', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
This preliminary interim analysis is based on intention - to - treat .,"(('This', 'O'), ('preliminary', 'O'), ('interim', 'O'), ('analysis', 'O'), ('is', 'O'), ('based', 'O'), ('on', 'O'), ('intention', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('treat', 'O'), ('.', 'O'))"
FINDINGS : 5408 women were randomised ; participating women have a median follow - up of 46 months for major endpoints .,"(('FINDINGS', 'O'), (':', 'O'), ('5408', 'O'), ('women', 'O'), ('were', 'O'), ('randomised', 'O'), (';', 'O'), ('participating', 'O'), ('women', 'O'), ('have', 'O'), ('a', 'O'), ('median', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('of', 'O'), ('46', 'O'), ('months', 'O'), ('for', 'O'), ('major', 'O'), ('endpoints', 'O'), ('.', 'O'))"
41 cases of breast cancer occurred so far ; there have been no deaths from breast cancer .,"(('41', 'O'), ('cases', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('occurred', 'O'), ('so', 'O'), ('far', 'O'), (';', 'O'), ('there', 'O'), ('have', 'O'), ('been', 'O'), ('no', 'O'), ('deaths', 'O'), ('from', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
There is no difference in breast - cancer frequency between the placebo ( 22 cases ) and tamoxifen ( 19 ) arms .,"(('There', 'O'), ('is', 'O'), ('no', 'O'), ('difference', 'O'), ('in', 'O'), ('breast', 'B'), ('-', 'I'), ('cancer', 'I'), ('frequency', 'O'), ('between', 'O'), ('the', 'O'), ('placebo', 'O'), ('(', 'O'), ('22', 'O'), ('cases', 'O'), (')', 'O'), ('and', 'O'), ('tamoxifen', 'O'), ('(', 'O'), ('19', 'O'), (')', 'O'), ('arms', 'O'), ('.', 'O'))"
"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen .","(('There', 'O'), ('is', 'O'), ('a', 'O'), ('statistically', 'O'), ('significant', 'O'), ('reduction', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('among', 'O'), ('women', 'O'), ('receiving', 'O'), ('tamoxifen', 'O'), ('who', 'O'), ('also', 'O'), ('used', 'O'), ('hormone', 'O'), ('-', 'O'), ('replacement', 'O'), ('therapy', 'O'), ('during', 'O'), ('the', 'O'), ('trial', 'O'), (':', 'O'), ('among', 'O'), ('390', 'O'), ('women', 'O'), ('on', 'O'), ('such', 'O'), ('therapy', 'O'), ('and', 'O'), ('allocated', 'O'), ('to', 'O'), ('placebo', 'O'), (',', 'O'), ('we', 'O'), ('found', 'O'), ('eight', 'O'), ('cases', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('compared', 'O'), ('with', 'O'), ('one', 'O'), ('case', 'O'), ('among', 'O'), ('362', 'O'), ('women', 'O'), ('allocated', 'O'), ('to', 'O'), ('tamoxifen', 'O'), ('.', 'O'))"
"INTERPRETATION : Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of breast cancer , the postulated protective effects of tamoxifen are not yet apparent .","(('INTERPRETATION', 'O'), (':', 'O'), ('Although', 'O'), ('this', 'O'), ('preliminary', 'O'), ('analysis', 'O'), ('has', 'O'), ('low', 'O'), ('power', 'O'), (',', 'O'), ('in', 'O'), ('this', 'O'), ('cohort', 'O'), ('of', 'O'), ('women', 'O'), ('at', 'O'), ('low', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('normal', 'O'), ('risk', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('the', 'O'), ('postulated', 'O'), ('protective', 'O'), ('effects', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('are', 'O'), ('not', 'O'), ('yet', 'O'), ('apparent', 'O'), ('.', 'O'))"
Women using hormone - replacement therapy appear to have benefited from use of tamoxifen .,"(('Women', 'O'), ('using', 'O'), ('hormone', 'O'), ('-', 'O'), ('replacement', 'O'), ('therapy', 'O'), ('appear', 'O'), ('to', 'O'), ('have', 'O'), ('benefited', 'O'), ('from', 'O'), ('use', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('.', 'O'))"
There were no deaths from breast cancer recorded in women in the study .,"(('There', 'O'), ('were', 'O'), ('no', 'O'), ('deaths', 'O'), ('from', 'O'), ('breast', 'B'), ('cancer', 'I'), ('recorded', 'O'), ('in', 'O'), ('women', 'O'), ('in', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
It is essential to continue follow - up to quantify the long - term risks and benefits of tamoxifen therapy .,"(('It', 'O'), ('is', 'O'), ('essential', 'O'), ('to', 'O'), ('continue', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('to', 'O'), ('quantify', 'O'), ('the', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('risks', 'O'), ('and', 'O'), ('benefits', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('therapy', 'O'), ('.', 'O'))"
"STUDY DESIGN : First a randomised trial , later periconception care including in total 12225 females .","(('STUDY', 'O'), ('DESIGN', 'O'), (':', 'O'), ('First', 'O'), ('a', 'O'), ('randomised', 'O'), ('trial', 'O'), (',', 'O'), ('later', 'O'), ('periconception', 'O'), ('care', 'O'), ('including', 'O'), ('in', 'O'), ('total', 'O'), ('12225', 'O'), ('females', 'O'), ('.', 'O'))"
Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin .,"(('Another', 'O'), ('patient', 'O'), ('exhibited', 'O'), ('with', 'O'), ('a', 'O'), ('cluster', 'O'), ('of', 'O'), ('seizures', 'O'), ('after', 'O'), ('the', 'O'), ('periconception', 'O'), ('period', 'O'), ('using', 'O'), ('another', 'O'), ('multivitamin', 'O'), ('.', 'O'))"
This case - control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California .,"(('This', 'O'), ('case', 'O'), ('-', 'O'), ('control', 'O'), ('study', 'O'), ('was', 'O'), ('conducted', 'O'), ('in', 'O'), ('the', 'O'), ('defined', 'O'), ('population', 'O'), ('comprising', 'O'), ('members', 'O'), ('of', 'O'), ('Kaiser', 'O'), ('Permanente', 'O'), ('of', 'O'), ('Northern', 'O'), ('and', 'O'), ('Southern', 'O'), ('California', 'O'), ('.', 'O'))"
"We selected controls , matched on age and facility of usual care , at random from healthy members of the health plan .","(('We', 'O'), ('selected', 'O'), ('controls', 'O'), (',', 'O'), ('matched', 'O'), ('on', 'O'), ('age', 'O'), ('and', 'O'), ('facility', 'O'), ('of', 'O'), ('usual', 'O'), ('care', 'O'), (',', 'O'), ('at', 'O'), ('random', 'O'), ('from', 'O'), ('healthy', 'O'), ('members', 'O'), ('of', 'O'), ('the', 'O'), ('health', 'O'), ('plan', 'O'), ('.', 'O'))"
We obtained information in face - to - face interviews .,"(('We', 'O'), ('obtained', 'O'), ('information', 'O'), ('in', 'O'), ('face', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('face', 'O'), ('interviews', 'O'), ('.', 'O'))"
"After further adjustment for potential confounders , the odds ratio in women who reported using cocaine and / or amphetamine was 7 . 0 ( 95 % confidence interval = 2 . 8 - 17 . 9 ) .","(('After', 'O'), ('further', 'O'), ('adjustment', 'O'), ('for', 'O'), ('potential', 'O'), ('confounders', 'O'), (',', 'O'), ('the', 'O'), ('odds', 'O'), ('ratio', 'O'), ('in', 'O'), ('women', 'O'), ('who', 'O'), ('reported', 'O'), ('using', 'O'), ('cocaine', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('amphetamine', 'O'), ('was', 'O'), ('7', 'O'), ('.', 'O'), ('0', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), ('=', 'O'), ('2', 'O'), ('.', 'O'), ('8', 'O'), ('-', 'O'), ('17', 'O'), ('.', 'O'), ('9', 'O'), (')', 'O'), ('.', 'O'))"
A follow - up study of cases reported earlier .,"(('A', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('study', 'O'), ('of', 'O'), ('cases', 'O'), ('reported', 'O'), ('earlier', 'O'), ('.', 'O'))"
A clinical presentation is made of a 2 - 3 year follow - up of six cases of acute renal failure that have been reported earlier .,"(('A', 'O'), ('clinical', 'O'), ('presentation', 'O'), ('is', 'O'), ('made', 'O'), ('of', 'O'), ('a', 'O'), ('2', 'O'), ('-', 'O'), ('3', 'O'), ('year', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('of', 'O'), ('six', 'O'), ('cases', 'O'), ('of', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('that', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('earlier', 'O'), ('.', 'O'))"
The patients had developed transient renal failure after the intermittent administration of rifampicin .,"(('The', 'O'), ('patients', 'O'), ('had', 'O'), ('developed', 'O'), ('transient', 'O'), ('renal', 'B'), ('failure', 'I'), ('after', 'O'), ('the', 'O'), ('intermittent', 'O'), ('administration', 'O'), ('of', 'O'), ('rifampicin', 'O'), ('.', 'O'))"
Two of the patients died due to unrelated causes during the follow - up period .,"(('Two', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('died', 'O'), ('due', 'O'), ('to', 'O'), ('unrelated', 'O'), ('causes', 'O'), ('during', 'O'), ('the', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('period', 'O'), ('.', 'O'))"
The four patients re - examined were clinically cured .,"(('The', 'O'), ('four', 'O'), ('patients', 'O'), ('re', 'O'), ('-', 'O'), ('examined', 'O'), ('were', 'O'), ('clinically', 'O'), ('cured', 'O'), ('.', 'O'))"
Pathologic findings by light microscopy and immunofluorescence at biopsy were scarce .,"(('Pathologic', 'O'), ('findings', 'O'), ('by', 'O'), ('light', 'O'), ('microscopy', 'O'), ('and', 'O'), ('immunofluorescence', 'O'), ('at', 'O'), ('biopsy', 'O'), ('were', 'O'), ('scarce', 'O'), ('.', 'O'))"
Nothing abnormal was seen by electron microscopy in two of the cases studied .,"(('Nothing', 'O'), ('abnormal', 'O'), ('was', 'O'), ('seen', 'O'), ('by', 'O'), ('electron', 'O'), ('microscopy', 'O'), ('in', 'O'), ('two', 'O'), ('of', 'O'), ('the', 'O'), ('cases', 'O'), ('studied', 'O'), ('.', 'O'))"
Renal function was normal .,"(('Renal', 'O'), ('function', 'O'), ('was', 'O'), ('normal', 'O'), ('.', 'O'))"
In three cases the excretion at 131I - hippuran renography was slightly slowed .,"(('In', 'O'), ('three', 'O'), ('cases', 'O'), ('the', 'O'), ('excretion', 'O'), ('at', 'O'), ('131I', 'O'), ('-', 'O'), ('hippuran', 'O'), ('renography', 'O'), ('was', 'O'), ('slightly', 'O'), ('slowed', 'O'), ('.', 'O'))"
"Although in the acute stage the renal lesions histologically appeared toxic , evidence suggestive of an immunological mechanism cannot be excluded .","(('Although', 'O'), ('in', 'O'), ('the', 'O'), ('acute', 'O'), ('stage', 'O'), ('the', 'O'), ('renal', 'O'), ('lesions', 'O'), ('histologically', 'O'), ('appeared', 'O'), ('toxic', 'O'), (',', 'O'), ('evidence', 'O'), ('suggestive', 'O'), ('of', 'O'), ('an', 'O'), ('immunological', 'O'), ('mechanism', 'O'), ('cannot', 'O'), ('be', 'O'), ('excluded', 'O'), ('.', 'O'))"
Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and doxorubicin - induced cardiomyopathy in beagle dogs .,"(('Chronic', 'O'), ('effects', 'O'), ('of', 'O'), ('a', 'O'), ('novel', 'O'), ('synthetic', 'O'), ('anthracycline', 'O'), ('derivative', 'O'), ('(', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), (')', 'O'), ('on', 'O'), ('normal', 'O'), ('heart', 'O'), ('and', 'O'), ('doxorubicin', 'B'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('in', 'O'), ('beagle', 'O'), ('dogs', 'O'), ('.', 'O'))"
"In the chronic treatment , beagle dogs of each sex were given intravenously once every 3 weeks , either a sublethal dose of doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) .","(('In', 'O'), ('the', 'O'), ('chronic', 'O'), ('treatment', 'O'), (',', 'O'), ('beagle', 'O'), ('dogs', 'O'), ('of', 'O'), ('each', 'O'), ('sex', 'O'), ('were', 'O'), ('given', 'O'), ('intravenously', 'O'), ('once', 'O'), ('every', 'O'), ('3', 'O'), ('weeks', 'O'), (',', 'O'), ('either', 'O'), ('a', 'O'), ('sublethal', 'O'), ('dose', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('or', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('.', 'O'))"
The experiment was terminated 3 weeks after the ninth dosing .,"(('The', 'O'), ('experiment', 'O'), ('was', 'O'), ('terminated', 'O'), ('3', 'O'), ('weeks', 'O'), ('after', 'O'), ('the', 'O'), ('ninth', 'O'), ('dosing', 'O'), ('.', 'O'))"
"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological cardiomyopathy , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .","(('Animals', 'O'), ('which', 'O'), ('received', 'O'), ('over', 'O'), ('six', 'O'), ('courses', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('demonstrated', 'O'), ('the', 'O'), ('electrocardiogram', 'O'), ('(', 'O'), ('ECG', 'O'), (')', 'O'), ('changes', 'O'), (',', 'O'), ('decrease', 'O'), ('of', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('high', 'O'), ('-', 'O'), ('grade', 'O'), ('histopathological', 'O'), ('cardiomyopathy', 'B'), (',', 'O'), ('while', 'O'), ('animals', 'O'), ('which', 'O'), ('were', 'O'), ('terminally', 'O'), ('sacrificed', 'O'), ('after', 'O'), ('the', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), ('administration', 'O'), ('did', 'O'), ('not', 'O'), ('show', 'O'), ('any', 'O'), ('changes', 'O'), ('in', 'O'), ('ECG', 'O'), (',', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('histopathological', 'O'), ('examinations', 'O'), ('.', 'O'))"
"Nine weeks after pre - treatment , dogs were given four courses of either doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) once every 3 weeks .","(('Nine', 'O'), ('weeks', 'O'), ('after', 'O'), ('pre', 'O'), ('-', 'O'), ('treatment', 'O'), (',', 'O'), ('dogs', 'O'), ('were', 'O'), ('given', 'O'), ('four', 'O'), ('courses', 'O'), ('of', 'O'), ('either', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('or', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('once', 'O'), ('every', 'O'), ('3', 'O'), ('weeks', 'O'), ('.', 'O'))"
"On the contrary , the SM - 5887 treatment did not progress the grade of cardiomyopathy .","(('On', 'O'), ('the', 'O'), ('contrary', 'O'), (',', 'O'), ('the', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), ('treatment', 'O'), ('did', 'O'), ('not', 'O'), ('progress', 'O'), ('the', 'O'), ('grade', 'O'), ('of', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
DESIGN : Cohort study .,"(('DESIGN', 'O'), (':', 'O'), ('Cohort', 'O'), ('study', 'O'), ('.', 'O'))"
SETTING : Academic primary care practices .,"(('SETTING', 'O'), (':', 'O'), ('Academic', 'O'), ('primary', 'O'), ('care', 'O'), ('practices', 'O'), ('.', 'O'))"
PATIENTS : 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy .,"(('PATIENTS', 'O'), (':', 'O'), ('46', 'O'), ('patients', 'O'), ('who', 'O'), ('used', 'O'), ('fenfluramine', 'O'), ('or', 'O'), ('dexfenfluramine', 'O'), ('for', 'O'), ('14', 'O'), ('days', 'O'), ('or', 'O'), ('more', 'O'), ('and', 'O'), ('had', 'O'), ('echocardiograms', 'O'), ('obtained', 'O'), ('before', 'O'), ('therapy', 'O'), ('.', 'O'))"
MEASUREMENTS : Follow - up echocardiography .,"(('MEASUREMENTS', 'O'), (':', 'O'), ('Follow', 'O'), ('-', 'O'), ('up', 'O'), ('echocardiography', 'O'), ('.', 'O'))"
"However , the incidence may be lower than that reported previously .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('may', 'O'), ('be', 'O'), ('lower', 'O'), ('than', 'O'), ('that', 'O'), ('reported', 'O'), ('previously', 'O'), ('.', 'O'))"
Therapeutic drug monitoring of tobramycin : once - daily versus twice - daily dosage schedules .,"(('Therapeutic', 'O'), ('drug', 'O'), ('monitoring', 'O'), ('of', 'O'), ('tobramycin', 'O'), (':', 'O'), ('once', 'O'), ('-', 'O'), ('daily', 'O'), ('versus', 'O'), ('twice', 'O'), ('-', 'O'), ('daily', 'O'), ('dosage', 'O'), ('schedules', 'O'), ('.', 'O'))"
OBJECTIVE : To evaluate the effect of dosage regimen ( once - daily vs . twice - daily ) of tobramicyn on steady - state serum concentrations and toxicity .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('dosage', 'O'), ('regimen', 'O'), ('(', 'O'), ('once', 'O'), ('-', 'O'), ('daily', 'O'), ('vs', 'O'), ('.', 'O'), ('twice', 'O'), ('-', 'O'), ('daily', 'O'), (')', 'O'), ('of', 'O'), ('tobramicyn', 'O'), ('on', 'O'), ('steady', 'O'), ('-', 'O'), ('state', 'O'), ('serum', 'O'), ('concentrations', 'O'), ('and', 'O'), ('toxicity', 'O'), ('.', 'O'))"
MATERIALS AND METHODS : Patients undergoing treatment with i . v . tobramycin ( 4 mg / kg / day ) were randomised to two groups .,"(('MATERIALS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('Patients', 'O'), ('undergoing', 'O'), ('treatment', 'O'), ('with', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('tobramycin', 'O'), ('(', 'O'), ('4', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('were', 'O'), ('randomised', 'O'), ('to', 'O'), ('two', 'O'), ('groups', 'O'), ('.', 'O'))"
Group OD ( n = 22 ) received a once - daily dose of tobramycin and group TD ( n = 21 ) received the same dose divided into two doses daily .,"(('Group', 'O'), ('OD', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('22', 'O'), (')', 'O'), ('received', 'O'), ('a', 'O'), ('once', 'O'), ('-', 'O'), ('daily', 'O'), ('dose', 'O'), ('of', 'O'), ('tobramycin', 'O'), ('and', 'O'), ('group', 'O'), ('TD', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('21', 'O'), (')', 'O'), ('received', 'O'), ('the', 'O'), ('same', 'O'), ('dose', 'O'), ('divided', 'O'), ('into', 'O'), ('two', 'O'), ('doses', 'O'), ('daily', 'O'), ('.', 'O'))"
Tobramycin serum concentrations ( peak and trough ) were measured by enzyme multiplied immunoassay .,"(('Tobramycin', 'O'), ('serum', 'O'), ('concentrations', 'O'), ('(', 'O'), ('peak', 'O'), ('and', 'O'), ('trough', 'O'), (')', 'O'), ('were', 'O'), ('measured', 'O'), ('by', 'O'), ('enzyme', 'O'), ('multiplied', 'O'), ('immunoassay', 'O'), ('.', 'O'))"
"The renal and auditory functions of the patients were monitored before , during and immediately after treatment .","(('The', 'O'), ('renal', 'O'), ('and', 'O'), ('auditory', 'O'), ('functions', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('were', 'O'), ('monitored', 'O'), ('before', 'O'), (',', 'O'), ('during', 'O'), ('and', 'O'), ('immediately', 'O'), ('after', 'O'), ('treatment', 'O'), ('.', 'O'))"
"RESULTS : The two groups were comparable with respect to sex , age , body weight and renal function .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('two', 'O'), ('groups', 'O'), ('were', 'O'), ('comparable', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('sex', 'O'), (',', 'O'), ('age', 'O'), (',', 'O'), ('body', 'O'), ('weight', 'O'), ('and', 'O'), ('renal', 'O'), ('function', 'O'), ('.', 'O'))"
"No statistically significant differences were found in mean daily dose , duration of treatment , or cumulative dose .","(('No', 'O'), ('statistically', 'O'), ('significant', 'O'), ('differences', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('mean', 'O'), ('daily', 'O'), ('dose', 'O'), (',', 'O'), ('duration', 'O'), ('of', 'O'), ('treatment', 'O'), (',', 'O'), ('or', 'O'), ('cumulative', 'O'), ('dose', 'O'), ('.', 'O'))"
Trough concentrations were < 2 g / ml in the two groups ( 100 % ) .,"(('Trough', 'O'), ('concentrations', 'O'), ('were', 'O'), ('<', 'O'), ('2', 'O'), ('g', 'O'), ('/', 'O'), ('ml', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('groups', 'O'), ('(', 'O'), ('100', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
Peak concentrations were > 6 microg / ml in 100 % of the OD group and in 67 % of the TD group ( P < 0 . 01 ) .,"(('Peak', 'O'), ('concentrations', 'O'), ('were', 'O'), ('>', 'O'), ('6', 'O'), ('microg', 'O'), ('/', 'O'), ('ml', 'O'), ('in', 'O'), ('100', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('OD', 'B'), ('group', 'O'), ('and', 'O'), ('in', 'O'), ('67', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('TD', 'B'), ('group', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
Mean peak concentrations were markedly different : 11 . 00 + / - 2 . 89 microg / ml in OD vs . 6 . 53 + / - 1 . 45 microg / ml in TD ( P < 0 . 01 ) .,"(('Mean', 'O'), ('peak', 'O'), ('concentrations', 'O'), ('were', 'O'), ('markedly', 'O'), ('different', 'O'), (':', 'O'), ('11', 'O'), ('.', 'O'), ('00', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('89', 'O'), ('microg', 'O'), ('/', 'O'), ('ml', 'O'), ('in', 'O'), ('OD', 'B'), ('vs', 'O'), ('.', 'O'), ('6', 'O'), ('.', 'O'), ('53', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('45', 'O'), ('microg', 'O'), ('/', 'O'), ('ml', 'O'), ('in', 'O'), ('TD', 'B'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
"The pharmacokinetics parameters were : Ke , ( 0 . 15 + / - 0 . 03 / h in OD vs . 0 . 24 + / - 0 . 06 / h in TD ) , t1 / 2 , ( 4 . 95 + / - 1 . 41 h in OD vs . 3 . 07 + / - 0 . 71 h in TD ) , Vd ( 0 . 35 + / - 0 . 11 l / kg in OD vs . 0 . 33 + / - 0 . 09 l / kg in TD ) , Cl ( 0 . 86 +","(('The', 'O'), ('pharmacokinetics', 'O'), ('parameters', 'O'), ('were', 'O'), (':', 'O'), ('Ke', 'O'), (',', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('15', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), ('/', 'O'), ('h', 'O'), ('in', 'O'), ('OD', 'O'), ('vs', 'O'), ('.', 'O'), ('0', 'O'), ('.', 'O'), ('24', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('06', 'O'), ('/', 'O'), ('h', 'O'), ('in', 'O'), ('TD', 'O'), (')', 'O'), (',', 'O'), ('t1', 'O'), ('/', 'O'), ('2', 'O'), (',', 'O'), ('(', 'O'), ('4', 'O'), ('.', 'O'), ('95', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('41', 'O'), ('h', 'O'), ('in', 'O'), ('OD', 'O'), ('vs', 'O'), ('.', 'O'), ('3', 'O'), ('.', 'O'), ('07', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('71', 'O'), ('h', 'O'), ('in', 'O'), ('TD', 'O'), (')', 'O'), (',', 'O'), ('Vd', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('35', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('11', 'O'), ('l', 'O'), ('/', 'O'), ('kg', 'O'), ('in', 'O'), ('OD', 'O'), ('vs', 'O'), ('.', 'O'), ('0', 'O'), ('.', 'O'), ('33', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('09', 'O'), ('l', 'O'), ('/', 'O'), ('kg', 'O'), ('in', 'O'), ('TD', 'O'), (')', 'O'), (',', 'O'), ('Cl', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('86', 'O'), ('+', 'O'))"
29 ml / min / kg in OD vs . 1 . 28 + / - 0 . 33 ml / min / kg in TD ) .,"(('29', 'O'), ('ml', 'O'), ('/', 'O'), ('min', 'O'), ('/', 'O'), ('kg', 'O'), ('in', 'O'), ('OD', 'B'), ('vs', 'O'), ('.', 'O'), ('1', 'O'), ('.', 'O'), ('28', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('33', 'O'), ('ml', 'O'), ('/', 'O'), ('min', 'O'), ('/', 'O'), ('kg', 'O'), ('in', 'O'), ('TD', 'B'), (')', 'O'), ('.', 'O'))"
CONCLUSION : This small study suggests that a once - daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice - daily regimen .,"(('CONCLUSION', 'O'), (':', 'O'), ('This', 'O'), ('small', 'O'), ('study', 'O'), ('suggests', 'O'), ('that', 'O'), ('a', 'O'), ('once', 'O'), ('-', 'O'), ('daily', 'O'), ('dosing', 'O'), ('regimen', 'O'), ('of', 'O'), ('tobramycin', 'O'), ('is', 'O'), ('at', 'O'), ('least', 'O'), ('as', 'O'), ('effective', 'O'), ('as', 'O'), ('and', 'O'), ('is', 'O'), ('no', 'O'), ('more', 'O'), ('and', 'O'), ('possibly', 'O'), ('less', 'O'), ('toxic', 'O'), ('than', 'O'), ('the', 'O'), ('twice', 'O'), ('-', 'O'), ('daily', 'O'), ('regimen', 'O'), ('.', 'O'))"
"Using a single - dose therapy , peak concentration determination is not necessary , only trough samples should be monitored to ensure levels below 2 microg / ml .","(('Using', 'O'), ('a', 'O'), ('single', 'O'), ('-', 'O'), ('dose', 'O'), ('therapy', 'O'), (',', 'O'), ('peak', 'O'), ('concentration', 'O'), ('determination', 'O'), ('is', 'O'), ('not', 'O'), ('necessary', 'O'), (',', 'O'), ('only', 'O'), ('trough', 'O'), ('samples', 'O'), ('should', 'O'), ('be', 'O'), ('monitored', 'O'), ('to', 'O'), ('ensure', 'O'), ('levels', 'O'), ('below', 'O'), ('2', 'O'), ('microg', 'O'), ('/', 'O'), ('ml', 'O'), ('.', 'O'))"
Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised .,"(('Enhancement', 'O'), ('was', 'O'), ('not', 'O'), ('observed', 'O'), ('in', 'O'), ('rats', 'O'), ('pretreated', 'O'), ('with', 'O'), ('methylatropine', 'O'), ('or', 'O'), ('previously', 'O'), ('vagotomised', 'O'), ('.', 'O'))"
These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone .,"(('These', 'O'), ('results', 'O'), ('are', 'O'), ('compatible', 'O'), ('with', 'O'), ('interference', 'O'), ('by', 'O'), ('isoniazid', 'O'), ('with', 'O'), ('GABAergic', 'O'), ('inhibition', 'O'), ('of', 'O'), ('cardiac', 'O'), ('parasympathetic', 'O'), ('tone', 'O'), ('.', 'O'))"
"Such interference could be exerted centrally , possibly at the nucleus ambiguus , or peripherally at the sinus node .","(('Such', 'O'), ('interference', 'O'), ('could', 'O'), ('be', 'O'), ('exerted', 'O'), ('centrally', 'O'), (',', 'O'), ('possibly', 'O'), ('at', 'O'), ('the', 'O'), ('nucleus', 'O'), ('ambiguus', 'O'), (',', 'O'), ('or', 'O'), ('peripherally', 'O'), ('at', 'O'), ('the', 'O'), ('sinus', 'O'), ('node', 'O'), ('.', 'O'))"
The use of adriamycin ( ADR ) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity .,"(('The', 'O'), ('use', 'O'), ('of', 'O'), ('adriamycin', 'O'), ('(', 'O'), ('ADR', 'O'), (')', 'O'), ('in', 'O'), ('cancer', 'B'), ('chemotherapy', 'O'), ('has', 'O'), ('been', 'O'), ('limited', 'O'), ('due', 'O'), ('to', 'O'), ('its', 'O'), ('cumulative', 'O'), ('cardiovascular', 'O'), ('toxicity', 'O'), ('.', 'O'))"
Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase ( COX ) and suppresses its enzyme activity led us to investigate ADR ' s action on the cardiovascular functions and heart mitochondrial morphology in Balb - c mice i . p . treated with ADR for several weeks .,"(('Earlier', 'O'), ('observations', 'O'), ('that', 'O'), ('ADR', 'O'), ('interacts', 'O'), ('with', 'O'), ('mitochondrial', 'O'), ('cytochrome', 'O'), ('c', 'O'), ('oxidase', 'O'), ('(', 'O'), ('COX', 'O'), (')', 'O'), ('and', 'O'), ('suppresses', 'O'), ('its', 'O'), ('enzyme', 'O'), ('activity', 'O'), ('led', 'O'), ('us', 'O'), ('to', 'O'), ('investigate', 'O'), ('ADR', 'O'), (""'"", 'O'), ('s', 'O'), ('action', 'O'), ('on', 'O'), ('the', 'O'), ('cardiovascular', 'O'), ('functions', 'O'), ('and', 'O'), ('heart', 'O'), ('mitochondrial', 'O'), ('morphology', 'O'), ('in', 'O'), ('Balb', 'O'), ('-', 'O'), ('c', 'O'), ('mice', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('treated', 'O'), ('with', 'O'), ('ADR', 'O'), ('for', 'O'), ('several', 'O'), ('weeks', 'O'), ('.', 'O'))"
"At various times during treatment , the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy .","(('At', 'O'), ('various', 'O'), ('times', 'O'), ('during', 'O'), ('treatment', 'O'), (',', 'O'), ('the', 'O'), ('animals', 'O'), ('were', 'O'), ('assessed', 'O'), ('for', 'O'), ('cardiovascular', 'O'), ('functions', 'O'), ('by', 'O'), ('electrocardiography', 'O'), ('and', 'O'), ('for', 'O'), ('heart', 'O'), ('tissue', 'O'), ('damage', 'O'), ('by', 'O'), ('electron', 'O'), ('microscopy', 'O'), ('.', 'O'))"
"In parallel , total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady - state level of three RNA transcripts encoded by the COXII , COXIII , and COXIV genes .","(('In', 'O'), ('parallel', 'O'), (',', 'O'), ('total', 'O'), ('RNA', 'O'), ('was', 'O'), ('extracted', 'O'), ('from', 'O'), ('samples', 'O'), ('of', 'O'), ('dissected', 'O'), ('heart', 'O'), ('and', 'O'), ('analyzed', 'O'), ('by', 'O'), ('Northern', 'O'), ('blot', 'O'), ('hybridization', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('steady', 'O'), ('-', 'O'), ('state', 'O'), ('level', 'O'), ('of', 'O'), ('three', 'O'), ('RNA', 'O'), ('transcripts', 'O'), ('encoded', 'O'), ('by', 'O'), ('the', 'O'), ('COXII', 'O'), (',', 'O'), ('COXIII', 'O'), (',', 'O'), ('and', 'O'), ('COXIV', 'O'), ('genes', 'O'), ('.', 'O'))"
"Similarly , samples obtained from the liver of the same animals were analyzed for comparative studies .","(('Similarly', 'O'), (',', 'O'), ('samples', 'O'), ('obtained', 'O'), ('from', 'O'), ('the', 'O'), ('liver', 'O'), ('of', 'O'), ('the', 'O'), ('same', 'O'), ('animals', 'O'), ('were', 'O'), ('analyzed', 'O'), ('for', 'O'), ('comparative', 'O'), ('studies', 'O'), ('.', 'O'))"
"Such abnormalities were not observed in the mitochondria of liver tissue ; and 3 ) among the three genes of COX enzyme examined , only COXII gene expression was suppressed by ADR treatment , mainly after 8 weeks in both heart and liver .","(('Such', 'O'), ('abnormalities', 'O'), ('were', 'O'), ('not', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('mitochondria', 'O'), ('of', 'O'), ('liver', 'O'), ('tissue', 'O'), (';', 'O'), ('and', 'O'), ('3', 'O'), (')', 'O'), ('among', 'O'), ('the', 'O'), ('three', 'O'), ('genes', 'O'), ('of', 'O'), ('COX', 'O'), ('enzyme', 'O'), ('examined', 'O'), (',', 'O'), ('only', 'O'), ('COXII', 'O'), ('gene', 'O'), ('expression', 'O'), ('was', 'O'), ('suppressed', 'O'), ('by', 'O'), ('ADR', 'O'), ('treatment', 'O'), (',', 'O'), ('mainly', 'O'), ('after', 'O'), ('8', 'O'), ('weeks', 'O'), ('in', 'O'), ('both', 'O'), ('heart', 'O'), ('and', 'O'), ('liver', 'O'), ('.', 'O'))"
